

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:44:45 ; Search time 4 Seconds  
(without alignments)  
2.954 Million cell updates/sec

Title: us-10-828-394-1  
Perfect score: 1643  
Sequence: 1 gaattccgcgcgtgaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 198 seqs, 3596 residues

Total number of hits satisfying chosen parameters: 396

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 198 summaries

Database : ruidb:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	26	1.6	26	1	US-08-859-998-747
2	26	1.6	26	1	US-09-225-928-747
3	26	1.6	26	1	US-09-225-928-747
C 4	25	1.5	25	1	US-08-859-998-748
C 5	25	1.5	25	1	US-09-225-928-748
C 6	25	1.5	25	1	US-09-225-928-748
C 7	23	1.4	23	1	US-09-659-791A-5
8	21.8	1.3	25	1	US-09-396-196G-31760
9	21	1.3	21	1	US-08-410-540-21
10	21	1.3	21	1	US-09-659-791A-6
11	21	1.3	21	1	US-09-459-749D-14
12	20.6	1.3	21	1	US-09-657-472-2421
13	20.6	1.3	21	1	US-09-657-472-2422
14	20.6	1.3	21	1	US-09-657-472-2423
15	20.6	1.3	21	1	US-09-657-472-2424
16	20.2	1.2	25	1	US-09-396-196G-31758
C 17	20	1.2	20	1	US-09-659-791A-14
C 18	20	1.2	20	1	US-09-659-791A-15
C 19	20	1.2	20	1	US-09-659-791A-16
C 20	20	1.2	20	1	US-09-659-791A-17
C 21	20	1.2	20	1	US-09-659-791A-18
C 22	20	1.2	20	1	US-09-659-791A-19
C 23	20	1.2	20	1	US-09-659-791A-20
C 24	20	1.2	20	1	US-09-659-791A-21
C 25	20	1.2	20	1	US-09-659-791A-22
C 26	20	1.2	20	1	US-09-659-791A-23
C 27	20	1.2	20	1	US-09-659-791A-24
C 28	20	1.2	20	1	US-09-659-791A-25
C 29	20	1.2	20	1	US-09-659-791A-26
C 30	20	1.2	20	1	US-09-659-791A-27
C 31	20	1.2	20	1	US-09-659-791A-28
C 32	20	1.2	20	1	US-09-659-791A-29
C 33	20	1.2	20	1	US-09-659-791A-30

Sequence 31, Appl	1	US-09-659-791A-31	20	1.2	C 34
Sequence 32, Appl	1	US-09-659-791A-32	20	1.2	C 35
Sequence 33, Appl	1	US-09-659-791A-33	20	1.2	C 36
Sequence 34, Appl	1	US-09-659-791A-34	20	1.2	C 37
Sequence 35, Appl	1	US-09-659-791A-35	20	1.2	C 38
Sequence 36, Appl	1	US-09-659-791A-36	20	1.2	C 39
Sequence 37, Appl	1	US-09-659-791A-37	20	1.2	C 40
Sequence 38, Appl	1	US-09-659-791A-38	20	1.2	C 41
Sequence 39, Appl	1	US-09-659-791A-39	20	1.2	C 42
Sequence 40, Appl	1	US-09-659-791A-40	20	1.2	C 43
Sequence 41, Appl	1	US-09-659-791A-41	20	1.2	C 44
Sequence 42, Appl	1	US-09-659-791A-42	20	1.2	C 45
Sequence 43, Appl	1	US-09-659-791A-43	20	1.2	C 46
Sequence 44, Appl	1	US-09-659-791A-44	20	1.2	C 47
Sequence 45, Appl	1	US-09-659-791A-45	20	1.2	C 48
Sequence 46, Appl	1	US-09-659-791A-46	20	1.2	C 49
Sequence 47, Appl	1	US-09-659-791A-47	20	1.2	C 50
Sequence 48, Appl	1	US-09-659-791A-48	20	1.2	C 51
Sequence 49, Appl	1	US-09-659-791A-49	20	1.2	C 52
Sequence 50, Appl	1	US-09-659-791A-50	20	1.2	C 53
Sequence 51, Appl	1	US-09-659-791A-51	20	1.2	C 54
Sequence 52, Appl	1	US-09-659-791A-52	20	1.2	C 55
Sequence 53, Appl	1	US-09-659-791A-53	20	1.2	C 56
Sequence 54, Appl	1	US-09-659-791A-54	20	1.2	C 57
Sequence 55, Appl	1	US-09-659-791A-55	20	1.2	C 58
Sequence 56, Appl	1	US-09-659-791A-56	20	1.2	C 59
Sequence 57, Appl	1	US-09-659-791A-57	20	1.2	C 60
Sequence 58, Appl	1	US-09-659-791A-58	20	1.2	C 61
Sequence 59, Appl	1	US-09-659-791A-59	20	1.2	C 62
Sequence 60, Appl	1	US-09-659-791A-60	20	1.2	C 63
Sequence 61, Appl	1	US-09-659-791A-61	20	1.2	C 64
Sequence 62, Appl	1	US-09-659-791A-62	20	1.2	C 65
Sequence 63, Appl	1	US-09-659-791A-63	20	1.2	C 66
Sequence 64, Appl	1	US-09-659-791A-64	20	1.2	C 67
Sequence 65, Appl	1	US-09-659-791A-65	20	1.2	C 68
Sequence 66, Appl	1	US-09-659-791A-66	20	1.2	C 69
Sequence 67, Appl	1	US-09-659-791A-67	20	1.2	C 70
Sequence 68, Appl	1	US-09-659-791A-68	20	1.2	C 71
Sequence 69, Appl	1	US-09-659-791A-69	20	1.2	C 72
Sequence 70, Appl	1	US-09-659-791A-70	20	1.2	C 73
Sequence 71, Appl	1	US-09-659-791A-71	20	1.2	C 74
Sequence 72, Appl	1	US-09-659-791A-72	20	1.2	C 75
Sequence 73, Appl	1	US-09-659-791A-73	20	1.2	C 76
Sequence 74, Appl	1	US-09-659-791A-74	20	1.2	C 77
Sequence 75, Appl	1	US-09-659-791A-75	20	1.2	C 78
Sequence 76, Appl	1	US-09-659-791A-76	20	1.2	C 79
Sequence 77, Appl	1	US-09-659-791A-77	20	1.2	C 80
Sequence 78, Appl	1	US-09-659-791A-78	20	1.2	C 81
Sequence 79, Appl	1	US-09-659-791A-79	20	1.2	C 82
Sequence 80, Appl	1	US-09-659-791A-80	20	1.2	C 83
Sequence 81, Appl	1	US-08-855-449-10	18	1.1	C 84
Sequence 82, Appl	1	US-08-855-449-10	18	1.1	C 85
Sequence 83, Appl	1	US-08-855-449-10	18	1.1	C 86
Sequence 84, Appl	1	US-08-855-449-10	18	1.1	C 87
Sequence 85, Appl	1	US-08-855-449-10	18	1.1	C 88
Sequence 86, Appl	1	US-08-855-449-10	18	1.1	C 89
Sequence 87, Appl	1	US-08-855-449-10	18	1.1	C 90
Sequence 88, Appl	1	US-08-855-449-10	18	1.1	C 91
Sequence 89, Appl	1	US-08-855-449-10	18	1.1	C 92
Sequence 90, Appl	1	US-08-855-449-10	18	1.1	C 93
Sequence 91, Appl	1	US-08-855-449-10	18	1.1	C 94
Sequence 92, Appl	1	US-08-855-449-10	18	1.1	C 95
Sequence 93, Appl	1	US-08-855-449-10	18	1.1	C 96
Sequence 94, Appl	1	US-08-855-449-10	18	1.1	C 97
Sequence 95, Appl	1	US-08-855-449-10	18	1.1	C 98
Sequence 96, Appl	1	US-08-855-449-10	18	1.1	C 99
Sequence 97, Appl	1	US-08-855-449-10	18	1.1	C 100
Sequence 98, Appl	1	US-08-855-449-10	18	1.1	C 101
Sequence 99, Appl	1	US-08-855-449-10	18	1.1	C 102
Sequence 100, Appl	1	US-08-855-449-10	18	1.1	C 103
Sequence 101, Appl	1	US-08-855-449-10	18	1.1	C 104
Sequence 102, Appl	1	US-08-855-449-10	18	1.1	C 105
Sequence 103, Appl	1	US-08-855-449-10	18	1.1	C 106

C 107	14.4	0.9	17	1	US-09-866-108A-10037	Sequence 10037, A																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																															</
-------	------	-----	----	---	----------------------	-------------------	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	----



```

; Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
;
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
;
; ZIP: 94025
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FASTSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/225,201B
; FILING DATE: 05-Jan-1999
; CLASSIFICATION: <Unknown>
;
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/859,998
; FILING DATE: 21-MAY-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Field, Bret E.
; REGISTRATION NUMBER: 37,620
; REFERENCE/DOCKET NUMBER: 09096/002001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-322-5070
; TELEFAX: 415-854-0875
;
; INFORMATION FOR SEQ ID NO: 747:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; OTHER INFORMATION: oligonucleotide primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 747:
US-09-225-201B-747

Query Match 1.6%; Score 26; DB 1; Length 26;
Best Local Similarity 100.0%; Pred. No. 2.3;
Matches 26; Conservative 0; Mismatches 0; Indels

Qy 934 TCGGGATGAAGGACCAGTGTGACAAG 959
Db 1 TCGGGATGAAGGACCAGTGTGACAAG 26

RESULT 4
US-08-859-998-748/C
; Sequence 748, Application US/08859998
; Patent No. 5994076
; GENERAL INFORMATION:
; APPLICANT: Chenchik, Alex
; APPLICANT: Jokhadze, George
; APPLICANT: Bibilashvilli, Robert
; TITLE OF INVENTION: METHOD OF ASSAYING DIFFERENTIAL
; EXPRESSION
; NUMBER OF SEQUENCES: 1375
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 2200 Sand Hill Road, Suite 100
; CITY: Menlo Park
; STATE: CA
; COUNTRY: US
;
; ZIP: 94025
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95

```

```

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 3;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0

```

```
Qy 1190 GTACTATCTCGGGTCAACCGGTG 1214
Db 25 GTACTATCTCGGGTCAACCGGTG 1

RESULT 7
US-09-659-791A-5/c
; Sequence 5, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 5
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-09-659-791A-5
Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 5.4;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 789 CTTGAGATGATACACGAGGCTCA 811
Db 23 CTTGAGATGATACACGAGGCTCA 1

RESULT 8
US-09-396-196G-31760
; Sequence 31760, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31760
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31760
Query Match 1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 10;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1270 AGCTCTTTGACTCTGATCCCATCAC 1294
Db 1 AGCTTTTGACTCTGATCCCATCAC 25

RESULT 9
US-08-410-540-21
; Sequence 21, Application US/08410540
; Patent No. 5807878
; GENERAL INFORMATION:
; APPLICANT: Miller, Walter L.
; APPLICANT: Lin, Dong
; APPLICANT: Straus III, Jerome F.
; TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS
; TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooley Godward Castro Huddleson & Tatum
; STREET: 5 Palo Alto Square
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/410,540
; FILING DATE: 23-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Neeley, Richard L.
; REGISTRATION NUMBER: 30,092
; REFERENCE/DOCKET NUMBER: UCAL-238/000S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 853 5070
; TELEFAX: 415 857 0663
; TELEX: 380816CCOLEYPA
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-410-540-21
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1354 AGAAGCGCTGCAGGAATACC 1374
Db 1 AGAAGCGCTGCAGGAATACC 21

RESULT 10
US-09-659-791A-6
; Sequence 6, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Probe
US-09-659-791A-6
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 766 TCCACGCCATGTTCCAGCCCT 786
```

```

Db      1  TCCACGCCATGTTCCAGCCT 21
|||||
RESULT 11
US-09-459-749D-14
; Sequence 14, Application US/09459749D
; Patent No. 6464975
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/09/459,749D
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer_bind
; OTHER INFORMATION: synthetic sense primer based on porcine clusterin
US-09-459-749D-14
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 9.2;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      274  AAGCCAGAGAGAGAGAGAGG 294
|||||
Db      1  AAGCCAGAGAGAGAGAGAGG 21
|||||

RESULT 12
US-09-657-472-2421
; Sequence 2421, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2421
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2421
Query Match      1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1050  GAGAGGTTGACGAGGAATAC 1070
|||||
Db      1  GAGAGGTTGACGAGGAATAC 21
|||||

RESULT 13
US-09-657-472-2422
; Sequence 2422, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2422
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2422
Query Match      1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      999  CCTCTCCAGGCTAAGCTGCG 1019
|||||
Db      1  CCTCTCCAGGCTAAGCTGCG 21
|||||

RESULT 14
US-09-657-472-2423
; Sequence 2423, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolk, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2423
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2423
Query Match      1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy      1170  CTCACGCAAGCGAAGACCAG 1190
|||||
```

```
Db 1 CTCACGCAAGSCGAAGACCAG 21
|||||
RESULT 15
US-09-657-472-2424
; Sequence 2424, Application US/09657472
; Patent No. 6727063
; GENERAL INFORMATION:
; APPLICANT: Lander, Eric S.
; APPLICANT: Cargill, Michele
; APPLICANT: Ireland, James S.
; APPLICANT: Bolik, Stacey
; APPLICANT: Daley, George Q.
; APPLICANT: McCarthy, Jeanette J.
; TITLE OF INVENTION: SINGLE NUCLEOTIDE POLYMORPHISMS IN GENES
; FILE REFERENCE: 2825.1027-001
; CURRENT APPLICATION NUMBER: US/09/657,472
; CURRENT FILING DATE: 2000-09-07
; PRIOR APPLICATION NUMBER: US 60/153,357
; PRIOR FILING DATE: 1999-09-10
; PRIOR APPLICATION NUMBER: US 60/220,947
; PRIOR FILING DATE: 2000-07-26
; PRIOR APPLICATION NUMBER: US 60/225,724
; PRIOR FILING DATE: 2000-08-16
; NUMBER OF SEQ ID NOS: 2551
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 2424
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-657-472-2424

Query Match 1.3%; Score 20.6; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 11;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1105 TCACACCTCTCTCTGCTGG 1125
|||||
Db 1 TCACACCTCTCTCTGCTGG 21

RESULT 16
US-09-396-196G-31758
; Sequence 31758, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 31758
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-31758

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 18;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1171 TCACGCAAGGCGAAGACCAAGTACTA 1195
|||||
Db 1 TCACACAGGCGCAAGACCAAGTACTA 25

RESULT 17
US-09-659-791A-14/c
; Sequence 14, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 14
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-14

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 13 TGACCGAGCGCGTCAAAAGAC 32
|||||
Db 20 TGACCGAGCGCGTCAAAAGAC 1

RESULT 18
US-09-659-791A-15/c
; Sequence 15, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 15
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-15

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 21 GCGTGCAAGACTCCAGAAT 40
|||||
Db 20 GCGTGCAAGACTCCAGAAT 1

RESULT 19
US-09-659-791A-16/c
; Sequence 16, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 16
; LENGTH: 20
```

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-16

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 39 ATTGGAGGCATCATGAAGAC 58
Db 20 ATTGGAGGCATCATGAAGAC 1

RESULT 20
US-09-659-791A-17/c
; Sequence 17, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 17
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-17

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 77 GCTGCTGCTGACCTGGGAGA 96
Db 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 21
US-09-659-791A-18/c
; Sequence 18, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-18

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 101 GCAGGTCCTGGGGACCAGA 120
Db 20 GCAGGTCCTGGGGACCAGA 1

RESULT 22
US-09-659-791A-19/c
; Sequence 19, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-19

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 122 GGTCTCAGACAATGAGCTCC 141
Db 20 GGTCTCAGACAATGAGCTCC 1

RESULT 23
US-09-659-791A-20/c
; Sequence 20, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 20
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-20

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 149 GTCCAATCAGGGAAGTAAGT 168
Db 20 GTCCAATCAGGGAAGTAAGT 1

RESULT 24
US-09-659-791A-21/c
; Sequence 21, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 21
; LENGTH: 20
; TYPE: DNA
```

```

; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-21

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 166 AGTACGTCATAAGGAATT 185
Db 20 AGTACGTCATAAGGAATT 1

RESULT 25
US-09-659-791A-22/c
; Sequence 22, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 22
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-22

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 201 GGGGTGAACAGATAAGAC 220
Db 20 GGGGTGAACAGATAAGAC 1

RESULT 26
US-09-659-791A-23/c
; Sequence 23, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-23

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 281 GAAGAAGAAAGAGATGCC 300
Db 20 GAAGAAGAAAGAGATGCC 1

RESULT 27
US-09-659-791A-24/c
; Sequence 24, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-24

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 286 AGAAGAGGATGCCCTAAAT 305
Db 20 AGAAGAGGATGCCCTAAAT 1

RESULT 28
US-09-659-791A-25/c
; Sequence 25, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-25

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 298 CCCTAAATGAGACCGGAA 317
Db 20 CCCTAAATGAGACCGGAA 1

RESULT 29
US-09-659-791A-26/c
; Sequence 26, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-26

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 307 AGACCAGGGAATCAGAGACA 326
    |||||
Db 20 AGACCAGGGAATCAGAGACA 1

RESULT 30
US-09-659-791A-27/c
; Sequence 27, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-29

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 364 TGATGGCCCTCTGGGAGAG 383
    |||||
Db 20 TGATGGCCCTCTGGGAGAG 1

RESULT 33
US-09-659-791A-30/c
; Sequence 30, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 30
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-30

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 380 AGAGTGTAGCCCTGCCTGA 399
    |||||
Db 20 AGAGTGTAGCCCTGCCTGA 1

RESULT 34
US-09-659-791A-31/c
; Sequence 31, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 31
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
```

```
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-26

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 307 AGACCAGGGAATCAGAGACA 326
    |||||
Db 20 AGACCAGGGAATCAGAGACA 1

RESULT 30
US-09-659-791A-27/c
; Sequence 27, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 27
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-27

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 324 ACAAAGCTGAAGGAGCTCCC 343
    |||||
Db 20 ACAAAGCTGAAGGAGCTCCC 1

RESULT 31
US-09-659-791A-28/c
; Sequence 28, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 28
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-28

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 359 GACCATGATGGCCCTCTGGG 378
    |||||
Db 20 GACCATGATGGCCCTCTGGG 1

RESULT 32
US-09-659-791A-29/c
```



```
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-31

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 CTGCATGAAGTTCTACGCAC 426
      |||||
Db 20 CTGCATGAAGTTCTACGCAC 1

RESULT 35
US-09-659-791A-32/c
; Sequence 32, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-34

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 TGGCGCCGACGTTGAGGAGT 474
      |||||
Db 20 TGGCGCCGACGTTGAGGAGT 1

RESULT 38
US-09-659-791A-35/c
; Sequence 35, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 35
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-35

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACT 501
      |||||
Db 20 CCAGAGCTCGCCCTTCTACT 1

RESULT 39
US-09-659-791A-36/c
; Sequence 36, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 36
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;

; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-31

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 CTGCATGAAGTTCTACGCAC 426
      |||||
Db 20 CTGCATGAAGTTCTACGCAC 1

RESULT 35
US-09-659-791A-32/c
; Sequence 32, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 32
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-32

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 443 CTCAGGCTGTTGGCGGCC 462
      |||||
Db 20 CTCAGGCTGTTGGCGGCC 1

RESULT 36
US-09-659-791A-33/c
; Sequence 33, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-33

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 444 TCAGGCTGTTGGCGGCCA 463
      |||||
Db 20 TCAGGCTGTTGGCGGCCA 1

RESULT 37
US-09-659-791A-34/c
; Sequence 34, Application US/09659791A
```

```
US-09-659-791A-36
Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 CCCTTCTACTTCTGGATGAA 511
   |||||
Db 20 CCCTTCTACTTCTGGATGAA 1

RESULT 40
US-09-659-791A-37/c
; Sequence 37, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-37

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 517 ACCGCATCGACTCCCTGCTG 536
   |||||
Db 20 ACCGCATCGACTCCCTGCTG 1

RESULT 41
US-09-659-791A-38/c
; Sequence 38, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-38

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 533 GCTGGAGAACGACCGGCAGC 552
   |||||
Db 20 GCTGGAGAACGACCGGCAGC 1

RESULT 42
US-09-659-791A-39/c
; Sequence 39, Application US/09659791A
; Patent No. 6383808
```

```
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-39

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 551 GCAGACGCACATGCTGGATG 570
   |||||
Db 20 GCAGACGCACATGCTGGATG 1

RESULT 43
US-09-659-791A-40/c
; Sequence 40, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-40

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 553 AGACGCACATGCTGGATGTC 572
   |||||
Db 20 AGACGCACATGCTGGATGTC 1

RESULT 44
US-09-659-791A-41/c
; Sequence 41, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-41
```

```
Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 565 TGGATGTCATGCAGGACCAC 584
    |||||
Db 20 TGGATGTCATGCAGGACCAC 1

RESULT 45
US-09-659-791A-42/c
; Sequence 42, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-42

Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 567 GATGTCATGCAGGACCACTT 586
    |||||
Db 20 GATGTCATGCAGGACCACTT 1

RESULT 46
US-09-659-791A-43/c
; Sequence 43, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-43

Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 604 TCATAGACGAGCTCTTCCAG 623
    |||||
Db 20 TCATAGACGAGCTCTTCCAG 1

RESULT 47
US-09-659-791A-44/c
; Sequence 44, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
```

```
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-44

Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 608 AGACGAGCTCTTCCAGGACA 627
    |||||
Db 20 AGACGAGCTCTTCCAGGACA 1

RESULT 48
US-09-659-791A-45/c
; Sequence 45, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-45

Query Match      1.2%: Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 613 AGCTCTTCCAGGACAGGTTT 632
    |||||
Db 20 AGCTCTTCCAGGACAGGTTT 1

RESULT 49
US-09-659-791A-46/c
; Sequence 46, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-46
```

```
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 AGGCTCACTTCTTCTTCC 709
Db 20 AGGCTCACTTCTTCTTCC 1

RESULT 50
US-09-659-791A-47/c
; Sequence 47, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-47

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 TCGTCCGCGCTTGATGCC 740
Db 20 TCGTCCGCGCTTGATGCC 1

RESULT 51
US-09-659-791A-48/c
; Sequence 48, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-48

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 775 TGTTCAGCCCTTCCTTGAG 794
Db 20 TGTTCAGCCCTTCCTTGAG 1

RESULT 52
US-09-659-791A-49/c
; Sequence 49, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-49

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 776 GTTCCAGCCCTTCCTTGAGA 795
Db 20 GTTCCAGCCCTTCCTTGAGA 1

RESULT 53
US-09-659-791A-50/c
; Sequence 50, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-50

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 783 CCCTTCCTTGAGATGATACA 802
Db 20 CCCTTCCTTGAGATGATACA 1

RESULT 54
US-09-659-791A-51/c
; Sequence 51, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-51

Query Match      1.2%; Score 20; DB 1; Length 20;
```

```
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 54
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-54

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      820 TGGACATCCACTTCCACAGC 839
Db      20 TGGACATCCACTTCCACAGC 1

RESULT 55
US-09-659-791A-52/c
; Sequence 52, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-52

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      848 CCAGCACCCGCCAACAGAAAT 867
Db      20 CCAGCACCCGCCAACAGAAAT 1

RESULT 56
US-09-659-791A-53/c
; Sequence 53, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-53

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      853 ACCCGCCCAACAGAAATTCATA 872
Db      20 ACCCGCCCAACAGAAATTCATA 1

RESULT 57
US-09-659-791A-54/c
; Sequence 54, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-56

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      884 ACTGTGTGCGCGGAGATCCG 913
Db      20 ACTGTGTGCGCGGAGATCCG 1

RESULT 58
US-09-659-791A-55/c
; Sequence 55, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-55

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      893 GACTGTGTGCGCGGAGATCC 912
Db      20 GACTGTGTGCGCGGAGATCC 1

RESULT 59
US-09-659-791A-56/c
; Sequence 56, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-56

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      894 ACTGTGTGCGCGGAGATCCG 913
Db      20 ACTGTGTGCGCGGAGATCCG 1
```

Matches	20;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	906	GAGATCCGCCACAACTCCAC	925						
Db	20	GAGATCCGCCACAACTCCAC	1						
<p>RESULT 60</p> <p>US-09-659-791A-57/c</p> <p>; Sequence 57, Application US/09659791A</p> <p>; Patent No. 6383808</p> <p>; GENERAL INFORMATION:</p> <p>; APPLICANT: Brett P. Monia</p> <p>; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION</p> <p>; FILE REFERENCE: RTS-0156</p> <p>; CURRENT APPLICATION NUMBER: US/09/659,791A</p> <p>; CURRENT FILING DATE: 2000-09-11</p> <p>; NUMBER OF SEQ ID NOS: 90</p> <p>; SEQ ID NO 57</p> <p>; LENGTH: 20</p> <p>; TYPE: DNA</p> <p>; ORGANISM: Artificial Sequence</p> <p>; FEATURE:</p> <p>; OTHER INFORMATION: Antisense Oligonucleotide</p> <p>US-09-659-791A-57</p> <p>Query Match 1.2%; Score 20; DB 1; Length 20;</p> <p>Best Local Similarity 100.0%; Pred. No. 12;</p> <p>Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</p>									
QY	928	GCTGCTCGCGATGAAGGAC	947						
Db	20	GCTGCTCGCGATGAAGGAC	1						
<p>RESULT 61</p> <p>US-09-659-791A-58/c</p> <p>; Sequence 58, Application US/09659791A</p> <p>; Patent No. 6383808</p> <p>; GENERAL INFORMATION:</p> <p>; APPLICANT: Brett P. Monia</p> <p>; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION</p> <p>; FILE REFERENCE: RTS-0156</p> <p>; CURRENT APPLICATION NUMBER: US/09/659,791A</p> <p>; CURRENT FILING DATE: 2000-09-11</p> <p>; NUMBER OF SEQ ID NOS: 90</p> <p>; SEQ ID NO 58</p> <p>; LENGTH: 20</p> <p>; TYPE: DNA</p> <p>; ORGANISM: Artificial Sequence</p> <p>; FEATURE:</p> <p>; OTHER INFORMATION: Antisense Oligonucleotide</p> <p>US-09-659-791A-58</p> <p>Query Match 1.2%; Score 20; DB 1; Length 20;</p> <p>Best Local Similarity 100.0%; Pred. No. 12;</p> <p>Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;</p>									
QY	967	AGATCTTGCTGCTGACTGT	986						
Db	20	AGATCTTGCTGCTGACTGT	1						
<p>RESULT 62</p> <p>US-09-659-791A-59/c</p> <p>; Sequence 59, Application US/09659791A</p> <p>; Patent No. 6383808</p> <p>; GENERAL INFORMATION:</p> <p>; APPLICANT: Brett P. Monia</p> <p>; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION</p>									

```

; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 64
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-64

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1121 GCTGGAGCAGCTGAACGAGC 1140
          |||||
Db       20  GCTGGAGCAGCTGAACGAGC 1

RESULT 68
US-09-659-791A-65/c
; Sequence 65, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 65
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-65

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1148 CTGGGTGTCCCGCTGGCAA 1167
          |||||
Db       20  CTGGGTGTCCCGCTGGCAA 1

RESULT 69
US-09-659-791A-66/c
; Sequence 66, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-66

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

QY 1182 GAAGACCACTACTATCTGGC 1201  
| | | | | | | | | | | | | | | | | |  
Db 20 GAAGACCACTACTATCTGGC 1

RESULT 70  
US-09-659-791A-67/c  
; Sequence 67, Application US/09659791A  
; Patent No. 6383808  
; GENERAL INFORMATION:  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/09/659,791A  
; CURRENT FILING DATE: 2000-09-11  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 67  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-659-791A-67

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1194 TATCTGGGGTCAACACGGT 1213  
| | | | | | | | | | | | | | | | | |  
Db 20 TATCTGGGGTCAACACGGT 1

RESULT 71  
US-09-659-791A-68/c  
; Sequence 68, Application US/09659791A  
; Patent No. 6383808  
; GENERAL INFORMATION:  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/09/659,791A  
; CURRENT FILING DATE: 2000-09-11  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 68  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-659-791A-68

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1216 CTTCACACACTTCTGACTCG 1235  
| | | | | | | | | | | | | | | | | |  
Db 20 CTTCACACACTTCTGACTCG 1

RESULT 72  
US-09-659-791A-69/c  
; Sequence 69, Application US/09659791A  
; Patent No. 6383808  
; GENERAL INFORMATION:  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/09/659,791A

; CURRENT FILING DATE: 2000-09-11  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 69  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-659-791A-69

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1275 TTTGACTCTGATCCCATCAC 1294  
| | | | | | | | | | | | | | | | | |  
Db 20 TTTGACTCTGATCCCATCAC 1

RESULT 73  
US-09-659-791A-70/c  
; Sequence 70, Application US/09659791A  
; Patent No. 6383808  
; GENERAL INFORMATION:  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/09/659,791A  
; CURRENT FILING DATE: 2000-09-11  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 70  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-659-791A-70

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 CGGTCCCTGTAGAAGTCTCC 1319  
| | | | | | | | | | | | | | | | | |  
Db 20 CGGTCCCTGTAGAAGTCTCC 1

RESULT 74  
US-09-659-791A-71/c  
; Sequence 71, Application US/09659791A  
; Patent No. 6383808  
; GENERAL INFORMATION:  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/09/659,791A  
; CURRENT FILING DATE: 2000-09-11  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 71  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-09-659-791A-71

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 12;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1332 AAATTATGAGACCGTGGC 1351



```
Db      20 AAATTTATGAGACCGTGGC 1
|||||
RESULT 75
US-09-659-791A-72/c
; Sequence 72, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-72
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      1398 GATGTGGATGTTGCTTTTGC 1417
|||||
Db      20 GATGTGGATGTTGCTTTTGC 1
|||||
RESULT 76
US-09-659-791A-73/c
; Sequence 73, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-73
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      1545 GCTCTGGATCCTGCACCTTA 1564
|||||
Db      20 GCTCTGGATCCTGCACCTTA 1
|||||
RESULT 77
US-09-659-791A-74/c
; Sequence 74, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-74
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      1615 CTAATTCATATAAACTGTCT 1634
|||||
Db      20 CTAATTCATATAAACTGTCT 1
|||||
RESULT 78
US-09-659-791A-75/c
; Sequence 75, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-75
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      1615 CTAATTCATATAAACTGTCT 1634
|||||
Db      20 CTAATTCATATAAACTGTCT 1
|||||
RESULT 79
US-09-659-791A-78/c
; Sequence 78, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-78
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Qy      979 TGGACTCTTCCACCAAC 998
|||||
```

```
Db      20 TGGACTGTTCCACCAACAAC 1

RESULT 80
US-09-659-791A-80/c
; Sequence 80, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-791A-80

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 12;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1383 CACCGGAGGAGTGAGATGT 1402
        |||||
Db      20 CACCGGAGGAGTGAGATGT 1

RESULT 81
US-09-459-749D-13
; Sequence 13, Application US/09459749D
; Patent No. 6464875
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/09/459,749D
; CURRENT FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer_bind
; OTHER INFORMATION: synthetic antisense primer based on murine clusterin
US-09-459-749D-13

Query Match      1.2%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 17;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      271 AGAAGCCCAAGAAGAAGAAG 291
        |||||
Db      1 AGGAAGCCCAAGAAGAAGAAG 21

RESULT 82
US-08-855-449-10
; Sequence 10, Application US/08855449
; Patent No. 5910412
; GENERAL INFORMATION:
; APPLICANT: AKAMATSU, TOYOKAZU
; APPLICANT: SUZUKI, TAKAO
; TITLE OF INVENTION: METHOD FOR IDENTIFYING THE SEX OF
; TITLE OF INVENTION: SPINACH BY DNA MARKERS

; NUMBER OF SEQUENCES: 24
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
; ADDRESS: P. C.
; STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, SUITE 400
; CITY: ARLINGTON
; STATE: VA
; COUNTRY: USA
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/855,449
; FILING DATE: 13-MAY-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: JP 119124/1996
; FILING DATE: 14-MAY-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: OBLON, NORMAN F.
; REGISTRATION NUMBER: 24,618
; REFERENCE/DOCKET NUMBER: 7828-0003-0
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-413-3000
; TELEFAX: 703-413-2220
; INFORMATION FOR SEQ ID NO: 10:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 22 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "SYNTHETIC DNA"
US-08-855-449-10

Query Match      1.1%; Score 18.8; DB 1; Length 22;
Best Local Similarity 90.9%; Pred. No. 23;
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      865 AATTCATACGAGAGCGACGA 886
        |||||
Db      1 AATTCATACGAGAGCGTACGA 22

RESULT 83
US-08-410-540-22/c
; Sequence 22, Application US/08410540
; Patent No. 5807678
; GENERAL INFORMATION:
; APPLICANT: Miller, Walter L.
; APPLICANT: Lin, Dong
; TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS
; TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooley Godward Castro Huddleson & Tatum
; STREET: 5 Palo Alto Square
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/410,540
; FILING DATE: 23-MAR-1995
```

```
;
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Neeley, Richard L.
; REGISTRATION NUMBER: 30,092
; REFERENCE/DOCKET NUMBER: UCAL-238/000S
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 853 5070
; TELEFAX: 415 857 0663
; TELEX: 380816COOLEYPA
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-410-540-22

Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1475 GAGAGCTCTGCACGTCAC 1492
Db 18 GAGAGCTCTGCACGTCAC 1

RESULT 84
US-09-659-791A-4
; Sequence 4, Application US/09659791A
; Patent No. 6383808
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/09/659,791A
; CURRENT FILING DATE: 2000-09-11
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 4
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
; US-09-659-791A-4

Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCCGTACGAGCCCTGAA 763
Db 1 TCCGTACGAGCCCTGAA 18

RESULT 85
US-08-397-220B-43/c
; Sequence 43, Application US/08397220B
; Patent No. 6284458
; GENERAL INFORMATION:
; APPLICANT: Anderson et al.
; TITLE OF INVENTION: Compositions And Methods For Treatment Of Hepatitis C Virus-Associated Diseases
; NUMBER OF SEQUENCE: 98
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jane Massey Licata, Esq.
; STREET: 210 Lake Drive East, Suite 201
; CITY: Cherry Hill
; STATE: NJ
; COUNTRY: USA
```

```
;
; ZIP: 08002
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM 486
; OPERATING SYSTEM: WINDOWS FOR WORKGROUPS
; SOFTWARE: WORDPERFECT 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/397,220B
; FILING DATE: 09-Mar-1995
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/JP93/01293
; FILING DATE: 10-Sep-93
; APPLICATION NUMBER: JP 5-87195
; FILING DATE: 14-Apr-93
; APPLICATION NUMBER: 07/945,289
; FILING DATE: 10-Sep-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-0031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 43:
US-08-397-220B-43

Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1510 GCCTCCAGGCCCCCACTCC 1529
Db 20 GCCTCCAGGCCCCCACTCC 1

RESULT 86
US-08-650-093C-43/c
; Sequence 43, Application US/08650093C
; Patent No. 6391542
; GENERAL INFORMATION:
; APPLICANT: Kevin P. Anderson et al.
; TITLE OF INVENTION: Compositions And Methods For Treatment Of Hepatitis C Virus-Associated Diseases
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LICATA & TYRRELL P.C.
; STREET: 66 E. Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.1 for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/650,093C
; FILING DATE: 17-May-1996
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/452,841
; FILING DATE: May 30, 1995
; APPLICATION NUMBER: 08/397,220
; FILING DATE: March 9, 1995
```

```

; APPLICATION NUMBER: 07/945,289
; FILING DATE: September 10, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: Yes
; SEQUENCE DESCRIPTION: SEQ ID NO: 43:
US-08-650-093C-43

Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1510 GCCTCCAGGCCCCCACTCC 1529
Db 20 GCCTCCAGGCCCCCCCCCTCC 1

RESULT 87
US-10-023-649A-37/c
; Sequence 37, Application US/10023649A
; Patent No. 6800289
; GENERAL INFORMATION:
; APPLICANT: Nagata, Leslie P.
; APPLICANT: Wong, Jonathan P.
; TITLE OF INVENTION: A STRAIN OF THE WESTERN EQUINE ENCEPHALITIS VIRUS (AS AMENDED)
; FILE REFERENCE: NEL-001
; CURRENT APPLICATION NUMBER: US/10/023,649A
; CURRENT FILING DATE: 2001-12-21
; PRIOR FILING DATE: 2000-12-21
; NUMBER OF SEQ ID NOS: 49
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: DNA Primer
US-10-023-649A-37

Query Match 1.0%; Score 16.8; DB 1; Length 20;
Best Local Similarity 90.0%; Pred. No. 39;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 524 CCAGTCCCTGCTGGAGACG 543
Db 20 CCACACGCTGCTGGAGACG 1

RESULT 88
US-08-256-568B-97/c
; Sequence 97, Application US/08256568B
; Patent No. 5846704
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,369B
```

```

; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/256,568B
; FILING DATE: 18-JUL-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
US-08-256-568B-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1523
Db 16 CAGCCTCCAGGCCCC 1

RESULT 89
US-09-038-369B-97/c
; Sequence 97, Application US/09038369B
; Patent No. 6171784
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; TITLE OF INVENTION: ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,369B
```

```
;
; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-09-378-900A-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCTCCAGGCCCC 1523
Db 16 CAGCTCCAGGCCCC 1

RESULT 91
US-09-899-044-97/c
; Sequence 97, Application US/09899044
; Patent No. 6548244
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/899,044
; FILING DATE: 06-Jul-2001
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/378,900
; FILING DATE: <Unknown>
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
;

;
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-AUG-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
; US-09-378-900A-97

Query Match 1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 32;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCTCCAGGCCCC 1523
Db 16 CAGCTCCAGGCCCC 1

RESULT 90
US-09-378-900A-97/c
; Sequence 97, Application US/09378900A
; Patent No. 6495670
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/378,900A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-JUL-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: EP/93/402,129.6
```

INFORMATION FOR SEQ ID NO: 97:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: YES  
SEQUENCE DESCRIPTION: SEQ ID NO: 97:  
US-09-899-044-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 32;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCCC 1523  
DB 16 CAGCCTCCAGGCCCCC 1

RESULT 92  
US-08-173-489C-37  
; Sequence 37, Application US/08173489C  
; Patent No. 5861244  
; GENERAL INFORMATION:  
; APPLICANT: WANG, C. -G.  
; APPLICANT: HEPBURN, A. G.  
; TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA  
; TITLE OF INVENTION: TRIPLE-STRAND FORMATION.  
; NUMBER OF SEQUENCES: 365  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,  
; STREET: 510 EAST 73RD STREET,  
; CITY: NEW YORK  
; STATE: NEW YORK  
; COUNTRY: USA  
; ZIP: 10021.

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5 inch, 1.44Mb storage  
COMPUTER: IBM PC/XT/AT  
OPERATING SYSTEM: MS-DOS version 6.2  
SOFTWARE: Wordperfect Version 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/173,489C  
FILING DATE: 22 DEC 1993  
CLASSIFICATION: 435

PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/968,436  
FILING DATE: 29 OCT 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Handelman, Joseph H.  
REGISTRATION NUMBER: 26,179  
REFERENCE/DOCKET NUMBER: U9518-6  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (attorney) (212) 708-1880  
TELEFAX: (attorney) (212) 246-8959

INFORMATION FOR SEQ ID NO: 37:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: Nucleic Acid  
STRANDEDNESS: double stranded  
TOPOLOGY: linear

MOLECULE TYPE: Genomic DNA  
DESCRIPTION: dystrophin gene (Accession # M18533, 5983  
DESCRIPTION: M17154, M18026) nucleotides 5967 to 5983  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
POSITION IN GENOME: X-chromosome  
CHROMOSOME/SEGMENT: Xp21.3-p21.1  
MAP POSITION: Xp21.3-p21.1

PUBLICATION INFORMATION:  
AUTHORS: Koenig, M, Hoffman, E P, Bertelson, C J,  
AUTHORS: Monaco, A P, Feener, C, Kunkel, L M.  
TITLE: Complete cloning of the  
TITLE: Duchenne muscular dystrophy (DMD) cDNA and  
TITLE: preliminary genomic organization of the DMD  
TITLE: gene in normal and affected individuals  
JOURNAL: Cell  
VOLUME: 50  
PAGES: 509-517  
DATE: 1987  
AUTHORS: Hoffman, E P, Monaco, A P, Feener, C C,  
AUTHORS: Kunkel, L M.  
TITLE: Conservation of the Duchenne  
TITLE: muscular dystrophy gene in mice and humans  
JOURNAL: Science  
VOLUME: 238  
PAGES: 347-350  
DATE: 1987  
AUTHORS: Koenig, M, Monaco, A P, Kunkel, L M.  
TITLE: The complete sequence of  
TITLE: dystrophin predicts a rod-shaped cytoskeletal  
TITLE: protein  
JOURNAL: Cell  
VOLUME: 53  
PAGES: 219-228  
DATE: 1988  
RELEVANT RESIDUES IN SEQ ID NO: 37 :FROM 1 TO 17  
US-08-173-489C-37

Query Match 1.0%; Score 16; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 37;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAGAAAGAGCA 295  
DB 1 AGAAGAAGAAAGAGCA 16

RESULT 93  
US-08-390-850-535/c  
; Sequence 535, Application US/08390850  
; Patent No. 5612215  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSeq Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/390,850  
FILING DATE: February 17, 1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5612215ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 535:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-390-850-535

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 46;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAGATTGCTCC 1605  
Db 17 AAGAACAGATTGCTCC 1

RESULT 94

US-08-435-634-535/c  
Sequence 535, Application US/08435634  
Patent No. 5731295  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
APPLICANT: Pavco, Pamela  
APPLICANT: McSwiggen, James  
APPLICANT: Gustofson, John  
APPLICANT: Stinchcomb, Dan T.  
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
NUMBER OF SEQUENCES: 1151  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
SUITE: Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071

COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
MEDIUM TYPE: storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: FastSEQ Version 1.5  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/435,634  
FILING DATE: 05-MAY-1995  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/390,850  
FILING DATE: February 17, 1995  
APPLICATION NUMBER: 08/354,920  
FILING DATE: December 13, 1994  
APPLICATION NUMBER: 08/152,487  
FILING DATE: No. 5731295ember 12, 1993  
APPLICATION NUMBER: 07/989,848  
FILING DATE: December 7, 1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 211/084  
TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 535:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-435-634-535

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 46;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAGATTGCTCC 1605  
Db 17 AAGAACAGATTGCTCC 1

RESULT 95

US-09-866-108A-8666  
Sequence 8666, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8666  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8666

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 46;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAAGCCAAAGAGAGAA 289  
Db 1 GAAGCCAAAGAGAGAA 17

RESULT 96  
US-08-105-483-280/c  
; Sequence 280, Application US/08105483  
; Patent No. 5494807  
; GENERAL INFORMATION:  
; APPLICANT: Paoletti, Enzo  
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE  
; TITLE OF INVENTION: STRAIN  
; NUMBER OF SEQUENCES: 462  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Curtis, Morris & Safford  
; ADDRESSEE: c/o William S. Frommer  
; STREET: 530 Fifth Avenue  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/105,483  
; FILING DATE: 12-AUG-1993  
; CLASSIFICATION: 424  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/847,951  
; FILING DATE: 06-MAR-1992  
; NAME: Frommer, William S.  
; REGISTRATION NUMBER: 25,506  
; REFERENCE/DOCKET NUMBER: 454310-2400  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 840-3333  
; TELEFAX: (212) 840-0712  
; INFORMATION FOR SEQ ID NO: 280:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-105-483-280  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 63;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 222 CTCATAGAAAAAACAAAC 239  
DB 18 CTAATAGAAAAAACCAAC 1  
RESULT 97  
US-08-709-209-280/c  
; Sequence 280, Application US/08709209  
; Patent No. 5762938  
; GENERAL INFORMATION:  
; APPLICANT: Paoletti, Enzo  
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE  
; TITLE OF INVENTION: STRAIN  
; NUMBER OF SEQUENCES: 462  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Curtis, Morris & Safford  
; ADDRESSEE: c/o William S. Frommer  
; STREET: 530 Fifth Avenue  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036  
; COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/709,209  
FILING DATE: 21-AUG-1996  
CLASSIFICATION: 424  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/105,483  
FILING DATE: 12-AUG-1993  
APPLICATION NUMBER: US 07/847,951  
FILING DATE: 06-MAR-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Frommer, William S.  
REGISTRATION NUMBER: 25,506  
REFERENCE/DOCKET NUMBER: 454310-2400  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (212) 840-3333  
TELEFAX: (212) 840-0712  
INFORMATION FOR SEQ ID NO: 280:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 18 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-709-209-280  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 63;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 222 CTCATAGAAAAAACAAAC 239  
DB 18 CTAATAGAAAAAACCAAC 1  
RESULT 98  
US-08-458-101-280/c  
; Sequence 280, Application US/08458101  
; Patent No. 5766599  
; GENERAL INFORMATION:  
; APPLICANT: Paoletti, Enzo  
; APPLICANT: Perkus, Marion E.  
; APPLICANT: Taylor, Jill  
; APPLICANT: Tartaglia, James  
; APPLICANT: No. 5766599ton, Elizabeth K.  
; APPLICANT: Riviere, Michel  
; APPLICANT: de Taisne, Charles  
; APPLICANT: Limbach, Keith J.  
; APPLICANT: Johnson, Gerard P.  
; APPLICANT: Pincus, Steven E.  
; APPLICANT: Cox, William I.  
; APPLICANT: Audonnet, Jean-Christophe Francis  
; APPLICANT: Gettig, Russell Robert  
; TITLE OF INVENTION: GENETICALLY ENGINEERED VACCINE  
; TITLE OF INVENTION: STRAIN  
; NUMBER OF SEQUENCES: 467  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Curtis, Morris & Safford  
; ADDRESSEE: c/o William S. Frommer  
; STREET: 530 Fifth Avenue  
; CITY: New York  
; STATE: NY  
; COUNTRY: USA  
; ZIP: 10036  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/458,101



; TOPOLOGY: linear  
; US-08-758-306-953  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 63;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1121 GCTGAGACGAGCTGAACGA 1138  
DB 18 GCAGGAGCAGCTGAAGGA 1  
RESULT 100  
US-08-390-850-536/c  
; Sequence 536, Application US/08390850  
; Patent No. 5612215  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSeq Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/390,850  
; FILING DATE: February 17, 1995  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/354,920  
; FILING DATE: December 13, 1994  
; APPLICATION NUMBER: 08/152,487  
; FILING DATE: No. 5612215ember 12, 1993  
; APPLICATION NUMBER: 07/989,848  
; FILING DATE: December 7, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 211/084  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 536:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-390-850-536  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 65;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1589 AAGAACAAGATTCCTC 1604  
DB 16 AAGAACAAGATTCCTC 1

; FILING DATE: 01-JUN-1995  
; CLASSIFICATION: 424  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Frommer, William S.  
; REGISTRATION NUMBER: 25,506  
; REFERENCE/DOCKET NUMBER: 454310-2740  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 840-3333  
; TELEFAX: (212) 840-0712  
; INFORMATION FOR SEQ ID NO: 280:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-458-101-280  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 63;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 222 CTCATAGAAAAAACAAC 239  
DB 18 CTAATAGAAAAAACCAAC 1  
RESULT 99  
US-08-758-306-953/c  
; Sequence 953, Application US/08758306  
; Patent No. 5807743  
; GENERAL INFORMATION:  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: McSwiggen, James A.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES  
; TITLE OF INVENTION: ASSOCIATED WITH  
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR  
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION  
; NUMBER OF SEQUENCES: 1379  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSeq Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/758,306  
; FILING DATE: December 3, 1996  
; CLASSIFICATION: 514  
; INFORMATION FOR SEQ ID NO: 953:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 18 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single

RESULT 101  
US-08-435-634-536/c  
; Sequence 536, Application US/08435634  
; Patent No. 5731295  
; GENERAL INFORMATION:  
; APPLICANT: Draper, Kenneth G.  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggan, James  
; APPLICANT: Gustofson, John  
; APPLICANT: Stinchcomb, Dan T.  
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT  
; OF ARTHRITIC CONDITIONS  
; NUMBER OF SEQUENCES: 1151  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: FastSeq Version 1.5  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/435,634  
; FILING DATE: 05-MAY-1995  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/390,850  
; FILING DATE: February 17, 1995  
; APPLICATION NUMBER: 08/354,920  
; FILING DATE: December 13, 1994  
; APPLICATION NUMBER: 08/152,487  
; FILING DATE: No. 5731295, September 12, 1993  
; APPLICATION NUMBER: 07/989,848  
; FILING DATE: December 7, 1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 211/084  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 536:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-435-634-536

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 65;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGACAGAAATTCCTC 1604  
DB 16 AAGACAGAAATTCCTC 1

RESULT 102  
US-09-282-146-7  
; Sequence 7, Application US/09282146A  
; Patent No. 6303847  
; GENERAL INFORMATION:  
; APPLICANT: KAWAOKA, Akiyoshi  
; APPLICANT: EBINUMA, Hiroyasu

; TITLE OF INVENTION: TRANSCRIPTION FACTOR CONTROLLING PHENYLPROPANOID  
; FILE REFERENCE: 4859-0027-0  
; CURRENT APPLICATION NUMBER: US/09/282,146A  
; CURRENT FILING DATE: 1999-03-31  
; EARLIER APPLICATION NUMBER: JP 10-125171  
; EARLIER FILING DATE: 1998-03-31  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: Patentin Ver. 2.1  
; SEQ ID NO 7  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA  
; US-09-282-146-7

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 65;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCAACACCTCTCTCT 1119  
DB 2 CTCAACACCTCTCTCT 17

RESULT 103  
US-09-866-108A-8352/c  
; Sequence 8352, Application US/09866108A  
; Patent No. 6686188  
; GENERAL INFORMATION:  
; APPLICANT: GU, Yizhong  
; APPLICANT: JI, Yonggang  
; APPLICANT: PENN, Sharron G.  
; APPLICANT: HANZEL, David K.  
; APPLICANT: RANK, David R.  
; APPLICANT: CHEN, Wensheng  
; APPLICANT: SHANNON, Mark  
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
; FILE REFERENCE: AEOMICA-7  
; CURRENT APPLICATION NUMBER: US/09/866,108A  
; CURRENT FILING DATE: 2001-05-25  
; PRIOR APPLICATION NUMBER: US 60/207,456  
; PRIOR FILING DATE: 2000-05-26  
; PRIOR APPLICATION NUMBER: GB 24263.6  
; PRIOR FILING DATE: 2000-10-04  
; PRIOR APPLICATION NUMBER: US 60/236,359  
; PRIOR FILING DATE: 2000-09-27  
; PRIOR APPLICATION NUMBER: PCT/US01/00666  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aeomica Sequence Listing Engine  
; Patent No. 6686188  
; SEQ ID NO 8352  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; US-09-866-108A-8352

Query Match 0.9%; Score 14.4; DB 1; Length 17;

```
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1109 CACCTCTCTCTGCTG 1124
Db 17 CAGCTCTCTCTGCTG 2

RESULT 104
US-09-866-108A-8353/C
; Sequence 8353, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8353

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 273 GAAGCCCAAGAAGA 288
Db 2 GAAGCCCAAGAAGA 17

RESULT 106
US-09-866-108A-8667
; Sequence 8667, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8353

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1109 CACCTCTCTCTGCTG 1124
Db 16 CAGCTCTCTCTGCTG 1

RESULT 105
US-09-866-108A-8665
; Sequence 8665, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8667

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 274 AAGCCAGAGAGAGAA 289
Db 1 AAGCCAGAGAGAGAA 16

RESULT 107
US-09-866-108A-10037/c
; Sequence 10037, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10037
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10037

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 715 CCGCATCGTCCGAC 730
Db 17 CCGCATCGTCCACAG 2

RESULT 108
US-09-866-108A-10038/c
; Sequence 10038, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AECOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 10038
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-10038

Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 65;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 715 CCGCATCGTCCGAC 730
Db 16 CCGCATCGTCCACAG 1

RESULT 109
US-08-117-952-797/c
; Sequence 797, Application US/08117952
; Patent No. 5851760
; GENERAL INFORMATION:
; APPLICANT: Evans, Glen A.
; APPLICANT: Smith, Michael W.
; TITLE OF INVENTION: METHOD FOR GENERATION OF SEQUENCE
; TITLE OF INVENTION: SAMPLED MAPS OF COMPLEX GENOMES

Mon Nov 7 09:26:59 2005

```
;
; NUMBER OF SEQUENCES: 797
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
; STREET: 444 South Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,952
; FILING DATE: 07-SEP-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/078,471
; FILING DATE: 15-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Reiter, Stephen E.
; REGISTRATION NUMBER: 31,192
; REFERENCE/DOCKET NUMBER: F41 9423
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-546-4737
; TELEFAX: 619-546-9392
; INFORMATION FOR SEQ ID NO: 797:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Oligonucleotide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-117-952-797

Query Match 0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 73;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1520 CCCCACTCCGCCAG 1535
Db 18 CCCTACTCCGCCAG 3

RESULT 110
US-08-758-306-467
; Sequence 467, Application US/08/58306
; Patent No. 580743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0

;
; NUMBER OF SEQUENCES: 797
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark
; STREET: 444 South Flower Street, Suite 2000
; CITY: Los Angeles
; STATE: CA
; COUNTRY: USA
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/117,952
; FILING DATE: 07-SEP-1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/078,471
; FILING DATE: 15-JUN-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Reiter, Stephen E.
; REGISTRATION NUMBER: 31,192
; REFERENCE/DOCKET NUMBER: F41 9423
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-546-4737
; TELEFAX: 619-546-9392
; INFORMATION FOR SEQ ID NO: 797:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Oligonucleotide
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-117-952-797

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 80;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

Qy 693 CCTCACTTCTTCTTCC 709
Db 1 CCUCCUCCUCCUCCUCC 17

RESULT 111
US-08-599-455B-25
; Sequence 25, Application US/08/599455B
; Patent No. 5972621
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS THAT
; TITLE OF INVENTION: MODULATE BODY WEIGHT USING THE OB RECEPTOR
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/599,455B
; FILING DATE: 22-JAN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Weiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
```

```

; REFERENCE/DOCKET NUMBER: 07334/017001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-599-455B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676
Db 1 CACTATTGGCCCTTCAG 17

RESULT 112
US-08-599-455B-27
; Sequence 27, Application US/08599455B
; Patent No. 5972621
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; TITLE OF INVENTION: METHODS OF IDENTIFYING COMPOUNDS THAT
; TITLE OF INVENTION: MODULATE BODY WEIGHT USING THE OB RECEPTOR
; NUMBER OF SEQUENCES: 44
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/599,455B
; FILING DATE: 22-JAN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/017001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

; REFERENCE/DOCKET NUMBER: 07334/017001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 21:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-474-700B-21

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTCATAGAAAAACAAA 238
Db 17 CTCAGAGAAAAACAAA 1

RESULT 114
US-08-757-024-874/c
; Sequence 874, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
```

Mon Nov 7 09:26:59 2005

```

; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 874:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-757-024-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCCAGCCTCTCCCGC 1546
Db 17 GCCCAGCCTGTGCCGC 1

RESULT 116
US-09-069-781B-25
; Sequence 25, Application US/09069781B
; Patent No. 6287782
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Cuipepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/069,781B
; FILING DATE: 29-APRIL-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: US 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: US 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: US 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: US 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: US 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: US 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: US 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: US 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/082001
; TELECOMMUNICATION INFORMATION:

; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:

```

TELEPHONE: (617) 542-5070  
TELEFAX: (617) 542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-09-069-781B-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
||||| |||||  
Db 1 CACTATTGCCCTTCAG 17

RESULT 118  
US-08-584-040-7759  
; Sequence 7759, Application US/08584040  
; Patent No. 6346398  
; GENERAL INFORMATION:  
; APPLICANT: Pavco, Pamela  
; APPLICANT: McSwiggen, James  
; APPLICANT: Stinchcomb, Dan T.  
; APPLICANT: Escobedo, Jaime  
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE  
; TITLE OF INVENTION: TREATMENT OF DISEASES OR  
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS  
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL  
; TITLE OF INVENTION: GROWTH FACTOR  
; NUMBER OF SEQUENCES: 8502  
; CORRESPONDENCE ADDRESS:  
; ADDRESSER: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: Storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/584,040  
; FILING DATE: January 11, 1996  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/005,974  
; FILING DATE: October 26, 1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 218/064  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 7759:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; US-08-584-040-7759

TELEPHONE: (617) 542-5070  
TELEFAX: (617) 542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-09-069-781B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
||||| |||||  
Db 1 CACTATTGCCCTTCAG 17

RESULT 117  
US-09-069-781B-27  
; Sequence 27, Application US/09069781B  
; Patent No. 6287782  
; GENERAL INFORMATION:  
; APPLICANT: Tartaglia, Louis A.  
; APPLICANT: Tepper, Robert I.  
; APPLICANT: Culpepper, Janice A.  
; APPLICANT: White, David W.  
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/069,781B  
; FILING DATE: 29-APRIL-1998  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/864,564  
; FILING DATE: 28-MAY-1997  
; APPLICATION NUMBER: US 08/708,123  
; FILING DATE: 03-SEP-1996  
; APPLICATION NUMBER: US 08/638,524  
; FILING DATE: 26-APR-1996  
; APPLICATION NUMBER: US 08/599,455  
; FILING DATE: 22-JAN-1996  
; APPLICATION NUMBER: US 08/583,153  
; FILING DATE: 28-DEC-1995  
; APPLICATION NUMBER: US 08/570,142  
; FILING DATE: 11-DEC-1995  
; APPLICATION NUMBER: US 08/569,485  
; FILING DATE: 08-DEC-1995  
; APPLICATION NUMBER: US 08/566,622  
; FILING DATE: 04-DEC-1995  
; APPLICATION NUMBER: US 08/562,663  
; FILING DATE: 27-NOV-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meiklejohn, Ph.D., Anita L.  
; REGISTRATION NUMBER: 35,283  
; REFERENCE/DOCKET NUMBER: 07334/082001  
; TELECOMMUNICATION INFORMATION:



Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 64.7%; Pred. No. 80;  
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 1112 CTCCTCTTCTGTCGAGC 1128  
Db 1 CUCGCCCUUGCUGAAGC 17

RESULT 119

US-08-679-645-687/c  
; Sequence 687, Application US/08679645  
; Patent No. 6350934  
; GENERAL INFORMATION:  
; APPLICANT: Zwick, Michael G.  
; APPLICANT: Edington, Brent E.  
; APPLICANT: McSwiggan, James A.  
; APPLICANT: Merlo, Patricia Ann Owens  
; APPLICANT: Guo, Lining  
; APPLICANT: Skokut, Thomas A.  
; APPLICANT: Young, Scott A.  
; APPLICANT: Folkerts, Otto  
; APPLICANT: Merlo, Donald J.  
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR  
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION  
; TITLE OF INVENTION: IN PLANTS  
; NUMBER OF SEQUENCES: 1263  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071-2066  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/679,645  
; FILING DATE: July 12, 1996  
; CLASSIFICATION: 800  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 60/001,135  
; FILING DATE: July 13, 1995  
; APPLICATION NUMBER: 08/300,726  
; FILING DATE: September 2, 1994  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard J.  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 219/247  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 687:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-679-645-687

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1213 TGGCTTCCCACTTCT 1229  
Db 17 TGGTGCCCACTTCT 1

RESULT 120

US-09-137-132-25  
; Sequence 25, Application US/09137132  
; Patent No. 6380363  
; GENERAL INFORMATION:  
; APPLICANT: Tartaglia, Louis A.  
; APPLICANT: Tepper, Robert I.  
; APPLICANT: Culpepper, Janice A.  
; APPLICANT: White, David W.  
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/137,132  
; FILING DATE: 18-AUG-1998  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/864,564  
; FILING DATE: 28-MAY-1997  
; APPLICATION NUMBER: 08/708,123  
; FILING DATE: 03-SEP-1996  
; APPLICATION NUMBER: 08/638,524  
; FILING DATE: 26-APR-1996  
; APPLICATION NUMBER: 08/599,455  
; FILING DATE: 22-JAN-1996  
; APPLICATION NUMBER: 08/583,153  
; FILING DATE: 28-DEC-1995  
; APPLICATION NUMBER: 08/570,142  
; FILING DATE: 11-DEC-1995  
; APPLICATION NUMBER: 08/569,485  
; FILING DATE: 08-DEC-1995  
; APPLICATION NUMBER: 08/566,622  
; FILING DATE: 04-DEC-1995  
; APPLICATION NUMBER: 08/562,663  
; FILING DATE: 27-NOV-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meiklejohn, Ph.D., Anita L.  
; REGISTRATION NUMBER: 35,283  
; REFERENCE/DOCKET NUMBER: 07334/019004  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-542-5070  
; TELEFAX: 617-542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
US-09-137-132-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACTTGGCCTTCAG 676  
Db 1 CACTATTGGCCTTCAG 17

RESULT 121  
US-09-137-132-27  
; Sequence 27, Application US/09137132  
; Patent No. 6380363  
; GENERAL INFORMATION:  
; APPLICANT: Tartaglia, Louis A.  
; APPLICANT: Tepper, Robert I.  
; APPLICANT: Culpepper, Janice A.  
; APPLICANT: White, David W.  
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/137,132  
; FILING DATE: 18-AUG-1998  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/864,564  
; FILING DATE: 28-MAY-1997  
; APPLICATION NUMBER: 08/708,123  
; FILING DATE: 03-SEP-1996  
; APPLICATION NUMBER: 08/638,524  
; FILING DATE: 26-APR-1996  
; APPLICATION NUMBER: 08/599,455  
; FILING DATE: 22-JAN-1996  
; APPLICATION NUMBER: 08/583,153  
; FILING DATE: 28-DEC-1995  
; APPLICATION NUMBER: 08/570,142  
; FILING DATE: 11-DEC-1995  
; APPLICATION NUMBER: 08/569,485  
; FILING DATE: 08-DEC-1995  
; APPLICATION NUMBER: 08/566,622  
; FILING DATE: 04-DEC-1995  
; APPLICATION NUMBER: 08/562,663  
; FILING DATE: 27-NOV-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meiklejohn, Ph.D., Anita L.  
; REGISTRATION NUMBER: 35,283  
; REFERENCE/DOCKET NUMBER: 07334/019004  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-542-5070  
; TELEFAX: 617-542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 27:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
US-09-137-132-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
|||||  
Db 1 CACTATTGCCCTTCAG 17

RESULT 122  
US-08-864-564A-25  
; Sequence 25, Application US/08864564A  
; Patent No. 6395498  
; GENERAL INFORMATION:  
; APPLICANT: Tartaglia, Louis A.  
; APPLICANT: Tepper, Robert I.  
; APPLICANT: Culpepper, Janice A.  
; APPLICANT: White, David W.  
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
; NUMBER OF SEQUENCES: 50  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Fish & Richardson, P.C.  
; STREET: 225 Franklin Street  
; CITY: Boston  
; STATE: MA  
; COUNTRY: US  
; ZIP: 02110-2804  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Diskette  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: Windows95  
; SOFTWARE: FastSeq for Windows Version 2.0  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/864,564A  
; FILING DATE: 28-MAY-1997  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 08/708,123  
; FILING DATE: 03-SEP-1996  
; APPLICATION NUMBER: 08/638,524  
; FILING DATE: 26-APR-1996  
; APPLICATION NUMBER: 08/599,455  
; FILING DATE: 22-JAN-1996  
; APPLICATION NUMBER: 08/583,153  
; FILING DATE: 28-DEC-1995  
; APPLICATION NUMBER: 08/570,142  
; FILING DATE: 11-DEC-1995  
; APPLICATION NUMBER: 08/569,485  
; FILING DATE: 08-DEC-1995  
; APPLICATION NUMBER: 08/566,622  
; FILING DATE: 04-DEC-1995  
; APPLICATION NUMBER: 08/562,663  
; FILING DATE: 27-NOV-1995  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Meiklejohn, Ph.D., Anita L.  
; REGISTRATION NUMBER: 35,283  
; REFERENCE/DOCKET NUMBER: 07334/019002  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 617-542-5070  
; TELEFAX: 617-542-8906  
; TELEX: 200154  
; INFORMATION FOR SEQ ID NO: 25:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA  
US-08-864-564A-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
|||||  
Db 1 CACTATTGCCCTTCAG 17

```

; Sequence 25, Application US/09094410
; Patent No. 6403552
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,410
; FILING DATE: 09-JUN-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-09-094-410-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTGCGCTTCAG 17

RESULT 125
US-09-094-410-27

```

```

; Sequence 27, Application US/08864564A
; Patent No. 6395498
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/864,564A
; FILING DATE: 28-MAY-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-864-564A-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTGCGCTTCAG 17

RESULT 124
US-09-094-410-25

```

```
; Sequence 27, Application US/09094410
; Patent No. 6403552
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/094,410
; FILING DATE: 09-JUN-1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/864,564
; FILING DATE: 28-MAY-1997
; APPLICATION NUMBER: 08/708,123
; FILING DATE: 03-SEP-1996
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019003
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 27:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-09-094-410-27
;
; Query Match 0.8%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 88.2%; Pred. No. 80;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; Qy 660 CACTACCTGCCCTTCAG 676
; Db 1 CACTATTTCCTTCAG 17
;
; RESULT 126
; US-08-708-123D-25
; Sequence 27, Application US/08708123D
; Patent No. 6482927
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
; APPLICANT: Tepper, Robert I.
; APPLICANT: Culpepper, Janice A.
; APPLICANT: White, David W.
; TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR
; TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,
; TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson, P.C.
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: MA
; COUNTRY: US
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows95
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/708,123D
; FILING DATE: 03-SEP-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/638,524
; FILING DATE: 26-APR-1996
; APPLICATION NUMBER: 08/599,455
; FILING DATE: 22-JAN-1996
; APPLICATION NUMBER: 08/583,153
; FILING DATE: 28-DEC-1995
; APPLICATION NUMBER: 08/570,142
; FILING DATE: 11-DEC-1995
; APPLICATION NUMBER: 08/569,485
; FILING DATE: 08-DEC-1995
; APPLICATION NUMBER: 08/566,622
; FILING DATE: 04-DEC-1995
; APPLICATION NUMBER: 08/562,663
; FILING DATE: 27-NOV-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Meiklejohn, Ph.D., Anita L.
; REGISTRATION NUMBER: 35,283
; REFERENCE/DOCKET NUMBER: 07334/019001
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-542-5070
; TELEFAX: 617-542-8906
; TELEX: 200154
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-708-123D-25
;
; Query Match 0.8%; Score 13.8; DB 1; Length 17;
; Best Local Similarity 88.2%; Pred. No. 80;
; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
;
; Qy 660 CACTACCTGCCCTTCAG 676
; Db 1 CACTATTTCCTTCAG 17
;
; RESULT 127
; US-08-708-123D-27
; Sequence 27, Application US/08708123D
; Patent No. 6482927
; GENERAL INFORMATION:
; APPLICANT: Tartaglia, Louis A.
```

APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
APPLICANT: White, David W.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/708,123D  
FILING DATE: 03-SEP-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/638,524  
FILING DATE: 26-APR-1996  
APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153  
FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Meiklejohn, Ph.D., Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/019001  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-708-123D-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACTGCGCCTTCAG 676  
Db 1 CACTATTGCGCCTTCAG 17

RESULT 128  
US-08-583-153A-25  
Sequence 25, Application US/08583153A  
Patent No. 6506877  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE  
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING

TITLE OF INVENTION: OBESITY AND CACHEXIA  
NUMBER OF SEQUENCES: 41  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/583,153A  
FILING DATE: 28-DEC-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Meiklejohn, Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/016001  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-583-153A-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACTGCGCCTTCAG 676  
Db 1 CACTATTGCGCCTTCAG 17

RESULT 129  
US-08-583-153A-27  
Sequence 27, Application US/08583153A  
Patent No. 6506877  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE  
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING

COMPUTER: IBM Compatible  
OPERATING SYSTEM: DOS  
SOFTWARE: FastSeq Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/583,153A  
FILING DATE: 28-DEC-1995  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Meiklejohn, Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/016001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-583-153A-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
||||| |||||||  
Db 1 CACTATTGCCCTTCAG 17

RESULT 130  
US-08-524B-25  
Sequence 25, Application US/08638524B  
Patent No. 6548269  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE  
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING OB  
TITLE OF INVENTION: CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/638,524B  
FILING DATE: 26-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153

FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Meiklejohn, Ph.D., Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/018001  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-08-638-524B-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
||||| |||||||  
Db 1 CACTATTGCCCTTCAG 17

RESULT 131  
US-08-524B-27  
Sequence 27, Application US/08638524B  
Patent No. 6548269  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
APPLICANT: White, David W.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR THE  
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS, INCLUDING OB  
TITLE OF INVENTION: CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/638,524B  
FILING DATE: 26-APR-1996  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153  
FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622



```

; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7355
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7355

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAAGAAGCCCAAGAGAA 286
DB 1 GAAGAAGCCCAAGAGAA 17

RESULT 137
US-09-866-108A-7485/c
; Sequence 7485, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30

QY 845 CTTCCAGCACCGCCAA 861
DB 17 CTTCCAGCACCGCCAA 1

RESULT 136
US-09-866-108A-7355
; Sequence 7355, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2643
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2643

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 CTTCCAGCACCGCCAA 861
DB 17 CTTCCAGCACCGCCAA 1

RESULT 136
US-09-866-108A-7355
; Sequence 7355, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; SOFTWARE: Aecomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 2643
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-2643
```



; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-7485

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCAGCCTCTCCCGC 1546
Db 17 GTCCAGCCTCTCTCGC 1

RESULT 138
US-09-866-108A-8568
; Sequence 8568, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8568
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens

US-09-866-108A-8568

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 292 AGGATGCCCTAAATGAG 308
Db 1 AGGATGACCTGAATGAG 17

RESULT 139
US-09-866-108A-8660
; Sequence 8660, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Acomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 8660
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-8660

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 267 CTGAGAGAGCCCAAGAA 283
Db 1 CTGAGAGAGCCCAAGAA 17

RESULT 140
US-09-866-108A-8661
; Sequence 8661, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang

APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8661  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8661

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 89.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 TAGAAGAGCCCAAGAG 284  
DB 1 TGGAGGAAGCCCAAGAG 17

RESULT 141  
US-09-866-108A-8663  
Sequence 8663, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8661  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8661

PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8663  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8663

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 80;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAGGAAGCCCAAGAGAA 286  
DB 1 GAGGAAGCCCAAGAGGA 17

RESULT 142  
US-09-866-108A-8664  
Sequence 8664, Application US/09866108A  
Patent No. 6686188  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharron G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: AEOMICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108A  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
Patent No. 6686188  
SEQ ID NO 8664  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108A-8664

```
; ORGANISM: Homo sapiens
US-09-866-108A-8664

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCAGAGAAG 287
Db 1 AGGAAGCCAGAGAAG 17

RESULT 143
US-09-866-108A-9687/c
; Sequence 9687, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9687
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9687

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCAGGTCT 109
Db 17 GAGAGTGGCAGGTCT 1

RESULT 144
US-09-866-108A-9688/c
; Sequence 9688, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
```

```
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; Patent No. 6686188
; SEQ ID NO 9688
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9688

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 92 GGAGAGTGGCAGGTCC 108
Db 17 GGAGAGTGGCAGGTCC 1

RESULT 145
US-09-866-108A-9689/c
; Sequence 9689, Application US/09866108A
; Patent No. 6686188
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108A
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
```

; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aemica Sequence Listing Engine
; Patent No. 686188
; SEQ ID NO 9689
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108A-9689

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GGGAGAGTGGCGAGTC 107
| | | | | | | | | | | | | | | | |
Db 17 GGGAGAGTGGCGAGTC 1

RESULT 146
US-09-685-664B-3543
; Sequence 3543, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Endothelial Growth Factor Receptor
; FILE REFERENCE: MEH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3543
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus musculus
US-09-685-664B-3543

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 80;
Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 1112 CTCCTCCTTGCGAGC 1128
| | | | | | | | | | | | | | | | |
Db 1 CUCCCCUUGCUGAGC 17

RESULT 147
US-09-093-972C-874/c
; Sequence 874, Application US/09093972C
; Patent No. 6825174

; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 08512
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/093,972C
; FILING DATE: 09-Jun-1998
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 08/757,024
; FILING DATE: 26-11-1996
; APPLICATION NUMBER: US 08/472,527
; FILING DATE: 7-June-1995
; APPLICATION NUMBER: US 09/016,464
; FILING DATE: 30-January-1998
; ATTORNEY/AGENT INFORMATION:
; NAME: Amzel, Viviana
; REGISTRATION NUMBER: 30,930
; REFERENCE/DOCKET NUMBER: EPI-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 874:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 874:
US-09-093-972C-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 80;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546
| | | | | | | | | | | | | | | | |
Db 17 GCCCAGCCTGTGCCGC 1

RESULT 148
US-09-093-972C-944/c
; Sequence 944, Application US/09093972C
; Patent No. 6825174
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey

COUNTRY: USA  
 ZIP: 08512  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC Compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent in Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 FILING DATE: 09-Jun-1998  
 FILING DATE: 09-Jun-1998  
 CLASSIFICATION: <Unknown>  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 08/472,527  
 FILING DATE: 7-June-1995  
 APPLICATION NUMBER: US 08/757,024  
 FILING DATE: 26-11-1996  
 APPLICATION NUMBER: US 08/472,527  
 FILING DATE: 7-June-1995  
 APPLICATION NUMBER: US 09/016,464  
 FILING DATE: 30-January-1998  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Amzel, Viviana  
 REGISTRATION NUMBER: 30,930  
 REFERENCE/DOCKET NUMBER: EPI-00672  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 609-409-3035  
 TELEFAX: 413-254-9245  
 TELEX: <Unknown>  
 INFORMATION FOR SEQ ID NO: 944:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 17 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA (Genomic)  
 SEQUENCE DESCRIPTION: SEQ ID NO: 944:  
 US-09-093-972C-944  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 80;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1530 GCCCAGCCTTCCCGC 1546  
 DB 17 GCCCAGCCTGTGCCGC 1  
 RESULT 149  
 PCT-US95-05812-21/c  
 ; Sequence 21, Application PC/TUS9505812  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wakita, Takaji  
 ; APPLICANT: Wands, Jack  
 ; TITLE OF INVENTION: ANTISENSE INHIBITION OF  
 ; TITLE OF INVENTION: HEPATITIS C VIRUS  
 ; NUMBER OF SEQUENCES: 38  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Fish & Richardson  
 ; STREET: 225 Franklin Street  
 ; CITY: Boston  
 ; STATE: Massachusetts  
 ; COUNTRY: U.S.A.  
 ; ZIP: 02110-2804  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 ; COMPUTER: IBM PS/2 Model 502 or 55SX  
 ; OPERATING SYSTEM: MS-DOS (Version 5.0)  
 ; SOFTWARE: WordPerfect (Version 5.1)  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/US95/05812  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 COUNTRY: USA  
 ZIP: 08512  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC Compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent in Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 FILING DATE: 09-Jun-1998  
 FILING DATE: 09-Jun-1998  
 CLASSIFICATION: <Unknown>  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 08/472,527  
 FILING DATE: 7-June-1995  
 APPLICATION NUMBER: US 08/757,024  
 FILING DATE: 26-11-1996  
 APPLICATION NUMBER: US 08/472,527  
 FILING DATE: 7-June-1995  
 APPLICATION NUMBER: US 09/016,464  
 FILING DATE: 30-January-1998  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Amzel, Viviana  
 REGISTRATION NUMBER: 30,930  
 REFERENCE/DOCKET NUMBER: EPI-00672  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 609-409-3035  
 TELEFAX: 413-254-9245  
 TELEX: <Unknown>  
 INFORMATION FOR SEQ ID NO: 944:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 17 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA (Genomic)  
 SEQUENCE DESCRIPTION: SEQ ID NO: 944:  
 US-09-093-972C-944  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 80;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1530 GCCCAGCCTTCCCGC 1546  
 DB 17 GCCCAGCCTGTGCCGC 1  
 RESULT 149  
 PCT-US95-05812-21/c  
 ; Sequence 21, Application PC/TUS9505812  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wakita, Takaji  
 ; APPLICANT: Wands, Jack  
 ; TITLE OF INVENTION: ANTISENSE INHIBITION OF  
 ; TITLE OF INVENTION: HEPATITIS C VIRUS  
 ; NUMBER OF SEQUENCES: 38  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Fish & Richardson  
 ; STREET: 225 Franklin Street  
 ; CITY: Boston  
 ; STATE: Massachusetts  
 ; COUNTRY: U.S.A.  
 ; ZIP: 02110-2804  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 ; COMPUTER: IBM PS/2 Model 502 or 55SX  
 ; OPERATING SYSTEM: MS-DOS (Version 5.0)  
 ; SOFTWARE: WordPerfect (Version 5.1)  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/US95/05812  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 COUNTRY: USA  
 ZIP: 08512  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC Compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent in Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 FILING DATE: 09-Jun-1998  
 FILING DATE: 09-Jun-1998  
 CLASSIFICATION: <Unknown>  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 08/472,527  
 FILING DATE: 7-June-1995  
 APPLICATION NUMBER: US 08/757,024  
 FILING DATE: 26-11-1996  
 APPLICATION NUMBER: US 08/472,527  
 FILING DATE: 7-June-1995  
 APPLICATION NUMBER: US 09/016,464  
 FILING DATE: 30-January-1998  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Amzel, Viviana  
 REGISTRATION NUMBER: 30,930  
 REFERENCE/DOCKET NUMBER: EPI-00672  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 609-409-3035  
 TELEFAX: 413-254-9245  
 TELEX: <Unknown>  
 INFORMATION FOR SEQ ID NO: 944:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 17 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA (Genomic)  
 SEQUENCE DESCRIPTION: SEQ ID NO: 944:  
 US-09-093-972C-944  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 80;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1530 GCCCAGCCTTCCCGC 1546  
 DB 17 GCCCAGCCTGTGCCGC 1  
 RESULT 149  
 PCT-US95-05812-21/c  
 ; Sequence 21, Application PC/TUS9505812  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wakita, Takaji  
 ; APPLICANT: Wands, Jack  
 ; TITLE OF INVENTION: ANTISENSE INHIBITION OF  
 ; TITLE OF INVENTION: HEPATITIS C VIRUS  
 ; NUMBER OF SEQUENCES: 38  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Fish & Richardson  
 ; STREET: 225 Franklin Street  
 ; CITY: Boston  
 ; STATE: Massachusetts  
 ; COUNTRY: U.S.A.  
 ; ZIP: 02110-2804  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 ; COMPUTER: IBM PS/2 Model 502 or 55SX  
 ; OPERATING SYSTEM: MS-DOS (Version 5.0)  
 ; SOFTWARE: WordPerfect (Version 5.1)  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/US95/05812  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 COUNTRY: USA  
 ZIP: 08512  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE: Floppy disk  
 COMPUTER: IBM PC Compatible  
 OPERATING SYSTEM: PC-DOS/MS-DOS  
 SOFTWARE: Patent in Release #1.0, Version #1.30  
 CURRENT APPLICATION DATA:  
 FILING DATE: 09-Jun-1998  
 FILING DATE: 09-Jun-1998  
 CLASSIFICATION: <Unknown>  
 PRIOR APPLICATION DATA:  
 APPLICATION NUMBER: US 08/472,527  
 FILING DATE: 7-June-1995  
 APPLICATION NUMBER: US 08/757,024  
 FILING DATE: 26-11-1996  
 APPLICATION NUMBER: US 08/472,527  
 FILING DATE: 7-June-1995  
 APPLICATION NUMBER: US 09/016,464  
 FILING DATE: 30-January-1998  
 ATTORNEY/AGENT INFORMATION:  
 NAME: Amzel, Viviana  
 REGISTRATION NUMBER: 30,930  
 REFERENCE/DOCKET NUMBER: EPI-00672  
 TELECOMMUNICATION INFORMATION:  
 TELEPHONE: 609-409-3035  
 TELEFAX: 413-254-9245  
 TELEX: <Unknown>  
 INFORMATION FOR SEQ ID NO: 944:  
 SEQUENCE CHARACTERISTICS:  
 LENGTH: 17 base pairs  
 TYPE: nucleic acid  
 STRANDEDNESS: single  
 TOPOLOGY: linear  
 MOLECULE TYPE: DNA (Genomic)  
 SEQUENCE DESCRIPTION: SEQ ID NO: 944:  
 US-09-093-972C-944  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 88.2%; Pred. No. 80;  
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
 QY 1530 GCCCAGCCTTCCCGC 1546  
 DB 17 GCCCAGCCTGTGCCGC 1  
 RESULT 149  
 PCT-US95-05812-21/c  
 ; Sequence 21, Application PC/TUS9505812  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Wakita, Takaji  
 ; APPLICANT: Wands, Jack  
 ; TITLE OF INVENTION: ANTISENSE INHIBITION OF  
 ; TITLE OF INVENTION: HEPATITIS C VIRUS  
 ; NUMBER OF SEQUENCES: 38  
 ; CORRESPONDENCE ADDRESS:  
 ; ADDRESSEE: Fish & Richardson  
 ; STREET: 225 Franklin Street  
 ; CITY: Boston  
 ; STATE: Massachusetts  
 ; COUNTRY: U.S.A.  
 ; ZIP: 02110-2804  
 ; COMPUTER READABLE FORM:  
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
 ; COMPUTER: IBM PS/2 Model 502 or 55SX  
 ; OPERATING SYSTEM: MS-DOS (Version 5.0)  
 ; SOFTWARE: WordPerfect (Version 5.1)  
 ; CURRENT APPLICATION DATA:  
 ; APPLICATION NUMBER: PCT/US95/05812  
 ; FILING DATE:  
 ; CLASSIFICATION:  
 ; PRIOR APPLICATION DATA:  
 COUNTRY: USA  
 ZIP: 08512  
 COMPUTER READABLE FORM:  
 MEDIUM TYPE

```
; INFORMATION FOR SEQ ID NO: 160:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-291-932A-160

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 71;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1507 CCAGCCTCCAGGCC 1521
Db 1 CCAGCUCCAGGCUC 15

RESULT 151
US-09-180-437-151/c
; Sequence 151, Application US/09180437
; Patent No. 6251873
; GENERAL INFORMATION:
; APPLICANT: FUKUSAKO, Shioji
; APPLICANT: MORISAWA, Yoshifumi
; APPLICANT: KUSUYAMA, Takeshi
; TITLE OF INVENTION: Antisense Compounds to CD14
; FILE REFERENCE: 1110-209F
; CURRENT APPLICATION NUMBER: US/09/180,437
; CURRENT FILING DATE: 1998-11-06
; EARLIER APPLICATION NUMBER: PCT/JP98/00953
; EARLIER FILING DATE: 1998-03-09
; EARLIER APPLICATION NUMBER: 09-053518 JAPAN
; EARLIER FILING DATE: 1997-03-07
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 151
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:other nucleic
US-09-180-437-151

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 432 TGCAGAGTGGCTCA 446
Db 15 TGCAGCAGTGGCTCA 1

RESULT 152
US-09-081-646-174/c
; Sequence 174, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 174
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: Primer
US-09-736-116-75

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1076 GCTGCTAAAGTCTTA 1090
Db 1076 GCTGCTAAAGTCTTA 1090

; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-174

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 GCTCAGCAGGCCATG 821
Db 15 GCCCAGCAGGCCATG 1

RESULT 153
US-09-081-646-783/c
; Sequence 783, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 783
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-783

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 807 GCTCAGCAGGCCATG 821
Db 15 GCCCAGCAGGCCATG 1

RESULT 154
US-09-736-116-75/c
; Sequence 75, Application US/09736116
; Patent No. 6727085
; GENERAL INFORMATION:
; APPLICANT: Sejersgard, Tina
; APPLICANT: Mikkelsen, Frank
; TITLE OF INVENTION: Subtilase variants having an improved wash performance on egg stain
; FILE REFERENCE: 6108.410
; CURRENT APPLICATION NUMBER: US/09/736,116
; CURRENT FILING DATE: 2001-05-24
; NUMBER OF SEQ ID NOS: 105
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 75
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-09-736-116-75

Query Match      0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 71;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1076 GCTGCTAAAGTCTTA 1090
Db 1076 GCTGCTAAAGTCTTA 1090
```

Db 15 GCTGTTAAAGTCCTA 1

RESULT 155

US-08-173-489C-32/C

Sequence 32, Application US/08173489C

Patent No. 5861244

GENERAL INFORMATION:

APPLICANT: WANG, C. -G.

APPLICANT: HEPBURN, A. G.

TITLE OF INVENTION: GENETIC SEQUENCE ASSAY USING DNA

TITLE OF INVENTION: TRIPLE-STRAND FORMATION.

NUMBER OF SEQUENCES: 365

CORRESPONDENCE ADDRESS:

ADDRESSEE: PROFILE DIAGNOSTIC SCIENCES, INC.,

STREET: 510 EAST 73RD STREET,

CITY: NEW YORK

STATE: NEW YORK

COUNTRY: USA

ZIP: 10021.

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5 inch, 1.44Mb storage

COMPUTER: IBM PC/XT/AT

OPERATING SYSTEM: MS-DOS version 6.2

SOFTWARE: Wordperfect Version 5.1

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/173,489C

FILING DATE: 22 DEC 1993

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/968,436

FILING DATE: 29 OCT 1992

ATTORNEY/AGENT INFORMATION:

NAME: Handelsman, Joseph H.

REGISTRATION NUMBER: 26,179

REFERENCE/DOCKET NUMBER: U9518-6

TELECOMMUNICATION INFORMATION:

TELEPHONE: (attorney) (212) 708-1880

TELEFAX: (attorney) (212) 246-8959

INFORMATION FOR SEQ ID NO: 32:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 bases

TYPE: Nucleic Acid

STRANDEDNESS: single stranded

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid

DESCRIPTION: third strand derived from dystrophin

HYPOTHETICAL: Yes

ANTI-SENSE: NO

PUBLICATION INFORMATION:

RELEVANT RESIDUES IN SEQ ID NO: 32 :FROM 1 TO 16

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 81;

Mismatches 14; Conservative 0; Indels 0; Gaps 0;

Qy 271 AAGAAGCAAGAAGA 285

Db 15 AAGAAGCAAGAAGA 1

RESULT 156

US-09-034-205-67

Sequence 67, Application US/09034205

Patent No. 6194149

GENERAL INFORMATION:

APPLICANT: Lyamichev, Victor I.

APPLICANT: Brow, Mary Ann D.

APPLICANT: Fors, Lance

APPLICANT: Neri, Bruce P.

TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING

TITLE OF INVENTION: STRUCTURE-BRIDGING OLIGONUCLEOTIDES

NUMBER OF SEQUENCES: 68

CORRESPONDENCE ADDRESS:

ADDRESSEE: MEDLEN & CARROLL, LLP

STREET: 220 Montgomery Street, Suite 2200

CITY: San Francisco

STATE: CA

COUNTRY: USA

ZIP: 94104

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/034,205

FILING DATE:

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

NAME: Macknight, Kamrin T.

REGISTRATION NUMBER: 38,230

REFERENCE/DOCKET NUMBER: FORS-03268

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 705-8410

TELEFAX: (415) 397-8338

INFORMATION FOR SEQ ID NO: 67:

SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: other nucleic acid

DESCRIPTION: /desc = "DNA"

US-09-034-205-67

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 81;

Mismatches 14; Conservative 0; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522

Db 2 CAGCCTCCAGGCCCC 16

RESULT 157

US-09-034-205-68

Sequence 68, Application US/09034205

Patent No. 6194149

GENERAL INFORMATION:

APPLICANT: Lyamichev, Victor I.

APPLICANT: Brow, Mary Ann D.

APPLICANT: Fors, Lance

APPLICANT: Neri, Bruce P.

TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING

TITLE OF INVENTION: STRUCTURE-BRIDGING OLIGONUCLEOTIDES

NUMBER OF SEQUENCES: 68

CORRESPONDENCE ADDRESS:

ADDRESSEE: MEDLEN & CARROLL, LLP

STREET: 220 Montgomery Street, Suite 2200

CITY: San Francisco

STATE: CA

COUNTRY: USA

ZIP: 94104

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/034,205

FILING DATE:

CLASSIFICATION:

ATTORNEY/AGENT INFORMATION:

```

; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-034-205-68
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 158
US-09-677-218B-67
; Sequence 67, Application US/09677218B
; Patent No. 6355437
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
; Brow, Mary Ann D.
; Fors, Lance P.
; Neri, Bruce P.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
; STRUCTURE-BRIDGING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/677,218B
; FILING DATE: 02-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/034,205
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-677-218B-67
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 158
US-09-677-218B-67
; Sequence 67, Application US/09677218B
; Patent No. 6355437
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
; Brow, Mary Ann D.
; Fors, Lance P.
; Neri, Bruce P.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
; STRUCTURE-BRIDGING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/677,218B
; FILING DATE: 02-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/034,205
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 67:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-677-218B-67
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 160
US-09-677-192-67
; Sequence 67, Application US/09677192
; Patent No. 6358691
; GENERAL INFORMATION:
```

```

; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-034-205-68
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 159
US-09-677-218B-68
; Sequence 68, Application US/09677218B
; Patent No. 6355437
; GENERAL INFORMATION:
; APPLICANT: Lyamichev, Victor I.
; Brow, Mary Ann D.
; Fors, Lance P.
; Neri, Bruce P.
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING
; STRUCTURE-BRIDGING OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 68
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL, LLP
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/677,218B
; FILING DATE: 02-Oct-2000
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/034,205
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: MacKnight, Kamrin T.
; REGISTRATION NUMBER: 38,230
; REFERENCE/DOCKET NUMBER: FORS-03268
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 68:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "DNA"
US-09-677-218B-68
Query Match 0.8%; Score 13.4; DB 1; Length 16;
Best Local Similarity 93.3%; Pred. No. 81;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGGCCCC 1522
Db 2 CAGCTCCAGGCCCC 16

RESULT 160
US-09-677-192-67
; Sequence 67, Application US/09677192
; Patent No. 6358691
; GENERAL INFORMATION:
```



; APPLICANT: Lyamichev, Victor I.  
; APPLICANT: Brow, Mary Ann D.  
; APPLICANT: Fors, Lance  
; APPLICANT: Neri, Bruce P.  
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING STRUCTURE-BRIDGING  
; FILE REFERENCE: FORS-04708  
; CURRENT APPLICATION NUMBER: US/09/677,192  
; CURRENT FILING DATE: 2000-10-02  
; PRIOR APPLICATION NUMBER: 09/034,205  
; PRIOR FILING DATE: 1998-03-03  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 67  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-09-677-192-67

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 81;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGACCC 16

RESULT 161  
US-09-677-192-68  
; Sequence 68, Application US/09677192  
; Patent No. 6358691  
; GENERAL INFORMATION:  
; APPLICANT: Lyamichev, Victor I.  
; APPLICANT: Brow, Mary Ann D.  
; APPLICANT: Fors, Lance  
; APPLICANT: Neri, Bruce P.  
; TITLE OF INVENTION: TARGET-DEPENDENT REACTIONS USING STRUCTURE-BRIDGING  
; FILE REFERENCE: FORS-04708  
; CURRENT APPLICATION NUMBER: US/09/677,192  
; CURRENT FILING DATE: 2000-10-02  
; PRIOR APPLICATION NUMBER: 09/034,205  
; PRIOR FILING DATE: 1998-03-03  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 68  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic  
US-09-677-192-68

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 81;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGACCC 16

RESULT 162  
US-09-402-618B-67  
; Sequence 67, Application US/09402618B  
; Patent No. 6709815  
; GENERAL INFORMATION:  
; APPLICANT: Dong, Fang  
; APPLICANT: Lyamichev, Victor  
; APPLICANT: Prudent, James  
; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides  
; FILE REFERENCE: FORS-04012  
; CURRENT APPLICATION NUMBER: US/09/402,618B  
; CURRENT FILING DATE: 2000-07-18  
; PRIOR APPLICATION NUMBER: PCT/US98/03194  
; PRIOR FILING DATE: 1998-05-05  
; NUMBER OF SEQ ID NOS: 128  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 67  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-402-618B-67

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 81;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGACCC 16

; APPLICANT: Fors, Lance  
; APPLICANT: Neri, Bruce  
; APPLICANT: Brow, Mary Ann  
; APPLICANT: Anderson, Todd  
; APPLICANT: Dahlberg, James  
; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides  
; FILE REFERENCE: FORS-04012  
; CURRENT APPLICATION NUMBER: US/09/402,618B  
; CURRENT FILING DATE: 2000-07-18  
; PRIOR APPLICATION NUMBER: PCT/US98/03194  
; PRIOR FILING DATE: 1998-05-05  
; NUMBER OF SEQ ID NOS: 128  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 67  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-402-618B-67

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 81;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGACCC 16

RESULT 163  
US-09-402-618B-68  
; Sequence 68, Application US/09402618B  
; Patent No. 6709815  
; GENERAL INFORMATION:  
; APPLICANT: Dong, Fang  
; APPLICANT: Lyamichev, Victor  
; APPLICANT: Prudent, James  
; APPLICANT: Fors, Lance  
; APPLICANT: Neri, Bruce  
; APPLICANT: Brow, Mary Ann  
; APPLICANT: Anderson, Todd  
; APPLICANT: Dahlberg, James  
; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides  
; FILE REFERENCE: FORS-04012  
; CURRENT APPLICATION NUMBER: US/09/402,618B  
; CURRENT FILING DATE: 2000-07-18  
; PRIOR APPLICATION NUMBER: PCT/US98/03194  
; PRIOR FILING DATE: 1998-05-05  
; NUMBER OF SEQ ID NOS: 128  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 68  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-402-618B-68

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 81;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGACCC 16

RESULT 164  
US-08-796-031-1/c  
; Sequence 1, Application US/08796031  
; Patent No. 5849903  
; GENERAL INFORMATION:  
; APPLICANT: Prudent, James  
; APPLICANT: Lyamichev, Victor  
; APPLICANT: Dahlberg, James  
; TITLE OF INVENTION: Target-Dependent Reactions Using Structure-Bridging Oligonucleotides  
; FILE REFERENCE: FORS-04012  
; CURRENT APPLICATION NUMBER: US/08/796,031  
; CURRENT FILING DATE: 2000-07-18  
; PRIOR APPLICATION NUMBER: PCT/US98/03194  
; PRIOR FILING DATE: 1998-05-05  
; NUMBER OF SEQ ID NOS: 128  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 68  
; LENGTH: 16  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-08-796-031-1/c

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 81;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGACCC 16

APPLICANT: Zbigniew Pietrzkowski, Gordana Olbina and Dariusz Cieslak  
TITLE OF INVENTION: Inhibition of Tumor Growth by Antisense  
TITLE OF INVENTION: Oligonucleotides for 11-8 and 11-8 Receptor  
NUMBER OF SEQUENCES: 6  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Crockett & Fish  
STREET: 3000 S. Augusta Court  
CITY: La Habra  
STATE: California  
COUNTRY: United States of America  
ZIP: 90631  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: WordPerfect 6.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/796,031  
FILING DATE: 1 January 1997  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/561,302  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Fish, Robert D.  
REGISTRATION NUMBER: 33,880  
REFERENCE/DOCKET NUMBER: 213/015-CIP  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 714-525-3433  
TELEFAX: 714-525-3303  
TELEX:  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 14 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: DNA (genomic)  
US-08-796-031-1  
Query Match 0.8%; Score 13; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 71;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1239 GTTCCTTCGGTG 1251  
Db 13 GTTCCTTCGGTG 1  
RESULT 165  
US-055-913-1/c  
Sequence 1, Application US/09055913  
Patent No. 6017898  
GENERAL INFORMATION:  
APPLICANT: Zbigniew Pietrzkowski, Gordana Olbina and Dariusz Cieslak  
TITLE OF INVENTION: Inhibition of Tumor Growth by Antisense  
TITLE OF INVENTION: Oligonucleotides for 11-8 and 11-8 Receptor  
NUMBER OF SEQUENCES: 6  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Crockett & Fish  
STREET: 3000 S. Augusta Court  
CITY: La Habra  
STATE: California  
COUNTRY: United States of America  
ZIP: 90631  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: WordPerfect 6.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/055,913  
FILING DATE:

CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/561,302  
FILING DATE: 1 January 1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Fish, Robert D.  
REGISTRATION NUMBER: 33,880  
REFERENCE/DOCKET NUMBER: 213/015-CIP  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 714-525-3433  
TELEFAX: 714-525-3303  
TELEX:  
INFORMATION FOR SEQ ID NO: 1:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 14 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: unknown  
TOPOLOGY: unknown  
MOLECULE TYPE: DNA (genomic)  
US-09-055-913-1  
Query Match 0.8%; Score 13; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 71;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1239 GTTCCTTCGGTG 1251  
Db 13 GTTCCTTCGGTG 1  
RESULT 166  
US-08-985-090-23/c  
Sequence 23, Application US/08985090  
Patent No. 5885893  
GENERAL INFORMATION:  
APPLICANT: Andrew D. J. Goodearl  
TITLE OF INVENTION: MUSCARINIC RECEPTORS AND USES THEREFOR  
NUMBER OF SEQUENCES: 28  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LAHIVE & COCKFIELD, LLP  
STREET: 28 State Street  
CITY: Boston  
STATE: Massachusetts  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/985,090  
FILING DATE:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER:  
FILING DATE:  
ATTORNEY/AGENT INFORMATION:  
NAME: Jean M. Silveri  
REGISTRATION NUMBER: 39,030  
REFERENCE/DOCKET NUMBER: MNI-032  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617)227-7400  
TELEFAX: (617)742-4214  
INFORMATION FOR SEQ ID NO: 23:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-985-090-23  
Query Match 0.8%; Score 12.8; DB 1; Length 16;

Mon Nov 7 09:26:59 2005

```
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 72 GTGGGGCTGCTGCTGA 87
Db 16 GTGGGGCAGCTGCTCA 1

RESULT 167
US-08-757-024-875/c
; Sequence 875, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 882:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-757-024-882

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1530 GCCCAGCCTCTCCCG 1545
Db 16 GCCCAGCCTGTGCCG 1

RESULT 169
US-08-757-024-945/c
; Sequence 945, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/757,024
; FILING DATE: 26-NOV-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Sibley, Kenneth D.
; REGISTRATION NUMBER: 31,665
; REFERENCE/DOCKET NUMBER: 5218-41
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-881-3140
; TELEFAX: 919-881-3175
; TELEX: 575102
; INFORMATION FOR SEQ ID NO: 945:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

Query Match 0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1531 CCCAGCCTCTCCCGC 1546
Db 16 CCCAGCCTGTGCCG 1

RESULT 168
US-08-757-024-882/c
; Sequence 882, Application US/08757024
; Patent No. 6025339
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: METHOD OF TREATMENT FOR ASTHMA
; NUMBER OF SEQUENCES: 952
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: BELL, SELTZER, PARK & GIBSON
; STREET: P.O. Drawer 34009
; CITY: Charlotte
; STATE: No. 6025339th Carolina
; COUNTRY: USA
; ZIP: 28234
```

```
/
; MOLECULE TYPE: DNA (genomic)
US-08-757-024-945

Query Match          0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCG 1545
Db 16 GCCCAGCCTGTGCCG 1

RESULT 170
US-09-165-543-25/c
; Sequence 25, Application US/09165543
; Patent No. 6093545
; GENERAL INFORMATION:
; APPLICANT: Andrew D.J. Goodearl and Sandra Glucksman
; TITLE OF INVENTION: Muscarinic Receptors and Uses Therefor
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/165,543
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/042,780
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Elizabeth A. Hanley
; REGISTRATION NUMBER: 33,505
; REFERENCE/DOCKET NUMBER: MNI-032CP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617)227-7400
; TELEFAX: (617)742-4214
; INFORMATION FOR SEQ ID NO: 25:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-09-165-543-25

Query Match          0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 72 GTGGGGCTGCTGCTCA 87
Db 16 GTGGGGCAGCTGCTCA 1

RESULT 171
US-08-679-645-523
; Sequence 523, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
```

```
/
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 523:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-523

Query Match          0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 62.5%; Pred. No. 99;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 666 CTGCCCTTCAGCCTGC 681
Db 1 CUGCGGUCAGCCUGC 16

RESULT 172
US-09-093-972C-875/c
; Sequence 875, Application US/09093972C
; Patent No. 6825174
; GENERAL INFORMATION:
; APPLICANT: Nyce, Jonathan W.
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH
; BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION
; NUMBER OF SEQUENCES: 996
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.
; STREET: 7 Clarke Drive
; CITY: Cranbury
; STATE: New Jersey
; COUNTRY: USA
```

ZIP: 08512  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/093,972C  
FILING DATE: 09-Jun-1998  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 08/757,024  
FILING DATE: 26-11-1996  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 09/016,464  
FILING DATE: 30-January-1998  
ATTORNEY/AGENT INFORMATION:  
NAME: Amzel, Viviana  
REGISTRATION NUMBER: 30,930  
REFERENCE/DOCKET NUMBER: EPI-00672  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 609-409-3035  
TELEFAX: 413-254-9245  
TELEX: <Unknown>  
INFORMATION FOR SEQ ID NO: 875:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 875:  
US-09-093-972C-875  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 99;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1531 CCCAGCCTCTCCCGC 1546  
Db 16 CCCAGCCTGTGCCG 1  
RESULT 173  
US-09-093-972C-882/c  
Sequence 882, Application US/09093972C  
Patent No. 6825174  
GENERAL INFORMATION:  
APPLICANT: Nyce, Jonathan W.  
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION  
NUMBER OF SEQUENCES: 996  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
STREET: 7 Clarke Drive  
CITY: Cranbury  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 08512  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/093,972C  
FILING DATE: 09-Jun-1998  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 08/757,024  
FILING DATE: 26-11-1996  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 09/016,464  
FILING DATE: 30-January-1998  
ATTORNEY/AGENT INFORMATION:  
NAME: Amzel, Viviana  
REGISTRATION NUMBER: 30,930  
REFERENCE/DOCKET NUMBER: EPI-00672  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 609-409-3035  
TELEFAX: 413-254-9245  
TELEX: <Unknown>  
INFORMATION FOR SEQ ID NO: 882:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 16 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA (genomic)  
SEQUENCE DESCRIPTION: SEQ ID NO: 882:  
US-09-093-972C-882  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 99;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1530 GCCAGCCTCTCCCGC 1545  
Db 16 GCCAGCCTGTGCCG 1  
RESULT 174  
US-09-093-972C-945/c  
Sequence 945, Application US/09093972C  
Patent No. 6825174  
GENERAL INFORMATION:  
APPLICANT: Nyce, Jonathan W.  
TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
& TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
BRONCHOCONSTRICTION, ALLERGY (IES) & INFLAMMATION  
NUMBER OF SEQUENCES: 996  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
STREET: 7 Clarke Drive  
CITY: Cranbury  
STATE: New Jersey  
COUNTRY: USA  
ZIP: 08512  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: PatentIn Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/093,972C  
FILING DATE: 09-Jun-1998  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 08/757,024  
FILING DATE: 26-11-1996  
APPLICATION NUMBER: US 08/472,527  
FILING DATE: 7-June-1995  
APPLICATION NUMBER: US 09/016,464  
FILING DATE: 30-January-1998  
ATTORNEY/AGENT INFORMATION:  
NAME: Amzel, Viviana  
REGISTRATION NUMBER: 30,930

```

; REFERENCE/DOCKET NUMBER: EPI-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 945:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 945:
US-09-093-972C-945

Query Match      0.8%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 99;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCACGCTCTCCCG 1545
Db 16 GCCACGCTGTGCCG 1

RESULT 175
US-08-650-093C-97
; Sequence 97, Application US/08650093C
; Patent No. 6391542
; GENERAL INFORMATION:
; APPLICANT: Kevin P. Anderson et al.
; TITLE OF INVENTION: Compositions And Methods For Treatment Of
; HEPATITIS C Virus-Associated Diseases
; NUMBER OF SEQUENCES: 118
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LICATA & TYRRELL P.C.
; STREET: 66 E. Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: USA
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 Mb STORAGE
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: WORDPERFECT 6.1 for Windows
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/650,093C
; FILING DATE: 17-May-1996
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/452,841
; FILING DATE: May 30, 1995
; APPLICATION NUMBER: 08/397,220
; FILING DATE: March 9, 1995
; APPLICATION NUMBER: 07/945,289
; FILING DATE: September 10, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Jane Massey Licata
; REGISTRATION NUMBER: 32,257
; REFERENCE/DOCKET NUMBER: ISPH-
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (609) 779-2400
; TELEFAX: (609) 779-8488
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 14
; TYPE: Nucleic Acid
; STRANDEDNESS: Single
; TOPOLOGY: Linear
; ANTI-SENSE: No
; SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-08-650-093C-97

; REFERENCE/DOCKET NUMBER: EPI-00672
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 609-409-3035
; TELEFAX: 413-254-9245
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 945:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 945:
US-09-093-972C-945

Query Match      0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 88;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1510 GCCTCCAGGCCCC 1523
Db 1 GCCUCCAGGACCCC 14

RESULT 176
US-09-720-435A-172
; Sequence 172, Application US/09720435A
; Patent No. 6803187
; GENERAL INFORMATION:
; APPLICANT: Stuyver, Lieven
; TITLE OF INVENTION: Method for detection of drug-selected mutations in the protease
; FILE REFERENCE: 11362.0030.PCUS00 INNS:030
; CURRENT APPLICATION NUMBER: US/09/720,435A
; PRIOR FILING DATE: 2001-06-25
; PRIOR APPLICATION NUMBER: PCT/EP99/04317
; PRIOR FILING DATE: 1999-06-22
; PRIOR APPLICATION NUMBER: 98870143.9
; PRIOR FILING DATE: 1998-06-24
; NUMBER OF SEQ ID NOS: 529
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 172
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Aids-associated retrovirus
US-09-720-435A-172

Query Match      0.8%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 88;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 37 GAATTGGAGGCATG 50
Db 1 GAATTGGAGGCCTG 14

RESULT 177
US-08-050-073-65
; Sequence 65, Application US/08050073
; Patent No. 5567809
; GENERAL INFORMATION:
; APPLICANT: Apple, Raymond J.
; APPLICANT: Begovich, Ann B.
; APPLICANT: Bugawan, Teodorica L.
; APPLICANT: Erlich, Henry A.
; APPLICANT: Griffith, Robert L.
; APPLICANT: Scharf, Stephen J.
; TITLE OF INVENTION: Methods and Reagents for HLA DRBeta DNA
; TITLE OF INVENTION: Typing
; NUMBER OF SEQUENCES: 315
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Hoffmann-La Roche Inc.
; STREET: 340 Kingsland Street
; CITY: Nutley
; STATE: New Jersey
; COUNTRY: U.S.A.
; ZIP: 07110
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/050,073
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Petry, Douglas A.
;
```

REGISTRATION NUMBER: 35,321  
REFERENCE/DOCKET NUMBER: 8769  
TELEPHONE: (510) 814-2974  
TELEFAX: (510) 814-2977  
INFORMATION FOR SEQ ID NO: 65:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: genomic DNA  
US-08-050-073-65

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1074 GAGCTGCTAAAGTC 1087  
Db 1 GAGCTGCTTAAGTC 14

RESULT 178  
US-08-182-968A-2  
Sequence 2, Application US/08182968A  
Patent No. 5610054  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
TITLE OF INVENTION: METHOD AND REAGENT FOR INHIBITING HEPATITIS C  
TITLE OF INVENTION: INHIBITING HEPATITIS C  
TITLE OF INVENTION: VIRUS REPLICATION  
NUMBER OF SEQUENCES: 497  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:  
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/182,968A  
FILING DATE: 13-JANUARY-1994  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 07/882,888  
FILING DATE: 14-MAY-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 205/277  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 422:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 15  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-182-968A-422

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 ATACGAGAGCGCA 883  
Db 15 ATACGATAGCGCA 2

RESULT 180  
US-08-182-968A-423/c  
Sequence 423, Application US/08182968A  
Patent No. 5610054  
GENERAL INFORMATION:  
APPLICANT: Draper, Kenneth G.  
TITLE OF INVENTION: METHOD AND REAGENT FOR INHIBITING HEPATITIS C  
TITLE OF INVENTION: INHIBITING HEPATITIS C  
TITLE OF INVENTION: VIRUS REPLICATION  
NUMBER OF SEQUENCES: 497  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Lyon & Lyon  
STREET: 633 West Fifth Street

```
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/882,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 423:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-182-968A-423

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 870 ATACGAGAGCGCA 883
Db 14 ATACGATAGCGCA 1

RESULT 181
US-08-363-240A-237
; Sequence 237, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 528:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; PRIORITY: 1; Indels 0; Gaps 0;

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 237:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-237

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 71.4%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1309 TAGAGTCTCCAGG 1322
Db 1 UAGAAGUCCUCCAG 14

RESULT 182
US-08-363-240A-528
; Sequence 528, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 528:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
```



TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-08-363-240A-528

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 78.6%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 841 CGGCCTTCCAGCAC 854  
|||||:|||||  
Db 2 CGGCCUCCAGCGC 15

RESULT 183  
US-08-363-240A-529  
; Sequence 529, Application US/08363240A  
; Patent No. 5705388  
; GENERAL INFORMATION:  
; APPLICANT: Couture, Larry  
; APPLICANT: McSwiggen, James  
; APPLICANT: Bisgaier, Charles  
; APPLICANT: Pape, Michael  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: PREVENTION, INHIBITION OF  
; TITLE OF INVENTION: PROGRESSION AND REGRESSION  
; TITLE OF INVENTION: OF VASCULAR DISEASES  
; NUMBER OF SEQUENCES: 1243  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/363,240A  
; FILING DATE: December 23, 1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 210/096  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 529:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-363-240A-529

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 78.6%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;  
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 841 CGGCCTTCCAGCAC 854  
|||||:|||||  
Db 1 CGGCCUCCAGCGC 14

RESULT 184  
US-08-363-240A-724/c  
; Sequence 724, Application US/08363240A  
; Patent No. 5705388  
; GENERAL INFORMATION:  
; APPLICANT: Couture, Larry  
; APPLICANT: McSwiggen, James  
; APPLICANT: Bisgaier, Charles  
; APPLICANT: Pape, Michael  
; TITLE OF INVENTION: METHOD AND REAGENT FOR  
; TITLE OF INVENTION: PREVENTION, INHIBITION OF  
; TITLE OF INVENTION: PROGRESSION AND REGRESSION  
; TITLE OF INVENTION: OF VASCULAR DISEASES  
; NUMBER OF SEQUENCES: 1243  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Lyon & Lyon  
; STREET: 633 West Fifth Street  
; STREET: Suite 4700  
; CITY: Los Angeles  
; STATE: California  
; COUNTRY: U.S.A.  
; ZIP: 90071  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb  
; MEDIUM TYPE: storage  
; COMPUTER: IBM Compatible  
; OPERATING SYSTEM: IBM P.C. DOS 5.0  
; SOFTWARE: Word Perfect 5.1  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/363,240A  
; FILING DATE: December 23, 1994  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER:  
; FILING DATE:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Warburg, Richard  
; REGISTRATION NUMBER: 32,327  
; REFERENCE/DOCKET NUMBER: 210/096  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (213) 489-1600  
; TELEFAX: (213) 955-0440  
; TELEX: 67-3510  
; INFORMATION FOR SEQ ID NO: 724:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 15 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
US-08-363-240A-724

Query Match 0.8%; Score 12.4; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;  
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1471 CAGAGAGAGCTCTG 1484  
|||||:|||||  
Db 14 CGGAGAGAGCTCTG 1

RESULT 185  
US-08-311-486C-533/c  
; Sequence 533, Application US/08311486C  
; Patent No. 581300  
; GENERAL INFORMATION:  
; APPLICANT: Sean Sullivan  
; APPLICANT: Kenneth Draper  
; APPLICANT: Kevin Kisich  
; APPLICANT: Dan T. Stinchcomb  
; APPLICANT: James McSwiggen  
; TITLE OF INVENTION: RIBOZYME TREATMENT OF  
; TITLE OF INVENTION: DISEASES OR CONDITIONS  
; TITLE OF INVENTION: RELATED TO LEVELS OF  
; TITLE OF INVENTION: TNF-  
US-08-363-240A-529



```

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/505,314
FILING DATE: 05-APR-1990
ATTORNEY/AGENT INFORMATION:
NAME: Brook Esq., David E.
REGISTRATION NUMBER: 22,592
REFERENCE/DOCKET NUMBER: RC90-01AZ
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617) 861-6240
TELEFAX: (617) 861-9540
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
US-08-452-724A-30

Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1303 TCCCTGTAGAAGTC 1316
DB      ||| ||||| |||||
        14 TCCATGTAGAAGTC 1

RESULT 188
US-08-774-306A-2
Sequence 2, Application US/08774306A
Patent No. 5869253
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 MB
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,306A
FILING DATE: December 26, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/227
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

```

```

US-08-774-306A-2
Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 85.7%; Pred. No. 1e+02;
Matches 12; Conservative 1; Mismatches 0; Gaps 0;

QY      1508 CAGCCTCCAGGCC 1521
      |||||:|||||
Db      2 CAGCCUCCAGGACC 15

RESULT 189
US-08-774-306A-422/c
; Sequence 422, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/774,306A
; FILING DATE: December 26, 1996
; PRIORITY APPLICATION DATA:
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 223/227
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 422:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-774-306A-422

Query Match      0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      870 ATACGAGAGGCCG 883
      |||||:|||||
Db      15 ATACGATAGGCCG 2

RESULT 190
US-08-774-306A-423/c
; Sequence 423, Application US/08774306A
; Patent No. 5869253
; GENERAL INFORMATION:

```



```
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 422:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-064-156A-422

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 870 ATACGAGAGCGCA 883
Db 15 ATACGATAAGCGCA 2

RESULT 193
US-09-064-156A-423/c
; Sequence 423, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 423:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-064-156A-423

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 870 ATACGAGAGCGCA 883
Db 15 ATACGATAAGCGCA 2

RESULT 194
US-09-081-646-126
; Sequence 126, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 126
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-126

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1101 ATGCTCAACACCTC 1114
Db 2 ATGCTCAACATCTC 15

RESULT 195
US-09-081-646-326
; Sequence 326, Application US/09081646
; Patent No. 6333152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSEQ for Windows Version 3.0
; SEQ ID NO 326
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-326

Query Match 0.8%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1e+02; 1; Indels 0; Gaps 0;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 923 CACGGGCTGCCTGC 936
Db 15 ATACGATAAGCGCA 2
```

Db 1 CATGGGCTGCCTGC 14

RESULT 196

US-09-081-646-808

; Sequence 808, Application US/09081646

; Patent No. 6333152

; GENERAL INFORMATION:

; APPLICANT: Kinzler, Kenneth

; APPLICANT: Vogelstein, Bert

; APPLICANT: Zhang, Lin

; APPLICANT: Zhou, Wei

; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and

; FILE REFERENCE: 01107.74664

; CURRENT APPLICATION NUMBER: US/09/081,646

; CURRENT FILING DATE: 1998-05-20

; EARLIER APPLICATION NUMBER: 60/047,352

; EARLIER FILING DATE: 1997-05-21

; NUMBER OF SEQ ID NOS: 871

; SOFTWARE: FastSeq for Windows Version 3.0

; SEQ ID NO 808

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-081-646-808

Query Match 0.8%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1101 ATGCTCAACACCTC 1114

Db 2 ATGCTCAACATCTC 15

RESULT 197

US-08-453-623-30/C

; Sequence 30, Application US/08453623

; Patent No. 6649340

; GENERAL INFORMATION:

; APPLICANT: Crea, Roberto

; TITLE OF INVENTION: Walk-Through Mutagenesis

; NUMBER OF SEQUENCES: 59

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.

; STREET: 2 Militia Drive

; CITY: Lexington

; STATE: MA

; COUNTRY: USA

; ZIP: 02173

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/453,623

FILING DATE: 30-May-1995

CLASSIFICATION: <Unknown>

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 07/930,600

FILING DATE: 05-APR-1991

APPLICATION NUMBER: PCT/US91/02362

FILING DATE: 05-APR-1991

APPLICATION NUMBER: US 07/505,314

FILING DATE: 05-APR-1990

ATTORNEY/AGENT INFORMATION:

NAME: Brook, David E.

REGISTRATION NUMBER: 22,592

REFERENCE/DOCKET NUMBER: RC90-01AY

TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 861-6240

TELEFAX: (617) 861-9540

INFORMATION FOR SEQ ID NO: 30:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: unknown

SEQUENCE DESCRIPTION: SEQ ID NO: 30:

US-08-453-623-30

Query Match 0.8%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1303 TCCCTGTAGAGTC 1316

Db 14 TCCATGTAGAGTC 1

RESULT 198

US-09-720-435A-171

; Sequence 171, Application US/09720435A

; Patent No. 6803187

; GENERAL INFORMATION:

; APPLICANT: Stuyver, Lieven

; TITLE OF INVENTION: Method for detection of drug-selected mutations in the protease

; FILE REFERENCE: 11362.0030.PCUS00 INNS:030

; CURRENT APPLICATION NUMBER: US/09/720,435A

; CURRENT FILING DATE: 2001-06-25

; PRIOR APPLICATION NUMBER: PCT/EP99/04317

; PRIOR FILING DATE: 1999-06-22

; PRIOR APPLICATION NUMBER: 98870143.9

; PRIOR FILING DATE: 1998-06-24

; NUMBER OF SEQ ID NOS: 529

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 171

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Aids-associated retrovirus

US-09-720-435A-171

Query Match 0.8%; Score 12.4; DB 1; Length 15;

Best Local Similarity 92.9%; Pred. No. 1e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 37 GAATTGGAGGCATG 50

Db 2 GAATTGGAGGCTTG 15

Search completed: September 13, 2005, 10:44:50

Job time : 5 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:39:51 ; Search time 5 Seconds  
(without alignments)  
3.649 Million cell updates/sec

Title: us-10-828-394-1  
Perfect score: 1643  
Sequence: 1 gaattccgcgtgaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5  
Searched: 298 seqs, 5552 residues

Total number of hits satisfying chosen parameters: 596

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 298 summaries

Database : rgdb.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	27.2	1.7	32	1 A21575	ACCESSION: A21575
2	26	1.6	26	1 AR090627	ACCESSION: AR090627
3	26	1.6	26	1 AR197662	ACCESSION: AR197662
4	26	1.6	26	1 AR259816	ACCESSION: AR259816
C 5	25	1.5	25	1 AR090628	ACCESSION: AR090628
C 6	25	1.5	25	1 AR197663	ACCESSION: AR197663
C 7	25	1.5	25	1 AR259817	ACCESSION: AR259817
8	23	1.4	23	1 CQ786169	ACCESSION: CQ786169
9	23	1.4	23	1 CQ786172	ACCESSION: CQ786172
10	23	1.4	23	1 CQ786175	ACCESSION: CQ786175
11	23	1.4	23	1 CQ786178	ACCESSION: CQ786178
C 12	23	1.4	23	1 AR208706	ACCESSION: AR208706
C 13	21	1.3	21	1 AR038687	ACCESSION: AR038687
14	21	1.3	21	1 CQ786113	ACCESSION: CQ786113
C 15	21	1.3	21	1 CQ786114	ACCESSION: CQ786114
C 16	21	1.3	21	1 CQ786115	ACCESSION: CQ786115
C 17	21	1.3	21	1 CQ786116	ACCESSION: CQ786116
C 18	21	1.3	21	1 CQ786117	ACCESSION: CQ786117
C 19	21	1.3	21	1 CQ786170	ACCESSION: CQ786170
C 20	21	1.3	21	1 CQ786171	ACCESSION: CQ786171
C 21	21	1.3	21	1 CQ786173	ACCESSION: CQ786173
C 22	21	1.3	21	1 CQ786174	ACCESSION: CQ786174
C 23	21	1.3	21	1 CQ786176	ACCESSION: CQ786176
C 24	21	1.3	21	1 CQ786177	ACCESSION: CQ786177
C 25	21	1.3	21	1 CQ786614	ACCESSION: CQ786614
C 26	21	1.3	21	1 CQ786615	ACCESSION: CQ786615
C 27	21	1.3	21	1 CQ786616	ACCESSION: CQ786616
C 28	21	1.3	21	1 CQ786617	ACCESSION: CQ786617
C 29	21	1.3	21	1 CQ786618	ACCESSION: CQ786618
C 30	21	1.3	21	1 CQ786619	ACCESSION: CQ786619
C 31	21	1.3	21	1 CQ786620	ACCESSION: CQ786620
C 32	21	1.3	21	1 CQ786621	ACCESSION: CQ786621
C 33	21	1.3	21	1 CQ786622	ACCESSION: CQ786622

C 34	21	1.3	21	1 CQ786622	ACCESSION: CQ786622
C 35	21	1.3	21	1 CQ786623	ACCESSION: CQ786623
C 36	21	1.3	21	1 CQ786631	ACCESSION: CQ786631
C 37	21	1.3	21	1 CQ786632	ACCESSION: CQ786632
C 38	21	1.3	21	1 CQ786633	ACCESSION: CQ786633
C 39	21	1.3	21	1 CQ786634	ACCESSION: CQ786634
C 40	21	1.3	21	1 CQ786636	ACCESSION: CQ786636
C 41	21	1.3	21	1 CQ786647	ACCESSION: CQ786647
C 42	21	1.3	21	1 CQ786648	ACCESSION: CQ786648
C 43	21	1.3	21	1 CQ786649	ACCESSION: CQ786649
C 44	21	1.3	21	1 CQ786650	ACCESSION: CQ786650
C 45	21	1.3	21	1 CQ786651	ACCESSION: CQ786651
C 46	21	1.3	21	1 CQ786652	ACCESSION: CQ786652
47	21	1.3	21	1 AR208707	ACCESSION: AR208707
48	21	1.3	21	1 AR236282	ACCESSION: AR236282
49	20.8	1.3	24	1 BD230318	ACCESSION: BD230318
50	20.6	1.3	21	1 AR531218	ACCESSION: AR531218
51	20.6	1.3	21	1 AR531219	ACCESSION: AR531219
52	20.6	1.3	21	1 AR531220	ACCESSION: AR531220
53	20.6	1.3	21	1 AR531221	ACCESSION: AR531221
54	20.6	1.3	21	1 AX097243	ACCESSION: AX097243
55	20.6	1.3	21	1 AX097244	ACCESSION: AX097244
56	20.6	1.3	21	1 AX097245	ACCESSION: AX097245
57	20.6	1.3	21	1 AX097246	ACCESSION: AX097246
58	20	1.2	20	1 CQ803453	ACCESSION: CQ803453
C 59	20	1.2	20	1 CQ803454	ACCESSION: CQ803454
C 60	20	1.2	20	1 AR208715	ACCESSION: AR208715
C 61	20	1.2	20	1 AR208716	ACCESSION: AR208716
C 62	20	1.2	20	1 AR208717	ACCESSION: AR208717
C 63	20	1.2	20	1 AR208718	ACCESSION: AR208718
C 64	20	1.2	20	1 AR208719	ACCESSION: AR208719
C 65	20	1.2	20	1 AR208720	ACCESSION: AR208720
C 66	20	1.2	20	1 AR208721	ACCESSION: AR208721
C 67	20	1.2	20	1 AR208722	ACCESSION: AR208722
C 68	20	1.2	20	1 AR208723	ACCESSION: AR208723
C 69	20	1.2	20	1 AR208724	ACCESSION: AR208724
C 70	20	1.2	20	1 AR208725	ACCESSION: AR208725
C 71	20	1.2	20	1 AR208726	ACCESSION: AR208726
C 72	20	1.2	20	1 AR208727	ACCESSION: AR208727
C 73	20	1.2	20	1 AR208728	ACCESSION: AR208728
C 74	20	1.2	20	1 AR208729	ACCESSION: AR208729
C 75	20	1.2	20	1 AR208730	ACCESSION: AR208730
C 76	20	1.2	20	1 AR208731	ACCESSION: AR208731
C 77	20	1.2	20	1 AR208732	ACCESSION: AR208732
C 78	20	1.2	20	1 AR208733	ACCESSION: AR208733
C 79	20	1.2	20	1 AR208734	ACCESSION: AR208734
C 80	20	1.2	20	1 AR208735	ACCESSION: AR208735
C 81	20	1.2	20	1 AR208736	ACCESSION: AR208736
C 82	20	1.2	20	1 AR208737	ACCESSION: AR208737
C 83	20	1.2	20	1 AR208738	ACCESSION: AR208738
C 84	20	1.2	20	1 AR208739	ACCESSION: AR208739
C 85	20	1.2	20	1 AR208740	ACCESSION: AR208740
C 86	20	1.2	20	1 AR208741	ACCESSION: AR208741
C 87	20	1.2	20	1 AR208742	ACCESSION: AR208742
C 88	20	1.2	20	1 AR208743	ACCESSION: AR208743
C 89	20	1.2	20	1 AR208744	ACCESSION: AR208744
C 90	20	1.2	20	1 AR208745	ACCESSION: AR208745
C 91	20	1.2	20	1 AR208746	ACCESSION: AR208746
C 92	20	1.2	20	1 AR208747	ACCESSION: AR208747
C 93	20	1.2	20	1 AR208748	ACCESSION: AR208748
C 94	20	1.2	20	1 AR208749	ACCESSION: AR208749
C 95	20	1.2	20	1 AR208750	ACCESSION: AR208750
C 96	20	1.2	20	1 AR208751	ACCESSION: AR208751
C 97	20	1.2	20	1 AR208752	ACCESSION: AR208752
C 98	20	1.2	20	1 AR208753	ACCESSION: AR208753
C 99	20	1.2	20	1 AR208754	ACCESSION: AR208754
C 100	20	1.2	20	1 AR208755	ACCESSION: AR208755
C 101	20	1.2	20	1 AR208756	ACCESSION: AR208756
C 102	20	1.2	20	1 AR208757	ACCESSION: AR208757
C 103	20	1.2	20	1 AR208758	ACCESSION: AR208758
C 104	20	1.2	20	1 AR208759	ACCESSION: AR208759
C 105	20	1.2	20	1 AR208760	ACCESSION: AR208760
C 106	20	1.2	20	1 AR208761	ACCESSION: AR208761

C 107	20	1.2	20	1	AR208762	ACCESSION:AR208762	C 180	14.4	0.9	17	1	AR466360	ACCESSION:AR466360
C 108	20	1.2	20	1	AR208763	ACCESSION:AR208763	C 181	14.4	0.9	17	1	AR466361	ACCESSION:AR466361
C 109	20	1.2	20	1	AR208764	ACCESSION:AR208764	C 182	14.4	0.9	17	1	AX214729	ACCESSION:AX214729
C 110	20	1.2	20	1	AR208765	ACCESSION:AR208765	C 183	14.4	0.9	17	1	AX688718	ACCESSION:AX688718
C 111	20	1.2	20	1	AR208766	ACCESSION:AR208766	C 184	14.4	0.9	17	1	AX688720	ACCESSION:AX688720
C 112	20	1.2	20	1	AR208767	ACCESSION:AR208767	C 185	14.4	0.9	17	1	AX732888	ACCESSION:AX732888
C 113	20	1.2	20	1	AR208768	ACCESSION:AR208768	C 186	14.4	0.9	17	1	AX760623	ACCESSION:AX760623
C 114	20	1.2	20	1	AR208769	ACCESSION:AR208769	C 187	14.4	0.9	17	1	AR067404	ACCESSION:AR067404
C 115	20	1.2	20	1	AR208770	ACCESSION:AR208770	C 188	14.4	0.9	17	1	AX837978	ACCESSION:AX837978
C 116	20	1.2	20	1	AR208771	ACCESSION:AR208771	C 189	14	0.9	17	1	AX324817	ACCESSION:AX324817
C 117	20	1.2	20	1	AR208772	ACCESSION:AR208772	C 190	14	0.9	17	1	AX324818	ACCESSION:AX324818
C 118	20	1.2	20	1	AR208773	ACCESSION:AR208773	C 191	13.8	0.8	17	1	AR039619	ACCESSION:AR039619
C 119	20	1.2	20	1	AR208774	ACCESSION:AR208774	C 192	13.8	0.8	17	1	AR081753	ACCESSION:AR081753
C 120	20	1.2	20	1	AR208775	ACCESSION:AR208775	C 193	13.8	0.8	17	1	AR081755	ACCESSION:AR081755
C 121	20	1.2	20	1	AR208776	ACCESSION:AR208776	C 194	13.8	0.8	17	1	AR094983	ACCESSION:AR094983
C 122	20	1.2	20	1	AR208777	ACCESSION:AR208777	C 195	13.8	0.8	17	1	AR167985	ACCESSION:AR167985
C 123	20	1.2	20	1	AR208781	ACCESSION:AR208781	C 196	13.8	0.8	17	1	AR167987	ACCESSION:AR167987
C 124	20	1.2	21	1	AR208782	ACCESSION:AR208782	C 197	13.8	0.8	17	1	BD254845	ACCESSION:BD254845
C 125	20	1.2	21	1	AR208783	ACCESSION:AR208783	C 198	13.8	0.8	17	1	CO617155	ACCESSION:CO617155
C 126	19.4	1.2	21	1	AR208784	ACCESSION:AR208784	C 199	13.8	0.8	17	1	CO617155	ACCESSION:CO617155
C 127	19	1.2	21	1	AR208785	ACCESSION:AR208785	C 200	13.8	0.8	17	1	CO622615	ACCESSION:CO622615
C 128	19	1.2	21	1	AR208786	ACCESSION:AR208786	C 201	13.8	0.8	17	1	CO622745	ACCESSION:CO622745
C 129	19	1.2	21	1	AR208787	ACCESSION:AR208787	C 202	13.8	0.8	17	1	CO622828	ACCESSION:CO622828
C 130	19	1.2	21	1	AR208788	ACCESSION:AR208788	C 203	13.8	0.8	17	1	CO622920	ACCESSION:CO622920
C 131	19	1.2	21	1	AR208789	ACCESSION:AR208789	C 204	13.8	0.8	17	1	CO622921	ACCESSION:CO622921
C 132	19	1.2	21	1	AR208790	ACCESSION:AR208790	C 205	13.8	0.8	17	1	CO622922	ACCESSION:CO622922
C 133	18.8	1.1	22	1	AR208791	ACCESSION:AR208791	C 206	13.8	0.8	17	1	CO622923	ACCESSION:CO622923
C 134	18.8	1.1	22	1	AR208792	ACCESSION:AR208792	C 207	13.8	0.8	17	1	CO622924	ACCESSION:CO622924
C 135	18	1.1	22	1	AR208793	ACCESSION:AR208793	C 208	13.8	0.8	17	1	CO622925	ACCESSION:CO622925
C 136	18	1.1	22	1	AR208794	ACCESSION:AR208794	C 209	13.8	0.8	17	1	CO622926	ACCESSION:CO622926
C 137	17	1.0	17	1	AR208795	ACCESSION:AR208795	C 210	13.8	0.8	17	1	CO622927	ACCESSION:CO622927
C 138	17	1.0	17	1	AR208796	ACCESSION:AR208796	C 211	13.8	0.8	17	1	CO622928	ACCESSION:CO622928
C 139	16.8	1.0	20	1	AR208797	ACCESSION:AR208797	C 212	13.8	0.8	17	1	CO622929	ACCESSION:CO622929
C 140	16.8	1.0	20	1	AR208798	ACCESSION:AR208798	C 213	13.8	0.8	17	1	CO622930	ACCESSION:CO622930
C 141	16	1.0	16	1	AR208799	ACCESSION:AR208799	C 214	13.8	0.8	17	1	CO622931	ACCESSION:CO622931
C 142	16	1.0	16	1	AR208800	ACCESSION:AR208800	C 215	13.8	0.8	17	1	CO622932	ACCESSION:CO622932
C 143	16	1.0	16	1	AR208801	ACCESSION:AR208801	C 216	13.8	0.8	17	1	CO622933	ACCESSION:CO622933
C 144	16	1.0	16	1	AR208802	ACCESSION:AR208802	C 217	13.8	0.8	17	1	CO622934	ACCESSION:CO622934
C 145	16	1.0	16	1	AR208803	ACCESSION:AR208803	C 218	13.8	0.8	17	1	CO622935	ACCESSION:CO622935
C 146	16	1.0	16	1	AR208804	ACCESSION:AR208804	C 219	13.8	0.8	17	1	CO622936	ACCESSION:CO622936
C 147	16	1.0	16	1	AR208805	ACCESSION:AR208805	C 220	13.8	0.8	17	1	CO622937	ACCESSION:CO622937
C 148	16	1.0	16	1	AR208806	ACCESSION:AR208806	C 221	13.8	0.8	17	1	CO622938	ACCESSION:CO622938
C 149	16	1.0	16	1	AR208807	ACCESSION:AR208807	C 222	13.8	0.8	17	1	CO622939	ACCESSION:CO622939
C 150	15.8	1.0	19	1	AR208808	ACCESSION:AR208808	C 223	13.8	0.8	17	1	CO622940	ACCESSION:CO622940
C 151	15.8	1.0	19	1	AR208809	ACCESSION:AR208809	C 224	13.8	0.8	17	1	CO622941	ACCESSION:CO622941
C 152	15.8	1.0	19	1	AR208810	ACCESSION:AR208810	C 225	13.8	0.8	17	1	CO622942	ACCESSION:CO622942
C 153	15.8	1.0	19	1	AR208811	ACCESSION:AR208811	C 226	13.8	0.8	17	1	CO622943	ACCESSION:CO622943
C 154	15.8	1.0	19	1	AR208812	ACCESSION:AR208812	C 227	13.8	0.8	17	1	CO622944	ACCESSION:CO622944
C 155	15.4	0.9	17	1	AR208813	ACCESSION:AR208813	C 228	13.8	0.8	17	1	CO622945	ACCESSION:CO622945
C 156	15.4	0.9	17	1	AR208814	ACCESSION:AR208814	C 229	13.8	0.8	17	1	CO622946	ACCESSION:CO622946
C 157	15.4	0.9	17	1	AR208815	ACCESSION:AR208815	C 230	13.8	0.8	17	1	CO622947	ACCESSION:CO622947
C 158	15.4	0.9	17	1	AR208816	ACCESSION:AR208816	C 231	13.8	0.8	17	1	CO622948	ACCESSION:CO622948
C 159	15.4	0.9	17	1	AR208817	ACCESSION:AR208817	C 232	13.8	0.8	17	1	CO622949	ACCESSION:CO622949
C 160	15.4	0.9	17	1	AR208818	ACCESSION:AR208818	C 233	13.8	0.8	17	1	CO622950	ACCESSION:CO622950
C 161	15.4	0.9	17	1	AR208819	ACCESSION:AR208819	C 234	13.8	0.8	17	1	CO622951	ACCESSION:CO622951
C 162	14.8	0.9	18	1	AR208820	ACCESSION:AR208820	C 235	13.8	0.8	17	1	CO622952	ACCESSION:CO622952
C 163	14.8	0.9	18	1	AR208821	ACCESSION:AR208821	C 236	13.8	0.8	17	1	CO622953	ACCESSION:CO622953
C 164	14.8	0.9	18	1	AR208822	ACCESSION:AR208822	C 237	13.8	0.8	17	1	CO622954	ACCESSION:CO622954
C 165	14.8	0.9	18	1	AR208823	ACCESSION:AR208823	C 238	13.8	0.8	17	1	CO622955	ACCESSION:CO622955
C 166	14.8	0.9	18	1	AR208824	ACCESSION:AR208824	C 239	13.8	0.8	17	1	CO622956	ACCESSION:CO622956
C 167	14.4	0.9	17	1	AR208825	ACCESSION:AR208825	C 240	13.8	0.8	17	1	CO622957	ACCESSION:CO622957
C 168	14.4	0.9	17	1	AR208826	ACCESSION:AR208826	C 241	13.8	0.8	17	1	CO622958	ACCESSION:CO622958
C 169	14.4	0.9	17	1	AR208827	ACCESSION:AR208827	C 242	13.8	0.8	17	1	CO622959	ACCESSION:CO622959
C 170	14.4	0.9	17	1	AR208828	ACCESSION:AR208828	C 243	13.8	0.8	17	1	CO622960	ACCESSION:CO622960
C 171	14.4	0.9	17	1	AR208829	ACCESSION:AR208829	C 244	13.8	0.8	17	1	CO622961	ACCESSION:CO622961
C 172	14.4	0.9	17	1	AR208830	ACCESSION:AR208830	C 245	13.8	0.8	17	1	CO622962	ACCESSION:CO622962
C 173	14.4	0.9	17	1	AR208831	ACCESSION:AR208831	C 246	13.8	0.8	17	1	CO622963	ACCESSION:CO622963
C 174	14.4	0.9	17	1	AR208832	ACCESSION:AR208832	C 247	13.8	0.8	17	1	CO622964	ACCESSION:CO622964
C 175	14.4	0.9	17	1	AR208833	ACCESSION:AR208833	C 248	13.8	0.8	17	1	CO622965	ACCESSION:CO622965
C 176	14.4	0.9	17	1	AR208834	ACCESSION:AR208834	C 249	13.8	0.8	17	1	CO622966	ACCESSION:CO622966
C 177	14.4	0.9	17	1	AR208835	ACCESSION:AR208835	C 250	13.8	0.8	17	1	CO622967	ACCESSION:CO622967
C 178	14.4	0.9	17	1	AR208836	ACCESSION:AR208836	C 251	13.8	0.8	17	1	CO622968	ACCESSION:CO622968
C 179	14.4	0.9	17	1	AR208837	ACCESSION:AR208837	C 252	13.8	0.8	17	1	CO622969	ACCESSION:CO622969



c 253	13.8	0.8	17	1	AX688721	ACSSSION:AX688721
254	13.8	0.8	17	1	AX690667	ACSSSION:AX690667
255	13.8	0.8	17	1	AX727197	ACSSSION:AX727197
c 256	13.8	0.8	17	1	AX728423	ACSSSION:AX728423
257	13.8	0.8	17	1	AX731740	ACSSSION:AX731740
258	13.8	0.8	17	1	AX734894	ACSSSION:AX734894
c 259	13.8	0.8	17	1	AX756729	ACSSSION:AX756729
260	13.4	0.8	15	1	I61606	ACSSSION:I61606
c 261	13.4	0.8	15	1	AR180106	ACSSSION:AR180106
c 262	13.4	0.8	15	1	AR180715	ACSSSION:AR180715
c 263	13.4	0.8	15	1	AR532147	ACSSSION:AR532147
c 264	13.4	0.8	15	1	AX167089	ACSSSION:AX167089
c 265	13.4	0.8	15	1	AX635964	ACSSSION:AX635964
c 266	13.4	0.8	16	1	AR029843	ACSSSION:AR029843
267	13.4	0.8	16	1	AR131574	ACSSSION:AR131574
c 268	13.4	0.8	16	1	AR131575	ACSSSION:AR131575
c 269	13.4	0.8	16	1	CO796994	ACSSSION:CO796994
c 270	13.4	0.8	16	1	CO858546	ACSSSION:CO858546
c 271	13.4	0.8	16	1	AR199508	ACSSSION:AR199508
272	13.4	0.8	16	1	AR199509	ACSSSION:AR199509
273	13.4	0.8	16	1	AR200979	ACSSSION:AR200979
274	13.4	0.8	16	1	AR200980	ACSSSION:AR200980
275	13.4	0.8	16	1	AR488738	ACSSSION:AR488738
276	13.4	0.8	16	1	AR488739	ACSSSION:AR488739
277	13.4	0.8	16	1	AX419730	ACSSSION:AX419730
278	13.4	0.8	16	1	AX419731	ACSSSION:AX419731
279	13.4	0.8	16	1	BD084992	ACSSSION:BD084992
280	13.4	0.8	16	1	BD084993	ACSSSION:BD084993
c 281	13.4	0.8	16	1	S81287	ACSSSION:S81287
c 282	13	0.8	14	1	AR066302	ACSSSION:AR066302
c 283	13	0.8	15	1	AX377347	ACSSSION:AX377347
c 284	13	0.8	15	1	ATH551605	ACSSSION:ATH551605
285	13	0.8	16	1	CO806753	ACSSSION:CO806753
286	12.8	0.8	16	1	A88141	ACSSSION:A88141
287	12.8	0.8	16	1	A89435	ACSSSION:A89435
c 288	12.8	0.8	16	1	AR0108	ACSSSION:AR0108
c 289	12.8	0.8	16	1	AR104209	ACSSSION:AR104209
c 290	12.8	0.8	16	1	CO786338	ACSSSION:CO786338
291	12.8	0.8	16	1	AR196058	ACSSSION:AR196058
292	12.8	0.8	16	1	AX003952	ACSSSION:AX003952
293	12.8	0.8	16	1	AX255603	ACSSSION:AX255603
294	12.8	0.8	16	1	AX255637	ACSSSION:AX255637
295	12.8	0.8	16	1	AX713247	ACSSSION:AX713247
296	12.8	0.8	16	1	BD065654	ACSSSION:BD065654
297	12.8	0.8	16	1	BD066948	ACSSSION:BD066948
c 298	12.8	0.8	16	1	BD086293	ACSSSION:BD086293
ALIGNMENTS						
RESULT 1						
LOCUS	A21575	32 bp	DNA	linear	PAT 26-JUL-1994	
DEFINITION	oligonucleotide.					
ACCESSION	A21575					
VERSION	A21575.1	GI:583580				
KEYWORDS	synthetic construct					
SOURCE	synthetic construct					
ORGANISM	other sequences; artificial sequences.					
REFERENCE	1 (bases 1 to 32)					
AUTHORS	CYTOLYSIS INHIBITOR PROTEINS (CLI) AND DNA SEQUENCES CODING FOR					
TITLE	SAID PROTEINS					
JOURNAL	Patent: WO 9105043-A 1 18-APR-1991;					
FEATURES	Location/Qualifiers					
source	1..32					
	/organism="synthetic construct"					
	/mol_type="unassigned DNA"					
	/db_xref="taxon:32630"					
Query Match	1.7%;	Score 27.2;	DB 1;	Length 32;		

Best Local Similarity	90.6%;	Pred. No. 8.1;				
Matches	29;	Conservative	0;	Mismatches	3;	Indels
						0;
						Gaps
						0;
QY	129	GACATGAGCTCCAGGAATGTCCAATCAGGG	160			
Db	1	GACATGAGCTCGAGGAGATGTCCAACACGGG	32			
RESULT 2						
LOCUS	AR090627	26 bp	DNA	linear	PAT 07-SEP-2000	
DEFINITION	Sequence 747 from patent US 5994076.					
ACCESSION	AR090627					
VERSION	AR090627.1	GI:10017382				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 26)					
AUTHORS	Chenchik,A., Jokhadze,G. and Bibilashvilli,R.					
TITLE	Methods of assaying differential expression					
JOURNAL	Patent: US 5994076-A 747 30-NOV-1999;					
FEATURES	Location/Qualifiers					
source	1..26					
	/organism="unknown"					
	/mol_type="unassigned DNA"					
Query Match	1.6%;	Score 26;	DB 1;	Length 26;		
Best Local Similarity	100.0%;	Pred. No. 6.5;				
Matches	26;	Conservative	0;	Mismatches	0;	Indels
						0;
						Gaps
						0;
QY	934	TCCGGATGAAGCACCAGTGTGACAAG	959			
Db	1	TCCGGATGAAGCACCAGTGTGACAAG	26			
RESULT 3						
LOCUS	AR197662	26 bp	DNA	linear	PAT 20-APR-2002	
DEFINITION	Sequence 747 from patent US 6352829.					
ACCESSION	AR197662					
VERSION	AR197662.1	GI:20247511				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unclassified.					
REFERENCE	1 (bases 1 to 26)					
AUTHORS	Chenchik,A., Jokhadze,G. and Bibilashvilli,R.					
TITLE	Methods of assaying differential expression					
JOURNAL	Patent: US 6352829-A 747 05-MAR-2002;					
FEATURES	Location/Qualifiers					
source	1..26					
	/organism="unknown"					
	/mol_type="unassigned DNA"					
Query Match	1.6%;	Score 26;	DB 1;	Length 26;		
Best Local Similarity	100.0%;	Pred. No. 6.5;				
Matches	26;	Conservative	0;	Mismatches	0;	Indels
						0;
						Gaps
						0;
QY	934	TCCGGATGAAGCACCAGTGTGACAAG	959			
Db	1	TCCGGATGAAGCACCAGTGTGACAAG	26			
RESULT 4						
LOCUS	AR259816	26 bp	DNA	linear	PAT 20-DEC-2002	
DEFINITION	Sequence 747 from patent US 6489455.					
ACCESSION	AR259816					
VERSION	AR259816.1	GI:27310327				
KEYWORDS	Unknown.					
SOURCE	Unknown.					
ORGANISM	Unknown.					



REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 60 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source  
1. .23  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AAGTCCCGCATCTCTCCGAGCTT 733  
|||||  
Db 1 AAGTCCCGCATCTCTCCGAGCTT 23

RESULT 10  
LOCUS CQ786175 23 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 63 from Patent WO2004018676.  
ACCESSION CQ786175  
VERSION CQ786175.1 GI:45721278  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 63 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source  
1. .23  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGCTT 1635  
|||||  
Db 1 AACTAATTCATAAACTGCTT 23

RESULT 11  
LOCUS CQ786178 23 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 66 from Patent WO2004018676.  
ACCESSION CQ786178  
VERSION CQ786178.1 GI:45721281  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 66 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source  
1. .23  
/organism="Homo sapiens"

/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 46 GCATGATGAAGACTCTGTGCTG 68  
|||||  
Db 1 GCATGATGAAGACTCTGTGCTG 23

RESULT 12  
LOCUS AR208706/c 23 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 5 from patent US 6383808.  
ACCESSION AR208706  
VERSION AR208706.1 GI:21509931  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 23)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 5 07-MAY-2002;  
FEATURES  
source  
1. .23  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 13;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 789 CTTGAGATGATACAGAGGCTCA 811  
|||||  
Db 23 CTTGAGATGATACAGAGGCTCA 1

RESULT 13  
LOCUS AR038687 21 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 21 from patent US 5807678.  
ACCESSION AR038687  
VERSION AR038687.1 GI:5958050  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
Unclassified.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Miller,W.L., Lin,D. and Strauss,J.F. III.  
TITLE Identification of gene mutations associated with congenital lipoid adrenal hyperplasia  
JOURNAL Patent: US 5807678-A 21 15-SEP-1998;  
FEATURES  
source  
1. .21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1354 AGAAGCGCTGCAGGAATACC 1374  
|||||  
Db 1 AGAAGCGCTGCAGGAATACC 21

RESULT 14  
LOCUS CQ786113 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 1 from Patent WO2004018676.

```
ACCESSION      CQ786113
VERSION        CQ786113.1  GI:45721216
KEYWORDS       synthetic construct
SOURCE          other sequences; artificial sequences.
ORGANISM       Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
                Gonos,E.
REFERENCE      1
AUTHORS        Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
                Gonos,E.
TITLE          Rnai probes targeting cancer-related proteins
JOURNAL        Patent: WO 2004018676-A 1 04-MAR-2004;
                The University of British Columbia (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
Query Match    1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches        21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY             482 CCAGAGCTCGCCCTTCTACTT 502
Db             1 CCAGAGCTCGCCCTTCTACTT 21
                |||
RESULT 15
CQ786114/c
LOCUS          CQ786114          21 bp      DNA          linear          PAT 24-MAR-2004
DEFINITION     Sequence 2 from Patent WO2004018676.
ACCESSION      CQ786114
VERSION        CQ786114.1  GI:45721217
KEYWORDS       synthetic construct
SOURCE          synthetic construct
ORGANISM        other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
                Gonos,E.
TITLE          Rnai probes targeting cancer-related proteins
JOURNAL        Patent: WO 2004018676-A 2 04-MAR-2004;
                The University of British Columbia (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
Query Match    1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches        21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY             480 AACGAGAGCTCGCCCTTCTAC 500
Db             21 AACGAGAGCTCGCCCTTCTAC 1
                |||
RESULT 16
CQ786115
LOCUS          CQ786115          21 bp      DNA          linear          PAT 24-MAR-2004
DEFINITION     Sequence 3 from Patent WO2004018676.
ACCESSION      CQ786115
VERSION        CQ786115.1  GI:45721218
KEYWORDS       synthetic construct
SOURCE          synthetic construct
ORGANISM        other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
                Gonos,E.
ACCESSION      CQ786113
VERSION        CQ786113.1  GI:45721216
KEYWORDS       synthetic construct
SOURCE          other sequences; artificial sequences.
ORGANISM       Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
                Gonos,E.
REFERENCE      1
AUTHORS        Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
                Gonos,E.
TITLE          Rnai probes targeting cancer-related proteins
JOURNAL        Patent: WO 2004018676-A 3 04-MAR-2004;
                The University of British Columbia (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
Query Match    1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches        21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY             1100 GATGCTCAACACCTCTCTCTT 1120
Db             1 GATGCTCAACACCTCTCTCTT 21
                |||
RESULT 17
CQ786116/c
LOCUS          CQ786116          21 bp      DNA          linear          PAT 24-MAR-2004
DEFINITION     Sequence 4 from Patent WO2004018676.
ACCESSION      CQ786116
VERSION        CQ786116.1  GI:45721219
KEYWORDS       synthetic construct
SOURCE          synthetic construct
ORGANISM        other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
                Gonos,E.
TITLE          Rnai probes targeting cancer-related proteins
JOURNAL        Patent: WO 2004018676-A 4 04-MAR-2004;
                The University of British Columbia (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
Query Match    1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches        21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY             1098 AAGATGCTCAACACCTCTCTCC 1118
Db             21 AAGATGCTCAACACCTCTCTCC 1
                |||
RESULT 18
CQ786117
LOCUS          CQ786117          21 bp      DNA          linear          PAT 24-MAR-2004
DEFINITION     Sequence 5 from Patent WO2004018676.
ACCESSION      CQ786117
VERSION        CQ786117.1  GI:45721220
KEYWORDS       synthetic construct
SOURCE          synthetic construct
ORGANISM        other sequences; artificial sequences.
REFERENCE      1
AUTHORS        Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
                Gonos,E.
TITLE          Rnai probes targeting cancer-related proteins
JOURNAL        Patent: WO 2004018676-A 5 04-MAR-2004;
                The University of British Columbia (CA)
FEATURES       Location/Qualifiers
source         1..21
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="RNAi for human clusterin"
```

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCAATAAACTGCTTT 1635  
|||||  
DB 1 CTAATTCAATAAACTGCTTT 21

RESULT 19  
CQ786118/c  
LOCUS 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 6 from Patent WO2004018676.  
ACCESSION CQ786118  
VERSION CQ786118.1 GI:45721221  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 6 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGTC 1633  
|||||  
DB 21 AACTAATTCATAAACTGTC 1

RESULT 20  
CQ786170  
LOCUS 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 58 from Patent WO2004018676.  
ACCESSION CQ786170  
VERSION CQ786170.1 GI:45721273  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 58 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502  
|||||  
DB 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 21  
CQ786171/c  
LOCUS 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 59 from Patent WO2004018676.  
ACCESSION CQ786171  
VERSION CQ786171.1 GI:45721274  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 59 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTTCTAC 500  
|||||  
DB 21 AACGAGCTCGCCCTTCTAC 1

RESULT 22  
CQ786173  
LOCUS 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 61 from Patent WO2004018676.  
ACCESSION CQ786173  
VERSION CQ786173.1 GI:45721276  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 61 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCCGCGATCGTCGCGAGCTT 733  
|||||  
DB 1 GTCCGCGATCGTCGCGAGCTT 21

RESULT 23  
CQ786174/c  
LOCUS 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 62 from Patent WO2004018676.  
ACCESSION CQ786174  
VERSION CQ786174.1 GI:45721277  
KEYWORDS  
SOURCE synthetic construct

```
ORGANISM    synthetic construct
REFERENCE    other sequences; artificial sequences.
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018676-A 62 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="RNAi for human clusterin"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          711 AAGTCCCGCATCGTCGGCAGC 731
Db          21 AAGTCCCGCATCGTCGGCAGC 1
RESULT 24
LOCUS       CQ786176                21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 64 from Patent WO2004018676.
ACCESSION   CQ786176
VERSION     CQ786176.1 GI:45721279
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 3 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES     Location/Qualifiers
source      1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          16 CCGAGGCGTGCAGAGACTCCA 36
Db          21 CCGAGGCGTGCAGAGACTCCA 1
RESULT 27
LOCUS       CQ786615/c             21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 4 from Patent WO2004018675.
ACCESSION   CQ786615
VERSION     CQ786615.1 GI:45721635
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 4 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES     Location/Qualifiers
source      1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          48 ATGATGAAGACTCTGCTGCTG 68
Db          48 ATGATGAAGACTCTGCTGCTG 68
```

```
ORGANISM    synthetic construct
REFERENCE    other sequences; artificial sequences.
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018676-A 62 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES     Location/Qualifiers
source       1..21
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="RNAi for human clusterin"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          1613 AACTAATTCATAAAACTGTC 1633
Db          21 AACTAATTCATAAAACTGTC 1
RESULT 26
LOCUS       CQ786614/c             21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 3 from Patent WO2004018675.
ACCESSION   CQ786614
VERSION     CQ786614.1 GI:45721634
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 3 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES     Location/Qualifiers
source      1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          16 CCGAGGCGTGCAGAGACTCCA 36
Db          21 CCGAGGCGTGCAGAGACTCCA 1
RESULT 27
LOCUS       CQ786615/c             21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 4 from Patent WO2004018675.
ACCESSION   CQ786615
VERSION     CQ786615.1 GI:45721635
KEYWORDS    .
SOURCE      Homo sapiens (human)
ORGANISM    Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE   1
AUTHORS     Jansen,B.
TITLE       Treatment of melanoma by reduction in clusterin levels
JOURNAL     Patent: WO 2004018675-A 4 04-MAR-2004;
              The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES     Location/Qualifiers
source      1..21
              /organism="Homo sapiens"
              /mol_type="unassigned DNA"
              /db_xref="taxon:9606"
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches      21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY          48 ATGATGAAGACTCTGCTGCTG 68
Db          48 ATGATGAAGACTCTGCTGCTG 68
```







```

other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Jansen,B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 21 04-MAR-2004; Gleave, Martin E. (CA)
The University of British Columbia (CA); Location/Qualifiers
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match
1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTTCTAC 500
Db 21 AACGAGCTCGCCCTTCTAC 1

RESULT 38
CQ786633
LOCUS
CQ786633
DEFINITION
Sequence 22 from Patent WO2004018675.
ACCESSION
CQ786633
VERSION
CQ786633.1 GI:45721653
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Jansen,B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 22 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
LOCATION/Qualifiers
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match
1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GATGCTCAACACCTCTCTT 1120
Db 1 GATGCTCAACACCTCTCTT 21

RESULT 39
CQ786634/c
LOCUS
CQ786634
DEFINITION
Sequence 23 from Patent WO2004018675.
ACCESSION
CQ786634
VERSION
CQ786634.1 GI:45721654
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Jansen,B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 23 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
LOCATION/Qualifiers
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Jansen,B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 21 04-MAR-2004; Gleave, Martin E. (CA)
The University of British Columbia (CA); Location/Qualifiers
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match
1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATAAACTGTC 1633
Db 21 AACTAATTCATAAACTGTC 1

RESULT 41
CQ786647
LOCUS
CQ786647
DEFINITION
Sequence 36 from Patent WO2004018675.
ACCESSION
CQ786647
VERSION
CQ786647.1 GI:45721667
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Jansen,B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 36 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
LOCATION/Qualifiers
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match
1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
Db 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 40
CQ786636/c
LOCUS
CQ786636
DEFINITION
Sequence 25 from Patent WO2004018675.
ACCESSION
CQ786636
VERSION
CQ786636.1 GI:45721656
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Jansen,B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 25 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
LOCATION/Qualifiers
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match
1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1098 AAGATGCTCAACACCTCTCC 1118
Db 21 AAGATGCTCAACACCTCTCC 1

RESULT 42
CQ786636/c
LOCUS
CQ786636
DEFINITION
Sequence 25 from Patent WO2004018675.
ACCESSION
CQ786636
VERSION
CQ786636.1 GI:45721656
KEYWORDS
synthetic construct
SOURCE
synthetic construct
ORGANISM
other sequences; artificial sequences.
REFERENCE
1
AUTHORS
Jansen,B.
TITLE
Treatment of melanoma by reduction in clusterin levels
JOURNAL
Patent: WO 2004018675-A 25 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
LOCATION/Qualifiers
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match
1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 20;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502
Db 1 CCAGAGCTCGCCCTTCTACTT 21

```

RESULT 42  
CQ786648/c  
LOCUS CQ786648 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 37 from Patent WO2004018675.  
ACCESSION CQ786648  
VERSION CQ786648.1 GI:45721668  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 37 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 480 AACGAGCTCGCCCTTCTAC 500  
Db 21 AACGAGCTCGCCCTTCTAC 1  
RESULT 43  
CQ786649  
LOCUS CQ786649 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 38 from Patent WO2004018675.  
ACCESSION CQ786649  
VERSION CQ786649.1 GI:45721669  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 38 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 480 AACGAGCTCGCCCTTCTAC 500  
Db 21 AACGAGCTCGCCCTTCTAC 1  
RESULT 44  
CQ786650/c  
LOCUS CQ786650 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 39 from Patent WO2004018675.  
ACCESSION CQ786650  
VERSION CQ786650.1 GI:45721670  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1

Jansen,B.  
Treatment of melanoma by reduction in clusterin levels  
Patent: WO 2004018675-A 39 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
Location/Qualifiers  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 711 AAGTCCCGCATCGTCCGAGC 731  
Db 21 AAGTCCCGCATCGTCCGAGC 1  
RESULT 45  
CQ786651  
LOCUS CQ786651 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 40 from Patent WO2004018675.  
ACCESSION CQ786651  
VERSION CQ786651.1 GI:45721671  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 40 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
Location/Qualifiers  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1615 CTAATTCAATAAAAGTGTCTT 1635  
Db 1 CTAATTCAATAAAAGTGTCTT 21  
RESULT 46  
CQ786652/c  
LOCUS CQ786652 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 41 from Patent WO2004018675.  
ACCESSION CQ786652  
VERSION CQ786652.1 GI:45721672  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 41 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
Location/Qualifiers  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATTAATAACTGTC 1633  
|||||  
Db 21 AACTAATTCATTAATAACTGTC 1

RESULT 47  
AR208707  
LOCUS AR208707 21 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 6 from patent US 6383808.  
ACCESSION AR208707  
VERSION AR208707.1 GI:21509932  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Monis,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 6 07-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..21  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCATGTTCCAGCCCT 786  
|||||  
Db 1 TCCACGCCATGTTCCAGCCCT 21

RESULT 48  
AR236282  
LOCUS AR236282 21 bp DNA linear PAT 20-DEC-2002  
DEFINITION Sequence 14 from patent US 6464975.  
ACCESSION AR236282  
VERSION AR236282.1 GI:27280110  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Millis,A.J.T.  
TITLE Compositions and methods for altering cell migration  
JOURNAL Patent: US 6464975-A 14 15-OCT-2002;  
FEATURES Location/Qualifiers  
source 1..21  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 20;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AACCCAAGAGAGAGAGAGAGG 294  
|||||  
Db 1 AACCCAAGAGAGAGAGAGAGG 21

RESULT 49  
BD230318  
LOCUS BD230318 24 bp DNA linear PAT 17-JUL-2003  
DEFINITION Total genome radiation hybrid map of canine genome and its use for identification of interesting genes.  
ACCESSION BD230318  
VERSION BD230318.1 GI:33040088  
KEYWORDS JP 2002530091-A/187.

SOURCE Canis familiaris (dog)  
ORGANISM Canis familiaris  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.  
REFERENCE 1 (bases 1 to 24)  
AUTHORS Galibert,F. and Andre,C.  
TITLE Total genome radiation hybrid map of canine genome and its use for identification of interesting genes  
JOURNAL Patent: JP 2002530091-A 187 17-SEP-2002;  
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE  
COMMENT OS Canis familiaris (dog)  
PN JP 2002530091-A/187  
PD 17-SEP-2002  
PF 15-NOV-1999 JP 2000582596  
PR 13-NOV-1998 US 60/108193  
PI FRANCIS GALIBERT,CATHERINE ANDRE  
PC C12N15/09,C12Q1/68,C12N15/00  
CC A0133  
FH Key Location/Qualifiers  
FT source 1..24  
FT /organism='Canis familiaris (dog)'.  
FEATURES Location/Qualifiers  
source 1..24  
/organism="Canis familiaris"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9615"

Query Match 1.3%; Score 20.8; DB 1; Length 24;  
Best Local Similarity 91.7%; Pred. No. 32;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1467 CCCCCAGAGAGAGCTCTGCAGTC 1490  
|||||  
Db 1 CCCCTAGAGAGAGCTCTGCATGTC 24

RESULT 50  
AR531218  
LOCUS AR531218 21 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 2421 from patent US 6727063.  
ACCESSION AR531218  
VERSION AR531218.1 GI:53919655  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 21)  
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and McCarthy,J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: US 6727063-A 2421 27-APR-2004;  
FEATURES Location/Qualifiers  
source 1..21  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.3%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 23;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1050 GAGAGGTTGACCGAGGAATAC 1070  
|||||  
Db 1 GAGAGGTTGAYCAGGAATAC 21

RESULT 51  
AR531219  
LOCUS AR531219 21 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 2422 from patent US 6727063.  
ACCESSION AR531219  
VERSION AR531219.1 GI:53919656  
KEYWORDS  
SOURCE Unknown.

```
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 2422 27-APR-2004;
FEATURES
source
1..21
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.3%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 999 CCTCTCCAGGCTAAGCTGCGG 1019
Db 1 CCTCTCCAGGYTAAGCTGCGG 21

RESULT 52
AR531220 21 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 2423 from patent US 6727063.
DEFINITION AR531220
ACCESSION AR531220
VERSION AR531220.1 GI:53919657
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 2423 27-APR-2004;
FEATURES
source
1..21
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.3%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1170 CTCACGCAAGCGGAAGACCAG 1190
Db 1 CTCACGCAAGSCGAAGACCAG 21

RESULT 53
AR531221 21 bp DNA linear PAT 08-OCT-2004
LOCUS Sequence 2424 from patent US 6727063.
DEFINITION AR531221
ACCESSION AR531221
VERSION AR531221.1 GI:53919658
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 21)
AUTHORS Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: US 6727063-A 2424 27-APR-2004;
FEATURES
source
1..21
/mol_type="genomic DNA"

Query Match
Best Local Similarity 1.3%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1105 TCAACACCTCCTCTTGCTGG 1125
Db 1 TCAACACCTCTCTTGCTGG 21

RESULT 54
AX097243 21 bp DNA linear PAT 30-MAR-2001
LOCUS Sequence 2421 from Patent WO0118250.
DEFINITION AX097243
ACCESSION AX097243
VERSION AX097243.1 GI:13513638
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 2421 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES
source
1..21
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.3%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1050 GAGAGTTTGACGAGGAATAC 1070
Db 1 GAGAGTTTGAYCAGGAATAC 21

RESULT 55
AX097244 21 bp DNA linear PAT 30-MAR-2001
LOCUS Sequence 2422 from Patent WO0118250.
DEFINITION AX097244
ACCESSION AX097244
VERSION AX097244.1 GI:13513640
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
AUTHORS Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Lander,E.S., Cargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and
McCarthy,J.J.
TITLE Single nucleotide polymorphisms in genes
JOURNAL Patent: WO 0118250-A 2422 15-MAR-2001;
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium
Pharmaceuticals, Inc. (US)
FEATURES
source
1..21
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 1.3%; Score 20.6; DB 1; Length 21;
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 999 CCTCTCCAGGCTAAGCTGCGG 1019
Db 1 CCTCTCCAGGYTAAGCTGCGG 21

RESULT 56
```

AX097245  
LOCUS AX097245 21 bp DNA linear PAT 30-MAR-2001  
DEFINITION Sequence 2423 from Patent WO0118250.  
ACCESSION AX097245  
VERSION AX097245.1 GI:13513642  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and  
McCarthy,J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 2423 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium  
Pharmaceuticals, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 1..3%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 23;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1170 CTCACGCAAGCGGAGACACG 1190  
Db 1 CTCACGCAAGCGGAGACACG 21  
RESULT 57  
AX097246  
LOCUS AX097246 21 bp DNA linear PAT 30-MAR-2001  
DEFINITION Sequence 2424 from Patent WO0118250.  
ACCESSION AX097246  
VERSION AX097246.1 GI:13513644  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1  
AUTHORS Lander,E.S., Gargill,M., Ireland,J.S., Bolk,S., Daley,G.Q. and  
McCarthy,J.J.  
TITLE Single nucleotide polymorphisms in genes  
JOURNAL Patent: WO 0118250-A 2424 15-MAR-2001;  
WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) ; Millennium  
Pharmaceuticals, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 1..3%; Score 20.6; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 23;  
Matches 20; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 1105 TCAACACCTCTCTCTGCTGG 1125  
Db 1 TCAACACCTCTCTCTGCTGG 21  
RESULT 58  
CQ803453  
LOCUS CQ803453 20 bp DNA linear PAT 10-MAY-2004  
DEFINITION Sequence 5 from Patent WO2004035827.  
ACCESSION CQ803453  
VERSION CQ803453.1 GI:47110310  
KEYWORDS  
SOURCE unidentified

ORGANISM unidentified  
REFERENCE 1 unclassified.  
AUTHORS Breban,M., Gidrol,X., Marion,S. and Chiochia,G.  
TITLE Microarrays allowing molecular profiling of rheumatoid arthritis  
comparatively to osteoarthritis andtheir use  
JOURNAL Patent: WO 2004035827-A 5 29-APR-2004;  
INSERM, The French Institute of Health and Medical Resear ch (FR);  
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR); COMMISSARIAT A  
L'ENERGIE ATOMIQUE (FR)  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
misc\_feature 1..20  
/note="CLU forward primer for PCR"  
Query Match 1..2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1180 GCGAAGACCACTACTATCTG 1199  
Db 1 GCGAAGACCACTACTATCTG 20  
RESULT 59  
CQ803454/c  
LOCUS CQ803454 20 bp DNA linear PAT 10-MAY-2004  
DEFINITION Sequence 6 from Patent WO2004035827.  
ACCESSION CQ803454  
VERSION CQ803454.1 GI:47110311  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 unclassified.  
AUTHORS Breban,M., Gidrol,X., Marion,S. and Chiochia,G.  
TITLE Microarrays allowing molecular profiling of rheumatoid arthritis  
comparatively to osteoarthritis andtheir use  
JOURNAL Patent: WO 2004035827-A 6 29-APR-2004;  
INSERM, The French Institute of Health and Medical Resear ch (FR);  
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR); COMMISSARIAT A  
L'ENERGIE ATOMIQUE (FR)  
FEATURES  
source Location/Qualifiers  
1..20  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
misc\_feature 1..20  
/note="CLU reverse primer for PCR"  
Query Match 1..2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1361 GCTGCAGGAATACCGCAAAA 1380  
Db 20 GCTGCAGGAATACCGCAAAA 1  
RESULT 60  
AR208715/c  
LOCUS AR208715 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 14 from patent US 6383808.  
ACCESSION AR208715  
VERSION AR208715.1 GI:21509942  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 20) unclassified.

AUTHORS Monia,B.P. and Freier,S.M. TITLE Antisense inhibition of clusterin expression JOURNAL Patent: US 6383808-A 14 07-MAY-2002; LOCATION/Qualifiers 1. .20 /organism="unknown" /mol_type="unassigned DNA"										Query Match Best Local Similarity 1.2%; Score 20; DB 1; Length 20; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;									
QY 13 TGACCGAGCGTGCAGAAC 32       20 TGACCGAGCGTGCAGAAC 1										Db									
RESULT 61 AR208716/c LOCUS DEFINITION Sequence 15 from patent US 6383808. ACCESSION AR208716 VERSION AR208716.1 GI:21509944 KEYWORDS Unknown. SOURCE Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 20) AUTHORS Monia,B.P. and Freier,S.M. TITLE Antisense inhibition of clusterin expression JOURNAL Patent: US 6383808-A 15 07-MAY-2002; LOCATION/Qualifiers 1. .20 /organism="unknown" /mol_type="unassigned DNA"										source									
Query Match Best Local Similarity 1.2%; Score 20; DB 1; Length 20; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										QY 77 GCTGCTGCTGACCTGGGAGA 96       20 GCTGCTGCTGACCTGGGAGA 1									
Db																			
RESULT 62 AR208717/c LOCUS DEFINITION Sequence 16 from patent US 6383808. ACCESSION AR208717 VERSION AR208717.1 GI:21509945 KEYWORDS Unknown. SOURCE Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 20) AUTHORS Monia,B.P. and Freier,S.M. TITLE Antisense inhibition of clusterin expression JOURNAL Patent: US 6383808-A 16 07-MAY-2002; LOCATION/Qualifiers 1. .20 /organism="unknown" /mol_type="unassigned DNA"										source									
Query Match Best Local Similarity 1.2%; Score 20; DB 1; Length 20; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										QY 21 GCGTGCAAGACTCCAGAT 40       20 GCGTGCAAGACTCCAGAT 1									
Db																			
RESULT 63 AR208718/c LOCUS DEFINITION Sequence 17 from patent US 6383808. ACCESSION AR208718 VERSION AR208718.1 GI:21509946 KEYWORDS Unknown. SOURCE Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 20) AUTHORS Monia,B.P. and Freier,S.M. TITLE Antisense inhibition of clusterin expression JOURNAL Patent: US 6383808-A 17 07-MAY-2002; LOCATION/Qualifiers 1. .20 /organism="unknown" /mol_type="unassigned DNA"										source									
Query Match Best Local Similarity 1.2%; Score 20; DB 1; Length 20; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										QY 77 GCTGCTGCTGACCTGGGAGA 96       20 GCTGCTGCTGACCTGGGAGA 1									
Db																			
RESULT 64 AR208719/c LOCUS DEFINITION Sequence 18 from patent US 6383808. ACCESSION AR208719 VERSION AR208719.1 GI:21509947 KEYWORDS Unknown. SOURCE Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 20) AUTHORS Monia,B.P. and Freier,S.M. TITLE Antisense inhibition of clusterin expression JOURNAL Patent: US 6383808-A 18 07-MAY-2002; LOCATION/Qualifiers 1. .20 /organism="unknown" /mol_type="unassigned DNA"										source									
Query Match Best Local Similarity 1.2%; Score 20; DB 1; Length 20; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										QY 101 GCAGGTCCTGGGGACCAGA 120       20 GCAGGTCCTGGGGACCAGA 1									
Db																			
RESULT 65 AR208720/c LOCUS DEFINITION Sequence 19 from patent US 6383808. ACCESSION AR208720 VERSION AR208720.1 GI:21509949 KEYWORDS Unknown. SOURCE Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 20) AUTHORS Monia,B.P. and Freier,S.M. TITLE Antisense inhibition of clusterin expression JOURNAL Patent: US 6383808-A 19 07-MAY-2002; LOCATION/Qualifiers 1. .20 /organism="unknown"										source									
Query Match Best Local Similarity 1.2%; Score 20; DB 1; Length 20; Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										QY 39 ATTGGAGGCATGATGAAGAC 58       20 ATTGGAGGCATGATGAAGAC 1									
Db																			



```
QY 286 AGAAGAGGATGCCCTAAAT 305
Db 20 AGAAGAGGATGCCCTAAAT 1

RESULT 71
AR208726/c
LOCUS AR208726 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 25 from patent US 6383808.
ACCESSION AR208726
VERSION AR208726.1 GI:21509956
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 25 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CCTTAATGAGACCGAGAA 317
Db 20 CCTTAATGAGACCGAGAA 1

RESULT 72
AR208727/c
LOCUS AR208727 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 26 from patent US 6383808.
ACCESSION AR208727
VERSION AR208727.1 GI:21509957
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 26 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 307 AGACCAGGAATCAGAGACA 326
Db 20 AGACCAGGAATCAGAGACA 1

RESULT 73
AR208728/c
LOCUS AR208728 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 27 from patent US 6383808.
ACCESSION AR208728
VERSION AR208728.1 GI:21509959
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.

TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 27 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 324 ACAAGCTGAAGGAGTCCC 343
Db 20 ACAAGCTGAAGGAGTCCC 1

RESULT 74
AR208729/c
LOCUS AR208729 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 28 from patent US 6383808.
ACCESSION AR208729
VERSION AR208729.1 GI:21509960
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 28 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 359 GACCATGATGGCCCTCTGGG 378
Db 20 GACCATGATGGCCCTCTGGG 1

RESULT 75
AR208730/c
LOCUS AR208730 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 29 from patent US 6383808.
ACCESSION AR208730
VERSION AR208730.1 GI:21509961
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 29 07-MAY-2002;
FEATURES
source
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred.No.24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 364 TGATGGCCCTCTGGGAAGAG 383
Db 20 TGATGGCCCTCTGGGAAGAG 1

RESULT 76
```



AR208731/c  
 LOCUS AR208731 20 bp DNA linear PAT 20-JUN-2002  
 DEFINITION Sequence 30 from patent US 6383808.  
 ACCESSION AR208731  
 VERSION AR208731.1 GI:21509962  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 30 07-MAY-2002;  
 FEATURES  
 Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 source

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 380 AGAGTGTAGCCCTGCTGA 399  
 Db 20 AGAGTGTAGCCCTGCTGA 1

RESULT 77  
 AR208732/c  
 LOCUS AR208732 20 bp DNA linear PAT 20-JUN-2002  
 DEFINITION Sequence 31 from patent US 6383808.  
 ACCESSION AR208732  
 VERSION AR208732.1 GI:21509964  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 31 07-MAY-2002;  
 FEATURES  
 Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 source

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 407 CTGCATGAAGTTCTACGCAC 426  
 Db 20 CTGCATGAAGTTCTACGCAC 1

RESULT 78  
 AR208733/c  
 LOCUS AR208733 20 bp DNA linear PAT 20-JUN-2002  
 DEFINITION Sequence 32 from patent US 6383808.  
 ACCESSION AR208733  
 VERSION AR208733.1 GI:21509965  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 32 07-MAY-2002;  
 FEATURES  
 Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 source

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 443 CTCAGGCTGTGGCCGCC 462  
 Db 20 CTCAGGCTGTGTGGCCGCC 1

RESULT 79  
 AR208734/c  
 LOCUS AR208734 20 bp DNA linear PAT 20-JUN-2002  
 DEFINITION Sequence 33 from patent US 6383808.  
 ACCESSION AR208734  
 VERSION AR208734.1 GI:21509966  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 33 07-MAY-2002;  
 FEATURES  
 Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 source

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 444 TCAGGCTGTGTGGCCGCCA 463  
 Db 20 TCAGGCTGTGTGGCCGCCA 1

RESULT 80  
 AR208735/c  
 LOCUS AR208735 20 bp DNA linear PAT 20-JUN-2002  
 DEFINITION Sequence 34 from patent US 6383808.  
 ACCESSION AR208735  
 VERSION AR208735.1 GI:21509967  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 20)  
 AUTHORS Monia,B.P. and Freier,S.M.  
 TITLE Antisense inhibition of clusterin expression  
 JOURNAL Patent: US 6383808-A 34 07-MAY-2002;  
 FEATURES  
 Location/Qualifiers  
 1..20  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 source

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 24;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 455 TGGCCGCCAGCTTGAGGAGT 474  
 Db 20 TGGCCGCCAGCTTGAGGAGT 1

RESULT 81  
 AR208736/c  
 LOCUS AR208736 20 bp DNA linear PAT 20-JUN-2002  
 DEFINITION Sequence 35 from patent US 6383808.  
 ACCESSION AR208736  
 VERSION AR208736.1 GI:21509969  
 KEYWORDS

SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 35 07-MAY-2002;  
FEATURES Location/Qualifiers  
source  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 482 CCAGAGCTCGCCCTTCTACT 501  
Db 20 CCAGAGCTCGCCCTTCTACT 1  
RESULT 82  
AR208737/c  
LOCUS AR208737 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 36 from patent US 6383808.  
ACCESSION AR208737  
VERSION AR208737.1 GI:21509970  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 36 07-MAY-2002;  
FEATURES Location/Qualifiers  
source  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 492 CCCTTCTACTTCTGGATGAA 511  
Db 20 CCCTTCTACTTCTGGATGAA 1  
RESULT 83  
AR208738/c  
LOCUS AR208738 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 37 from patent US 6383808.  
ACCESSION AR208738  
VERSION AR208738.1 GI:21509971  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 37 07-MAY-2002;  
FEATURES Location/Qualifiers  
source  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 517 ACCGATCGACTCCCTGCTG 536

Db 20 ACCGATCGACTCCCTGCTG 1  
RESULT 84  
AR208739/c  
LOCUS AR208739 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 38 from patent US 6383808.  
ACCESSION AR208739  
VERSION AR208739.1 GI:21509972  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 38 07-MAY-2002;  
FEATURES Location/Qualifiers  
source  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 533 GCTGGAGAACGACCGCAGC 552  
Db 20 GCTGGAGAACGACCGCAGC 1  
RESULT 85  
AR208740/c  
LOCUS AR208740 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 39 from patent US 6383808.  
ACCESSION AR208740  
VERSION AR208740.1 GI:21509974  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 39 07-MAY-2002;  
FEATURES Location/Qualifiers  
source  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 551 GCAGACGCACATGCTGGATG 570  
Db 20 GCAGACGCACATGCTGGATG 1  
RESULT 86  
AR208741/c  
LOCUS AR208741 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 40 from patent US 6383808.  
ACCESSION AR208741  
VERSION AR208741.1 GI:21509975  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression

```
JOURNAL Patent: US 6383808-A 40 07-MAY-2002;
FEATURES
source
  1..20
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 553 AGACGCACATGCTGGATGTC 572
    |||||
Db 20 AGACGCACATGCTGGATGTC 1

RESULT 87
AR208742/c
LOCUS AR208742 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 41 from patent US 6383808.
ACCESSION AR208742
VERSION AR208742.1 GI:21509976
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 41 07-MAY-2002;
FEATURES
source
  1..20
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 TGGATGTCATGCAGGACCAC 584
    |||||
Db 20 TGGATGTCATGCAGGACCAC 1

RESULT 88
AR208743/c
LOCUS AR208743 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 42 from patent US 6383808.
ACCESSION AR208743
VERSION AR208743.1 GI:21509977
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 42 07-MAY-2002;
FEATURES
source
  1..20
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 567 GATGTCATGCAGGACCACCTT 586
    |||||
Db 20 GATGTCATGCAGGACCACCTT 1

RESULT 89
AR208744/c
LOCUS AR208744 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 43 from patent US 6383808.
ACCESSION AR208744
VERSION AR208744.1 GI:21509979
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 43 07-MAY-2002;
FEATURES
source
  1..20
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 TCATAGCAGGCTCTTCCAG 623
    |||||
Db 20 TCATAGCAGGCTCTTCCAG 1

RESULT 90
AR208745/c
LOCUS AR208745 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 44 from patent US 6383808.
ACCESSION AR208745
VERSION AR208745.1 GI:21509980
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 44 07-MAY-2002;
FEATURES
source
  1..20
  /organism="unknown"
  /mol_type="unassigned DNA"

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 608 AGACGAGCTCTTCCAGGACA 627
    |||||
Db 20 AGACGAGCTCTTCCAGGACA 1

RESULT 91
AR208746/c
LOCUS AR208746 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 45 from patent US 6383808.
ACCESSION AR208746
VERSION AR208746.1 GI:21509981
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 45 07-MAY-2002;
FEATURES
source
  1..20
  /organism="unknown"
  /mol_type="unassigned DNA"
```

Query Match		1.2%; Score 20; DB 1; Length 20;	
Best Local Similarity		100.0%; Pred. No. 24;	
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	613	AGCTCTCCAGGACAGGTTCC 632	
DB	20	AGCTCTCCAGGACAGGTTCC 1	
RESULT 92			
AR208747/c			PAT 20-JUN-2002
LOCUS		20 bp DNA	
DEFINITION		Sequence 46 from patent US 6383808.	
ACCESSION		AR208747	
VERSION		AR208747.1 GI:21509982	
KEYWORDS			
SOURCE		Unknown.	
ORGANISM		Unknown.	
REFERENCE		1 (bases 1 to 20)	
AUTHORS		Monia,B.P. and Freier,S.M.	
TITLE		Antisense inhibition of clusterin expression	
JOURNAL		Patent: US 6383808-A 46 07-MAY-2002;	
FEATURES		Location/Qualifiers	
source		1..20	
		/organism="unknown"	
		/mol_type="unassigned DNA"	
Query Match		1.2%; Score 20; DB 1; Length 20;	
Best Local Similarity		100.0%; Pred. No. 24;	
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	690	AGGCCTCACTTCTTCTTCC 709	
DB	20	AGGCCTCACTTCTTCTTCC 1	
RESULT 93			
AR208748/c			PAT 20-JUN-2002
LOCUS		20 bp DNA	
DEFINITION		Sequence 47 from patent US 6383808.	
ACCESSION		AR208748	
VERSION		AR208748.1 GI:21509984	
KEYWORDS			
SOURCE		Unknown.	
ORGANISM		Unknown.	
REFERENCE		1 (bases 1 to 20)	
AUTHORS		Monia,B.P. and Freier,S.M.	
TITLE		Antisense inhibition of clusterin expression	
JOURNAL		Patent: US 6383808-A 47 07-MAY-2002;	
FEATURES		Location/Qualifiers	
source		1..20	
		/organism="unknown"	
		/mol_type="unassigned DNA"	
Query Match		1.2%; Score 20; DB 1; Length 20;	
Best Local Similarity		100.0%; Pred. No. 24;	
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	721	TCGTCGCGAGCTTGATGCC 740	
DB	20	TCGTCGCGAGCTTGATGCC 1	
RESULT 94			
AR208749/c			PAT 20-JUN-2002
LOCUS		20 bp DNA	
DEFINITION		Sequence 48 from patent US 6383808.	
ACCESSION		AR208749	
VERSION		AR208749.1 GI:21509985	
KEYWORDS			
SOURCE		Unknown.	
ORGANISM		Unknown.	
REFERENCE		1 (bases 1 to 20)	
AUTHORS		Monia,B.P. and Freier,S.M.	
TITLE		Antisense inhibition of clusterin expression	
JOURNAL		Patent: US 6383808-A 48 07-MAY-2002;	
FEATURES		Location/Qualifiers	
source		1..20	
		/organism="unknown"	
		/mol_type="unassigned DNA"	
Query Match		1.2%; Score 20; DB 1; Length 20;	
Best Local Similarity		100.0%; Pred. No. 24;	
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	775	TGTTCCAGCCCTTCCTTGAG 794	
DB	20	TGTTCCAGCCCTTCCTTGAG 1	
RESULT 95			
AR208750/c			PAT 20-JUN-2002
LOCUS		20 bp DNA	
DEFINITION		Sequence 49 from patent US 6383808.	
ACCESSION		AR208750	
VERSION		AR208750.1 GI:21509986	
KEYWORDS			
SOURCE		Unknown.	
ORGANISM		Unknown.	
REFERENCE		1 (bases 1 to 20)	
AUTHORS		Monia,B.P. and Freier,S.M.	
TITLE		Antisense inhibition of clusterin expression	
JOURNAL		Patent: US 6383808-A 49 07-MAY-2002;	
FEATURES		Location/Qualifiers	
source		1..20	
		/organism="unknown"	
		/mol_type="unassigned DNA"	
Query Match		1.2%; Score 20; DB 1; Length 20;	
Best Local Similarity		100.0%; Pred. No. 24;	
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	776	GTTCAGCCCTTCCTTGAGA 795	
DB	20	GTTCAGCCCTTCCTTGAGA 1	
RESULT 96			
AR208751/c			PAT 20-JUN-2002
LOCUS		20 bp DNA	
DEFINITION		Sequence 50 from patent US 6383808.	
ACCESSION		AR208751	
VERSION		AR208751.1 GI:21509987	
KEYWORDS			
SOURCE		Unknown.	
ORGANISM		Unknown.	
REFERENCE		1 (bases 1 to 20)	
AUTHORS		Monia,B.P. and Freier,S.M.	
TITLE		Antisense inhibition of clusterin expression	
JOURNAL		Patent: US 6383808-A 50 07-MAY-2002;	
FEATURES		Location/Qualifiers	
source		1..20	
		/organism="unknown"	
		/mol_type="unassigned DNA"	
Query Match		1.2%; Score 20; DB 1; Length 20;	
Best Local Similarity		100.0%; Pred. No. 24;	
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	783	CCCTTCCTTGAGATGATACA 802	
DB			
Query Match		1.2%; Score 20; DB 1; Length 20;	
Best Local Similarity		100.0%; Pred. No. 24;	
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	



DEFINITION Sequence 56 from patent US 6383808.  
ACCESSION AR208757  
VERSION AR208757.1 GI:21509995  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 56 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 906 GAGATCCGCCCAACTCCAC 925  
Db 20 GAGATCCGCCCAACTCCAC 1

RESULT 103  
LOCUS AR208758/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 57 from patent US 6383808.  
ACCESSION AR208758  
VERSION AR208758.1 GI:21509996  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of Clusterin expression  
JOURNAL Patent: US 6383808-A 57 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 GCTGCTCGCGATGAGGAC 947  
Db 20 GCTGCTCGCGATGAGGAC 1

RESULT 104  
LOCUS AR208759/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 58 from patent US 6383808.  
ACCESSION AR208759  
VERSION AR208759.1 GI:21509997  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 58 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 967 AGATCTTGCTGTGGACTGT 986  
Db 20 AGATCTTGCTGTGGACTGT 1

RESULT 105  
LOCUS AR208760/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 59 from patent US 6383808.  
ACCESSION AR208760  
VERSION AR208760.1 GI:21509999  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 59 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTAAGCTCGCGGGAGCTC 1028  
Db 20 CTAAGCTCGCGGGAGCTC 1

RESULT 106  
LOCUS AR208761/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 60 from patent US 6383808.  
ACCESSION AR208761  
VERSION AR208761.1 GI:21510000  
KEYWORDS  
SOURCE  
ORGANISM

REFERENCE 1 (bases 1 to 20)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 60 07-MAY-2002;  
FEATURES Location/Qualifiers  
1..20  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 24;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1022 GGAGCTCGAGCAATCCCTCC 1041  
Db 20 GGAGCTCGAGCAATCCCTCC 1

RESULT 107  
LOCUS AR208762/c 20 bp DNA linear PAT 20-JUN-2002  
DEFINITION Sequence 61 from patent US 6383808.  
ACCESSION AR208762  
VERSION AR208762.1 GI:21510001  
KEYWORDS  
SOURCE  
ORGANISM

```
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 61 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 AAGTCTTACCAGTGGAGAT 1102
|||||
Db 20 AAGTCTTACCAGTGGAGAT 1

RESULT 108
AR208763/c
LOCUS AR208763 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 62 from patent US 6383808.
ACCESSION AR208763
VERSION AR208763.1 GI:21510002
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 62 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1091 CCAGTGAAGATGCTCAACA 1110
|||||
Db 20 CCAGTGAAGATGCTCAACA 1

RESULT 109
AR208764/c
LOCUS AR208764 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 63 from patent US 6383808.
ACCESSION AR208764
VERSION AR208764.1 GI:21510003
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 63 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1113 TCCTCCTTGTGGAGCAGCT 1132
|||||
Db 20 TCCTCCTTGTGGAGCAGCT 1

Unclassified.
REFERENCE 110
AR208765/c
LOCUS AR208765 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 64 from patent US 6383808.
ACCESSION AR208765
VERSION AR208765.1 GI:21510005
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 64 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 GCTGGAGCAGCTGAACGAGC 1140
|||||
Db 20 GCTGGAGCAGCTGAACGAGC 1

RESULT 111
AR208766/c
LOCUS AR208766 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 65 from patent US 6383808.
ACCESSION AR208766
VERSION AR208766.1 GI:21510006
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 65 07-MAY-2002;
FEATURES Location/Qualifiers
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"

Query Match 1..2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1148 CTGGGTGTCCCGCTGGCAA 1167
|||||
Db 20 CTGGGTGTCCCGCTGGCAA 1

RESULT 112
AR208767/c
LOCUS AR208767 20 bp DNA linear PAT 20-JUN-2002
DEFINITION Sequence 66 from patent US 6383808.
ACCESSION AR208767
VERSION AR208767.1 GI:21510007
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 66 07-MAY-2002;
FEATURES Location/Qualifiers
```

source		1. .20	/organism="unknown"		/mol_type="unassigned DNA"							
Accession		AR208770	GI:21510011									
Version		AR208770.1										
Keywords		Unknown.										
Source		Unknown.										
Organism		Unclassified.										
Reference		1 (bases 1 to 20)										
Authors		Monia,B.P. and Freier,S.M.										
Title		Antisense inhibition of clusterin expression										
Journal		Patent: US 6383808-A 69 07-MAY-2002;										
Features		Location/Qualifiers										
Qy		1182	GAAGACCAGTACTATCTGCG 1201									
Db		20	GAAGACCAGTACTATCTGCG 1									
Result 113												
AR208768/c		AR208768	20 bp DNA		linear							
Locus		Sequence 67 from patent US 6383808.										
Definition												
Accession		AR208768										
Version		AR208768.1	GI:21510008									
Keywords		Unknown.										
Source		Unknown.										
Organism		Unclassified.										
Reference		1 (bases 1 to 20)										
Authors		Monia,B.P. and Freier,S.M.										
Title		Antisense inhibition of clusterin expression										
Journal		Patent: US 6383808-A 67 07-MAY-2002;										
Features		Location/Qualifiers										
Qy		1194	TATCTGCGGGTCACACGGT 1213									
Db		20	TATCTGCGGGTCACACGGT 1									
Query Match		1.2%; Score 20; DB 1; Length 20;										
Best Local Similarity		100.0%; Pred. No. 24;										
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										
Result 114												
AR208769/c		AR208769	20 bp DNA		linear							
Locus		Sequence 68 from patent US 6383808.										
Definition												
Accession		AR208769										
Version		AR208769.1	GI:21510010									
Keywords		Unknown.										
Source		Unknown.										
Organism		Unclassified.										
Reference		1 (bases 1 to 20)										
Authors		Monia,B.P. and Freier,S.M.										
Title		Antisense inhibition of clusterin expression										
Journal		Patent: US 6383808-A 68 07-MAY-2002;										
Features		Location/Qualifiers										
Qy		1216	CTTCCACACTTCTGACTCG 1235									
Db		20	CTTCCACACTTCTGACTCG 1									
Query Match		1.2%; Score 20; DB 1; Length 20;										
Best Local Similarity		100.0%; Pred. No. 24;										
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										
Result 115												
AR208770/c		AR208770	20 bp DNA		linear							
Locus		Sequence 69 from patent US 6383808.										
Definition												
Accession		AR208770										
Version		AR208770.1	GI:21510011									
Keywords		Unknown.										
Source		Unknown.										
Organism		Unclassified.										
Reference		1 (bases 1 to 20)										
Authors		Monia,B.P. and Freier,S.M.										
Title		Antisense inhibition of clusterin expression										
Journal		Patent: US 6383808-A 69 07-MAY-2002;										
Features		Location/Qualifiers										
Qy		1275	TTTGACTCTGATCCCATCAC 1294									
Db		20	TTTGACTCTGATCCCATCAC 1									
Query Match		1.2%; Score 20; DB 1; Length 20;										
Best Local Similarity		100.0%; Pred. No. 24;										
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										
Result 116												
AR208771/c		AR208771	20 bp DNA		linear							
Locus		Sequence 70 from patent US 6383808.										
Definition												
Accession		AR208771										
Version		AR208771.1	GI:21510012									
Keywords		Unknown.										
Source		Unknown.										
Organism		Unclassified.										
Reference		1 (bases 1 to 20)										
Authors		Monia,B.P. and Freier,S.M.										
Title		Antisense inhibition of clusterin expression										
Journal		Patent: US 6383808-A 70 07-MAY-2002;										
Features		Location/Qualifiers										
Qy		1300	CGGTCCCTGTAGAGTCTCC 1319									
Db		20	CGGTCCCTGTAGAGTCTCC 1									
Query Match		1.2%; Score 20; DB 1; Length 20;										
Best Local Similarity		100.0%; Pred. No. 24;										
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										
Result 117												
AR208772/c		AR208772	20 bp DNA		linear							
Locus		Sequence 71 from patent US 6383808.										
Definition												
Accession		AR208772										
Version		AR208772.1	GI:21510013									
Keywords		Unknown.										
Source		Unknown.										
Organism		Unclassified.										
Reference		1 (bases 1 to 20)										
Authors		Monia,B.P. and Freier,S.M.										
Title		Antisense inhibition of clusterin expression										
Journal		Patent: US 6383808-A 71 07-MAY-2002;										
Features		Location/Qualifiers										
Qy		1216	CTTCCACACTTCTGACTCG 1235									
Db		20	CTTCCACACTTCTGACTCG 1									
Query Match		1.2%; Score 20; DB 1; Length 20;										
Best Local Similarity		100.0%; Pred. No. 24;										
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										
Result 118												
AR208773/c		AR208773	20 bp DNA		linear							
Locus		Sequence 72 from patent US 6383808.										
Definition												
Accession		AR208773										
Version		AR208773.1	GI:21510014									
Keywords		Unknown.										
Source		Unknown.										
Organism		Unclassified.										
Reference		1 (bases 1 to 20)										
Authors		Monia,B.P. and Freier,S.M.										
Title		Antisense inhibition of clusterin expression										
Journal		Patent: US 6383808-A 72 07-MAY-2002;										
Features		Location/Qualifiers										
Qy		1275	TTTGACTCTGATCCCATCAC 1294									
Db		20	TTTGACTCTGATCCCATCAC 1									
Query Match		1.2%; Score 20; DB 1; Length 20;										
Best Local Similarity		100.0%; Pred. No. 24;										
Matches		20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;										



Matches	20;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	1332	AAATTTATGGAGACCGTGGC 1351							
Db	20	AAATTTATGGAGACCGTGGC 1							
RESULT 118									
AR208773/c									
LOCUS	AR208773	20 bp	DNA	linear	PAT 20-JUN-2002				
DEFINITION	Sequence 72 from patent US 6383808.								
ACCESSION	AR208773								
VERSION	AR208773.1	GI:21510015							
KEYWORDS	Unknown.								
SOURCE	Unknown.								
ORGANISM	Unclassified.								
REFERENCE	1 (bases 1 to 20)								
AUTHORS	Monia,B.P. and Freier,S.M.								
TITLE	Antisense inhibition of clusterin expression								
JOURNAL	Patent: US 6383808-A 72 07-MAY-2002;								
FEATURES	Location/Qualifiers								
source	1..20								
	/organism="unknown"								
	/mol_type="unassigned DNA"								
Query Match	1.2%; Score 20; DB 1; Length 20;								
Best Local Similarity	100.0%; Pred. No. 24;								
Matches	20;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	1398	GATGTGGATGTCCTTTTGC 1417							
Db	20	GATGTGGATGTCCTTTTGC 1							
RESULT 119									
AR208774/c									
LOCUS	AR208774	20 bp	DNA	linear	PAT 20-JUN-2002				
DEFINITION	Sequence 73 from patent US 6383808.								
ACCESSION	AR208774								
VERSION	AR208774.1	GI:21510016							
KEYWORDS	Unknown.								
SOURCE	Unknown.								
ORGANISM	Unclassified.								
REFERENCE	1 (bases 1 to 20)								
AUTHORS	Monia,B.P. and Freier,S.M.								
TITLE	Antisense inhibition of clusterin expression								
JOURNAL	Patent: US 6383808-A 73 07-MAY-2002;								
FEATURES	Location/Qualifiers								
source	1..20								
	/organism="unknown"								
	/mol_type="unassigned DNA"								
Query Match	1.2%; Score 20; DB 1; Length 20;								
Best Local Similarity	100.0%; Pred. No. 24;								
Matches	20;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	1545	GCTCTGGATCCTGCACTCTA 1564							
Db	20	GCTCTGGATCCTGCACTCTA 1							
RESULT 120									
AR208775/c									
LOCUS	AR208775	20 bp	DNA	linear	PAT 20-JUN-2002				
DEFINITION	Sequence 74 from patent US 6383808.								
ACCESSION	AR208775								
VERSION	AR208775.1	GI:21510017							
KEYWORDS	Unknown.								
SOURCE	Unknown.								
ORGANISM	Unclassified.								
REFERENCE	1 (bases 1 to 20)								
AUTHORS	Monia,B.P. and Freier,S.M.								
TITLE	Antisense inhibition of clusterin expression								
JOURNAL	Patent: US 6383808-A 74 07-MAY-2002;								
FEATURES	Location/Qualifiers								
source	1..20								
	/organism="unknown"								
	/mol_type="unassigned DNA"								
Query Match	1.2%; Score 20; DB 1; Length 20;								
Best Local Similarity	100.0%; Pred. No. 24;								
Matches	20;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	1615	CTAATTCATAATAAACTGTCT 1634							
Db	20	CTAATTCATAATAAACTGTCT 1							
RESULT 122									
AR208779/c									
LOCUS	AR208779	20 bp	DNA	linear	PAT 20-JUN-2002				
DEFINITION	Sequence 78 from patent US 6383808.								
ACCESSION	AR208779								
VERSION	AR208779.1	GI:21510022							
KEYWORDS	Unknown.								
SOURCE	Unknown.								
ORGANISM	Unclassified.								
REFERENCE	1 (bases 1 to 20)								
AUTHORS	Monia,B.P. and Freier,S.M.								
TITLE	Antisense inhibition of clusterin expression								
JOURNAL	Patent: US 6383808-A 78 07-MAY-2002;								
FEATURES	Location/Qualifiers								
source	1..20								
	/organism="unknown"								
	/mol_type="unassigned DNA"								
Query Match	1.2%; Score 20; DB 1; Length 20;								
Best Local Similarity	100.0%; Pred. No. 24;								
Matches	20;	Conservative	0;	Mismatches	0;	Indels	0;	Gaps	0;
QY	979	TGGACTGTTCACCAACAAC 998							
Db	20	TGGACTGTTCACCAACAAC 1							

```
RESULT 123
AR208781/c
LOCUS AR208781 linear PAT 20-JUN-2002
DEFINITION Sequence 80 from patent US 6383808.
ACCESSION AR208781
VERSION AR208781.1 GI:21510025
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Monia,B.P. and Freier,S.M.
TITLE Antisense inhibition of clusterin expression
JOURNAL Patent: US 6383808-A 80 07-MAY-2002;
FEATURES
source
1..20
/organism="unknown"
/mol_type="unassigned DNA"
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 24;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1383 CACCGGAGGAGTGTGATGT 1402
Db 20 CACCGGAGGAGTGTGATGT 1
RESULT 124
CQ786121
LOCUS CQ786121 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 9 from Patent WO2004018676.
ACCESSION CQ786121
VERSION CQ786121.1 GI:45721224
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 9 04-MAR-2004;
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"
Query Match 1.2%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGCT 67
Db 1 ATGATGAAGACTCTGCTGCT 20
RESULT 125
CQ786639
LOCUS CQ786639 21 bp DNA linear PAT 24-MAR-2004
DEFINITION Sequence 28 from Patent WO2004018675.
ACCESSION CQ786639
VERSION CQ786639.1 GI:45721659
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Jansen,B.
Treatment of melanoma by reduction in clusterin levels
Patent: WO 2004018675-A 28 04-MAR-2004;
The University of British Columbia (CA); Gleave, Martin E. (CA)
TITLE
JOURNAL
FEATURES
source
1..21
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"
Query Match 1.2%; Score 20; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 48 ATGATGAAGACTCTGCTGCT 67
Db 1 ATGATGAAGACTCTGCTGCT 20
RESULT 126
AR236281
LOCUS AR236281 21 bp DNA linear PAT 20-DEC-2002
DEFINITION Sequence 13 from patent US 6464975.
ACCESSION AR236281
VERSION AR236281.1 GI:27280109
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
FEATURES
source
1..21
/organism="unknown"
/mol_type="genomic DNA"
Query Match 1.2%; Score 19.4; DB 1; Length 21;
Best Local Similarity 95.2%; Pred. No. 35;
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 271 AAGAAGCCCAAGAGAGAAAG 291
Db 1 ACGAAGCCCAAGAGAGAAAG 21
RESULT 127
CQ786179
LOCUS CQ786179 19 bp RNA linear PAT 24-MAR-2004
DEFINITION Sequence 67 from Patent WO2004018676.
ACCESSION CQ786179
VERSION CQ786179.1 GI:45721282
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
Gonos,E.
TITLE Rnai probes targeting cancer-related proteins
JOURNAL Patent: WO 2004018676-A 67 04-MAR-2004;
FEATURES
source
1..19
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/notes="RNAi for human clusterin"
Query Match 1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 30;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 48 ATGATGAAGACTCTGCTGC 66  
 Db 1 ATGATGAAGACTCTGCTGC 19

RESULT 128  
 CQ786180/c  
 LOCUS 19 bp RNA linear PAT 24-MAR-2004  
 DEFINITION Sequence 68 from Patent WO2004018676.  
 ACCESSION CQ786180  
 VERSION CQ786180.1 GI:45721283  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM other sequences; artificial sequences.  
 REFERENCE 1  
 AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
 TITLE Rnai probes targeting cancer-related proteins  
 JOURNAL Patent: WO 2004018676-A 68 04-MAR-2004;  
 The University of British Columbia (CA)  
 FEATURES Location/Qualifiers  
 source 1..19  
 /organism="synthetic construct"  
 /mol\_type="unassigned RNA"  
 /db\_xref="taxon:32630"  
 /note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 30;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGC 66  
 Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 129  
 CQ786653  
 LOCUS 19 bp RNA linear PAT 24-MAR-2004  
 DEFINITION Sequence 42 from Patent WO2004018675.  
 ACCESSION CQ786653  
 VERSION CQ786653.1 GI:45721673  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM other sequences; artificial sequences.  
 REFERENCE 1  
 AUTHORS Jansen,B.  
 TITLE Treatment of melanoma by reduction in clusterin levels  
 JOURNAL Patent: WO 2004018675-A 42 04-MAR-2004;  
 The University of British Columbia (CA)  
 FEATURES Location/Qualifiers  
 source 1..19  
 /organism="synthetic construct"  
 /mol\_type="unassigned RNA"  
 /db\_xref="taxon:32630"  
 /note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 19;  
 Best Local Similarity 100.0%; Pred. No. 30;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGC 66  
 Db 1 ATGATGAAGACTCTGCTGC 19

RESULT 130  
 CQ786654/c  
 LOCUS 19 bp RNA linear PAT 24-MAR-2004  
 DEFINITION Sequence 43 from Patent WO2004018675.

QY 48 ATGATGAAGACTCTGCTGC 66  
 Db 1 ATGATGAAGACTCTGCTGC 19

RESULT 131  
 CQ786122/c  
 LOCUS 21 bp DNA linear PAT 24-MAR-2004  
 DEFINITION Sequence 10 from Patent WO2004018676.  
 ACCESSION CQ786122  
 VERSION CQ786122.1 GI:45721225  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM other sequences; artificial sequences.  
 REFERENCE 1  
 AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
 TITLE Rnai probes targeting cancer-related proteins  
 JOURNAL Patent: WO 2004018676-A 10 04-MAR-2004;  
 The University of British Columbia (CA)  
 FEATURES Location/Qualifiers  
 source 1..21  
 /organism="synthetic construct"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:32630"  
 /note="RNAi for human clusterin"

Query Match 1.2%; Score 19; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 40;  
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGC 66  
 Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 132  
 CQ786640/c  
 LOCUS 21 bp DNA linear PAT 24-MAR-2004  
 DEFINITION Sequence 29 from Patent WO2004018675.  
 ACCESSION CQ786640  
 VERSION CQ786640.1 GI:45721660  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM other sequences; artificial sequences.  
 REFERENCE 1  
 AUTHORS Jansen,B.  
 TITLE Treatment of melanoma by reduction in clusterin levels  
 JOURNAL Patent: WO 2004018675-A 29 04-MAR-2004;

QY 48 ATGATGAAGACTCTGCTGC 66  
 Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 133  
 CQ786654/c  
 LOCUS 21 bp DNA linear PAT 24-MAR-2004  
 DEFINITION Sequence 29 from Patent WO2004018675.  
 ACCESSION CQ786654  
 VERSION CQ786654.1 GI:45721660  
 KEYWORDS synthetic construct  
 SOURCE synthetic construct  
 ORGANISM other sequences; artificial sequences.  
 REFERENCE 1  
 AUTHORS Jansen,B.  
 TITLE Treatment of melanoma by reduction in clusterin levels  
 JOURNAL Patent: WO 2004018675-A 29 04-MAR-2004;

QY 48 ATGATGAAGACTCTGCTGC 66  
 Db 19 ATGATGAAGACTCTGCTGC 1

The University of British Columbia (CA); Gleave, Martin E. (CA)

FEATURES  
source  
1. .21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="RNAi for human clusterin"

Query Match  
Best Local Similarity 1.2%; Score 19; DB 1; Length 21;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGC 66  
|||||  
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 133  
AR071119 22 bp DNA linear PAT 18-FEB-2000  
LOCUS  
DEFINITION Sequence 10 from patent US 5910412.  
ACCESSION AR071119  
VERSION AR071119.1 GI:7222007  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 22)  
AUTHORS Akamatsu,T. and Suzuki,T.  
TITLE Method for identifying the sex of spinach by DNA markers  
JOURNAL Patent: US 5910412-A 10 08-JUN-1999;  
FEATURES Location/Qualifiers  
source  
1. .22  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 1.1%; Score 18.8; DB 1; Length 22;  
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 865 AATTCATACGAGGCGACGA 886  
|||||  
Db 1 AATTCATACGAGGCGACGA 22

RESULT 134  
E15141 22 bp DNA linear PAT 28-JUL-1999  
LOCUS  
DEFINITION PCR primer for detecting male spinach DNA.  
ACCESSION E15141  
VERSION E15141.1 GI:5709824  
KEYWORDS JP 1998052284-A/10.  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 22)  
AUTHORS Akamatsu,T., Suzuki,T. and Uchimiya,H.  
TITLE DETERMINATION OF MALE OR FEMALE OF SPINACH BY USING DNA MARKER  
JOURNAL Patent: JP 1998052284-A 10 24-FEB-1998;  
COMMENT SAKATA NO TANE:KK  
OS None  
OC Artificial sequences.  
PN JP 1998052284-A/10  
PD 24-FEB-1998  
PF 14-MAY-1997 JP 1997124012  
PI 14-MAY-1996 JP 96P 119124  
PR AKAMATSU TOYOKAZU, SUZUKI TAKAO, UCHIMIYA HIROBUMI PC  
C12N15/09,C07H21/04,C12Q1/68;  
CC strandedness: Single;  
CC topology: linear;  
CC hypothetical: No;  
CC anti-sense: No; Location/Qualifiers  
FH Key

1. .22  
/organism="Artificial sequences".

FEATURES  
source  
1. .22  
Location/Qualifiers  
1. .22  
/organism="unidentified"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32644"

Query Match  
Best Local Similarity 1.1%; Score 18.8; DB 1; Length 22;  
Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 865 AATTCATACGAGGCGACGA 886  
|||||  
Db 1 AATTCATACGAGGCGACGA 22

RESULT 135  
AR038688 18 bp DNA linear PAT 29-SEP-1999  
LOCUS  
DEFINITION Sequence 22 from patent US 5807678.  
ACCESSION AR038688  
VERSION AR038688.1 GI:5958051  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Miller,W.L., Lin,D. and Strauss,J.F. III.  
TITLE Identification of gene mutations associated with congenital lipoid adrenal hyperplasia  
JOURNAL Patent: US 5807678-A 22 15-SEP-1998;  
FEATURES Location/Qualifiers  
source  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 1.1%; Score 18; DB 1; Length 18;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1475 GAGAGCTCTGCACGTAC 1492  
|||||  
Db 18 GAGAGCTCTGCACGTAC 1

RESULT 136  
AR208705 18 bp DNA linear PAT 20-JUN-2002  
LOCUS  
DEFINITION Sequence 4 from patent US 6383808.  
ACCESSION AR208705  
VERSION AR208705.1 GI:21509929  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Monia,B.P. and Freier,S.M.  
TITLE Antisense inhibition of clusterin expression  
JOURNAL Patent: US 6383808-A 4 07-MAY-2002;  
FEATURES Location/Qualifiers  
source  
1. .18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 1.1%; Score 18; DB 1; Length 18;  
Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 TCCGTACGAGCCCTGAA 763  
|||||  
Db 1 TCCGTACGAGCCCTGAA 18

VERSION	AR167026.1	GI:16243448
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unknown.	
REFERENCE	Unclassified.	
AUTHORS	1 (bases 1 to 20)	
TITLE	Anderson,K.P., Hanecek,R.C., Hoshiko,K., Nozaki,C., Nishihara,T., Nakatake,H., Hamada,F., Eto,T. and Furukawa,S. Compositions and methods for treatment of hepatitis C virus-associated diseases	
JOURNALS	Patent: US 6284458-A 43 04-SEP-2001;	
FEATURES	Location/Qualifiers 1..20 /organism="unknown" /mol_type="unassigned DNA"	
source		
Query Match	1.0%; Score 16.8; DB 1; Length 20;	
Best Local Similarity	90.0%; Pred. No. 74;	
Matches	18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Qy	1510 GCCTCCAGGCCCCCAACTCC 1529 	
Dd	20 GCCTCCAGGCCCCCCTCC 1	
RESULT 140		
AR210681/c		PAT 20-JUN-2002
LOCUS	AR210681 20 bp DNA linear	
DEFINITION	Sequence 43 from patent US 6391542.	
ACCESSION	AR210681	
VERSION	AR210681.1 GI:21513473	
KEYWORDS	.	
SOURCE	Unknown.	
ORGANISM	Unknown.	
REFERENCE	Unclassified.	
AUTHORS	1 (bases 1 to 20) Anderson,K.P., Hanecek,R.C., Hoshiko,K., Nozaki,C., Nishihara,T., Nakatake,H., Hamada,F., Eto,T., Furukawa,S., Furasako,S., Bruce,T.W. and Lima,W.F. Compositions and methods for treatment of Hepatitis C virus-associated diseases	
TITLE	Patent: US 6391542-A 43 21-MAY-2002;	
JOURNAL	Location/Qualifiers	
FEATURES	1..20 /organism="unknown" /mol_type="unassigned DNA"	
source		
Query Match	1.0%; Score 16.8; DB 1; Length 20;	
Best Local Similarity	90.0%; Pred. No. 74;	
Matches	18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Qy	1510 GCCTCCAGGCCCCCAACTCC 1529 	
Dd	20 GCCTCCAGGCCCCCCTCC 1	
RESULT 141		PAT 05-MAR-1997
A39125/c		
LOCUS	A39125 16 bp DNA linear	
DEFINITION	Sequence 97 from Patent WO9412670.	
ACCESSION	A39125	
VERSION	A39125.1 GI:2295500	
KEYWORDS	.	
SOURCE	unidentified	
ORGANISM	unclassified.	
REFERENCE	1 (bases 1 to 16) Maertens,G., Stuyver,L., Rossau,R. and Van,H.H. PROCESS FOR TYPING OF HCV ISOLATES TITLE Patent: WO 9412670-A 97 09-JUN-1994; JOURNAL INOGENETICS NV (BE) Other publication AU 5628294 940622 COMMENT Other publication CA 2128528 940609	

Other publication JP 7503143T 950406.						
FEATURES	source	Location/Qualifiers				
	1..16	/organism="unidentified"				
		/mol_type="unassigned DNA"				
		/db_xref="taxon:32644"				
Query Match	1.0%; Score 16; DB 1;	Length 16;				
Best Local Similarity	100.0%; Pred. No. 50;					
Matches	16; Conservative	0; Mismatches	0; Indels	0; Gaps	0;	
QY	1508 CAGCCTCCAGGCCCCC 1523					
Dd	16 CAGCCTCCAGGCCCCC 1					
RESULT 142						
LOCUS	AR063448	16 bp	DNA	linear	PAT 29-SEP-1999	
DEFINITION	Sequence 97 from patent US 5846704.					
ACCESSION	AR063448					
VERSION	AR063448.1	GI:5992756				
KEYWORDS	.					
SOURCE	Unknown.					
ORGANISM	Unklassified.					
REFERENCE	1 (bases 1 to 16)					
AUTHORS	Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.					
TITLE	Process for typing of HCV isolates					
JOURNAL	Patent: US 5846704-A 97 08-DEC-1998;					
FEATURES	Location/Qualifiers					
source	1..16					
	/organism="unknown"					
	/mol_type="unassigned DNA"					
Query Match	1.0%; Score 16; DB 1;	Length 16;				
Best Local Similarity	100.0%; Pred. No. 50;					
Matches	16; Conservative	0; Mismatches	0; Indels	0; Gaps	0;	
QY	1508 CAGCCTCCAGGCCCCC 1523					
Dd	16 CAGCCTCCAGGCCCCC 1					
RESULT 143						
LOCUS	AR123639/c	16 bp	DNA	linear	PAT 16-MAY-2001	
DEFINITION	Sequence 97 from patent US 6171784.					
ACCESSION	AR123639					
VERSION	AR123639.1	GI:14109000				
KEYWORDS	.					
SOURCE	Unknown.					
ORGANISM	Unklassified.					
REFERENCE	1 (bases 1 to 16)					
AUTHORS	Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.					
TITLE	Process for typing of HCV isolates					
JOURNAL	Patent: US 6171784-A 97 09-JAN-2001;					
FEATURES	Location/Qualifiers					
source	1..16					
	/organism="unknown"					
	/mol_type="unassigned DNA"					
Query Match	1.0%; Score 16; DB 1;	Length 16;				
Best Local Similarity	100.0%; Pred. No. 50;					
Matches	16; Conservative	0; Mismatches	0; Indels	0; Gaps	0;	
QY	1508 CAGCCTCCAGGCCCCC 1523					
Dd	16 CAGCCTCCAGGCCCCC 1					
RESULT 143						
LOCUS	AR123639/c	16 bp	DNA	linear	PAT 16-MAY-2001	
DEFINITION	Sequence 97 from patent US 6171784.					
ACCESSION	AR123639					
VERSION	AR123639.1	GI:14109000				
KEYWORDS	.					
SOURCE	Unknown.					
ORGANISM	Unklassified.					
REFERENCE	1 (bases 1 to 16)					
AUTHORS	Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.					
TITLE	Process for typing of HCV isolates					
JOURNAL	Patent: US 6171784-A 97 09-JAN-2001;					
FEATURES	Location/Qualifiers					
source	1..16					
	/organism="unknown"					
	/mol_type="unassigned DNA"					
Query Match	1.0%; Score 16; DB 1;	Length 16;				
Best Local Similarity	100.0%; Pred. No. 50;					
Matches	16; Conservative	0; Mismatches	0; Indels	0; Gaps	0;	
QY	1508 CAGCCTCCAGGCCCCC 1523					
Dd	16 CAGCCTCCAGGCCCCC 1					
RESULT 143						
LOCUS	AR123639/c	16 bp	DNA	linear	PAT 16-MAY-2001	
DEFINITION	Sequence 97 from patent US 6171784.					
ACCESSION	AR123639					
VERSION	AR123639.1	GI:14109000				
KEYWORDS	.					
SOURCE	Unknown.					
ORGANISM	Unklassified.					
REFERENCE	1 (bases 1 to 16)					
AUTHORS	Maertens,G., Stuyver,L., Rossau,R. and Van Heuverswyn,H.					
TITLE	Process for typing of HCV isolates					
JOURNAL	Patent: US 6171784-A 97 09-JAN-2001;					
FEATURES	Location/Qualifiers					
source	1..					

```
/organism="unidentified"
/mol_type="unassigned DNA"
/db_xref="taxon:32644"

Query Match      1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
Db 16 CAGCCTCCAGGCCCC 1

RESULT 147
AX417393/c
LOCUS      AX417393      16 bp      DNA      linear      PAT 18-JUN-2002
DEFINITION Sequence 97 from Patent EP1197568.
ACCESSION  AX417393
VERSION     AX417393.1 GI:21522686
KEYWORDS    .
SOURCE      Hepatitis C virus
ORGANISM    Hepatitis C virus
REFERENCE   1
AUTHORS     Maertens,G., Rossau,R., Stuyver,L. and van Heuverswyn,H.
TITLE       Detection and typing of hcv using 5'utr and ns5 nucleic acid
            sequences
JOURNAL     Patent: EP 1197568-A 97 17-APR-2002;
            Innogenetics N.V. (BE)
FEATURES    Location/Qualifiers
            source
              1..16
              /organism="Hepatitis C virus"
              /mol_type="unassigned DNA"
              /db_xref="taxon:11103"

Query Match      1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 50;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523
Db 16 CAGCCTCCAGGCCCC 1

RESULT 148
AR029848
LOCUS      AR029848      17 bp      DNA      linear      PAT 29-SEP-1999
DEFINITION Sequence 37 from patent US 5861244.
ACCESSION  AR029848
VERSION     AR029848.1 GI:5943062
KEYWORDS    .
SOURCE      Unknown.
ORGANISM    Unclassified.
REFERENCE   1 (bases 1 to 17)
AUTHORS     Wang,C.-G. and Hepburn,A.G.
TITLE       Genetic sequence assay using DNA triple strand formation
JOURNAL     Patent: US 5861244-A 37 19-JAN-1999;
FEATURES    Location/Qualifiers
            source
              1..17
              /organism="unknown"
              /mol_type="unassigned DNA"

Query Match      1.0%; Score 16; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 61;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAGAAAGAGGA 295
Db 1 AGAAGAAGAAAGAGGA 16
```

```
RESULT 149
CQ881900/c
LOCUS      CQ881900      19 bp      RNA      linear      PAT 11-OCT-2004
DEFINITION Sequence 15 from Patent WO2004083446.
ACCESSION  CQ881900
VERSION     CQ881900.1 GI:54034672
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    synthetic construct
REFERENCE   1
AUTHORS     van Ommeren,G.J., van Deutekom,J.C., den Dunnen,J.T. and
            Aartema-Rus,A.
TITLE       Modulation of exon recognition in pre-mrna by interfering with the
            secondary rna structure
JOURNAL     Patent: WO 2004083446-A 15 30-SEP-2004;
            Academisch Ziekenhuis Leiden (NL)
FEATURES    Location/Qualifiers
            source
              1..19
              /organism="synthetic construct"
              /mol_type="unassigned RNA"
              /db_xref="taxon:32630"
              /notes="Description of Artificial Sequence: h41AON1"

Query Match      1.0%; Score 16; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 84;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAGAAAGAGGA 295
Db 17 AGAAGAAGAAAGAGGA 2

RESULT 150
CQ786119
LOCUS      CQ786119      19 bp      DNA      linear      PAT 24-MAR-2004
DEFINITION Sequence 7 from Patent WO2004018676.
ACCESSION  CQ786119
VERSION     CQ786119.1 GI:45721222
KEYWORDS    .
SOURCE      synthetic construct
ORGANISM    synthetic construct
REFERENCE   1
AUTHORS     Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
            Gonos,E.
TITLE       Rnai probes targeting cancer-related proteins
JOURNAL     Patent: WO 2004018676-A 7 04-MAR-2004;
            The University of British Columbia (CA)
FEATURES    Location/Qualifiers
            source
              1..19
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /notes="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATATAAACTGTCT 1634
Db 1 TAATTCATACAAAACGTGTTT 19

RESULT 151
CQ786120/c
LOCUS      CQ786120      19 bp      DNA      linear      PAT 24-MAR-2004
DEFINITION Sequence 8 from Patent WO2004018676.
ACCESSION  CQ786120
VERSION     CQ786120.1 GI:45721223
KEYWORDS    .
SOURCE      synthetic construct
```

```
ORGANISM      synthetic construct
other sequences; artificial sequences.
REFERENCE
AUTHORS      Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and
              Gonos,E.
TITLE        Rnai probes targeting cancer-related proteins
JOURNAL      Patent: WO 2004018676-A 8 04-MAR-2004;
              The University of British Columbia (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1616 TAATTCAATAAAACTGCT 1634
Db      1 TAATTCAACAACAACTGTT 19
|||||
|

RESULT 152
LOCUS      CQ786635
DEFINITION Sequence 24 from Patent WO2004018675.
ACCESSION  CQ786635
VERSION     CQ786635.1 GI:45721655
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Jansen,B.
TITLE      Treatment of melanoma by reduction in clusterin levels
JOURNAL    Patent: WO 2004018675-A 24 04-MAR-2004;
            The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1614 ACTAATTCATAAACTGCT 1632
Db      19 AATAATTCACAACAACTGT 1
|||||
|

RESULT 152
LOCUS      CQ786635
DEFINITION Sequence 24 from Patent WO2004018675.
ACCESSION  CQ786635
VERSION     CQ786635.1 GI:45721655
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Jansen,B.
TITLE      Treatment of melanoma by reduction in clusterin levels
JOURNAL    Patent: WO 2004018675-A 24 04-MAR-2004;
            The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="RNAi for human clusterin"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1616 TAATTCAATAAACTGCT 1634
Db      1 TAATTCAACAACAACTGTT 19
|||||
|

RESULT 153
LOCUS      CQ786637
DEFINITION Sequence 26 from Patent WO2004018675.
ACCESSION  CQ786637
VERSION     CQ786637.1 GI:45721657
KEYWORDS   .
SOURCE     synthetic construct
ORGANISM   other sequences; artificial sequences.
REFERENCE  1
AUTHORS    Jansen,B.
TITLE      Treatment of melanoma by reduction in clusterin levels
JOURNAL    Patent: WO 2004018675-A 26 04-MAR-2004;
            The University of British Columbia (CA); Gleave, Martin E. (CA)
FEATURES
source
1. .19
/organism="synthetic construct"

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 90;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1616 TAATTCAATAAACTGCT 1634
Db      1 TAATTCAACAACAACTGTT 19
|||||
|

RESULT 153
LOCUS      CQ786637
DEFINITION Sequence 26 from Patent WO0192524.
ACCESSION  CQ623926
VERSION     CQ623926.1 GI:41674144
KEYWORDS   .
SOURCE     Homo sapiens (human)
ORGANISM   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE  1
AUTHORS    Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
            Shannon,M.E.
TITLE      Myosin-like gene expressed in human heart and muscle
JOURNAL    Patent: WO 0192524-A 8666 06-DEC-2001;
            Asomica, Inc. (US)
FEATURES
source
1. .17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 74;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      273 GAACCCAGAGAGAGAA 289
|||||
|
```



Db 1 GAAGCCAAGAAGGAGAA 17

RESULT 156  
LOCUS 137522/c  
DEFINITION Sequence 535 from patent US 5612215.  
ACCESSION 137522  
VERSION 137522.1 GI:2085482  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Stromelysin targeted ribozymes  
JOURNAL Patent: US 5612215-A 535 18-MAR-1997;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAAGATTGCTCC 1605  
|||||  
17 AAGAACAAGATTGCTCC 1

Db 17 AAGAACAAGATTGCTCC 1

RESULT 157  
LOCUS 194372/c  
DEFINITION Sequence 535 from patent US 5731295.  
ACCESSION 194372  
VERSION 194372.1 GI:3938842  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 535 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAAGATTGCTCC 1605  
|||||  
17 AAGAACAAGATTGCTCC 1

Db 17 AAGAACAAGATTGCTCC 1

RESULT 158  
LOCUS AR464989  
DEFINITION Sequence 8666 from patent US 6686188.  
ACCESSION AR464989  
VERSION AR464989.1 GI:42700046  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and

Shannon,M.E.  
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
Patent: US 6686188-A 8666 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAAGCCAAGAAGAGAA 289  
|||||  
1 GAAGCCAAGAAGAGAA 17

Db 1 GAAGCCAAGAAGAGAA 17

RESULT 159  
LOCUS AX214728/c  
DEFINITION Sequence 170 from Patent WO0159103.  
ACCESSION AX214728  
VERSION AX214728.1 GI:15524771  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1  
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 170 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; Blatt, Lawrence (US) ; McSwiggen, James (US) ; Chowrira, Bharat M. (US)

FEATURES Location/Qualifiers  
source 1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1619 TTCAATAAAACTGTCTT 1635  
|||||  
17 TTCATTAAAACTGTCTT 1

Db 17 TTCATTAAAACTGTCTT 1

RESULT 160  
LOCUS AX688719/c  
DEFINITION Sequence 1451 from Patent EP1281759.  
ACCESSION AX688719  
VERSION AX688719.1 GI:29411423  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1451 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1619 TTCAATAAAACTGTCTT 1635  
|||||  
17 TTCATTAAAACTGTCTT 1

Db 17 TTCATTAAAACTGTCTT 1

RESULT 160  
LOCUS AX688719/c  
DEFINITION Sequence 1451 from Patent EP1281759.  
ACCESSION AX688719  
VERSION AX688719.1 GI:29411423  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.  
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12  
JOURNAL Patent: EP 1281758-A 1451 05-FEB-2003;  
Aeomica, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 928 GCTGCTCGGATGAAG 944  
Db 17 GCTGCTCGGCTGAAG 1

RESULT 161  
LOCUS AX762505 17 bp DNA linear PAT 25-JUN-2003  
DEFINITION Sequence 5826 from Patent WO03040369.  
ACCESSION AX762505  
VERSION AX762505.1 GI:32257121  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
Telerman,A., Anson,R. and Tuijnder,M.  
AUTHORS Sequences involved in tumoral suppression, tumoral reversion,  
TITLE apoptosis and/or viral resistance phenomena and their use as  
medicines  
JOURNAL Patent: WO 03040369-A 5826 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1.17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 74;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1551 GATCCTGCACCTTAACA 1567  
Db 1 GATCCTGCACCTTACCA 17

RESULT 162  
LOCUS AR011407/c 18 bp DNA linear PAT 04-DEC-1998  
DEFINITION Sequence 280 from patent US 5762938.  
ACCESSION AR011407  
VERSION AR011407.1 GI:3969397  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Paoletti,E., Perkus,M.E., Taylor,J., Tartaglia,J., Norton,E.K.,  
Riviere,M., de Taisne,C., Limbach,K.J., Johnson,G.P., Pincus,S.E.,  
Cox,W.I., Audonnet,J.-C.Francis. and Gettig,R.Robert.  
TITLE Modified recombinant vaccinia virus and expression vectors thereof  
JOURNAL Patent: US 5762938-A 280 09-JUN-1998;  
FEATURES Location/Qualifiers  
source 1.18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTCATAGAAAAACAAAC 239  
Db 18 CTAATAGAAAAACCAAC 1

RESULT 163  
LOCUS AR040105/c 18 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 953 from patent US 5807743.  
ACCESSION AR040105  
VERSION AR040105.1 GI:5959468  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.  
TITLE Interleukin-2 receptor gamma-chain ribozymes  
JOURNAL Patent: US 5807743-A 953 15-SEP-1998;  
FEATURES Location/Qualifiers  
source 1.18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1121 GCTGAGCAGCTGAACGA 1138  
Db 18 GCAGGAGCAGCTGAAGGA 1

RESULT 164  
LOCUS I18045/c 18 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 280 from patent US 5494807.  
ACCESSION I18045  
VERSION I18045.1 GI:1598400  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 18)  
AUTHORS Paoletti,E., Perkus,M.E., Taylor,J., Tartaglia,J., Norton,E.K.,  
Riviere,M., de Taisne,C., Limbach,K.J., Johnson,G.P., Pincus,S.E.,  
Cox,W.I., Audonnet,J.-C.F. and Gettig,R.R.  
TITLE NYVAC vaccinia virus recombinants comprising heterologous inserts  
JOURNAL Patent: US 5494807-A 280 27-FEB-1996;  
FEATURES Location/Qualifiers  
source 1.18  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTCATAGAAAAACAAAC 239  
Db 18 CTAATAGAAAAACCAAC 1

RESULT 165  
LOCUS AX115178 18 bp DNA linear PAT 11-MAY-2001  
DEFINITION Sequence 301 from Patent WO0129262.  
ACCESSION AX115178  
VERSION AX115178.1 GI:14032120  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Picoult-Newburg,L. and Pohl,M.  
TITLE Genotyping reagents, kits and methods of use thereof  
JOURNAL Patent: WO 0129262-A 301 26-APR-2001;  
Orchid Biosciences, Inc. (US)

```
FEATURES
source
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="Primer"

Query Match
Best Local Similarity 0.9%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1492 CCAAGTAACGAGGCCCA 1509
Db 1 CCAGGTGACGAGGCCCA 18

RESULT 166
AX776586
LOCUS AX776586 18 bp DNA linear PAT 14-JUL-2003
DEFINITION Sequence 11 from Patent WO03047611.
ACCESSION AX776586
VERSION AX776586.1 GI:32694120
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
other sequences; artificial sequences.
REFERENCE 1
AUTHORS Weise,M., Eulenberg,K., Fritsch,R., Haeder,T., Broenner,G. and
Steuernagel,A.
TITLE Peplod, tec protein tyrosine kinase and edtp homologous proteins
involved in the regulation of energy homeostasis
JOURNAL Patent: WO 03047611-A 11 12-JUN-2003;
DeveloGen Aktiengesellschaft fuer entwicklungsbiologische Forschung
(DE)
FEATURES
source
Location/Qualifiers
1..18
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="mouse PTPRB reverse primer"

Query Match
Best Local Similarity 0.9%; Score 14.8; DB 1; Length 18;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 764 CTCCAGCCCATCTCCA 781
Db 1 CTCCAGCCCATCTCCA 18

RESULT 167
AR173373
LOCUS AR173373 17 bp DNA linear PAT 17-DEC-2001
DEFINITION Sequence 7 from patent US 6303847.
ACCESSION AR173373
VERSION AR173373.1 GI:17912864
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Kawaoka,A. and Ebinuma,H.
TITLE DNA encoding a transcription factor controlling phenylpropanoid
biosynthesis pathway
JOURNAL Patent: US 6303847-A 7 16-OCT-2001;
FEATURES
source
Location/Qualifiers
1..17
/organism="unknown"
/mol_type="unassigned DNA"

Query Match
Best Local Similarity 0.9%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCAACACCTCTCTCT 1119
Db 2 CTCAACACCTCTCTCT 17

RESULT 168
CQ623612/c
LOCUS CQ623612 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8352 from Patent WO0192524.
ACCESSION CQ623612
VERSION CQ623612.1 GI:41673830
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8352 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCTCTCTTGCTG 1124
Db 17 CAGCTCTCTCTTGCTG 2

RESULT 169
CQ623613/c
LOCUS CQ623613 17 bp DNA linear PAT 02-FEB-2004
DEFINITION Sequence 8353 from Patent WO0192524.
ACCESSION CQ623613
VERSION CQ623613.1 GI:41673831
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.
REFERENCE 1
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
Shannon,M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8353 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 14.4; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCTCTCTTGCTG 1124
Db 16 CAGCTCTCTCTTGCTG 1

RESULT 170
CQ623925
LOCUS CQ623925 17 bp DNA linear PAT 02-FEB-2004
```

DEFINITION	Sequence 8665 from Patent WO0192524.									
ACCESSION	CQ623925									
VERSION	CQ623925.1 GI:41674143									
KEYWORDS	Homo sapiens (human)									
SOURCE	Homo sapiens									
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.									
REFERENCE	1 Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E. Myosin-like gene expressed in human heart and muscle Patent: WO 0192524-A 8665 06-DEC-2001;									
TITLE	Aeomica, Inc. (US)									
JOURNAL	Location/Qualifiers									
FEATURES	1. 17									
source	/organism="Homo sapiens"									
	/mol_type="unassigned DNA"									
	/db_xref="taxon:9606"									
Query Match	0.9%; Score 14.4; DB 1; Length 17;									
Best Local Similarity	93.8%; Pred.No.1e+02;									
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	273 GAAGCCCAAGAGAAGA 288									
Db										
	2 GAAGCCCAAGAGAAGA 17									
RESULT 171	17 bp DNA linear PAT 02-FEB-2004									
CQ623927	CQ623927									
LOCUS	Sequence 8667 from Patent WO0192524.									
DEFINITION	CQ623927									
ACCESSION	CQ623927.1 GI:41674145									
VERSION	CQ623927.1									
KEYWORDS	Homo sapiens (human)									
SOURCE	Homo sapiens									
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.									
REFERENCE	1 Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E. Myosin-like gene expressed in human heart and muscle Patent: WO 0192524-A 8667 06-DEC-2001;									
AUTHORS	Aeomica, Inc. (US)									
TITLE	Location/Qualifiers									
JOURNAL	1. 17									
FEATURES	/organism="Homo sapiens"									
source	/mol_type="unassigned DNA"									
	/db_xref="taxon:9606"									
Query Match	0.9%; Score 14.4; DB 1; Length 17;									
Best Local Similarity	93.8%; Pred.No.1e+02;									
Matches	15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;									
QY	274 AAGCCCAAGAGAAGA 289									
Db										
	1 AAGCCCAAGAGAAGA 16									
RESULT 172	17 bp DNA linear PAT 02-FEB-2004									
CQ625297/c	CQ625297									
LOCUS	Sequence 10037 from Patent WO0192524.									
DEFINITION	CQ625297									
ACCESSION	CQ625297.1 GI:41675515									
VERSION	CQ625297.1									
KEYWORDS	Homo sapiens (human)									
SOURCE	Homo sapiens									
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.									
REFERENCE	1									

AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
 TITLE Myosin-like gene expressed in human heart and muscle  
 JOURNAL Patent: WO 0192524-A 10037 06-DEC-2001;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
     source 1..17  
         /organism="Homo sapiens"  
         /mol\_type="unassigned DNA"  
         /db\_xref="taxon:9606"  
 Query Match 0.9%; Score 14.4; DB 1; Length 17;  
 Best Local Similarity 93.8%; Pred. NO. 1e+02;  
 Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
 QY 715 CCGCATCGTCCGAC 730  
     |||||  
 Db 17 CCGCATCGTCCAC 2  
 RESULT 173  
 CQ625298/c 17 bp DNA linear PAT 02-FEB-2004  
 LOCUS CQ625298 10038 from Patent WO0192524.  
 DEFINITION Sequence 10038 from Patent WO0192524.  
 ACCESSION CQ625298  
 VERSION CQ625298.1 GI:41675516  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
     Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
     Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
 TITLE Myosin-like gene expressed in human heart and muscle  
 JOURNAL Patent: WO 0192524-A 10038 06-DEC-2001;  
 Aeomica, Inc. (US)  
 FEATURES Location/Qualifiers  
     source 1..17  
         /organism="Homo sapiens"  
         /mol\_type="unassigned DNA"  
         /db\_xref="taxon:9606"

Query Match	0.9%;	Score 14.4;	DB 1;	Length 17;
Beat Local Similarity	93.8%;	Pred. No. 1e+02;		
Matches 15;	Conservative 0;	Mismatches 1;	Indels 0;	Gaps 0;
QY	715	CCCGCATCGTCGCAG	730	
Db	16	CCCGCATCGTCACAG	1	
RESULT 174				
I37523/c				
LOCUS	I37523	Sequence 536 from patent US 5612215.	17 bp	DNA
DEFINITION	I37523			
ACCESSION	I37523			
VERSION	I37523.1	GI:2085483		
KEYWORDS				
SOURCE	Unknown.			
ORGANISM	Unknown.			
REFERENCE	Unclassified.			
AUTHORS	1 (bases 1 to 17)			
	Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and			
	Stinchcomb,D.T.			
TITLE	Stromelysin targeted ribozymes			
JOURNAL	Patent: US 5612215-A 536 18-MAR-1997;			
FEATURES	Location/Qualifiers			
	1..17			
source	/organism="unknown"			
	/mol_type="DNA"			

Query Match

Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0;

QY 1589 AAGACAGAAATTCCTC 1604  
|||||  
Db 16 AAGACAGAAATTCCTC 1

RESULT 175  
I94373/c  
LOCUS I94373 17 bp DNA linear PAT 01-DEC-1998  
DEFINITION Sequence 536 from patent US 5731295.  
ACCESSION I94373  
VERSION I94373.1 GI:3938843  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Draper,K.G., Pavco,P., McSwiggen,J., Gustofson,J. and Stinchcomb,D.T.  
TITLE Method of reducing stromelysin RNA via ribozymes  
JOURNAL Patent: US 5731295-A 536 24-MAR-1998;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0;

QY 1589 AAGACAGAAATTCCTC 1604  
|||||  
Db 16 AAGACAGAAATTCCTC 1

RESULT 176  
AR464675/c  
LOCUS AR464675 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8352 from patent US 6686188.  
ACCESSION AR464675  
VERSION AR464675.1 GI:42699732  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8352 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0;

QY 1109 CAGCTCCTCCTTGCTG 1124  
|||||  
Db 17 CAGCTCCTCCTTGCTG 2

RESULT 177  
AR464676/c  
LOCUS AR464676 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8353 from patent US 6686188.  
ACCESSION AR464676  
VERSION AR464676.1 GI:42699733

KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8353 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0;

QY 1109 CAGCTCCTCCTTGCTG 1124  
|||||  
Db 16 CAGCTCCTCCTTGCTG 1

RESULT 178  
AR464988  
LOCUS AR464988 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8665 from patent US 6686188.  
ACCESSION AR464988  
VERSION AR464988.1 GI:42700045  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8665 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1e+02; Mismatches 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0;

QY 273 GAAGCCCAAGAAGAAGA 288  
|||||  
Db 2 GAAGCCCAAGAAGAAGA 17

RESULT 179  
AR464990  
LOCUS AR464990 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8667 from patent US 6686188.  
ACCESSION AR464990  
VERSION AR464990.1 GI:42700047  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8667 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"

```

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 274 AAGCCAAGAAGAA 289
DB 1 AAGCCAAGAAGGAGAA 16

RESULT 180
LOCUS AX466360/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10037 from patent US 6686188.
ACCESSION AR466360
VERSION AR466360.1 GI:42701417
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
          Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
        predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10037 03-FEB-2004;
FEATURES
    source
        1..17
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCGCATCGTCCGAC 730
DB 17 CCGCATCGTCCACAG 2

RESULT 181
LOCUS AR466361/c 17 bp DNA linear PAT 20-FEB-2004
DEFINITION Sequence 10038 from patent US 6686188.
ACCESSION AR466361
VERSION AR466361.1 GI:42701418
KEYWORDS .
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 17)
AUTHORS Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and
          Shannon,M.E.
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed
        predominantly in heart and muscle
JOURNAL Patent: US 6686188-A 10038 03-FEB-2004;
FEATURES
    source
        1..17
        /organism="unknown"
        /mol_type="genomic DNA"

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCGCATCGTCCGAC 730
DB 16 CCGCATCGTCCACAG 1

RESULT 182
LOCUS AX214729/c 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1452 from Patent EPI281758.
ACCESSION AX688720
VERSION AX688720.1 GI:29411424
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.

LOCUS AX214729 17 bp RNA linear PAT 07-SEP-2001
DEFINITION Sequence 171 from Patent WO0159103.
ACCESSION AX214729
VERSION AX214729.1 GI:15524772
KEYWORDS .
SOURCE synthetic construct
ORGANISM other sequences; artificial sequences.
REFERENCE 1
AUTHORS Blatt,L., Mcswiggen,J. and Chowrira,B.M.
TITLE Method and reagent for the modulation and diagnosis of cd20 and
        nogo gene expression
JOURNAL Patent: WO 0159103-A 171 16-AUG-2001;
        RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);
        McSwiggen, James (US); Chowrira, Bharat M. (US)
FEATURES
    source
        1..17
        /organism="synthetic construct"
        /mol_type="unassigned RNA"
        /db_xref="taxon:32630"
        /note="Nucleic Acid"

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1619 TTCAATAAACTGTCT 1634
DB 16 TTCATTAATAACTGTCT 1

RESULT 183
LOCUS AX688718/c 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1450 from Patent EPI281758.
ACCESSION AX688718
VERSION AX688718.1 GI:29411422
KEYWORDS .
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Shannon,M., Gu,Y. and Nguyen,C.T.
TITLE Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and
        mdz12
JOURNAL Patent: EP 1281758-A 1450 05-FEB-2003;
        Aeomica, Inc. (US)
FEATURES
    source
        1..17
        /organism="Homo sapiens"
        /mol_type="unassigned DNA"
        /db_xref="taxon:9606"

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 929 CTCGCTCGGATGAAG 944
DB 17 CTGCTCGGCTGAAG 2

RESULT 184
LOCUS AX688720/c 17 bp DNA linear PAT 31-MAR-2003
DEFINITION Sequence 1452 from Patent EPI281758.
ACCESSION AX688720
VERSION AX688720.1 GI:29411424
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

FEATURES	source	Location/Qualifiers
Query Match		0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity		93.8%; Pred. No. 1e+02;
Matches	15; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
QY	154 ATCAGGGAAGTAAGTA 169	
DB	2 ATCAGGGAAGTAAGTA 17	
RESULT 187		
AR067404/C		linear PAT 29-SEP-1999
LOCUS	AR067404	18 bp DNA
DEFINITION	Sequence 797 from patent US 5851760.	
ACCESSION	AR067404	
VERSION	AR067404.1	GI:5998626
KEYWORDS		
SOURCE	Unknown.	
ORGANISM	Unclassified.	
REFERENCE	1 (bases 1 to 18)	
AUTHORS	Evans, G.A. and Smith, M.W.	
TITLE	Method for generation of sequence sampled maps of complex genomes	
JOURNAL	Patent: US 5851760-A 797 22-DEC-1998;	
FEATURES	Location/Qualifiers	
source	1..18	
	/organism="unknown"	
	/mol_type="unassigned DNA"	
Query Match		0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity		93.8%; Pred. No. 1.2e+02;
Matches	15; Conservative	0; Mismatches 1; Indels 0; Gaps 0;
QY	1520 CCCCAACTCCGCCAG 1535	
DB	18 CCTTAACCCGCCAG 3	
RESULT 188		
AX837978		linear PAT 15-DEC-2003
LOCUS	AX837978	18 bp DNA
DEFINITION	Sequence 5102 from Patent EP1347046.	
ACCESSION	AX837978	
VERSION	AX837978.1	GI:39921670
KEYWORDS		
SOURCE	unidentified	
ORGANISM	unidentified	
REFERENCE	1	
AUTHORS	Isogai, T., Sugiyama, T., Otsuki, T., Wakamatsu, A., Sato, H., Ishii, S., Yamamoto, J. I., Isono, Y., Hio, Y., Otsuka, K., Nagai, K., Irie, R., Tameshika, I., Seki, N., Yoshikawa, T., Otsuka, M., Nagahata, K. and Masuho, Y.	
TITLE	Full-length cDNA sequences	
JOURNAL	Patent: EP 1347046-A 5102 24-SEP-2003;	
FEATURES	Research Association for Biotechnology (JP)	
source	Location/Qualifiers	
	1..18	
	/organism="unidentified"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:32644"	
	/note="Description of Artificial Sequence: an artificially synthesized primer se q"	
Query Match		0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity		93.8%; Pred. No. 1.2e+02;
Matches	15; Conservative	0; Mismatches 1; Indels 0; Gaps 0;

QY 1094 GTGGAAGATGCTCAAC 1109 17 bp DNA linear PAT 02-SEP-2002  
Db 1 GTGGAAGATGCTCGAC 16  
|||||

RESULT 189  
AX324817/c  
LOCUS AX324817 17 bp DNA linear PAT 02-SEP-2002  
DEFINITION Sequence 955 from Patent WO0192512.  
ACCESSION AX324817  
VERSION AX324817.1 GI:18095570  
KEYWORDS Eucalyptus camaldulensis (Murray red gum)  
SOURCE Eucalyptus camaldulensis  
ORGANISM Eucalyptus camaldulensis  
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
AUTHORS Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
TITLE rosids; Myrtales; Myrtaceae; Eucalyptus.  
JOURNAL 1  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source 1..17  
/organism="Eucalyptus camaldulensis"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:34316"

Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1202 GGTCAACACGGTGG 1215  
Db 14 GGTCAACACGGTGG 1  
|||||

RESULT 190  
AX324818  
LOCUS AX324818 17 bp DNA linear PAT 02-SEP-2002  
DEFINITION Sequence 956 from Patent WO0192512.  
ACCESSION AX324818  
VERSION AX324818.1 GI:18095571  
KEYWORDS Eucalyptus camaldulensis (Murray red gum)  
SOURCE Eucalyptus camaldulensis  
ORGANISM Eucalyptus camaldulensis  
REFERENCE Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
AUTHORS Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
TITLE rosids; Myrtales; Myrtaceae; Eucalyptus.  
JOURNAL 1  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source 1..17  
/organism="Eucalyptus camaldulensis"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:34316"

Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1202 GGTCAACACGGTGG 1215  
Db 4 GGTCAACACGGTGG 17  
|||||

RESULT 191  
AR039619

LOCUS AR039619 17 bp DNA linear PAT 29-SEP-1999  
DEFINITION Sequence 467 from patent US 5807743.  
ACCESSION AR039619  
VERSION AR039619.1 GI:5958982  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Stinchcomb,D.T. and McSwiggen,J.A.  
TITLE Interleukin-2 receptor gamma-chain ribozymes  
JOURNAL Patent: US 5807743-A 467 15-SEP-1998;  
FEATURES  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 693 CCTCATTCTTCTTTTC 709  
Db 1 CCTCCTTCTCTTTC 17  
|||||

RESULT 192  
AR081753  
LOCUS AR081753 17 bp DNA linear PAT 31-AUG-2000  
DEFINITION Sequence 25 from patent US 5972621.  
ACCESSION AR081753  
VERSION AR081753.1 GI:10008479  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.  
TITLE Methods of identifying compounds that modulate body weight using the OB receptor  
JOURNAL Patent: US 5972621-A 25 26-OCT-1999;  
FEATURES  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
|||||

RESULT 193  
AR081755  
LOCUS AR081755 17 bp DNA linear PAT 31-AUG-2000  
DEFINITION Sequence 27 from patent US 5972621.  
ACCESSION AR081755  
VERSION AR081755.1 GI:10008481  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A.  
TITLE Methods of identifying compounds that modulate body weight using the OB receptor  
JOURNAL Patent: US 5972621-A 27 26-OCT-1999;  
FEATURES  
source 1..17  
/organism="unknown"



KEYWORDS	Unknown.
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.
TITLE	Methods of using the Ob receptor to identify therapeutic compounds
JOURNAL	Patent: US 6287782-A 27 11-SEP-2001;
FEATURES	Location/Qualifiers
source	1..17
source	/organism="unknown"
source	/mol_type="unassigned DNA"
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	660 CACTACCTGCCTTCAG 676
Db	1 CACTATTGGCCCTTCAG 17
RESULT 197	
LOCUS	BD254845 17 bp DNA linear PAT 17-JUL-2003
DEFINITION	Regulation of repressor genes using nucleic acid molecules.
ACCESSION	BD254845
VERSION	BD254845.1 GI:33064615
KEYWORDS	JP 2002541795-A/2638.
SOURCE	unidentified
ORGANISM	unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Blatt,L., Zwick,M., Pavco,P. and Mcswiggen,J.
TITLE	Regulation of repressor genes using nucleic acid molecules
JOURNAL	Patent: JP 2002541795-A 2638 10-DEC-2002;
COMMENT	RIBOZYME PHARMACEUTICALS INC
OS	Eukaryote
PN	JP 2002541795-A/2638
PD	10-DEC-2002
PP	11-APR-2000 JP 2000611654
PR	12-APR-1999 US 60/129390
PI	LAWRENCE BLATT,MICHAEL ZWICK,PAMELA PAVCO,JAMES MCSWIGGEN PC
C12N15/09,A61K38/00,A61P43/00,A61P43/00,C12N5/10, PC	
C12P21/02,	
PC	
C12P21/02,C12P21/02//A61K31/711,(C12N5/10,C12R1:91),(C12P21/02, PC	
C12R1:91),	
PC	(C12P21/02,C12R1:91),(C12P21/02,C12R1:91),C12N15/00,C12N5/00,
PC	A61K37/02,
PC	(C12N5/00,C12R1:91)
CC	Regulation of repressor genes using nucleic acid molecules FH
Key source	Location/Qualifiers
FT	1..17
FT	/organism='Eukaryote'.
FEATURES	Location/Qualifiers
source	1..17
source	/organism="unidentified"
source	/mol_type="genomic DNA"
source	/db_xref="taxon:32644"
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	116 CCAGACGCTCTCAGACA 132
Db	1 CCAGACGCTCTCAGTCA 17
RESULT 198	
LOCUS	CQ617155 17 bp DNA linear PAT 02-FEB-2004
DEFINITION	Regulation of repressor genes using nucleic acid molecules
ACCESSION	CQ617155/c
VERSION	AR167987.1 GI:17903801
KEYWORDS	JP 2002541795-A/2638.
SOURCE	unidentified
ORGANISM	unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Wands,J.R., Wakita,T. and Moradpour,D.
TITLE	Antisense inhibition of hepatitis C virus
JOURNAL	Patent: US 6001990-A 21 14-DEC-1999;
FEATURES	Location/Qualifiers
source	1..17
source	/organism="unknown"
source	/mol_type="unassigned DNA"
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	222 CTCATGAGAAAAACAAA 238
Db	17 CTCAAAGAAAAACAAA 1
RESULT 195	
LOCUS	AR167985 17 bp DNA linear PAT 17-DEC-2001
DEFINITION	Sequence 25 from patent US 6287782.
ACCESSION	AR167985
VERSION	AR167985.1 GI:17903799
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.
TITLE	Methods of using the Ob receptor to identify therapeutic compounds
JOURNAL	Patent: US 6287782-A 25 11-SEP-2001;
FEATURES	Location/Qualifiers
source	1..17
source	/organism="unknown"
source	/mol_type="unassigned DNA"
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	660 CACTACTGCCTTCAG 676
Db	1 CACTATTGGCCCTTCAG 17
RESULT 196	
LOCUS	AR167987 17 bp DNA linear PAT 17-DEC-2001
DEFINITION	Sequence 27 from patent US 6287782.
ACCESSION	AR167987
VERSION	AR167987.1 GI:17903801
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Wands,J.R., Wakita,T. and Moradpour,D.
TITLE	Antisense inhibition of hepatitis C virus
JOURNAL	Patent: US 6001990-A 21 14-DEC-1999;
FEATURES	Location/Qualifiers
source	1..17
source	/organism="unknown"
source	/mol_type="unassigned DNA"
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	660 CACTACTGCCTTCAG 676
Db	1 CACTATTGGCCCTTCAG 17
RESULT 194	
LOCUS	AR094983/c 17 bp DNA linear PAT 08-SEP-2000
DEFINITION	Sequence 21 from patent US 6001990.
ACCESSION	AR094983
VERSION	AR094983.1 GI:10022419
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unclassified.
REFERENCE	1 (bases 1 to 17)
AUTHORS	Wands,J.R., Wakita,T. and Moradpour,D.
TITLE	Antisense inhibition of hepatitis C virus
JOURNAL	Patent: US 6001990-A 21 14-DEC-1999;
FEATURES	Location/Qualifiers
source	1..17
source	/organism="unknown"
source	/mol_type="unassigned DNA"
Query Match	0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity	88.2%; Pred. No. 1.3e+02;
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	660 CACTACTGCCTTCAG 676
Db	1 CACTATTGGCCCTTCAG 17
RESULT 193	
LOCUS	AR094983/c 17 bp DNA linear PAT 08-SEP-2000
DEFINITION	Sequence 21 from patent US 6001990.
ACCESSION	AR094983
VERSION	AR094983.1 GI:10022419
KEYWORDS	
SOURCE	Unknown.

DEFINITION Sequence 1895 from Patent WO0192524.  
ACCESSION CQ617155  
VERSION CQ617155.1 GI:41667373  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 1895 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 93 GAGAGTGGCAGGTCTCT 109  
Db 17 GAGAGAGCCAGGTCTCT 1  
RESULT 199  
LOCUS CQ617903 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 2643 from Patent WO0192524.  
ACCESSION CQ617903  
VERSION CQ617903.1 GI:41668121  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 2643 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 845 CTTCCAGCACCGCCAA 861  
Db 17 CTGCCAGGACCGCCAA 1  
RESULT 200  
LOCUS CQ622615 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 7355 from Patent WO0192524.  
ACCESSION CQ622615  
VERSION CQ622615.1 GI:41672833  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1

AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 7355 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 270 GAGAGAGCCCAAGAGAA 286  
Db 1 GAGAGAGCCCAAGAGAA 17  
RESULT 201  
LOCUS CQ622745 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 7485 from Patent WO0192524.  
ACCESSION CQ622745  
VERSION CQ622745.1 GI:41672963  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 7485 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1530 GCCCAGCCTCTCCCGC 1546  
Db 17 GTCCAGCCTCTCTCTCGC 1  
RESULT 202  
LOCUS CQ623828 17 bp DNA linear PAT 02-FEB-2004  
DEFINITION Sequence 8568 from Patent WO0192524.  
ACCESSION CQ623828  
VERSION CQ623828.1 GI:41674046  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and  
Shannon, M.E.  
TITLE Myosin-like gene expressed in human heart and muscle  
JOURNAL Patent: WO 0192524-A 8568 06-DEC-2001;  
Aeomica, Inc. (US)  
FEATURES  
source Location/Qualifiers  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"

```

/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 292 AGGATCCCTAATGAG 308
Db 1 AGGATGACCTGAATGAG 17

RESULT 203
LOCUS CQ623920
DEFINITION Sequence 8660 from Patent WO0192524.
ACCESSION CQ623920
VERSION CQ623920.1 GI:41674138
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8660 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 267 CTAGAAGAGCCCAAGAA 283
Db 1 CTGAGGAGCCCAAGAA 17

RESULT 204
LOCUS CQ623921
DEFINITION Sequence 8661 from Patent WO0192524.
ACCESSION CQ623921
VERSION CQ623921.1 GI:41674139
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8661 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 TAGAAGAGCCCAAGAA 284
Db 1 TGGAGGAGCCCAAGAA 17

RESULT 205
LOCUS CQ623923
DEFINITION Sequence 8663 from Patent WO0192524.
ACCESSION CQ623923
VERSION CQ623923.1 GI:41674141
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8663 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAAGAAGCCCAAGAA 286
Db 1 GAGGAAGCCCAAGAA 17

RESULT 206
LOCUS CQ623924
DEFINITION Sequence 8664 from Patent WO0192524.
ACCESSION CQ623924
VERSION CQ623924.1 GI:41674142
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8664 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAA 287
Db 1 AGGAAGCCCAAGAA 17

RESULT 207
LOCUS CQ624947/c
DEFINITION Sequence 9687 from Patent WO0192524.
ACCESSION CQ624947
VERSION CQ624947.1 GI:41675165
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.
TITLE Myosin-like gene expressed in human heart and muscle
JOURNAL Patent: WO 0192524-A 8667 06-DEC-2001;
Aeomica, Inc. (US)
FEATURES
source
Location/Qualifiers
1..17
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 272 TAGAAGAGCCCAAGAA 284
Db 1 TGGAGGAGCCCAAGAA 17

```

SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Myosin-like gene expressed in human heart and muscle
JOURNAL	Patent: WO 0192524-A 9687 06-DEC-2001;
FEATURES	<p>source</p> <p>Query Match 0.8%; Score 13.8; DB 1; Length 17;</p> <p>Best Local Similarity 88.2%; Pred. No. 1.3e+02;</p> <p>Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>
QY	93 GAGAGTGGCAGGTCT 109
DB	17 GAGAGTGGCAGGTCT 1
LOCUS	17 bp DNA linear PAT 02-FEB-2004
DEFINITION	CQ624948 Sequence 9688 from Patent WO0192524.
ACCESSION	CQ624948
VERSION	CQ624948.1 GI:41675166
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Myosin-like gene expressed in human heart and muscle
JOURNAL	Patent: WO 0192524-A 9688 06-DEC-2001;
FEATURES	<p>source</p> <p>Query Match 0.8%; Score 13.8; DB 1; Length 17;</p> <p>Best Local Similarity 88.2%; Pred. No. 1.3e+02;</p> <p>Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;</p>
QY	92 GGAGAGTGGCAGGTCC 108
DB	17 GGAGAGTGGCAGGTCC 1
LOCUS	17 bp DNA linear PAT 02-FEB-2004
DEFINITION	CQ624949 Sequence 9689 from Patent WO0192524.
ACCESSION	CQ624949
VERSION	CQ624949.1 GI:41675167
KEYWORDS	
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Gu,Y., Ji,Y., Penn,S.G., Hanzel,D.K., Rank,D.R., Chen,W. and Shannon,M.E.
TITLE	Myosin-like gene expressed in human heart and muscle
JOURNAL	Patent: WO 0192524-A 9689 06-DEC-2001;

FEATURES	source	Aeomica, Inc. (US)										
		1. .17 Location/Qualifiers										
		/organism="Homo sapiens"										
		/mol_type="unassigned DNA"										
		/db_xref="taxon:9606"										
Query Match		0.8%;	Score 13.8;	DB 1;	Length 17;							
Best Local Similarity		88.2%;	Pred. No. 1.3e+02;									
Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;			
QY	91	GGGAGAGTGGCAGGTC 107										
Db	17	GGGAGAGTGGCAGGTC 1										
RESULT 210												
E65210/c		E65210	17 bp		DNA	linear	PAT 18-JUN-2001					
LOCUS		Method for analyzing oligonucleotide.										
DEFINITION		E65210										
ACCESSION		E65210.1	GI:13025986									
VERSION		JP 1999046800-A/4.										
KEYWORDS		synthetic construct										
SOURCE		synthetic construct										
ORGANISM		other sequences; artificial sequences.										
REFERENCE		1. (bases 1 to 17)										
AUTHORS		Leroy, E.H., Michael, W.H., Lloyd, M.S. and Tim, J.H.										
TITLE		Method for analyzing oligonucleotide										
JOURNAL		Patent: JP 1999046800-A 4 23-FEB-1999;										
		CALIFORNIA INSTITUTE OF TECHNOLOGY										
COMMENT		OS	Artificial Sequence									
		PN	JP 1999046800-A/4									
		PD	23-FEB-1999									
		PF	12-FEB-1998 JP 1998030272									
		PR	16-JAN-1984 US 570973									
		PI	LEROY E HOOD, MICHAEL W HANKAPILA, LLOYD M SMITH, TIM J HANKAPILA									
		PC	C12Q1/68, G01N21/76, G01N27/447, G01N33/50, G01N33/58, C12N15/09									
		CC										
		FH	Key									
		FT	source									
		FT	1. .17 Location/Qualifiers									
			/organism='Artificial Sequence'.									
FEATURES	source	Location/Qualifiers										
		1. .17										
		/organism="synthetic construct"										
		/mol_type="genomic DNA"										
		/db_xref="taxon:32630"										
Query Match		0.8%;	Score 13.8;	DB 1;	Length 17;							
Best Local Similarity		88.2%;	Pred. No. 1.3e+02;									
Matches	15;	Conservative	0;	Mismatches	2;	Indels	0;	Gaps	0;			
QY	1357	AAGCGCTGCAGGAATAC 1373										
Db	17	ATGCTCTGCAGGAATAC 1										
RESULT 211												
AR192271		Sequence 7759 from patent US 6346398.									linear	
LOCUS		AR192271									17 bp	
DEFINITION		Sequence 7759 from patent US 6346398.									DNA	
ACCESSION		AR192271										
VERSION		AR192271.1									GI:20238236	
KEYWORDS		Unknown.										
SOURCE		Unknown.										
ORGANISM		Unclassified.										
REFERENCE		1. (bases 1 to 17)										
AUTHORS		Pavco, P., McSwigen, J., Stinchcomb, D. and Escobedo, J.										
TITLE		Method and reagent for the treatment of diseases or conditions										
JOURNAL		related to levels of vascular endothelial growth factor receptor										
FEATURES		Patent: US 6346398-A 7759 12-FEB-2002;										
		Location/Qualifiers										

source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1112 CTCCTCCTTCTGCGAGC 1128  
Db 1 CTCCTCCTTCTGCGAGC 17

RESULT 212  
AR196222/c  
LOCUS AR196222 17 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 687 from patent US 6350934.  
ACCESSION AR196222  
VERSION AR196222.1 GI:20245659  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Zwick,M.G., Edington,B.E., McSwiggen,J.A., Merlo,P.Ann.Owens.,  
Guo,L., Skokut,T.A., Young,S.A., Folkerts,O. and Merlo,D.J.  
TITLE Nucleic acid encoding delta-9 desaturase  
JOURNAL Patent: US 6350934-A 687 26-FEB-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1213 TGGCTTCCACACTTCT 1229  
Db 17 TGGCTGCGCACTTCT 1

RESULT 213  
AR213316  
LOCUS AR213316 17 bp DNA linear PAT 25-SEP-2002  
DEFINITION Sequence 25 from patent US 6403552.  
ACCESSION AR213316  
VERSION AR213316.1 GI:23310499  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.  
TITLE Ob receptor and methods for the diagnosis and treatment of body weight disorders  
JOURNAL Patent: US 6403552-A 25 11-JUN-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCGCTTCAG 17

RESULT 214  
AR213318

LOCUS AR213318 17 bp DNA linear PAT 25-SEP-2002  
DEFINITION Sequence 27 from patent US 6403552.  
ACCESSION AR213318  
VERSION AR213318.1 GI:23310501  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.  
TITLE Ob receptor and methods for the diagnosis and treatment of body weight disorders  
JOURNAL Patent: US 6403552-A 27 11-JUN-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCGCTTCAG 17

RESULT 215  
AR256153  
LOCUS AR256153 17 bp DNA linear PAT 20-DEC-2002  
DEFINITION Sequence 25 from patent US 6482927.  
ACCESSION AR256153  
VERSION AR256153.1 GI:27305555  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.  
TITLE Chimeric proteins comprising the extracellular domain of murine Ob receptor  
JOURNAL Patent: US 6482927-A 25 19-NOV-2002;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCGCTTCAG 17

RESULT 216  
AR256155  
LOCUS AR256155 17 bp DNA linear PAT 20-DEC-2002  
DEFINITION Sequence 27 from patent US 6482927.  
ACCESSION AR256155  
VERSION AR256155.1 GI:27305557  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia,L.A., Tepper,R.I., Culpepper,J.A. and White,D.W.  
TITLE Chimeric proteins comprising the extracellular domain of murine Ob receptor  
JOURNAL Patent: US 6482927-A 27 19-NOV-2002;  
FEATURES Location/Qualifiers  
source 1. .17

/organism="unknown" /mol_type="genomic DNA"		Query Match Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	660 CACTACCTGCCCTTCAG 676 	
Db	1 CACTATTGGCCCTTCAG 17	
RESULT 217 AR275110 LOCUS AR275110 17 bp DNA linear PAT 10-APR-2003 DEFINITION Sequence 25 from patent US 6506877. ACCESSION AR275110 VERSION AR275110.1 GI:29708051 KEYWORDS SOURCE Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 17) AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A. TITLE Ob receptor JOURNAL Patent: US 6506877-A 25 14-JAN-2003; FEATURES Location/Qualifiers source 1..17 /organism="unknown" /mol_type="genomic DNA"		
Query Match Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	660 CACTACCTGCCCTTCAG 676 	
Db	1 CACTATTGGCCCTTCAG 17	
RESULT 218 AR275112 LOCUS AR275112 17 bp DNA linear PAT 10-APR-2003 DEFINITION Sequence 27 from patent US 6506877. ACCESSION AR275112 VERSION AR275112.1 GI:29708053 KEYWORDS SOURCE Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 17) AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A. TITLE Ob receptor JOURNAL Patent: US 6506877-A 27 14-JAN-2003; FEATURES Location/Qualifiers source 1..17 /organism="unknown" /mol_type="genomic DNA"		
Query Match Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	660 CACTACCTGCCCTTCAG 676 	
Db	1 CACTATTGGCCCTTCAG 17	
RESULT 219 AR306243 LOCUS AR306243 17 bp DNA linear PAT 12-JUN-2003 DEFINITION Sequence 25 from patent US 6548269. ACCESSION AR306243		
Query Match Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	660 CACTACCTGCCCTTCAG 676 	
Db	1 CACTATTGGCCCTTCAG 17	
RESULT 220 AR306245 LOCUS AR306245 17 bp DNA linear PAT 12-JUN-2003 DEFINITION Sequence 27 from patent US 6548269. ACCESSION AR306245 VERSION AR306245.1 GI:31695968 KEYWORDS SOURCE Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 17) AUTHORS Tartaglia,L.A., Tepper,R.I. and Culpepper,J.A. TITLE Ob receptor and methods for the diagnosis and treatment of body weight disorders including obesity and cachexia JOURNAL Patent: US 6548269-A 27 15-APR-2003; FEATURES Location/Qualifiers source 1..17 /organism="unknown" /mol_type="genomic DNA"		
Query Match Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	660 CACTACCTGCCCTTCAG 676 	
Db	1 CACTATTGGCCCTTCAG 17	
RESULT 221 AR326141 LOCUS AR326141 17 bp RNA linear PAT 17-AUG-2003 DEFINITION Sequence 3543 from patent US 6566127. ACCESSION AR326141 VERSION AR326141.1 GI:33711949 KEYWORDS SOURCE Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 17) AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J. TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor JOURNAL Patent: US 6566127-A 3543 20-MAY-2003; FEATURES Location/Qualifiers source 1..17 /organism="unknown" /mol_type="unassigned RNA"		
Query Match Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17; Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	660 CACTACCTGCCCTTCAG 676 	
Db	1 CACTATTGGCCCTTCAG 17	

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1112 CTCCTCTGCTGAGC 1128  
|||||  
Db 1 CTCCTCTGCTGAGC 17

RESULT 222  
AR326780 AR326780 17 bp RNA linear PAT 17-AUG-2003  
LOCUS  
DEFINITION Sequence 4182 from patent US 6566127.  
ACCESSION AR326780  
VERSION AR326780.1 GI:33712588  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Pavco, P., McSwiggen, J.A., Stinchcomb, D.T. and Escobedo, J.  
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor  
JOURNAL Patent: US 6566127-A 4182 20-MAY-2003;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="unassigned RNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1115 CTCCTGCTGAGCAGC 1131  
|||||  
Db 1 CTCCTGCTGAGCCGC 17

RESULT 223  
AR371631 AR371631 17 bp DNA linear PAT 12-SEP-2003  
LOCUS  
DEFINITION Sequence 25 from patent US 6395498.  
ACCESSION AR371631  
VERSION AR371631.1 GI:34608616  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia, L.A., Tepper, R.I., Culpepper, J.A. and White, D.W.  
TITLE Methods of identifying compounds that modulate body weight using the OB receptor  
JOURNAL Patent: US 6395498-A 25 28-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676  
|||||  
Db 1 CACTATTGCCCTTCAG 17

RESULT 224  
AR371633 AR371633 17 bp DNA linear PAT 12-SEP-2003  
LOCUS  
DEFINITION Sequence 27 from patent US 6395498.  
ACCESSION AR371633  
VERSION AR371633.1 GI:34608618

KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Tartaglia, L.A., Tepper, R.I., Culpepper, J.A. and White, D.W.  
TITLE Methods of identifying compounds that modulate body weight using the OB receptor  
JOURNAL Patent: US 6395498-A 27 28-MAY-2002;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACCTGCCCTTCAG 676  
|||||  
Db 1 CACTATTGCCCTTCAG 17

RESULT 225  
AR458218/c AR458218 17 bp DNA linear PAT 20-FEB-2004  
LOCUS  
DEFINITION Sequence 1895 from patent US 6686188.  
ACCESSION AR458218  
VERSION AR458218.1 GI:42693275  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 1895 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 93 GAGAGTGGCAGGTCTCT 109  
|||||  
Db 17 GAGAGAGCCAGGTCTCT 1

RESULT 226  
AR458966/c AR458966 17 bp DNA linear PAT 20-FEB-2004  
LOCUS  
DEFINITION Sequence 2643 from patent US 6686188.  
ACCESSION AR458966  
VERSION AR458966.1 GI:42694023  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 2643 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1..17  
/organism="unknown"  
/mol\_type="genomic DNA"





FEATURES  
source

Location/Qualifiers  
1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 268 TAGAAGAGCCCAAGAAG 284  
| | | | | | | | | | | | | | | | | | | | |  
Db 1 TGGAGGAGCCCAAGAAG 17

RESULT 232  
LOCUS AR464986 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8663 from patent US 6686188.  
ACCESSION AR464986  
VERSION AR464986.1 GI:42700043  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8663 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAAGAGCCCAAGAAGAA 286  
| | | | | | | | | | | | | | | | | | | | |  
Db 1 GAGGAGCCCAAGAAGGA 17

RESULT 233  
LOCUS AR464987 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 8664 from patent US 6686188.  
ACCESSION AR464987  
VERSION AR464987.1 GI:42700044  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 8664 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAAG 287  
| | | | | | | | | | | | | | | | | | | | |  
Db 1 AGGAAGCCCAAGAAGGAG 17

RESULT 234  
LOCUS AR466010/c 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 9687 from patent US 6686188.  
ACCESSION AR466010  
VERSION AR466010.1 GI:42701067  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 9687 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGGCAGGTCTCT 109  
| | | | | | | | | | | | | | | | | | | | |  
Db 17 GAGAGTGGGCAGGTCTCT 1

RESULT 235  
LOCUS AR466011/c 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 9688 from patent US 6686188.  
ACCESSION AR466011  
VERSION AR466011.1 GI:42701068  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.  
TITLE Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
JOURNAL Patent: US 6686188-A 9688 03-FEB-2004;  
FEATURES Location/Qualifiers  
source 1. .17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 92 GGAGAGTGGGCAGGTCTC 108  
| | | | | | | | | | | | | | | | | | | | |  
Db 17 GGAGAGTGGGCAGGTCTC 1

RESULT 236  
LOCUS AR466012/c 17 bp DNA linear PAT 20-FEB-2004  
DEFINITION Sequence 9689 from patent US 6686188.  
ACCESSION AR466012  
VERSION AR466012.1 GI:42701069  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 17)  
AUTHORS Gu, Y., Ji, Y., Penn, S.G., Hanzel, D.K., Rank, D.R., Chen, W. and Shannon, M.E.

Shannon,M.E.  
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
Patent: US 6686188-A 9689 03-FEB-2004;  
JOURNAL Location/Qualifiers  
FEATURES  
source  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 91 GGGAGAGTGGGAGGTC 107  
Db 17 GGGAGAGTGGGCGAGTC 1

RESULT 237  
AX215611/c  
LOCUS 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 1053 from Patent WO0159103.  
ACCESSION AX215611  
VERSION AX215611.1 GI:15525654  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE  
1  
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 1053 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source  
1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Nucleic Acid"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1622 AATAAACTGCTGTGTG 1638  
Db 17 ATTAAAACTGCTCTTTG 1

RESULT 238  
AX216443/c  
LOCUS 17 bp RNA linear PAT 07-SEP-2001  
DEFINITION Sequence 1885 from Patent WO0159103.  
ACCESSION AX216443  
VERSION AX216443.1 GI:15526504  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE  
1  
AUTHORS Blatt,L., McSwiggen,J. and Chowrira,B.M.  
TITLE Method and reagent for the modulation and diagnosis of cd20 and nogo gene expression  
JOURNAL Patent: WO 0159103-A 1885 16-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); Blatt, Lawrence (US);  
McSwiggen, James (US); Chowrira, Bharat M. (US)  
FEATURES  
source  
1..17  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"

Shannon,M.E.  
Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle  
Patent: US 6686188-A 9689 03-FEB-2004;  
JOURNAL Location/Qualifiers  
FEATURES  
source  
1..17  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1621 CAATAAACTGCTGTGT 1637  
Db 17 CATTAAAACTGCTCTTTT 1

RESULT 239  
AX272871/c  
LOCUS 17 bp RNA linear PAT 29-OCT-2001  
DEFINITION Sequence 440 from Patent WO0162911.  
ACCESSION AX272871  
VERSION AX272871.1 GI:16545608  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
1  
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Hamblin,P.A. and Ellis,J.H.  
TITLE Method and reagent for the inhibition of grid  
JOURNAL Patent: WO 0162911-A 440 30-AUG-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1539 CTCCTCCGCTCTGGATCC 1555  
Db 17 CTCCTCCGCTGTGGAACC 1

RESULT 240  
AX422540  
LOCUS 17 bp RNA linear PAT 18-JUN-2002  
DEFINITION Sequence 876 from Patent WO0188124.  
ACCESSION AX422540  
VERSION AX422540.1 GI:21525922  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE  
1  
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., McLaughlin,F.G. and Randi,A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0188124-A 876 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US); GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1504 GCCCCAGCCTCCAGGCC 1520  
Db 1 GCCCCAGCCTCCAGCCC 17

RESULT 241  
AX423446  
LOCUS AX423446 17 bp RNA linear PAT 18-JUN-2002  
DEFINITION Sequence 1782 from Patent WO0186124.  
ACCESSION AX423446  
VERSION AX423446.1 GI:21526828  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Jarvis,T., von Carlowitz,I., Mcswiggen,J.A., Mclaughlin,F.G. and Randi,A.M.  
TITLE Method and reagent for the inhibition of erg  
JOURNAL Patent: WO 0186124-A 1782 22-NOV-2001;  
RIBOZYME PHARMACEUTICALS, INC. (US) ; GLAXO GROUP LIMITED (GB)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 218 GACTCTCATGAAAAA 234  
|||||  
Db 1 GACTCACAGAAAAA 17  
RESULT 242  
AX475287  
LOCUS AX475287 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 508 from Patent WO0224750.  
ACCESSION AX475287  
VERSION AX475287.1 GI:22214572  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 508 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 520 GCATCGACTCCCTGCTG 536  
|||||  
Db 1 GCATCTACTCCAGCTG 17  
RESULT 243  
AX475288  
LOCUS AX475288 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 509 from Patent WO0224750.  
ACCESSION AX475288  
VERSION AX475288.1 GI:22214573  
KEYWORDS  
SOURCE Homo sapiens (human)

ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 509 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 521 CATCGACTCCCTGCTGG 537  
|||||  
Db 1 CATCTACTCCAGCTGG 17  
RESULT 244  
AX475289  
LOCUS AX475289 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 510 from Patent WO0224750.  
ACCESSION AX475289  
VERSION AX475289.1 GI:22214574  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 510 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 522 ATCGACTCCCTGCTGGA 538  
|||||  
Db 1 ATCTACTCCAGCTGGA 17  
RESULT 245  
AX475290  
LOCUS AX475290 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 511 from Patent WO0224750.  
ACCESSION AX475290  
VERSION AX475290.1 GI:22214575  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Zhang,J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 511 28-MAR-2002;  
Aeomica, Inc. (US)  
FEATURES  
source  
1. .17  
/organism="Homo sapiens"

/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 523 TCAGCTCCCTGCTGGAG 539  
Db 1 TCTACTCCAGCTGGAG 17

RESULT 246  
AX475291  
LOCUS AX475291 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 512 from Patent WO0224750.  
ACCESSION AX475291  
VERSION AX475291.1 GI:22214576  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 512 28-MAR-2002;  
Aeomica, Inc. (US)

FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 524 CGACTCCCTGCTGGAGA 540  
Db 1 CTACTCCAGCTGGAGA 17

RESULT 247  
AX475293  
LOCUS AX475293 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 514 from Patent WO0224750.  
ACCESSION AX475293  
VERSION AX475293.1 GI:22214578  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 514 28-MAR-2002;  
Aeomica, Inc. (US)

FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 526 ACTCCCTGCTGGAGAC 542  
Db 1 ACTCCAGCTGGAGACC 17

RESULT 248  
AX475720  
LOCUS AX475720 17 bp DNA linear PAT 12-AUG-2002  
DEFINITION Sequence 941 from Patent WO0224750.  
ACCESSION AX475720  
VERSION AX475720.1 GI:22215005  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Zhang, J.  
TITLE Human kidney tumor overexpressed membrane protein 1  
JOURNAL Patent: WO 0224750-A 941 28-MAR-2002;  
Aeomica, Inc. (US)

FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1203 GTCACCACGGTGGCTTC 1219  
Db 1 GTCACCACCTGTGGCTGC 17

RESULT 249  
AX499441  
LOCUS AX499441 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 748 from Patent EP1229046.  
ACCESSION AX499441  
VERSION AX499441.1 GI:23381734  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1  
AUTHORS Zhan, J.  
TITLE Human testis expressed patched like protein  
JOURNAL Patent: EP 1229046-A 748 07-AUG-2002;  
Aeomica, Inc. (US)

FEATURES  
source  
1..17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 521 CATCGACTCCCTGCTGG 537  
Db 1 CAGCGACTCACTGCTGG 17

RESULT 250  
AX499442  
LOCUS AX499442 17 bp DNA linear PAT 27-SEP-2002  
DEFINITION Sequence 749 from Patent EP1229046.  
ACCESSION AX499442  
VERSION AX499442.1 GI:23381735  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE	1	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS	Zhan, J.	
TITLE	Human testis expressed patched like protein	
JOURNAL	Patent: EP 1229046-A 749 07-AUG-2002;	
FEATURES	Acemica, Inc. (US)	
source	Location/Qualifiers	
	1. .17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.8%; Score 13.8; DB 1; Length 17;	
Best Local Similarity	88.2%; Pred. No. 1.3e+02;	
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Qy	522 ATCGACTCCCTGCTGGA 538	
Db		
	1 AGCGACTCACTGCTGGA 17	
RESULT 251		
AX499931	AX499931	17 bp DNA linear PAT 27-SEP-2002
LOCUS	Sequence 1238 from Patent EP1229046.	
DEFINITION	Human testis expressed patched like protein	
ACCESSION	AX499931	
VERSION	AX499931.1 GI:23382224	
KEYWORDS	Homo sapiens (human)	
SOURCE	Homo sapiens	
ORGANISM	Homo sapiens	
REFERENCE	1	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS	Zhan, J.	
TITLE	Human testis expressed patched like protein	
JOURNAL	Patent: EP 1229046-A 1238 07-AUG-2002;	
FEATURES	Acemica, Inc. (US)	
source	Location/Qualifiers	
	1. .17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.8%; Score 13.8; DB 1; Length 17;	
Best Local Similarity	88.2%; Pred. No. 1.3e+02;	
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
Qy	1273 TCTTTGACTCTGATCCC 1289	
Db		
	1 TCTGTGACTGTGATCCC 17	
RESULT 252		
AX687958	AX687958	17 bp DNA linear PAT 31-MAR-2003
LOCUS	Sequence 690 from Patent EP1281758.	
DEFINITION	Human testis expressed patched like protein	
ACCESSION	AX687958	
VERSION	AX687958.1 GI:29410656	
KEYWORDS	Homo sapiens (human)	
SOURCE	Homo sapiens	
ORGANISM	Homo sapiens	
REFERENCE	1	Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
AUTHORS	Shannon, M., Gu, Y. and Nguyen, C.T.	
TITLE	Four human zinc-finger-containing proteins : mdz3, mdz4, mdz7 and mdz12	
JOURNAL	Patent: EP 1281758-A 690 05-FEB-2003;	
FEATURES	Acemica, Inc. (US)	
source	Location/Qualifiers	
	1. .17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	

VERSION	AX731740.1	GI:30511083
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE		
AUTHORS	Teleman, A., Amson, R. and Tuijinder, M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines	
JOURNAL	Patent: WO 03025175-A 3374 27-MAR-2003;	
FEATURES	Molecular Engines Laboratories (FR)	
source	Location/Qualifiers	
	1. .17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.8%; Score 13.8; DB 1; Length 17;	
Best Local Similarity	88.2%; Pred. No. 1.3e+02;	
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	359 GACCATGATGCGCCTCT 375	
Db	1 GATCATGATGCGCCTCT 17	
RESULT 258		
AX734894		
LOCUS	AX734894 17 bp DNA linear PAT 08-MAY-2003	
DEFINITION	Sequence 484 from Patent WO03025177.	
ACCESSION	AX734894	
VERSION	AX734894.1 GI:30514171	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE		
AUTHORS	Teleman, A., Amson, R. and Tuijinder, M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or resistance to viruses and the use thereof as medicaments	
JOURNAL	Patent: WO 03025177-A 484 27-MAR-2003;	
FEATURES	Molecular Engines Laboratories (FR)	
source	Location/Qualifiers	
	1. .17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.8%; Score 13.8; DB 1; Length 17;	
Best Local Similarity	88.2%; Pred. No. 1.3e+02;	
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	1551 GATCCTGCACTCTAACA 1567	
Db	1 GATCCTGCACTCTAATA 17	
RESULT 256		
AX728423/c		
LOCUS	AX728423 17 bp DNA linear PAT 08-MAY-2003	
DEFINITION	Sequence 57 from Patent WO03025175.	
ACCESSION	AX728423	
VERSION	AX728423.1 GI:30507766	
KEYWORDS		
SOURCE	Homo sapiens (human)	
ORGANISM	Homo sapiens	
REFERENCE		
AUTHORS	Teleman, A., Amson, R. and Tuijinder, M.	
TITLE	Sequences involved in phenomena of tumour suppression, tumour reversal, apoptosis and/or virus resistance and their use as medicines	
JOURNAL	Patent: WO 03025175-A 57 27-MAR-2003;	
FEATURES	Molecular Engines Laboratories (FR)	
source	Location/Qualifiers	
	1. .17	
	/organism="Homo sapiens"	
	/mol_type="unassigned DNA"	
	/db_xref="taxon:9606"	
Query Match	0.8%; Score 13.8; DB 1; Length 17;	
Best Local Similarity	88.2%; Pred. No. 1.3e+02;	
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	
QY	374 CTGGGAAGAGTGTGATC 390	
Db	17 CTGGGAAGAGTGTGATC 1	
RESULT 257		
AX731740		
LOCUS	AX731740 17 bp DNA linear PAT 08-MAY-2003	
DEFINITION	Sequence 3374 from Patent WO03025175.	

AUTHORS Telerman,A., Anson,R. and Tuijnder,M.  
TITLE Sequences involved in tumoral suppression, tumoral reversion, apoptosis and/or viral resistance phenomena and their use as medicines  
JOURNAL Patent: WO 03040369-A 50 15-MAY-2003;  
FEATURES Molecular Engines Laboratories (FR)  
source Location/Qualifiers  
1. .17  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. NO. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 91 GGGAGAGTGGCGAGGTC 107  
||||| ||||||| ||  
Db 17 GGGAGGTTGGCGAGATC 1  
RESULT 260  
161606  
LOCUS 161606 15 bp DNA linear PAT 07-OCT-1997  
DEFINITION Sequence 160 from patent US 5658780.  
ACCESSION 161606  
VERSION 161606.1 GI:2479554  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Stinchcomb,D.T., Draper,K.G. and McSwiggen,J.  
TITLE Rel a targeted ribozymes  
JOURNAL Patent: US 5658780-A 160 19-AUG-1997;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1507 CCAGCCTCCAGGCC 1521  
||||| ||||||| ||  
Db 1 CCAGCCTCCAGGCTC 15  
RESULT 261  
AR180106/c  
LOCUS AR180106 15 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 174 from patent US 6333152.  
ACCESSION AR180106  
VERSION AR180106.1 GI:20222139  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.  
TITLE Gene expression profiles in normal and cancer cells  
JOURNAL Patent: US 6333152-A 174 25-DEC-2001;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 807 GCTCAGCAGGCCATG 821

Db 15 GCCCAGCAGGCCATG 1  
||||| ||||||| ||  
RESULT 262  
AR180715/c  
LOCUS AR180715 15 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 783 from patent US 6333152.  
ACCESSION AR180715  
VERSION AR180715.1 GI:20222748  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Vogelstein,B., Kinzler,K.W., Zhang,L. and Zhou,W.  
TITLE Gene expression profiles in normal and cancer cells  
JOURNAL Patent: US 6333152-A 783 25-DEC-2001;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 807 GCTCAGCAGGCCATG 821  
||||| ||||||| ||  
Db 15 GCCCAGCAGGCCATG 1  
RESULT 263  
AR532147/c  
LOCUS AR532147 15 bp DNA linear PAT 08-OCT-2004  
DEFINITION Sequence 75 from patent US 6727085.  
ACCESSION AR532147  
VERSION AR532147.1 GI:53920820  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 15)  
AUTHORS Fano,T.S. and Mikkelsen,F.  
TITLE Subtilase variants having an improved wash performance on egg stains  
JOURNAL Patent: US 6727085-A 75 27-APR-2004;  
FEATURES Location/Qualifiers  
source 1. .15  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. NO. 1e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1076 GCTGTAAAGTCCTA 1090  
||||| ||||||| ||  
Db 15 GCTGTAAAGTCCTA 1  
RESULT 264  
AX167089/c  
LOCUS AX167089 15 bp DNA linear PAT 03-JUL-2001  
DEFINITION Sequence 75 from Patent WO0144452.  
ACCESSION AX167089  
VERSION AX167089.1 GI:14596577  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
REFERENCE 1 other sequences; artificial sequences.  
AUTHORS Fan,T.S. and Mikkelsen,F.F.

TITLE Subtilase variants having an improved wash performance on egg stains

JOURNAL Patent: WO 0144452-A 75 21-JUN-2001; Novozymes A/S (DK)

FEATURES Location/Qualifiers

source 1..15

/organism="synthetic construct"

/mol\_type="unassigned DNA"

/db\_xref="taxon:32630"

/note="Antisense primer"

Query Match 0.8%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1076 GCTGCTAAAGTCCTA 1090

Db 15 GCTGTTAAAGTCCTA 1

RESULT 265

AX635964

LOCUS AX635964 15 bp RNA linear PAT 21-FEB-2003

DEFINITION Sequence 3103 from Patent EP1260586.

ACCESSION AX635964

VERSION AX635964.1 GI:28471578

KEYWORDS .

SOURCE unidentified

ORGANISM unidentified

REFERENCE 1 unclassified.

AUTHORS Stinchcomb,D.T., Dudycz,L.W., Chowrira,B., Grimm,S., Direnzo,A., Karpeisky,A., Draper,K.G., Kisich,K., Matulic-Adamic,J., Mcswiggen,J.A., Modak,A., Pavco,P., Beigelman,L., Sullivan,S.M., Sweedler,D., Thompson,J.D., Tracz,D., Usman,N., Wincott,F.E. and Wolf,T.

TITLE Method and reagent for inhibiting the expression of disease related genes

JOURNAL Patent: EP 1260586-A 3103 27-NOV-2002;

FEATURES RIBOZYME PHARMACEUTICALS, INC. (US)

source 1..15

/organism="unidentified"

/mol\_type="unassigned RNA"

/db\_xref="taxon:32644"

Query Match 0.8%; Score 13.4; DB 1; Length 15;

Best Local Similarity 93.3%; Pred. No. 1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1507 CCAGCCTCCAGGCC 1521

Db 1 CCAGCCTCCAGGCTC 15

RESULT 266

AR029843/c

LOCUS AR029843 16 bp DNA linear PAT 29-SEP-1999

DEFINITION Sequence 32 from patent US 5861244.

ACCESSION AR029843

VERSION AR029843.1 GI:5943057

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)

AUTHORS Wang,C.-G. and Hepburn,A.G.

TITLE Genetic sequence assay using DNA triple strand formation

JOURNAL Patent: US 5861244-A 32 19-JAN-1999;

FEATURES Location/Qualifiers

source 1..16

/organism="unknown"

/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 271 AAGAGCCACAAGA 285

Db 15 AAGAAGCAAGAAGA 1

RESULT 267

AR131574

LOCUS AR131574 16 bp DNA linear PAT 16-MAY-2001

DEFINITION Sequence 67 from patent US 6194149.

ACCESSION AR131574

VERSION AR131574.1 GI:14120477

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)

AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.

TITLE Target-dependent reactions using structure-bridging oligonucleotides

JOURNAL Patent: US 6194149-A 67 27-FEB-2001;

FEATURES Location/Qualifiers

source 1..16

/organism="unknown"

/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1522

Db 2 CAGCCTCCAGGACCC 16

RESULT 268

AR131575

LOCUS AR131575 16 bp DNA linear PAT 16-MAY-2001

DEFINITION Sequence 68 from patent US 6194149.

ACCESSION AR131575

VERSION AR131575.1 GI:14120478

KEYWORDS .

SOURCE Unknown.

ORGANISM Unknown.

REFERENCE 1 (bases 1 to 16)

AUTHORS Neri,B., Dong,F., Lyamichev,V., Brow,M. Ann.D. and Fors,L.

TITLE Target-dependent reactions using structure-bridging oligonucleotides

JOURNAL Patent: US 6194149-A 68 27-FEB-2001;

FEATURES Location/Qualifiers

source 1..16

/organism="unknown"

/mol\_type="unassigned DNA"

Query Match 0.8%; Score 13.4; DB 1; Length 16;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCC 1522

Db 2 CAGCCTCCAGGACCC 16

RESULT 269

CQ796994/c

LOCUS CQ796994 16 bp DNA linear PAT 19-APR-2004

DEFINITION Sequence 11 from Patent WO2004027066.

ACCESSION CQ796994



VERSION CQ796994.1 GI:46408576  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
unclassified.  
REFERENCE 1  
AUTHORS Letourneur,O.  
TITLE Chimeric recombinant protein and in vitro diagnosis  
JOURNAL Patent: WO 2004027066-A 11 01-APR-2004;  
Blomerieux (FR)  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
/note="artificial sequence"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 476 CCTGAACCCAGAGCTC 490  
Db 15 CCTGAACCCGAGCTC 1  
RESULT 270  
CQ858546/c  
LOCUS CQ858546 16 bp DNA linear PAT 31-AUG-2004  
DEFINITION Sequence 8 from Patent WO2004069991.  
ACCESSION CQ858546  
VERSION CQ858546.1 GI:51852513  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Hansen,B., Thruue,C.A., Petersen,K.D., Westergaard,M. and Wissenbach,M.  
TITLE Oligomeric compounds for the modulation of survivin expression  
JOURNAL Patent: WO 2004069991-A 8 19-AUG-2004;  
Santaris Pharma A/S (DK)  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 278 CAAGAAGAAGAAGA 292  
Db 16 CAATAAGAAGAAGA 2  
RESULT 271  
AR199508  
LOCUS AR199508 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 67 from patent US 6355437.  
ACCESSION AR199508  
VERSION AR199508.1 GI:20249582  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri,B., Dong,F., Lyamichiev,V., Brow,M. Ann.D. and Fors,L.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides  
JOURNAL Patent: US 6355437-A 67 12-MAR-2002;  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unassigned DNA"  
/db\_xref="taxon:32644"

FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGCCCC 16  
RESULT 272  
AR199509  
LOCUS AR199509 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 68 from patent US 6355437.  
ACCESSION AR199509  
VERSION AR199509.1 GI:20249583  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri,B., Dong,F., Lyamichiev,V., Brow,M. Ann.D. and Fors,L.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides  
JOURNAL Patent: US 6355437-A 68 12-MAR-2002;  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGCCCC 16  
RESULT 273  
AR200979  
LOCUS AR200979 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 67 from patent US 6358691.  
ACCESSION AR200979  
VERSION AR200979.1 GI:20251867  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri,B., Dong,F., Lyamichiev,V., Brow,M. Ann.D. and Fors,L.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides  
JOURNAL Patent: US 6358691-A 67 19-MAR-2002;  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
Db 2 CAGCCTCCAGGCCCC 16  
RESULT 274  
AR199508  
LOCUS AR199508 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 67 from patent US 6355437.  
ACCESSION AR199508  
VERSION AR199508.1 GI:20249582  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri,B., Dong,F., Lyamichiev,V., Brow,M. Ann.D. and Fors,L.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides  
JOURNAL Patent: US 6355437-A 67 12-MAR-2002;  
FEATURES Location/Qualifiers  
source  
1. .16  
/organism="unassigned DNA"  
/db\_xref="taxon:32644"

AR200980 LOCUS 16 bp DNA linear PAT 20-APR-2002  
DEFINITION Sequence 68 from patent US 6358691.  
ACCESSION AR200980  
VERSION AR200980.1 GI:20251868  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Neri, B., Dong, F., Lyamichev, V., Brow, M. Ann. D. and Fors, L.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides  
JOURNAL Patent: US 6358691-A 68 19-MAR-2002;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 275  
AR488738 LOCUS 16 bp DNA linear PAT 15-MAY-2004  
DEFINITION Sequence 67 from patent US 6709815.  
ACCESSION AR488738  
VERSION AR488738.1 GI:47254936  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Dong, F., Lyamichev, V. I., Prudent, J. R., Fors, L., Neri, B. P.,  
Brow, M. A. D., Anderson, T. A. and Dahlberg, J. E.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides  
JOURNAL Patent: US 6709815-A 67 23-MAR-2004;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 276  
AR488739 LOCUS 16 bp DNA linear PAT 15-MAY-2004  
DEFINITION Sequence 68 from patent US 6709815.  
ACCESSION AR488739  
VERSION AR488739.1 GI:47254937  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Dong, F., Lyamichev, V. I., Prudent, J. R., Fors, L., Neri, B. P.,  
Brow, M. A. D., Anderson, T. A. and Dahlberg, J. E.  
TITLE Target-dependent reactions using structure-bridging oligonucleotides

JOURNAL Patent: US 6709815-A 68 23-MAR-2004;  
FEATURES  
source  
1. .16  
/organism="unknown"  
/mol\_type="genomic DNA"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 277  
AX419730 LOCUS 16 bp DNA linear PAT 18-JUN-2002  
DEFINITION Sequence 67 from Patent WO0198537.  
ACCESSION AX419730  
VERSION AX419730.1 GI:21524097  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B. P. and Vener, I. T.  
TITLE Nucleic acid accessible hybridization sites  
JOURNAL Patent: WO 0198537-A 67 27-DEC-2001;  
THIRD WAVE TECHNOLOGIES, INC. (US)  
FEATURES  
source  
1. .16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 278  
AX419731 LOCUS 16 bp DNA linear PAT 18-JUN-2002  
DEFINITION Sequence 68 from Patent WO0198537.  
ACCESSION AX419731  
VERSION AX419731.1 GI:21524098  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B. P. and Vener, I. T.  
TITLE Nucleic acid accessible hybridization sites  
JOURNAL Patent: WO 0198537-A 68 27-DEC-2001;  
THIRD WAVE TECHNOLOGIES, INC. (US)  
FEATURES  
source  
1. .16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16  
RESULT 279  
AX419731 LOCUS 16 bp DNA linear PAT 18-JUN-2002  
DEFINITION Sequence 68 from Patent WO0198537.  
ACCESSION AX419731  
VERSION AX419731.1 GI:21524098  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Lyamichev, V., Allawi, H., Dong, F., Neri, B. P. and Vener, I. T.  
TITLE Nucleic acid accessible hybridization sites  
JOURNAL Patent: WO 0198537-A 68 27-DEC-2001;  
THIRD WAVE TECHNOLOGIES, INC. (US)  
FEATURES  
source  
1. .16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
DB 2 CAGCCTCCAGGACCC 16

PR 05-MAY-1997 US 08/851588,19-SEP-1997 US 08/934097 PR  
03-MAR-1998 US 09/034205  
PI FANG DONG, VICTOR I LYAMICHEV, JAMES R PRUDENT, LANCE FORS, BRUCE  
P NERI,  
PI MARY ANN D BROW, TODD A ANDERSON, JAMES E DAHLBERG PC  
C07H21/04, C07H21/02, C12Q1/68  
CC Strandedness: Single;  
CC Topology: Linear;  
CC /desc = 'DNA'  
FH Key Location/Qualifiers  
FT source 1..16 /organism='Unidentified'.  
FT FEATURES  
source  
1..16  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCC 1522  
|||||  
Db 2 CAGCCTCCAGGCC 16  
RESULT 281  
S81287/c  
LOCUS  
DEFINITION  
S81287  
Mitochondrial acetoacetyl-coenzyme A thiolase [human, Genomic  
Mutant, 16 nt].  
S81287.1 GI:245359  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
AUTHORS  
1 (bases 1 to 16)  
Fukao, T., Yamaguchi, S., Orii, T., Schutgens, R.B., Osumi, T. and  
Hashimoto, T.  
TITLE  
Identification of three mutant alleles of the gene for  
mitochondrial acetoacetyl-coenzyme A thiolase. A complete analysis  
of two generations of a family with 3-ketothiolase deficiency  
J. Clin. Invest. 89 (2), 474-479 (1992)  
JOURNAL  
MEDLINE  
PUBMED  
REMARK  
GenBank staff at the National Library of Medicine created this  
entry [NCBI gibbsg 81287] from the original journal article.  
COMMENT  
A->C mutation at 3, splice site intron 10.  
FEATURES  
source  
1..16  
/organism='Homo sapiens'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:9606'  
1..16  
/gene='mitochondrial acetoacetyl-coenzyme A thiolase'  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1323 AAGAACCCTAAATTT 1337  
|||||  
Db 15 AAGAACCCTAAATTT 1  
RESULT 282  
AR066302/c  
LOCUS  
DEFINITION  
AR066302  
Sequence 1 from patent US 5849903.  
ACCESSION

BD084992 16 bp DNA linear PAT 27-AUG-2002  
Target-dependent reactions using structure-bridging  
oligonucleotides.  
BD084992  
BD084992.1 GI:22630602  
JP 2001523111-A/67.  
unidentified  
unclassified.  
REFERENCE  
1 (bases 1 to 16)  
Dong, F., Lyamichev, V.I., Prudent, J.R., Fors, L., Neri, B.P.,  
Brow, M.A.D., Anderson, T.A. and Dahlberg, J.E.  
TITLE  
Target-dependent reactions using structure-bridging  
oligonucleotides  
JOURNAL  
Patent: JP 2001523111-A 67 20-NOV-2001;  
THIRD WAVE TECHNOLOGIES INC  
COMMENT  
OS Unidentified  
PN JP 2001523111-A/67  
PD 20-NOV-2001  
PF 05-MAY-1998 JP 1998548047  
PR 05-MAY-1997 US 08/851588,19-SEP-1997 US 08/934097 PR  
03-MAR-1998 US 09/034205  
PI FANG DONG, VICTOR I LYAMICHEV, JAMES R PRUDENT, LANCE FORS, BRUCE  
P NERI,  
PI MARY ANN D BROW, TODD A ANDERSON, JAMES E DAHLBERG PC  
C07H21/04, C07H21/02, C12Q1/68  
CC Strandedness: Single;  
CC Topology: Linear;  
CC /desc = 'DNA'  
FH Key Location/Qualifiers  
FT source 1..16 /organism='Unidentified'.  
FT FEATURES  
source  
1..16  
/organism='unidentified'  
/mol\_type='genomic DNA'  
/db\_xref='taxon:32644'  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.2e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCC 1522  
|||||  
Db 2 CAGCCTCCAGGCC 16  
RESULT 280  
BD084993 16 bp DNA linear PAT 27-AUG-2002  
LOCUS  
DEFINITION  
BD084993  
Target-dependent reactions using structure-bridging  
oligonucleotides.  
BD084993  
BD084993.1 GI:22630603  
JP 2001523111-A/68.  
unidentified  
unclassified.  
REFERENCE  
1 (bases 1 to 16)  
Dong, F., Lyamichev, V.I., Prudent, J.R., Fors, L., Neri, B.P.,  
Brow, M.A.D., Anderson, T.A. and Dahlberg, J.E.  
TITLE  
Target-dependent reactions using structure-bridging  
oligonucleotides  
JOURNAL  
Patent: JP 2001523111-A 68 20-NOV-2001;  
THIRD WAVE TECHNOLOGIES INC  
COMMENT  
OS Unidentified  
PN JP 2001523111-A/68  
PD 20-NOV-2001  
PF 05-MAY-1998 JP 1998548047

VERSION AR066302.1 GI:5996518  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 14)  
AUTHORS Pietrzkowski, Z., Cieslak, D. and Olbina, G.  
TITLE Antisense oligonucleotides for IL-8 and IL-8 receptor  
JOURNAL Patent: US 5849903-A 1 15-DEC-1998;  
FEATURES Location/Qualifiers  
source 1..14  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 13; DB 1; Length 14;  
Best Local Similarity 100.0%; Pred. No. 95;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1239 GTTCCTCCGGTG 1251  
Db 13 GTTCCTCCGGTG 1  
RESULT 283  
AX377347/c 15 bp DNA . linear PAT 18-MAR-2002  
LOCUS Sequence 11 from Patent WO0212499.  
DEFINITION AX377347  
ACCESSION AX377347  
VERSION AX377347.1 GI:19573633  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kliem, S.E., Koshi, B. and Lanz, E.M.  
TITLE Haplotypes of the ntf3 gene  
JOURNAL Patent: WO 0212499-A 1 14-FEB-2002;  
Genaisance Pharmaceuticals, Inc. (US)  
FEATURES Location/Qualifiers  
source 1..15  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13; DB 1; Length 15;  
Best Local Similarity 86.7%; Pred. No. 1.2e+02;  
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
QY 1537 CTCCTCCCGCTCTGG 1551  
Db 15 CTCCTCCCGCTCTGG 1  
RESULT 284  
ATH551605/c 15 bp DNA linear PLN 29-MAR-2003  
LOCUS Arabidopsis thaliana T-DNA flanking sequence, left border, clone  
DEFINITION 282G05.  
ACCESSION AJ551605  
AJ551605.1 GI:29367738  
VERSION left border; T-DNA flanking sequence.  
KEYWORDS Arabidopsis thaliana (thale cress)  
SOURCE Arabidopsis thaliana  
ORGANISM Arabidopsis thaliana  
Eukaryota; Viridiplantae; Streptophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsi  
REFERENCE 1  
AUTHORS Brunaud, V., Balzerque, S., Dubreucq, B., Aubourg, S., Samson, F.,  
Chauvin, S., Bechtold, N., Cruaud, C., DeRose, R., Pelletier, G.,  
Lepiniec, L., Caboche, M. and Lecharny, A.  
TITLE T-DNA integration into the Arabidopsis genome depends on sequences  
of pre-insertion sites

JOURNAL EMBO Rep. 3 (12), 1152-1157 (2002)  
MEDLINE 22363535  
PUBMED 12446565  
REFERENCE 2 (bases 1 to 15)  
AUTHORS Balzerque, S.  
TITLE Direct Submission  
JOURNAL Submitted (21-NOV-2002) Balzerque S., UMRGV, INRA/CNRS, 2 rue  
Gaston Cremieux, 91057 Evry cedex, FRANCE  
COMMENT PCR was performed on DNA from transformants of Arabidopsis thaliana  
plants from INRA (Versailles). The DNA fragment(s) resulting from  
the PCR were directly sequenced from the left or the right border  
to determine the genomic sequence flanking the insertion. T-DNA  
derived sequences were removed. Information to order the  
corresponding mutant line and a link to a database providing a  
graphical display of the insertion site are available at  
http://dbsgap.versailles.inra.fr/publiclines/. This sequence has  
been generated in the framework of the French plant genomics  
program 'Genoplante' (http://www.genoplante.com and  
http://genoplante-info.infobiogen.fr).  
FEATURES Location/Qualifiers  
source 1..15  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/cultivar="Wassiliewskaja"  
/db\_xref="taxon:3702"  
/clone="282G05"  
misc\_feature 1..15  
/note="T-DNA flanking sequence  
left border"  
Query Match 0.8%; Score 13; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 229 AAAAACAACGCA 241  
Db 14 AAAAACAACGCA 2  
RESULT 285  
CQ806753 16 bp DNA linear PAT 10-MAY-2004  
LOCUS Sequence 203 from Patent WO2004035803.  
DEFINITION CQ806753  
ACCESSION CQ806753  
VERSION CQ806753.1 GI:47112135  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Foekens, J., Harbeck, N., Koenig, T., Maier, S., Martens, J., Model, F.,  
Nimrich, I., Rujan, T., Schmitt, A., Schmitt, M., Look, M.P. and  
Marx, A.  
TITLE Method and nucleic acids for the improved treatment of breast cell  
proliferative disorders  
JOURNAL Patent: WO 2004035803-A 203 29-APR-2004;  
Epigenomics AG (DE)  
FEATURES Location/Qualifiers  
source 1..16  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.8%; Score 13; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1345 CCGTGGCGGAGAA 1357  
Db 3 CCGTGGCGGAGAA 15

RESULT 286  
A88141  
LOCUS A88141 16 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 289 from Patent WO9833904.  
ACCESSION A88141  
VERSION A88141.1 GI:6736711  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL PATENT: WO 9833904-A 289 06-AUG-1998;  
BIOGHOSTIK GES (DE); BRYSCH WOLFGANG (DE)  
FEATURES  
source  
1..16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 456 GGCGGCACCTTGAGG 471  
Db 1 GGCGGCACCTTGAGG 16  
RESULT 287  
A89435  
LOCUS A89435 16 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 1583 from Patent WO9833904.  
ACCESSION A89435  
VERSION A89435.1 GI:6738005  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W. and Schlingensiepen,K.  
TITLE AN ANTISENSE OLIGONUCLEOTIDE PREPARATION METHOD  
JOURNAL PATENT: WO 9833904-A 1583 06-AUG-1998;  
BIOGHOSTIK GES (DE); BRYSCH WOLFGANG (DE)  
FEATURES  
source  
1..16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 456 GGCGGCACCTTGAGG 471  
Db 1 GGCGGCACCTTGAGG 16  
RESULT 288  
A90108  
LOCUS A90108 16 bp DNA linear PAT 22-JAN-2000  
DEFINITION Sequence 289 from Patent EP0856579.  
ACCESSION A90108  
VERSION A90108.1 GI:6738622  
KEYWORDS  
SOURCE unidentified  
ORGANISM unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Brysch,W.D. and Schlingensiepen,K.D.

TITLE An antisense oligonucleotide preparation method  
JOURNAL BIOGHOSTIK GES (DE)  
FEATURES  
source  
1..16  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 456 GGCGGCACCTTGAGG 471  
Db 1 GGCGGCACCTTGAGG 16  
RESULT 289  
AR104209/c  
LOCUS AR104209 16 bp DNA linear PAT 14-FEB-2001  
DEFINITION Sequence 25 from patent US 6093545.  
ACCESSION AR104209  
VERSION AR104209.1 GI:12816917  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 16)  
AUTHORS Goodearl,A.D.J. and Glucksmann,M.Alexandra.  
TITLE Methods for detecting nucleic acid molecules encoding a member of the muscarinic family of receptors  
JOURNAL PATENT: US 6093545-A 25 25-JUL-2000;  
FEATURES  
source  
1..16  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 72 GTGGGCTGCTGTCTGA 87  
Db 16 GTGGGCTGCTGTCTCA 1  
RESULT 290  
CQ786338/c  
LOCUS CQ786338 16 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 146 from Patent WO2004020668.  
ACCESSION CQ786338  
VERSION CQ786338.1 GI:45721440  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Nakamura,Y. and Katagiri,T.  
TITLE Method for treating synovial sarcoma  
JOURNAL Patent: WO 2004020668-A 146 11-MAR-2004;  
Oncotherapy Science, Inc. (JP); The University of Tokyo (JP)  
FEATURES  
source  
1..16  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Description of Artificial Sequence: synthetic oligonucleotide"  
Query Match 0.8%; Score 12.8; DB 1; Length 16;  
Best Local Similarity 87.5%; Pred. No. 1.5e+02;  
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```
.
synthetic construct
synthetic construct
other sequences; artificial sequences.
1
Beger,C., Barber,J. and Wong-Staal,F.
Brca-1 regulators and methods of use
Patent: WO 0170982-A 24 27-SEP-2001;
Immusol Incorporated (US) ; Beger, Carmela (DE)
Location/Qualifiers
1..16
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="Synthetic oligonucleotide"

Query Match      0.8%;   Score 12.8;   DB 1;   Length 16;
Best Local Similarity 87.5%;   Pred.No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy    530 CCTGCTGGAGAACGAC 545
Db    1 CCGATGGAGAACGAC 16

RESULT 294
AX255637          AX255637          16 bp DNA linear PAT 10-OCT-2001
LOCUS            Sequence 58 from Patent WO0170982.
ACCESSION        AX255637
VERSION          AX255637.1 GI:16074693
KEYWORDS         Homo sapiens (human)
ORGANISM         Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1
Beger,C., Barber,J. and Wong-Staal,F.
Brca-1 regulators and methods of use
Patent: WO 0170982-A 58 27-SEP-2001;
Immusol Incorporated (US) ; Beger, Carmela (DE)
Location/Qualifiers
1..16
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"

Query Match      0.8%;   Score 12.8;   DB 1;   Length 16;
Best Local Similarity 87.5%;   Pred.No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy    530 CCTGCTGGAGAACGAC 545
Db    1 CCGATGGAGAACGAC 16

RESULT 295
AX713247          AX713247          16 bp DNA linear PAT 11-APR-2003
LOCUS            Sequence 133 from Patent WO03018837.
ACCESSION        AX713247
VERSION          AX713247.1 GI:29823836
KEYWORDS         .
SOURCE           synthetic construct
ORGANISM         other sequences; artificial sequences.
1
Waschuerza,S., Schnakenberg,E. and Lustig,M.
Method and diagnostic kit for the molecular diagnosis of
pharmacologically relevant genes
Patent: WO 03018837-A 133 06-MAR-2003;
Adnagen AG (DE)
Location/Qualifiers
```

```
source
1. .16
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonukleotid"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 669 CCCTTCAGCTGCC 684
DB 1 CCCACCAGCTGCC 16

RESULT 296
BD066948
LOCUS
DEFINITION An antisense oligonucleotide preparation method.
ACCESSION
VERSION BD066948.1 GI:22612551
KEYWORDS JP 2001511000-A/1583.
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 16)
AUTHORS Schlengensiepen,K.H. and Brysch,W.
TITLE An antisense oligonucleotide preparation method
JOURNAL Patent: JP 2001511000-A 1583 07-AUG-2001;
COMMENT BIOLOGISTIK GESELLSCHAFT FUR BIOMOLEKULARE DIAGNOSTIK MBH
OS Unknown
PN JP 2001511000-A/1583
PD 07-AUG-2001
PF 30-JAN-1998 JP 1998532533
PR 31-JAN-1997 EP 97101531.8
PI KARL HERMANN SCHLINGENSIEPEN,WOLFGANG BRYSCH
PC C12N15/11,C07H21/04,A61K31/70
CC An antisense oligonucleotide preparation method FH Key
FT source
FT Location/Qualifiers
1. .16
/organism="unassigned DNA"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 630 TTCTTACCCGGAGC 645
DB 1 TTCTTCATCCGGAGC 16

RESULT 298
BD086293/c
LOCUS
DEFINITION G protein-coupled receptor and utilization thereof.
ACCESSION
VERSION BD086293.1 GI:22631903
KEYWORDS JP 2001525174-A/9.
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 16)
AUTHORS Goodear,A.D.J., Glucksmann,A.M., Xie,M. and Distefano,P.
TITLE G protein-coupled receptor and utilization thereof
JOURNAL Patent: JP 2001525174-A 9 11-DEC-2001;
COMMENT MILLENNIUM PHARMACEUTICALS INC
OS Unidentified
PN JP 2001525174-A/9
PD 11-DEC-2001
PF 04-DEC-1998 JP 2000523346
PR 04-DEC-1997 US 08/985090,17-MAR-1998 US 09/042780 PI
DISTEFANO
PC C12N15/09,C07K14/705,C07K16/28,C12N5/10,C12P21/02,C12Q1/68//
CC Strandedness: Single;
CC Topology: Linear;
CC G protein-coupled receptor and utilization thereof FH Key
FT source
FT Location/Qualifiers
1. .16
/organism="Unidentified".

FEATURES
source
1. .16
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match
Best Local Similarity 0.8%; Score 12.8; DB 1; Length 16;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 72 GTGGGGCTGCTGCTGA 87
DB 16 GTGGGGCAGCTGCTCA 1

Search completed: September 13, 2005, 10:39:58
Job time : 7 secs
```

**This Page Blank (uspto)**



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:42:36 ; Search time 8 Seconds  
(without alignments)  
3.180 Million cell updates/sec

Title: us-10-828-394-1  
Perfect score: 1643  
Sequence: 1 gaattccgcgtgaccgag.....taaaactgctgtgagctcg 1643

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 0.5

Searched: 411 seqs, 7741 residues

Total number of hits satisfying chosen parameters: 822

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 411 summaries

Database : rngdb:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	27.2	1.7	32	1	AAQ11501
2	26	1.6	26	1	ABK66659
3	25	1.5	25	1	ABK66660
4	25	1.5	25	1	ADP14589
5	25	1.5	25	1	ADP14593
6	25	1.5	25	1	ADP14578
7	25	1.5	25	1	ADP14583
8	25	1.5	25	1	ADP14580
9	25	1.5	25	1	ADP14585
10	25	1.5	25	1	ADP14587
11	25	1.5	25	1	ADP14582
12	25	1.5	25	1	ADP14584
13	25	1.5	25	1	ADP14586
14	25	1.5	25	1	ADP14588
15	25	1.5	25	1	ADP14592
16	25	1.5	25	1	ADP14579
17	25	1.5	25	1	ADP14581
18	25	1.5	25	1	ADP14591
19	25	1.5	25	1	ABN99658
20	23	1.4	23	1	ABN99641
21	23	1.4	23	1	ACF36411
22	23	1.4	23	1	ACF36410
23	23	1.4	23	1	ADM83082
24	23	1.4	23	1	ADM83081
25	23	1.4	23	1	ADL70521
26	23	1.4	23	1	ADL70512
27	23	1.4	23	1	ADL70515
28	23	1.4	23	1	ADL70518
29	21	1.3	21	1	AAT39500
30	21	1.3	21	1	AAA52783
31	21	1.3	21	1	AAA94227
32	21	1.3	21	1	AAA94231
33	21	1.3	21	1	AAA94230

C 34	21	1.3	21	1	AAA94232	Human testostosterone
C 35	21	1.3	21	1	AAA94233	Human testostosterone
C 36	21	1.3	21	1	AAA94229	Human testostosterone
C 37	21	1.3	21	1	AAA94226	Human testostosterone
C 38	21	1.3	21	1	AAA94234	Human testostosterone
C 39	21	1.3	21	1	AAA94228	Human testostosterone
C 40	21	1.3	21	1	AAA94225	Human testostosterone
C 41	21	1.3	21	1	AAF97658	Human gene single
C 42	21	1.3	21	1	AAF97656	Human gene single
C 43	21	1.3	21	1	AAF97657	Human gene single
C 44	21	1.3	21	1	AAF97659	Human gene single
C 45	21	1.3	21	1	ABN99659	Human clusterin PC
C 46	21	1.3	21	1	ACF36397	TRPM-2 antisense o
C 47	21	1.3	21	1	ACF36405	TRPM-2 antisense o
C 48	21	1.3	21	1	ACF36406	TRPM-2 antisense o
C 49	21	1.3	21	1	ACF36399	TRPM-2 antisense o
C 50	21	1.3	21	1	ACF36402	TRPM-2 antisense o
C 51	21	1.3	21	1	ACF36401	TRPM-2 antisense o
C 52	21	1.3	21	1	ACF36398	TRPM-2 antisense o
C 53	21	1.3	21	1	ACF36403	TRPM-2 antisense o
C 54	21	1.3	21	1	ACF36404	TRPM-2 antisense o
C 55	21	1.3	21	1	ACF36400	TRPM-2 antisense o
C 56	21	1.3	21	1	ADF75347	Human RT-PCR prime
C 57	21	1.3	21	1	ADF75348	Human TRPM-2 antis
C 58	21	1.3	21	1	ADM83075	Human TRPM-2 antis
C 59	21	1.3	21	1	ADM83077	Human TRPM-2 antis
C 60	21	1.3	21	1	ADM83072	Human TRPM-2 antis
C 61	21	1.3	21	1	ADM83074	Human TRPM-2 antis
C 62	21	1.3	21	1	ADM83076	Human TRPM-2 antis
C 63	21	1.3	21	1	ADM83068	Human TRPM-2 antis
C 64	21	1.3	21	1	ADM83069	Human TRPM-2 antis
C 65	21	1.3	21	1	ADM83070	Human TRPM-2 antis
C 66	21	1.3	21	1	ADM83073	Human TRPM-2 antis
C 67	21	1.3	21	1	ADM83071	Human TRPM-2 antis
C 68	21	1.3	21	1	ADL70456	RNAi for human clu
C 69	21	1.3	21	1	ADL70460	RNAi for human clu
C 70	21	1.3	21	1	ADL70513	RNAi for human clu
C 71	21	1.3	21	1	ADL70458	RNAi for human clu
C 72	21	1.3	21	1	ADL70520	RNAi for human clu
C 73	21	1.3	21	1	ADL70461	RNAi for human clu
C 74	21	1.3	21	1	ADL70519	RNAi for human clu
C 75	21	1.3	21	1	ADL70517	RNAi for human clu
C 76	21	1.3	21	1	ADL70516	RNAi for human clu
C 77	21	1.3	21	1	ADL70457	RNAi for human clu
C 78	21	1.3	21	1	ADL70459	RNAi for human clu
C 79	21	1.3	21	1	ADL70514	RNAi for human clu
C 80	21	1.3	21	1	ADL70410	Antisense oligonuc
C 81	21	1.3	21	1	ADL70440	RNAi for human clu
C 82	21	1.3	21	1	ADL70422	RNAi for human clu
C 83	21	1.3	21	1	ADL70413	Antisense oligonuc
C 84	21	1.3	21	1	ADL70408	Antisense oligonuc
C 85	21	1.3	21	1	ADL70412	Antisense oligonuc
C 86	21	1.3	21	1	ADL70425	RNAi for human clu
C 87	21	1.3	21	1	ADL70442	RNAi for human clu
C 88	21	1.3	21	1	ADL70406	Antisense oligonuc
C 89	21	1.3	21	1	ADL70423	RNAi for human clu
C 90	21	1.3	21	1	ADL70441	RNAi for human clu
C 91	21	1.3	21	1	ADL70443	Antisense oligonuc
C 92	21	1.3	21	1	ADL70411	RNAi for human clu
C 93	21	1.3	21	1	ADL70439	RNAi for human clu
C 94	21	1.3	21	1	ADL70438	RNAi for human clu
C 95	21	1.3	21	1	ADL70414	Antisense oligonuc
C 96	21	1.3	21	1	ADL70409	Antisense oligonuc
C 97	21	1.3	21	1	ADL70427	RNAi for human clu
C 98	21	1.3	21	1	ADL70405	Antisense oligonuc
C 99	21	1.3	21	1	ADL70407	Antisense oligonuc
100	21	1.3	21	1	ADL70424	RNAi for human clu
101	20.8	1.3	24	1	AAA66325	Dog genomic marker
C 102	20	1.2	20	1	ABN99680	Human clusterin in
C 103	20	1.2	20	1	ABN99682	Human clusterin in
C 104	20	1.2	20	1	ABN99684	Human clusterin in
C 105	20	1.2	20	1	ABN99686	Human clusterin in
C 106	20	1.2	20	1	ABN99709	Human clusterin in

C 107	20	1.2	20	1	ABN99711	Human clusterin in	C 180	18	1.1	18	1	AAT39501	Chromosome 8p clus
C 108	20	1.2	20	1	ABN99718	Human clusterin in	C 181	18	1.1	18	1	ABN99657	Human clusterin PC
C 109	20	1.2	20	1	ABN99677	Human clusterin in	C 182	17.8	1.1	21	1	ACF36409	DNA sequence of a
C 110	20	1.2	20	1	ABN99681	Human clusterin in	C 183	17.8	1.1	21	1	ACM83080	Control TRPM-2 mis
C 111	20	1.2	20	1	ABN99668	Human clusterin in	C 184	17	1.0	17	1	AAT41526	Human apolipoprote
C 112	20	1.2	20	1	ABN99675	Human clusterin in	C 185	17	1.0	17	1	AAT41542	Human apolipoprote
C 113	20	1.2	20	1	ABN99695	Human clusterin in	C 186	17	1.0	17	1	ABT34616	Tumour suppression
C 114	20	1.2	20	1	ABN99697	Human clusterin in	C 187	17	1.0	17	1	ADB45708	Tumour suppression
C 115	20	1.2	20	1	ABN99701	Human clusterin in	C 188	16.8	1.0	20	1	AAQ58405	Antisense oligonuc
C 116	20	1.2	20	1	ABN99702	Human clusterin in	C 189	16.8	1.0	20	1	ADN02449	Western equine enc
C 117	20	1.2	20	1	ABN99704	Human clusterin in	C 190	16	1.0	16	1	AAQ68062	Antisense probe 15
C 118	20	1.2	20	1	ABN99716	Human clusterin in	C 191	16	1.0	17	1	AAI14650	Triple helix formi
C 119	20	1.2	20	1	ABN99726	Human clusterin in	C 192	16	1.0	19	1	ADS00161	Duchenne muscular
C 120	20	1.2	20	1	ABN99727	Human clusterin in	C 193	16	1.0	19	1	ADSF52411	DMD gene specific
C 121	20	1.2	20	1	ABN99670	Human clusterin in	C 194	16	1.0	20	1	ADI19217	Human PCTAIRE prot
C 122	20	1.2	20	1	ABN99683	Human clusterin in	C 195	16	1.0	20	1	ADI19270	Human PCTAIRE prot
C 123	20	1.2	20	1	ABN99722	Human clusterin in	C 196	15.8	1.0	19	1	ABN88070	Caenorhabditis ele
C 124	20	1.2	20	1	ABN99667	Human clusterin in	C 197	15.8	1.0	19	1	ABN88070	HCV coding region-
C 125	20	1.2	20	1	ABN99672	Human clusterin in	C 198	15.8	1.0	19	1	ADDF52411	HCV coding region-
C 126	20	1.2	20	1	ABN99712	Human clusterin in	C 199	15.8	1.0	19	1	ADDF52411	Hepatitis C virus
C 127	20	1.2	20	1	ABN99675	Human clusterin in	C 200	15.8	1.0	19	1	ADDF52411	Hepatitis C virus
C 128	20	1.2	20	1	ABN99671	Human clusterin in	C 201	15.8	1.0	19	1	ADDF52411	RNAi for human clu
C 129	20	1.2	20	1	ABN99678	Human clusterin in	C 202	15.8	1.0	19	1	ADDF52411	RNAi for human clu
C 130	20	1.2	20	1	ABN99694	Human clusterin in	C 203	15.8	1.0	19	1	ADDF52411	RNAi for human clu
C 131	20	1.2	20	1	ABN99700	Human clusterin in	C 204	15.8	1.0	19	1	ADDF52411	Human apolipoprote
C 132	20	1.2	20	1	ABN99721	Human clusterin in	C 205	15.8	1.0	19	1	ADDF52411	Human apolipoprote
C 133	20	1.2	20	1	ABN99669	Human clusterin in	C 206	15.4	0.9	17	1	AAAT41543	Human apolipoprote
C 134	20	1.2	20	1	ABN99668	Human clusterin in	C 207	15.4	0.9	17	1	AAAT41543	Human apolipoprote
C 135	20	1.2	20	1	ABN99689	Human clusterin in	C 208	15.4	0.9	17	1	AAAT41543	Rabbit stromelysin
C 136	20	1.2	20	1	ABN99703	Human clusterin in	C 209	15.4	0.9	17	1	AAAT41543	Human NODG Hammet
C 137	20	1.2	20	1	ABN99720	Human clusterin in	C 210	15.4	0.9	17	1	ABN08674	Human MD23 scannin
C 138	20	1.2	20	1	ABN99713	Human clusterin in	C 211	15.4	0.9	17	1	ABN08674	HCV minus strand D
C 139	20	1.2	20	1	ABN99724	Human clusterin in	C 212	15.4	0.9	17	1	ABN08674	HCV DNazyme substr
C 140	20	1.2	20	1	ABN99690	Human clusterin in	C 213	15.4	0.9	17	1	ADCD59852	Tumour suppression
C 141	20	1.2	20	1	ABN99708	Human clusterin in	C 214	15.4	0.9	17	1	ADCD59852	HCV DNazyme substr
C 142	20	1.2	20	1	ABN99717	Human clusterin in	C 215	15.4	0.9	17	1	ADCD59852	Human GDMPLP-1 prob
C 143	20	1.2	20	1	ABN99672	Human clusterin in	C 216	15.4	0.9	17	1	ADCD59852	PCR primer for DNA
C 144	20	1.2	20	1	ABN99693	Human clusterin in	C 217	15.4	0.9	18	1	ADCD59852	Allele specific pr
C 145	20	1.2	20	1	ABN99698	Human clusterin in	C 218	15.4	0.9	18	1	ADCD59852	Peptide nucleic ac
C 146	20	1.2	20	1	ABN99715	Human clusterin in	C 219	15	0.9	18	1	ADCD59852	HCV minus strand D
C 147	20	1.2	20	1	ABN99719	Human clusterin in	C 220	15	0.9	17	1	ADCD59852	HCV DNazyme substr
C 148	20	1.2	20	1	ABN99728	Human clusterin in	C 221	15	0.9	17	1	ADCD59852	Human GDMPLP-1 prob
C 149	20	1.2	20	1	ABN99733	Human clusterin in	C 222	15	0.9	17	1	ADCD59852	Mouse IL-2 recepto
C 150	20	1.2	20	1	ABN99673	Human clusterin in	C 223	14.8	0.9	18	1	ADCD59852	SNP specific upper
C 151	20	1.2	20	1	ABN99679	Human clusterin in	C 224	14.8	0.9	18	1	ADCD59852	Mouse pTPRB revers
C 152	20	1.2	20	1	ABN99696	Human clusterin in	C 225	14.8	0.9	18	1	ADCD59852	Hepatitis C virus
C 153	20	1.2	20	1	ABN99705	Human clusterin in	C 226	14.6	0.9	18	1	ADCD59852	Rabbit stromelysin
C 154	20	1.2	20	1	ABN99706	Human clusterin in	C 227	14.4	0.9	17	1	ADCD59852	Human B-raf substr
C 155	20	1.2	20	1	ABN99723	Human clusterin in	C 228	14.4	0.9	17	1	ADCD59852	Human NODG Hammet
C 156	20	1.2	20	1	ABN99731	Human clusterin in	C 229	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 157	20	1.2	20	1	ABN99714	Human clusterin in	C 230	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 158	20	1.2	20	1	ABN99674	Human clusterin in	C 231	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 159	20	1.2	20	1	ABN99699	Human clusterin in	C 232	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 160	20	1.2	20	1	ABN99710	Human clusterin in	C 233	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 161	20	1.2	20	1	ABN99688	Human clusterin in	C 234	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 162	20	1.2	20	1	ABN99676	Human clusterin in	C 235	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 163	20	1.2	20	1	ABN99692	Human clusterin in	C 236	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 164	20	1.2	20	1	ABN99707	Human clusterin in	C 237	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 165	20	1.2	20	1	AD007105	Human clusterin in	C 238	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 166	20	1.2	20	1	AD007106	Human clusterin in	C 239	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 167	20	1.2	20	1	AD007106	Human clusterin in	C 240	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 168	20	1.2	20	1	AD007106	Human clusterin in	C 241	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 169	20	1.2	20	1	AD007106	Human clusterin in	C 242	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 170	20	1.2	20	1	AD007106	Human clusterin in	C 243	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 171	20	1.2	20	1	AD007106	Human clusterin in	C 244	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 172	20	1.2	20	1	AD007106	Human clusterin in	C 245	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 173	20	1.2	20	1	AD007106	Human clusterin in	C 246	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 174	20	1.2	20	1	AD007106	Human clusterin in	C 247	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 175	20	1.2	20	1	AD007106	Human clusterin in	C 248	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 176	20	1.2	20	1	AD007106	Human clusterin in	C 249	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 177	20	1.2	20	1	AD007106	Human clusterin in	C 250	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 178	20	1.2	20	1	AD007106	Human clusterin in	C 251	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m
C 179	20	1.2	20	1	AD007106	Human clusterin in	C 252	14.4	0.9	17	1	ADCD59852	Human GDMPLP-1 17-m

253	14.4	0.9	17	1	ADL18587	RT-PCR primer HP6.	326	13.8	0.8	17	1	ABK18229	Human ERG hammerhe
254	14.4	0.9	17	1	ADM59611	Hepatitis B virus	327	13.8	0.8	17	1	ABK18135	Human ERG Ambergzym
255	14.4	0.9	17	1	AD184297	HCV DNazyme substr	328	13.8	0.8	17	1	ABK18269	Mouse Ob receptor
256	14.4	0.9	17	1	AD185767	HCV DNazyme substr	329	13.8	0.8	17	1	AD18271	Mouse Ob receptor
257	14.4	0.9	17	1	ACN71763	Human GDMPLP-1 prob	330	13.8	0.8	17	1	ACN05936	WNV Ambergzyme subs
258	14.4	0.9	17	1	ACN73136	Human GDMPLP-1 prob	331	13.8	0.8	17	1	ACN08391	WNV minus strand H
259	14.4	0.9	17	1	ACN73135	Human GDMPLP-1 prob	332	13.8	0.8	17	1	ACN15008	WNV minus strand A
260	14.4	0.9	17	1	ACN731450	Human GDMPLP-1 prob	333	13.8	0.8	17	1	ACN00398	WNV Hammerhead Rib
261	14.4	0.9	17	1	ACN71451	Human GDMPLP-1 prob	334	13.8	0.8	17	1	ACN14016	WNV minus strand D
262	14.4	0.9	17	1	ACN71765	Human GDMPLP-1 prob	335	13.8	0.8	17	1	ACN15009	WNV minus strand A
263	14.4	0.9	18	1	AAQ80949	PCR primer to gene	336	13.8	0.8	17	1	ACN06460	WNV Ambergzyme subs
264	14.4	0.9	18	1	ADM06417	Human PCR primer 8	337	13.8	0.8	17	1	ACN01953	WNV Inozyme substr
265	14.4	0.9	18	1	ADM92954	SNP-containing car	338	13.8	0.8	17	1	ACN08392	WNV minus strand H
266	14.4	0.9	18	1	ADH71057	Human Vbeta point	339	13.8	0.8	17	1	ACN11835	WNV DNazyme strand I
267	14	0.9	15	1	AAAF47085	IGFBP3 oligonucleo	340	13.8	0.8	17	1	ACN05385	WNV DNazyme substr
268	14	0.9	15	1	AAAF47084	IGFBP3 oligonucleo	341	13.8	0.8	17	1	ACN08973	WNV minus strand H
269	14	0.9	17	1	ABK25595	Stress tolerance c	342	13.8	0.8	17	1	ABT34420	Tumour suppression
270	14	0.9	17	1	ABK25596	Stress tolerance c	343	13.8	0.8	17	1	ABT37737	Tumour suppression
271	14	0.9	17	1	AD184295	HCV DNazyme substr	344	13.8	0.8	17	1	ACA06296	NFKB sub-unit modu
272	14	0.9	17	1	AD184295	HCV DNazyme substr	345	13.8	0.8	17	1	ACA07700	NFKB sub-unit modu
273	14	0.9	17	1	ADN44286	Mutant cell identi	346	13.8	0.8	17	1	ACA07701	NFKB sub-unit modu
274	14	0.9	17	1	ADN44287	Mutant cell identi	347	13.8	0.8	17	1	ACA08217	NFKB sub-unit modu
275	13.8	0.8	17	1	AAT05231	Hepatitis C virus	348	13.8	0.8	17	1	ACA06298	NFKB sub-unit modu
276	13.8	0.8	17	1	AAAF75009	Mouse flt-1 VEGF r	349	13.8	0.8	17	1	ACA06394	NFKB sub-unit modu
277	13.8	0.8	17	1	AAAF62812	Delta-9 desaturase	350	13.8	0.8	17	1	ACA06396	NFKB sub-unit modu
278	13.8	0.8	17	1	AAT69614	Murine obr gene fo	351	13.8	0.8	17	1	ACA06517	NFKB sub-unit modu
279	13.8	0.8	17	1	AAAF61074	Synthetic DNA frag	352	13.8	0.8	17	1	ADA99701	Human MD23 scannin
280	13.8	0.8	17	1	AAAF7411	Antisense oligonuc	353	13.8	0.8	17	1	ADB00467	Human MD23 scannin
281	13.8	0.8	17	1	AAAF46535	Antisense oligonuc	354	13.8	0.8	17	1	ADB02413	Human MD23 scannin
282	13.8	0.8	17	1	AAAF94804	Human IL-2 recepto	355	13.8	0.8	17	1	ACD58046	HCV DNazyme substr
283	13.8	0.8	17	1	AAAF92651	Human A-Raf substr	356	13.8	0.8	17	1	ACD61087	HCV DNazyme substr
284	13.8	0.8	17	1	AAAF53788	Human adenosine A1	357	13.8	0.8	17	1	ACD62816	HCV minus strand D
285	13.8	0.8	17	1	AAAF52912	Human adenosine A1	358	13.8	0.8	17	1	ACG67637	Murine oligonucleo
286	13.8	0.8	17	1	AAAF33231	Low adenosine anti	359	13.8	0.8	17	1	ADB39727	Tumour suppression
287	13.8	0.8	17	1	AAAF32356	Low adenosine anti	360	13.8	0.8	17	1	AD147981	Human tumour suppr
288	13.8	0.8	17	1	AAAF25766	Hepatitis C virus	361	13.8	0.8	17	1	ABZ94171	Human adenosine A1
289	13.8	0.8	17	1	AAAF03590	Human adenosine A1	362	13.8	0.8	17	1	ABZ95047	Human adenosine A1
290	13.8	0.8	17	1	AAAF03660	Human adenosine A1	363	13.8	0.8	17	1	ADL48005	Human IKK-gamma su
291	13.8	0.8	17	1	AAAF19353	Human adenosine A1	364	13.8	0.8	17	1	ADL50256	Human PKR substrat
292	13.8	0.8	17	1	AAAF18477	Human adenosine A1	365	13.8	0.8	17	1	ADL48380	Human IKK-gamma su
293	13.8	0.8	17	1	AAAF02647	Hammerhead ribozym	366	13.8	0.8	17	1	ADM09485	Human NKG2 recepto
294	13.8	0.8	17	1	ABK01885	Human NKG2 zinzyme	367	13.8	0.8	17	1	ADM54165	Human GRD mRNA su
295	13.8	0.8	17	1	ABK01053	Human NKG2 Inozyme	368	13.8	0.8	17	1	ABD18019	Human adenosine A1
296	13.8	0.8	17	1	ABD20527	Mouse OBR genomic	369	13.8	0.8	17	1	ABD18895	Human adenosine A1
297	13.8	0.8	17	1	AAAF20529	Mouse famj5312 Obr	370	13.8	0.8	17	1	ADG63002	Mouse genomic DNA
298	13.8	0.8	17	1	AAAF79852	DNA sequencing met	371	13.8	0.8	17	1	ADG63000	Mouse genomic DNA
299	13.8	0.8	17	1	ABL46807	Human GRD NCH rib	372	13.8	0.8	17	1	ADK98279	Primer of the inve
300	13.8	0.8	17	1	AAAF41482	Mouse Ob receptor	373	13.8	0.8	17	1	AD184915	HCV DNazyme substr
301	13.8	0.8	17	1	AAAF41484	Mouse Ob receptor	374	13.8	0.8	17	1	AD183386	HCV DNazyme substr
302	13.8	0.8	17	1	AAAF42341	Mouse obesity rece	375	13.8	0.8	17	1	ACN64993	Human GDMPLP-1 prob
303	13.8	0.8	17	1	AAAF42339	Mouse obesity rece	376	13.8	0.8	17	1	ACN71759	Human GDMPLP-1 prob
304	13.8	0.8	17	1	ABN01903	Human GDMPLP-1 17-m	377	13.8	0.8	17	1	ACN72785	Human GDMPLP-1 prob
305	13.8	0.8	17	1	ABN07493	Human GDMPLP-1 17-m	378	13.8	0.8	17	1	ACN72787	Human GDMPLP-1 prob
306	13.8	0.8	17	1	ABN08576	Human GDMPLP-1 17-m	379	13.8	0.8	17	1	ACN71758	Human GDMPLP-1 prob
307	13.8	0.8	17	1	ABN08695	Human GDMPLP-1 17-m	380	13.8	0.8	17	1	ACN71761	Human GDMPLP-1 prob
308	13.8	0.8	17	1	ABN08671	Human GDMPLP-1 17-m	381	13.8	0.8	17	1	ACN65741	Human GDMPLP-1 prob
309	13.8	0.8	17	1	ABN08696	Human GDMPLP-1 17-m	382	13.8	0.8	17	1	ACN70453	Human GDMPLP-1 prob
310	13.8	0.8	17	1	ABN09697	Human GDMPLP-1 17-m	383	13.8	0.8	17	1	ACN70583	Human GDMPLP-1 prob
311	13.8	0.8	17	1	ABN07363	Human GDMPLP-1 17-m	384	13.8	0.8	17	1	ACN71782	Human GDMPLP-1 prob
312	13.8	0.8	17	1	ABN08672	Human GDMPLP-1 17-m	385	13.8	0.8	17	1	ACN71666	Human GDMPLP-1 prob
313	13.8	0.8	17	1	ABN08669	Human GDMPLP-1 17-m	386	13.8	0.8	17	1	ACN72786	Human GDMPLP-1 prob
314	13.8	0.8	17	1	ABN02651	Human GDMPLP-1 17-m	387	13.6	0.8	15	1	ABL52123	Human PER1 allele
315	13.8	0.8	17	1	ABN08668	Human GDMPLP-1 17-m	388	13.6	0.8	15	1	AAAS95535	Human IL18RB gene a
316	13.8	0.8	17	1	ABQ63736	Human KTM1a porti	389	13.4	0.8	15	1	AAAT54903	Mouse rela hammerh
317	13.8	0.8	17	1	ABQ63734	Human KTM1a porti	390	13.4	0.8	15	1	AAV31969	Peptide nucleic ac
318	13.8	0.8	17	1	ABQ63732	Human KTM1a porti	391	13.4	0.8	15	1	AAV31970	Peptide nucleic ac
319	13.8	0.8	17	1	ABQ63733	Human KTM1a porti	392	13.4	0.8	15	1	AAV31967	Peptide nucleic ac
320	13.8	0.8	17	1	ABQ63735	Human KTM1a porti	393	13.4	0.8	15	1	AAV31120	Tag sequence of a
321	13.8	0.8	17	1	ABQ63738	Human KTM1a porti	394	13.4	0.8	15	1	AAV311728	Transcript tag seq
322	13.8	0.8	17	1	ABQ64165	Human KTM1a porti	395	13.4	0.8	15	1	AAE50848	IGF-I oligonucleot
323	13.8	0.8	17	1	ABV79503	Human HTPL scannin	396	13.4	0.8	15	1	ABK32682	Human colorectal a
324	13.8	0.8	17	1	ABV79992	Human HTPL scannin	397	13.4	0.8	15	1	ABK32073	Human colon cancer
325	13.8	0.8	17	1	ABV79502	Human HTPL scannin	398	13.4	0.8	15	1	ABX01805	Hepatitis C virus

399 13.4 0.8 15 1 ABX01804 Hepatitis C virus  
400 13.4 0.8 16 1 AAV70490 Sequence ID# 68 fr  
401 13.4 0.8 16 1 AAV70489 Sequence ID# 67 fr  
c 402 13.4 0.8 16 1 AAX14645 Triple helix third  
403 13.4 0.8 16 1 ABL46101 Hepatitis C virus  
404 13.4 0.8 16 1 ABL46100 Hepatitis C virus  
405 13.4 0.8 16 1 ADK82290 Nucleic acid analy  
406 13.4 0.8 16 1 ADK82291 Nucleic acid analy  
c 407 13.4 0.8 16 1 ADM80152 Linker peptide enc  
408 13.4 0.8 16 1 ADR32381 E. coli nicking ag  
409 13.4 0.8 16 1 ADR32430 E. coli fingerprin  
410 13.4 0.8 16 1 ADR33575 E. coli strain K12  
c 411 13.4 0.8 16 1 ADR69939 Human survivin gen

ALIGNMENTS

RESULT 1  
AAQ11501  
ID AAQ11501 standard; DNA; 32 BP.  
XX AAQ11501;  
DT 20-JUN-1991 (first entry)  
XX  
DE Probe based on amino acids 6-15 of the Cytolysis Inhibitor A-chain.  
XX  
KW cytolysis inhibitor; perforin; immunological effector molecule;  
KW infertility; ss.  
XX  
OS Homo sapiens.  
XX  
PN DE3933850-A.  
XX  
PD 18-APR-1991.  
XX  
PF 06-OCT-1989; 89DE-03933850.  
XX  
PR 06-OCT-1989; 89DE-03933850.  
XX  
PA (SCHD ) SCHERING AG.  
XX  
PI Tschopp J, Jenne D;  
XX  
DR WPI; 1991-118338/17.  
XX  
XX DNA sequence coding for cytolysis inhibitor - is strong inhibitor of  
PT terminal complement protein, e.g. perforin secreted by killer cells.  
XX  
XX Example 1; Page 4; 15pp; German.  
XX  
XX The partial amino acid sequences of both chains of the Cytolysis  
CC Inhibitor were known. This probe is one of two which were prepared based  
CC on the N-terminal sequences of the inhibitor. It corresponds to the  
CC sequence DNEIQEMSNQG. Both probes were radioactively labelled and used to  
CC screen a liver-specific cDNA library. One clone which hybridised  
CC positively to both probes was found to contain a 1.7kb BamHI-KpnI  
CC fragment. This was inserted into plasmid pGEM4, to give DSM 5269, and  
CC sequenced. See also AAQ11502 and AAQ11503  
XX  
XX Sequence 32 BP; 10 A; 7 C; 11 G; 4 T; 0 U; 0 Other;  
SQ

Query Match 1.7%; Score 27.2; DB 1; Length 32;  
Best Local Similarity 90.6%; Pred. No. 23;  
Matches 29; Conservative 0; Mismatches 3; Indels 0; Gaps 0;  
QY 129 GACATGAGCTCCAGGAATGTCCCAATCAGG 160  
Db 1 GACATGAGCTCGAGGAGATGTCCCAACGAGG 32

RESULT 2

ABK66659  
ID ABK66659 standard; DNA; 26 BP.  
XX  
AC ABK66659;  
DT 02-JUL-2002 (first entry)  
XX  
DE Human gene specific PCR primer #747.  
XX  
KW Primer; ss; DNA microarray; differential expression analysis; human.  
XX  
OS Homo sapiens.  
XX  
PN US6352829-B1.  
XX  
XX 05-MAR-2002.  
XX  
PF 05-JAN-1999; 99US-00225928.  
XX  
PR 21-MAY-1997; 97US-00859998.  
XX  
PA (CLON-) CLONTECH LAB INC.  
XX  
PI Chenchik A, Johhadze G, Bibilashvilli R;  
XX  
DR WPI; 2002-314699/35.  
XX  
PT Producing sub-population of labeled nucleic acids, useful for analyzing  
PT differences in RNA profiles between several different physiological  
PT sources, using set of distinct gene specific primers.  
XX  
PS Example 3; SEQ ID NO 747; 11pp; English.  
XX  
XX The invention relates to producing a sub-population of labeled nucleic  
CC acids (NAs) comprising contacting a NA sample from a physiological  
CC source with a pool of 50 distinct gene specific primers under suitable  
CC conditions to enzymatically generate sub-population of NAs, where each  
CC gene specific primer has a sequence complementary to a distinct mRNA, and  
CC each labeled NA is generated using a single gene specific primer. The  
CC method is useful for producing a sub-population of labeled NAs which is  
CC useful for analysing the differences in the RNA profiles between several  
CC different physiological sources, where the method comprises producing  
CC subpopulation of labeled NAs for the different physiological sources,  
CC comprising the populations for each physiological source to identify  
CC differences in the population, where the comparison is preferably  
CC performed by hybridising the labeled NAs for each of the distinct  
CC physiological sources to an array of probe NAs stably associated with the  
CC surface of a substrate to produce a hybridisation pattern for each of the  
CC sources, and comparing the patterns for each of the sources, where  
CC differential analysis of diseased a normal tissue e.g. neoplastic a normal  
CC tissue, or different tissue or sub-tissue types. The present sequence is a  
CC human gene specific PCR primer used in the method of the invention. Note:  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from USPTO  
CC at http.wipo.segdata.uspto.gov/sequence.html?DocID=6352829B1  
XX  
SQ Sequence 26 BP; 8 A; 4 C; 10 G; 4 T; 0 U; 0 Other;

Query Match 1.6%; Score 26; DB 1; Length 26;  
Best Local Similarity 100.0%; Pred. No. 16;  
Matches 26; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 934 TCGGATGAAGGACCAGTGTCACAAG 959  
Db 1 TCGGATGAAGGACCAGTGTCACAAG 26

RESULT 3  
ABK66660/C  
ID ABK66660 standard; DNA; 25 BP.  
XX  
AC ABK66660;

XX 02-JUL-2002 (first entry)  
 XX Human gene specific PCR primer #748.  
 DE  
 XX Primer; ss; DNA microarray; differential expression analysis; human.  
 XX Homo sapiens.  
 XX OS  
 XX PN US6352829-B1.  
 XX PD 05-MAR-2002.  
 XX PF 05-JAN-1999; 99US-00225928.  
 XX PR 21-MAY-1997; 97US-00859998.  
 XX (CLON-) CLONTECH LAB INC.  
 XX PA Chenchik A, Johhadze G, Bibilashvili R;  
 XX PI WPI; 2002-314699/35.  
 XX DR  
 XX Producing sub-population of labeled nucleic acids, useful for analyzing  
 PT differences in RNA profiles between several different physiological  
 PT sources, using set of distinct gene specific primers.  
 XX  
 XX Example 3; SEQ ID NO 748; 11pp; English.  
 XX  
 XX The invention relates to producing a sub-population of labeled nucleic  
 CC acids (NAs) comprising contacting a NA sample from a physiological  
 CC source, with a pool of 50 distinct gene specific primers under suitable  
 CC conditions to enzymatically generate sub-population of NAs, where each  
 CC gene specific primer has a sequence complementary to a distinct mRNA, and  
 CC each labeled NA is generated using a single gene specific primer. The  
 CC method is useful for producing a sub-population of labeled NAs which is  
 CC useful for analysing the differences in the RNA profiles between several  
 CC different physiological sources, where the method comprises producing  
 CC subpopulation of labeled NAs for the different physiological sources,  
 CC comprising the populations for each physiological source to identify  
 CC differences in the population, where the comparison is preferably  
 CC performed by hybridising the labeled NAs for each of the distinct  
 CC physiological sources to an array of probe NAs stably associated with the  
 CC surface of a substrate to produce a hybridisation pattern for each of the  
 CC sources, and comparing the patterns for each of the sources, where  
 CC differential gene expression assays are utilised in differential  
 CC expression analysis of diseased a normal tissue e.g. neoplastic a normal  
 CC tissue, or different tissue or subtype types. The present sequence is a  
 CC human gene specific PCR primer used in the method of the invention. Note:  
 CC The sequence data for this patent did not form part of the printed  
 CC specification, but was obtained in electronic format directly from USPTO  
 CC at <http://wipo.segdata.uspto.gov/sequence.html?docID=6352829B1>  
 XX  
 XX Sequence 25 BP; 6 A; 8 C; 7 G; 4 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 19;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1190 GTACTATCTGGGGTCCACCGGTG 1214  
 DB 25 GTACTATCTGGGGTCCACCGGTG 1  
 RESULT 4  
 ADP14589  
 ID ADP14589 standard; DNA; 25 BP.  
 XX  
 XX AC ADP14589;  
 XX 26-AUG-2004 (first entry)  
 DT  
 XX Renal cell carcinoma differentially expressed gene probe #994.  
 DE

XX ss; diagnosis; non-blood disease; solid tumor; gene expression;  
 KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
 KW head/neck cancer; differential expression; probe.  
 XX Homo sapiens.  
 XX OS  
 XX PN WO2004048933-A2.  
 XX PD 10-JUN-2004.  
 XX PF 21-NOV-2003; 2003WO-US037481.  
 XX PR 21-NOV-2002; 2002US-0427982P.  
 XX PR 03-APR-2003; 2003US-0459782P.  
 XX (AMHP ) WYETH.  
 XX PA (TWIN/) TWINE N C.  
 XX PA (BURC/) BURCZYNSKI M E.  
 XX PA (TREP/) TREPICCHIO W L.  
 XX PA (DORN/) DORNER A.  
 XX PA (STOV/) STOVER J A.  
 XX PA (SLON/) SLONI D K.  
 XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
 PI Sloni DK;  
 XX WPI; 2004-460799/43.  
 XX  
 XX Diagnosing non-blood disease such as solid tumor, involves comparing  
 PT differential expression profile of specific genes in peripheral blood  
 PT sample of subject with reference expression profile of specific genes.  
 XX  
 XX Disclosure; SEQ ID NO 1325; 350pp; English.  
 XX  
 XX The invention relate to a method of diagnosing (M1) non-blood disease  
 CC such as solid tumor by providing peripheral blood sample of human having  
 CC non-blood disease, and comparing an expression profile of specific genes  
 CC in the peripheral blood sample to reference expression profile of the  
 CC genes, where each of the genes is differentially expressed in peripheral  
 CC blood mononuclear cells (PBMCs) of patients having the disease as  
 CC compared to PBMCs of normal humans. The method is useful for diagnosing  
 CC non-blood disease such as solid tumor. The solid tumor is chosen from  
 CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
 CC peripheral blood sample comprises enriched PBMCs. The peripheral blood  
 CC sample is a whole blood sample (claimed). (M1) is useful for identifying  
 CC genes that are differentially expressed in peripheral blood samples  
 CC isolated at different stages of progression, development or treatment of  
 CC RCC and/or other solid tumors. This sequence corresponds to a probe to  
 CC detect a gene that is differentially expressed and detected by the method  
 CC of the invention.  
 XX  
 XX Sequence 25 BP; 6 A; 9 C; 4 G; 6 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 19;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1550 GGATCTGCACTCTAACACTCGACT 1574  
 DB 1 GGATCTGCACTCTAACACTCGACT 25  
 RESULT 5  
 ADP14593  
 ID ADP14593 standard; DNA; 25 BP.  
 XX  
 XX AC ADP14593;  
 XX 26-AUG-2004 (first entry)  
 DT  
 XX Renal cell carcinoma differentially expressed gene probe #998.  
 DE  
 XX

ss; diagnosis; non-blood disease; solid tumor; gene expression;  
peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
head/neck cancer; differential expression; probe.  
Homo sapiens.  
WO2004048933-A2.  
10-JUN-2004.  
21-NOV-2003; 2003WO-US037481.  
21-NOV-2002; 2002US-0427982P.  
03-APR-2003; 2003US-0459782P.  
(AMHP ) WYETH.  
(TWIN/) TWINE N C.  
(BURC/) BURCZYNSKI M E.  
(TREP/) TREPICCHIO W L.  
(DORN/) DORNER A.  
(STOV/) STOVER J A.  
(SLON/) SLONI D K.  
Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
Sloni DK;  
WPI; 2004-460799/43.  
Diagnosing non-blood disease such as solid tumor, involves comparing  
differential expression profile of specific genes in peripheral blood  
sample of subject with reference expression profile of specific genes.  
Disclosure; SEQ ID NO 1329; 350pp; English.  
The invention relate to a method of diagnosing (M1) non-blood disease  
such as solid tumor by providing peripheral blood sample of human having  
non-blood disease, and comparing an expression profile of specific genes  
in the peripheral blood sample to reference expression profile of the  
genes, where each of the genes is differentially expressed in peripheral  
blood mononuclear cells (PBMCs) of patients having the disease as  
compared to PBMCs of normal humans. The method is useful for diagnosing  
non-blood disease such as solid tumor. The solid tumor is chosen from  
renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
peripheral blood sample comprises enriched PBMCs. The peripheral blood  
sample is a whole blood sample (claimed). (M1) is useful for identifying  
genes that are differentially expressed in peripheral blood samples  
isolated at different stages of progression, development or treatment of  
RCC and/or other solid tumors. This sequence corresponds to a probe to  
detect a gene that is differentially expressed and detected by the method  
of the invention.  
Sequence 25 BP; 5 A; 8 C; 6 G; 6 T; 0 U; 0 Other;  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1564 AACACTCGACTCTGCTGCTCATGGG 1588  
DB 1 AACACTCGACTCTGCTGCTCATGGG 25  
RESULT 6  
ADP14578  
ID ADP14578 standard; DNA; 25 BP.  
XX AC  
XX ADP14578;  
XX 26-AUG-2004 (first entry)  
DT Renal cell carcinoma differentially expressed gene probe #983.  
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
KW ss; diagnosis; non-blood disease; solid tumor; gene expression;

peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
head/neck cancer; differential expression; probe.  
Homo sapiens.  
WO2004048933-A2.  
10-JUN-2004.  
21-NOV-2003; 2003WO-US037481.  
21-NOV-2002; 2002US-0427982P.  
03-APR-2003; 2003US-0459782P.  
(AMHP ) WYETH.  
(TWIN/) TWINE N C.  
(BURC/) BURCZYNSKI M E.  
(TREP/) TREPICCHIO W L.  
(DORN/) DORNER A.  
(STOV/) STOVER J A.  
(SLON/) SLONI D K.  
Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
Sloni DK;  
WPI; 2004-460799/43.  
Diagnosing non-blood disease such as solid tumor, involves comparing  
differential expression profile of specific genes in peripheral blood  
sample of subject with reference expression profile of specific genes.  
Disclosure; SEQ ID NO 1314; 350pp; English.  
The invention relate to a method of diagnosing (M1) non-blood disease  
such as solid tumor by providing peripheral blood sample of human having  
non-blood disease, and comparing an expression profile of specific genes  
in the peripheral blood sample to reference expression profile of the  
genes, where each of the genes is differentially expressed in peripheral  
blood mononuclear cells (PBMCs) of patients having the disease as  
compared to PBMCs of normal humans. The method is useful for diagnosing  
non-blood disease such as solid tumor. The solid tumor is chosen from  
renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
peripheral blood sample comprises enriched PBMCs. The peripheral blood  
sample is a whole blood sample (claimed). (M1) is useful for identifying  
genes that are differentially expressed in peripheral blood samples  
isolated at different stages of progression, development or treatment of  
RCC and/or other solid tumors. This sequence corresponds to a probe to  
detect a gene that is differentially expressed and detected by the method  
of the invention.  
Sequence 25 BP; 8 A; 8 C; 5 G; 4 T; 0 U; 0 Other;  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1088 CTACCACTGGAGATGCTCAACACC 1112  
DB 1 CTACCACTGGAGATGCTCAACACC 25  
RESULT 7  
ADP14583  
ID ADP14583 standard; DNA; 25 BP.  
XX AC  
XX ADP14583;  
XX 26-AUG-2004 (first entry)  
DT Renal cell carcinoma differentially expressed gene probe #988.  
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
KW ss; diagnosis; non-blood disease; solid tumor; gene expression;

KW head/neck cancer; differential expression; probe.  
XX  
OS Homo sapiens.  
XX  
PN WO2004048933-A2.  
XX  
XX 10-JUN-2004.  
XX  
XX 21-NOV-2003; 2003WO-US037481.  
XX  
XX 21-NOV-2002; 2002US-0427982P.  
XX  
XX 03-APR-2003; 2003US-0459782P.  
XX  
XX (AMHP ) WYETH.  
XX (TWIN/) TWINE N C.  
XX (BURC/) BURCZYNSKI M E.  
XX (TREP/) TREPICCHIO W L.  
XX (DORN/) DORNER A.  
XX (STOV/) STOVER J A.  
XX (SLOW/) SLONI D K.  
XX  
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
XX Sloni DK;  
XX  
XX WPI; 2004-460799/43.  
XX  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
XX differential expression profile of specific genes in peripheral blood  
XX sample of subject with reference expression profile of specific genes.  
XX  
XX Disclosure; SEQ ID NO 1319; 350pp; English.  
XX  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
XX such as solid tumor by providing peripheral blood sample of human having  
XX non-blood disease, and comparing an expression profile of specific genes  
XX in the peripheral blood sample to reference expression profile of the  
XX genes, where each of the genes is differentially expressed in peripheral  
XX blood mononuclear cells (PBMCs) of patients having the disease as  
XX compared to PBMCs of normal humans. The method is useful for diagnosing  
XX non-blood disease such as solid tumor. The solid tumor is chosen from  
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood  
XX sample is a whole blood sample (claimed). (M1) is useful for identifying  
XX genes that are differentially expressed in peripheral blood samples  
XX isolated at different stages of progression, development or treatment of  
XX RCC and/or other solid tumors. This sequence corresponds to a probe to  
XX detect a gene that is differentially expressed and detected by the method  
XX of the invention.  
XX  
XX Sequence 25 BP; 5 A; 8 C; 4 G; 8 T; 0 U; 0 Other;  
SQ  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1268 GAGCTCTTTGACTCTGTATCCATC 1292  
DB 1 GAGCTCTTTGACTCTGTATCCATC 25  
RESULT 8  
ADP14580  
ID ADP14580 standard; DNA; 25 BP.  
XX  
XX ADP14580;  
XX  
XX 26-AUG-2004 (first entry)  
XX  
XX Renal cell carcinoma differentially expressed gene probe #985.  
XX  
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
XX head/neck cancer; differential expression; probe.  
KW

XX  
OS Homo sapiens.  
XX  
PN WO2004048933-A2.  
XX  
XX 10-JUN-2004.  
XX  
XX 21-NOV-2003; 2003WO-US037481.  
XX  
XX 21-NOV-2002; 2002US-0427982P.  
XX  
XX 03-APR-2003; 2003US-0459782P.  
XX  
XX (AMHP ) WYETH.  
XX (TWIN/) TWINE N C.  
XX (BURC/) BURCZYNSKI M E.  
XX (TREP/) TREPICCHIO W L.  
XX (DORN/) DORNER A.  
XX (STOV/) STOVER J A.  
XX (SLOW/) SLONI D K.  
XX  
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
XX Sloni DK;  
XX  
XX WPI; 2004-460799/43.  
XX  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
XX differential expression profile of specific genes in peripheral blood  
XX sample of subject with reference expression profile of specific genes.  
XX  
XX Disclosure; SEQ ID NO 1319; 350pp; English.  
XX  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
XX such as solid tumor by providing peripheral blood sample of human having  
XX non-blood disease, and comparing an expression profile of specific genes  
XX in the peripheral blood sample to reference expression profile of the  
XX genes, where each of the genes is differentially expressed in peripheral  
XX blood mononuclear cells (PBMCs) of patients having the disease as  
XX compared to PBMCs of normal humans. The method is useful for diagnosing  
XX non-blood disease such as solid tumor. The solid tumor is chosen from  
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood  
XX sample is a whole blood sample (claimed). (M1) is useful for identifying  
XX genes that are differentially expressed in peripheral blood samples  
XX isolated at different stages of progression, development or treatment of  
XX RCC and/or other solid tumors. This sequence corresponds to a probe to  
XX detect a gene that is differentially expressed and detected by the method  
XX of the invention.  
XX  
XX Sequence 25 BP; 5 A; 8 C; 4 G; 8 T; 0 U; 0 Other;  
SQ  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1268 GAGCTCTTTGACTCTGTATCCATC 1292  
DB 1 GAGCTCTTTGACTCTGTATCCATC 25  
RESULT 9  
ADP14590  
ID ADP14590 standard; DNA; 25 BP.  
XX  
XX ADP14590;  
XX  
XX 26-AUG-2004 (first entry)  
XX  
XX Renal cell carcinoma differentially expressed gene probe #995.  
XX  
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
XX head/neck cancer; differential expression; probe.  
KW

```
OS Homo sapiens.
XX WO2004048933-A2.
XX PN
XX PD
XX PF
XX 10-JUN-2004.
XX 21-NOV-2003; 2003WO-US037481.
XX 21-NOV-2002; 2002US-0427982P.
XX 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
XX (TWIN/) TWINE N C.
XX (BURC/) BURCZYNSKI M E.
XX (TREP/) TREPICCHIO W L.
XX (DORN/) DORNER A.
XX (STOV/) STOVER J A.
XX (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
XX PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
XX differential expression profile of specific genes in peripheral blood
XX sample of subject with reference expression profile of specific genes.
XX Disclosure; SEQ ID NO 1326; 350pp; English.
XX The invention relate to a method of diagnosing (M1) non-blood disease
XX such as solid tumor by providing peripheral blood sample of human having
XX non-blood disease, and comparing an expression profile of specific genes
XX in the peripheral blood sample to reference expression profile of the
XX genes, where each of the genes is differentially expressed in peripheral
XX blood mononuclear cells (PBMCs) of patients having the disease as
XX compared to PBMCs of normal humans. The method is useful for diagnosing
XX non-blood disease such as solid tumor. The solid tumor is chosen from
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood
XX sample is a whole blood sample (claimed). (M1) is useful for identifying
XX genes that are differentially expressed in peripheral blood samples
XX isolated at different stages of progression, development or treatment of
XX RCC and/or other solid tumors. This sequence corresponds to a probe to
XX detect a gene that is differentially expressed and detected by the method
XX of the invention.
XX Sequence 25 BP; 5 A; 9 C; 4 G; 7 T; 0 U; 0 Other;
XX Query Match 1.5%; Score 25; DB 1; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 19;
XX Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1556 TGCACCTTAACACTCGACTCTGCTG 1580
DB 1 TGCACCTTAACACTCGACTCTGCTG 25
RESULT 10
ADP14585
ID ADP14585 standard; DNA; 25 BP.
XX AC ADP14585;
XX 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #990.
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
XX head/neck cancer; differential expression; probe.
XX Homo sapiens.
XX
```

```
XX WO2004048933-A2.
XX PN
XX PD
XX PF
XX 10-JUN-2004.
XX 21-NOV-2003; 2003WO-US037481.
XX 21-NOV-2002; 2002US-0427982P.
XX 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
XX (TWIN/) TWINE N C.
XX (BURC/) BURCZYNSKI M E.
XX (TREP/) TREPICCHIO W L.
XX (DORN/) DORNER A.
XX (STOV/) STOVER J A.
XX (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
XX PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
XX differential expression profile of specific genes in peripheral blood
XX sample of subject with reference expression profile of specific genes.
XX Disclosure; SEQ ID NO 1321; 350pp; English.
XX The invention relate to a method of diagnosing (M1) non-blood disease
XX such as solid tumor by providing peripheral blood sample of human having
XX non-blood disease, and comparing an expression profile of specific genes
XX in the peripheral blood sample to reference expression profile of the
XX genes, where each of the genes is differentially expressed in peripheral
XX blood mononuclear cells (PBMCs) of patients having the disease as
XX compared to PBMCs of normal humans. The method is useful for diagnosing
XX non-blood disease such as solid tumor. The solid tumor is chosen from
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood
XX sample is a whole blood sample (claimed). (M1) is useful for identifying
XX genes that are differentially expressed in peripheral blood samples
XX isolated at different stages of progression, development or treatment of
XX RCC and/or other solid tumors. This sequence corresponds to a probe to
XX detect a gene that is differentially expressed and detected by the method
XX of the invention.
XX Sequence 25 BP; 4 A; 4 C; 7 G; 10 T; 0 U; 0 Other;
XX Query Match 1.5%; Score 25; DB 1; Length 25;
XX Best Local Similarity 100.0%; Pred. No. 19;
XX Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1397 AGATGTGGATGTGCTTTGCACCT 1421
DB 1 AGATGTGGATGTGCTTTGCACCT 25
RESULT 11
ADP14587
ID ADP14587 standard; DNA; 25 BP.
XX AC ADP14587;
XX 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #992.
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
XX head/neck cancer; differential expression; probe.
XX Homo sapiens.
XX
```



PN WO2004048933-A2.  
XX 10-JUN-2004.  
XX 21-NOV-2003; 2003WO-US037481.  
XX 21-NOV-2002; 2002US-0427982P.  
XX 03-APR-2003; 2003US-0459782P.  
XX (AMHP ) WYETH.  
XX (TWIN/) TWINE N C.  
XX (BURC/) BURCZYNSKI M E.  
XX (TREP/) TREPICCHIO W L.  
XX (DORN/) DORNER A.  
XX (STOV/) STOVER J A.  
XX (SLON/) SLONI D K.  
XX Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;  
XX Sloni DK;  
XX WPI; 2004-460799/43.  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
XX differential expression profile of specific genes in peripheral blood  
XX sample of subject with reference expression profile of specific genes.  
XX Disclosure; SEQ ID NO 1323; 350pp; English.  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
XX such as solid tumor by providing peripheral blood sample of human having  
XX non-blood disease, and comparing an expression profile of specific genes  
XX in the peripheral blood sample to reference expression profile of the  
XX genes, where each of the genes is differentially expressed in peripheral  
XX blood mononuclear cells (PBMCs) of patients having the disease as  
XX compared to PBMCs of normal humans. The method is useful for diagnosing  
XX non-blood disease such as solid tumor. The solid tumor is chosen from  
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood  
XX sample is a whole blood sample (claimed). (M1) is useful for identifying  
XX genes that are differentially expressed in peripheral blood samples  
XX isolated at different stages of progression, development or treatment of  
XX RCC and/or other solid tumors. This sequence corresponds to a probe to  
XX detect a gene that is differentially expressed and detected by the method  
XX of the invention.  
XX Sequence 25 BP; 8 A; 7 C; 6 G; 4 T; 0 U; 0 Other;  
SQ Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1474 AGAGAGCTCTGCACGTCACCAAGTA 1498  
DB 1 AGAGAGCTCTGCACGTCACCAAGTA 25  
RESULT 12  
ADP14582  
ID ADP14582 standard; DNA; 25 BP.  
AC ADP14582;  
XX ADP14582;  
XX 26-AUG-2004 (first entry)  
XX Renal cell carcinoma differentially expressed gene probe #987.  
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
KW head/neck cancer; differential expression; probe.  
XX Homo sapiens.  
XX WO2004048933-A2.  
DN

XX 10-JUN-2004.  
XX 21-NOV-2003; 2003WO-US037481.  
XX 21-NOV-2002; 2002US-0427982P.  
XX 03-APR-2003; 2003US-0459782P.  
XX (AMHP ) WYETH.  
XX (TWIN/) TWINE N C.  
XX (BURC/) BURCZYNSKI M E.  
XX (TREP/) TREPICCHIO W L.  
XX (DORN/) DORNER A.  
XX (STOV/) STOVER J A.  
XX (SLON/) SLONI D K.  
XX Twine NC, Burczynski ME, Trepicchio WL, Dornier A, Stover JA;  
XX Sloni DK;  
XX WPI; 2004-460799/43.  
XX Diagnosing non-blood disease such as solid tumor, involves comparing  
XX differential expression profile of specific genes in peripheral blood  
XX sample of subject with reference expression profile of specific genes.  
XX Disclosure; SEQ ID NO 1318; 350pp; English.  
XX The invention relate to a method of diagnosing (M1) non-blood disease  
XX such as solid tumor by providing peripheral blood sample of human having  
XX non-blood disease, and comparing an expression profile of specific genes  
XX in the peripheral blood sample to reference expression profile of the  
XX genes, where each of the genes is differentially expressed in peripheral  
XX blood mononuclear cells (PBMCs) of patients having the disease as  
XX compared to PBMCs of normal humans. The method is useful for diagnosing  
XX non-blood disease such as solid tumor. The solid tumor is chosen from  
XX renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
XX peripheral blood sample comprises enriched PBMCs. The peripheral blood  
XX sample is a whole blood sample (claimed). (M1) is useful for identifying  
XX genes that are differentially expressed in peripheral blood samples  
XX isolated at different stages of progression, development or treatment of  
XX RCC and/or other solid tumors. This sequence corresponds to a probe to  
XX detect a gene that is differentially expressed and detected by the method  
XX of the invention.  
XX Sequence 25 BP; 4 A; 5 C; 7 G; 9 T; 0 U; 0 Other;  
SQ Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 19;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1262 GGTCTGGAAGCTCTTGTGACTCTGAT 1286  
DB 1 GGTCTGGAAGCTCTTGTGACTCTGAT 25  
RESULT 13  
ADP14584  
ID ADP14584 standard; DNA; 25 BP.  
AC ADP14584;  
XX ADP14584;  
XX 26-AUG-2004 (first entry)  
XX Renal cell carcinoma differentially expressed gene probe #989.  
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;  
XX peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
KW head/neck cancer; differential expression; probe.  
XX Homo sapiens.  
XX WO2004048933-A2.  
DN

```
PD 10-JUN-2004.
XX PF
XX 21-NOV-2003; 2003WO-US037481.
XX PR
XX 21-NOV-2002; 2002US-0427982P.
XX PR
XX 03-APR-2003; 2003US-0459782P.
XX PA
XX (AMHP ) WYETH.
XX PA (TWIN/) TWINE N C.
XX PA (BURC/) BURCZYNSKI M E.
XX PA (TREP/) TREPICCHIO W L.
XX PA (DORN/) DORNER A.
XX PA (STOV/) STOVER J A.
XX PA (SLON/) SLONI D K.
XX PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
XX PI Sloni DK;
XX DR WPI; 2004-460799/43.
XX DR
XX Diagnosing non-blood disease such as solid tumor, involves comparing
XX PT differential expression profile of specific genes in peripheral blood
XX PT sample of subject with reference expression profile of specific genes.
XX PS
XX Disclosure; SEQ ID NO 1320; 350pp; English.
XX CC
XX The invention relate to a method of diagnosing (M1) non-blood disease
XX CC such as solid tumor by providing peripheral blood sample of human having
XX CC non-blood disease, and comparing an expression profile of specific genes
XX CC in the peripheral blood sample to reference expression profile of the
XX CC genes, where each of the genes is differentially expressed in peripheral
XX CC blood mononuclear cells (PBMCs) of patients having the disease as
XX CC compared to PBMCs of normal humans. The method is useful for diagnosing
XX CC non-blood disease such as solid tumor. The solid tumor is chosen from
XX CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
XX CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
XX CC sample is a whole blood sample (claimed). (M1) is useful for identifying
XX CC genes that are differentially expressed in peripheral blood samples
XX CC isolated at different stages of progression, development or treatment of
XX CC RCC and/or other solid tumors. This sequence corresponds to a probe to
XX CC detect a gene that is differentially expressed and detected by the method
XX CC of the invention.
XX SQ Sequence 25 BP; 4 A; 8 C; 4 G; 9 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. NO. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1274 CTTTGACTCTGATCCCATCTGTG 1298
DB 1 CTTTGACTCTGATCCCATCTGTG 25
XX
RESULT 14
ADP14586
ID ADP14586 standard; DNA; 25 BP.
XX AC
XX ADP14586;
XX DT
XX 26-AUG-2004 (first entry)
XX DE Renal cell carcinoma differentially expressed gene probe #991.
XX ss; diagnosis; non-blood disease; solid tumor; gene expression;
XX KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
XX KW head/neck cancer; differential expression; probe.
XX OS Homo sapiens.
XX PN WO2004048933-A2.
XX PD 10-JUN-2004.
```

```
XX 21-NOV-2003; 2003WO-US037481.
XX PF
XX 21-NOV-2002; 2002US-0427982P.
XX PR
XX 03-APR-2003; 2003US-0459782P.
XX PA
XX (AMHP ) WYETH.
XX PA (TWIN/) TWINE N C.
XX PA (BURC/) BURCZYNSKI M E.
XX PA (TREP/) TREPICCHIO W L.
XX PA (DORN/) DORNER A.
XX PA (STOV/) STOVER J A.
XX PA (SLON/) SLONI D K.
XX PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
XX PI Sloni DK;
XX DR WPI; 2004-460799/43.
XX DR
XX Diagnosing non-blood disease such as solid tumor, involves comparing
XX PT differential expression profile of specific genes in peripheral blood
XX PT sample of subject with reference expression profile of specific genes.
XX PS
XX Disclosure; SEQ ID NO 1322; 350pp; English.
XX CC
XX The invention relate to a method of diagnosing (M1) non-blood disease
XX CC such as solid tumor by providing peripheral blood sample of human having
XX CC non-blood disease, and comparing an expression profile of specific genes
XX CC in the peripheral blood sample to reference expression profile of the
XX CC genes, where each of the genes is differentially expressed in peripheral
XX CC blood mononuclear cells (PBMCs) of patients having the disease as
XX CC compared to PBMCs of normal humans. The method is useful for diagnosing
XX CC non-blood disease such as solid tumor. The solid tumor is chosen from
XX CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
XX CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
XX CC sample is a whole blood sample (claimed). (M1) is useful for identifying
XX CC genes that are differentially expressed in peripheral blood samples
XX CC isolated at different stages of progression, development or treatment of
XX CC RCC and/or other solid tumors. This sequence corresponds to a probe to
XX CC detect a gene that is differentially expressed and detected by the method
XX CC of the invention.
XX SQ Sequence 25 BP; 7 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
XX
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1470 CCAGAGAGAGCTCTGCACGTACCA 1494
DB 1 CCAGAGAGAGCTCTGCACGTACCA 25
XX
RESULT 15
ADP14588
ID ADP14588 standard; DNA; 25 BP.
XX AC
XX ADP14588;
XX DT
XX 26-AUG-2004 (first entry)
XX DE Renal cell carcinoma differentially expressed gene probe #993.
XX KW ss; diagnosis; non-blood disease; solid tumor; gene expression;
XX KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
XX KW head/neck cancer; differential expression; probe.
XX OS Homo sapiens.
XX PN WO2004048933-A2.
XX PD 10-JUN-2004.
XX
```

PF 21-NOV-2003; 2003WO-US037481.  
 XX  
 PR 21-NOV-2002; 2002US-0427982P.  
 PR 03-APR-2003; 2003US-0459782P.  
 XX  
 PA (AMHP ) WYETH.  
 PA (TWIN/) TWINE N C.  
 PA (BURC/) BURCZYNSKI M E.  
 PA (TREP/) TREPICCHIO W L.  
 PA (DORN/) DORNER A.  
 PA (STOV/) STOVER J A.  
 PA (SLOW/) SLOWI D K.  
 XX  
 PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
 PI Sloni DK;  
 XX  
 DR WPI; 2004-460799/43.  
 XX  
 XX Diagnosing non-blood disease such as solid tumor, involves comparing  
 PT differential expression profile of specific genes in peripheral blood  
 PT sample of subject with reference expression profile of specific genes.  
 XX  
 PS Disclosure; SEQ ID NO 1324; 350pp; English.  
 XX  
 CC The invention relate to a method of diagnosing (M1) non-blood disease  
 CC such as solid tumor by providing peripheral blood sample of human having  
 CC non-blood disease, and comparing an expression profile of specific genes  
 CC in the peripheral blood sample to reference expression profile of the  
 CC genes, where each of the genes is differentially expressed in peripheral  
 CC blood mononuclear cells (PBMCs) of patients having the disease as  
 CC compared to PBMCs of normal humans. The method is useful for diagnosing  
 CC non-blood disease such as solid tumor. The solid tumor is chosen from  
 CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
 CC peripheral blood sample comprises enriched PBMCs. The peripheral blood  
 CC sample is a whole blood sample (claimed). (M1) is useful for identifying  
 CC genes that are differentially expressed in peripheral blood samples  
 CC isolated at different stages of progression, development or treatment of  
 CC RCC and/or other solid tumors. This sequence corresponds to a probe to  
 CC detect a gene that is differentially expressed and detected by the method  
 CC of the invention.  
 XX  
 SQ Sequence 25 BP; 7 A; 9 C; 5 G; 4 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 19;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1480 CTCGCACGTCCACCAAGTACCAGG 1504  
 DB 1 CTCGCACGTCCACCAAGTACCAGG 25  
 RESULT 16  
 ADP14592  
 ID ADP14592 standard; DNA; 25 BP.  
 XX  
 AC ADP14592;  
 XX  
 DT 26-AUG-2004 (first entry)  
 XX  
 DE Renal cell carcinoma differentially expressed gene probe #997.  
 XX  
 KW ss; diagnosis; non-blood disease; solid tumor; gene expression;  
 KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
 KW head/neck cancer; differential expression; probe.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2004048933-A2.  
 XX  
 PD 10-JUN-2004.  
 XX  
 PF 21-NOV-2003; 2003WO-US037481.  
 XX

XX 21-NOV-2002; 2002US-0427982P.  
 PR 03-APR-2003; 2003US-0459782P.  
 XX  
 PA (AMHP ) WYETH.  
 PA (TWIN/) TWINE N C.  
 PA (BURC/) BURCZYNSKI M E.  
 PA (TREP/) TREPICCHIO W L.  
 PA (DORN/) DORNER A.  
 PA (STOV/) STOVER J A.  
 PA (SLOW/) SLOWI D K.  
 XX  
 PI Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;  
 PI Sloni DK;  
 XX  
 DR WPI; 2004-460799/43.  
 XX  
 XX Diagnosing non-blood disease such as solid tumor, involves comparing  
 PT differential expression profile of specific genes in peripheral blood  
 PT sample of subject with reference expression profile of specific genes.  
 XX  
 PS Disclosure; SEQ ID NO 1328; 350pp; English.  
 XX  
 CC The invention relate to a method of diagnosing (M1) non-blood disease  
 CC such as solid tumor by providing peripheral blood sample of human having  
 CC non-blood disease, and comparing an expression profile of specific genes  
 CC in the peripheral blood sample to reference expression profile of the  
 CC genes, where each of the genes is differentially expressed in peripheral  
 CC blood mononuclear cells (PBMCs) of patients having the disease as  
 CC compared to PBMCs of normal humans. The method is useful for diagnosing  
 CC non-blood disease such as solid tumor. The solid tumor is chosen from  
 CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The  
 CC peripheral blood sample comprises enriched PBMCs. The peripheral blood  
 CC sample is a whole blood sample (claimed). (M1) is useful for identifying  
 CC genes that are differentially expressed in peripheral blood samples  
 CC isolated at different stages of progression, development or treatment of  
 CC RCC and/or other solid tumors. This sequence corresponds to a probe to  
 CC detect a gene that is differentially expressed and detected by the method  
 CC of the invention.  
 XX  
 SQ Sequence 25 BP; 5 A; 8 C; 5 G; 7 T; 0 U; 0 Other;  
 Query Match 1.5%; Score 25; DB 1; Length 25;  
 Best Local Similarity 100.0%; Pred. No. 19;  
 Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1563 TAACACTCGACTCTGCTCATGG 1587  
 DB 1 TAACACTCGACTCTGCTCATGG 25  
 RESULT 17  
 ADP14579  
 ID ADP14579 standard; DNA; 25 BP.  
 XX  
 AC ADP14579;  
 XX  
 DT 26-AUG-2004 (first entry)  
 XX  
 DE Renal cell carcinoma differentially expressed gene probe #984.  
 XX  
 KW ss; diagnosis; non-blood disease; solid tumor; gene expression;  
 KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;  
 KW head/neck cancer; differential expression; probe.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2004048933-A2.  
 XX  
 PD 10-JUN-2004.  
 XX  
 PF 21-NOV-2003; 2003WO-US037481.  
 XX

```
PR 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
PS Disclosure; SEQ ID NO 1315; 350pp; English.
XX
CC The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
SQ Sequence 25 BP; 8 A; 6 C; 7 G; 4 T; 0 U; 0 Other;
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1177 AAGCGAAGACCAGTACTACTCTGCG 1201
Db 1 AAGCGAAGACCAGTACTACTCTGCG 25
RESULT 18
ADP14581
ID ADP14581 standard; DNA; 25 BP.
XX
AC ADP14581;
XX
XX 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #986.
XX
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX
OS Homo sapiens.
XX
XX WO2004048933-A2.
XX
XX 10-JUN-2004.
XX
XX 21-NOV-2003; 2003WO-US037481.
XX
XX 21-NOV-2002; 2002US-0427982P.
PR 21-NOV-2002; 2002US-0427982P.
```

```
PR 03-APR-2003; 2003US-0459782P.
XX (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLON/) SLONI D K.
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX WPI; 2004-460799/43.
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
PS Disclosure; SEQ ID NO 1317; 350pp; English.
XX
CC The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
SQ Sequence 25 BP; 4 A; 4 C; 9 G; 8 T; 0 U; 0 Other;
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
Oy 1256 TGAGGTGCTCGTGAAGCTCTTTGAC 1280
Db 1 TGAGGTGCTCGTGAAGCTCTTTGAC 25
RESULT 19
ADP14591
ID ADP14591 standard; DNA; 25 BP.
XX
AC ADP14591;
XX
XX 26-AUG-2004 (first entry)
XX Renal cell carcinoma differentially expressed gene probe #996.
XX
DE ss; diagnosis; non-blood disease; solid tumor; gene expression;
KW peripheral blood mononuclear cell; renal cell carcinoma; prostate cancer;
KW head/neck cancer; differential expression; probe.
XX
OS Homo sapiens.
XX
XX WO2004048933-A2.
XX
XX 10-JUN-2004.
XX
XX 21-NOV-2003; 2003WO-US037481.
XX
XX 21-NOV-2002; 2002US-0427982P.
PR 03-APR-2003; 2003US-0459782P.
```

```
XX (AMHP ) WYETH.
PA (TWIN/) TWINE N C.
PA (BURC/) BURCZYNSKI M E.
PA (TREP/) TREPICCHIO W L.
PA (DORN/) DORNER A.
PA (STOV/) STOVER J A.
PA (SLOW/) SLONI D K.
XX
XX Twine NC, Burczynski ME, Trepicchio WL, Dorner A, Stover JA;
PI Sloni DK;
XX
XX WPI; 2004-460799/43.
XX
XX Diagnosing non-blood disease such as solid tumor, involves comparing
PT differential expression profile of specific genes in peripheral blood
PT sample of subject with reference expression profile of specific genes.
XX
XX Disclosure; SEQ ID NO 1327; 350pp; English.
XX
XX The invention relate to a method of diagnosing (M1) non-blood disease
CC such as solid tumor by providing peripheral blood sample of human having
CC non-blood disease, and comparing an expression profile of specific genes
CC in the peripheral blood sample to reference expression profile of the
CC genes, where each of the genes is differentially expressed in peripheral
CC blood mononuclear cells (PBMCs) of patients having the disease as
CC compared to PBMCs of normal humans. The method is useful for diagnosing
CC non-blood disease such as solid tumor. The solid tumor is chosen from
CC renal cell carcinoma (RCC), prostate cancer and head/neck cancer. The
CC peripheral blood sample comprises enriched PBMCs. The peripheral blood
CC sample is a whole blood sample (claimed). (M1) is useful for identifying
CC genes that are differentially expressed in peripheral blood samples
CC isolated at different stages of progression, development or treatment of
CC RCC and/or other solid tumors. This sequence corresponds to a probe to
CC detect a gene that is differentially expressed and detected by the method
CC of the invention.
XX
XX Sequence 25 BP; 5 A; 9 C; 4 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. NO. 19;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1562 CTAACACTCGACTCTGCTGCTCATG 1586
DB 1 CTAACACTCGACTCTGCTGCTCATG 25
XX
RESULT 20
ABN99658/C
XX ID ABN99658 standard; DNA; 23 BP.
XX
XX AC ABN99658;
XX
XX 16-AUG-2002 (first entry)
XX
XX Human clusterin PCR primer 2.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX hypercholesterolaemia; cardiovascular disorder; ss; PCR; primer;
XX hyperproliferative disorder; hyperlipidemic disorder.
XX
XX Homo sapiens.
XX
XX WO200222635-A1.
XX
XX 21-MAR-2002.
XX
XX 10-SEP-2001; 2001WO-US028235.
XX
XX 11-SEP-2000; 2000US-00659791.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Monia BP, Freier SM;
XX
XX WPI; 2002-404805/43.
XX
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Example 13; Page 80; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia, cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a PCR primer used to amplify the human clusterin
CC gene
XX
XX Sequence 23 BP; 5 A; 6 C; 5 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. NO. 28;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 789 CTTGAGATGATACACGAGGCTCA 811
DB 23 CTTGAGATGATACACGAGGCTCA 1
XX
RESULT 21
ACF36411/C
XX ID ACF36411 standard; DNA; 23 BP.
XX
XX AC ACF36411;
XX
XX 18-DEC-2003 (first entry)
XX
XX Human TRPM-2 cDNA amplifying RT-PCR antisense primer.
XX
XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; RT-PCR;
XX androgen; prostate cancer; anti-apoptotic protein; antisense; primer; ss.
XX
XX Homo sapiens.
XX
XX WO2003072591-A1.
XX
XX 04-SEP-2003.
XX
XX 20-FEB-2003; 2003WO-US005305.
XX
XX 22-FEB-2002; 2002US-00080794.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX
XX WPI; 2003-689981/65.
XX
XX New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
XX Example 13; Page 20; 44pp; English.
XX
XX The invention relates to a compound consisting of an oligonucleotide with
CC a phosphorothioate backbone throughout, in which: (a) sugars on
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC prostatic cancer cells to the androgen-independent state, in vivo or in
```

CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. The present sequence represents a RT-  
CC PCR primer for amplifying the anti-apoptotic protein TRPM-2 (testosterone  
CC -repressed prostate message-2) cDNA  
XX  
SQ Sequence 23 BP; 7 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 957 AAGTCCGGGAGATCTTGCTGT 979  
|||  
Db 23 AAGTCCGGGAGATCTTGCTGT 1

RESULT 22  
ACF36410  
ID ACF36410 standard; DNA; 23 BP.  
XX  
AC ACF36410;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE Human TRPM-2 cDNA amplifying RT-PCR sense primer.  
XX  
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; RT-PCR;  
XX androgen; prostate cancer; anti-apoptotic protein; antisense; primer; ss.  
XX  
OS Homo sapiens.  
XX  
FN WO2003072591-A1.  
XX  
PD 04-SEP-2003.  
XX  
PF 20-FEB-2003; 2003WO-US005305.  
XX  
PR 22-FEB-2002; 2002US-00080794.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
XX  
DR WPI; 2003-689981/65.  
XX  
PT New modified antisense oligonucleotide, useful particularly for treating  
XX prostatic cancer, inhibits the testosterone-repressed prostate message-2.  
XX  
PS Example 13; Page 20; 44pp; English.

XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. The present sequence represents a RT-

CC PCR primer for amplifying the anti-apoptotic protein TRPM-2 (testosterone  
CC -repressed prostate message-2) cDNA  
XX  
SQ Sequence 23 BP; 11 A; 3 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 177 AAGGAAATTCAAAATGCTGTCAA 199  
|||  
Db 1 AAGGAAATTCAAAATGCTGTCAA 23

RESULT 23  
ADM83082/c  
ID ADM83082 standard; DNA; 23 BP.  
XX  
AC ADM83082;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 amplifying antisense RT-PCR primer.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
XX radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
XX lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
XX reverse transcription; RT-PCR; primer; ss.  
XX  
OS Homo sapiens.  
XX  
FN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
XX  
PR 28-SEP-2000; 2000US-0236301P.  
XX  
PR 10-AUG-2001; 2001US-00913325.  
XX

(GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX that expresses testosterone-repressed prostate message-2 (TRPM-2)  
XX comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 17; 14pp; English.

XX The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) amplifying RT-PCR primer. The primer is used in the exemplification  
CC of the invention.  
XX  
SQ Sequence 23 BP; 7 A; 8 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy 957 AAGTCCGGGAGATCTTGTCTGT 979
Db 23 AAGTCCGGGAGATCTTGTCTGT 1

RESULT 24
ADM83081
ID ADM83081 standard; DNA; 23 BP.
XX AC
XX ADM83081;
XX AC
XX 03-JUN-2004 (first entry)
XX DE
XX Human TRPM-2 amplifying sense RT-PCR primer.
XX XX
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;
XX radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;
XX lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;
XX reverse transcription; RT-PCR; primer; ss.
XX OS
XX Homo sapiens.
XX XX
XX US2003158130-A1.
XX PN
XX 21-AUG-2003.
XX PD
XX 28-SEP-2001; 2001US-00967726.
XX PF
XX 25-FEB-2000; 2000WO-US004875.
XX PR
XX 28-SEP-2000; 2000US-0236301P.
XX PR
XX 10-AUG-2001; 2001US-00913325.
XX XX
XX (GLEA/) GLEAVE M.
XX PA (RENN/) RENNIE P S.
XX PA (MIYA/) MIYAKE H.
XX PA (NELS/) NELSON C.
XX PA (ZELL/) ZELLWEGER T.
XX XX
XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;
XX WPI; 2003-778017/73.
XX DR
XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells
XX PT that expresses testosterone-repressed prostate message-2 (TRPM-2)
XX PT comprises administering a composition that inhibits expression of TRPM-2.
XX XX
XX Disclosure; SEQ ID NO 16; 14pp; English.
XX XX
XX The present invention provides a method for treating cancer in which
XX cancer cells express testosterone-repressed prostate message-2 (TRPM-2).
XX CC The invention is useful for enhancing the chemo-sensitivity or radiation-
XX CC sensitivity of cancer cells for treating cancer such as prostate cancer,
XX CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma
XX CC (RCC). The invention is also useful in antisense gene therapy. The
XX CC present sequence is human testosterone-repressed prostate message-2 (TRPM
XX CC -2) amplifying RT-PCR primer. The primer is used in the exemplification
XX CC of the invention.
XX SQ Sequence 23 BP; 11 A; 3 C; 4 G; 5 T; 0 U; 0 Other;
Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 177 AAGGAAATTCAAATGCTGCA 199
Db 1 AAGGAAATTCAAATGCTGCA 23

RESULT 25
ADL70521
ID ADL70521 standard; cDNA; 23 BP.
XX DE
XX XX
```

```
AC ADL70521;
XX 20-MAY-2004 (first entry)
XX DE
XX Human clusterin target for RNAi.
XX XX
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
XX cytosolic; neuroprotective; neurotrophic; gene silencing; DNA-RNA hybrid;
XX ss.
XX OS
XX Homo sapiens.
XX OS Synthetic.
XX XX
XX WO2004018676-A2.
XX PN
XX 04-MAR-2004.
XX PD
XX 21-AUG-2003; 2003WO-CA001277.
XX PF
XX 21-AUG-2002; 2002US-0405193P.
XX PR
XX 03-SEP-2002; 2002US-0408152P.
XX PR
XX 20-MAY-2003; 2003US-0472387P.
XX PR
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX PA
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
XX PI Gonos ES;
XX PI
XX WPI; 2004-226852/21.
XX DR
XX New RNA molecule less than 49 bases and having a sequence effective to
XX PT mediate degradation or block translation of mRNA that is the
XX PT transcriptional product of a target gene, useful for treating Alzheimer's
XX PT disease or cancer.
XX XX
XX Example 6; SEQ ID NO 66; 63pp; English.
XX XX
XX The present sequence is a human clusterin cDNA target for a double-
XX CC stranded short interfering RNA (siRNA) of the invention ADL70522-
XX CC ADL70523. It was used in an example from the invention to demonstrate
XX CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also
XX CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated
XX CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
XX CC tumour cells following androgen withdrawal, and has also been shown to be
XX CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
XX CC siRNAs of the invention can be used alone or in combination with other
XX CC chemotherapy or apoptosis inducing treatments for the treatment of
XX CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
XX CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
XX CC anaplastic large cell lymphoma and melanoma, and also for the treatment
XX CC of Alzheimer's disease.
XX XX
XX Sequence 23 BP; 5 A; 5 C; 7 G; 6 T; 0 U; 0 Other;
Query Match 1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 28;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 46 GCATGATGAAGACTCTGCTG 68
Db 1 GCATGATGAAGACTCTGCTG 23

RESULT 26
ADL70512
ID ADL70512 standard; cDNA; 23 BP.
XX AC
XX ADL70512;
XX AC
XX 20-MAY-2004 (first entry)
XX DE
XX Human clusterin target for RNAi.
XX XX
```

KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
XX ss.  
XX Homo sapiens.  
OS Synthetic.  
OS  
PN WO2004018676-A2.  
XX  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
PI  
XX  
DR WPI; 2004-226852/21.  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
PS Example 6; SEQ ID NO 57; 63pp; English.  
XX  
XX The present sequence is a human clusterin cDNA target for a double-  
CC stranded short interfering RNA (siRNA) of the invention to demonstrate  
CC ADL70514. It was used in an example from the invention to demonstrate  
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also  
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapies or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease.  
XX  
SQ Sequence 23 BP; 5 A; 9 C; 3 G; 6 T; 0 U; 0 Other;  
Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 480 AACGAGCTCGCCCTTCTACTT 502  
DB 1 AACGAGCTCGCCCTTCTACTT 23  
RESULT 27  
ADL70515  
ID ADL70515 standard; cDNA; 23 BP.  
XX  
XX  
AC ADL70515;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX Human clusterin target for RNAi.  
XX  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
OS Synthetic.

XX WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
PI  
XX  
DR WPI; 2004-226852/21.  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
PS Example 6; SEQ ID NO 60; 63pp; English.  
XX  
XX The present sequence is a human clusterin cDNA target for a double-  
CC stranded short interfering RNA (siRNA) of the invention to demonstrate  
CC ADL70517. It was used in an example from the invention to demonstrate  
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also  
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapies or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease.  
XX  
SQ Sequence 23 BP; 4 A; 9 C; 5 G; 5 T; 0 U; 0 Other;  
Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 711 AAGTCCCGCATCGTCGCGAGCTT 733  
DB 1 AAGTCCCGCATCGTCGCGAGCTT 23  
RESULT 28  
ADL70518  
ID ADL70518 standard; cDNA; 23 BP.  
XX  
XX  
AC ADL70518;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX Human clusterin target for RNAi.  
XX  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
PF



XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX WPI; 2004-226852/21.  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX Example 6; SEQ ID NO 63; 63pp; English.  
XX The present sequence is a human clusterin cDNA target for a double-  
CC stranded short interfering RNA (siRNA) of the invention ADL70519-  
CC ADL70520. It was used in an example from the invention to demonstrate  
CC clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also  
CC known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapy or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease.  
XX Sequence 23 BP; 10 A; 4 C; 1 G; 8 T; 0 U; 0 Other;  
SQ Query Match 1.4%; Score 23; DB 1; Length 23;  
Best Local Similarity 100.0%; Pred. No. 28;  
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1613 AACTAATTCATTAATAACTGCTT 1635  
DB 1 AACTAATTCATTAATAACTGCTT 23  
RESULT 29  
AAT39500  
ID AAT39500 standard; DNA; 21 BP.  
XX AC AAT39500;  
XX 21-MAY-1997 (first entry)  
XX Chromosome 8p clusterin gene (CL1) specific primer (nt 2504-2524).  
XX Chromosome 8p; polymerase chain reaction; PCR; primer; CL1;  
KW Clusterin gene; human; steroidogenesis; acute regulatory protein;  
KW regional mapping; confirmation; hSTAR; ss.  
XX Synthetic.  
XX OS  
XX WO9629338-A1.  
XX 26-SEP-1996.  
XX 22-MAR-1996; 96WO-US003896.  
XX 23-MAR-1995; 95US-00410540.  
XX (REGC ) UNIV CALIFORNIA.  
PA (UYPE-) UNIV PENNSYLVANIA.  
XX Miller WL, Lin D, Strauss JF;

XX WPI; 1996-443130/44.  
XX Isolated human steroidogenesis acute regulatory protein gene - used for  
PT detection of mutation(s) of this gene that cause congenital lipoid  
PT adrenal hyperplasia.  
XX Example 7; Page 51; 89pp; English.  
XX The present sequence is a human chromosome 8p clusterin gene (CL1)  
CC specific PCR primer, which was used in the confirmation of the regional  
CC mapping of the human steroidogenesis acute regulatory protein (hSTAR)  
XX Sequence 21 BP; 8 A; 5 C; 6 G; 2 T; 0 U; 0 Other;  
SQ Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1354 AGAAGCGCTGCAGGAATACC 1374  
DB 1 AGAAGCGCTGCAGGAATACC 21  
RESULT 30  
AAA52783  
ID AAA52783 standard; DNA; 21 BP.  
XX AC AAA52783;  
XX 03-JAN-2001 (first entry)  
XX Porcine clusterin PCR primer #1.  
XX Pig; clusterin; cell migration; wound healing; angiogenesis; cancer;  
KW vascular trauma; vascular disease; atherosclerosis; restenosis;  
KW complement cytotoxicity inhibitor; SP-40; 40; apoJ;  
KW testosterone repressed prostate message-2; sulfated glycoprotein-2;  
KW PCR primer; ss.  
XX OS  
XX Sus scrofa.  
XX WO200034469-A1.  
XX 15-JUN-2000.  
XX 10-DEC-1999; 99WO-US029262.  
XX 11-DEC-1998; 98US-0111856P.  
XX (UYNY ) UNIV NEW YORK STATE RES FOUND.  
XX Millis AJT;  
XX WPI; 2000-431300/37.  
XX Clusterin and gp38K-related peptide capable of altering cell migration  
PT useful for treating atherosclerosis, cancer and stenosis following  
PT vascular trauma or disease.  
XX Disclosure; Page 12; 43pp; English.  
XX The present sequence is a PCR primer for the porcine clusterin gene.  
CC Clusterin (also known as complement cytotoxicity inhibitor, sulfated  
CC glycoprotein-2, testosterone repressed prostate message-2, SP-40, 40 and  
CC ApoJ) is essential for the migration of vascular smooth muscle cells  
CC (VSMC). The gene and protein can, therefore, be used to promote wound  
CC healing, angiogenesis and vasculogenesis, in the treatment of stenosis  
CC following vascular trauma or disease and to treat atherosclerosis, and  
CC antisense sequences can be used to treat cancer, as angiogenesis is vital  
CC for tumour survival  
XX Sequence 21 BP; 12 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

```

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AAGCCCAAGAGAGAGAGAGG 294
DB 1 AAGCCCAAGAGAGAGAGAGG 21

RESULT 31
AAA94227/c
ID AAA94227 standard; DNA; 21 BP.
XX
AC AAA94227;
DT 12-JAN-2001 (first entry)
XX
DE Human testosterone-repressed prostate message-2 antisense oligo #3.
XX
KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO200049937-A2.
XX
PD 31-AUG-2000.
XX
PF 25-FEB-2000; 2000WO-US004875.
XX
PR 26-FEB-1999; 99US-0121726P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX
DR WPI; 2000-533132/48.
XX
PT Treating prostatic tumors and renal cancers by antisense inhibition of
PT sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO200049937-A2.
XX
PD 31-AUG-2000.
XX
PF 25-FEB-2000; 2000WO-US004875.
XX
PR 26-FEB-1999; 99US-0121726P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C;
XX
DR WPI; 2000-533132/48.
XX
PT Treating prostatic tumors and renal cancers by antisense inhibition of
PT the testosterone-repressed prostate messenger-2 gene.
XX
PS Claim 4; Page 36; 38pp; English.
XX
CC The present sequence is an antisense oligonucleotide directed at the
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
CC promote the regression of tumours, and oligonucleotides directed at human
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
CC gene. These include prostate cancer, renal cell cancer and some breast
CC cancer cells. In addition to this, they also increase the
CC chemosensitivity of the cells, meaning that conventional chemotherapy is
CC more effective
XX
SQ Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCACGGGCTGCCTGC 936
DB 21 ACAACTCCACGGGCTGCCTGC 1

RESULT 33
AAA94230/c
ID AAA94230 standard; DNA; 21 BP.
XX
AC AAA94230;
XX
DT 12-JAN-2001 (first entry)
XX
DE Human testosterone-repressed prostate message-2 antisense oligo #6.
XX
KW Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
XX
OS Homo sapiens.
XX
PN WO200049937-A2.
XX
PD 31-AUG-2000.
XX
PF 25-FEB-2000; 2000WO-US004875.
XX
PR 26-FEB-1999; 99US-0121726P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C;

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
DB 21 GACCAGACGGTCTCAGACAAT 1

RESULT 32
AAA94231/c
ID AAA94231 standard; DNA; 21 BP.
XX
AC AAA94231;
XX
DT 12-JAN-2001 (first entry)
XX
```

XX WPI; 2000-533132/48.  
XX Treating prostatic tumors and renal cancers by antisense inhibition of  
PT the testosterone-repressed prostate messenger-2 gene.  
XX  
XX Example 5; Page 37; 38pp; English.  
XX  
XX The present sequence is an antisense oligonucleotide directed at the  
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as  
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
CC promote the regression of tumours, and oligonucleotides directed at human  
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2  
CC gene. These include prostate cancer, renal cell cancer and some breast  
CC cancer cells. In addition to this, they also increase the  
CC chemosensitivity of the cells, meaning that conventional chemotherapy is  
CC more effective  
XX  
SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 716 CCGCATCGTCCGAGCTTGAT 736  
Db 21 CCGCATCGTCCGAGCTTGAT 1  
RESULT 34  
ID AAA94232/c  
AC AAA94232;  
XX  
XX 12-JAN-2001 (first entry)  
XX Human testosterone-repressed prostate message-2 antisense oligo #8.  
XX  
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;  
XX sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.  
XX Homo sapiens.  
XX WO200049937-A2.  
XX  
XX 31-AUG-2000.  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
XX  
XX 26-FEB-1999; 99US-0121726P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C;  
XX WPI; 2000-533132/48.  
XX  
XX Treating prostatic tumors and renal cancers by antisense inhibition of  
PT the testosterone-repressed prostate messenger-2 gene.  
XX  
XX Example 5; Page 37; 38pp; English.  
XX  
XX The present sequence is an antisense oligonucleotide directed at the  
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as  
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
CC promote the regression of tumours, and oligonucleotides directed at human  
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2  
CC gene. These include prostate cancer, renal cell cancer and some breast  
CC cancer cells. In addition to this, they also increase the  
CC chemosensitivity of the cells, meaning that conventional chemotherapy is  
CC more effective  
XX

SQ Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
Db 21 CTCCTTGCTGGAGCAGCTGAA 1  
RESULT 35  
ID AAA94233/c  
AC AAA94233;  
XX  
XX 12-JAN-2001 (first entry)  
XX Human testosterone-repressed prostate message-2 antisense oligo #9.  
XX  
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;  
XX sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.  
XX Homo sapiens.  
XX WO200049937-A2.  
XX  
XX 31-AUG-2000.  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
XX  
XX 26-FEB-1999; 99US-0121726P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C;  
XX WPI; 2000-533132/48.  
XX  
XX Treating prostatic tumors and renal cancers by antisense inhibition of  
PT the testosterone-repressed prostate messenger-2 gene.  
XX  
XX Example 5; Page 38; 38pp; English.  
XX  
XX The present sequence is an antisense oligonucleotide directed at the  
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as  
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
CC promote the regression of tumours, and oligonucleotides directed at human  
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2  
CC gene. These include prostate cancer, renal cell cancer and some breast  
CC cancer cells. In addition to this, they also increase the  
CC chemosensitivity of the cells, meaning that conventional chemotherapy is  
CC more effective  
XX  
SQ Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1316 CTCGAGGAGAACCTTAATTT 1336  
Db 21 CTCGAGGAGAACCTTAATTT 1  
RESULT 36  
ID AAA94229/c  
AC AAA94229;  
XX  
XX 12-JAN-2001 (first entry)  
XX

XX Human testosterone-repressed prostate message-2 antisense oligo #5.  
DE  
XX  
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;  
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.  
XX  
XX Homo sapiens.  
OS  
XX WO200049937-A2.  
PN  
XX  
XX 31-AUG-2000.  
PD  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
PF  
XX  
XX 26-FEB-1999; 99US-0121726P.  
PR  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C;  
PI  
XX  
XX WPI; 2000-533132/48.  
DR  
XX  
XX Treating prostatic tumors and renal cancers by antisense inhibition of  
PT the testosterone-repressed prostate messenger-2 gene.  
PT  
XX  
XX Example 5; Page 37; 38pp; English.  
PS  
XX  
XX The present sequence is an antisense oligonucleotide directed at the  
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as  
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
CC promote the regression of tumours, and oligonucleotides directed at human  
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2  
CC gene. These include prostate cancer, renal cell cancer and some breast  
CC cancer cells. In addition to this, they also increase the  
CC chemosensitivity of the cells, meaning that conventional chemotherapy is  
CC more effective  
XX  
XX Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 515 TGACCGCATCGACTCCCTGCT 535  
DB 21 TGACCGCATCGACTCCCTGCT 1  
RESULT 37  
AAA94226/C  
ID AAA94226 standard; DNA; 21 BP.  
XX  
XX AAA94226;  
AC  
XX  
XX 12-JAN-2001 (first entry)  
DT  
XX  
XX Human testosterone-repressed prostate message-2 antisense oligo #2.  
DE  
XX  
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;  
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200049937-A2.  
PN  
XX  
XX 31-AUG-2000.  
PD  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
PF  
XX  
XX 26-FEB-1999; 99US-0121726P.  
PR  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C;  
PI  
XX  
XX WPI; 2000-533132/48.  
DR  
XX  
XX Treating prostatic tumors and renal cancers by antisense inhibition of  
PT the testosterone-repressed prostate messenger-2 gene.  
PT  
XX  
XX Example 5; Page 37; 38pp; English.  
PS  
XX  
XX The present sequence is an antisense oligonucleotide directed at the  
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as  
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
CC promote the regression of tumours, and oligonucleotides directed at human  
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2  
CC gene. These include prostate cancer, renal cell cancer and some breast  
CC cancer cells. In addition to this, they also increase the  
CC chemosensitivity of the cells, meaning that conventional chemotherapy is  
CC more effective  
XX  
XX Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 515 TGACCGCATCGACTCCCTGCT 535  
DB 21 TGACCGCATCGACTCCCTGCT 1

PI Gleave M, Rennie PS, Miyake H, Nelson C;  
XX  
XX WPI; 2000-533132/48.  
XX  
XX Treating prostatic tumors and renal cancers by antisense inhibition of  
PT the testosterone-repressed prostate messenger-2 gene.  
PT  
XX  
XX Claim 3; Page 36; 38pp; English.  
PS  
XX  
XX The present sequence is an antisense oligonucleotide directed at the  
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as  
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
CC promote the regression of tumours, and oligonucleotides directed at human  
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2  
CC gene. These include prostate cancer, renal cell cancer and some breast  
CC cancer cells. In addition to this, they also increase the  
CC chemosensitivity of the cells, meaning that conventional chemotherapy is  
CC more effective  
XX  
XX Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 48 ATGATGAAGACTCTGCTGCTG 68  
DB 21 ATGATGAAGACTCTGCTGCTG 1  
RESULT 38  
AAA94234/C  
ID AAA94234 standard; DNA; 21 BP.  
XX  
XX AAA94234;  
AC  
XX  
XX 12-JAN-2001 (first entry)  
DT  
XX  
XX Human testosterone-repressed prostate message-2 antisense oligo #10.  
DE  
XX  
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;  
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200049937-A2.  
PN  
XX  
XX 31-AUG-2000.  
PD  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
PF  
XX  
XX 26-FEB-1999; 99US-0121726P.  
PR  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C;  
PI  
XX  
XX WPI; 2000-533132/48.  
DR  
XX  
XX Treating prostatic tumors and renal cancers by antisense inhibition of  
PT the testosterone-repressed prostate messenger-2 gene.  
PT  
XX  
XX Example 5; Page 38; 38pp; English.  
PS  
XX  
XX The present sequence is an antisense oligonucleotide directed at the  
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as  
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to  
CC promote the regression of tumours, and oligonucleotides directed at human  
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2  
CC gene. These include prostate cancer, renal cell cancer and some breast  
CC cancer cells. In addition to this, they also increase the  
CC chemosensitivity of the cells, meaning that conventional chemotherapy is  
CC more effective  
XX

```
XX SQ Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCACTCCGCCAGC 1536
Db 21 AGGCCCCCACTCCGCCAGC 1

RESULT 39
AAA94228/c
ID AAA94228 standard; DNA; 21 BP.
XX
AC AAA94228;
XX
DT 12-JAN-2001 (first entry)
XX Human testosterone-repressed prostate message-2 antisense oligo #4.
DE
DE Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
KW
XX Homo sapiens.
OS
XX WO200049937-A2.
PN
XX 31-AUG-2000.
PD
XX
XX 25-FEB-2000; 2000WO-US004875.
PF
XX
XX 26-FEB-1999; 99US-0121726P.
PR
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
XX Gleave M, Rennie PS, Miyake H, Nelson C;
PI WPI; 2000-533132/48.
DR
XX
XX Treating prostatic tumors and renal cancers by antisense inhibition of
PT the testosterone-repressed prostate messenger-2 gene.
XX
XX Homo sapiens.
OS
XX WO200049937-A2.
PN
XX 31-AUG-2000.
PD
XX
XX 25-FEB-2000; 2000WO-US004875.
PF
XX
XX 26-FEB-1999; 99US-0121726P.
PR
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
XX Gleave M, Rennie PS, Miyake H, Nelson C;
PI WPI; 2000-533132/48.
DR
XX
XX Treating prostatic tumors and renal cancers by antisense inhibition of
PT the testosterone-repressed prostate messenger-2 gene.
XX
XX Example 5; Page 36; 38pp; English.
PS
XX The present sequence is an antisense oligonucleotide directed at the
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
CC promote the regression of tumours, and oligonucleotides directed at human
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
CC gene. These include prostate cancer, renal cell cancer and some breast
CC cancer cells. In addition to this, they also increase the
CC chemosensitivity of the cells, meaning that conventional chemotherapy is
CC more effective
XX
XX Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGAGACAAGCTGAAG 336
Db 21 AATCAGAGACAAGCTGAAG 1

RESULT 40
AAA94225/c
ID AAA94225 standard; DNA; 21 BP.
XX
AC AAA94225;
XX
```

```
DT 12-JAN-2001 (first entry)
XX Human testosterone-repressed prostate message-2 antisense oligo #1.
DE
XX Human; testosterone-repressed prostate message-2; TRPM-2; clusterin;
KW sulfated glycoprotein-2; SGP-2; cancer; antisense oligonucleotide; ss.
KW
XX Homo sapiens.
OS
XX WO200049937-A2.
PN
XX 31-AUG-2000.
PD
XX
XX 25-FEB-2000; 2000WO-US004875.
PF
XX
XX 26-FEB-1999; 99US-0121726P.
PR
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
XX Gleave M, Rennie PS, Miyake H, Nelson C;
PI WPI; 2000-533132/48.
DR
XX
XX Treating prostatic tumors and renal cancers by antisense inhibition of
PT the testosterone-repressed prostate messenger-2 gene.
XX
XX Example 5; Page 36; 38pp; English.
PS
XX The present sequence is an antisense oligonucleotide directed at the
CC human testosterone-repressed prostate message-2 (TRPM-2, also known as
CC clusterin, sulfated glycoprotein-2 or SGP-2). The sequence was shown to
CC promote the regression of tumours, and oligonucleotides directed at human
CC TRPM-2 can be used in the treatment of tumour cells expressing the TRPM-2
CC gene. These include prostate cancer, renal cell cancer and some breast
CC cancer cells. In addition to this, they also increase the
CC chemosensitivity of the cells, meaning that conventional chemotherapy is
CC more effective
XX
XX Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGCGGTGCAAAAGACTCCA 36
Db 21 CCGAGCGGTGCAAAAGACTCCA 1

RESULT 41
AAF97658
ID AAF97658 standard; DNA; 21 BP.
XX
AC AAF97658;
XX
XX 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX
XX Human gene single nucleotide polymorphism #2419.
DE
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
OS
XX Unidentified.
XX
XX Key Location/Qualifiers
XX variation 11
XX /*tag= a
XX /standard_name= "Single nucleotide polymorphism"
XX
```

```
PN WO200118250-A2.
XX
XX
PD 15-MAR-2001.
XX
XX PF 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX
XX WPI; 2001-226749/23.
DR
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 212; 242pp; English.
PS
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
CC
CC Revised record issued on 18-NOV-2004 : The variantion feature was
CC incorrectly given a captial V
XX
XX Sequence 21 BP; 7 A; 7 C; 6 G; 1 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1170 CTCACGCAAGCGGAGACCCAG 1190
DB 1 CTCACGCAAGCGGAGACCCAG 21
RESULT 42
AAF97656
ID AAF97656 standard; DNA; 21 BP.
XX
XX AAF97656;
AC
XX 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX
XX Human gene single nucleotide polymorphism #2417.
DE
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
OS
XX Unidentified.
OS
XX Key Location/Qualifiers
FH variation 11
FT /*tag= a
FT /standard_name= "Single nucleotide polymorphism"
```

```
XX WO200118250-A2.
XX
XX
PD 15-MAR-2001.
XX
XX PF 07-SEP-2000; 2000WO-US024503.
XX
XX 10-SEP-1999; 99US-0153357P.
PR 26-JUL-2000; 2000US-0220947P.
PR 16-AUG-2000; 2000US-0225724P.
XX
XX (WHED ) WHITEHEAD INST BIOMEDICAL RES.
PA (MILL-) MILLENNIUM PHARM INC.
XX
XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX
XX WPI; 2001-226749/23.
DR
XX
XX Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis.
XX
XX Example; Page 212; 242pp; English.
PS
XX The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification
CC
CC Revised record issued on 18-NOV-2004 : The variantion feature was
CC incorrectly given a captial V
XX
XX Sequence 21 BP; 8 A; 3 C; 7 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY 1050 GAGAGGTTGACCAGGAATAC 1070
DB 1 GAGAGGTTGACCAGGAATAC 21
RESULT 43
AAF97657
ID AAF97657 standard; DNA; 21 BP.
XX
XX AAF97657;
AC
XX 18-NOV-2004 (revised)
DT 06-JUN-2001 (first entry)
XX
XX Human gene single nucleotide polymorphism #2418.
DE
XX Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.
XX
XX Homo sapiens.
OS
XX Unidentified.
OS
XX Key Location/Qualifiers
FH variation 11
FT /*tag= a
FT
```

```
FT      /standard_name= "Single nucleotide polymorphism"
XX      WO200118250-A2.
XX      15-MAR-2001.
XX      07-SEP-2000; 2000WO-US024503.
XX      10-SEP-1999; 99US-0153357P.
XX      26-JUL-2000; 2000US-0220947P.
XX      16-AUG-2000; 2000US-0225724P.
XX      (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX      (MILL-) MILLENNIUM PHARM INC.
XX      Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX      WPI; 2001-226749/23.
XX      Nucleic acids comprising single nucleotide polymorphisms, useful in
XX      PT applications such as forensics, paternity testing, medicine, genetic
XX      PT analysis and phenotype correlations to diseases such as diabetes and
XX      PT atherosclerosis.
XX      Example; Page 212; 242pp; English.
XX      The present invention provides a method of diagnosing a vascular disease
XX      CC in an individual, involving determining the sequence at various
XX      CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX      CC genes. The sequences at a number of polymorphic sites are also provided
XX      CC in the specification. In particular, the method can be used in the
XX      CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX      CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX      CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX      CC useful in forensics, paternity testing, genetic analysis and phenotype
XX      CC correlations to diseases. The present sequence is an example of one of
XX      CC the human gene SNPs shown in the specification
XX      CC Revised record issued on 18-NOV-2004 : The variation feature was
XX      CC incorrectly given a capital V
XX      SQ Sequence 21 BP; 3 A; 9 C; 6 G; 3 T; 0 U; 0 Other;
XX      Query Match 1.3%; Score 21; DB 1; Length 21;
XX      Best Local Similarity 100.0%; Pred. No. 39;
XX      Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX      QY 999 CCTCCAGGCTAAGTCGG 1019
XX      1 CCTCCAGGCTAAGTCGG 21
XX      Db
XX      RESULT 44
XX      AAF97659
XX      ID AAF97659 standard; DNA; 21 BP.
XX      AC AAF97659;
XX      XX 18-NOV-2004 (revised)
XX      DT 06-JUN-2001 (first entry)
XX      XX Human gene single nucleotide polymorphism #2420.
XX      XX Human, variant thrombospondin 1; variant thrombospondin 4; SNP;
XX      KW polymorphism; vascular disease; coronary artery disease; forensics;
XX      KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
XX      KW pulmonary embolism; paternity test; ds.
XX      OS Homo sapiens.
XX      OS Unidentified.
XX      XX Key Location/Qualifiers
XX      FT variation 11
XX      11
```

```
FT      /*tag= a
XX      /standard_name= "Single nucleotide polymorphism"
XX      WO200118250-A2.
XX      15-MAR-2001.
XX      07-SEP-2000; 2000WO-US024503.
XX      10-SEP-1999; 99US-0153357P.
XX      26-JUL-2000; 2000US-0220947P.
XX      16-AUG-2000; 2000US-0225724P.
XX      (WHED ) WHITEHEAD INST BIOMEDICAL RES.
XX      (MILL-) MILLENNIUM PHARM INC.
XX      Lander ES, Gargill M, Ireland JS, Bolk S, Daley GQ, Mccarthy JJ;
XX      WPI; 2001-226749/23.
XX      Nucleic acids comprising single nucleotide polymorphisms, useful in
XX      PT applications such as forensics, paternity testing, medicine, genetic
XX      PT analysis and phenotype correlations to diseases such as diabetes and
XX      PT atherosclerosis.
XX      Example; Page 213; 242pp; English.
XX      The present invention provides a method of diagnosing a vascular disease
XX      CC in an individual, involving determining the sequence at various
XX      CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
XX      CC genes. The sequences at a number of polymorphic sites are also provided
XX      CC in the specification. In particular, the method can be used in the
XX      CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
XX      CC disease, stroke, peripheral vascular diseases, venous thromboembolism and
XX      CC pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
XX      CC useful in forensics, paternity testing, genetic analysis and phenotype
XX      CC correlations to diseases. The present sequence is an example of one of
XX      CC the human gene SNPs shown in the specification
XX      CC Revised record issued on 18-NOV-2004 : The variation feature was
XX      CC incorrectly given a capital V
XX      SQ Sequence 21 BP; 3 A; 9 C; 3 G; 6 T; 0 U; 0 Other;
XX      Query Match 1.3%; Score 21; DB 1; Length 21;
XX      Best Local Similarity 100.0%; Pred. No. 39;
XX      Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX      QY 1105 TCAACACCTCCTCTGCTGG 1125
XX      1 TCAACACCTCCTCTGCTGG 21
XX      Db
XX      RESULT 45
XX      ABN99659
XX      ID ABN99659 standard; DNA; 21 BP.
XX      AC ABN99659;
XX      XX 16-AUG-2002 (first entry)
XX      DT Human clusterin PCR probe.
XX      DE Human, antisense inhibition; antisense oligonucleotide; clusterin;
XX      KW hypercholesterolaemia; cardiovascular disorder; ss; PCR; probe;
XX      KW hyperproliferative disorder; hyperlipidemic disorder.
XX      OS Homo sapiens.
XX      OS WO200222635-A1.
XX      XX 21-MAR-2002.
XX      XX
```

```
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
PI WPI; 2002-404805/43.
XX
DR Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Example 13; Page 80; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a PCR probe specific for the human clusterin
CC gene. NOTE: The present sequence is labelled with a fluorescent reporter
CC dye (FAM) and a quencher dye (TAMRA)
XX
SQ Sequence 21 BP; 3 A; 10 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCCATGTTCCAGCCCT 786
DB 1 TCCACGCCCATGTTCCAGCCCT 21

RESULT 46
ACF36397/c
ID ACF36397 standard; DNA; 21 BP.
XX
AC ACF36397;
XX
XX 18-DEC-2003 (first entry)
DT
DE TRPM-2 antisense oligonucleotide.
XX
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO2003072591-A1.
XX
PD 04-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005305.
XX
PR 22-FEB-2002; 2002US-00080794.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX
XX WPI; 2003-689981/65.
XX
DR New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
XX Example 5; Page 40; 44pp; English.
XX

PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
PI WPI; 2002-404805/43.
XX
DR Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Example 13; Page 80; 125pp; English.
XX
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a PCR probe specific for the human clusterin
CC gene. NOTE: The present sequence is labelled with a fluorescent reporter
CC dye (FAM) and a quencher dye (TAMRA)
XX
SQ Sequence 21 BP; 3 A; 10 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCCATGTTCCAGCCCT 786
DB 1 TCCACGCCCATGTTCCAGCCCT 21

RESULT 47
ACF36405/c
ID ACF36405 standard; DNA; 21 BP.
XX
AC ACF36405;
XX
XX 18-DEC-2003 (first entry)
DT
DE TRPM-2 antisense oligonucleotide #11.
XX
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO2003072591-A1.
XX
PD 04-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005305.
XX
PR 22-FEB-2002; 2002US-00080794.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX
XX WPI; 2003-689981/65.
XX
DR New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
XX Example 5; Page 42; 44pp; English.
XX

The invention relates to a compound consisting of an oligonucleotide with
a phosphorothioate backbone throughout, in which: (a) sugars on
nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
prostatic cancer cells to the androgen-independent state, in vivo or in
vitro; (b) to treat prostatic cancer (after initially withdrawing
androgens to induce apoptosis); and (c) to increase sensitivity of cancer
cells (prostatic, renal, non-small cell lung, urothelial transitional,
ovarian and some breast cancer cells) that express abnormal levels of
TRPM-2 to chemotherapy or radiation. The modifications present in (I)
increase stability in vivo and activity (both in vivo or in vitro) and
result in a synergistic increase in effect when (I) is used with
chemotherapeutic agents or other antisense oligonucleotides directed
against other antiapoptotic genes. The present sequence represents an
anti-apoptotic protein TRPM-2 (testosterone-repressed prostate message-2)
antisense oligonucleotide
SQ Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGGGCGTGCAAGACTCCA 36
DB 21 CCGAGGGCGTGCAAGACTCCA 1

RESULT 47
ACF36405/c
ID ACF36405 standard; DNA; 21 BP.
XX
AC ACF36405;
XX
XX 18-DEC-2003 (first entry)
DT
DE TRPM-2 antisense oligonucleotide #11.
XX
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS Synthetic.
XX
OS Homo sapiens.
XX
PN WO2003072591-A1.
XX
PD 04-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005305.
XX
PR 22-FEB-2002; 2002US-00080794.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX
XX WPI; 2003-689981/65.
XX
DR New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
XX Example 5; Page 42; 44pp; English.
XX

The invention relates to a compound consisting of an oligonucleotide with
a phosphorothioate backbone throughout, in which: (a) sugars on
nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
prostatic cancer cells to the androgen-independent state, in vivo or in
vitro; (b) to treat prostatic cancer (after initially withdrawing
```



CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent  
CC antisense oligonucleotides targeted against human anti-apoptotic protein  
CC TRPM-2 (testosterone-repressed prostate message-2) gene  
XX  
SQ Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCGAGGAGAACCTAAATT 1336  
DB 21 CTCGAGGAGAACCTAAATT 1

## RESULT 48

ACF36406/c

ID ACF36406 standard; DNA; 21 BP.

XX AC ACF36406;

DT 18-DEC-2003 (first entry)

XX TRPM-2 antisense oligonucleotide #12.

XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.

OS Synthetic.

OS Homo sapiens.

XX WO2003072591-A1.

XX 04-SEP-2003.

XX 20-FEB-2003; 2003WO-US005305.

XX 22-FEB-2002; 2002US-00080794.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;

XX WPI; 2003-689981/65.

XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.

XX Example 5; Page 42; 44pp; English.

XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent

CC antisense oligonucleotides targeted against human anti-apoptotic protein  
CC TRPM-2 (testosterone-repressed prostate message-2) gene  
XX  
SQ Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCGAGC 1536  
DB 21 AGGCCCCCAACTCCGCCGAGC 1

## RESULT 49

ACF36399/c

ID ACF36399 standard; DNA; 21 BP.

XX AC ACF36399;

DT 18-DEC-2003 (first entry)

XX TRPM-2 antisense oligonucleotide #5.

XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.

OS Synthetic.

OS Homo sapiens.

XX WO2003072591-A1.

XX 04-SEP-2003.

XX 20-FEB-2003; 2003WO-US005305.

XX 22-FEB-2002; 2002US-00080794.

XX (UYBR-) UNIV BRITISH COLUMBIA.

XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;

XX WPI; 2003-689981/65.

XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.

XX Example 5; Page 40; 44pp; English.

XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent  
CC antisense oligonucleotides targeted against human anti-apoptotic protein  
CC TRPM-2 (testosterone-repressed prostate message-2) gene

SQ Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
OY 114 GACCAGCGGTCTCAGACAAAT 134
DB 21 GACCAGACGGTCTCAGACAAAT 1

RESULT 50
ACF36402/c
ID ACF36402 standard; DNA; 21 BP.
XX
AC ACF36402;
XX
DT 18-DEC-2003 (first entry)
XX
DE TRPM-2 antisense oligonucleotide #8.
XX
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;
KW prostate cancer; anti-apoptotic protein; antisense; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
PN WO2003072591-A1.
XX
PD 04-SEP-2003.
XX
PF 20-FEB-2003; 2003WO-US005305.
XX
PR 22-FEB-2002; 2002US-00080794.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
XX
PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;
XX WPI; 2003-689981/65.
XX
PT New modified antisense oligonucleotide, useful particularly for treating
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.
XX
PS Example 5; Page 41; 44pp; English.
XX
CC The invention relates to a compound consisting of an oligonucleotide with
CC a phosphorothioate backbone throughout, in which: (a) sugars on
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive
CC prostatic cancer cells to the androgen-independent state, in vivo or in
CC vitro; (b) to treat prostatic cancer (after initially withdrawing of cancer
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,
CC ovarian and some breast cancer cells) that express abnormal levels of
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)
CC increase stability in vivo and activity (both in vivo or in vitro) and
CC result in a synergistic increase in effect when (I) is used with
CC chemotherapeutic agents or other antisense oligonucleotides directed
CC against other antiapoptotic genes. Sequences ACF36399-406 represent
CC antisense oligonucleotides targeted against human anti-apoptotic protein
CC TRPM-2 (testosterone-repressed prostate message-2) gene
XX
SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 716 CCGCATCGTCCGAGCTTGAT 736
DB 21 CCGCATCGTCCGAGCTTGAT 1

RESULT 51
ACF36401/c
```

KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.  
OS Synthetic.  
OS Homo sapiens.  
XX WO2003072591-A1.  
PN 04-SEP-2003.  
XX 20-FEB-2003; 2003WO-US005305.  
PF 22-FEB-2002; 2002US-00080794.  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
PI WPI; 2003-689981/65.  
DR New modified antisense oligonucleotide, useful particularly for treating  
XX prostate cancer, inhibits the testosterone-repressed prostate message-2.  
XX Claim 1; Page 25; 44pp; English.  
XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. The present sequence represents a  
CC specific example of an anti-apoptotic protein TRPM-2 (testosterone-  
CC repressed prostate message-2) antisense oligonucleotide  
XX  
SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 48 ATGATGAAGACTCTGCTGCTG 68  
Db ||||||||||||||||||||  
21 ATGATGAAGACTCTGCTGCTG 1  
  
RESULT 53  
ACF36403/C  
ID ACF36403 standard; DNA; 21 BP.  
XX  
AC ACF36403;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE TRPM-2 antisense oligonucleotide #9.  
XX  
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.  
XX Synthetic.  
OS Homo sapiens.  
XX WO2003072591-A1.  
PN

PD 04-SEP-2003.  
XX 20-FEB-2003; 2003WO-US005305.  
XX 22-FEB-2002; 2002US-00080794.  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
PI WPI; 2003-689981/65.  
DR New modified antisense oligonucleotide, useful particularly for treating  
XX prostate cancer, inhibits the testosterone-repressed prostate message-2.  
XX Example 5; Page 41; 44pp; English.  
XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent  
CC antisense oligonucleotides targeted against human anti-apoptotic protein  
CC TRPM-2 (testosterone-repressed prostate message-2) gene  
XX  
SQ Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;  
  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 916 ACAATCTCCACGGGCTGCTGTC 936  
Db ||||||||||||||||||||  
21 ACAATCTCCACGGGCTGCTGTC 1  
  
RESULT 54  
ACF36404/C  
ID ACF36404 standard; DNA; 21 BP.  
XX  
AC ACF36404;  
XX  
DT 18-DEC-2003 (first entry)  
XX  
DE TRPM-2 antisense oligonucleotide #10.  
XX  
KW TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.  
XX Synthetic.  
OS Homo sapiens.  
XX WO2003072591-A1.  
PN  
PD 04-SEP-2003.  
XX 20-FEB-2003; 2003WO-US005305.  
XX 22-FEB-2002; 2002US-00080794.  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX

PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
XX WPI; 2003-689981/65.  
XX  
XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.  
XX  
XX Example 5; Page 41; 44pp; English.  
XX  
XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent  
CC antisense oligonucleotides targeted against human anti-apoptotic protein  
CC TRPM-2 (testosterone-repressed prostate message-2) gene  
XX  
XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
DB 21 CTCCTTGCTGGAGCAGCTGAA 1  
RESULT 55  
ACF36400/C  
ID ACF36400 standard; DNA; 21 BP.  
XX  
XX ACF36400;  
XX  
XX 18-DEC-2003 (first entry)  
XX  
XX TRPM-2 antisense oligonucleotide #6.  
XX  
XX TRPM-2; testosterone-repressed prostate message-2; cytostatic; androgen;  
KW prostate cancer; anti-apoptotic protein; antisense; ss.  
XX  
XX Synthetic.  
OS Homo sapiens.  
XX  
XX WO2003072591-A1.  
EN  
XX  
XX 04-SEP-2003.  
XX  
XX 20-FEB-2003; 2003WO-US005305.  
XX  
XX 22-FEB-2002; 2002US-00080794.  
PR  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
PI WPI; 2003-689981/65.  
XX  
XX New modified antisense oligonucleotide, useful particularly for treating  
PT prostatic cancer, inhibits the testosterone-repressed prostate message-2.  
XX  
XX Example 5; Page 40; 44pp; English.  
PS

XX The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout, in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostatic cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostatic cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. Sequences ACF36399-406 represent  
CC antisense oligonucleotides targeted against human anti-apoptotic protein  
CC TRPM-2 (testosterone-repressed prostate message-2) gene  
XX  
XX Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 316 AATCAGACACAAAGCTGAAG 336  
DB 21 AATCAGACACAAAGCTGAAG 1  
RESULT 56  
ADF75347  
ID ADF75347 standard; DNA; 21 BP.  
XX  
XX ADF75347;  
XX  
XX 26-FEB-2004 (first entry)  
XX  
XX Human RT-PCR primer to amplify an epigenetically silenced gene (SeqID27).  
XX  
XX human; primer; RT-PCR; PCR; ss; epigenetically silenced gene;  
KW tumour suppressor; cancer; proliferative disorder; head and neck cancer;  
KW oesophageal squamous cell carcinoma; ESCC; gene therapy;  
KW methyltransferase inhibitor; 5Aza-dC; histone deacetylase inhibitor.  
XX  
XX Homo sapiens.  
XX  
XX WO2003076594-A2.  
PN  
XX  
XX 18-SEP-2003.  
PD  
XX  
XX 07-MAR-2003; 2003WO-US007245.  
PF  
XX  
XX 07-MAR-2002; 2002US-0362577P.  
PR  
XX  
XX (UYJO ) UNIV JOHNS HOPKINS.  
PA  
XX  
XX Sidransky D;  
PI  
XX  
XX WPI; 2003-756817/71.  
DR  
XX Identifying at least one epigenetically silenced gene associated with  
CC cancer useful for treating cancer comprises contacting an array of genome  
PT with nucleic acid molecule that reactivates expression of epigenetically  
PT silenced gene.  
XX  
XX Example 1; SEQ ID NO 27; 97pp; English.  
PS  
XX This invention relates to novel methods of screening to identify  
CC epigenetically silenced genes. Specifically, it refers to the detection  
CC of epigenetically silenced tumour suppressor genes in cancer cells, which  
CC are transcriptionally inactive due to aberrant methylation at normally

CC unmethylated CpG islands. Accordingly, these genes provide diagnostic  
 CC markers for immortalised and transformed cells and hence can be used to  
 CC diagnose various proliferative disorders, particularly oesophageal cancer  
 CC and head and neck cancer. The present invention describes a genomic  
 CC screening method to identify silenced genes in a cell suspected of a  
 CC predisposition to, or exhibiting, unregulated growth. Accordingly,  
 CC oligonucleotides of the genes identified herein are useful for detecting  
 CC oesophageal squamous cell carcinoma (ESCC) or neck squamous cell  
 CC carcinoma. Furthermore, treatment can occur via gene therapy, using a  
 CC demethylation agent such as a methyltransferase inhibitor (5aza-dC) or a  
 CC histone deacetylase inhibitor to restore expression of at least one  
 CC methylation silenced gene in cancer cells. This oligonucleotide sequence  
 CC is an RT-PCR primer used to amplify those genes that were up-regulated as  
 CC a result of treatment with a demethylation agent i.e epigenetically  
 CC silenced genes of the invention.

XX  
 SQ Sequence 21 BP; 6 A; 10 C; 3 G; 2 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 39;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 994 ACAACCCCTCCAGGCTAAGC 1014  
 DB 1 ACAACCCCTCCAGGCTAAGC 21

RESULT 57  
 ADM75348/c  
 ID ADF75348 standard; DNA; 21 BP.  
 XX  
 AC ADF75348;  
 XX  
 DT 26-FEB-2004 (first entry)  
 XX  
 DE Human RT-PCR primer to amplify an epigenetically silenced gene (SeqID28).  
 XX  
 KW human; primer; RT-PCR; PCR; ss; epigenetically silenced gene;  
 KW tumour suppressor; cancer; proliferative disorder; head and neck cancer;  
 KW oesophageal squamous cell carcinoma; ESCC; gene therapy;  
 KW methyltransferase inhibitor; 5aza-dC; histone deacetylase inhibitor.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO2003076594-A2.  
 XX  
 PD 18-SEP-2003.  
 XX  
 PF 07-MAR-2003; 2003WO-US007245.  
 XX  
 PR 07-MAR-2002; 2002US-0362577P.  
 XX  
 PA (UYJO ) UNIV JOHNS HOPKINS.  
 XX  
 PI Sidransky D;  
 XX  
 DR WPI; 2003-756817/71.  
 XX  
 PT Identifying at least one epigenetically silenced gene associated with  
 PT cancer useful for treating cancer comprises contacting an array of genome  
 PT with nucleic acid molecule that reactivates expression of epigenetically  
 PT silenced gene.

PS Example 1; SEQ ID NO 28; 97pp; English.  
 XX  
 CC This invention relates to novel methods of screening to identify  
 CC epigenetically silenced genes. Specifically, it refers to the detection  
 CC of epigenetically silenced tumour suppressor genes in cancer cells, which  
 CC are transcriptionally inactive due to aberrant methylation at normally  
 CC unmethylated CpG islands. Accordingly, these genes provide diagnostic  
 CC markers for immortalised and transformed cells and hence can be used to  
 CC diagnose various proliferative disorders, particularly oesophageal cancer  
 CC and head and neck cancer. The present invention describes a genomic

CC screening method to identify silenced genes in a cell suspected of a  
 CC predisposition to, or exhibiting, unregulated growth. Accordingly,  
 CC oligonucleotides of the genes identified herein are useful for detecting  
 CC oesophageal squamous cell carcinoma (ESCC) or neck squamous cell  
 CC carcinoma. Furthermore, treatment can occur via gene therapy, using a  
 CC demethylation agent such as a methyltransferase inhibitor (5aza-dC) or a  
 CC histone deacetylase inhibitor to restore expression of at least one  
 CC methylation silenced gene in cancer cells. This oligonucleotide sequence  
 CC is an RT-PCR primer used to amplify those genes that were up-regulated as  
 CC a result of treatment with a demethylation agent i.e epigenetically  
 CC silenced genes of the invention.

XX  
 SQ Sequence 21 BP; 5 A; 8 C; 3 G; 5 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;  
 Best Local Similarity 100.0%; Pred. No. 39;  
 Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1334 ATTTATGGAGACCGTGGCGGA 1354  
 DB 21 ATTTATGGAGACCGTGGCGGA 1

RESULT 58  
 ADM83075/c  
 ID ADM83075 standard; DNA; 21 BP.  
 XX  
 AC ADM83075;  
 XX  
 DT 03-JUN-2004 (first entry)  
 XX  
 DE Human TRPM-2 antisense oligonucleotide #10.  
 XX  
 KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
 KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
 KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
 KW antisense; ss.  
 XX  
 OS Homo sapiens.  
 OS Synthetic.  
 XX  
 FH Key Location/Qualifiers  
 FT modified\_base 1..21  
 FT /\*tag= a  
 FT /mod\_base= OTHER  
 FT /note= "Phosphorothioate backbone"  
 XX  
 PN US2003158130-A1.  
 XX  
 PD 21-AUG-2003.  
 XX  
 PF 28-SEP-2001; 2001US-00967726.  
 XX  
 PR 25-FEB-2000; 2000WO-US004875.  
 PR 28-SEP-2000; 2000US-0236301P.  
 PR 10-AUG-2001; 2001US-00913325.  
 XX  
 PA (GLEA/) GLEAVE M.  
 PA (RENN/) RENNIE P S.  
 PA (MIYA/) MIYAKE H.  
 PA (NELS/) NELSON C.  
 PA (ZELL/) ZELLWEGER T.  
 XX  
 PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
 XX  
 DR WPI; 2003-778017/73.

XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
 XX PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
 XX PT comprises administering a composition that inhibits expression of TRPM-2.  
 XX  
 XX PS Disclosure; SEQ ID NO 10; 14pp; English.

CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
CC  
XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
Db 21 CTCCTTGCTGGAGCAGCTGAA 1  
RESULT 59  
ADM83077/c  
ID ADM83077 standard; DNA; 21 BP.  
XX  
AC ADM83077;  
XX  
DT 03-JUN-2004 (first entry)  
DE Human TRPM-2 antisense oligonucleotide #12.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Claim 6; SEQ ID NO 12; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM-2)  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
CC  
XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
Db 21 CTCCTTGCTGGAGCAGCTGAA 1  
RESULT 59  
ADM83077/c  
ID ADM83077 standard; DNA; 21 BP.  
XX  
AC ADM83077;  
XX  
DT 03-JUN-2004 (first entry)  
DE Human TRPM-2 antisense oligonucleotide #12.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Claim 6; SEQ ID NO 12; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM-2)  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
CC  
XX Sequence 21 BP; 5 A; 6 C; 6 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
Db 21 CTCCTTGCTGGAGCAGCTGAA 1  
RESULT 60  
ADM83072/c  
ID ADM83072 standard; DNA; 21 BP.  
XX  
AC ADM83072;  
XX  
DT 03-JUN-2004 (first entry)  
DE Human TRPM-2 antisense oligonucleotide #7.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 7; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM-2)  
CC -2) antisense oligodeoxyribonucleotide (ODN).

CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
CC  
XX Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 1516 AGGCCCCCAACTCGCCGAGC 1536  
Db 21 AGGCCCCCAACTCGCCGAGC 1  
RESULT 60  
ADM83072/c  
ID ADM83072 standard; DNA; 21 BP.  
XX  
AC ADM83072;  
XX  
DT 03-JUN-2004 (first entry)  
DE Human TRPM-2 antisense oligonucleotide #7.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX  
DR WPI; 2003-778017/73.  
XX  
PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 7; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM-2)  
CC -2) antisense oligodeoxyribonucleotide (ODN).

CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CX -2) antisense oligodeoxyribonucleotide (ODN).  
SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 515 TGACCGCATCGACTCCCTGCT 535  
DB 21 TGACCGCATCGACTCCCTGCT 1  
RESULT 61  
ADM83074/C  
ID ADM83074 standard; DNA; 21 BP.  
XX  
AC  
XX  
AC  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #9.  
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
XX 28-SEP-2001; 2001US-00967726.  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
XX (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX WPI; 2003-778017/73.  
XX  
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 9; 14pp; English.  
XX  
XX The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CX -2) antisense oligodeoxyribonucleotide (ODN).

SQ Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 916 ACAACTCCACGGCTGCTGTC 936  
DB 21 ACAACTCCACGGCTGCTGTC 1  
RESULT 62  
ADM83076/C  
ID ADM83076 standard; DNA; 21 BP.  
XX  
AC  
XX  
AC  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #11.  
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
XX 28-SEP-2001; 2001US-00967726.  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
XX (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX WPI; 2003-778017/73.  
XX  
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 11; 14pp; English.  
XX  
XX The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CX -2) antisense oligodeoxyribonucleotide (ODN).

Query Match 1.3%; Score 21; DB 1; Length 21;

Best Local Similarity 100.0%; Pred. No. 39;		0; Indels 0; Gaps 0;	
Matches 21; Conservative 0; Mismatches			
Qy	1316 CTCCAGGAAGAACCTTAATT 1336		
Db	21 CTCCAGGAAGAACCTTAATT 1		
RESULT 63			
ADM83068/c			
ID	ADM83068 standard; DNA; 21 BP.		
XX			
AC	ADM83068;		
DT	03-JUN-2004 (first entry)		
DE	Human TRPM-2 antisense oligonucleotide #3.		
XX			
KW	Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;		
KW	radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;		
KW	lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;		
KW	antisense; ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
FH	Key Location/Qualifiers		
FT	modified_base 1..21		
FT	/*tag= a		
FT	/mod_base= OTHER		
FT	/note= "Phosphorothioate backbone"		
XX			
PN	US2003158130-A1.		
XX			
PD	21-AUG-2003.		
XX			
PF	28-SEP-2001; 2001US-00967726.		
XX			
PR	25-FEB-2000; 2000WO-US004875.		
PR	28-SEP-2000; 2000US-0236301P.		
PR	10-AUG-2001; 2001US-00913325.		
XX			
PA	(GLEA/) GLEAVE M.		
PA	(RENN/) RENNIE P S.		
PA	(MIYA/) MIYAKE H.		
PA	(NELS/) NELSON C.		
PA	(ZELL/) ZELLWEGER T.		
XX			
PI	Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;		
XX			
XX	WPI; 2003-778017/73.		
DR			
XX	Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells		
PT	that expresses testosterone-repressed prostate message-2 (TRPM-2)		
PT	comprises administering a composition that inhibits expression of TRPM-2.		
XX			
PS	Disclosure; SEQ ID NO 3; 14pp; English.		
XX			
CC	The present invention provides a method for treating cancer in which		
CC	cancer cells express testosterone-repressed prostate message-2 (TRPM-2).		
CC	The invention is useful for enhancing the chemo-sensitivity or radiation-		
CC	sensitivity of cancer cells for treating cancer such as prostate cancer,		
CC	bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma		
CC	(RCC). The invention is also useful in antisense gene therapy. The		
CC	present sequence is human testosterone-repressed prostate message-2 (TRPM		
CC	-2) antisense oligodeoxyribonucleotide (ODN).		
XX			
SQ	Sequence 21 BP; 2 A; 6 C; 7 G; 6 T; 0 U; 0 Other;		
Query Match 1.3%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 39;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
Qy	48 ATGATGAAGACTCTGCTGCTG 68		
Db	21 ATGATGAAGACTCTGCTGCTG 1		

Best Local Similarity 100.0%; Pred. No. 39;		0; Indels 0; Gaps 0;	
Matches 21; Conservative 0; Mismatches			
Qy	16 CCGAGGCGTCAAAAGACTCCA 36		
Db	21 CCGAGGCGTCAAAAGACTCCA 1		
RESULT 64			
ADM83069/c			
ID	ADM83069 standard; DNA; 21 BP.		
XX			
AC	ADM83069;		
DT	03-JUN-2004 (first entry)		
DE	Human TRPM-2 antisense oligonucleotide #4.		
XX			
KW	Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;		
KW	radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;		
KW	lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;		
KW	antisense; ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
FH	Key Location/Qualifiers		
FT	modified_base 1..21		
FT	/*tag= a		
FT	/mod_base= OTHER		
FT	/note= "Phosphorothioate backbone"		
XX			
PN	US2003158130-A1.		
XX			
PD	21-AUG-2003.		
XX			
PF	28-SEP-2001; 2001US-00967726.		
XX			
PR	25-FEB-2000; 2000WO-US004875.		
PR	28-SEP-2000; 2000US-0236301P.		
PR	10-AUG-2001; 2001US-00913325.		
XX			
PA	(GLEA/) GLEAVE M.		
PA	(RENN/) RENNIE P S.		
PA	(MIYA/) MIYAKE H.		
PA	(NELS/) NELSON C.		
PA	(ZELL/) ZELLWEGER T.		
XX			
PI	Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;		
XX			
XX	WPI; 2003-778017/73.		
DR			
XX	Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells		
PT	that expresses testosterone-repressed prostate message-2 (TRPM-2)		
PT	comprises administering a composition that inhibits expression of TRPM-2.		
XX			
PS	Claim 4; SEQ ID NO 4; 14pp; English.		
XX			
CC	The present invention provides a method for treating cancer in which		
CC	cancer cells express testosterone-repressed prostate message-2 (TRPM-2).		
CC	The invention is useful for enhancing the chemo-sensitivity or radiation-		
CC	sensitivity of cancer cells for treating cancer such as prostate cancer,		
CC	bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma		
CC	(RCC). The invention is also useful in antisense gene therapy. The		
CC	present sequence is human testosterone-repressed prostate message-2 (TRPM		
CC	-2) antisense oligodeoxyribonucleotide (ODN).		
XX			
SQ	Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;		
Query Match 1.3%; Score 21; DB 1; Length 21;			
Best Local Similarity 100.0%; Pred. No. 39;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
Qy	48 ATGATGAAGACTCTGCTGCTG 68		
Db	21 ATGATGAAGACTCTGCTGCTG 1		



ADM83073/c  
ID ADM83073 standard; DNA; 21 BP.  
XX  
AC ADM83073;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #8.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX WPI; 2003-778017/73.  
XX  
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
XX PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Disclosure; SEQ ID NO 8; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
XX  
SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 716 CCGCATCGTCCGAGCTTGAT 736  
DB 21 CCGCATCGTCCGAGCTTGAT 1  
RESULT 67  
ADM83071/c  
ID ADM83071 standard; DNA; 21 BP.  
XX

RESULT 65  
ADM83070/c  
ID ADM83070 standard; DNA; 21 BP.  
XX  
AC ADM83070;  
XX  
DT 03-JUN-2004 (first entry)  
XX  
DE Human TRPM-2 antisense oligonucleotide #5.  
XX  
KW Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KW radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
PN US2003158130-A1.  
XX  
PD 21-AUG-2003.  
XX  
PF 28-SEP-2001; 2001US-00967726.  
XX  
PR 25-FEB-2000; 2000WO-US004875.  
PR 28-SEP-2000; 2000US-0236301P.  
PR 10-AUG-2001; 2001US-00913325.  
XX  
PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
PI Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
XX WPI; 2003-778017/73.  
XX  
DR Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
XX PT comprises administering a composition that inhibits expression of TRPM-2.  
XX  
PS Claim 5; SEQ ID NO 5; 14pp; English.  
XX  
CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
XX  
SQ Sequence 21 BP; 3 A; 5 C; 6 G; 7 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 114 GACCAGACGGTCTCAGACAAT 134  
DB 21 GACCAGACGGTCTCAGACAAT 1  
RESULT 66

AC ADH83071;  
XX 03-JUN-2004 (first entry)  
XX Human TRPM-2 antisense oligonucleotide #6.  
DE  
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
XX radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KW lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
KW antisense; ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX  
XX US2003158130-A1.  
XX  
XX 21-AUG-2003.  
PD  
XX 28-SEP-2001; 2001US-00967726.  
XX  
XX 25-FEB-2000; 2000WO-US004875.  
PR  
XX 28-SEP-2000; 2000US-0236301P.  
PR  
XX 10-AUG-2001; 2001US-00913325.  
PR  
XX (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
PA (ZELL/) ZELLWEGER T.  
XX  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
PI  
XX WPI; 2003-778017/73.  
DR  
XX Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
XX that expresses testosterone-repressed prostate message-2 (TRPM-2)  
XX comprises administering a composition that inhibits expression of TRPM-2.  
XX  
XX Disclosure; SEQ ID NO 6; 14pp; English.  
PS  
XX The present invention provides a method for treating cancer in which  
XX cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
XX The invention is useful for enhancing the chemo-sensitivity or radiation-  
XX sensitivity of cancer cells for treating cancer such as prostate cancer,  
XX bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
XX (RCC). The invention is also useful in antisense gene therapy. The  
XX present sequence is human testosterone-repressed prostate message-2 (TRPM  
XX -2) antisense oligodeoxynucleotide (ODN).  
XX  
XX Sequence 21 BP; 2 A; 6 C; 3 G; 10 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 316 AATCAGACAAAGCTGAAGG 336  
DB 21 AATCAGACAAAGCTGAAGG 1  
RESULT 68  
ADL70456  
ID ADL70456 standard; RNA; 21 BP.  
XX  
XX ADL70456;  
AC  
XX 20-MAY-2004 (first entry)  
DT

XX RNAi for human clusterin.  
DE  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dTdT"  
XX  
XX WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
PD  
XX 21-AUG-2003; 2003WO-CA001277.  
PF  
XX 21-AUG-2002; 2002US-0405193P.  
PR  
XX 03-SEP-2002; 2002US-0408152P.  
PR  
XX 20-MAY-2003; 2003US-0472387P.  
PR  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
XX Gonos ES;  
PI  
XX WPI; 2004-226852/21.  
DR  
XX New RNA molecule less than 49 bases and having a sequence effective to  
XX mediate degradation or block translation of mRNA that is the  
XX transcriptional product of a target gene, useful for treating Alzheimer's  
XX disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 1; 63pp; English.  
PS  
XX The present sequence is the sense strand of a short interfering RNA  
XX (siRNA) targeted to nucleotides 487-505 of human clusterin cDNA. The  
XX antisense strand is also provided ADL70457. The siRNA can be used to  
XX interfere with the expression of clusterin. Clusterin, also known as  
XX testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
XX tumour cells following androgen withdrawal, and has also been shown to be  
XX critical for neuritic toxicity in mouse models of Alzheimer's disease.  
XX siRNAs of the invention can be used alone or in combination with other  
XX chemotherapies or apoptosis inducing treatments for the treatment of  
XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
XX anaplastic large cell lymphoma and melanoma, and also for the treatment  
XX of Alzheimer's disease.  
XX  
XX Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 81.0%; Pred. No. 39;  
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 482 CCAGAGCTCGCCCTTCTACTT 502  
DB 1 CCAGAGCTCGCCCTTCTACTT 21  
RESULT 69  
ADL70460  
ID ADL70460 standard; RNA; 21 BP.  
XX  
XX ADL70460;  
AC  
XX 20-MAY-2004 (first entry)  
DT

XX RNAi for human clusterin.  
XX  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontoxic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
OS  
XX  
XX Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
XX  
XX WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX  
XX WPI; 2004-226852/21.  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 58; 63pp; English.  
XX  
XX The present sequence is the sense strand of a short interfering RNA  
CC (siRNA) targeted to a specific portion ADL70512 of human clusterin cDNA.  
CC The antisense strand is also provided ADL70514. The siRNA can be used to  
CC interfere with the expression of clusterin. Clusterin, also known as  
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapies or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease. In an example from the invention, the present  
CC siRNA was used to examine the effects of clusterin gene silencing in PC-3  
CC prostate cancer cells. A reduction in clusterin transcript was observed.  
XX  
XX Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 81.0%; Pred. No. 39;  
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 482 CCAGAGCTCGCCCTTCTACTT 502  
DB 1 CCAGAGCTCGCCCTTCTACTT 21  
RESULT 71  
ADL70458  
ID ADL70458 standard; RNA; 21 BP.  
XX  
XX ADL70458;

XX RNAi for human clusterin.  
XX  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontoxic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
OS  
XX  
XX Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
XX  
XX WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX  
XX WPI; 2004-226852/21.  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 5; 63pp; English.  
XX  
XX The present sequence is the sense strand of a short interfering RNA  
CC (siRNA) targeted to nucleotides 1620-1638 of human clusterin cDNA. The  
CC antisense strand is also provided ADL70461. The siRNA can be used to  
CC interfere with the expression of clusterin. Clusterin, also known as  
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated  
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate  
CC tumour cells following androgen withdrawal, and has also been shown to be  
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.  
CC siRNAs of the invention can be used alone or in combination with other  
CC chemotherapies or apoptosis inducing treatments for the treatment of  
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,  
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,  
CC anaplastic large cell lymphoma and melanoma, and also for the treatment  
CC of Alzheimer's disease.  
XX  
XX Sequence 21 BP; 8 A; 4 C; 1 G; 2 T; 6 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 71.4%; Pred. No. 39;  
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;  
QY 1615 CTAATTCATATAAACTGCTCT 1635  
DB 1 CUAUUCUCAAUAAAACUGUCTT 21  
RESULT 70  
ADL70513  
ID ADL70513 standard; RNA; 21 BP.  
XX  
XX ADL70513;  
XX  
XX 20-MAY-2004 (first entry)  
DT

```
XX 20-MAY-2004 (first entry)
DT RNAi for human clusterin.
DE
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosolic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX Homo sapiens.
OS Synthetic.
OS
XX Key Location/Qualifiers
FH modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dTdT"
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Claim 4; SEQ ID NO 3; 63pp; English.
XX
XX The present sequence is the sense strand of a short interfering RNA
CC (siRNA) targeted to nucleotides 1105-1123 of human clusterin cDNA. The
CC antisense strand is also provided ADL70459. The siRNA can be used to
CC interfere with the expression of clusterin. Clusterin, also known as
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapy or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease.
XX
XX Sequence 21 BP; 4 A; 9 C; 2 G; 2 T; 4 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 1100 GATGCTCAACACCTCCTCTT 1120
||:|||||:||||:|||||
Db 1 GAUGUCUACACCCUCCCTT 21
RESULT 72
ADL70520/c
ID ADL70520 standard; RNA; 21 BP.
XX
AC ADL70520;
```

```
XX 20-MAY-2004 (first entry)
DT RNAi for human clusterin.
DE
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosolic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
KW ss.
XX Homo sapiens.
OS Synthetic.
OS
XX Key Location/Qualifiers
FH modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= dTdT"
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;
XX
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.
XX
XX Claim 4; SEQ ID NO 65; 63pp; English.
XX
XX The present sequence is the antisense strand of a short interfering RNA
CC (siRNA) targeted to a specific portion ADL70518 of human clusterin cDNA.
CC The sense strand is also provided ADL70519. The siRNA can be used to
CC interfere with the expression of clusterin. Clusterin, also known as
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC tumour cells following androgen withdrawal, and has also been shown to be
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC siRNAs of the invention can be used alone or in combination with other
CC chemotherapy or apoptosis inducing treatments for the treatment of
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC of Alzheimer's disease. In an example from the invention, the present
CC siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC prostate cancer cells. A reduction in clusterin transcript was observed.
XX
XX Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1613 AACATAATTCAATAAACTGTC 1633
|||||:|||||:|||||
Db 21 AACATAATTCAATAAACTGTC 1
RESULT 73
ADL70461/c
ID ADL70461 standard; RNA; 21 BP.
```

RESULT 75

## RESULT 74

ADL70519  
ID ADL70519 standard; RNA; 21 BP.

ADL70517/C	RESULT 76
ID ADL70517 standard; RNA; 21 BP.	ADL70516
XX AC ADL70517;	XX ADL70516;
XX DT 20-MAY-2004 (first entry)	XX 20-MAY-2004 (first entry)
XX DE RNAi for human clusterin.	XX RNAi for human clusterin.
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;	XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;	KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW ss.	KW ss.
XX Homo sapiens.	XX Homo sapiens.
OS Synthetic.	OS Synthetic.
XX Key	XX Key
FT modified_base	FT modified_base
FT 20..21	FT 20..21
FT /*tag= a	FT /*tag= a
FT /mod_base= OTHER	FT /mod_base= OTHER
FT /note= "OTHER= dTdT"	FT /note= "OTHER= dTdT"
XX WO2004018676-A2.	XX WO2004018676-A2.
PN 04-MAR-2004.	PN 04-MAR-2004.
XX 21-AUG-2003; 2003WO-CA001277.	XX 21-AUG-2003; 2003WO-CA001277.
XX 21-AUG-2002; 2002US-0405193P.	XX 21-AUG-2002; 2002US-0405193P.
PR 03-SEP-2002; 2002US-0408152P.	PR 03-SEP-2002; 2002US-0408152P.
PR 20-MAY-2003; 2003US-0472387P.	PR 20-MAY-2003; 2003US-0472387P.
XX (UYBR-) UNIV BRITISH COLUMBIA.	XX (UYBR-) UNIV BRITISH COLUMBIA.
PA Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;	PA Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI Gonos ES;	PI Gonos ES;
XX WPI; 2004-226852/21.	XX WPI; 2004-226852/21.
XX New RNA molecule less than 49 bases and having a sequence effective to	XX New RNA molecule less than 49 bases and having a sequence effective to
PT mediate degradation or block translation of mRNA that is the	PT mediate degradation or block translation of mRNA that is the
PT transcriptional product of a target gene, useful for treating Alzheimer's	PT transcriptional product of a target gene, useful for treating Alzheimer's
PT disease or cancer.	PT disease or cancer.
XX Claim 4; SEQ ID NO 62; 63pp; English.	XX Claim 4; SEQ ID NO 61; 63pp; English.
XX The present sequence is the antisense strand of a short interfering RNA	XX The present sequence is the sense strand of a short interfering RNA
CC (siRNA) targeted to a specific portion ADL70516 of human clusterin cDNA.	CC (siRNA) targeted to a specific portion ADL70515 of human clusterin cDNA.
CC The sense strand is also provided ADL70516. The siRNA can be used to	CC The antisense strand is also provided ADL70517. The siRNA can be used to
CC interfere with the expression of clusterin. Clusterin, also known as	CC interfere with the expression of clusterin. Clusterin, also known as
CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated	CC interfere with the expression of clusterin. Clusterin, also known as
CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate	CC testosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC tumour cells following androgen withdrawal, and has also been shown to be	CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC critical for neuritic toxicity in mouse models of Alzheimer's disease.	CC glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC siRNAs of the invention can be used alone or in combination with other	CC critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC chemotherapeutic agents for the treatment of	CC siRNAs of the invention can be used alone or in combination with other
CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,	CC chemotherapeutic agents for the treatment of
CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,	CC prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
CC anaplastic large cell lymphoma and melanoma, and also for the treatment	CC breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
CC of Alzheimer's disease. In an example from the invention, the present	CC anaplastic large cell lymphoma and melanoma, and also for the treatment
CC siRNA was used to examine the effects of clusterin gene silencing in PC-3	CC of Alzheimer's disease. In an example from the invention, the present
CC prostate cancer cells. A reduction in clusterin transcript was observed.	CC siRNA was used to examine the effects of clusterin gene silencing in PC-3
XX Sequence 21 BP; 3 A; 5 C; 9 G; 2 T; 2 U; 0 Other;	XX Sequence 21 BP; 2 A; 9 C; 5 G; 2 T; 3 U; 0 Other;
Query Match	Query Match
Best Local Similarity 100.0%; Pred.No. 39;	Best Local Similarity 1.3%; Score 21; DB 1; Length 21;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
QY 711 AAGTCCCGCATCGTCCGAGC 731	QY 713 GTCCCGCATCGTCCGAGCTT 733
DB 21 AAGTCCCGCATCGTCCGAGC 1	

Db	1	GUCCCGCAUCGUCGAGCTT	21
RESULT 77			
ADL70457/C			
ID	ADL70457	standard; RNA; 21 BP.	
XX			
AC	ADL70457;		
XX			
DT	20-MAY-2004	(first entry)	
XX			
DE	RNAi for human clusterin.		
XX			
KW	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;		
KW	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;		
KW	ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
FT	Key	Location/Qualifiers	
FT	modified_base	20..21	
FT		/*tag= a	
FT		/mod_base= OTHER	
FT		/note= "OTHER= dtdt"	
XX			
PN	WO2004018676-A2.		
XX			
PD	04-MAR-2004.		
XX			
PF	21-AUG-2003; 2003WO-CA001277.		
XX			
PR	21-AUG-2002; 2002US-0405193P.		
PR	03-SEP-2002; 2002US-0408152P.		
PR	20-MAY-2003; 2003US-0472387P.		
XX			
PA	(UYBR-) UNIV BRITISH COLUMBIA.		
XX			
PI	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;		
PI	Gonos ES;		
XX			
DR	WPI; 2004-226852/21.		
XX			
PT	New RNA molecule less than 49 bases and having a sequence effective to		
PT	mediate degradation or block translation of mRNA that is the		
PT	transcriptional product of a target gene, useful for treating Alzheimer's		
PT	disease or cancer.		
XX			
PS	Claim 4; SEQ ID NO 2; 63pp; English.		
XX			
CC	The present sequence is the antisense strand of a short interfering RNA		
CC	(siRNA) targeted to nucleotides 487-505 of human clusterin cDNA. The		
CC	sense strand is also provided ADL70456. The siRNA can be used to		
CC	interfere with the expression of clusterin. Clusterin, also known as		
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated		
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate		
CC	tumour cells following androgen withdrawal, and has also been shown to be		
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.		
CC	siRNAs of the invention can be used alone or in combination with other		
CC	chemotherapy or apoptosis inducing treatments for the treatment of		
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,		
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,		
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment		
CC	of Alzheimer's disease.		
XX			
SQ	Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;		
Query Match	1.3%;	Score 21; DB 1; Length 21;	
Best Local Similarity	100.0%;	Pred. No. 39;	
Matches	21; Conservative	0; Mismatches	0; Indels
			0; Gaps
			0;
Qy	480	AACCAGAGCTCGCCCTTCTAC	500

Db	21	AACCAGAGCTCGCCCTTCTAC	1
RESULT 78			
ADL70459/c			
ID	ADL70459	standard; RNA; 21 BP.	
XX			
AC	ADL70459;		
XX			
DT	20-MAY-2004	(first entry)	
XX			
DE	RNAi for human clusterin.		
XX			
KW	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;		
KW	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;		
KW	ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
FT	Key	Location/Qualifiers	
FT	modified_base	20..21	
FT		/*tag= a	
FT		/mod_base= OTHER	
FT		/note= "OTHER= dtdt"	
XX			
PN	WO2004018676-A2.		
XX			
PD	04-MAR-2004.		
XX			
PF	21-AUG-2003; 2003WO-CA001277.		
XX			
PR	21-AUG-2002; 2002US-0405193P.		
PR	03-SEP-2002; 2002US-0408152P.		
PR	20-MAY-2003; 2003US-0472387P.		
XX			
PA	(UYBR-) UNIV BRITISH COLUMBIA.		
XX			
PI	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;		
PI	Gonos ES;		
XX			
DR	WPI; 2004-226852/21.		
XX			
PT	New RNA molecule less than 49 bases and having a sequence effective to		
PT	mediate degradation or block translation of mRNA that is the		
PT	transcriptional product of a target gene, useful for treating Alzheimer's		
PT	disease or cancer.		
XX			
PS	Claim 4; SEQ ID NO 4; 63pp; English.		
XX			
CC	The present sequence is the antisense strand of a short interfering RNA		
CC	(siRNA) targeted to nucleotides 1105-1123 of human clusterin cDNA. The		
CC	sense strand is also provided ADL70458. The siRNA can be used to		
CC	interfere with the expression of clusterin. Clusterin, also known as		
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated		
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate		
CC	tumour cells following androgen withdrawal, and has also been shown to be		
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.		
CC	siRNAs of the invention can be used alone or in combination with other		
CC	chemotherapy or apoptosis inducing treatments for the treatment of		
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,		
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,		
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment		
CC	of Alzheimer's disease.		
XX			
SQ	Sequence 21 BP; 4 A; 2 C; 9 G; 2 T; 4 U; 0 Other;		
Query Match			
Best Local Similarity 1.3%; Score 21; DB 1; Length 21;			
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;			
QY	1098	AAGATGCTCAACACCTCTCC	1118

DB	21	AAGATGCTCAACACCTCTCTCC	1
RESULT 79			
ADL70514/c			
ID	ADL70514	standard; RNA; 21 BP.	
XX			
AC	ADL70514;		
XX			
DT	20-MAY-2004	(first entry)	
XX			
DE	RNAi for human clusterin.		
XX			
KW	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;		
KW	cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;		
KW	ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
FH	Key	Location/Qualifiers	
FT	modified_base	20..21	
FT	/tag=	a	
FT	/mod_base=	OTHER	
FT	/note=	"OTHER= dtdt"	
XX			
PN	WO2004018676-A2.		
XX			
PD	04-MAR-2004.		
XX			
PF	21-AUG-2003; 2003WO-CA001277.		
XX			
PR	21-AUG-2002; 2002US-0405193P.		
PR	03-SEP-2002; 2002US-0408152P.		
PR	20-MAY-2003; 2003US-0472387P.		
XX			
PA	(UYBR-) UNIV BRITISH COLUMBIA.		
XX			
PI	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;		
PI	Gonos ES;		
XX			
DR	WPI; 2004-226852/21.		
XX			
PT	New RNA molecule less than 49 bases and having a sequence effective to		
PT	mediate degradation or block translation of mRNA that is the		
PT	transcriptional product of a target gene, useful for treating Alzheimer's		
PT	disease or cancer.		
XX			
PS	Claim 4; SEQ ID NO 59; 63pp; English.		
XX			
CC	The present sequence is the antisense strand of a short interfering RNA		
CC	(siRNA) targeted to a specific portion ADL70512 of human clusterin cDNA.		
CC	The sense strand is also provided ADL70513. The siRNA can be used to		
CC	interfere with the expression of clusterin. Clusterin, also known as		
CC	testosterone-repressed prostate message-2 (TRPM-2) or sulfated		
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate		
CC	tumour cells following androgen withdrawal, and has also been shown to be		
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.		
CC	siRNAs of the invention can be used alone or in combination with other		
CC	chemotherapy or apoptosis inducing treatments for the treatment of		
CC	prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,		
CC	breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,		
CC	anaplastic large cell lymphoma and melanoma, and also for the treatment		
CC	of Alzheimer's disease. In an example from the invention, the present		
CC	siRNA was used to examine the effects of clusterin gene silencing in PC-3		
CC	prostate cancer cells. A reduction in clusterin transcript was observed.		
XX			
SQ	Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;		
	Query Match	1.3%; Score 21; DB 1; Length 21;	
	Best Local Similarity	100.0%; Pred. No. 39;	
	Matches 21; Conservative	0; Mismatches 0; Indels 0; Gaps 0;	

QY	480	AACCAGAGCTCGCCCTTCTAC	500
DB	21	AACCAGAGCTCGCCCTTCTAC	1
RESULT 80			
ADL70410/c			
ID	ADL70410	standard; DNA; 21 BP.	
XX			
AC	ADL70410;		
XX			
DT	20-MAY-2004	(first entry)	
XX			
DE	Antisense oligonucleotide to human clusterin.		
XX			
KW	Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.		
XX			
OS	Homo sapiens.		
OS	Synthetic.		
XX			
FH	Key	Location/Qualifiers	
FT	modified_base	1..21	
FT	/tag=	b	
FT	/mod_base=	OTHER	
FT	/note=	"OTHER= optional phosphorothioate nucleotides"	
FT	modified_base	1..4	
FT	/tag=	a	
FT	/mod_base=	OTHER	
FT	/note=	"OTHER= optional 2'O-methoxyethyl modifications"	
FT	modified_base	18..21	
FT	/tag=	c	
FT	/mod_base=	OTHER	
FT	/note=	"OTHER= optional 2'O-methoxyethyl modifications"	
XX			
PN	WO2004018675-A1.		
XX			
PD	04-MAR-2004.		
XX			
PF	21-AUG-2003; 2003WO-CA001276.		
XX			
PR	21-AUG-2002; 2002US-0405193P.		
PR	03-SEP-2002; 2002US-0408152P.		
PR	02-DEC-2002; 2002US-0319748P.		
PR	20-MAY-2003; 2003US-0472387P.		
XX			
PA	(UYBR-) UNIV BRITISH COLUMBIA.		
PA	(GLEA/) GLEAVE M E.		
XX			
PI	Jansen B;		
XX			
DR	WPI; 2004-226851/21.		
XX			
PT	Treating melanoma in a mammalian subject comprises administering to the		
PT	subject a therapeutic agent effective to reduce the effective amount of		
PT	clusterin in the melanoma cells.		
XX			
PS	Claim 6; SEQ ID NO 8; 32pp; English.		
XX			
CC	The present sequence is that of an antisense oligonucleotide targeted to		
CC	human clusterin ADL70403. The invention relates to the treatment of		
CC	melanoma through reduction in the effective amount of clusterin. The		
CC	therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421		
CC	or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.		
CC	The antisense oligonucleotides are complementary to a region of the		
CC	clusterin mRNA spanning either the translation initiation site or the		
CC	termination site. They may be modified to increase stability in vivo,		
CC	e.g. they may be employed as phosphorothioate derivatives and may have 2'		
CC	-O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for		
CC	regulating expression of bcl-xL in a subject or cell line comprises		
CC	administering an agent effective to modulate the amount of clusterin		
CC	expression. In clusterin-expressing cells, expression of bcl-xL is down-		
CC	regulated when the effective amount of clusterin is reduced. Such		
CC	inhibition is significant because bcl-xL is known to act as an inhibitor		



```
CC of apoptosis.
XX Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;
SQ Sequence 21 BP; 5 A; 5 C; 8 G; 3 T; 0 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCCGCGAGCTTGAT 736
Db 21 CCGCATCGTCCGCGAGCTTGAT 1

RESULT 81
ADL70440
ID ADL70440 standard; RNA; 21 BP.
XX
AC ADL70440;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
PN WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
XX
PR 03-SEP-2002; 2002US-0408152P.
XX
PR 02-DEC-2002; 2002US-0319748P.
XX
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
DR WPI; 2004-226851/21.
XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 20; SEQ ID NO 38; 32pp; English.
XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 2 A; 9 C; 5 G; 2 T; 3 U; 0 Other;

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCCCGCATCGTCCGCGAGCTT 733
Db 1 GUCCCGCAUCGUCCGCGAGCTT 21

RESULT 82
ADL70422
ID ADL70422 standard; RNA; 21 BP.
XX
AC ADL70422;
XX
DT 20-MAY-2004 (first entry)
XX
DE RNAi for human clusterin.
XX
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
FH Key Location/Qualifiers
FT modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
PN WO2004018675-A1.
XX
PD 04-MAR-2004.
XX
PF 21-AUG-2003; 2003WO-CA001276.
XX
PR 21-AUG-2002; 2002US-0405193P.
XX
PR 03-SEP-2002; 2002US-0408152P.
XX
PR 02-DEC-2002; 2002US-0319748P.
XX
PR 20-MAY-2003; 2003US-0472387P.
XX
PA (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX
PI Jansen B;
XX
DR WPI; 2004-226851/21.
XX
PT Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
PS Claim 10; SEQ ID NO 20; 32pp; English.
XX
CC The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
SQ Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;
```

Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTGCGCCCTTCTACTT 502  
|||||:||||:|||||  
Db 1 CCAGAGCUGCCCUUUACTT 21

RESULT 83  
ADL70413/c  
ID ADL70413 standard; DNA; 21 BP.  
XX AC  
XX ADL70413;  
DT 20-MAY-2004 (first entry)  
XX  
XX Antisense oligonucleotide to human clusterin.  
XX DE  
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
KW  
XX Homo sapiens.  
OS  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
DE modified\_base 1..21  
FT /tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional phosphorothioate nucleotides"  
FT modified\_base 1..4  
FT /tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"  
FT modified\_base 18..21  
FT /tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX PI  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
XX subject a therapeutic agent effective to reduce the effective amount of  
XX clusterin in the melanoma cells.  
XX  
XX Claim 6; SEQ ID NO 11; 32pp; English.  
XX  
XX The present sequence is that of an antisense oligonucleotide targeted to  
XX human clusterin ADL70403. The invention relates to the treatment of  
XX melanoma through reduction in the effective amount of clusterin. The  
XX therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421  
XX or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.  
XX The antisense oligonucleotides are complementary to a region of the  
XX clusterin mRNA spanning either the translation initiation site or the  
XX termination site. They may be modified to increase stability in vivo,  
XX e.g. they may be employed as phosphorothioate derivatives and may have 2'  
XX -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for  
XX regulating expression of bcl-xL in a subject or cell line comprises  
XX administering an agent effective to modulate the amount of clusterin  
XX expression. In clusterin-expressing cells, expression of bcl-xL is down-  
XX

CC regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
XX Sequence 21 BP; 4 A; 3 C; 6 G; 8 T; 0 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1316 CTCCAGGAAGAACCTAAATT 1336  
Db 21 CTCCAGGAAGAACCTAAATT 1

RESULT 84  
ADL70408/c  
ID ADL70408 standard; DNA; 21 BP.  
XX  
XX ADL70408;  
DT 20-MAY-2004 (first entry)  
XX  
XX Antisense oligonucleotide to human clusterin.  
DE  
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
KW  
XX Homo sapiens.  
OS  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
DE modified\_base 1..21  
FT /tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional phosphorothioate nucleotides"  
FT modified\_base 1..4  
FT /tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"  
FT modified\_base 18..21  
FT /tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX PI  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
XX subject a therapeutic agent effective to reduce the effective amount of  
XX clusterin in the melanoma cells.  
XX  
XX Claim 6; SEQ ID NO 6; 32pp; English.  
XX  
XX The present sequence is that of an antisense oligonucleotide targeted to  
XX human clusterin ADL70403. The invention relates to the treatment of  
XX melanoma through reduction in the effective amount of clusterin. The  
XX therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421  
XX or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.  
XX The antisense oligonucleotides are complementary to a region of the  
XX clusterin mRNA spanning either the translation initiation site or the  
XX termination site. They may be modified to increase stability in vivo,  
XX e.g. they may be employed as phosphorothioate derivatives and may have 2'  
XX -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for  
XX regulating expression of bcl-xL in a subject or cell line comprises  
XX administering an agent effective to modulate the amount of clusterin  
XX expression. In clusterin-expressing cells, expression of bcl-xL is down-  
XX



PT clusterin in the melanoma cells.  
PS Claim 10; SEQ ID NO 23; 32pp; English.  
XX  
CC The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
SQ Sequence 21 BP; 4 A; 2 C; 9 G; 2 T; 4 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1098 AGATGCTCAACACCTCTCC 1118  
Db 21 AGATGCTCAACACCTCTCC 1  
RESULT 87  
ADL70442  
ID ADL70442 standard; RNA; 21 BP.  
XX  
AC ADL70442;  
XX  
DT 20-MAY-2004 (first entry)  
DE RNAi for human clusterin.  
DE  
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
FN WO2004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001276.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
PI Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX  
PT Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
PS Claim 20; SEQ ID NO 40; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
SQ Sequence 21 BP; 8 A; 4 C; 1 G; 2 T; 6 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 71.4%; Pred. No. 39;  
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;  
QY 1615 CTAATTCAATAAAACTGCTT 1635  
Db 1 CUAUUCAAUAAACUGUCTT 21  
RESULT 88  
ADL70406/c  
ID ADL70406 standard; DNA; 21 BP.  
XX  
AC ADL70406;  
XX  
DT 20-MAY-2004 (first entry)  
DE Antisense oligonucleotide to human clusterin.  
DE  
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
KW  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= phosphorothioate nucleotides"  
XX  
FT modified\_base 1..4  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'O-methoxyethyl modifications"  
XX  
FT modified\_base 18..21  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'O-methoxyethyl modifications"  
XX  
FN WO2004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001276.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
PI Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX  
PT Treating melanoma in a mammalian subject comprises administering to the

PR 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX Jansen B;  
PI  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT clusterin a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
XX Claim 10; SEQ ID NO 21; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
XX Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 480 AACACAGAGCTCGCCCTTCTAC 500  
DB 21 AACACAGAGCTCGCCCTTCTAC 1  
RESULT 90  
ADL70441/c  
ID ADL70441 standard; RNA; 21 BP.  
XX  
XX AC ADL70441;  
XX  
XX DT 20-MAY-2004 (first entry)  
XX  
XX DE RNAi for human clusterin.  
XX  
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
XX OS Homo sapiens.  
XX OS Synthetic.  
XX  
XX PH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
XX PN WO2004018675-A1.  
XX  
XX PD 04-MAR-2004.  
XX  
XX PF 21-AUG-2003; 2003WO-CA001276.  
XX  
XX PF 21-AUG-2002; 2002US-0405193P.  
XX PF 03-SEP-2002; 2002US-0408152P.  
XX PR 02-DEC-2002; 2002US-0319748P.  
XX PR 20-MAY-2003; 2003US-0472387P.  
XX

PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
XX Claim 7; SEQ ID NO 4; 32pp; English.  
XX  
XX The present sequence is that of an antisense oligonucleotide targeted to  
CC human clusterin ADL70403. The invention relates to the treatment of  
CC melanoma through reduction in the effective amount of clusterin. The  
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421  
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.  
CC The antisense oligonucleotides are complementary to a region of the  
CC clusterin mRNA spanning either the translation initiation site or the  
CC termination site. They may be modified to increase stability in vivo,  
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'  
CC -O-(2-methoxyethyl) (MOE) modifications in the 5' and 3' 'wings'. The  
CC present antisense oligonucleotide is particularly preferred. It is  
CC targeted to the translation initiation codon and next 6 codons of the  
CC human clusterin sequence. It has a phosphorothioate backbone throughout  
CC and MOE wings, the remaining nucleotides being 2'-deoxynucleotides. In an  
CC example from the invention, this antisense oligonucleotide provided a  
CC dose-dependent down-regulation of clusterin in human melanoma cells,  
CC leading to an increase in apoptotic cell death. In one melanoma cell line  
CC (607B) this alone was sufficient to lead to complete cell death. In  
CC another melanoma cell line, the surviving cells showed increased  
CC sensitivity to subsequent treatment with cisplatin. A claimed method for  
CC regulating expression of bcl-xL in a subject or cell line comprises  
CC administering an agent effective to modulate the amount of clusterin  
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-  
CC regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
XX Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 48 ATGATGAAGACTCTGCTGCTG 68  
DB 21 ATGATGAAGACTCTGCTGCTG 1  
RESULT 89  
ADL70423/c  
ID ADL70423 standard; RNA; 21 BP.  
XX  
XX AC ADL70423;  
XX  
XX DT 20-MAY-2004 (first entry)  
XX  
XX DE RNAi for human clusterin.  
XX  
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
XX OS Homo sapiens.  
XX OS Synthetic.  
XX  
XX PH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
XX PN WO2004018675-A1.  
XX  
XX PD 04-MAR-2004.  
XX  
XX PF 21-AUG-2003; 2003WO-CA001276.  
XX PF 21-AUG-2002; 2002US-0405193P.  
XX PR 03-SEP-2002; 2002US-0408152P.  
XX PR

PI Jansen B;  
XX WPI; 2004-226851/21.  
XX Treating melanoma in a mammalian subject comprises administering to the  
XX subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
PT  
XX  
XX Claim 20; SEQ ID NO 41; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
XX of apoptosis.  
XX  
SQ Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1613 AACTAATTCAATAAACTGTC 1633  
DB 21 AACTAATTCAATAAACTGTC 1  
RESULT 92  
ADL70411/c  
ID ADL70411 standard; DNA; 21 BP.  
XX  
XX AC ADL70411;  
XX  
XX DT 20-MAY-2004 (first entry)  
XX  
XX DE Antisense oligonucleotide to human clusterin.  
XX  
XX KW Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
XX  
XX OS Homo sapiens.  
XX  
XX OS Synthetic.  
XX  
XX FH Key Location/Qualifiers  
XX modified\_base 1..21  
XX /tag= b  
XX /mod\_base= OTHER  
XX /note= "OTHER= optional phosphorothioate nucleotides"  
FT  
FT modified\_base 1..4  
FT /tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"  
FT  
FT modified\_base 18..21  
FT /tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"  
XX  
XX WO2004018675-A1.  
XX  
XX PD 04-MAR-2004.  
XX  
XX PD 21-AUG-2003; 2003WO-CA001276.  
XX  
XX PF 21-AUG-2002; 2002US-0405193P.  
XX  
XX PR 03-SEP-2002; 2002US-0408152P.  
XX  
XX PR 02-DEC-2002; 2002US-0319748P.  
XX  
XX PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX PR (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX PA (GLEA/) GLEAVE M E.  
XX

PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
PT  
XX  
XX Claim 20; SEQ ID NO 39; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
XX of apoptosis.  
XX  
SQ Sequence 21 BP; 3 A; 5 C; 9 G; 2 T; 2 U; 0 Other;  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 711 AAGTCCGCATCGTCGCAGC 731  
DB 21 AAGTCCGCATCGTCGCAGC 1  
RESULT 91  
ADL70443/c  
ID ADL70443 standard; RNA; 21 BP.  
XX  
XX AC ADL70443;  
XX  
XX DT 20-MAY-2004 (first entry)  
XX  
XX DE RNAi for human clusterin.  
XX  
XX KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
XX short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
XX KW Homo sapiens.  
XX  
XX OS Synthetic.  
XX  
XX FH Key Location/Qualifiers  
XX modified\_base 20..21  
XX /tag= a  
XX /mod\_base= OTHER  
XX /note= "OTHER= TT"  
FT  
FT  
FT  
XX  
XX WO2004018675-A1.  
XX  
XX PD 04-MAR-2004.  
XX  
XX PD 21-AUG-2003; 2003WO-CA001276.  
XX  
XX PF 21-AUG-2002; 2002US-0405193P.  
XX  
XX PR 03-SEP-2002; 2002US-0408152P.  
XX  
XX PR 02-DEC-2002; 2002US-0319748P.  
XX  
XX PR 20-MAY-2003; 2003US-0472387P.  
XX  
XX PR (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX PA (GLEA/) GLEAVE M E.  
XX

```
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX Jansen B;
PI WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
XX Claim 6; SEQ ID NO 9; 32pp; English.
XX
XX The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
XX Sequence 21 BP; 3 A; 5 C; 9 G; 4 T; 0 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 916 ACAATCCACGGGCTGCTGC 936
DB 21 ACAATCCACGGGCTGCTGC 1
RESULT 93
ADL70439/c
ID ADL70439 standard; RNA; 21 BP.
XX
XX AC ADL70439;
XX
XX 20-MAY-2004 (first entry)
XX RNAi for human clusterin.
XX
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
XX WO2004018675-A1.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX
XX 03-SEP-2002; 2002US-0408152P.
XX
XX 02-DEC-2002; 2002US-0319748P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
```

```
PR 20-MAY-2003; 2003US-0472387P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA (GLEA/) GLEAVE M E.
XX Jansen B;
PI WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX
XX Claim 20; SEQ ID NO 37; 32pp; English.
XX
XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX
XX Sequence 21 BP; 4 A; 3 C; 9 G; 2 T; 3 U; 0 Other;
SQ
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 480 AACGAGCTCGCCCTTCTAC 500
DB 21 AACGAGCTCGCCCTTCTAC 1
RESULT 94
ADL70438
ID ADL70438 standard; RNA; 21 BP.
XX
XX AC ADL70438;
XX
XX 20-MAY-2004 (first entry)
XX RNAi for human clusterin.
XX
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 20..21
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= TT"
XX
XX WO2004018675-A1.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX
XX 03-SEP-2002; 2002US-0408152P.
XX
XX 02-DEC-2002; 2002US-0319748P.
XX
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
PA
```

```
PA (GLEA/) GLEAVE M E.
XX Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX Claim 20; SEQ ID NO 36; 32pp; English.
XX The present sequence is that of a short interfering RNA (siRNA) molecule
CC targeted to human clusterin ADL70403. The invention relates to the
CC treatment of melanoma through reduction in the effective amount of
CC clusterin. The therapeutic agent may be an antisense oligonucleotide
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell
CC line comprises administering an agent effective to modulate the amount of
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL
CC is down-regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX Sequence 21 BP; 3 A; 9 C; 3 G; 2 T; 4 U; 0 Other;
SQ Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 39;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
QY 482 CCAGAGCTCGCCCTTCTACTT 502
DB 1 CCAGAGCUCGCCCUUUAUATT 21
RESULT 95
ID ADL70414/c
XX ADL70414 standard; DNA; 21 BP.
XX AC ADL70414;
XX DT 20-MAY-2004 (first entry)
XX Antisense oligonucleotide to human clusterin.
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"
FT modified_base 18..21
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"
XX WO2004018675-A1.
XX 04-MAR-2004.
XX 21-AUG-2003; 2003WO-CA001276.
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
```

```
PR 02-DEC-2002; 2002US-0319748P.
XX 20-MAY-2003; 2003US-0472387P.
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (GLEA/) GLEAVE M E.
XX Jansen B;
XX WPI; 2004-226851/21.
XX Treating melanoma in a mammalian subject comprises administering to the
PT subject a therapeutic agent effective to reduce the effective amount of
PT clusterin in the melanoma cells.
XX Claim 6; SEQ ID NO 12; 32pp; English.
XX The present sequence is that of an antisense oligonucleotide targeted to
CC human clusterin ADL70403. The invention relates to the treatment of
CC melanoma through reduction in the effective amount of clusterin. The
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
CC The antisense oligonucleotides are complementary to a region of the
CC clusterin mRNA spanning either the translation initiation site or the
CC termination site. They may be modified to increase stability in vivo,
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for
CC regulating expression of bcl-xL in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xL is known to act as an inhibitor
CC of apoptosis.
XX Sequence 21 BP; 1 A; 4 C; 12 G; 4 T; 0 U; 0 Other;
SQ Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 39;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1516 AGGCCCCCAACTCCGCCGAGC 1536
DB 21 AGGCCCCCAACTCCGCCGAGC 1
RESULT 96
ID ADL70409/c
XX ADL70409 standard; DNA; 21 BP.
XX AC ADL70409;
XX DT 20-MAY-2004 (first entry)
XX Antisense oligonucleotide to human clusterin.
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX Homo sapiens.
XX Synthetic.
XX Key Location/Qualifiers
FH modified_base 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= optional phosphorothioate nucleotides"
FT modified_base 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"
FT modified_base 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= optional 2'O-methoxyethyl modifications"
XX
```



PN WO2004018675-A1.  
XX 04-MAR-2004.  
XX 21-AUG-2003; 2003WO-CA001276.  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX Jansen B;  
XX WPI; 2004-226851/21.  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX Claim 6; SEQ ID NO 7; 32pp; English.  
XX The present sequence is that of an antisense oligonucleotide targeted to  
CC human clusterin ADL70403. The invention relates to the treatment of  
CC melanoma through reduction in the effective amount of clusterin. The  
CC therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421  
CC or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.  
CC The antisense oligonucleotides are complementary to a region of the  
CC clusterin mRNA spanning either the translation initiation site or the  
CC termination site. They may be modified to increase stability in vivo,  
CC e.g. they may be employed as phosphorothioate derivatives and may have 2'  
CC -O-(2-methoxyethyl) modifications in the 5' and 3' 'wings'. A method for  
CC regulating expression of bcl-xL in a subject or cell line comprises  
CC administering an agent effective to modulate the amount of clusterin  
CC expression. In clusterin-expressing cells, expression of bcl-xL is down-  
CC regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX SQ Sequence 21 BP; 5 A; 4 C; 9 G; 3 T; 0 U; 0 Other;  
SQ Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 515 TGACCGCATCGACTCCCTGCT 535  
Db 21 TGACCGCATCGACTCCCTGCT 1  
RESULT 97  
ADL70427/c  
ID ADL70427 standard; RNA; 21 BP.  
XX AC ADL70427;  
XX 20-MAY-2004 (first entry)  
XX RNAi for human clusterin.  
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"

XX WO2004018675-A1.  
XX 04-MAR-2004.  
XX 21-AUG-2003; 2003WO-CA001276.  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX Jansen B;  
XX WPI; 2004-226851/21.  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX Claim 10; SEQ ID NO 25; 32pp; English.  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX SQ Sequence 21 BP; 6 A; 1 C; 4 G; 2 T; 8 U; 0 Other;  
SQ Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 39;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1613 AACTAATTCAATAAAACTGTC 1633  
Db 21 AACTAATTCAATAAAACTGTC 1  
RESULT 98  
ADL70405/c  
ID ADL70405 standard; DNA; 21 BP.  
XX AC ADL70405;  
XX 20-MAY-2004 (first entry)  
XX Antisense oligonucleotide to human clusterin.  
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.  
OS Homo sapiens.  
OS Synthetic.  
XX Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional phosphorothioate nucleotides"  
FT modified\_base 1..4  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= optional 2'-O-methoxyethyl modifications"



KW chromosome location; gene marker; polymorphic microsatellite marker;  
KW phenotype; behaviour; pedigree; ss.  
OS Canis familiaris.  
XX  
PN WO200029615-A2.  
XX  
PD 25-MAY-2000.  
XX  
PF 15-NOV-1999; 99WO-IB001907.  
XX  
XX 13-NOV-1998; 98US-0108193P.  
PR  
XX (CNRS ) CNRS CENT NAT RECH SCI.  
PA  
XX Galibert F, Andre C;  
PI  
XX WPI; 2000-387821/33.  
DR  
XX New radiation hybrid map of the dog, Canine familiaris, genome, useful  
PT for e.g. identifying genes implicated in phenotypic and behavioral traits  
PT or in genetic diseases and for studying dog pedigree.  
XX  
PS Claim 1; Page 61; 87pp; English.  
XX  
CC The present invention describes a radiation hybrid map of the dog (Canine  
CC familiaris) genome comprising the genome location of a marker selected  
CC from AA66139 to AA66942. The radiation hybrid map is useful for  
CC identifying and localising dog genes, since it covers approximately 80 %  
CC of the dog genome and provides a dense map integrating different types  
CC (i.e. Type I and Type II) of markers. The map and the dog genome markers  
CC (or complementary sequences) are especially useful to identify genes  
CC responsible for phenotypic and behavioural traits in dogs, to identify  
CC morbid genes, to analyse diseases and identify implicated genes in such  
CC diseases and their alleles, and to study dog pedigrees. They may also be  
CC useful for isolating corresponding human gene sequences e.g. genes  
CC involved in genetic diseases  
XX  
SQ Sequence 24 BP; 5 A; 8 C; 6 G; 5 T; 0 U; 0 Other;  
Query Match 1.3%; Score 20.8; DB 1; Length 24;  
Best Local Similarity 91.7%; Pred. No. 67;  
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1467 CCCCCAGAGAGAGCTCTGCACGTC 1490  
Db 1 CCCCAGAGAGAGAGCTCTGCATGTC 24  
RESULT 102  
ABN99680/C  
ID ABN99680 standard; DNA; 20 BP.  
XX  
AC ABN99680;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 14.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX Homo sapiens.  
OS  
XX WO200222635-A1.  
PN  
XX 21-MAR-2002.  
PD  
XX 10-SEP-2001; 2001WO-US028235.  
PF  
XX 11-SEP-2000; 2000US-00659791.  
PR

DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
XX Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
XX WO2004018675-A1.  
PN  
XX 04-MAR-2004.  
PD  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
PR  
XX 03-SEP-2002; 2002US-0408152P.  
PR  
XX 02-DEC-2002; 2002US-0319748P.  
PR  
XX 20-MAY-2003; 2003US-0472387P.  
PR  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
PA  
XX Jansen B;  
PI  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
XX Claim 10; SEQ ID NO 22; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
XX Sequence 21 BP; 4 A; 9 C; 2 G; 2 T; 4 U; 0 Other;  
SQ  
Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 81.0%; Pred. No. 39;  
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
QY 1100 GATGCTCAACACCTCTCTCTT 1120  
Db 1 GAUGCUCAACACCUCCUCCCT 21  
RESULT 101  
AAA66325  
ID AAA66325 standard; DNA; 24 BP.  
XX  
AC AAA66325;  
XX  
XX 09-OCT-2000 (first entry)  
DT  
XX Dog genomic marker oligonucleotide sequence SEQ ID NO:187.  
DE  
XX Dog; genome; genomic marker; radiation hybrid map; identification;  
KW

XX	PA	(ISIS-) ISIS PHARM INC.	CC	inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
XX	PI	Monia BP, Freier SM;	CC	
XX	DR	WPI; 2002-404805/43.	CC	
XX	PT	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.	CC	
XX	PT		CC	
XX	PS	Claim 3; Page 83; 125pp; English.	XX	Sequence 20 BP; 4 A; 8 C; 4 G; 4 T; 0 U; 0 Other;
XX	XX		Query Match	1.2%; Score 20; DB 1; Length 20;
XX	XX	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings	Best Local Similarity	100.0%; Pred. No. 45;
XX	XX		Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	324	ACAAAGCTGAAGGAGCTCCC 343	QY	364 TGATGGCCCTCTGGGAGAG 383
DB	20	ACAAAGCTGAAGGAGCTCCC 1	DB	20 TGATGGCCCTCTGGGAGAG 1
RESULT 103			RESULT 104	
ABN99682/c			ABN99684/c	
ID	ABN99682	standard; DNA; 20 BP.	ID	ABN99684
XX	AC	ABN99682;	XX	AC
XX	XX		XX	ABN99684;
XX	DT	16-AUG-2002 (first entry)	XX	DT
XX	DE	Human clusterin inhibiting antisense oligonucleotide 16.	XX	DE
XX	XX		XX	XX
XX	XX	Human; antisense inhibition; antisense oligonucleotide; clusterin; hypercholesterolaemia; cardiovascular disorder; ss;	XX	XX
XX	XX	hyperproliferative disorder; hyperlipidemic disorder;	XX	XX
XX	XX	phosphorothioate backbone; 2'-O-methoxyethyl wing.	XX	XX
XX	OS	Homo sapiens.	XX	OS
XX	XX		XX	XX
XX	PN	WO200222635-A1.	XX	PN
XX	AC	ABN99682;	XX	XX
XX	XX		XX	XX
XX	DT	16-AUG-2002 (first entry)	XX	DT
XX	DE	Human clusterin inhibiting antisense oligonucleotide 16.	XX	DE
XX	XX		XX	XX
XX	XX	Human; antisense inhibition; antisense oligonucleotide; clusterin; hypercholesterolaemia; cardiovascular disorder; ss;	XX	XX
XX	XX	hyperproliferative disorder; hyperlipidemic disorder;	XX	XX
XX	XX	phosphorothioate backbone; 2'-O-methoxyethyl wing.	XX	XX
XX	XX		XX	XX
XX	OS	Homo sapiens.	XX	OS
XX	XX		XX	XX
XX	PN	WO200222635-A1.	XX	PN
XX	AC	21-MAR-2002.	XX	XX
XX	PD		XX	XX
XX	PF	10-SEP-2001; 2001WO-US028235.	XX	XX
XX	XX		XX	XX
XX	XX	11-SEP-2000; 2000US-00659791.	XX	XX
XX	XX	(ISIS-) ISIS PHARM INC.	XX	XX
XX	PA	Monia BP, Freier SM;	XX	XX
XX	PI		XX	XX
XX	XX		XX	XX
XX	XX	WPI; 2002-404805/43.	XX	XX
XX	DR	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.	XX	XX
XX	PT		XX	XX
XX	PT		XX	XX
XX	PS	Claim 3; Page 83; 125pp; English.	XX	XX
XX	XX		XX	XX
XX	XX	The invention comprises antisense oligonucleotides that are capable of	XX	XX

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 CTCATGAGTTCACGCAC 426  
Db 20 CTCATGAGTTCACGCAC 1

RESULT 105  
ABN99686/C  
ID ABN99686 standard; DNA; 20 BP.  
XX AC  
XX AC ABN99686;  
DT 16-AUG-2002 (first entry)  
XX DE Human clusterin inhibiting antisense oligonucleotide 20.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX OS Homo sapiens.  
XX WO200222635-A1.  
XX PN 21-MAR-2002.  
XX PD 10-SEP-2001; 2001WO-US028235.  
XX PF 11-SEP-2000; 2000US-00659791.  
XX PR (ISIS-) ISIS PHARM INC.  
XX PA Monia BP, Freier SM;  
XX PI WPI; 2002-404805/43.  
XX DR Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX PS Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 444 TCAGGCTGGTGGCGCCA 463  
Db 20 TCAGGCTGGTGGCGCCA 1

RESULT 106  
ABN99709/C  
ID ABN99709 standard; DNA; 20 BP.  
XX AC  
XX AC ABN99709;  
DT 16-AUG-2002 (first entry)

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX Human clusterin inhibiting antisense oligonucleotide 43.  
DE Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX OS Homo sapiens.  
XX WO200222635-A1.  
XX PN 21-MAR-2002.  
XX PD 10-SEP-2001; 2001WO-US028235.  
XX PF 11-SEP-2000; 2000US-00659791.  
XX PR (ISIS-) ISIS PHARM INC.  
XX PA Monia BP, Freier SM;  
XX PI WPI; 2002-404805/43.  
XX DR Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX PS Claim 3; Page 84; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX SQ Sequence 20 BP; 2 A; 3 C; 9 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 906 GAGATCGCCACAACTCCAC 925  
Db 20 GAGATCGCCACAACTCCAC 1

RESULT 107  
ABN99711/C  
ID ABN99711 standard; DNA; 20 BP.  
XX AC  
XX AC ABN99711;  
DT 16-AUG-2002 (first entry)  
XX DE Human clusterin inhibiting antisense oligonucleotide 45.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX OS Homo sapiens.  
XX WO200222635-A1.  
XX PN 21-MAR-2002.  
XX PD

PS Claim 3; Page 84; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of

CC inhibiting expression of the human clusterin gene. The antisense

CC oligonucleotides of the invention are useful for inhibiting the

CC expression of clusterin in cells. The antisense oligonucleotides are also

CC useful for treating an animal with a disease or condition associated with

CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

CC hyperproliferative disorders; and hyperlipidemic disorders). The present

CC DNA sequence represents a clusterin antisense oligonucleotide of the

CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

CC and also contains 2'-O-methoxyethyl wings

XX

SQ Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1148 CTGGGTGTCCTCCGGCTGGCAA 1167

Db 20 CTGGGTGTCCTCCGGCTGGCAA 1

RESULT 109

ABN99677/C

ID ABN99677 standard; DNA; 20 BP.

XX AC

XX ABN99677;

XX DT

XX 16-AUG-2002 (first entry)

XX Human clusterin inhibiting antisense oligonucleotide 11.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;

KW hypercholesterolaemia; cardiovascular disorder; ss;

KW hyperproliferative disorder; hyperlipidemic disorder;

KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX

OS Homo sapiens.

XX

XX WO200222635-A1.

PN XX

XX 21-MAR-2002.

PD XX

PF 10-SEP-2001; 2001WO-US028235.

XX

PR 11-SEP-2000; 2000US-00659791.

XX

PA (ISIS-) ISIS PHARM INC.

XX

PI Monia BP, Freier SM;

PI

XX WPI; 2002-404805/43.

DR

XX Novel antisense compound targeted to nucleic acid molecule encoding

PT clusterin, useful for treating animal having disease associated with

PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX

PS Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of

CC inhibiting expression of the human clusterin gene. The antisense

CC oligonucleotides of the invention are useful for inhibiting the

CC expression of clusterin in cells. The antisense oligonucleotides are also

CC useful for treating an animal with a disease or condition associated with

CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

CC hyperproliferative disorders; and hyperlipidemic disorders). The present

CC DNA sequence represents a clusterin antisense oligonucleotide of the

CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

CC and also contains 2'-O-methoxyethyl wings

XX

SQ Sequence 20 BP; 3 A; 5 C; 3 G; 9 T; 0 U; 0 Other;

```
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 AGAAGAGGATGCCCTAAAT 305
Db 20 AGAAGAGGATGCCCTAAAT 1

RESULT 110
ABN99681/c
ID ABN99681 standard; DNA; 20 BP.
XX
AC ABN99681;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 15.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
WPI; 2002-404805/43.
XX
Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
Claim 3; Page 83; 125pp; English.
XX
The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 U; 0 Other;

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 359 GACCATGATGCCCTCTGGG 378
Db 20 GACCATGATGCCCTCTGGG 1

RESULT 111
ABN99668/c
ID ABN99668 standard; DNA; 20 BP.
XX
```

```
AC ABN99668;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 2.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
XX
PD 21-MAR-2002.
XX
PF 10-SEP-2001; 2001WO-US028235.
XX
PR 11-SEP-2000; 2000US-00659791.
XX
PA (ISIS-) ISIS PHARM INC.
XX
PI Monia BP, Freier SM;
XX
WPI; 2002-404805/43.
XX
Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
Example 15; Page 83; 125pp; English.
XX
The invention comprises antisense oligonucleotides that are capable of
XX inhibiting expression of the human clusterin gene. The antisense
XX oligonucleotides of the invention are useful for inhibiting the
XX expression of clusterin in cells. The antisense oligonucleotides are also
XX useful for treating an animal with a disease or condition associated with
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX hyperproliferative disorders; and hyperlipidemic disorders). The present
XX DNA sequence represents a clusterin antisense oligonucleotide of the
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX and also contains 2'-O-methoxyethyl wings
XX
Sequence 20 BP; 3 A; 5 C; 5 G; 7 T; 0 U; 0 Other;

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 GCCTGCAAGACTCCAGAT 40
Db 20 GCCTGCAAGACTCCAGAT 1

RESULT 112
ABN99675/c
ID ABN99675 standard; DNA; 20 BP.
XX
AC ABN99675;
XX
DT 16-AUG-2002 (first entry)
XX
DE Human clusterin inhibiting antisense oligonucleotide 9.
XX
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
OS Homo sapiens.
XX
PN WO200222635-A1.
```





CC	and also contains 2'-O-methoxyethyl wings
XX	
SQ	Sequence 20 BP; 3 A; 5 C; 6 G; 6 T; 0 U; 0 Other;
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 45;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	608 AGACGAGCTTTCACGACA 627 
Dd	20 AGACGAGCTTTCACGACA 1 
RESULT 115	
ABN99701/c	
ID	ABN99701 standard; DNA; 20 BP.
XX	
AC	ABN99701;
XX	
DT	16-AUG-2002 (first entry)
DE	Human clusterin inhibiting antisense oligonucleotide 35.
XX	
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW	hypercholesterolaemia; cardiovascular disorder; ss;
KW	hyperproliferative disorder; hyperlipidemic disorder;
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX	
OS	Homo sapiens.
XX	
PV	WO200222635-A1.
PN	
PD	21-MAR-2002.
XX	
PF	10-SEP-2001; 2001WO-US028235.
PP	
PR	11-SEP-2000; 2000US-00659791.
PA	(ISIS-) ISIS PHARM INC.
PI	Monia BP, Freier SM;
PI	
DR	WPI; 2002-404805/43.
XX	
PT	Novel antisense compound targeted to nucleic acid molecule encoding
PT	clusterin, useful for treating animal having disease associated with
PT	clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX	
PS	Claim 3; Page 83; 125pp; English.
XX	
CC	The invention comprises antisense oligonucleotides that are capable of
CC	inhibiting expression of the human clusterin gene. The antisense
CC	oligonucleotides of the invention are useful for inhibiting the
CC	expression of clusterin in cells. The antisense oligonucleotides are also
CC	useful for treating an animal with a disease or condition associated with
CC	clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC	hyperproliferative disorders; and hyperlipidemic disorders). The present
CC	DNA sequence represents a clusterin antisense oligonucleotide of the
CC	invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC	and also contains 2'-O-methoxyethyl wings
XX	
SQ	Sequence 20 BP; 7 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 45;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	775 TGTTCCAGCCTTCCTTGAG 794 
Dd	20 TGTTCCAGCCTTCCTTGAG 1 
RESULT 116	
ABN99704/c	
ID	ABN99704 standard; DNA; 20 BP.
XX	
AC	ABN99704;
XX	
DT	16-AUG-2002 (first entry)
DE	Human clusterin inhibiting antisense oligonucleotide 38.
XX	
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW	hypercholesterolaemia; cardiovascular disorder; ss;
KW	hyperproliferative disorder; hyperlipidemic disorder;
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX	

DR WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 84; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 6 A; 5 C; 7 G; 2 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1113 TCCCTCTTCTGGAGCAGCT 1132  
Db 20 TCCCTCTTCTGGAGCAGCT 1  
RESULT 119  
ABN99726/c  
ID ABN99726 standard; DNA; 20 BP.  
XX  
AC ABN99726;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 60.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 84; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 820 TGGACATCCACTTCCACAGC 839  
Db 20 TGGACATCCACTTCCACAGC 1  
RESULT 118  
ABN99716/c  
ID ABN99716 standard; DNA; 20 BP.  
XX  
AC ABN99716;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 50.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX

OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
XX 21-MAR-2002.  
PD  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 820 TGGACATCCACTTCCACAGC 839  
Db 20 TGGACATCCACTTCCACAGC 1  
RESULT 118  
ABN99716/c  
ID ABN99716 standard; DNA; 20 BP.  
XX  
AC ABN99716;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 50.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX

CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings  
 XX  
 SQ Sequence 20 BP; 6 A; 4 C; 7 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCTCTGGATCCTGCACCTCTA 1564  
 Db 20 GCTCTGGATCCTGCACCTCTA 1

RESULT 120  
 ABN99727/c  
 ID ABN99727 standard; DNA; 20 BP.  
 XX  
 AC ABN99727;  
 XX  
 DT 16-AUG-2002 (first entry)  
 DE Human clusterin inhibiting antisense oligonucleotide 61.  
 XX  
 KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200222635-A1.  
 XX  
 PD 21-MAR-2002.  
 XX  
 PF 10-SEP-2001; 2001WO-US028235.  
 XX  
 PR 11-SEP-2000; 2000US-00659791.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Monia BP, Freier SM;  
 XX  
 WPI; 2002-404805/43.  
 XX  
 DR Novel antisense compound targeted to nucleic acid molecule encoding  
 PT clusterin, useful for treating animal having disease associated with  
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX  
 PS Claim 3; Page 84; 125pp; English.

CC The invention comprises antisense oligonucleotides that are capable of  
 CC inhibiting expression of the human clusterin gene. The antisense  
 CC oligonucleotides of the invention are useful for inhibiting the  
 CC expression of clusterin in cells. The antisense oligonucleotides are also  
 CC useful for treating an animal with a disease or condition associated with  
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings  
 XX  
 SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1600 TGCTCTGCTGCACTAAT 1619  
 Db 20 TGCTCTGCTGCACTAAT 1

RESULT 121  
 ABN99670/c  
 ID ABN99670 standard; DNA; 20 BP.  
 XX  
 AC ABN99670;  
 XX  
 DT 16-AUG-2002 (first entry)  
 DE Human clusterin inhibiting antisense oligonucleotide 4.  
 XX  
 KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200222635-A1.  
 XX  
 PD 21-MAR-2002.  
 XX  
 PF 10-SEP-2001; 2001WO-US028235.  
 XX  
 PR 11-SEP-2000; 2000US-00659791.  
 XX  
 PA (ISIS-) ISIS PHARM INC.  
 XX  
 PI Monia BP, Freier SM;  
 XX  
 WPI; 2002-404805/43.  
 XX  
 DR Novel antisense compound targeted to nucleic acid molecule encoding  
 PT clusterin, useful for treating animal having disease associated with  
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
 XX  
 PS Example 15; Page 83; 125pp; English.

CC The invention comprises antisense oligonucleotides that are capable of  
 CC inhibiting expression of the human clusterin gene. The antisense  
 CC oligonucleotides of the invention are useful for inhibiting the  
 CC expression of clusterin in cells. The antisense oligonucleotides are also  
 CC useful for treating an animal with a disease or condition associated with  
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings  
 XX  
 SQ Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 77 GCTGCTGCTGACCTGGGAGA 96  
 Db 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 122  
 ABN99683/c  
 ID ABN99683 standard; DNA; 20 BP.  
 XX  
 AC ABN99683;  
 XX  
 DT 16-AUG-2002 (first entry)  
 DE Human clusterin inhibiting antisense oligonucleotide 17.  
 XX  
 KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;

KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
XX WO200222635-A1.  
XX 21-MAR-2002.  
XX 10-SEP-2001; 2001WO-US028235.  
XX 11-SEP-2000; 2000US-00659791.  
XX (ISIS-) ISIS PHARM INC.  
PA Monia BP, Freier SM;  
PI WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
XX Query Match 1.2%; Score 20; DB 1; Length 20;  
XX Best Local Similarity 100.0%; Pred. No. 45;  
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 380 AGAGTGTAAAGCCCTGCCTGA 399  
Db 20 AGAGTGTAAAGCCCTGCCTGA 1  
RESULT 123  
ABN99722/c  
ID ABN99722 standard; DNA; 20 BP.  
XX AC ABN99722;  
XX DT 16-AUG-2002 (first entry)  
XX DE Human clusterin inhibiting antisense oligonucleotide 56.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
XX OS WO200222635-A1.  
XX PN 21-MAR-2002.  
XX PD 10-SEP-2001; 2001WO-US028235.  
XX PF 11-SEP-2000; 2000US-00659791.  
XX PR (ISIS-) ISIS PHARM INC.  
XX PA Monia BP, Freier SM;  
XX PI WPI; 2002-404805/43.  
XX DR Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX Example 15; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the

XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX Claim 3; Page 84; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX Sequence 20 BP; 7 A; 2 C; 7 G; 4 T; 0 U; 0 Other;  
XX Query Match 1.2%; Score 20; DB 1; Length 20;  
XX Best Local Similarity 100.0%; Pred. No. 45;  
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1275 TTTCAGTCTGATCCCATCAC 1294  
Db 20 TTTCAGTCTGATCCCATCAC 1  
RESULT 124  
ABN99667/c  
ID ABN99667 standard; DNA; 20 BP.  
XX AC ABN99667;  
XX DT 16-AUG-2002 (first entry)  
XX DE Human clusterin inhibiting antisense oligonucleotide 1.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX Homo sapiens.  
XX OS WO200222635-A1.  
XX PN 21-MAR-2002.  
XX PD 10-SEP-2001; 2001WO-US028235.  
XX PF 11-SEP-2000; 2000US-00659791.  
XX PR (ISIS-) ISIS PHARM INC.  
XX PA Monia BP, Freier SM;  
XX PI WPI; 2002-404805/43.  
XX DR Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX Example 15; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the

CC expression of clusterin in cells. The antisense oligonucleotides are also  
 CC useful for treating an animal with a disease or condition associated with  
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings  
 XX  
 SQ Sequence 20 BP; 2 A; 7 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGGCGTCAAGAC 32  
 Db 20 TGACCGAGGCGTCAAGAC 1  
 |||||

RESULT 125  
 ABN99687/c  
 ID ABN99687 standard; DNA; 20 BP.  
 XX  
 AC ABN99687;

XX 16-AUG-2002 (first entry)  
 DT Human clusterin inhibiting antisense oligonucleotide 21.  
 DE  
 DE Human clusterin inhibiting antisense oligonucleotide 21.

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX Homo sapiens.  
 OS  
 XX WO200222635-A1.  
 PN  
 XX 21-MAR-2002.  
 PD

XX 10-SEP-2001; 2001WO-US028235.  
 PF  
 XX 11-SEP-2000; 2000US-00659791.  
 PR  
 XX (ISIS-) ISIS PHARM INC.  
 PA

XX Monia BP, Freier SM;  
 PI  
 XX WPI; 2002-404805/43.  
 DR

XX Novel antisense compound targeted to nucleic acid molecule encoding  
 PT clusterin, useful for treating animal having disease associated with  
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX Claim 3; Page 83; 125pp; English.  
 PS  
 XX The invention comprises antisense oligonucleotides that are capable of  
 CC inhibiting expression of the human clusterin gene. The antisense  
 CC oligonucleotides of the invention are useful for inhibiting the

CC expression of clusterin in cells. The antisense oligonucleotides are also  
 CC useful for treating an animal with a disease or condition associated with  
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 TGGCCCCCAGCTTGAGGACT 474  
 Db 20 TGGCCCCCAGCTTGAGGACT 1  
 |||||

RESULT 126  
 ABN99712/c  
 ID ABN99712 standard; DNA; 20 BP.  
 XX  
 AC ABN99712;

XX 16-AUG-2002 (first entry)  
 DT Human clusterin inhibiting antisense oligonucleotide 46.  
 DE

XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
 KW hypercholesterolaemia; cardiovascular disorder; ss;  
 KW hyperproliferative disorder; hyperlipidemic disorder;  
 KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX Homo sapiens.  
 OS  
 XX WO200222635-A1.  
 PN  
 XX 21-MAR-2002.  
 PD

XX 10-SEP-2001; 2001WO-US028235.  
 PF  
 XX 11-SEP-2000; 2000US-00659791.  
 PR  
 XX (ISIS-) ISIS PHARM INC.  
 PA

XX Monia BP, Freier SM;  
 PI  
 XX WPI; 2002-404805/43.  
 DR

XX Novel antisense compound targeted to nucleic acid molecule encoding  
 PT clusterin, useful for treating animal having disease associated with  
 PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX Claim 3; Page 84; 125pp; English.  
 PS  
 XX The invention comprises antisense oligonucleotides that are capable of  
 CC inhibiting expression of the human clusterin gene. The antisense  
 CC oligonucleotides of the invention are useful for inhibiting the

CC expression of clusterin in cells. The antisense oligonucleotides are also  
 CC useful for treating an animal with a disease or condition associated with  
 CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
 CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
 CC DNA sequence represents a clusterin antisense oligonucleotide of the  
 CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
 CC and also contains 2'-O-methoxyethyl wings

XX Sequence 20 BP; 3 A; 8 C; 6 G; 3 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.2%; Score 20; DB 1; Length 20;  
 Best Local Similarity 100.0%; Pred. No. 45;  
 Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTAAGCTGCGCGGAGCTC 1028  
 Db 20 CTAAGCTGCGCGGAGCTC 1  
 |||||

RESULT 127  
 ABN99725/c  
 ID ABN99725 standard; DNA; 20 BP.  
 XX  
 AC ABN99725;

XX 16-AUG-2002 (first entry)  
 DT Human clusterin inhibiting antisense oligonucleotide 59.  
 DE



CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CCTAAATGAGACGAGGAA 317  
DB 20 CCTAAATGAGACGAGGAA 1  
|||||

RESULT 130  
ABN99694/C  
ID ABN99694 standard; DNA; 20 BP.  
XX  
AC ABN99694;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 28.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
DR WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 565 TGGATGTCATGCGAGGACCAC 584  
DB 20 TGGATGTCATGCGAGGACCAC 1  
|||||

RESULT 131  
ABN99700/C  
ID ABN99700 standard; DNA; 20 BP.  
XX  
AC ABN99700;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 34.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
DR WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 5 A; 5 C; 8 G; 2 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 721 TCGTCCGACGCTTGATGCC 740  
DB 20 TCGTCCGACGCTTGATGCC 1  
|||||

RESULT 132  
ABN99721/C  
ID ABN99721 standard; DNA; 20 BP.  
XX  
AC ABN99721;  
XX

```

DT 16-AUG-2002 (first entry)
DE Human clusterin inhibiting antisense oligonucleotide 55.
XX
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
OS
XX WO200222635-A1.
PN
XX 21-MAR-2002.
PD
XX
XX 10-SEP-2001; 2001WO-US028235.
PF
XX 11-SEP-2000; 2000US-00659791.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Monia BP, Freier SM;
PI
XX WPI; 2002-404805/43.
DR
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Claim 3; Page 84; 125pp; English.
PS
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 6 A; 2 C; 9 G; 3 T; 0 U; 0 Other;
SQ
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1216 CTTCCACACTTCTGACTCG 1235
Db 20 CTTCCACACTTCTGACTCG 1

RESULT 133
ABN99669/C
ID ABN99669 standard; DNA; 20 BP.
XX
XX AC ABN99669;
XX
XX 16-AUG-2002 (first entry)
DT
XX Human clusterin inhibiting antisense oligonucleotide 3.
DE
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
OS
XX WO200222635-A1.
PN
XX 21-MAR-2002.
PD
```

```

XX 10-SEP-2001; 2001WO-US028235.
PF
XX 11-SEP-2000; 2000US-00659791.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Monia BP, Freier SM;
PI
XX WPI; 2002-404805/43.
DR
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX
XX Example 15; Page 83; 125pp; English.
PS
XX The invention comprises antisense oligonucleotides that are capable of
CC inhibiting expression of the human clusterin gene. The antisense
CC oligonucleotides of the invention are useful for inhibiting the
CC expression of clusterin in cells. The antisense oligonucleotides are also
CC useful for treating an animal with a disease or condition associated with
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
CC hyperproliferative disorders; and hyperlipidemic disorders). The present
CC DNA sequence represents a clusterin antisense oligonucleotide of the
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
CC and also contains 2'-O-methoxyethyl wings
XX
XX Sequence 20 BP; 4 A; 7 C; 2 G; 7 T; 0 U; 0 Other;
SQ
Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 39 ATTGGAGGCATGATGAGAC 58
Db 20 ATTGGAGGCATGATGAGAC 1

RESULT 134
ABN99685/C
ID ABN99685 standard; DNA; 20 BP.
XX
XX AC ABN99685;
XX
XX 16-AUG-2002 (first entry)
DT
XX Human clusterin inhibiting antisense oligonucleotide 19.
DE
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW hypercholesterolaemia; cardiovascular disorder; ss;
KW hyperproliferative disorder; hyperlipidemic disorder;
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX
XX Homo sapiens.
OS
XX WO200222635-A1.
PN
XX 21-MAR-2002.
PD
XX 10-SEP-2001; 2001WO-US028235.
PF
XX 11-SEP-2000; 2000US-00659791.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Monia BP, Freier SM;
PI
XX WPI; 2002-404805/43.
DR
XX Novel antisense compound targeted to nucleic acid molecule encoding
PT clusterin, useful for treating animal having disease associated with
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
PT
```



XX PS Claim 3; Page 83; 125pp; English.

XX CC The invention comprises antisense oligonucleotides that are capable of

XX CC inhibiting expression of the human clusterin gene. The antisense

XX CC oligonucleotides of the invention are useful for inhibiting the

XX CC expression of clusterin in cells. The antisense oligonucleotides are also

XX CC useful for treating an animal with a disease or condition associated with

XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present

XX CC DNA sequence represents a clusterin antisense oligonucleotide of the

XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

XX CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 4 A; 7 C; 8 G; 1 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 443 CTCAGCGCTGGTGGCGCC 462

Db 20 CTCAGCGCTGGTGGCGCC 1

RESULT 135

ABN99689/c

ID ABN99689 standard; DNA; 20 BP.

XX AC ABN99689;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 23.

XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;

XX KW hypercholesterolaemia; cardiovascular disorder; ss;

XX KW hyperproliferative disorder; hyperlipidemic disorder;

XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX PN WO200222635-A1.

XX PD 21-MAR-2002.

XX PF 10-SEP-2001; 2001WO-US028235.

XX PR 11-SEP-2000; 2000US-00659791.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Freier SM;

XX PI WPI; 2002-404805/43.

XX PT Novel antisense compound targeted to nucleic acid molecule encoding

XX PT clusterin, useful for treating animal having disease associated with

XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX PS Claim 3; Page 83; 125pp; English.

XX CC The invention comprises antisense oligonucleotides that are capable of

XX CC inhibiting expression of the human clusterin gene. The antisense

XX CC oligonucleotides of the invention are useful for inhibiting the

XX CC expression of clusterin in cells. The antisense oligonucleotides are also

XX CC useful for treating an animal with a disease or condition associated with

XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present

XX CC DNA sequence represents a clusterin antisense oligonucleotide of the

XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

XX CC and also contains 2'-O-methoxyethyl wings

SQ Sequence 20 BP; 7 A; 3 C; 6 G; 4 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 CCCTTCTACTTCTGGATGAA 511

Db 20 CCCTTCTACTTCTGGATGAA 1

RESULT 136

ABN99703/c

ID ABN99703 standard; DNA; 20 BP.

XX AC ABN99703;

XX DT 16-AUG-2002 (first entry)

XX DE Human clusterin inhibiting antisense oligonucleotide 37.

XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;

XX KW hypercholesterolaemia; cardiovascular disorder; ss;

XX KW hyperproliferative disorder; hyperlipidemic disorder;

XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.

XX OS Homo sapiens.

XX PN WO200222635-A1.

XX PD 21-MAR-2002.

XX PF 10-SEP-2001; 2001WO-US028235.

XX PR 11-SEP-2000; 2000US-00659791.

XX PA (ISIS-) ISIS PHARM INC.

XX PI Monia BP, Freier SM;

XX PI WPI; 2002-404805/43.

XX PT Novel antisense compound targeted to nucleic acid molecule encoding

XX PT clusterin, useful for treating animal having disease associated with

XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.

XX PS Claim 3; Page 83; 125pp; English.

XX CC The invention comprises antisense oligonucleotides that are capable of

XX CC inhibiting expression of the human clusterin gene. The antisense

XX CC oligonucleotides of the invention are useful for inhibiting the

XX CC expression of clusterin in cells. The antisense oligonucleotides are also

XX CC useful for treating an animal with a disease or condition associated with

XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;

XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present

XX CC DNA sequence represents a clusterin antisense oligonucleotide of the

XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone

XX CC and also contains 2'-O-methoxyethyl wings

XX SQ Sequence 20 BP; 6 A; 3 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 45;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 783 CCCTTCTCTGAGATGATACA 802

Db 20 CCCTTCTCTGAGATGATACA 1

RESULT 137

ABN99720/c

ID ABN99720 standard; DNA; 20 BP.

```
XX AC ABN99720;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 54.
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX DR Novel antisense compound targeted to nucleic acid molecule encoding
XX PT clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PS Claim 3; Page 84; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
XX CC inhibiting expression of the human clusterin gene. The antisense
XX CC oligonucleotides of the invention are useful for inhibiting the
XX CC expression of clusterin in cells. The antisense oligonucleotides are also
XX CC useful for treating an animal with a disease or condition associated with
XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present
XX CC DNA sequence represents a clusterin antisense oligonucleotide of the
XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 5 A; 6 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1194 TATCTGCGGGTACCACGGT 1213
Db 20 TATCTGCGGGTACCACGGT 1

RESULT 138
ABN99691/c
ID ABN99691 standard; DNA; 20 BP.
XX AC ABN99691;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 25.
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX
```

```
PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX DR Novel antisense compound targeted to nucleic acid molecule encoding
XX PT clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX PS Claim 3; Page 83; 125pp; English.
XX CC The invention comprises antisense oligonucleotides that are capable of
XX CC inhibiting expression of the human clusterin gene. The antisense
XX CC oligonucleotides of the invention are useful for inhibiting the
XX CC expression of clusterin in cells. The antisense oligonucleotides are also
XX CC useful for treating an animal with a disease or condition associated with
XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present
XX CC DNA sequence represents a clusterin antisense oligonucleotide of the
XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 1 A; 8 C; 6 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 533 GCTGGAGAACGACCGCGCAGC 552
Db 20 GCTGGAGAACGACCGCGCAGC 1

RESULT 139
ABN99713/c
ID ABN99713 standard; DNA; 20 BP.
XX AC ABN99713;
XX DT 16-AUG-2002 (first entry)
XX DE Human clusterin inhibiting antisense oligonucleotide 47.
XX KW Human; antisense inhibition; antisense oligonucleotide; clusterin;
XX KW hypercholesterolaemia; cardiovascular disorder; ss;
XX KW hyperproliferative disorder; hyperlipidemic disorder;
XX KW phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX OS Homo sapiens.
XX PN WO200222635-A1.
XX PD 21-MAR-2002.
XX PF 10-SEP-2001; 2001WO-US028235.
XX PR 11-SEP-2000; 2000US-00659791.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Freier SM;
XX PI WPI; 2002-404805/43.
XX
```

PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX  
PS Claim 3; Page 84; 125pp; English.  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 3 A; 5 C; 8 G; 4 T; 0 U; 0 Other;  
  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1022 GGAGCTCGACGAATCCCTCC 1041  
Db 20 GGAGCTCGACGAATCCCTCC 1  
  
RESULT 140  
ABN99724/C  
ID ABN99724 standard; DNA; 20 BP.  
XX  
AC ABN99724;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 58.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
PI WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX  
PS Claim 3; Page 84; 125pp; English.  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the

CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 5 A; 6 C; 3 G; 6 T; 0 U; 0 Other;  
  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1332 AAATTTATGGAGACCGCTGGC 1351  
Db 20 AAATTTATGGAGACCGCTGGC 1  
  
RESULT 141  
ABN99690/C  
ID ABN99690 standard; DNA; 20 BP.  
XX  
AC ABN99690;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 24.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
PD 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
PI WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 4 A; 4 C; 9 G; 3 T; 0 U; 0 Other;  
  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 517 ACCGCATCGACTCCCTGCTG 536  
Db 20 ACCGCATCGACTCCCTGCTG 1

[illegible]

XX	Homo sapiens.
OS	WO200222635-A1.
XX	21-MAR-2002.
PD	
XX	10-SEP-2001; 2001WO-US028235.
Pf	
XX	11-SEP-2000; 2000US-00659791.
PR	(ISIS-) ISIS PHARM INC.
XX	Monia BP, Freier SM;
PI	WPI; 2002-404805/43.
XX	
DR	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX	
XX	Claim 3; Page 84; 125pp; English.
PS	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
CC	Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
SQ	
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 45;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1121 GCTGGAGCAGCTGACGAGC 1140                                 Db 20 GCTGGAGCAGCTGACGAGC 1
RESULT 144	
ABN99672/c	
ID	ABN99672 standard; DNA; 20 BP.
XX	
AC	ABN99672;
XX	
DT	16-AUG-2002 (first entry)
XX	
DE	Human clusterin inhibiting antisense oligonucleotide 6.
XX	
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW	hypercholesterolemia; cardiovascular disorder; ss;
KW	hyperproliferative disorder; hyperlipidemic disorder;
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX	
OS	Homo sapiens.
XX	
PN	WO200222635-A1.
XX	
PD	21-MAR-2002.
XX	
Pf	10-SEP-2001; 2001WO-US028235.
XX	
PR	11-SEP-2000; 2000US-00659791.
XX	(ISIS-) ISIS PHARM INC.
PA	Monia BP, Freier SM;
XX	WPI; 2002-404805/43.
PI	
XX	
DR	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX	
XX	Claim 3; Page 83; 125pp; English.
PS	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
CC	Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ	
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 45;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	894 ACTGTGTGCCGGAGATCCG 913                                 Db 20 ACTGTGTGCCGGAGATCCG 1
RESULT 143	
ABN99717/c	
ID	ABN99717 standard; DNA; 20 BP.
XX	
AC	ABN99717;
XX	
DT	16-AUG-2002 (first entry)
XX	
DE	Human clusterin inhibiting antisense oligonucleotide 51.
XX	
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW	hypercholesterolemia; cardiovascular disorder; ss;
KW	hyperproliferative disorder; hyperlipidemic disorder;
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX	

XX	Homo sapiens.
OS	WO200222635-A1.
XX	21-MAR-2002.
PD	
XX	10-SEP-2001; 2001WO-US028235.
Pf	
XX	11-SEP-2000; 2000US-00659791.
PR	(ISIS-) ISIS PHARM INC.
XX	Monia BP, Freier SM;
PI	WPI; 2002-404805/43.
XX	
DR	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX	
XX	Claim 3; Page 84; 125pp; English.
PS	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
CC	Sequence 20 BP; 2 A; 8 C; 5 G; 5 T; 0 U; 0 Other;
SQ	
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 45;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	1121 GCTGGAGCAGCTGACGAGC 1140                                     Db 20 GCTGGAGCAGCTGACGAGC 1
RESULT 144	
ABN99672/c	
ID	ABN99672 standard; DNA; 20 BP.
XX	
AC	ABN99672;
XX	
DT	16-AUG-2002 (first entry)
XX	
DE	Human clusterin inhibiting antisense oligonucleotide 6.
XX	
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW	hypercholesterolaemia; cardiovascular disorder; ss;
KW	hyperproliferative disorder; hyperlipidemic disorder;
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX	
OS	Homo sapiens.
XX	
PN	WO200222635-A1.
XX	
PD	21-MAR-2002.
XX	
Pf	10-SEP-2001; 2001WO-US028235.
XX	
PR	11-SEP-2000; 2000US-00659791.
XX	(ISIS-) ISIS PHARM INC.
PA	Monia BP, Freier SM;
XX	WPI; 2002-404805/43.
PI	
XX	
DR	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX	
XX	Claim 3; Page 83; 125pp; English.
PS	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
CC	Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ	
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 45;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	894 ACTGTGTGCCGGAGATCCG 913                                     Db 20 ACTGTGTGCCGGAGATCCG 1
RESULT 143	
ABN99717/c	
ID	ABN99717 standard; DNA; 20 BP.
XX	
AC	ABN99717;
XX	
DT	16-AUG-2002 (first entry)
XX	
DE	Human clusterin inhibiting antisense oligonucleotide 51.
XX	
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW	hypercholesterolaemia; cardiovascular disorder; ss;
KW	hyperproliferative disorder; hyperlipidemic disorder;
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX	
PI	Monia BP, Freier SM;
XX	(ISIS-) ISIS PHARM INC.
PR	11-SEP-2000; 2000US-00659791.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	Monia BP, Freier SM;
PI	WPI; 2002-404805/43.
XX	
DR	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX	
XX	Claim 3; Page 83; 125pp; English.
PS	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
CC	Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ	
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 45;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	894 ACTGTGTGCCGGAGATCCG 913                                     Db 20 ACTGTGTGCCGGAGATCCG 1
RESULT 143	
ABN99717/c	
ID	ABN99717 standard; DNA; 20 BP.
XX	
AC	ABN99717;
XX	
DT	16-AUG-2002 (first entry)
XX	
DE	Human clusterin inhibiting antisense oligonucleotide 51.
XX	
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin;
KW	hypercholesterolaemia; cardiovascular disorder; ss;
KW	hyperproliferative disorder; hyperlipidemic disorder;
KW	phosphorothioate backbone; 2'-O-methoxyethyl wing.
XX	
PI	Monia BP, Freier SM;
XX	(ISIS-) ISIS PHARM INC.
PR	11-SEP-2000; 2000US-00659791.
XX	
PA	(ISIS-) ISIS PHARM INC.
XX	Monia BP, Freier SM;
PI	WPI; 2002-404805/43.
XX	
DR	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX	
XX	Claim 3; Page 83; 125pp; English.
PS	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings
CC	Sequence 20 BP; 4 A; 8 C; 5 G; 3 T; 0 U; 0 Other;
SQ	
Query Match	1.2%; Score 20; DB 1; Length 20;
Best Local Similarity	100.0%; Pred. No. 45;
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
OY	894 ACTGTGTGCCGGAGATCCG 913                                     Db 20 ACTGTGTGCCGGAGATCCG 1
RESULT 143	
ABN99717/c	
ID	ABN99717 standard; DNA; 20 BP.
XX	
AC	

XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 4 A; 5 C; 6 G; 5 T; 0 U; 0 Other;  
  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 122 GGTCTCAGACATGAGCTCC 141  
DB 20 GGTCTCAGACATGAGCTCC 1  
  
RESULT 145  
ABN99693/C  
ID ABN99693 standard; DNA; 20 BP.  
XX  
AC ABN99693;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 27.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
AC  
XX  
DT 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
PI WPI; 2002-404805/43.  
XX  
OS  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with

CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 4 A; 6 C; 5 G; 5 T; 0 U; 0 Other;  
  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 553 AGACGCACATGCTGGATGTC 572  
DB 20 AGACGCACATGCTGGATGTC 1  
  
RESULT 146  
ABN99698/C  
ID ABN99698 standard; DNA; 20 BP.  
XX  
AC ABN99698;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 32.  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
PN WO200222635-A1.  
XX  
AC  
XX  
DT 21-MAR-2002.  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
PI Monia BP, Freier SM;  
XX  
PI WPI; 2002-404805/43.  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
PT clusterin, useful for treating animal having disease associated with  
PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
CC inhibiting expression of the human clusterin gene. The antisense  
CC oligonucleotides of the invention are useful for inhibiting the  
CC expression of clusterin in cells. The antisense oligonucleotides are also  
CC useful for treating an animal with a disease or condition associated with  
CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
CC hyperproliferative disorders; and hyperlipidemic disorders). The present  
CC DNA sequence represents a clusterin antisense oligonucleotide of the  
CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
CC and also contains 2'-O-methoxyethyl wings  
XX  
SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 U; 0 Other;  
  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 613 AGCTCTTCAGGACAGTTC 632  
|||||||



(ISIS-) ISIS PHARM INC.  
Monia BP, Freier SM;  
WPI; 2002-404805/43.  
Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
Claim 3; Page 84; 125pp; English.  
The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings  
Sequence 20 BP; 7 A; 1 C; 4 G; 8 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1615 CTAATTCATAAACTGTCT 1634  
Db 20 CTAATTCATAAACTGTCT 1  
RESULT 150  
ABN99733/C  
ID ABN99733 standard; DNA; 20 BP.  
AC ABN99733;  
XX  
XX  
XX 16-AUG-2002 (first entry)  
XX Human clusterin inhibiting antisense oligonucleotide 67.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
XX ABN99733;  
XX  
XX 16-AUG-2002 (first entry)  
XX Human clusterin inhibiting antisense oligonucleotide 67.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
XX 21-MAR-2002.  
XX  
XX 10-SEP-2001; 2001WO-US028235.  
XX  
XX 11-SEP-2000; 2000US-00659791.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 84; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense

oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings  
Sequence 20 BP; 3 A; 9 C; 3 G; 5 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1383 CACCGGAGGAGTGAGATGT 1402  
Db 20 CACCGGAGGAGTGAGATGT 1  
RESULT 151  
ABN99673/C  
ID ABN99673 standard; DNA; 20 BP.  
XX  
XX ABN99673;  
XX  
XX 16-AUG-2002 (first entry)  
XX Human clusterin inhibiting antisense oligonucleotide 7.  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
XX 21-MAR-2002.  
XX  
XX 10-SEP-2001; 2001WO-US028235.  
XX  
XX 11-SEP-2000; 2000US-00659791.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings  
Sequence 20 BP; 4 A; 6 C; 3 G; 7 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy	149	GTCCAATCAGGAACTAAGT 168	Human clusterin inhibiting antisense oligonucleotide 30.
Db	20	GTCCAATCAGGAACTAAGT 1	Human; antisense inhibition; antisense oligonucleotide; clusterin; hypercholesterolaemia; cardiovascular disorder; ss; hyperproliferative disorder; hyperlipidemic disorder; phosphorothioate backbone; 2'-O-methoxyethyl wing.
RESULT 152			
ABN99679/c			Homo sapiens.
ID	ABN99679	standard; DNA; 20 BP.	WO200222635-A1.
XX			
AC	ABN99679;		
XX			
DT	16-AUG-2002	(first entry)	21-MAR-2002.
XX			
DE	Human clusterin inhibiting antisense oligonucleotide 13.		
XX			
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin; hypercholesterolaemia; cardiovascular disorder; ss; hyperproliferative disorder; hyperlipidemic disorder; phosphorothioate backbone; 2'-O-methoxyethyl wing.		
XX			
OS	Homo sapiens.		
XX			
PN	WO200222635-A1.		
XX			
PD	21-MAR-2002.		
XX			
PF	10-SEP-2001; 2001WO-US028235.		
XX			
PR	11-SEP-2000; 2000US-00659791.		
XX			
PA	(ISIS-) ISIS PHARM INC.		
XX			
PI	Monia BP, Freier SM;		
XX			
DR	WPI; 2002-404805/43.		
XX			
PT	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.		
XX			
PS	Claim 3; Page 83; 125pp; English.		
XX			
CC	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings		
XX			
Sequence	20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;		
Query Match	1.2%; Score 20; DB 1; Length 20;		
Best Local Similarity	100.0%; Pred. No. 45;		
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Oy	307	AGACCAGGGAATCAGAGACA 326	Human clusterin inhibiting antisense oligonucleotide 39.
Db	20	AGACCAGGGAATCAGAGACA 1	Human; antisense inhibition; antisense oligonucleotide; clusterin; hypercholesterolaemia; cardiovascular disorder; ss; hyperproliferative disorder; hyperlipidemic disorder; phosphorothioate backbone; 2'-O-methoxyethyl wing.
RESULT 153			
ABN99696/c			Homo sapiens.
ID	ABN99696	standard; DNA; 20 BP.	WO200222635-A1.
XX			
AC	ABN99696;		
XX			
DT	16-AUG-2002	(first entry)	21-MAR-2002.
XX			
PF	10-SEP-2001; 2001WO-US028235.		
XX			
PS	Claim 3; Page 83; 125pp; English.		
XX			
CC	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings		
XX			
Sequence	20 BP; 1 A; 6 C; 4 G; 9 T; 0 U; 0 Other;		
Query Match	1.2%; Score 20; DB 1; Length 20;		
Best Local Similarity	100.0%; Pred. No. 45;		
Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		
Oy	604	TCATAGACGAGCTCTCCAG 623	Human clusterin inhibiting antisense oligonucleotide 39.
Db	20	TCATAGACGAGCTCTCCAG 1	Human; antisense inhibition; antisense oligonucleotide; clusterin; hypercholesterolaemia; cardiovascular disorder; ss; hyperproliferative disorder; hyperlipidemic disorder; phosphorothioate backbone; 2'-O-methoxyethyl wing.
RESULT 154			
ABN99705/c			Homo sapiens.
ID	ABN99705	standard; DNA; 20 BP.	WO200222635-A1.
XX			
AC	ABN99705;		
XX			
DT	16-AUG-2002	(first entry)	21-MAR-2002.
XX			
DE	Human clusterin inhibiting antisense oligonucleotide 39.		
XX			
KW	Human; antisense inhibition; antisense oligonucleotide; clusterin; hypercholesterolaemia; cardiovascular disorder; ss; hyperproliferative disorder; hyperlipidemic disorder; phosphorothioate backbone; 2'-O-methoxyethyl wing.		
XX			
OS	Homo sapiens.		
XX			
PN	WO200222635-A1.		
XX			
PD	21-MAR-2002.		
XX			
PF	10-SEP-2001; 2001WO-US028235.		
XX			



XX 11-SEP-2000; 2000US-00659791.  
XX (ISIS-) ISIS PHARM INC.  
XX Monia BP, Freier SM;  
XX WPI; 2002-404805/43.  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX Claim 3; Page 83; 125pp; English.  
XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX Sequence 20 BP; 1 A; 3 C; 9 G; 7 T; 0 U; 0 Other;  
XX  
XX Query Match 1.2%; Score 20; DB 1; Length 20;  
XX Best Local Similarity 100.0%; Pred. No. 45;  
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
QY 848 CCAGCACCAGCAACAGCAAT 867  
DB 20 CCAGCACCAGCAACAGCAAT 1  
RESULT 155  
ABN99706/C  
ID ABN99706 standard; DNA; 20 BP.  
XX  
AC ABN99706;  
XX  
DT 16-AUG-2002 (first entry)  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 40.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX hypercholesterolaemia; cardiovascular disorder; ss;  
XX hyperproliferative disorder; hyperlipidemic disorder;  
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
OS Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
XX 21-MAR-2002.  
XX  
XX 10-SEP-2001; 2001WO-US028235.  
XX  
XX 11-SEP-2000; 2000US-00659791.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Monia BP, Freier SM;  
XX  
XX WPI; 2002-404805/43.  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 83; 125pp; English.

XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX Sequence 20 BP; 3 A; 2 C; 7 G; 8 T; 0 U; 0 Other;  
XX  
XX Query Match 1.2%; Score 20; DB 1; Length 20;  
XX Best Local Similarity 100.0%; Pred. No. 45;  
XX Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
QY 853 ACCGCCAACAGAAATTCATA 872  
DB 20 ACCGCCAACAGAAATTCATA 1  
RESULT 156  
ABN99723/C  
ID ABN99723 standard; DNA; 20 BP.  
XX  
AC ABN99723;  
XX  
XX 16-AUG-2002 (first entry)  
XX  
XX Human clusterin inhibiting antisense oligonucleotide 57.  
XX  
XX Human; antisense inhibition; antisense oligonucleotide; clusterin;  
XX hypercholesterolaemia; cardiovascular disorder; ss;  
XX hyperproliferative disorder; hyperlipidemic disorder;  
XX phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX Homo sapiens.  
XX  
XX WO200222635-A1.  
XX  
XX 21-MAR-2002.  
XX  
XX 10-SEP-2001; 2001WO-US028235.  
XX  
XX 11-SEP-2000; 2000US-00659791.  
XX  
XX (ISIS-) ISIS PHARM INC.  
XX  
XX Monia BP, Freier SM;  
XX  
XX WPI; 2002-404805/43.  
XX  
XX Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX Claim 3; Page 84; 125pp; English.  
XX  
XX The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX Sequence 20 BP; 5 A; 5 C; 7 G; 3 T; 0 U; 0 Other;  
XX



PD 21-MAR-2002.  
XX  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
XX  
PI Monia BP, Freier SM;  
XX  
XX  
DR WPI; 2002-404805/43.  
XX  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX  
PS Claim 3; Page 84; 125pp; English.  
XX  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX  
XX  
SQ Sequence 20 BP; 4 A; 5 C; 4 G; 7 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1083 AAGTCCTACCAGTGGAGAT 1102  
DB 20 AAGTCCTACCAGTGGAGAT 1  
RESULT 160  
ABN99674/c  
ID ABN99674 standard; DNA; 20 BP.  
XX  
XX  
AC ABN99674;  
XX  
XX  
DT 16-AUG-2002 (first entry)  
XX  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 8.  
XX  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX  
OS Homo sapiens.  
XX  
XX  
PN WO200222635-A1.  
XX  
XX  
AC ABN99674;  
XX  
XX  
DT 16-AUG-2002 (first entry)  
XX  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 8.  
XX  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX  
OS Homo sapiens.  
XX  
XX  
PN WO200222635-A1.  
XX  
XX  
PD 21-MAR-2002.  
XX  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
XX  
PI Monia BP, Freier SM;  
XX  
XX  
DR WPI; 2002-404805/43.  
XX  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with

PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX  
XX  
SQ Sequence 20 BP; 5 A; 4 C; 2 G; 9 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 166 AGTACGCTCAATAGGAAATT 185  
DB 20 AGTACGCTCAATAGGAAATT 1  
RESULT 161  
ABN99688/c  
ID ABN99688 standard; DNA; 20 BP.  
XX  
XX  
AC ABN99688;  
XX  
XX  
DT 16-AUG-2002 (first entry)  
XX  
XX  
DE Human clusterin inhibiting antisense oligonucleotide 22.  
XX  
XX  
KW Human; antisense inhibition; antisense oligonucleotide; clusterin;  
KW hypercholesterolaemia; cardiovascular disorder; ss;  
KW hyperproliferative disorder; hyperlipidemic disorder;  
KW phosphorothioate backbone; 2'-O-methoxyethyl wing.  
XX  
XX  
OS Homo sapiens.  
XX  
XX  
PN WO200222635-A1.  
XX  
XX  
PD 21-MAR-2002.  
XX  
XX  
PF 10-SEP-2001; 2001WO-US028235.  
XX  
XX  
PR 11-SEP-2000; 2000US-00659791.  
XX  
XX  
PA (ISIS-) ISIS PHARM INC.  
XX  
XX  
PI Monia BP, Freier SM;  
XX  
XX  
DR WPI; 2002-404805/43.  
XX  
XX  
PT Novel antisense compound targeted to nucleic acid molecule encoding  
XX clusterin, useful for treating animal having disease associated with  
XX clusterin such as hyperlipidemic disorder, cardiovascular disorder.  
XX  
XX  
PS Claim 3; Page 83; 125pp; English.  
XX  
XX  
CC The invention comprises antisense oligonucleotides that are capable of  
XX inhibiting expression of the human clusterin gene. The antisense  
XX oligonucleotides of the invention are useful for inhibiting the  
XX expression of clusterin in cells. The antisense oligonucleotides are also  
XX useful for treating an animal with a disease or condition associated with  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;  
XX hyperproliferative disorders; and hyperlipidemic disorders). The present  
XX DNA sequence represents a clusterin antisense oligonucleotide of the  
XX invention. NOTE: The present DNA sequence has a phosphorothioate backbone  
XX and also contains 2'-O-methoxyethyl wings  
XX

XX	Sequence	20 BP; 5 A; 3 C; 9 G; 3 T; 0 U; 0 Other;	
XX	Query Match	1.2%; Score 20; DB 1; Length 20;	
XX	Best Local Similarity	100.0%; Pred. No. 45;	
XX	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	482	CCAGAGCTCGCCCTTCTACT 501	
Db	20	CCAGAGCTCGCCCTTCTACT 1	
XX	RESULT 162		
XX	ABN99710/c		
XX	ID	ABN99710 standard; DNA; 20 BP.	
XX	AC	ABN99710;	
XX	DT	16-AUG-2002 (first entry)	
XX	DE	Human clusterin inhibiting antisense oligonucleotide 44.	
XX	Human	antisense inhibition; antisense oligonucleotide; clusterin;	
XX	Hypercholesterolaemia;	cardiovascular disorder; ss;	
XX	Hyperproliferative disorder;	hyperlipidemic disorder;	
XX	phosphorothioate backbone;	2'-O-methoxyethyl wing.	
XX	Homo sapiens.		
XX	WO200222635-A1.		
XX	21-MAR-2002.		
XX	10-SEP-2001;	2001WO-US028235.	
XX	11-SEP-2000;	2000US-00659791.	
XX	(ISIS-) ISIS PHARM INC.		
XX	Monia BP, Freier SM;		
XX	WPI; 2002-404805/43.		
XX	Novel antisense compound targeted to nucleic acid molecule encoding clusterin, useful for treating animal having disease associated with clusterin such as hyperlipidemic disorder, cardiovascular disorder.		
XX	Claim 3; Page 83; 125pp; English.		
XX	The invention comprises antisense oligonucleotides that are capable of inhibiting expression of the human clusterin gene. The antisense oligonucleotides of the invention are useful for inhibiting the expression of clusterin in cells. The antisense oligonucleotides are also useful for treating an animal with a disease or condition associated with clusterin (e.g. hypercholesterolaemia; cardiovascular disorders; hyperproliferative disorders; and hyperlipidemic disorders). The present DNA sequence represents a clusterin antisense oligonucleotide of the invention. NOTE: The present DNA sequence has a phosphorothioate backbone and also contains 2'-O-methoxyethyl wings		
XX	Sequence	20 BP; 1 A; 7 C; 3 G; 9 T; 0 U; 0 Other;	
XX	Query Match	1.2%; Score 20; DB 1; Length 20;	
XX	Best Local Similarity	100.0%; Pred. No. 45;	
XX	Matches	20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;	
QY	281	GAAGAAGAAAGAGGATGCC 300	
Db	20	GAAGAAGAAAGAGGATGCC 1	
XX	RESULT 164		
XX	ABN99692/c		
XX	ID	ABN99692 standard; DNA; 20 BP.	
XX	AC	ABN99692;	
XX	DT	16-AUG-2002 (first entry)	
XX	DE	Human clusterin inhibiting antisense oligonucleotide 26.	
XX	Human	antisense inhibition; antisense oligonucleotide; clusterin;	
XX	Hypercholesterolaemia;	cardiovascular disorder; ss;	
XX	Hyperproliferative disorder;	hyperlipidemic disorder;	
XX	phosphorothioate backbone;	2'-O-methoxyethyl wing.	
XX	Homo sapiens.		

```
XX PN WO200222635-A1.
XX XX Novel antisense compound targeted to nucleic acid molecule encoding
XX PD clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX XX
XX PF 21-MAR-2002.
XX XX
XX PR 10-SEP-2001; 2001WO-US028235.
XX XX
XX PR 11-SEP-2000; 2000US-00659791.
XX XX (ISIS-) ISIS PHARM INC.
XX PA
XX PI Monia BP, Freier SM;
XX XX
XX DR WPI; 2002-404805/43.
XX XX
XX XX Novel antisense compound targeted to nucleic acid molecule encoding
XX PT clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX XX
XX PS Claim 3; Page 83; 125pp; English.
XX XX
XX CC The invention comprises antisense oligonucleotides that are capable of
XX CC inhibiting expression of the human clusterin gene. The antisense
XX CC oligonucleotides of the invention are useful for inhibiting the
XX CC expression of clusterin in cells. The antisense oligonucleotides are also
XX CC useful for treating an animal with a disease or condition associated with
XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present
XX CC DNA sequence represents a clusterin antisense oligonucleotide of the
XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX XX
XX AC ADO07105;
XX XX
XX DT 15-JUL-2004 (first entry)
XX XX
XX DE CUU gene forward PCR primer.
XX XX
XX KW Rheumatoid arthritis; osteoarthritis; microarray; molecular profiling;
XX KW diagnosis; antiarthritic; CLU; PCR; primer; human; ss.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO2004035827-A2.
XX XX
XX PD 29-APR-2004.
XX XX
XX PF 20-OCT-2003; 2003WO-IB005143.
XX XX
XX PR 18-OCT-2002; 2002US-0419650P.
XX XX
XX XX (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX PA (COMS ) COMMISSARIAT ENERGIE ATOMIQUE.
XX XX
XX PI Breban M, Gidrol X, Marion S, Chicocchia G;
XX XX
XX DR WPI; 2004-348476/32.
XX XX
XX PT New library of polynucleotide sequences expressed in cells from synovial
XX PT tissues, useful for diagnosing and treating rheumatoid arthritis or
XX PT osteoarthritis.
XX XX
XX PS Disclosure; SEQ ID NO 5; 71pp; English.
XX XX
XX CC The present invention concerns an analysis of genes differentially
XX CC expressed in synovial tissues from rheumatoid arthritis (RA) and
XX CC osteoarthritis (OA) patients. Microarray technology was used to compare
XX CC gene expression profiles, and sets of genes were identified based on over
XX CC -expression or under-expression in RA samples compared to OA samples.
XX CC Results for 6 of the selected genes (GBPI,CLU, RH70, GLO1, DXS and CTSL)
XX CC were verified by real-time, quantitative PCR using samples identical to
```

```
XX PN WO200222635-A1.
XX XX Novel antisense compound targeted to nucleic acid molecule encoding
XX PD clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX XX
XX PF 21-MAR-2002.
XX XX
XX PR 10-SEP-2001; 2001WO-US028235.
XX XX
XX PR 11-SEP-2000; 2000US-00659791.
XX XX (ISIS-) ISIS PHARM INC.
XX PA
XX PI Monia BP, Freier SM;
XX XX
XX DR WPI; 2002-404805/43.
XX XX
XX XX Novel antisense compound targeted to nucleic acid molecule encoding
XX PT clusterin, useful for treating animal having disease associated with
XX PT clusterin such as hyperlipidemic disorder, cardiovascular disorder.
XX XX
XX PS Claim 3; Page 83; 125pp; English.
XX XX
XX CC The invention comprises antisense oligonucleotides that are capable of
XX CC inhibiting expression of the human clusterin gene. The antisense
XX CC oligonucleotides of the invention are useful for inhibiting the
XX CC expression of clusterin in cells. The antisense oligonucleotides are also
XX CC useful for treating an animal with a disease or condition associated with
XX CC clusterin (e.g. hypercholesterolaemia; cardiovascular disorders;
XX CC hyperproliferative disorders; and hyperlipidemic disorders). The present
XX CC DNA sequence represents a clusterin antisense oligonucleotide of the
XX CC invention. NOTE: The present DNA sequence has a phosphorothioate backbone
XX CC and also contains 2'-O-methoxyethyl wings
XX SQ Sequence 20 BP; 3 A; 7 C; 5 G; 5 T; 0 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 45;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

XX XX
XX AC ADO07105;
XX XX
XX DT 15-JUL-2004 (first entry)
XX XX
XX DE CUU gene forward PCR primer.
XX XX
XX KW Rheumatoid arthritis; osteoarthritis; microarray; molecular profiling;
XX KW diagnosis; antiarthritic; CLU; PCR; primer; human; ss.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO2004035827-A2.
XX XX
XX PD 29-APR-2004.
XX XX
XX PF 20-OCT-2003; 2003WO-IB005143.
XX XX
XX PR 18-OCT-2002; 2002US-0419650P.
XX XX
XX XX (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.
XX PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.
XX PA (COMS ) COMMISSARIAT ENERGIE ATOMIQUE.
XX XX
XX PI Breban M, Gidrol X, Marion S, Chicocchia G;
XX XX
XX DR WPI; 2004-348476/32.
XX XX
XX PT New library of polynucleotide sequences expressed in cells from synovial
XX PT tissues, useful for diagnosing and treating rheumatoid arthritis or
XX PT osteoarthritis.
XX XX
XX PS Disclosure; SEQ ID NO 5; 71pp; English.
XX XX
XX CC The present invention concerns an analysis of genes differentially
XX CC expressed in synovial tissues from rheumatoid arthritis (RA) and
XX CC osteoarthritis (OA) patients. Microarray technology was used to compare
XX CC gene expression profiles, and sets of genes were identified based on over
XX CC -expression or under-expression in RA samples compared to OA samples.
XX CC Results for 6 of the selected genes (GBPI,CLU, RH70, GLO1, DXS and CTSL)
XX CC were verified by real-time, quantitative PCR using samples identical to
```

CC those used in the microarray experiments and also entirely separate  
CC samples. The present sequence is that of a forward PCR primer for CLU; a  
CC reverse primer is also provided ADO07106. CLU was shown to be under-  
CC expressed in RA relative to OA samples. The invention provides libraries  
CC and arrays of polynucleotide sequences useful for prognosticating or  
CC diagnosing RA or OA. Methods are also provided for following the  
CC efficiency of a treatment against RA or OA, and for screening potential  
CC therapeutic agents for treating RA or OA.  
XX  
SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1180 GCGAAGACCACTACTCTG 1199  
Db 1 GCGAAGACCACTACTCTG 20  
RESULT 167  
ADO07106/c  
ID ADO07106 standard; DNA; 20 BP.  
XX  
AC ADO07106;  
XX  
DT 15-JUL-2004 (first entry)  
XX  
DE CLU gene reverse PCR primer.  
XX  
KW Rheumatoid arthritis; osteoarthritis; microarray; molecular profiling;  
KW diagnosis; antiarthritic; CLU; PCR; primer; human; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035827-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 20-OCT-2003; 2003WO-IB005143.  
XX  
PR 18-OCT-2002; 2002US-0419650P.  
XX  
PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.  
PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.  
PA (COMS ) COMMISSARIAT ENERGIE ATOMIQUE.  
XX  
PI Breban M, Gidrol X, Marion S, Chiocchia G;  
XX  
DR WPI; 2004-348476/32.  
XX  
PT New library of polynucleotide sequences expressed in cells from synovial  
PT tissues, useful for diagnosing and treating rheumatoid arthritis or  
PT osteoarthritis.  
XX  
PS Disclosure; SEQ ID NO 6; 71bp; English.  
XX  
CC The present invention concerns an analysis of genes differentially  
CC expressed in synovial tissues from rheumatoid arthritis (RA) and  
CC osteoarthritis (OA) patients. Microarray technology was used to compare  
CC gene expression profiles, and sets of genes were identified based on over  
CC -expression or under-expression in RA samples compared to OA samples.  
CC Results for 6 of the selected genes (GBP1, CLU, RH70, GLO1, DXS and CTSL)  
CC were verified by real-time, quantitative PCR using samples identical to  
CC those used in the microarray experiments and also entirely separate  
CC samples. The present sequence is that of a reverse PCR primer for CLU; a  
CC forward primer is also provided ADO07105. CLU was shown to be under-  
CC expressed in RA relative to OA samples. The invention provides libraries  
CC and arrays of polynucleotide sequences useful for prognosticating or  
CC diagnosing RA or OA. Methods are also provided for following the  
CC efficiency of a treatment against RA or OA, and for screening potential  
CC therapeutic agents for treating RA or OA.  
XX  
SQ Sequence 20 BP; 6 A; 5 C; 5 G; 4 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1180 GCGAAGACCACTACTCTG 1199  
Db 1 GCGAAGACCACTACTCTG 20  
RESULT 167  
ADO07106/c  
ID ADO07106 standard; DNA; 20 BP.  
XX  
AC ADO07106;  
XX  
DT 15-JUL-2004 (first entry)  
XX  
DE CLU gene reverse PCR primer.  
XX  
KW Rheumatoid arthritis; osteoarthritis; microarray; molecular profiling;  
KW diagnosis; antiarthritic; CLU; PCR; primer; human; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO2004035827-A2.  
XX  
PD 29-APR-2004.  
XX  
PF 20-OCT-2003; 2003WO-IB005143.  
XX  
PR 18-OCT-2002; 2002US-0419650P.  
XX  
PA (INRM ) INSERM INST NAT SANTE & RECH MEDICALE.  
PA (ASSI-) ASSISTANCE PUBLIQUE HOPITAUX PARIS.  
PA (COMS ) COMMISSARIAT ENERGIE ATOMIQUE.  
XX  
PI Breban M, Gidrol X, Marion S, Chiocchia G;  
XX  
DR WPI; 2004-348476/32.  
XX  
PT New library of polynucleotide sequences expressed in cells from synovial  
PT tissues, useful for diagnosing and treating rheumatoid arthritis or  
PT osteoarthritis.  
XX  
PS Disclosure; SEQ ID NO 6; 71bp; English.  
XX  
CC The present invention concerns an analysis of genes differentially  
CC expressed in synovial tissues from rheumatoid arthritis (RA) and  
CC osteoarthritis (OA) patients. Microarray technology was used to compare  
CC gene expression profiles, and sets of genes were identified based on over  
CC -expression or under-expression in RA samples compared to OA samples.  
CC Results for 6 of the selected genes (GBP1, CLU, RH70, GLO1, DXS and CTSL)  
CC were verified by real-time, quantitative PCR using samples identical to  
CC those used in the microarray experiments and also entirely separate  
CC samples. The present sequence is that of a reverse PCR primer for CLU; a  
CC forward primer is also provided ADO07105. CLU was shown to be under-  
CC expressed in RA relative to OA samples. The invention provides libraries  
CC and arrays of polynucleotide sequences useful for prognosticating or  
CC diagnosing RA or OA. Methods are also provided for following the  
CC efficiency of a treatment against RA or OA, and for screening potential  
CC therapeutic agents for treating RA or OA.  
XX  
SQ Sequence 20 BP; 2 A; 5 C; 5 G; 8 T; 0 U; 0 Other;  
Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 45;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1361 GCTGCAGGAATACCGCAAAA 1380  
Db 20 GCTGCAGGAATACCGCAAAA 1  
RESULT 168  
ADL70464  
ID ADL70464 standard; RNA; 21 BP.  
XX  
AC ADL70464;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosstatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtGt"  
XX  
PN WO2004018676-A2.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001277.  
XX  
PR 01-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
PI Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX  
XX WPI; 2004-226852/21.  
XX  
PT New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
PS Claim 4; SEQ ID NO 9; 63pp; English.  
XX  
CC The present sequence is the sense strand of a short interfering RNA  
CC (siRNA) targeted to human clusterin. The antisense strand is also  
CC provided ADL70465. The siRNA can be used to interfere with the expression  
CC of clusterin. Clusterin, also known as testosterone-repressed prostate  
CC message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
CC increased amounts by prostate tumour cells following androgen withdrawal,  
CC and has also been shown to be critical for neuritic toxicity in mouse  
CC models of Alzheimer's disease. siRNAs of the invention can be used alone  
CC or in combination with other chemotherapy or apoptosis inducing  
CC treatments for the treatment of prostate cancer, sarcomas such as  
CC osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
CC cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
CC melanoma, and also for the treatment of Alzheimer's disease.  
XX  
SQ Sequence 21 BP; 5 A; 4 C; 5 G; 2 T; 5 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 21;  
Best Local Similarity 75.0%; Pred. No. 54;  
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGTGGTCT 67  
DB 1 AUGAUGAGACUCUGCUGCT 20  
| : | | | | | | | | | | | | |  
| : | | | | | | | | | | | | |

RESULT 169  
ADL70430  
ID ADL70430 standard; RNA; 21 BP.  
XX AC ADL70430;  
XX XX  
DT 20-MAY-2004 (first entry)  
XX RNaI for human clusterin.  
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX Homo sapiens.  
OS Synthetic.

Key Location/Qualifiers  
modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX WO2004018675-A1.  
XX XX  
PD 04-MAR-2004.  
XX 21-AUG-2003; 2003WO-CA001276.  
XX 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX Jansen B;  
DR WPI; 2004-226851/21.  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX Claim 20; SEQ ID NO 28; 32pp; English.  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX Sequence 21 BP; 5 A; 4 C; 5 G; 2 T; 5 U; 0 Other;

Query Match 1.2%; Score 20; DB 1; Length 21;  
Best Local Similarity 75.0%; Pred. No. 54;

[illegible]

XX	RNAi for human clusterin.
DE	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
XX	Cytostatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
KW	ss.
OS	Homo sapiens.
OS	Synthetic.
PH	Key Location/Qualifiers
FT	modified_base 18..19
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= dTdT"
PN	WO2004018676-A2.
XX	
PD	04-MAR-2004.
XX	
PB	21-AUG-2003; 2003WO-CAN001277.
XX	
PR	21-AUG-2002; 2002US-0405193P.
PR	03-SEP-2002; 2002US-0408152P.
PR	20-MAY-2003; 2003US-0472387P.
XX	(UYBR-) UNIV BRITISH COLUMBIA.
PA	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI	Gonos ES;
PI	WPI; 2004-226852/21.
DR	New RNA molecule less than 49 bases and having a sequence effective to
PT	mediate degradation or block translation of mRNA that is the
PT	transcriptional product of a target gene, useful for treating Alzheimer's
PT	disease or cancer.
PS	Claim 4; SEQ ID NO 67; 63pp; English.
CC	The present sequence is the sense strand of a short interfering RNA
CC	(siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.
CC	The antisense strand is also provided ADL70523. The siRNA can be used to
CC	interfere with the expression of clusterin. Clusterin, also known as
CC	tetosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC	tumour cells following androgen withdrawal, and has also been shown to be
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC	siRNAs of the invention can be used alone or in combination with other
CC	therapies such as osteosarcoma, renal cell carcinoma,
CC	prostate cancer, sarcomas such as osteosarcoma, lung cancer, ovarian cancer,
CC	breast cancer, bladder cancer, melanoma, and also for the treatment
CC	of Alzheimer's disease. In an example from the invention, the present
CC	siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC	prostate cancer cells. A reduction in clusterin transcript was observed.
XX	
SQ	Sequence 19 BP; 5 A; 4 G; 0 T; 5 U; 0 Other;
	Query Match 1.2%; Score 19; DB 1; Length 19;
	Best Local Similarity 73.7%; Pred. No. 52;
	Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;
QY	48 ATGATGAAGACTCTGTGC 66  ::   ::   ::   :
Dd	1 AUGAAGAAGACUCUGCUGC 19
RESULT 172	
ID	ADL70523/C standard; RNA; 19 BP.
XC	ADL70523;

XX	20-MAY-2004 (first entry)
DT	RNAi for human clusterin.
DE	RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
KW	Cytostatic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;
SS	
OS	Homo sapiens.
OS	Synthetic.
PH	Key Location/Qualifiers
FT	modified_base 18..19
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= dTdT"
PN	WO2004018676-A2.
XX	
PD	04-MAR-2004.
XX	
PB	21-AUG-2003; 2003WO-CAN001277.
XX	
PR	21-AUG-2002; 2002US-0405193P.
PR	03-SEP-2002; 2002US-0408152P.
PR	20-MAY-2003; 2003US-0472387P.
XX	(UYBR-) UNIV BRITISH COLUMBIA.
PA	Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;
PI	Gonos ES;
PI	WPI; 2004-226852/21.
DR	New RNA molecule less than 49 bases and having a sequence effective to
PT	mediate degradation or block translation of mRNA that is the
PT	transcriptional product of a target gene, useful for treating Alzheimer's
PT	disease or cancer.
PS	Claim 4; SEQ ID NO 68; 63pp; English.
CC	The present sequence is the antisense strand of a short interfering RNA
CC	(siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.
CC	The sense strand is also provided ADL70522. The siRNA can be used to
CC	interfere with the expression of clusterin. Clusterin, also known as
CC	tetosterone-repressed prostate message-2 (TRPM-2) or sulfated
CC	glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
CC	tumour cells following androgen withdrawal, and has also been shown to be
CC	critical for neuritic toxicity in mouse models of Alzheimer's disease.
CC	siRNAs of the invention can be used alone or in combination with other
CC	therapies such as osteosarcoma, renal cell carcinoma,
CC	prostate cancer, sarcomas such as osteosarcoma, lung cancer, ovarian cancer,
CC	breast cancer, bladder cancer, melanoma, and also for the treatment
CC	of Alzheimer's disease. In an example from the invention, the present
CC	siRNA was used to examine the effects of clusterin gene silencing in PC-3
CC	prostate cancer cells. A reduction in clusterin transcript was observed.
XX	
SQ	Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
	Query Match 1.2%; Score 19; DB 1; Length 19;
	Best Local Similarity 100.0%; Pred. No. 52;
	Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	48 ATGATGAAGACTCTGTGC 66 
Dd	19 ATGATGAAGACTCTGTGC 1
RESULT 173	
ID	ADL70444 standard; RNA; 19 BP.
ID	ADL70444



ADL70444;  
20-MAY-2004 (first entry)  
RNAi for human clusterin.  
Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
Homo sapiens.  
Synthetic.  
Key Location/Qualifiers  
modified\_base 18..19  
/\*tag= a  
/mod\_base= OTHER  
/note= "OTHER= TT"  
WO2004018675-A1.  
04-MAR-2004.  
21-AUG-2003; 2003WO-CA001276.  
21-AUG-2002; 2002US-0405193P.  
03-SEP-2002; 2002US-0408152P.  
02-DEC-2002; 2002US-0319748P.  
20-MAY-2003; 2003US-0472387P.  
(UYBR-) UNIV BRITISH COLUMBIA.  
(GLEA/) GLEAVE M E.  
Jansen B;  
WPI; 2004-226851/21.  
Treating melanoma in a mammalian subject comprises administering to the  
subject a therapeutic agent effective to reduce the effective amount of  
clusterin in the melanoma cells.  
Claim 20; SEQ ID NO 43; 32pp; English.  
The present sequence is that of a short interfering RNA (siRNA) molecule  
targeted to human clusterin ADL70403. The invention relates to the  
treatment of melanoma through reduction in the effective amount of  
clusterin. The therapeutic agent may be an antisense oligonucleotide  
ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
mRNA. A method for regulating expression of bcl-xL in a subject or cell  
line comprises administering an agent effective to modulate the amount of  
clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
is down-regulated when the effective amount of clusterin is reduced. Such  
inhibition is significant because bcl-xL is known to act as an inhibitor  
of apoptosis.  
Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;  
Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 52;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 48 ATGATGAAGACTCTGCTGC 66  
Db 19 ATGATGAAGACTCTGCTGC 1  
RESULT 175  
ADL70465/c  
ID ADL70465 standard; RNA; 21 BP.  
XX  
AC ADL70465;  
XX  
XX  
DT 20-MAY-2004 (first entry)  
XX RNAi for human clusterin.

ADL70444;  
20-MAY-2004 (first entry)  
RNAi for human clusterin.  
Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
Homo sapiens.  
Synthetic.  
Key Location/Qualifiers  
modified\_base 18..19  
/\*tag= a  
/mod\_base= OTHER  
/note= "OTHER= TT"  
WO2004018675-A1.  
04-MAR-2004.  
21-AUG-2003; 2003WO-CA001276.  
21-AUG-2002; 2002US-0405193P.  
03-SEP-2002; 2002US-0408152P.  
02-DEC-2002; 2002US-0319748P.  
20-MAY-2003; 2003US-0472387P.  
(UYBR-) UNIV BRITISH COLUMBIA.  
(GLEA/) GLEAVE M E.  
Jansen B;  
WPI; 2004-226851/21.  
Treating melanoma in a mammalian subject comprises administering to the  
subject a therapeutic agent effective to reduce the effective amount of  
clusterin in the melanoma cells.  
Claim 20; SEQ ID NO 42; 32pp; English.  
The present sequence is that of a short interfering RNA (siRNA) molecule  
targeted to human clusterin ADL70403. The invention relates to the  
treatment of melanoma through reduction in the effective amount of  
clusterin. The therapeutic agent may be an antisense oligonucleotide  
ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
mRNA. A method for regulating expression of bcl-xL in a subject or cell  
line comprises administering an agent effective to modulate the amount of  
clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
is down-regulated when the effective amount of clusterin is reduced. Such  
inhibition is significant because bcl-xL is known to act as an inhibitor  
of apoptosis.  
Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;  
Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 73.7%; Pred. No. 52;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;  
Qy 48 ATGATGAAGACTCTGCTGC 66  
Db 1 AUGAUGAAGACUCUGCUGC 19  
RESULT 174  
ADL70445/c  
ID ADL70445 standard; RNA; 19 BP.  
XX  
AC ADL70445;  
XX

KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; neurotropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
XX  
PN WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX  
XX 03-SEP-2002; 2002US-0408152P.  
XX  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
XX Gonos ES;  
XX  
XX WPI; 2004-226852/21.  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
XX mediate degradation or block translation of mRNA that is the  
XX transcriptional product of a target gene, useful for treating Alzheimer's  
XX disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 10; 63pp; English.  
XX  
XX The present sequence is the antisense strand of a short interfering RNA  
XX (siRNA) targeted to human clusterin. The sense strand is also provided  
XX ADL70464. The siRNA can be used to interfere with the expression of  
XX clusterin. Clusterin, also known as testosterone-repressed prostate  
XX message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
XX increased amounts by prostate tumour cells following androgen withdrawal,  
XX and has also been shown to be critical for neuritic toxicity in mouse  
XX models of Alzheimer's disease. siRNAs of the invention can be used alone  
XX or in combination with other chemotherapy or apoptosis inducing  
XX treatments for the treatment of prostate cancer, sarcomas such as  
XX osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
XX cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
XX melanoma, and also for the treatment of Alzheimer's disease.  
XX  
XX Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;  
SQ  
Query Match 1.2%; Score 19; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 75;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 48 ATGATGAAGACTCTGCTGC 66  
Db 19 ATGATGAAGACTCTGCTGC 1  
RESULT 176  
ADL70431/c  
ID ADL70431 standard; RNA; 21 BP.  
XX  
XX ADL70431;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX RNAi for human clusterin.  
XX

KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
PN WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX  
XX 03-SEP-2002; 2002US-0408152P.  
XX  
XX 02-DEC-2002; 2002US-0319748P.  
XX  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
XX subject a therapeutic agent effective to reduce the effective amount of  
XX clusterin in the melanoma cells.  
XX  
XX Claim 20; SEQ ID NO 29; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
XX targeted to human clusterin ADL70403. The invention relates to the  
XX treatment of melanoma through reduction in the effective amount of  
XX clusterin. The therapeutic agent may be an antisense oligonucleotide  
XX ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
XX targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
XX mRNA. A method for regulating expression of bcl-xL in a subject or cell  
XX line comprises administering an agent effective to modulate the amount of  
XX clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
XX is down-regulated when the effective amount of clusterin is reduced. Such  
XX inhibition is significant because bcl-xL is known to act as an inhibitor  
XX of apoptosis.  
XX  
XX Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;  
SQ  
Query Match 1.2%; Score 19; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 75;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 48 ATGATGAAGACTCTGCTGC 66  
Db 19 ATGATGAAGACTCTGCTGC 1  
RESULT 177  
ADC10398/c  
ID ADC10398 standard; DNA; 22 BP.  
XX  
XX ADC10398;  
XX  
XX 18-DEC-2003 (first entry)  
XX  
XX Human NOVX polypeptide gene reverse primer SEQ ID NO: 417.  
XX  
XX ss; primer; cytostatic; antidiabetic; anorectic; cerebroprotective;  
KW neuroprotective; antiinflammatory; gene therapy; antisense therapy;  
KW thyromimetic; NOVX; pathology; cancer; diabetes; obesity;  
KW

endocrine disorder; CNS disorder; inflammatory disorder;  
chromosome mapping; tissue typing; predictive medicine.

Homo sapiens.

WO2003000842-A2.

03-JAN-2003.

04-JUN-2002; 2002WO-US017443.

04-JUN-2001; 2001US-0295607P.

04-JUN-2001; 2001US-0295661P.

06-JUN-2001; 2001US-0296404P.

06-JUN-2001; 2001US-0296418P.

07-JUN-2001; 2001US-0296575P.

11-JUN-2001; 2001US-0297414P.

12-JUN-2001; 2001US-0295573P.

12-JUN-2001; 2001US-0297567P.

14-JUN-2001; 2001US-0298285P.

15-JUN-2001; 2001US-0298528P.

18-JUN-2001; 2001US-0299133P.

19-JUN-2001; 2001US-0299230P.

21-JUN-2001; 2001US-0299949P.

22-JUN-2001; 2001US-0300177P.

26-JUN-2001; 2001US-0300883P.

28-JUN-2001; 2001US-0301530P.

28-JUN-2001; 2001US-0301550P.

03-JUL-2001; 2001US-0302951P.

31-JUL-2001; 2001US-0308909P.

14-SEP-2001; 2001US-0322297P.

25-SEP-2001; 2001US-0324669P.

03-DEC-2001; 2001US-0337477P.

14-DEC-2001; 2001US-0341562P.

21-FEB-2002; 2002US-0358656P.

21-FEB-2002; 2002US-0359122P.

22-FEB-2002; 2002US-0358978P.

22-FEB-2002; 2002US-0359034P.

22-FEB-2002; 2002US-0359035P.

22-FEB-2002; 2002US-0359121P.

27-FEB-2002; 2002US-0359964P.

01-MAR-2002; 2002US-0360858P.

12-MAR-2002; 2002US-0363430P.

12-MAR-2002; 2002US-0363676P.

10-APR-2002; 2002US-0371346P.

10-MAY-2002; 2002US-0379444P.

04-JUN-2002; 2002US-00379444.

(CURA-) CURAGEN CORP.

Agee ML, Anderson DW, Berghs C, Casman SJ, Catterton E,  
Dipippo VA, Edinger SR, Eisen A, Ellerman K, Gangolli EA,  
Gerlach VL, Gorman L, Guo X, Herrmann JL, Hjalt T, Ji W, Kekuda R,  
Khrantsov NV, Li L, Liu X, Malyankar UM, Miller CE, Millet I,  
Ort T, Padigar M, Pattarajan M, Pena CE, Rastelli L, Rieger DK,  
Rothenberg ME, Shenoy SG, Shinkets RA, Smithson G, Spaderna SK,  
Spytek KA, Stone DJ, Vernet CM, Zhong H, Zhong M, Alsbrook JP,  
Burgess CE, Lepley DM;  
WPI; 2003-210149/20.

New isolated NOVX polypeptides and nucleic acid molecules useful for  
treating, preventing and diagnosing pathological conditions with NOVX-  
associated disorders, such as cancer, obesity, diabetes and inflammatory  
or CNS diseases.

Example B; SEQ ID NO 417; 772pp; English.

The invention relates to novel isolated polypeptides, mature form of the  
polypeptide, a sequence that is 95% identical to the polypeptide or the  
polypeptide comprising one or more conservative substitutions. The NOVX  
polypeptide is useful for treating or preventing a pathology associated  
with the polypeptide e.g. disorders associated with aberrant expression

CC or activity of the polypeptide, such as cancer, diabetes, obesity, and  
CC endocrine, CNS and inflammatory disorders. They can also be used in  
CC various detection and screening assays, chromosome mapping, tissue typing  
CC and predictive medicine. This sequence corresponds to a primer used to  
CC amplify and isolate the coding sequence for one of the polypeptides of  
CC the invention.

XX Sequence 22 BP; 1 A; 7 C; 3 G; 11 T; 0 U; 0 Other;

Query Match 1.1%; Score 18.8; DB 1; Length 22;

Best Local Similarity 90.9%; Pred. No. 94;

Matches 20; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 264 AACCTAGAGAGAGCCCAAGAAGA 285

Db 22 AAGCTAGAGAGAGCCCAAGAAGA 1

RESULT 178

AAT41539/C

ID AAT41539 standard; DNA; 18 BP.

XX AAT41539;

AC AAT41539;

DT 24-JUN-1997 (first entry)

XX Human apolipoprotein-J gene exon 7-specific 3' PCR primer.

XX Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;

KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;

KW diagnosis; ss.

XX OS Synthetic.

XX WO96322502-A1.

XX PD 17-OCT-1996.

XX PF 02-APR-1996; 96WO-US004510.

XX PR 11-APR-1995; 95US-00420291.

XX PA (UYCO ) UNIV COLUMBIA NEW YORK.

XX PI Mayeux R, Tycko B;

XX WPI; 1996-477152/47.

XX New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used  
PT to identify patients susceptible to Alzheimer's disease or prostate  
PT cancer.

XX Example 1; Page 20; 62pp; English.

XX AAT41527-T41541 are exon-specific PCR primers used for the amplification  
CC of exons 2-8 of the human apolipoprotein-J (ApoJ) gene. The primers were  
CC used in a method for detecting polymorphisms associated with an allelic  
CC variation in the ApoJ gene. The oligonucleotide (OG) detects the  
CC probability of a person developing Alzheimer's disease (AD), preferably  
CC in patients of African or Hispanic descent. The OG also detects the  
CC probability of a person developing a cognitive disorder, or a prostatic  
CC carcinoma. Transgenic mammals expressing an allelic variant of an ApoJ  
CC gene may be used as a prognostic and diagnostic means for studying AD,  
CC and to determine the effectiveness of therapeutic drugs

XX Sequence 18 BP; 3 A; 4 C; 5 G; 6 T; 0 U; 0 Other;

Query Match 1.1%; Score 18; DB 1; Length 18;

Best Local Similarity 100.0%; Pred. No. 60;

Matches 18; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1070 CAACGAGCTGCTAAAGTC 1087

|||||

Db	18	CAACGAGCTGCTAAAGTC	1
RESULT 179			
AAT41527			
ID	AAT41527	standard; DNA; 18 BP.	
XX	XX		
AC	AAT41527;		
XX	XX		
DT	24-JUN-1997	(first entry)	
XX	XX		
DE	Human apolipoprotein-J	gene exon 2-specific 5' PCR primer.	
XX	XX		
KW	Apolipoprotein J; ApolJ; polymorphism; detection; allele; exon; probe;		
KW	primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;		
KW	diagnosis; ss.		
XX	XX		
OS	Synthetic.		
XX	XX		
PN	WO9632502-A1.		
XX	XX		
PD	17-OCT-1996.		
XX	XX		
PF	02-APR-1996;	96WO-US004510.	
XX	XX		
PR	11-APR-1995;	95US-00420291.	
XX	XX		
PA	(UYCO ) UNIV COLUMBIA NEW YORK.		
XX	XX		
PI	Mayeux R, Tycko B;		
XX	XX		
DR	WPI; 1996-477152/47.		
XX	XX		
PT	New oligonucleotide specific for apolipoprotein-J polymorphisms - used		
PT	to identify patients susceptible to Alzheimer's disease or prostate		
PT	cancer.		
XX	XX		
PS	Example 1; Page 20; 62pp; English.		
XX	XX		
CC	AAT41527-T41541 are exon-specific PCR primers used for the amplification		
CC	of exons 2-8 of the human apolipoprotein-J (ApoJ) gene. The primers were		
CC	used in a method for detecting polymorphisms associated with an allelic		
CC	variation in the ApoJ gene. The oligonucleotide (OG) detects the		
CC	probability of a person developing Alzheimer's disease (AD), preferably		
CC	in patients of African or Hispanic descent. The OG also detects the		
CC	probability of a person developing a cognitive disorder, or a prostatic		
CC	carcinoma. Transgenic mammals expressing an allelic variant of an ApoJ		
CC	gene may be used as a prognostic and diagnostic means for studying AD,		
CC	and to determine the effectiveness of therapeutic drugs		
XX	XX		
SQ	Sequence 18 BP; 7 A; 5 C; 4 G; 2 T; 0 U; 0 Other;		
Query Match	1.1%;	Score 18; DB 1; Length 18;	
Best Local Similarity	100.0%;	Pred. No. 60;	
Matches 18;	Conservative 0;	Mismatches 0; Indels 0; Gaps 0;	
QY	22	CGTGCAGAGACTCCAGAA	39
DB	1	CGTGCAGAGACTCCAGAA	18
RESULT 180			
AAT39501/C			
ID	AAT39501	standard; DNA; 18 BP.	
XX	XX		
AC	AAT39501;		
XX	XX		
DT	21-MAY-1997	(first entry)	
XX	XX		
DE	Chromosome 8p	clustrin gene (CLU1) specific primer (nt 2836-2854).	
XX	XX		
KW	Chromosome 8p; polymerase chain reaction; PCR; primer; CLU1;		
KW	clustrin gene; human; steroidogenesis; acute regulatory protein;		



QY 48 ATGATGAGACTCTGCTGCTG 68  
DB 21 ATGATAAATACTCTGCTGCTG 1

RESULT 184  
AAT41526  
ID AAT41526 standard; DNA; 17 BP.  
XX  
AC AAT41526;  
XX  
DT 24-JUN-1997 (first entry)  
XX  
DE Human apolipoprotein-J gene J3-allelic variant primer/probe.  
XX  
KW Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;  
KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;  
KW diagnosis; ss.  
XX  
OS Synthetic.  
XX  
PN WO9632502-A1.  
XX  
PD 17-OCT-1996.  
XX  
PF 02-APR-1996; 96WO-US004510.  
XX  
DT 11-APR-1995; 95US-00420291.  
XX  
DE (UYCO ) UNIV COLUMBIA NEW YORK.  
XX  
PI Mayeux R, Tycko B;  
XX  
DR WPI; 1996-477152/47.  
XX  
PT New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used  
PT to identify patients susceptible to Alzheimer's disease or prostate  
PT cancer.  
XX  
PS Example 1; Page 21; 62pp; English.  
XX  
CC AAT41526 is a primer/probe used to detect a J3 allelic variation in the  
CC human apolipoprotein-J (ApoJ) gene. The primer/probe is used for  
CC detecting polymorphisms associated with an allelic variation in the ApoJ  
CC gene. The oligonucleotide (OG) detects the probability of a person  
CC developing Alzheimer's disease (AD), preferably in patients of African or  
CC Hispanic descent. The OG also detects the probability of a person  
CC developing a cognitive disorder, or a prostatic carcinoma. Transgenic  
CC mammals expressing an allelic variant of an ApoJ gene may be used as a  
CC prognostic and diagnostic means for studying AD, and to determine the  
CC effectiveness of therapeutic drugs  
XX  
SQ Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 17; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1023 GAGCTCGACGAATCCCT 1039  
DB 1 GAGCTCGACGAATCCCT 17

RESULT 185  
AAT41542  
ID AAT41542 standard; DNA; 17 BP.  
XX  
AC AAT41542;  
XX  
DT 24-JUN-1997 (first entry)  
XX  
DE Human apolipoprotein-J gene J1-allelic specific primer/probe.  
XX

KW Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;  
KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;  
KW diagnosis; ss.  
XX  
OS Synthetic.  
XX  
PN WO9632502-A1.  
XX  
PD 17-OCT-1996.  
XX  
PF 02-APR-1996; 96WO-US004510.  
XX  
DT 11-APR-1995; 95US-00420291.  
XX  
DE (UYCO ) UNIV COLUMBIA NEW YORK.  
XX  
PI Mayeux R, Tycko B;  
XX  
DR WPI; 1996-477152/47.  
XX  
PT New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used  
PT to identify patients susceptible to Alzheimer's disease or prostate  
PT cancer.  
XX  
PS Example 1; Page 21; 62pp; English.  
XX  
CC AAT41542 and AAT41543 are J1 allele-specific primer/probes used as  
CC controls in an example of a method for detecting polymorphisms associated  
CC with an allelic variation in the human apolipoprotein-J (ApoJ) gene. The  
CC oligonucleotide (OG) detects the probability of a person developing  
CC Alzheimer's disease (AD), preferably in patients of African or Hispanic  
CC descent. The OG also detects the probability of a person developing a  
CC cognitive disorder, or a prostatic carcinoma. Transgenic mammals  
CC expressing an allelic variant of an ApoJ gene may be used as a prognostic  
CC and diagnostic means for studying AD, and to determine the effectiveness  
CC of therapeutic drugs  
XX  
SQ Sequence 17 BP; 5 A; 8 C; 1 G; 3 T; 0 U; 0 Other;

Query Match 1.0%; Score 17; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 984 TGTTCACCAACAACCC 1000  
DB 1 TGTTCACCAACAACCC 17

RESULT 186  
ABT34616  
ID ABT34616 standard; DNA; 17 BP.  
XX  
AC ABT34616;  
XX  
DT 12-JUN-2003 (first entry)  
XX  
DE Tumour suppression related human fukutin oligo SEQ ID No 253.  
XX  
KW Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;  
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;  
KW schizophrenia; protein chip; gene therapy; tumour suppression;  
KW human fukutin; ds.  
XX  
OS Homo sapiens.  
XX  
PN WO2003025175-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004208.  
XX  
DR 17-SEP-2001; 2001FR-00011978.  
XX

PI Telerman A, Amson R, Tuijnder M;  
XX WPI; 2003-441574/41.  
XX  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX  
XX Disclosure; Page 737; 771pp; French.  
XX  
XX The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
XX Sequence 17 BP; 5 A; 6 C; 2 G; 4 T; 0 U; 0 Other;  
SQ

Query Match 1.0%; Score 17; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1551 GATCCTGCCTCTAACA 1567  
DB 1 GATCCTGCCTCTAACA 17  
|||||

RESULT 188  
AAQ58405/C  
ID AAQ58405 standard; DNA; 20 BP.  
XX  
XX AAQ58405;  
XX  
XX 25-MAR-2003 (revised)  
DT 04-OCT-1994 (first entry)  
XX  
XX Antisense oligonucleotide CAS-110-G-119 to HCV 5'-UTR.  
XX  
XX Hepatitis C virus; HCV; non-A, non-B hepatitis virus; NANBHV;  
KW antisense oligonucleotide; translation inhibition; therapy; 5'-UTR;  
KW 5'-untranslated region; loop C; ss.  
XX  
XX Synthetic.  
OS  
XX WO9405813-A1.  
XX  
XX 17-MAR-1994.  
XX  
XX 10-SEP-1993; 93WO-JP001293.  
PF  
XX 10-SEP-1992; 92US-00945289.  
PR 14-APR-1993; 93JP-00087195.  
PR  
XX (MOCH ) MOCHIDA PHARM CO LTD.  
PA (KAGA ) CHEMO SERO THERAPEUTIC RES INST.  
PA (ISIS-) ISIS PHARM INC.  
XX  
XX Anderson KP, Hanecak RC, Hoshiko K, Nozaki C, Nishihara T;  
PI

PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
XX Telerman A, Amson R, Tuijnder M;  
XX  
XX WPI; 2003-313353/30.  
XX  
XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
XX  
XX Disclosure; Page 63; 720pp; French.  
XX  
XX The invention relates to a novel isolated 17 mer nucleic acid sequence,  
CC given in the specification, a sequence containing at least 15 consecutive  
CC nucleotides from the 17 mer sequence, a sequence with, after optimal  
CC alignment, at least 80% identity to the 17 mer sequence, a sequence that  
CC hybridizes to them under highly stringent conditions, or the complement  
CC of any of them, or the corresponding RNA. The novel isolated nucleic  
CC acids of the invention are useful as probes and primers for detecting,  
CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one  
CC component of a gene chip, in vitro as (anti)sense reagents, and for  
CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterized by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
XX Sequence 17 BP; 5 A; 6 C; 2 G; 4 T; 0 U; 0 Other;  
SQ

Query Match 1.0%; Score 17; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 68;  
Matches 17; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1551 GATCCTGCCTCTAACA 1567  
DB 1 GATCCTGCCTCTAACA 17  
|||||

RESULT 187  
ADB45708  
ID ADB45708 standard; DNA; 17 BP.  
XX  
XX ADB45708;  
XX  
XX 18-DEC-2003 (first entry)  
DT  
XX Tumour suppression/reversion associated nucleotide #6031.  
DE  
XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
KW  
XX Homo sapiens.  
OS  
XX WO2003040369-A2.  
XX  
XX 15-MAY-2003.  
XX  
XX 17-SEP-2002; 2002WO-IB004219.  
PF  
XX 17-SEP-2001; 2001FR-00011981.  
PR  
XX (MOLE-) MOLECULAR ENGINES LAB.  
PA  
XX

PI Nakatake H, Hamada F, Eto T, Furukawa S;  
XX WPI; 1994-101217/12.  
XX Antisense oligo:nucleotide(s) complementary to hepatitis C viral genome  
PT - useful for inhibiting HCV replication, to treat related diseases.  
XX  
XX Example 7; Page 24; 91pp; English.  
XX Antisense oligonucleotides were synthesised which are complementary to  
CC target sequences located at 10-nucleotide intervals from nucleotide 1 to  
CC 339 in the HCV RNA 5'-untranslated region. Of these sequences (CAS-1 to  
CC CAS-320), oligonucleotide CAS-110 (AAQ58403), which is complementary to a  
CC portion of loop C, was found to cause greater than 80% inhibition of core  
CC protein translation. The nucleotide at position 119 in loop C has a high  
CC variation rate among HCV strains so oligonucleotide CAS-110-I-119 was  
CC synthesised in which inosine replaced the T (corresp. to A at position  
CC 119) in CAS-110. The CAS-110-I-119 showed an inhibitory activity of more  
CC than 70%. A control oligonucleotide (CAS-110-G-119) showed much lower  
CC activity. See AAQ58388-Q58422, AAQ44885-Q44892 and AAQ58383. (Updated on  
CC 25-MAR-2003 to correct PN field.)  
XX  
XX Sequence 20 BP; 2 A; 3 C; 14 G; 1 T; 0 U; 0 Other;  
XX  
XX Query Match 1.0%; Score 16.8; DB 1; Length 20;  
XX Best Local Similarity 90.0%; Pred. No. 1.3e+02;  
XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
XX  
XX 1510 GCCTCAGGCCCCCACTCC 1529  
XX |||||  
XX 20 GCCTCAGGCCCCCCCTCC 1  
XX  
XX RESULT 189  
XX ADN02449/C  
XX ID ADN02449 standard; DNA; 20 BP.  
XX  
XX AC ADN02449;  
XX  
XX DT 17-JUN-2004 (first entry)  
XX  
XX DE Western equine encephalomyelitis virus 26S region PCR primer WEEP2.  
XX  
XX ss; expression vector; western equine encephalitis; WEE;  
XX anti-encephalitis; Venezuelan equine encephalitis virus; encephalitis;  
XX PCR; primer.  
XX  
XX OS Western equine encephalomyelitis virus.  
XX  
XX PN CA2327189-A1.  
XX  
XX PD 21-JUN-2002.  
XX  
XX PF 21-DEC-2000; 2000CA-02327189.  
XX  
XX PR 21-DEC-2000; 2000CA-02327189.  
XX  
XX PA (MIND ) CANADA MIN NAT DEFENCE.  
XX  
XX PI Wong JP, Negata LP;  
XX  
XX DR WPI; 2002-600289/65.  
XX  
XX PT A western equine encephalitis (WEE) virus strain used to develop DNA  
XX vaccines to WEE virus and related alphaviruses.  
XX  
XX PS Disclosure; Page 28; 52pp; English.  
XX  
XX The invention relates to a novel mammalian expression vector, under which  
XX expression of the structural genes of western equine encephalitis (WEE)  
XX virus strain 71V-1658 have been placed under the control of a eukaryotic  
XX promoter. The expression vector has anti-encephalitis activity. The  
XX invention provides a means of developing a vaccine to the WEE virus which

CC is important for protection against an aerosol challenge of WEE used in  
CC biological warfare. The prophylactic method of the invention is used for  
CC inducing a protective immune response to eastern equine encephalitis  
CC virus and Venezuelan equine encephalitis virus in a mammal. The present  
CC sequence represents a WEE virus 26S region PCR primer.  
XX  
XX Sequence 20 BP; 2 A; 7 C; 6 G; 5 T; 0 U; 0 Other;  
XX  
XX Query Match 1.0%; Score 16.8; DB 1; Length 20;  
XX Best Local Similarity 90.0%; Pred. No. 1.3e+02;  
XX Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX  
XX  
XX 524 CGACTCCCTGCTGGAGAACG 543  
XX |||||  
XX 20 CGACACGCTGCTGGAGAACG 1  
XX  
XX RESULT 190  
XX AAQ68062/c  
XX ID AAQ68062 standard; DNA; 16 BP.  
XX  
XX AC AAQ68062;  
XX  
XX DT 25-MAR-2003 (revised)  
XX  
XX DT 19-DEC-1994 (first entry)  
XX  
XX DE Antisense probe 155 for HCV LipA typing.  
XX  
XX Hepatitis C virus; HCV; probe; genotyping; hybridisation;  
XX non-A, non-B hepatitis; NANBH; amplification; primer;  
XX polymerase chain reaction; PCR; line probe assay; LipA; ss.  
XX  
XX OS Synthetic.  
XX  
XX PN WO9412670-A2.  
XX  
XX PD 09-JUN-1994.  
XX  
XX PF 26-NOV-1993; 93WO-EP0033325.  
XX  
XX PR 27-NOV-1992; 92EP-00403222.  
XX  
XX PR 31-AUG-1993; 93EP-00402129.  
XX  
XX PA (INNO-) INNOGENETICS NV SA.  
XX  
XX PI Maertens G, Stuyver L, Rossau R, Van Heuverswyn H;  
XX  
XX DR WPI; 1994-200296/24.  
XX  
XX PT Process for genotyping Hepatitis C virus (HCV) isolates - utilises probes  
XX hybridising to HCV isolate domains.  
XX  
XX PS Disclosure; Page 29; 96pp; English.  
XX  
XX CC Genotyping HCV utilises probes hybridising to HCV isolate domains. HCV  
XX types 2, 3, 4, 5 or 6 and subtypes 1a, 1b, 2a, 2b, 3a, 3b, 3c, 4a, 4b,  
XX 4c, 4d, 4e, 4f, 4g and 4h can be typed. Antisense probe 155 was used in  
XX the identification of type 4 isolates. (Updated on 25-MAR-2003 to correct  
XX PN field.)  
XX  
XX Sequence 16 BP; 1 A; 3 C; 10 G; 2 T; 0 U; 0 Other;  
XX  
XX Query Match 1.0%; Score 16; DB 1; Length 16;  
XX Best Local Similarity 100.0%; Pred. No. .75;  
XX Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
XX  
XX  
XX 1508 CAGCCTCCAGGCCCCC 1523  
XX |||||  
XX 16 CAGCCTCCAGGCCCCC 1  
XX  
XX RESULT 191  
XX AAX14650



ID	AAAX14650 standard; DNA; 17 BP.	XX	Key	Location/Qualifiers
XX	AAAX14650;	FT	modified_base	1..19
XX		FT		/*tag= a
XX	24-MAR-1999 (first entry)	FT		/mod_base= OTHER
DT		FT		/note= "OTHER = Phosphorothioate backbone"
DE	Triple helix forming nucleotides 5967-5983 of the dystrophin gene.	XX		WO2004083432-A1.
DE		PN		
XX	Triple-helix forming region; Triplex formation; DNA detection;	XX		30-SEP-2004.
KW	identification; bacteria; oncogene; virus; ds.	XX		
XX		XX		21-MAR-2003; 2003WO-NL000214.
OS	Homo sapiens.	XX		
XX	US5861244-A.	XX		21-MAR-2003; 2003WO-NL000214.
PN	19-JAN-1999.	PR		(ZIEK-) ACAD ZIEKENHUIS LEIDEN.
PD		PA		
XX	22-DEC-1993; 93US-00173489.	PI		Van Ommen GB, Van Deutekom JCT, Den Dunnen JT, Aartsma-Rus A;
XX	29-OCT-1992; 92US-00968436.	DR		WPI; 2004-691055/67.
XX	(PROF-) PROFILE DIAGNOSTIC SCI INC.	XX		Generating an oligonucleotide for treating diseases, comprises
PA	Hepburn AG, Wang C;	PT		determining from a structure of RNA from an exon, a region that assumes a
PI		PT		structure hybridized to another part of the RNA and a region that is not
XX	WPI; 1999-130384/11.	PT		hybridized in the structure.
XX		XX		Example 2; Page 48; 71pp; English.
XX	Assay of genetic sequences based on triplex formation from double	XX		The invention comprises a method for generating an oligonucleotide
PT	stranded analyte - and hybrid of anchor and reporter sequences, with	CC		involving: determining from a secondary structure of RNA from an exon, a
PT	reporter released if triplex formation occurs, used e.g. to identify	CC		region that assumes a structure that is hybridised to another part of the
PT	bacteria.	CC		RNA (closed structure) and a region that is not hybridised in the
XX		CC		structure (open structure); and subsequently generating an
PS	Disclosure; Col 15-16; 168pp; English.	CC		oligonucleotide, where at least one part of the oligonucleotide is
XX		CC		complementary to the closed structure and at least one part of the
CC	The present sequence represents a potential triple-helix forming region.	CC		oligonucleotide is complementary to the open structure. The gene from
CC	It can be used to demonstrate the assay of the invention. The assay	CC		which the RNA comprising the exon is transcribed, may be selected from:
CC	comprises adding a sample containing double-stranded DNA test sequences,	CC		an aberrant Duchenne muscular dystrophy gene (DMD), a collagen VI alpha 1
CC	e.g. containing the present sequence, to an aqueous medium containing at	CC		gene (COL6A1), a myotubular myopathy 1 gene (MTM1), a dysferlin gene
CC	least one complex of anchor DNA, attached to a solid support, and	CC		(DYSF), a laminin-alpha 2 gene (LAMA2), an emery-dryfuss muscular
CC	reporter DNA, where either a part of the anchor DNA or reporter DNA is	CC		dystrophy gene (EMD), and/or a calpain 3 gene (CAPN3). The
CC	designed to form a triple-strand structure with part of the test	CC		oligonucleotides produced by the method of the invention are useful for:
CC	sequence. Triplex formation results in displacement of the reporter DNA	CC		for the treatment of an inherited disease; for inducing exon skipping in
CC	which is detected as an indication of the presence of the DNA test	CC		a pre-mRNA; for altering exon-recognition in a pre-mRNA; and for altering
CC	sequence. The method is used to detect DNA sequences, particularly for	CC		the efficiency with which a splice donor or splice acceptor sequence is
CC	identification of bacteria (by detecting genes for ribosomal RNA) in	CC		used by a splicing machinery. The present RNA sequence represents an
CC	clinical samples, but also detection of oncogenes and Hepatitis B virus	CC		antisense oligonucleotide that is targeted to the DMD gene.
XX		XX		
SQ	Sequence 17 BP; 10 A; 0 C; 7 G; 0 T; 0 U; 0 Other;	SQ		Sequence 19 BP; 0 A; 8 C; 1 G; 0 T; 10 U; 0 Other;
Query Match 1.0%; Score 16; DB 1; Length 17;				
Best Local Similarity 100.0%; Pred. No. 94;				
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;				
QY	280 AGAAGAAGAAAGAGGA 295	QY	280 AGAAGAAGAAAGAGGA 295	
Db	1 AGAAGAAGAAAGAGGA 16	Db	17 AGAAGAAGAAAGAGGA 2	
RESULT 192				
ADS00161/c				
ID	ADS00161 standard; RNA; 19 BP.	ID	ADS73873/c	
XX		XX	ADS73873 standard; RNA; 19 BP.	
AC	ADS00161;	AC	ADS73873;	
XX		XX		
DT	16-DEC-2004 (first entry)	DT	16-DEC-2004 (first entry)	
XX		XX		
DE	Duchenne muscular dystrophy gene-specific antisense oligonucleotide #7.	DE	DMD gene specific antisense oligonucleotide h41AON1.	
XX		XX		
KW	antisense oligonucleotide; Duchenne muscular dystrophy gene; DMD gene;	KW	DMD; Duchenne muscular dystrophy; collagen VI alpha 1; COL6A1;	
KW	pre-mRNA recognition alteration; inherited disease;	KW	myotubular myopathy 1; MTM1; dysferlin; DYSF; laminin-alpha 2; LAMA2;	
KW	pre-mRNA exon skipping induction; splicing machinery efficiency; ss.	KW	emery-dryfuss muscular dystrophy; EMD; calpain 3; CAPN3; antisense; ss.	
XX		XX		
OS	Unidentified.	XX		

XX	Synthetic.
DT	WO2004083446-A2.
XX	30-SEP-2004.
XX	22-MAR-2004; 2004WO-NL000196.
KW	21-MAR-2003; 2003WO-NL000214.
XX	(ZIEK-) ACAD ZIEKENHUIS LEIDEN.
XX	Van Ommeren GB, Van Deutekom JCT, Den Dunnen JT, Aartsma-Rus A;
PPI	WTPI; 2004-691060/67.
DR	Generating an oligonucleotide for treating diseases, comprises
XX	determining from a structure of RNA from an exon, a region that assumes a
PPT	structure hybridized to another part of the RNA and a region that is not
PPT	hybridized in the structure.
XX	Example 1; Page 88; 117pp; English.
XX	The invention relates to generating an oligonucleotide and involves
CC	determining from a secondary structure of RNA from an exon, a region that
CC	assumes a structure that is hybridized to another part of the RNA (closed
CC	structure) and a region that is not hybridize in the structure (open
CC	structure), and subsequently generating an oligonucleotide, where at
CC	least a part of the oligonucleotide is complementary to the closed
CC	structure and at least another part of the oligonucleotide is
CC	complementary to the open structure. In generating an oligonucleotide,
CC	the open and closed structures are adjacent to each other. The
CC	oligonucleotide is complementary to a consecutive part of 14-50
CC	nucleotides of the RNA. It also comprises RNA, where the RNA contains a
CC	modification, preferably a 2'-O-methyl modified ribose (RNA) or
CC	deoxyribose (DNA) modification. The pre-mRNA comprising the exon exhibits
CC	undesired splicing in a subject. The absence of the exon from mRNA
CC	produced from the pre-mRNA generates a coding region for a protein. The
CC	gene from which the RNA comprising the exon is transcribed encodes an
CC	aberrant Duchenne muscular dystrophy gene (DMD), a collagen VI alpha 1
CC	gene (COL6A1), a myotubular myopathy 1 gene (MTM1), a dysferlin gene
CC	(DYSPF), a laminin-alpha 2 gene (LAMA2), an emery-dreyfuss muscular
CC	dystrophy gene (EMD), and/or a calpain 3 gene (CAPN3). Preferably, the
CC	gene is the DMD gene. The oligonucleotide, its equivalent, or the
CC	compound is useful for at least in part altering recognition of the exon
CC	or exons in a pre-mRNA; for the preparation of a medicament for the
CC	treatment of an inherited disease; for inducing exon skipping in a pre-
CC	mRNA; for altering exon-recognition in a pre-mRNA; for altering the
CC	efficiency with which a splice donor or splice acceptor sequence is used
CC	by a splicing machinery; for inducing exon-skipping of two, three, or
CC	more exons in a pre-mRNA; or for inducing skipping of the at least two
CC	exons and a sequence located between the at least two exons (intervening
CC	sequence) on the pre-mRNA, where intervening sequence further comprises
CC	exon or exons. Sequences ADS73865-ADS73903 represent antisense
CC	oligonucleotides (AONs) used to study targeted skipping of 15 different
CC	DMD exons.
XX	Sequence 19 BP; 0 A; 8 C; 1 G; 0 T; 10 U; 0 Other;
SQ	Query Match 1.0%; Score 16; DB 1; Length 19;
	Best Local Similarity 100.0%; Pred.No. 1.4e+02;
	Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	280 AGAAGAAGAAAGGCA 295
Db	17 AGAAGAAGAAAGGCA 2
RESULT 194	
ID ADI19217/c	
ID ADI19217 standard; DNA; 20 BP.	
XX	Human PCTAIRE protein kinase 2 antisense oligonucleotide #124.
XX	AD19217.
XX	22-APR-2004 (first entry)
XX	Human PCTAIRE protein kinase 2 antisense oligonucleotide #71.
DE	gene therapy; PCTAIRE technology; PCTAIRE protein kinase 2;
XX	neurological disorder; human; PCTAIRE protein kinase 2; ss.
XX	Homo sapiens.
OS	Key Location/Qualifiers
XX	modified_base 1..20
FH	/tag= b
FT	/mod_base= OTHER
FT	/note= "OTHER= Phosphorothioate backbone. All cytidines
FT	are 5-methylcytidines"
FT	modified_base 1..5
FT	/tag= a
FT	/mod_base= OTHER
FT	/note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
FT	modified_base 15..20
FT	/tag= c
FT	/mod_base= OTHER
FT	/note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"
XX	US2003225256-A1.
PN	04-DEC-2003.
XX	31-MAY-2002; 2002US-00160787.
PD	31-MAY-2002; 2002US-00160787.
XX	(ISIS-) ISIS PHARM INC.
PR	Watt AT;
XX	WTPI; 2004-022085/02.
XX	New antisense oligonucleotide, having a sequence targeted to a nucleic
PA	acid encoding PCTAIRE protein kinase 2, useful for preparing a
PI	composition for treating neurological disorders.
XX	Claim 1; SEQ ID NO 84; 58pp; English.
PS	The invention describes a new antisense oligonucleotide, having a
CC	sequence comprising 8-80 bp targeted to a nucleic acid encoding PCTAIRE
CC	protein kinase 2, that specifically hybridizes with the nucleic acid
CC	encoding PCTAIRE protein kinase 2 and having a sequence comprising 20 bp.
CC	The antisense oligonucleotide is useful for preparing a composition for
CC	treating e.g., neurological disorders. This sequence represents a human
CC	PCTAIRE protein kinase 2 antisense oligonucleotide.
XX	Sequence 20 BP; 1 A; 8 C; 2 G; 9 T; 0 U; 0 Other;
SQ	Query Match 1.0%; Score 16; DB 1; Length 20;
	Best Local Similarity 100.0%; Pred.No. 1.6e+02;
	Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY	1583 CATGGGAAGACAGAA 1598
Db	17 CATGGGAAGACAGAA 2
RESULT 195	
ID ADI19270	
ID ADI19270 standard; DNA; 20 BP.	
XX	ADI19270;
AC	ADI19270;
XX	22-APR-2004 (first entry)
DT	Human PCTAIRE protein kinase 2 antisense oligonucleotide #124.
XX	AD19217.

XX gene therapy; antisense technology; PCTAIRE protein kinase 2;  
KW neurological disorder; human; PCTAIRE protein kinase 2; ss.  
XX  
XX Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FH modified\_base 1..20  
FT /\*tag= b  
FT /mod\_base= OTHER  
FT /note= "OTHER= Phosphorothioate backbone. All cytidines  
FT are 5-methylcytidines"  
FT modified\_base 1..5  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"  
FT modified\_base 15..20  
FT /\*tag= c  
FT /mod\_base= OTHER  
FT /note= "OTHER= 2'-O-Methoxyethyl (2'-MOE) nucleotides"  
XX US2003225256-A1.  
XX 04-DEC-2003.  
XX  
XX 31-MAY-2002; 2002US-00160787.  
XX  
XX 31-MAY-2002; 2002US-00160787.  
XX (ISIS-) ISIS PHARM INC.  
XX Watt AT;  
XX WPI; 2004-022085/02.  
XX  
XX New antisense oligonucleotide, having a sequence targeted to a nucleic  
PT acid encoding PCTAIRE protein kinase 2, useful for preparing a  
PT composition for treating neurological disorders.  
XX  
XX Example 15; SEQ ID NO 137; 58pp; English.  
XX  
XX The invention describes a new antisense oligonucleotide, having a  
CC sequence comprising 8-80 bp targeted to a nucleic acid encoding PCTAIRE  
CC protein kinase 2, that specifically hybridises with the nucleic acid  
CC encoding PCTAIRE protein kinase 2 and having a sequence comprising 20 bp.  
CC The antisense oligonucleotide is useful for preparing a composition for  
CC treating e.g., neurological disorders. This sequence represents a human  
CC PCTAIRE protein kinase 2 antisense oligonucleotide.  
XX  
XX Sequence 20 BP; 9 A; 2 C; 8 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 1.0%; Score 16; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.6e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1583 CATGGGAAGAACAGAA 1598  
Db |||||  
4 CATGGGAAGAACAGAA 19  
RESULT 196  
ABN88070  
ID ABN88070 standard; DNA; 19 BP.  
XX  
XX ABN88070;  
XX  
XX 12-AUG-2002 (first entry)  
DT  
XX Caenorhabditis elegans related dsRNA2 upstream primer.  
DE  
XX Caenorhabditis elegans; C. elegans; reproduction; development;  
KW antineurotic; nematocyst; plant protectant; gene therapy; infection;  
KW calabar swelling; lymphatic filariasis; elephantiasis; onchocercosis;  
KW

KW primer; ss.  
XX Caenorhabditis elegans.  
OS Synthetic.  
XX  
XX WO200238600-A2.  
XX 16-MAY-2002.  
XX  
XX 09-NOV-2001; 2001WO-EP013038.  
XX  
XX 09-NOV-2000; 2000US-0246721P.  
XX  
XX (CENI-) CENIX BIOSCIENCE GMBH.  
XX Echeverri C, Goenczy P, Hyman A, Coulson A, Jones S, Oegema K;  
PI Kirkham M;  
XX WPI; 2002-471547/50.  
XX  
XX New Caenorhabditis elegans genes required for viability, growth or  
PT reproduction of nematodes, useful for diagnosing or treating e.g.  
PT onchocercosis or elephantiasis in humans or animals, or plant diseases  
PT caused by e.g. Heterodera.  
XX  
XX Example 2; Page 28; 35pp; English.  
XX  
XX The present invention describes an isolated nucleic acid molecule (I),  
CC which encodes a polypeptide (II) required for the viability and/or growth  
CC and/or reproduction of nematodes (Caenorhabditis elegans), or its  
CC fragment. (I) and (II) have nematocyst and plant protectant activities,  
CC and can be used in gene therapy. (I) is useful for producing (II)  
CC required for the viability, growth and/or reproduction of nematodes.  
CC Nucleic acids, probes, polypeptides, fusion proteins and antibodies from  
CC the present invention are also useful in a screening assay for  
CC interacting drugs that inhibit, stimulate or affect worm growth,  
CC viability or reproduction. They are useful for diagnosing or treating  
CC human or animal diseases associated with the infection or presence of  
CC nematode worms, e.g. Wuchereria bancrofti, Brugia malayi, Loa loa or  
CC Onchocerca volvulus. These diseases include calabar swellings, lymphatic  
CC filariasis (elephantiasis) or onchocercosis. The nucleic acids, probes,  
CC polypeptides, fusion proteins and antibodies are also useful for  
CC diagnosing or treating plant diseases associated with the infection or  
CC presence of nematode worms. Furthermore, the nucleic acid and amino acid  
CC sequences are useful for developing computational models, structural  
CC models or other models for evaluating drug binding and efficacy. The  
CC present sequence represents a primer which is used in an example from the  
CC present invention in RNAi experiments  
XX  
XX Sequence 19 BP; 6 A; 3 C; 7 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 551 GCAGACGCACATGCTGGAT 569  
Db |||||  
1 GCAGACGCACATGCTGGAT 19  
RESULT 197  
ADD00110  
ID ADD00110 standard; RNA; 19 BP.  
XX  
XX ADD00110;  
XX  
XX 01-JAN-2004 (first entry)  
DT  
XX HCV coding region-derived 60% conserved RNA sequence 56.  
DE  
XX HCV infection; replication; pathogenesis; virucide; vaccine;  
KW gene therapy; ds.  
KW

OS Hepatitis C virus.  
PN WO2003016572-A1.  
XX  
PD  
XX  
PT 27-FEB-2003.  
XX  
PF  
XX 16-AUG-2002; 2002WO-US021843.  
XX  
PR 17-AUG-2001; 2001US-0313076P.  
PR 20-DEC-2001; 2001US-0344116P.  
PR 01-FEB-2002; 2002US-0353750P.  
XX  
PA (ELIL ) LILLY & CO ELI.  
XX  
PI Zhao G, Lu J, Glass JI, Martinez A, Yang Y;  
XX  
DR WPI; 2003-268345/26.  
XX  
PT New double stranded RNA oligonucleotide, useful for preparing a  
PT composition for treating or preventing hepatitis C virus.  
XX  
PS Disclosure; Page 48; 173pp; English.  
XX  
CC The invention relates to a novel isolated double stranded RNA  
CC oligonucleotide about 19 to about 25 ribonucleotides in length or its  
CC equivalent. One strand of the oligonucleotide comprises the same  
CC nucleotide sequence as a region of a hepatitis C virus (HCV) target RNA  
CC polynucleotide sequence required for hepatitis C virus infection.  
CC replication or pathogenesis in vitro or in vivo in a host cell. The  
CC oligonucleotide of the invention demonstrates virucide activity and may  
CC be useful for preparing a composition or vaccine for treating or  
CC preventing hepatitis C virus, as well as during gene therapy procedures.  
CC The current sequence is that of the HCV coding region-derived conserved  
CC RNA sequence of the invention.  
XX  
SQ Sequence 19 BP; 11 A; 5 C; 2 G; 0 T; 1 U; 0 Other;  
XX  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 84.2%; Pred. No. 1.5e+02;  
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 222 CTCATAGAAAAACCAACG 240  
Db 1 CUCAAAGAAAAACCAACG 19  
XX  
RESULT 198  
ADD00259  
ID ADD00259 standard; RNA; 19 BP.  
XX  
AC ADD00259;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
DE HCV coding region-derived 50% conserved RNA sequence 205.  
XX  
KW HCV infection; replication; pathogenesis; virucide; vaccine;  
KW gene therapy; ds.  
XX  
OS Hepatitis C virus.  
XX  
PN WO2003016572-A1.  
XX  
PD 27-FEB-2003.  
XX  
PR 16-AUG-2002; 2002WO-US021843.  
XX  
PR 17-AUG-2001; 2001US-0313076P.  
PR 20-DEC-2001; 2001US-0344116P.  
PR 01-FEB-2002; 2002US-0353750P.  
XX  
PA (ELIL ) LILLY & CO ELI.  
XX  
PI Zhao G, Lu J, Glass JI, Martinez A, Yang Y;  
XX  
DR WPI; 2003-268345/26.  
XX  
PT New double stranded RNA oligonucleotide, useful for preparing a  
PT composition for treating or preventing hepatitis C virus.  
XX  
PS Disclosure; Page 48; 173pp; English.  
XX  
CC The invention relates to a novel isolated double stranded RNA  
CC oligonucleotide about 19 to about 25 ribonucleotides in length or its  
CC equivalent. One strand of the oligonucleotide comprises the same  
CC nucleotide sequence as a region of a hepatitis C virus (HCV) target RNA  
CC polynucleotide sequence required for hepatitis C virus infection.  
CC replication or pathogenesis in vitro or in vivo in a host cell. The  
CC oligonucleotide of the invention demonstrates virucide activity and may  
CC be useful for preparing a composition or vaccine for treating or  
CC preventing hepatitis C virus, as well as during gene therapy procedures.  
CC The current sequence is that of the HCV coding region-derived conserved  
CC RNA sequence of the invention.  
XX  
SQ Sequence 19 BP; 11 A; 5 C; 2 G; 0 T; 1 U; 0 Other;  
XX  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 84.2%; Pred. No. 1.5e+02;  
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 222 CTCATAGAAAAACCAACG 240  
Db 1 CUCAAAGAAAAACCAACG 19  
XX  
RESULT 198  
ADD00259  
ID ADD00259 standard; RNA; 19 BP.  
XX  
AC ADD00259;  
XX  
DT 01-JAN-2004 (first entry)  
XX  
DE HCV coding region-derived 50% conserved RNA sequence 205.  
XX  
KW HCV infection; replication; pathogenesis; virucide; vaccine;  
KW gene therapy; ds.  
XX  
OS Hepatitis C virus.  
XX  
PN WO2003016572-A1.  
XX  
PD 27-FEB-2003.  
XX  
PR 16-AUG-2002; 2002WO-US021843.  
XX  
PR 17-AUG-2001; 2001US-0313076P.  
PR 20-DEC-2001; 2001US-0344116P.  
PR 01-FEB-2002; 2002US-0353750P.  
XX  
PA (ELIL ) LILLY & CO ELI.  
XX  
PI Zhao G, Lu J, Glass JI, Martinez A, Yang Y;  
XX  
DR WPI; 2003-268345/26.  
XX  
PT New double stranded RNA oligonucleotide, useful for preparing a  
PT composition for treating or preventing hepatitis C virus.  
XX  
PS Disclosure; Page 48; 173pp; English.  
XX  
CC The invention relates to a novel isolated double stranded RNA  
CC oligonucleotide about 19 to about 25 ribonucleotides in length or its  
CC equivalent. One strand of the oligonucleotide comprises the same  
CC nucleotide sequence as a region of a hepatitis C virus (HCV) target RNA  
CC polynucleotide sequence required for hepatitis C virus infection.  
CC replication or pathogenesis in vitro or in vivo in a host cell. The  
CC oligonucleotide of the invention demonstrates virucide activity and may  
CC be useful for preparing a composition or vaccine for treating or  
CC preventing hepatitis C virus, as well as during gene therapy procedures.  
CC The current sequence is that of the HCV coding region-derived conserved  
CC RNA sequence of the invention.  
XX  
SQ Sequence 19 BP; 11 A; 5 C; 2 G; 0 T; 1 U; 0 Other;  
XX  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 84.2%; Pred. No. 1.5e+02;  
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 222 CTCATAGAAAAACCAACG 240  
Db 1 CUCAAAGAAAAACCAACG 19  
XX  
RESULT 199  
ADP51715  
ID ADP51715 standard; RNA; 19 BP.  
XX  
AC ADP51715;  
XX  
DT 12-FEB-2004 (first entry)  
XX  
DE Hepatitis C virus short interfering nucleic acid sense strand SeqID305.  
XX  
KW short interfering nucleic acid; siNA; virus replication inhibition;  
KW hepatitis C virus; HCV; sugar modification; virucide; antiinflammatory;  
KW hepatotropic; cytostatic; RNA interference; HCV infection; liver failure;  
KW hepatocellular cancer; cirrhosis; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO2003070750-A2.  
XX  
PD 28-AUG-2003.  
XX  
PF 20-FEB-2003; 2003WO-US005043.  
XX  
PR 20-FEB-2002; 2002US-0359580P.  
PR 11-MAR-2002; 2002US-0363124P.  
PR 26-MAR-2002; 2002WO-US009187.  
PR 06-JUN-2002; 2002US-0386782P.  
PR 05-AUG-2002; 2002US-0401104P.  
PR 29-AUG-2002; 2002US-0406784P.  
PR 05-SEP-2002; 2002US-0408378P.  
PR 09-SEP-2002; 2002US-0409293P.  
PR 15-JAN-2003; 2003US-0440129P.  
XX  
PA (SIRN-) SIRNA THERAPEUTICS INC.  
XX  
PI Mcswiggen J, Beigelman L, Macejak D, Morrissey D;  
XX  
DR WPI; 2003-689778/65.  
XX  
PT New double-stranded short interfering nucleic acid comprises sugar-  
PT modified pyrimidine bases useful for treating infection with hepatitis C

PI Zhao G, Lu J, Glass JI, Martinez A, Yang Y;  
XX  
DR WPI; 2003-268345/26.  
XX  
PT New double stranded RNA oligonucleotide, useful for preparing a  
PT composition for treating or preventing hepatitis C virus.  
XX  
PS Disclosure; Page 61; 173pp; English.  
XX  
CC The invention relates to a novel isolated double stranded RNA  
CC oligonucleotide about 19 to about 25 ribonucleotides in length or its  
CC equivalent. One strand of the oligonucleotide comprises the same  
CC nucleotide sequence as a region of a hepatitis C virus (HCV) target RNA  
CC polynucleotide sequence required for hepatitis C virus infection.  
CC replication or pathogenesis in vitro or in vivo in a host cell. The  
CC oligonucleotide of the invention demonstrates virucide activity and may  
CC be useful for preparing a composition or vaccine for treating or  
CC preventing hepatitis C virus, as well as during gene therapy procedures.  
CC The current sequence is that of the HCV coding region-derived conserved  
CC RNA sequence of the invention.  
XX  
SQ Sequence 19 BP; 11 A; 5 C; 2 G; 0 T; 1 U; 0 Other;  
XX  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 84.2%; Pred. No. 1.5e+02;  
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
XX  
QY 222 CTCATAGAAAAACCAACG 240  
Db 1 CUCAAAGAAAAACCAACG 19  
XX  
RESULT 199  
ADP51715  
ID ADP51715 standard; RNA; 19 BP.  
XX  
AC ADP51715;  
XX  
DT 12-FEB-2004 (first entry)  
XX  
DE Hepatitis C virus short interfering nucleic acid sense strand SeqID305.  
XX  
KW short interfering nucleic acid; siNA; virus replication inhibition;  
KW hepatitis C virus; HCV; sugar modification; virucide; antiinflammatory;  
KW hepatotropic; cytostatic; RNA interference; HCV infection; liver failure;  
KW hepatocellular cancer; cirrhosis; ss.  
XX  
OS Hepatitis C virus.  
XX  
PN WO2003070750-A2.  
XX  
PD 28-AUG-2003.  
XX  
PF 20-FEB-2003; 2003WO-US005043.  
XX  
PR 20-FEB-2002; 2002US-0359580P.  
PR 11-MAR-2002; 2002US-0363124P.  
PR 26-MAR-2002; 2002WO-US009187.  
PR 06-JUN-2002; 2002US-0386782P.  
PR 05-AUG-2002; 2002US-0401104P.  
PR 29-AUG-2002; 2002US-0406784P.  
PR 05-SEP-2002; 2002US-0408378P.  
PR 09-SEP-2002; 2002US-0409293P.  
PR 15-JAN-2003; 2003US-0440129P.  
XX  
PA (SIRN-) SIRNA THERAPEUTICS INC.  
XX  
PI Mcswiggen J, Beigelman L, Macejak D, Morrissey D;  
XX  
DR WPI; 2003-689778/65.  
XX  
PT New double-stranded short interfering nucleic acid comprises sugar-  
PT modified pyrimidine bases useful for treating infection with hepatitis C

virus.

Example 3; SEQ ID NO 305; 183pp; English.

This invention relates to novel double-stranded short interfering nucleic acids (siRNA) that inhibits replication of hepatitis C virus (HCV), where one strand is an antisense strand (ASS) that is complementary to (part of) an HCV RNA (portion) and a sense strand (SS) that is complementary to ASS, and where most of the pyrimidine nucleotides comprise a sugar modification. The invention may allow development of compounds with virucide, antiinflammatory, hepatotropic or cytostatic activities by modulation (inhibition) of expression or activity of HCV RNA, by RNA interference. The siRNAs of the invention may be used to inhibit replication of HCV, in cells, tissue explants or organisms, for treating HCV infection and its consequences (liver failure; hepatocellular cancer and cirrhosis), and also for drug screening, diagnosis, target identification and validation, genetic engineering, pharmacogenomics, studying gene function and gene mapping (for example of single-nucleotide polymorphisms). The chemical modification improves stability, activity, cellular uptake and/or binding affinity. The siNA can be directed to conserved regions of HCV genes, so are active against many different strains.

Sequence 19 BP; 11 A; 5 C; 2 G; 0 T; 1 U; 0 Other;

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 84.2%; Pred. No. 1.5e+02;  
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0

OY 222 CTCATAGAAAAACAAACG 240  
|::| ||||| |||||  
Db 1 CUCAAGAAGAAAACCAACG 19

RESULT 200  
ADFS2411/c  
ID ADFS2411 standard; RNA; 19 BP.  
XX  
XX ADFS2411;  
DT 12-FEB-2004 (first entry)  
XX  
XX Hepatitis C virus siRNA antisense strand SeqID1001.  
DE short interfering nucleic acid; siRNA; virus replication inhibition;  
KW hepatitis C virus; HCV; sugar modification; virucide; antiinflammatory;  
KW hepatotropic; cystostatic; RNA interference; HCV infection; liver failure;  
KW hepatocellular cancer; cirrhosis; ss.  
XX  
XX Hepatitis C virus.  
OS  
PN WO2003070750-A2.  
XX  
XX 28-AUG-2003.  
XX  
XX 20-FEB-2003; 2003WO-US005043.  
XX  
XX 20-FEB-2002; 2002US-0358580P.  
PR 11-MAR-2002; 2002US-0363124P.  
PR 26-MAR-2002; 2002WO-US009187.  
PR 06-JUN-2002; 2002US-0386782P.  
PR 05-AUG-2002; 2002US-0401104P.  
PR 29-AUG-2002; 2002US-0406784P.  
PR 05-SEP-2002; 2002US-0408378P.  
PR 09-SEP-2002; 2002US-0409293P.  
PR 15-JAN-2003; 2003US-0440129P.  
XX  
XX (SIRN-) SIRNA THERAPEUTICS INC.  
PA  
XX Mcswiggen J, Beigelman L, Macejak D, Morrissey D;  
PI WPI; 2003-689778/65.  
XX  
XX

XX WPI; 2004-226852/21.  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 7; 63pp; English.  
XX  
XX The present sequence is the sense strand of a short interfering RNA  
CC (siRNA) targeted to human clusterin. The antisense strand is also  
CC provided ADL70463. The siRNA can be used to interfere with the expression  
CC of clusterin. Clusterin, also known as testosterone-repressed prostate  
CC message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
CC increased amounts by prostate tumour cells following androgen withdrawal,  
CC and has also been shown to be critical for neuritic toxicity in mouse  
CC models of Alzheimer's disease. siRNAs of the invention can be used alone  
CC or in combination with other chemotherapy or apoptosis inducing  
CC treatments for the treatment of prostate cancer, sarcomas such as  
CC osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
CC cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
CC melanoma, and also for the treatment of Alzheimer's disease.  
XX  
XX Sequence 19 BP; 8 A; 3 C; 1 G; 2 T; 5 U; 0 Other;  
SQ  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 1.5e+02;  
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
QY 1616 TAATTCAATTAATAACTGCT 1634  
DB 1 UAAUUCACACAAACUGUTT 19  
RESULT 202  
ADL70463/c  
ID ADL70463 standard; RNA; 19 BP.  
XX  
XX ADL70463;  
XX  
XX 20-MAY-2004 (first entry)  
DT  
DE RNAi for human clusterin.  
XX  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX Key Location/Qualifiers  
FH modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtdt"  
FT  
XX WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX  
XX 03-SEP-2002; 2002US-0408152P.  
XX  
XX 02-DEC-2002; 2002US-0319748P.  
XX  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX

DR WPI; 2004-226852/21.  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 8; 63pp; English.  
XX  
XX The present sequence is the antisense strand of a short interfering RNA  
CC (siRNA) targeted to human clusterin. The sense strand is also provided  
CC ADL70462. The siRNA can be used to interfere with the expression of  
CC clusterin. Clusterin, also known as testosterone-repressed prostate  
CC message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
CC increased amounts by prostate tumour cells following androgen withdrawal,  
CC and has also been shown to be critical for neuritic toxicity in mouse  
CC models of Alzheimer's disease. siRNAs of the invention can be used alone  
CC or in combination with other chemotherapy or apoptosis inducing  
CC treatments for the treatment of prostate cancer, sarcomas such as  
CC osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
CC cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
CC melanoma, and also for the treatment of Alzheimer's disease.  
XX  
XX Sequence 19 BP; 5 A; 1 C; 3 G; 2 T; 8 U; 0 Other;  
SQ  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 1.5e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1614 ACTAATTCATATAAACTGCT 1632  
DB 19 AATAATTCACACAACTGCT 1  
RESULT 203  
ADL70429/c  
ID ADL70429 standard; RNA; 19 BP.  
XX  
XX ADL70429;  
XX  
XX 20-MAY-2004 (first entry)  
DT  
DE RNAi for human clusterin.  
XX  
XX Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
XX Homo sapiens.  
OS Synthetic.  
XX  
XX Key Location/Qualifiers  
FH modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX  
XX 03-SEP-2002; 2002US-0408152P.  
XX  
XX 02-DEC-2002; 2002US-0319748P.  
XX  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
PI  
XX WPI; 2004-226851/21.  
DR

XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.

XX Claim 20; SEQ ID NO 27; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.

XX Sequence 19 BP; 5 A; 1 C; 3 G; 2 T; 8 U; 0 Other;

XX Query Match 1.0%; Score 15.8; DB 1; Length 19;  
PS Best Local Similarity 89.5%; Pred. No. 1.5e+02;  
PT Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1614 ACTAATTCAATAAACTGT 1632  
DB 19 AATAATTCAACAAACTGT 1

RESULT 204  
ADL70426  
ID ADL70426 standard; RNA; 19 BP.  
XX  
AC ADL70426;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.

XX Key Location/Qualifiers  
FH modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX  
XX 03-SEP-2002; 2002US-0408152P.  
XX  
XX 02-DEC-2002; 2002US-0319748P.  
XX  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of

PT clusterin in the melanoma cells.

XX Claim 10; SEQ ID NO 24; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.

XX Sequence 19 BP; 8 A; 3 C; 1 G; 2 T; 5 U; 0 Other;

XX Query Match 1.0%; Score 15.8; DB 1; Length 19;  
PS Best Local Similarity 63.2%; Pred. No. 1.5e+02;  
PT Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCAATAAACTGTCT 1634  
DB 1 UAAUUCACAAACACUGUTT 19

RESULT 205  
ADL70428  
ID ADL70428 standard; RNA; 19 BP.  
XX  
AC ADL70428;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.

XX Key Location/Qualifiers  
FH modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX  
XX 03-SEP-2002; 2002US-0408152P.  
XX  
XX 02-DEC-2002; 2002US-0319748P.  
XX  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEA/) GLEAVE M E.  
XX  
XX Jansen B;  
XX  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.

XX Claim 20; SEQ ID NO 26; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xL in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xL  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xL is known to act as an inhibitor  
CC of apoptosis.  
XX  
SQ Sequence 19 BP; 8 A; 3 C; 1 G; 2 T; 5 U; 0 Other;  
  
Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 1.5e+02;  
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1616 TAATTCATAATAAACTGTCT 1634  
Db :||:|||||:|  
1 UAAUUAUCAAACAACUGUTT 19  
  
RESULT 206  
AAT41543  
ID AAT41543 standard; DNA; 17 BP.  
AC AAT41543;  
XX  
XX 24-JUN-1997 (first entry)  
XX Human apolipoprotein-J gene J1-allelic specific primer/probe.  
XX  
XX Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;  
KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;  
KW diagnosis; ss.  
XX  
XX Synthetic.  
OS  
XX WO9632502-Al.  
PN  
XX 17-OCT-1996.  
PD  
XX 02-APR-1996; 96WO-US004510.  
PF  
XX 11-APR-1995; 95US-00420291.  
PR  
XX (UYCO ) UNIV COLUMBIA NEW YORK.  
PA  
XX Mayeux R, Tycko B;  
PI  
XX WPI; 1996-477152/47.  
DR  
XX New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used  
PT to identify patients susceptible to Alzheimer's disease or prostate  
PT cancer.  
XX  
PS Example 1; Page 21; 62pp; English.  
XX  
XX AAT41542 and AAT41543 are J1 allele-specific primer/probes used as  
CC controls in an example of a method for detecting polymorphisms associated  
CC with an allelic variation in the human apolipoprotein-J (ApoJ) gene. The  
CC oligonucleotide (OG) detects the probability of a person developing  
CC Alzheimer's disease (AD), preferably in patients of African or Hispanic  
CC descent. The OG also detects the probability of a person developing a  
CC cognitive disorder, or a prostatic carcinoma. Transgenic mammals  
CC expressing an allelic variant of an ApoJ gene may be used as a prognostic  
CC and diagnostic means for studying AD, and to determine the effectiveness  
CC of therapeutic drugs  
XX  
SQ Sequence 17 BP; 5 A; 6 C; 3 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 1023 GAGCTCGACCAATCCCT 1039  
Db :|||||:|  
1 GAGCTCAACGAATCCCT 17  
  
RESULT 207  
AAT41525  
ID AAT41525 standard; DNA; 17 BP.  
XX  
XX AAT41525;  
XX  
XX 24-JUN-1997 (first entry)  
XX Human apolipoprotein-J gene J2-allelic variant primer/probe.  
XX  
XX Apolipoprotein J; ApoJ; polymorphism; detection; allele; exon; probe;  
KW primer; specific; Alzheimer's disease; polymerase chain reaction; PCR;  
KW diagnosis; ss.  
XX  
XX Synthetic.  
OS  
XX WO9632502-Al.  
PN  
XX 17-OCT-1996.  
PD  
XX 02-APR-1996; 96WO-US004510.  
PF  
XX 11-APR-1995; 95US-00420291.  
PR  
XX (UYCO ) UNIV COLUMBIA NEW YORK.  
PA  
XX Mayeux R, Tycko B;  
PI  
XX WPI; 1996-477152/47.  
DR  
XX New oligo:nucleotide specific for apolipoprotein-J polymorphisms - used  
PT to identify patients susceptible to Alzheimer's disease or prostate  
PT cancer.  
XX  
PS Claim 27; Page 40; 62pp; English.  
XX  
XX AAT41525 is a primer/probe used to detect a J2 allelic variation in the  
CC human apolipoprotein-J (ApoJ) gene. The primer/probe is used for  
CC detecting polymorphisms associated with an allelic variation in the ApoJ  
CC gene. The oligonucleotide (OG) detects the probability of a person  
CC developing Alzheimer's disease (AD), preferably in patients of African or  
CC Hispanic descent. The OG also detects the probability of a person  
CC developing a cognitive disorder, or a prostatic carcinoma. Transgenic  
CC mammals expressing an allelic variant of an ApoJ gene may be used as a  
CC prognostic and diagnostic means for studying AD, and to determine the  
CC effectiveness of therapeutic drugs  
XX  
SQ Sequence 17 BP; 4 A; 9 C; 1 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 984 TGTTCACCAACCAACCC 1000  
Db :|||||:|  
1 TGTTCACCAACCAACCC 17  
  
RESULT 208  
AAX63903/c  
ID AAX63903 standard; RNA; 17 BP.  
XX  
AC AAX63903;



XX 20-JUL-1999 (first entry)  
DT  
XX Rabbit stromelysin hammerhead target SEQ ID NO:535.  
DE  
XX  
XX Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
KW diagnosis; ss.  
XX  
XX Oryctolagus cuniculus.  
OS  
XX  
XX WO9618736-A2.  
PN  
XX  
XX 20-JUN-1996.  
PD  
XX  
XX 22-NOV-1995; 95WO-US015516.  
PF  
XX  
XX 13-DEC-1994; 94US-00354920.  
PR  
XX 23-DEC-1994; 94US-00363253.  
PR  
XX 17-FEB-1995; 94US-00363254.  
PR  
XX 20-APR-1995; 95US-00390850.  
PR  
XX 02-MAY-1995; 95US-00426124.  
PR  
XX 04-MAY-1995; 95US-00432874.  
PR  
XX 07-JUL-1995; 95US-00434509.  
PR  
XX 07-JUL-1995; 95US-0000951P.  
PR  
XX 07-AUG-1995; 95US-0000974P.  
PR  
XX 05-OCT-1995; 95US-00512861.  
PR  
XX 05-OCT-1995; 95US-00541365.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI McSwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
XX WPI; 1996-300653/30.  
DR  
XX  
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
PT  
XX  
XX Example 1; Page 154; 307pp; English.  
PS  
XX  
XX The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment  
CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 4 A; 2 C; 4 G; 0 T; 7 U; 0 Other;

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1589 AAGAACAGAAATGGTCC 1605  
DB 17 AAGAACAGAAATTTCTCC 1

RESULT 209  
ABK00170/c  
ID ABK00170 standard; RNA; 17 BP.  
XX  
AC ABK00170;  
XX  
DT 12-MAR-2002 (first entry)  
XX  
DE Human NOGO Hammerhead Ribozyme #170.  
XX  
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;  
KW DNzyme; inozyme; G-cleaver; amberyzyme; zinzyme; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
XX WO200159103-A2.  
PN  
XX  
XX 16-AUG-2001.  
PD  
XX  
XX 09-FEB-2001; 2001WO-US004273.  
PF  
XX  
XX 11-FEB-2000; 2000US-0181797P.  
PR  
XX 28-FEB-2000; 2000US-0185516P.  
PR  
XX 06-MAR-2000; 2000US-0187128P.  
PR  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
XX Blatt L, McSwiggen J, Chowrira BM;  
PI  
XX WPI; 2001-607195/69.  
DR  
XX  
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
CC constructs, which down regulate expression of a CD20 gene or neurite  
CC growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
CC central nervous system injury.  
PT  
XX  
XX Claim 88; Page 68; 200pp; English.  
PS  
XX  
XX The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNzyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
CC an amberyzyme (cleaving RNA with an NGN triplet), a zinzyme (cleaving RNA  
CC with a YGV motif). The CD20-targeting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the

CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a hammerhead ribozyme of the invention  
XX  
XX Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;  
XX  
XX Query Match 0.9%; Score 15.4; DB 1; Length 17;  
XX Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
XX QY 1619 TTCATTAATAAAGTGTCTT 1635  
XX Db 17 TTCATTAATAAAGTGTCTT 1  
XX  
XX RESULT 210  
XX ABN08674  
XX ID ABN08674 standard; DNA; 17 BP.  
XX AC ABN08674;  
XX  
XX 29-MAY-2002 (first entry)  
XX  
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8666.  
XX  
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
XX skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX Homo sapiens.  
XX  
XX W0200192524-A2.  
XX  
XX 06-DEC-2001.  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX  
XX 21-SEP-2000; 2000US-0234687P.  
XX  
XX 27-SEP-2000; 2000US-0236359P.  
XX  
XX 04-OCT-2000; 2000GB-00024263.  
XX  
XX 30-JAN-2001; 2001WO-US000661.  
XX  
XX 30-JAN-2001; 2001WO-US000662.  
XX  
XX 30-JAN-2001; 2001WO-US000663.  
XX  
XX 30-JAN-2001; 2001WO-US000664.  
XX  
XX 30-JAN-2001; 2001WO-US000665.  
XX  
XX 30-JAN-2001; 2001WO-US000666.  
XX  
XX 30-JAN-2001; 2001WO-US000667.  
XX  
XX 30-JAN-2001; 2001WO-US000668.  
XX  
XX 30-JAN-2001; 2001WO-US000669.  
XX  
XX 30-JAN-2001; 2001WO-US000670.  
XX  
XX 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX or as specific biomolecule capture probes for surface-enhanced laser  
XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 8666; 214pp; English.

XX The present invention describes a human genome-derived myosin-like  
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX nucleic acids can be used as probes to detect, characterise and quantify  
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX protein variants having desired phenotypic improvements, and for  
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP  
XX -1 proteins, as standards in assays used to determine the concentration  
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
XX capture probes for surface-enhanced laser desorption/ionisation, as  
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
XX production, and in vaccines or for replacement therapy. The  
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
XX disorder associated with the expression of hGDMPLP-1, in particular heart  
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
XX The present sequence represents an oligomer used in the screening of the  
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
XX The sequence data for this patent did not form part of the printed  
XX specification, but was obtained in electronic format directly from WIPO  
XX at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
XX Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;  
XX  
XX Query Match 0.9%; Score 15.4; DB 1; Length 17;  
XX Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
XX Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
XX  
XX QY 273 GAAGCCACAGAGAGAA 289  
XX Db 1 GAAGCCACAGAGAGAA 17  
XX  
XX RESULT 211  
XX ADB00465/c  
XX ID ADB00465 standard; DNA; 17 BP.  
XX AC ADB00465;  
XX  
XX 20-NOV-2003 (first entry)  
XX  
XX Human MDZ3 scanning oligonucleotide SEQ ID 1451.  
XX  
XX Cytostatic; immunostimulant; gene therapy; vaccine; human;  
XX zinc finger protein; MDZ3; MDZ4; MDZ7; chromosome 7q22.1;  
XX chromosome 6p21.3-22.2; chromosome 16p11.2; chromosome 15q26.1; cancer;  
XX developmental disorder; ss.  
XX  
XX Homo sapiens.  
XX  
XX EP1281758-A2.  
XX  
XX 05-FEB-2003.  
XX  
XX 30-JUL-2002; 2002EP-00016874.  
XX  
XX 02-AUG-2001; 2001US-00922181.  
XX  
XX (AEOM-) AEOMICA INC.  
XX  
XX Shannon M, Gu Y, Nguyen C;  
XX  
XX WPI; 2003-423107/40.  
XX  
XX New zinc finger-containing proteins and nucleic acids, useful in  
XX manufacturing a medicament for treating or preventing a disorder  
XX associated with decreased or increased expression or activity of MDZ3,  
XX MDZ4, MDZ7 or MDZ12, e.g. cancer.  
XX  
XX Example 8; SEQ ID NO 1451; 103pp; English.

CC	The present invention relates to novel human zinc finger-containing	DR	WPI; 2003-229207/22.
CC	proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is	XX	Novel compound useful for treating cirrhosis, liver failure,
CC	encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,	PT	hepatocellular carcinoma, or condition associated with hepatitis C virus
CC	MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome	PT	infection.
CC	15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,	XX	
CC	or in manufacturing a medicament for treating or preventing a disorder	PS	Claim 1; Page 288; 387pp; English.
CC	associated with decreased or increased expression or activity of MD23,	XX	The present invention relates to nucleic acid molecules which modulate
CC	MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic	CC	the synthesis, expression and/or stability of Hepatitis C virus (HCV) or
CC	acids and proteins are also useful for diagnosing or monitoring a disease	CC	Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense
CC	caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic	CC	and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,
CC	acids can also be used as probes to detect and characterize gross	CC	inozymes, zinyzemes, amberzemes, and G-cleaver ribozymes. Also disclosed
CC	alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are	CC	are nucleic acid decoy molecules and aptamers that bind to HBV reverse
CC	useful in constructing microarrays for measuring gene expression. The	CC	transcriptase and/or HBV reverse transcriptase primer sequences, as well
CC	proteins are useful as therapeutic agents for gene therapy or as	CC	as oligonucleotides that specifically bind the Enhancer I region of HBV
CC	vaccines. The present sequence was used to illustrate the invention.	CC	DNA. The nucleic acids may be used to modulate the expression of HBV
XX		CC	genes and HBV viral replication. Also disclosed is a method for screening
SQ	Sequence 17 BP; 3 A; 7 C; 5 G; 2 T; 0 U; 0 Other;	CC	compounds and/or potential therapies directed against HBV, and compounds
	Query Match 0.9%; Score 15.4; DB 1; Length 17;	CC	that modulate the expression and/or replication of HCV. The compounds and
	Best Local Similarity 94.1%; Pred. No. 1.1e+02;	CC	methods of the invention are useful for the treatment of degenerative and
	Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	CC	disease states related to HBV and HCV infection, replication and gene
		CC	expression such as cirrhosis, liver failure, and hepatocellular
OY	928 GCTGCCTCGCGATGAAG 944	CC	carcinoma. The present sequence represents a substrate for one of the HCV
		CC	carcinoma. The present sequence represents a substrate for one of the HCV
Db	17 GCTGCCTCGCGCTGAAG 1	CC	invention
		XX	
RESULT 212		SQ	Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
ACD62817/c			Query Match 0.9%; Score 15.4; DB 1; Length 17;
ID	ACD62817 standard; RNA; 17 BP.		Best Local Similarity 94.1%; Pred. No. 1.1e+02;
XX			Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
AC	ACD62817;		
XX			
DT	24-SEP-2003 (first entry)		
XX			
DE	HCV minus strand DNazyme substrate sequence #736.		
XX			
KW	Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;		
KW	RNA stability; RNA expression; RNA synthesis; antisense;		
KW	enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinyzeme;		
KW	amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;		
KW	HBV reverse transcriptase; Enhancer I region; viral replication;		
KW	degenerative; disease state; HBV infection; HCV infection; cirrhosis;		
KW	liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;		
KW	virucide; antiinflammatory; substrate; ss.		
XX			
OS	Hepatitis C virus.		
XX			
PN	WO200281494-A1.		
XX			
PD	17-OCT-2002.		
XX			
PF	26-MAR-2002; 2002WO-US009187.		
XX			
PR	26-MAR-2001; 2001US-00817879.		
PR	08-JUN-2001; 2001US-00877478.		
PR	08-JUN-2001; 2001US-0296876P.		
PR	24-OCT-2001; 2001US-0335059P.		
PR	05-DEC-2001; 2001US-0337055P.		
XX			
PA	(RIBO-) RIBOZYME PHARM INC.		
PA	(BLAT/) BLATT L.		
PA	(MACE/) MACEJAK D.		
PA	(MCSW/) MCSWIGGEN J.		
PA	(MORR/) MORRISSEY D.		
PA	(PAVC/) PAVCO P.		
PA	(LEEP/) LEE P.		
PA	(DRAP/) DRAPER K.		
PA	(ROBE/) ROBERTS E.		
XX			
PI	Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;		
PI	Draper K, Roberts E;		
XX			

XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV; RNA stability; RNA expression; RNA synthesis; antisense; enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinyzeme; amberzyme; G-cleaver ribozyme; decoy molecule; aptamer; HBV reverse transcriptase; Enhancer I region; viral replication; degenerative; disease state; HBV infection; HCV infection; cirrhosis; liver failure; hepatocellular carcinoma; hepatotropic; cytostatic; virucide; antiinflammatory; substrate; ss.

OS Hepatitis C virus.

XX WO200281494-A1.

PN 17-OCT-2002.

XX 26-MAR-2002; 2002WO-US009187.

XX 26-MAR-2001; 2001US-00817879.

PR 08-JUN-2001; 2001US-00877478.

PR 08-JUN-2001; 2001US-0296876P.

PR 24-OCT-2001; 2001US-0335059P.

PR 05-DEC-2001; 2001US-0337055P.

XX (RIBO-) RIBOZYME PHARM INC.

XX (BLAT/) BLATT L.

XX (MACE/) MACEJAK D.

XX (MCSW/) MCSWIGGEN J.

XX (MORR/) MORRISSEY D.

XX (PAVC/) PAVCO P.

XX (LEEP/) LEE P.

XX (DRAP/) DRAPER K.

XX (ROBE/) ROBERTS E.

XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;

PI Draper K, Roberts E;

XX

PA (MACE/) MACEJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEF/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.  
XX  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
XX  
XX WPI; 2003-229207/22.  
XX  
XX Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
XX  
XX Claim 1; Page 261; 387pp; English.  
XX  
XX The present invention relates to nucleic acid molecules which modulate  
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNzyme or minus strand DNzyme sequences disclosed in the present  
CC invention  
XX  
XX Sequence 17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;  
SQ  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 1.1e+02;  
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;  
QY 766 TCCACGCCATGTTCCAG 782  
Db :|||||:|:|:  
1 UCCACGCCAUGUCCGG 17  
RESULT 214  
ADB45503  
ID ADB45503 standard; DNA; 17 BP.  
XX  
XX ADB45503;  
XX  
XX 18-DEC-2003 (first entry)  
XX  
XX Tumour suppression/reversion associated nucleotide #5826.  
XX  
XX cytostatic; antiviral; neuroprotective; nootropic; neuroleptic; ss;  
KW primer; probe; tumour suppression; tumour reversion; apoptosis;  
KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
KW diagnosis.  
XX  
XX Homo sapiens.  
OS  
XX WO2003040369-A2.  
FN  
XX 15-MAY-2003.  
PD  
XX 17-SEP-2002; 2002WO-IB004219.  
PF  
XX 17-SEP-2001; 2001FR-00011981.  
PR

XX (MOLE-) MOLECULAR ENGINES LAB.  
XX  
XX Telerman A, Amson R, Tuijnder M;  
XX  
XX WPI; 2003-441574/41.  
XX  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX  
XX Disclosure; Page 713; 771pp; French.  
XX  
XX The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX  
XX Sequence 17 BP; 4 A; 7 C; 2 G; 4 T; 0 U; 0 Other;  
SQ  
Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 1.1e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1551 GATCTGCACTCTAACA 1567  
Db :|||||:|:|:  
1 GATCTGCACTCTACCA 17  
RESULT 215  
ADI84296  
ID ADI84296 standard; RNA; 17 BP.  
XX  
XX ADI84296;  
XX  
XX 03-JUN-2004 (first entry)  
XX  
XX HCV DNzyme substrate sequence #1542.  
XX  
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
KW HCV infection; type I interferon; DNzyme.  
XX  
XX Hepatitis C virus.  
OS  
XX US2003125270-A1.  
PN  
XX 03-JUL-2003.  
PD  
XX 18-DEC-2000; 2000US-00740332.  
PF  
XX 18-DEC-2000; 2000US-00740332.  
PR  
XX (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (ROBE/) ROBERTS E.  
PA (PAVC/) PAVCO P A.  
PA (MACE/) MACEJACK D.  
PA

```
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 1542; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNase substrate
CC sequence.
XX
XX Sequence 17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;
SQ
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 1.1e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 766 TCCACGCCATGTTCCAG 782
DB 1 UCCACGCCAUGUCCGG 17
RESULT 216
ACNT1764
ID ACNT1764 standard; DNA; 17 BP.
XX
XX ACNT1764;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMPLP-1 probe SEQ ID NO:8666.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;
XX hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
XX
XX 30-JAN-2001; 2001WO-US000665.
XX
XX 30-JAN-2001; 2001WO-US000666.
XX
XX 30-JAN-2001; 2001WO-US000667.
XX
XX 30-JAN-2001; 2001WO-US000668.
XX
XX 30-JAN-2001; 2001WO-US000669.
XX
XX 05-FEB-2001; 2001WO-US000670.
XX
XX 25-MAY-2001; 2001US-0266860P.
XX
XX 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA
(HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
PI WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
PT associated with decreased expression or activity of human genome-derived
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle
PT function.
XX
XX Disclosure; SEQ ID NO 8666; 0pp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully
CC defined in the specification, a fragment of at least 8 amino acids of
CC (S1), 95% deviation from (S1) which are conservative substitutions, and
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A
CC pharmaceutical composition of the invention is useful for treating or
CC preventing a disorder associated with decreased expression or activity of
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.
CC The present sequence represents a 17-mer nucleotide, used in the
CC invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 1.1e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 273 GAAGCCCAAGAGAGAA 289
DB 1 GAAGCCCAAGAGAGAGAA 17
RESULT 217
AA85604/C
ID AA85604 standard; DNA; 18 BP.
XX
XX AA85604;
XX
XX 06-SEP-1999 (first entry)
XX
XX PCR primer for DNA encoding a human growth factor designated zapol.
XX
XX Human; growth factor; zapol; angiotensin homologue; cell growth;
XX tissue development; multimeric protein; hematopoietic; angiogenic;
XX tissue revascularization; full-thickness skin wound; venous stasis ulcer;
XX fracture repair; skin grafting; reconstructive surgery;
XX transplanted cell; PCR primer; ss.
XX
XX Synthetic.
XX
XX Homo sapiens.
XX
XX W09932515-A2.
XX
XX 01-JUL-1999.
XX
XX 17-DEC-1998; 98WO-US027055.
XX
XX 19-DEC-1997; 97US-0068268P.
XX
XX (ZYMO) ZYMOGENETICS INC.
XX
XX Presnell SR, Conklin DC;
XX
XX WPI; 1999-405158/34.
XX
XX Zapol, a novel angiotensin homologue, and related DNA, useful for the
```

CC (comprising at least 8 contiguous nucleotides where one of the  
CC nucleotides is an SNP as cited above, or their complement), an isolated  
CC polypeptide comprising an amino acid sequence selected from any of the  
CC 696 amino acid sequences (not defined in the specification), an antibody  
CC that specifically binds to the polypeptide (or its antigen-binding  
CC fragment), an amplified polynucleotide containing the SNP as cited (where  
CC the amplified polynucleotide is between about 16 and about 1,000  
CC nucleotides in length), an isolated polynucleotide which specifically  
CC hybridises to a nucleic acid molecule containing the SNP, a kit for  
CC detecting a SNP in a nucleic acid, detecting a SNP in a nucleic acid  
CC molecule, detecting a variant polypeptide and identifying an agent useful  
CC in therapeutically or prophylactically treating stenosis. The detection  
CC step of the method is carried out by a process selected from allele-  
CC specific probe hybridisation, allele-specific primer extension, allele-  
CC specific amplification, sequencing, 5' nuclease digestion, molecular  
CC beacon assay, oligonucleotide ligation assay, size analysis, and single-  
CC stranded conformation polymorphism. The method is useful for identifying  
CC an individual who has altered risk for developing coronary stenosis,  
CC which can lead to angina (ischaemic chest pain), myocardial infarction  
CC and ultimately sudden cardiac death. The present sequence is an allele  
CC specific primer for amplifying a SNP-containing region of a human marker  
CC gene associated with stenosis. NOTE: SEQ ID 1-67771 are not shown in the  
CC specification but are provided on a CD-R named CU001510CDR which was not  
CC supplied with the specification.

XX Sequence 18 BP; 4 A; 3 C; 5 G; 5 T; 0 U; 1 Other;

QY 500 CTTCTGGATGATGGTGA 517  
DB 1 CTTCTGCANGAATGGTGA 18

RESULT 219  
AAV31968/c  
ID AAV31968 standard; DNA; 15 BP.  
XX  
AC AAV31968;  
DT 21-AUG-1998 (first entry)  
XX  
DE Peptide nucleic acid probe 111.  
XX  
KW Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;  
KW ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.  
XX  
OS Synthetic.  
OS Mycobacterium sp.  
XX  
XX Key Location/Qualifiers  
FH modified\_base 1..15  
FT /\*tag= a  
FT /note= "This sequence contains a polyamide backbone  
FT instead of a deoxyribose backbone"  
XX  
XX WO9815648-A1.  
XX  
XX 16-APR-1998.  
XX  
XX 03-OCT-1997; 97WO-DK000425.  
XX  
XX 04-OCT-1996; 96DK-00001096.  
XX 18-OCT-1996; 96DK-00001156.  
XX 05-MAY-1997; 97DK-00000512.  
XX (DAKO-) DAKO AS.  
XX Stender H, Lund K, Mollerup TA;  
XX WPI; 1998-240831/21.  
DR

PT study and regulation of angiogenesis and for developing inhibitors.  
XX  
PS Example 3; Page 55; 56pp; English.  
XX  
CC PCR primers AAX85603-04 were used to amplify DNA encoding a human growth  
CC factor designated zapol. Zapol is an angiotensin homologue. The  
CC polypeptide is used to stimulate cell growth and tissue development. The  
CC polypeptides form multimeric proteins. Zapol has angiogenic or  
CC hematopoietic activity. The proteins can be used in assays for angiogenic  
CC activity. Zapol proteins may be used therapeutically to stimulate  
CC revascularization of tissue. Specific applications include treatment of  
CC chronic, non-healing wounds, including venous stasis ulcers and other  
CC full-thickness skin wounds, as well as fracture repair, skin grafting,  
CC reconstructive surgery, and establishment of vascular networks in  
CC transplanted cells and tissues. Zapol is also useful as a research agent,  
CC such as in the expansion of hematopoietic cells (including stem cells)  
CC and endothelial cells. The polypeptides are added to tissue culture media  
CC for these cell types

XX Sequence 18 BP; 1 A; 7 C; 4 G; 6 T; 0 U; 0 Other;

QY 284 GAAGAAGAGGATGCC 300  
DB 18 GAAGAAGAGGCTGCC 2

RESULT 218  
ADR74784  
ID ADR74784 standard; DNA; 18 BP.  
XX  
AC ADR74784;  
DT 16-DEC-2004 (first entry)  
XX  
DE Allele specific primer A for human stenosis marker hCV25612495.  
XX  
KW Human; ss; PCR; primer; Allele specific primer; coronary stenosis;  
KW angina; ischaemic chest pain; myocardial infarction;  
KW sudden cardiac death; SNP; single nucleotide polymorphism.  
XX  
OS Homo sapiens.  
XX  
XX WO2004081186-A2.  
XX  
XX 23-SEP-2004.  
XX  
XX 10-MAR-2004; 2004WO-US007140.  
XX  
XX 10-MAR-2003; 2003US-0453050P.  
XX 30-APR-2003; 2003US-0466437P.  
XX  
XX (APPL-) APPLERA CORP.  
XX  
XX Cargill M, Devlin J, Luke MW;  
XX  
XX WPI; 2004-668949/65.  
XX  
XX Identifying an individual who has altered risk for developing stenosis  
XX comprises detecting single nucleotide polymorphism (SNP), in the  
XX individual's nucleic acids.  
XX  
XX Claim 19; SEQ ID NO 68096; 146pp; English.  
XX  
CC The invention relates to identifying an individual who has altered risk  
CC for developing coronary stenosis comprising detecting a single nucleotide  
CC polymorphism (SNP) in any one of the 67073 nucleotide sequences (not  
CC given in the specification), in the individual's nucleic acids, where the  
CC presence of the SNP is correlated with an altered risk for stenosis in  
CC the individual. Also included are an isolated nucleic acid molecule

XX Peptide nucleic acid probes for detection of ribosomal nucleic acid of  
PT mycobacteria - allow differentiation between species of tuberculosis  
PT complex and others and can penetrate cell membranes without pretreatment.  
XX  
XX Claim 22; Page 67; 106pp; English.  
XX  
XX This is the nucleotide sequence of the peptide nucleic acid (PNA) probe  
CC used in the method of the invention, to detect ribosomal nucleic acid of  
CC mycobacteria. The probes are used, in situ or in vitro, for detection of  
CC the Mycobacterium tuberculosis complex (MTC), specifically M.  
CC tuberculosis, and especially in sputum samples, but also in other body  
CC fluids, biopsy specimens, foods, soil, air and water. Particularly, they  
CC are used to diagnose, stage or monitor infection, or for identification  
CC of drug-resistant strains (which generally have mutations in rRNA)  
XX  
XX Sequence 15 BP; 3 A; 2 C; 1 G; 9 T; 0 U; 0 Other;  
SQ  
Query Match 0.9%; Score 15; DB 1; Length 15;  
Best Local Similarity 100.0%; Pred. No. 83;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 177 AAGGAATTCAAAAT 191  
DB 15 AAGGAATTCAAAAT 1  
RESULT 220  
ACD62818/c  
ID ACD62818 standard; RNA; 17 BP.  
XX  
XX ACD62818;  
XX  
XX 24-SEP-2003 (first entry)  
XX  
XX HCV minus strand DNazyme substrate sequence #737.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
XX RNA stability; RNA expression; RNA synthesis; antisense;  
XX enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
XX amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
XX HBV reverse transcriptase; Enhancer I region; viral replication;  
XX degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
XX liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
XX virucide; antiinflammatory; substrate; ss.  
XX  
XX Hepatitis C virus.  
XX  
XX WO200281494-A1.  
XX  
XX 17-OCT-2002.  
XX  
XX 26-MAR-2002; 2002WO-US009187.  
XX  
XX 26-MAR-2001; 2001US-00817879.  
XX  
XX 08-JUN-2001; 2001US-00877478.  
XX  
XX 08-JUN-2001; 2001US-0296876P.  
XX  
XX 24-OCT-2001; 2001US-0335059P.  
XX  
XX 05-DEC-2001; 2001US-0337055P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX (BLAT/) BLATT L.  
XX  
XX (MACE/) MACEJACK D.  
XX  
XX (MCSW/) MCSWIGGEN J.  
XX  
XX (MORR/) MORRISSEY D.  
XX  
XX (PVC/) PAVCO P.  
XX  
XX (LEEP/) LEE P.  
XX  
XX (DRAP/) DRAPER K.  
XX  
XX (ROBE/) ROBERTS E.  
XX  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
PT

DR WPI; 2003-229207/22.  
XX  
XX Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
XX  
XX Claim 1; Page 288; 387pp; English.  
XX  
XX The present invention relates to nucleic acid molecules which modulate  
CC the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV, and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNazyme or minus strand DNazyme sequences disclosed in the present  
CC invention  
XX  
XX Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;  
SQ  
Query Match 0.9%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 766 TCCACGCCATGTTCC 780  
DB 15 TCCACGCCATGTTCC 1  
RESULT 221  
AD185768/c  
ID AD185768 standard; RNA; 17 BP.  
XX  
XX AD185768;  
XX  
XX 03-JUN-2004 (first entry)  
XX  
XX HCV DNazyme substrate sequence #3014.  
XX  
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
XX HCV infection; type I interferon; DNazyme.  
XX  
XX Hepatitis C virus.  
XX  
XX US2003125270-A1.  
XX  
XX 03-JUL-2003.  
XX  
XX 18-DEC-2000; 2000US-00740332.  
XX  
XX 18-DEC-2000; 2000US-00740332.  
XX  
XX (BLAT/) BLATT L.  
XX  
XX (MCSW/) MCSWIGGEN J.  
XX  
XX (ROBE/) ROBERTS E.  
XX  
XX (PVC/) PAVCO P A.  
XX  
XX (MACE/) MACEJACK D.  
XX  
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
PI  
XX WPI; 2004-031273/03.  
XX  
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived  
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
PT

```
PT especially in combination with type I interferon therapy.
XX
PS Claim 1; SEQ ID NO 3014; 198pp; English.
XX
CC The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNase substrate
CC sequence.
XX
XX Sequence 17 BP; 4 A; 3 C; 8 G; 0 T; 2 U; 0 Other;
SQ
Query Match 0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 766 TCCACGCCATGTTCC 780
Db 15 TCCACGCCATGTTCC 1
RESULT 223
AD079635/c
ID AD079635 standard; DNA; 17 BP.
XX
AC AD079635;
XX
XX 26-AUG-2004 (first entry)
XX
XX KIAA0783 extend primer #27.
XX
XX Cytostatic; Gene therapy; breast cancer; human; DLG1; KIAA0783; DPF3;
XX CENPC1; SNP; single nucleotide polymorphism; PHF14;
XX PHD finger protein 14; chromosome 7p21.3; zinc finger protein;
XX transcription factor; extend; primer; ss.
XX
XX Homo sapiens.
XX
XX WO2004047514-A2.
XX
XX 10-JUN-2004.
XX
XX 25-NOV-2003; 2003WO-US037943.
XX
XX 25-NOV-2002; 2002US-0429136P.
XX
XX 24-JUL-2003; 2003US-0490234P.
XX
XX (SEQU-) SEQUENOM INC.
XX
XX Roth RB, Nelson MR, Braun A, Kammerer SM, Reneland R;
XX
XX WPI; 2004-441037/41.
XX
XX Identifying a subject at risk of breast cancer by detecting the presence
XX of polymorphic variations in the DLG1, KIAA0783, DPF3 or CENPC1 regions
XX which are associated with breast cancer in a nucleic acid sample from a
XX subject.
XX
XX Example 4; Page 78; 227pp; English.
XX
XX The present invention relates to a method for identifying a subject at
XX risk of breast cancer. The method comprising detecting the presence or
XX absence of one or more polymorphic variations associated with breast
XX cancer in a nucleic acid sample from a subject. The nucleic acid sample
XX comprises the DLG1 region (AD079402), KIAA0783 region (AD079403), DPF3
XX region (AD079404) or CENPC1 region (AD079405). The gene DLG1 (discs,
XX large homolog 1 (Drosophila)) is also known as synapse-associated protein
XX 97, hdlg or SAP97. DLG1 has been mapped to chromosomal position 3q29. The
XX gene KIAA0783 is also known as PHF14 and PHD finger protein 14. KIAA0783
XX has been mapped to chromosomal position 7p21.3. The KIAA0783 protein is a
XX
```

```
CC novel gene with unknown function, however, being a zinc finger protein,
CC it likely to be a transcription factor. The gene DPF3 (D4, zinc and
CC double PHD fingers, family 3) is also known as CERD4, cer-04, FLJ14079
CC and 2810403B03Rik. DPF3 is a Rho family guanine-nucleotide exchange
CC factor. DPF3 has been mapped to chromosomal position 14q24.3-q31.1. The
CC gene CENPC1 (centromere protein C1) is also known as Centromere
CC autoantigen C1. CENPC1 has been mapped to chromosomal position 4q12-
CC q13.3. CENPC1 is a centromere autoantigen and a component of the inner
CC kinetochore plate. The CENPC1 protein is required for maintaining proper
CC kinetochore size and a timely transition to anaphase. The method is
CC useful for identifying a subject at risk of breast cancer, for early
CC diagnosis, prevention and treatment of breast cancer, to analyze and
CC predict a response to a breast cancer treatment, and in clinical drug
CC trials. The present sequence was used in an example from the invention.
XX
XX Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;
SQ
Query Match 0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 438 AGTGGCTCAGGCTG 452
Db 15 AGTGGCTCAGGCTG 1
RESULT 223
AAQ35721/c
ID AAQ35721 standard; DNA; 18 BP.
XX
AC AAQ35721;
XX
XX 25-MAR-2003 (revised)
XX
XX 24-FEB-1993 (first entry)
XX
XX EIV primer EIVAIP7A.
XX
XX Expression cassette; equine influenza virus; EIV; hemagglutinin; HA;
XX A1/Prague/56; NYVAC; ALVAC; recombinant vector; PCR; amplify; pCPCV1;
XX polymerase chain reaction; pRW764.2; H6 promoter; canarypox virus;
XX Copenhagen vaccine; vaccinia virus; virulence factors; deletion loci;
XX recipient loci; ss.
XX
XX Synthetic.
XX
XX WO9215672-A1.
XX
XX 17-SEP-1992.
XX
XX 09-MAR-1992; 92WO-US001906.
XX
XX 07-MAR-1991; 91US-00666056.
XX
XX 11-JUN-1991; 91US-00713967.
XX
XX 06-MAR-1992; 92US-00847951.
XX
XX (VIRO-) VIROGENETICS CORP.
XX
XX Paolotti E, Perkus MF, Taylor J, Tartaglia J, Norton EK;
XX Riviere M, De Taisne C, Limbach KJ, Johnson GP, Pincus SE, Cox WI;
XX Francis J, Gettig RR;
XX
XX WPI; 1992-331718/40.
XX
XX Vaccine comprises recombinant, attenuated pox-virus - use for vaccinating
XX against viral infections such as rabies, hepatitis B, HIV, HSV, BBV, CMV,
XX mumps etc.
XX
XX Disclosure; Page 220; 456pp; English.
XX
XX The sequences given in AAQ35720-23 were used to generate an expression
XX cassette for the insertion of the equine influenza virus (EIV)
XX hemagglutinin (HA) (A1/Prague/56) into NYVAC and ALVAC recombinant
XX vectors. The HA gene sequence was isolated from an EIV cDNA library and
XX
```



CC was amplified by polymerase chain reaction. The amplified sequence was  
CC inserted into the linearised plasmid pRW764.2. The resultant plasmid was  
CC designated pPCV1 and contains the vaccinia virus H6 promoter followed by  
CC a polylinker region and flanked by canarypox virus homologous sequences.  
CC NIVAC is derived from a Copenhagen vaccine strain of vaccinia virus and  
CC ALVAC is derived from a canarypox virus which has been modified by  
CC deletion of non-essential regions of the genome encoding known or  
CC potential virulence factors. The deletion loci of both vectors were  
CC engineered as recipient loci for the insertion of foreign genes. See also  
CC AAQ35501-864. (Updated on 25-MAR-2003 to correct PN field.)  
XX  
SQ Sequence 18 BP; 2 A; 1 C; 4 G; 11 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 222 CTTATAGAAAAAACAAC 239  
DB 18 CTAATAGAAAAAACAAC 1  
|| |||||

RESULT 224  
ID AAV95047 standard; RNA; 18 BP.  
AC AAV95047;  
XX  
XX 24-FEB-1999 (first entry)  
DT  
XX  
XX Mouse IL-2 receptor g-chain substrate position 51.  
DE  
XX  
XX Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;  
KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;  
KW autoimmune disease; psoriasis; allergy; inflammatory disease;  
KW graft rejection; ss.  
XX  
XX Mus sp.  
OS  
XX  
XX WO9824913-A2.  
PN  
XX  
XX 11-JUN-1998.  
PD  
XX  
XX 02-DEC-1997; 97WO-US021748.  
PF  
XX  
XX 03-DEC-1996; 96US-00758306.  
PR  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Stinchcomb DT, Mcswigen JA;  
PI  
XX  
XX WPI; 1998-333332/29.  
DR  
XX  
XX Ribozymes targetted to interleukin 2 - useful for treating e.g. cancer,  
PT autoimmune disease and allergies.  
PT  
XX  
XX Claim 4; Page 44; 61pp; English.

CC The present sequence invention describes ribozymes targeted to modulate  
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.  
CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and  
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences  
CC from the present invention. The ribozymes can be used for the treatment  
CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy  
CC and other inflammatory conditions. The ribozymes are also used to induce  
CC tolerance in a recipient to alloantigen from a donor  
XX  
SQ Sequence 18 BP; 1 A; 8 C; 3 G; 0 T; 6 U; 0 Other;

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1121 GCTGGAGCAGCTGAACGA 1138  
DB 18 GCAGGAGCAGCTGAACGA 1  
|| |||||

RESULT 225  
ID AAH37505 standard; DNA; 18 BP.  
XX  
XX AAH37505;  
AC  
XX  
XX 14-AUG-2001 (first entry)  
DT  
XX  
XX SNP specific upper PCR primer SEQ ID 301.

DE  
XX  
XX Single nucleotide polymorphism; SNP; single nucleotide primer extension;  
KW SNPE; genotyping; agammaglobulinaemia; diabetes insipidus; cancer;  
KW Lesch-Nyhan syndrome; muscular dystrophy; familial hypercholesterolaemia;  
KW polycystic kidney disease; osteogenesis imperfecta; autoimmune disease;  
KW acute intermittent porphyria; rheumatoid arthritis; multiple sclerosis;  
KW inflammation; forensic investigation; paternity analysis; PCR primer; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO200129262-A2.  
PN  
XX  
XX 26-APR-2001.  
PD  
XX  
XX 13-OCT-2000; 2000WO-US028436.  
PF  
XX  
XX 15-OCT-1999; 99US-0160096P.  
PR  
XX  
XX (ORCH-) ORCHID BIOSCIENCES INC.  
PA  
XX  
XX Picoult-Newburg L, Pohl M;  
PI  
XX  
XX WPI; 2001-290930/30.  
DR  
XX  
XX New genotyping oligonucleotide, useful for detecting the presence,  
PT absence or identity of single polynucleotide polymorphism in a nucleic  
PT acid sample.

CC Claim 1; Page 51; 83pp; English.  
PS  
XX  
XX Sequences AAH37205 - AAH40944 represent PCR primers, single nucleotide  
CC primer extension (SNPE) primers, and the sequences of regions flanking  
CC sites of single nucleotide polymorphisms SNPs. The present invention  
CC includes kits for determining the presence or absence of a SNP, using the  
CC oligonucleotides of the invention. The PCR primers are used to amplify a  
CC SNP flanking sequence, the SNPE primer is used as a genotyping primer.  
CC The oligonucleotides are useful for genotyping a nucleic acid sample by  
CC performing a single-nucleotide primer extension reaction. The  
CC oligonucleotides are useful for determining the presence, absence or  
CC identity of a SNP and for genotyping nucleic acid samples, for e.g. to  
CC assess by association analysis the genotype of an individual or group of  
CC individuals, having a pathological phenotypic trait suspected of being  
CC caused by one or more SNPs. Phenotypic traits include diseases e.g.  
CC agammaglobulinaemia, diabetes insipidus, Lesch-Nyhan syndrome, muscular  
CC dystrophy, familial hypercholesterolaemia, polycystic kidney disease,  
CC osteogenesis imperfecta and acute intermittent porphyria. Phenotypic  
CC traits also include symptoms of or susceptibility to multifactorial  
CC diseases of which a component is or may be genetic such as autoimmune  
CC diseases, including, rheumatoid arthritis, multiple sclerosis,  
CC inflammation, cancer, nervous system diseases and infection by pathogenic  
CC microorganism. The method is also useful in forensic investigations and  
CC paternity analysis. The present sequence represents a PCR primer specific  
CC for a human SNP containing DNA sequence

SQ Sequence 18 BP; 4 A; 8 C; 5 G; 1 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

CC PTP10D, Tec or EDPG homologous polypeptide. The nucleic acid molecule of  
CC PTP10D, Tec, or EDPG family or their fragments, may be used in the  
CC preparation of a non-human animal which over- or under-expresses the  
CC PTP10D, Tec, or EDPG gene product. The present sequence represents a PCR  
CC primer for mouse protein tyrosine phosphatase receptor type B precursor  
CC (PTPRB), which is used in an example from the present invention  
XX  
SQ Sequence 18 BP; 3 A; 10 C; 1 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 1.7e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 764 CTTCCACGCCCATGTTCCTCA 781  
DB 1 CTTCCACGCCCATGTTCCTCA 18  
  
RESULT 227  
ACF04428  
ID ACF04428 standard; DNA; 18 BP.  
XX  
AC ACF04428;  
XX  
DT 04-DEC-2003 (first entry)  
XX  
DE Hepatitis C virus RNA probe.  
XX  
KW Silicon; silicon containing magnetic particle; superparamagnetic;  
KW silicon dioxide; nucleic acid isolation; probe; ss; HCV.  
XX  
OS Hepatitis C virus.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 1 /\*tag= a  
FT /\*mod\_base= OTHER  
FT /\*note= "modified by FAM"  
FT modified\_base 18 /\*tag= b  
FT /\*mod\_base= OTHER  
FT /\*note= "modified by TAMRA"  
XX  
PN WO2003058649-A1.  
XX  
PD 17-JUL-2003.  
XX  
PP 07-JAN-2003; 2003WO-BP000054.  
XX  
PR 14-JAN-2002; 2002DE-01001084.  
XX  
PA (FARB ) BAYER AG.  
XX  
PI Hennig G, Hildenbrand K;  
XX  
DR WPI; 2003-542203/51.  
XX  
PT Silicon-coated magnetic particles, useful for purification of nucleic  
PT acid from body samples, do not need to be separated before quantification  
PT by polymerase chain reaction.  
XX  
PS Example 7; Page 23; 35pp; German.  
XX  
CC The present invention relates to silicon-coated magnetic particles in  
CC which the silicon content is less than 20wt.% of total. These can be used  
CC to isolate nucleic acids from body samples, especially serum,  
CC particularly for diagnostic detection of RNA from hepatitis C virus or  
CC HIV. The present sequence is a probe used to isolate RNA from hepatitis C  
CC virus from serum in the exemplification of the invention  
XX  
SQ Sequence 18 BP; 2 A; 11 C; 3 G; 1 T; 0 U; 1 Other;  
  
Query Match 0.9%; Score 14.6; DB 1; Length 18;

QY 1492 CCAAGTAACAGGCCCA 1509  
DB 1 CCAAGGTACAGGCCCA 18  
  
RESULT 226  
ACC79773  
ID ACC79773 standard; DNA; 18 BP.  
XX  
AC ACC79773;  
XX  
DT 02-SEP-2003 (first entry)  
XX  
DE Mouse PTPRB reverse PCR primer SEQ ID NO:11.  
XX  
KW Tec; protein tyrosine kinase; protein tyrosine phosphatase; PTP10D;  
KW egg derived tyrosine phosphatase; EDPG; antidiabetic; hypotensive;  
KW cardiant; antilipidemic; osteopathic; cytostatic; anorectic; obesity;  
KW immunomodulator; gene therapy; metabolic disease; eating disorder;  
KW body weight regulation disorder; cachexia; diabetes mellitus; cancer;  
KW hypertension; coronary heart disease; hypercholesterolaemia; gallstone;  
KW dyslipidaemia; osteoarthritis; sleep apnea; mouse; PTPRB;  
KW protein tyrosine phosphatase receptor type B precursor; PCR primer; ss.  
XX  
OS Mus sp.  
OS Synthetic.  
PN WO2003047611-A2.  
XX  
PD 12-JUN-2003.  
XX  
PF 04-DEC-2002; 2002WO-EP013744.  
XX  
PR 04-DEC-2001; 2001EP-00128844.  
PR 07-DEC-2001; 2001EP-00129138.  
PR 02-JAN-2002; 2002EP-00000010.  
XX  
PA (DEVE-) DEVELOPEN ENTWICKLUNGSBIOLOGISCHE FORSCH.  
XX  
PI Meise M, Eulenberger K, Fritsch R, Haeder T, Broenner G;  
PI Steuernagel A;  
XX  
XX WPI; 2003-532801/50.  
XX  
FT New compositions comprising tyrosine phosphatase PTP10D, protein tyrosine  
FT kinase Tec or egg-derived tyrosine phosphatase genes or proteins, useful  
FT for treating or preventing metabolic diseases, e.g. as obesity or  
FT cachexia.  
XX  
PS Example 4; Page 52; 83pp; English.  
XX  
CC The present invention describes a pharmaceutical composition comprising a  
CC nucleic acid (I) protein tyrosine phosphatase PTP10D, non-receptor  
CC protein tyrosine kinase Tec, egg derived tyrosine phosphatase (EDPG) gene  
CC family or encoded polypeptide, fragment or variant of nucleic acid  
CC molecule or polypeptide, an antibody, an aptamer or receptor recognising  
CC a nucleic acid molecule of PTP10D, Tec, or EDPG gene family or encoded  
CC polypeptide, and a carrier, diluent and/or adjuvant. The pharmaceutical  
CC composition can have antidiabetic, hypotensive, cardiant, antilipidemic,  
CC osteopathic, cytostatic, anorectic and immunomodulator activities, and  
CC can be used in gene therapy. The composition is useful for the  
CC manufacture of an agent for detecting and/or verifying, for treating and  
CC alleviating and/or preventing a disorder, including metabolic diseases  
CC such as obesity and other body weight regulation disorders, as well as  
CC related disorders such as eating disorder, cachexia, diabetes mellitus,  
CC hypertension, coronary heart disease, hypercholesterolaemia,  
CC dyslipidaemia, osteoarthritis, gallstones, cancers (cancers of the  
CC reproductive organ), sleep apnea, and other diseases, in cells, cell  
CC masses, organs and/or subjects. The components of the composition may  
CC also be used in controlling the function of a gene and/or gene product  
CC which is influenced and/or modified by a PTP10D, Tec, or EDPG homologous  
CC polypeptide, and for identifying substances capable of interacting with a

Best Local Similarity 93.3%; Pred. No. 1.8e+02; Mismatches 1; Mismatches 0; Indels 0; Gaps 0;

QY 1509 AGCTCCAGGCCCCC 1523  
1 AGCTCCAGGCCCCC 15

Db

RESULT 228  
AA63904/c  
ID AAX63904 standard; RNA; 17 BP.  
XX AAX63904;  
AC AAX63904;  
XX  
XX 20-JUL-1999 (first entry)  
DE Rabbit stromelysin hammerhead target SEQ ID NO:536.  
XX  
XX Arthritic condition; graft tolerance; immune response; target; cleavage;  
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;  
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;  
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;  
XX diagnosis; ss.  
XX  
XX Oryctolagus cuniculus.  
XX  
XX WO9618736-A2.  
XX  
XX 20-JUN-1996.  
XX  
XX 22-NOV-1995; 95WO-US015516.  
XX  
XX 13-DEC-1994; 94US-00354920.  
XX 23-DEC-1994; 94US-00363253.  
XX 23-DEC-1994; 94US-00363254.  
XX 17-FEB-1995; 95US-00390850.  
XX 20-APR-1995; 95US-00426124.  
XX 02-MAY-1995; 95US-00432874.  
XX 04-MAY-1995; 95US-00434509.  
XX 07-JUL-1995; 95US-0000951P.  
XX 07-JUL-1995; 95US-0000974P.  
XX 07-AUG-1995; 95US-00512861.  
XX 05-OCT-1995; 95US-00541365.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Beigelman L, Stinchcomb DT, Jarvis T, Draper K, Pavco P;  
PI McSwiggen J, Gustofson J, Usman N, Wincott F, Matulic-Adamic J;  
PI Karpeisky A, Thompson JD, Modak A, Burgin A;  
XX  
XX WPI; 1996-300653/30.  
XX  
XX Enzymatic nucleic acid molecules having a hammer-head motif - used for  
PT the treatment of arthritis, induction of graft tolerance or treatment of  
PT auto-immune diseases.  
XX  
XX Example 1; Page 154; 307pp; English.

CC The present invention describes a novel enzymatic nucleic acid (ENA)  
CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose residues  
CC; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii) at least  
CC ten 2'-O-methyl modifications; and (iv) a 3'-end modification. The ENA's  
CC can inhibit collagenase and stromelysin production in the synovial  
CC membrane of joints for the treatment or prevention of arthritis,  
CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also  
CC be used to treat antigen presenting cells of a donor to induce tolerance  
CC in a recipient to an alloantigen of a donor. They can also be used for  
CC enhancing graft tolerance or for treating autoimmune disease, and for  
CC treating allergies and other inflammatory conditions. The ENA's can also  
CC be used in diagnosis. Ribozyme therapy impacts on the expression of  
CC stromelysin without introducing the non-specific effects upon gene  
CC expression which accompany treatment with retinoids and dexamethasone.  
CC The concentration of ribozyme required to affect a therapeutic treatment

CC is lower than that required of antisense molecules, and is highly  
CC specific. The present sequence is used in the exemplification of the  
CC present invention

XX  
XX Sequence 17 BP; 4 A; 2 C; 3 G; 0 T; 8 U; 0 Other;  
SQ

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1589 AAGAACAGAAATTCCTC 1604  
Db 16 AAGAACAGAAATTCCTC 1

RESULT 229  
AAV93469  
ID AAV93469 standard; RNA; 17 BP.  
XX AAV93469;  
AC AAV93469;  
XX  
XX 18-FEB-1999 (first entry)  
DT  
XX Human B-raf substrate nucleotide position 1085.  
DE  
XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;  
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;  
KW screening; identification; synthesis; deprotection; purification; cancer;  
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;  
KW restenosis; rheumatoid arthritis; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO9850530-A2.  
XX  
XX 12-NOV-1998.  
XX  
XX 05-MAY-1998; 98WO-US009249.  
XX  
XX 09-MAY-1997; 97US-0046059P.  
XX 03-JUN-1997; 97US-0049002P.  
XX 03-JUL-1997; 97US-0051718P.  
XX 22-AUG-1997; 97US-0056808P.  
XX 02-OCT-1997; 97US-0061321P.  
XX 02-OCT-1997; 97US-0061324P.  
XX 05-NOV-1997; 97US-0064866P.  
XX 19-DEC-1997; 97US-0068212P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;  
PI Parry T, Beigelman L, McSwiggen JA, Karpeisky A, Burgin A;  
PI Thompson J, Workman CT, Beaudry A, Sweedler D;  
XX  
XX WPI; 1999-009494/01.  
XX  
XX Identifying new catalytic nucleic acid that modulates selected processes  
PT - especially ribozymes that cleave Raf RNA for treating cancer.  
PT restenosis, and also new ribozymes and modified nucleoside triphosphates  
PT used as antiviral agents and synthons.  
XX  
XX Claim 177; Page 168; 259pp; English.

CC A method has been developed for the identification of a nucleic acid  
CC capable of modulating a process in a biological system. The method  
CC comprises: (a) introducing into the system a random library of nucleic  
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising  
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC  
CC in systems where modulation has occurred and/or determining the sequence  
CC of at least part of the SBDs in such systems. Nucleic acid molecules with  
CC endonuclease activity and catalytic activity, from the present invention,  
CC are used to modulate gene expression in plant and mammalian cells and to  
CC cleave target nucleic acid, particularly for treating systemic diseases

```
CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic
CC ascites and infection. They may also be used to detect genetic drift and
CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs
CC with RNA-cleaving activity that modulate expression of the Raf gene, are
CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or
CC generally any condition associated with the level of c-raf. Introduction
CC of sugar/phosphate modifications increases stability against nuclease and
CC activity. AAV90922 to AAV93877 represent NACs that can be used in the
CC method, specifically for modulating the expression of a Raf gene
XX
SQ Sequence 17 BP; 4 A; 8 C; 1 G; 0 T; 4 U; 0 Other;
  Query Match 0.9%; Score 14.4; DB 1; Length 17;
  Best Local Similarity 75.0%; Pred. No. 1.6e+02;
  Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 826 TCACATTCACAGCCC 841
  :|||:|||||||
Db 2 UCCAAUCCACAGCCC 17
RESULT 230
ABK00171/C
ID ABK00171 standard; RNA; 17 BP.
XX
AC ABK00171;
XX
DT 12-MAR-2002 (first entry)
XX
DE Human NOGO Hammerhead Ribozyme #171.
XX
KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
KW DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
KW Human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;
KW inflammatory arthropathy; central nervous system injury;
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
KW Parkinson's disease; ataxia; Huntington's disease;
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
OS Homo sapiens.
OS Synthetic.
XX
XX WO200159103-A2.
XX
XX 16-AUG-2001.
XX
XX 09-FEB-2001; 2001WO-US004273.
XX
XX 11-FEB-2000; 2000US-0181797P.
XX
XX 28-FEB-2000; 2000US-0185516P.
XX
XX 06-MAR-2000; 2000US-0187128P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX
XX Blatt L, Mcswiggen J, Chowrira BM;
XX
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and
XX central nervous system injury.
XX
XX Claim 88; Page 68; 200pp; English.
XX
```

```
CC The invention relates to a nucleic acid molecule which down regulates
CC expression of a CD20 gene and a nucleic acid molecule which down
CC regulates expression of a neurite growth inhibitor gene (NOGO). The
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
CC DNazyme) an inozyme (an endolytic nucleic acid cleaving a an RNA molecule
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) pr
CC an amberzyme (cleaving RNA with an NGN triplet), a zinczyme (cleaving RNA
CC with a YGY motif). The CD20-targetting nucleic acid is used to cleave RNA
CC of CD20 in the presence of a divalent cation that is preferably Mg2+.
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of
CC the cell and treat a patient having a condition associated with the level
CC of CD20. The treatment may further comprise the use of one or more
CC therapies. In particular, the CD20 targetting nucleic acid may be used to
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular NHL, lymphocytic
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-
CC targetting nucleic acid is used to cleave RNA of the NOGO gene in the
CC presence of a divalent cation that is preferably Mg2+. Furthermore, the
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the
CC cell and treat a patient having a condition associated with the level of
CC NOGO. The treatment may further comprise the use of one or more
CC therapies. In particular, the NOGO-targetting nucleic acid may be used to
CC treat central nervous system (CNS) injury and cerebrovascular accident
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The present
CC sequence is a hammerhead ribozyme of the invention
XX
SQ Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;
  Query Match 0.9%; Score 14.4; DB 1; Length 17;
  Best Local Similarity 93.8%; Pred. No. 1.6e+02;
  Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1619 TTCATATAAACGTCTCT 1634
  |||||
Db 16 TTCATATAAACGTCTCT 1
RESULT 231
ABN08360/C
ID ABN08360 standard; DNA; 17 BP.
XX
AC ABN08360;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8352.
XX
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
XX
XX Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US016981.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
XX 27-SEP-2000; 2000US-0236359P.
XX
XX 04-OCT-2000; 2000GB-00024263.
XX
XX 30-JAN-2001; 2001WO-US000661.
XX
XX 30-JAN-2001; 2001WO-US000662.
XX
XX 30-JAN-2001; 2001WO-US000663.
XX
XX 30-JAN-2001; 2001WO-US000664.
```

30-JAN-2001; 2001WO-US000665.  
30-JAN-2001; 2001WO-US000666.  
30-JAN-2001; 2001WO-US000667.  
30-JAN-2001; 2001WO-US000668.  
30-JAN-2001; 2001WO-US000669.  
30-JAN-2001; 2001WO-US000670.  
05-FEB-2001; 2001US-0266860P.  
(AEOM-) AEOMICA INC.  
Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
WPI; 2002-179446/23.  
New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
or as specific biomolecule capture probes for surface-enhanced laser  
desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
Disclosure; SEQ ID NO 8352; 214pp; English.  
The present invention describes a human genome-derived myosin-like  
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
nucleic acids can be used as probes to detect, characterise and quantify  
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
provide initial substrates for the recombinant engineering of hGDMPLP-1  
protein variants having desired phenotypic improvements, and for  
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
used as immunogens to raise antibodies that specifically recognise hGDMPLP  
-1 proteins, as standards in assays used to determine the concentration  
and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
capture probes for surface-enhanced laser desorption ionisation, as  
therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
production, and in vaccines or for replacement therapy. The  
polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
disorder associated with the expression of hGDMPLP-1, in particular heart  
and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
The present sequence represents an oligomer used in the screening of the  
hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
The sequence data for this patent did not form part of the printed  
specification, but was obtained in electronic format directly from WIPO  
at ftp.wipo.int/pub/published\_pct\_sequence  
Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1109 CACCTCTCTCTTGCTG 1124  
DB 17 CAGCTCTCTCTTGCTG 2  
RESULT 232  
ABN08675  
ID AEN08675 standard; DNA; 17 BP.  
AC AEN08675;  
XX XX  
29-MAY-2002 (first entry)  
XX XX  
Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8667.  
DE DE  
XX XX  
Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX XX  
OS Homo sapiens.  
XX XX  
PN WO200192524-A2.  
XX XX  
PD 06-DEC-2001.  
25-MAY-2001; 2001WO-US016981.  
26-MAY-2000; 2000US-0207456P.  
21-SEP-2000; 2000US-0234687P.  
27-SEP-2000; 2000US-0236359P.  
04-OCT-2000; 2000GB-00024263.  
30-JAN-2001; 2001WO-US000661.  
30-JAN-2001; 2001WO-US000662.  
30-JAN-2001; 2001WO-US000664.  
30-JAN-2001; 2001WO-US000665.  
30-JAN-2001; 2001WO-US000666.  
30-JAN-2001; 2001WO-US000667.  
30-JAN-2001; 2001WO-US000668.  
30-JAN-2001; 2001WO-US000669.  
30-JAN-2001; 2001WO-US000670.  
05-FEB-2001; 2001US-0266860P.  
(AEOM-) AEOMICA INC.  
Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
WPI; 2002-179446/23.  
New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
or as specific biomolecule capture probes for surface-enhanced laser  
desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
Disclosure; SEQ ID NO 8667; 214pp; English.  
The present invention describes a human genome-derived myosin-like  
protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
nucleic acids can be used as probes to detect, characterise and quantify  
hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
provide initial substrates for the recombinant engineering of hGDMPLP-1  
protein variants having desired phenotypic improvements, and for  
expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
used as immunogens to raise antibodies that specifically recognise hGDMPLP  
-1 proteins, as standards in assays used to determine the concentration  
and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
capture probes for surface-enhanced laser desorption ionisation, as  
therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
production, and in vaccines or for replacement therapy. The  
polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
disorder associated with the expression of hGDMPLP-1, in particular heart  
and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
The present sequence represents an oligomer used in the screening of the  
hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
The sequence data for this patent did not form part of the printed  
specification, but was obtained in electronic format directly from WIPO  
at ftp.wipo.int/pub/published\_pct\_sequence  
Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 274 AAGCCAAGAGAGAGAA 289  
DB 1 AAGCCAAGAGAGAGAA 16  
RESULT 233  
ABN08361/c  
ID ABN08361 standard; DNA; 17 BP.  
XX XX  
AC AEN08361;  
XX XX  
DT 29-MAY-2002 (first entry)  
XX XX

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8353.  
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX WO200192524-A2.  
XX 06-DEC-2001.  
XX 25-MAY-2001; 2001WO-US016981.  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 05-FEB-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX (AEOM-) AEOMICA INC.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
PI WPI; 2002-179446/23.  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX Disclosure; SEQ ID NO 8353; 214pp; English.  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;  
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. NO. 1.6e-02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1109 GACCTCTCTCTTGTCTG 1124  
|||||

Db 16 CAGCTCTCTCTTGTCTG 1  
RESULT 234  
ABN10046/C  
ID ABN10046 standard; DNA; 17 BP.  
XX  
XX AC ABN10046;  
XX 29-MAY-2002 (first entry)  
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10038.  
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX WO200192524-A2.  
XX 06-DEC-2001.  
XX 25-MAY-2001; 2001WO-US016981.  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 05-FEB-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX (AEOM-) AEOMICA INC.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
PI WPI; 2002-179446/23.  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX Disclosure; SEQ ID NO 10038; 214pp; English.  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP-  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;  
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. NO. 1.6e-02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1109 GACCTCTCTCTTGTCTG 1124  
|||||

CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 715 CCGCATCGTCCGAC 730  
Db 16 CCGCATCGTCCGAC 1  
  
RESULT 235  
ABN08673  
ID ABN08673 standard; DNA; 17 BP.  
XX  
AC ABN08673;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8665.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX or as specific biomolecule capture probes for surface-enhanced laser  
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
XX Disclosure; SEQ ID NO 8665; 214pp; English.  
XX  
XX The present invention describes a human genome-derived myosin-like  
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX nucleic acids can be used as probes to detect, characterise and quantify  
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX protein variants having desired phenotypic improvements, and for  
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP

CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
  
QY 273 GAAGCCCAAGAAGA 288  
Db 2 GAAGCCCAAGAAGA 17  
  
RESULT 236  
ABN10045/c  
ID ABN10045 standard; DNA; 17 BP.  
XX  
AC ABN10045;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10037.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX or as specific biomolecule capture probes for surface-enhanced laser  
XX desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX

PS Disclosure; SEQ ID NO 10037; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-

CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1

CC nucleic acids can be used as probes to detect, characterise and quantify

CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to

CC provide initial substrates for the recombinant engineering of hGDMLP-1

CC protein variants having desired phenotypic improvements, and for

CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be

CC used as immunogens to raise antibodies that specifically recognise hGDMLP

CC -1 proteins, as standards in assays used to determine the concentration

CC and/or amount specifically of hGDMLP proteins, as specific biomolecule

CC capture probes for surface-enhanced laser desorption/ionisation, as

CC therapeutic supplement in patients having specific deficiency in hGDMLP-1

CC production, and in vaccines or for replacement therapy. The

CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a

CC disorder associated with the expression of hGDMLP-1, in particular heart

CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.

CC The present sequence represents an oligomer used in the screening of the

CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.

CC The sequence data for this patent did not form part of the printed

CC specification, but was obtained in electronic format directly from WIPO

CC at [ftp.wipo.int/pub/published\\_pct\\_sequence](http://ftp.wipo.int/pub/published_pct_sequence)

XX

XX SQ Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 715 CCGCATCGTCCGCG 730

DB 17 CCGCATCGTCCAC 2

RESULT 237

ACN07604

ID ACN07604 standard; RNA; 17 BP.

XX

XX ACN07604;

XX

XX 22-APR-2004 (first entry)

XX

XX WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7607.

DE

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

XX virucide; neuroprotective; antibacterial; replication; pancreatitis;

KW encephalitis; myocarditis; meningitis; infection; hepatitis;

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;

KW Amberzyme; Zinzyme; ss.

XX

XX West Nile Virus.

OS

XX WO200268637-A2.

PN

XX 06-SEP-2002.

PD

XX 19-OCT-2001; 2001WO-US048350.

PF

XX 20-OCT-2000; 2000US-0242411P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX

XX Blatt L, Mcswiggen JA;

PI

XX WPI; 2002-706994/76.

DR

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PT

XX Claim 23; SEQ ID NO 7607; 495pp; English.

XX

XX The invention relates to nucleic acid molecules that modulate replication

CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,

CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of

CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at

CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a

CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid

CC molecule of the invention

XX

XX SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 1.6e+02;

Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1234 CGACGTCCTTCGCG 1249

DB 1 CGACGUUCCAUCCGG 16

RESULT 238

ACN09975

ID ACN09975 standard; RNA; 17 BP.

XX

XX ACN09975;

XX

XX 22-APR-2004 (first entry)

XX

XX WNV minus strand Inozyme substrate SEQ ID NO 9978.

DE

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

XX virucide; neuroprotective; antibacterial; replication; pancreatitis;

KW encephalitis; myocarditis; meningitis; infection; hepatitis;

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;

KW Amberzyme; Zinzyme; ss.

XX

XX West Nile Virus.

OS

XX WO200268637-A2.

PN

XX 06-SEP-2002.

PD

XX 19-OCT-2001; 2001WO-US048350.

PF

XX 20-OCT-2000; 2000US-0242411P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX

XX Blatt L, Mcswiggen JA;

PI

XX WPI; 2002-706994/76.

DR

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PT

XX Claim 23; SEQ ID NO 9978; 495pp; English.

XX

XX The invention relates to nucleic acid molecules that modulate replication

CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,

CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of

CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at

CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a

CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid

CC molecule of the invention

XX

XX SQ Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 1.6e+02;

Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1234 CGACGTCCTTCGCG 1249

DB 1 CGACGUUCCAUCCGG 16

RESULT 238

ACN09975

ID ACN09975 standard; RNA; 17 BP.

XX

XX ACN09975;

XX

XX 22-APR-2004 (first entry)

XX

XX WNV minus strand Inozyme substrate SEQ ID NO 9978.

DE

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;

XX virucide; neuroprotective; antibacterial; replication; pancreatitis;

KW encephalitis; myocarditis; meningitis; infection; hepatitis;

KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;

KW Amberzyme; Zinzyme; ss.

XX

XX West Nile Virus.

OS

XX WO200268637-A2.

PN

XX 06-SEP-2002.

PD

XX 19-OCT-2001; 2001WO-US048350.

PF

XX 20-OCT-2000; 2000US-0242411P.

PR

XX (RIBO-) RIBOZYME PHARM INC.

PA (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J A.

XX

XX Blatt L, Mcswiggen JA;

PI

XX WPI; 2002-706994/76.

DR

XX New nucleic acid molecule that modulates replication of West Nile Virus

XX (WNV), useful for treating a condition related to WNV infection e.g.

PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

PT



CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

XX Sequence 17 BP; 2 A; 9 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 68.8%; Pred. No. 1.6e+02;  
Matches 11; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCACACCTCTCTCT 1119  
DB 1 CUGACACCUCCUCCU 16

RESULT 239  
ACN07053/c  
ID ACN07053 standard; RNA; 17 BP.

XX ACN07053;  
XX 22-APR-2004 (first entry)  
XX WNV Amberzyme substrate SEQ ID NO 7056.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; virucide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.

XX West Nile Virus.  
XX WO200268637-A2.  
XX 06-SEP-2002.  
XX 19-OCT-2001; 2001WO-US048350.  
XX 20-OCT-2000; 2000US-0242411P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX (BLAT/) BLATT L.  
XX (MCSW/) MCSWIGGEN J A.  
XX Blatt L, Mcswiggen JA;  
XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 7056; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

XX Sequence 17 BP; 2 A; 9 C; 2 G; 0 T; 4 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1104 CTCACACCTCTCTCT 1119  
DB 17 CTCGACACCTCTCTCT 2

RESULT 240  
ACN07193/c  
ID ACN07193 standard; RNA; 17 BP.

XX ACN07193;  
XX 22-APR-2004 (first entry)  
XX WNV Amberzyme substrate SEQ ID NO 7196.

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic; virucide; neuroprotective; antibacterial; replication; pancreatitis; encephalitis; myocarditis; meningitis; infection; hepatitis; liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme; Amberzyme; Zinzyme; ss.

XX West Nile Virus.  
XX WO200268637-A2.  
XX 06-SEP-2002.  
XX 19-OCT-2001; 2001WO-US048350.  
XX 20-OCT-2000; 2000US-0242411P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX (BLAT/) BLATT L.  
XX (MCSW/) MCSWIGGEN J A.  
XX Blatt L, Mcswiggen JA;  
XX WPI; 2002-706994/76.

XX New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 7196; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication of the West Nile Virus (WNV). The nucleic acid molecules are useful for treating a condition related to WNV infection e.g. pancreatitis, encephalitis, myocarditis, meningitis, neurologic infection, hepatitis, liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid molecule is selected from the group of ribozymes consisting of Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The nucleic acid molecules further comprise at least five ribose residues, at least ten 2'-O-methyl modifications, phosphorothioate linkages on at least three of the 5' terminal nucleotides and a 3' end modification of a 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080 are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given in the specification. The present sequence is that of a nucleic acid molecule of the invention

XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;

Best Local Similarity 93.8%; Pred. No. 1.6e+02;		Pred. No. 1.6e+02;		0; Mismatches 1; Indels 0; Gaps 0;							
Matches 15; Conservative 0;		0; Mismatches 1; Indels 0; Gaps 0;		0; Gaps 0;							
QY	1234 CGGACGTTCTTCCCG 1249										
DB	17 CGGACGTTCCATCCGG 2										
RESULT 241											
ACN04500/c											
ID	ACN04500 standard; RNA; 17 BP.										
XX	ACN04500;										
XX	22-APR-2004 (first entry)										
DT	WNV Zinzyne substrate SEQ ID NO 4503.										
DE	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;										
XX	viricide; neuroprotective; antibacterial; replication; pancreatitis;										
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;										
KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;										
KW	Amberzyme; Zinzyne; ss.										
XX	West Nile Virus.										
OS	WO200268637-A2.										
XX	06-SEP-2002.										
XX	19-OCT-2001; 2001WO-US048350.										
XX	20-OCT-2000; 2000US-0242411P.										
XX	(RIBO-) RIBOZYME PHARM INC.										
PA	(BLAT/) BLATT L.										
PA	(MCSW/) MCSWIGGEN J A.										
XX	Blatt L, Mcswiggen JA;										
PI	WPI; 2002-706994/76.										
XX	New nucleic acid molecule that modulates replication of West Nile Virus										
XX	(WNV), useful for treating a condition related to WNV infection e.g.										
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.										
PT	Claim 23; SEQ ID NO 4503; 495pp; English.										
XX	The invention relates to nucleic acid molecules that modulate replication										
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for										
CC	treating a condition related to WNV infection e.g. pancreatitis,										
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,										
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid										
CC	molecule is selected from the group of ribozymes consisting of										
CC	Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The										
CC	nucleic acid molecules further comprise at least five ribose residues, at										
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at										
CC	least three of the 5' terminal nucleotides and a 3' end modification of a										
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080										
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given										
CC	in the specification. The present sequence is that of a nucleic acid										
CC	molecule of the invention										
XX	Sequence 17 BP; 4 A; 1 C; 10 G; 0 T; 2 U; 0 Other;										
QY	Query Match 0.9%; Score 14.4; DB 1; Length 17;										
DB	Best Local Similarity 93.8%; Pred. No. 1.6e+02;										
DB	Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;										
QY	1104 CTCACACCTCTCTCT 1119										
DB	16 CTCGACACTCTCTCT 1										

Best Local Similarity 93.8%; Pred. No. 1.6e+02;		Pred. No. 1.6e+02;		0; Mismatches 1; Indels 0; Gaps 0;							
Matches 15; Conservative 0;		0; Mismatches 1; Indels 0; Gaps 0;		0; Gaps 0;							
QY	1234 CGGACGTTCTTCCCG 1249										
DB	17 CGGACGTTCCATCCGG 2										
RESULT 241											
ACN07603											
ID	ACN07603 standard; RNA; 17 BP.										
XX	ACN07603;										
XX	22-APR-2004 (first entry)										
DT	WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7606.										
XX	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;										
XX	viricide; neuroprotective; antibacterial; replication; pancreatitis;										
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;										
KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;										
KW	Amberzyme; Zinzyne; ss.										
XX	West Nile Virus.										
OS	WO200268637-A2.										
XX	06-SEP-2002.										
XX	19-OCT-2001; 2001WO-US048350.										
XX	20-OCT-2000; 2000US-0242411P.										
XX	(RIBO-) RIBOZYME PHARM INC.										
PA	(BLAT/) BLATT L.										
PA	(MCSW/) MCSWIGGEN J A.										
XX	Blatt L, Mcswiggen JA;										
PI	WPI; 2002-706994/76.										
XX	New nucleic acid molecule that modulates replication of West Nile Virus										
XX	(WNV), useful for treating a condition related to WNV infection e.g.										
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.										
PT	Claim 23; SEQ ID NO 7606; 495pp; English.										
XX	The invention relates to nucleic acid molecules that modulate replication										
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for										
CC	treating a condition related to WNV infection e.g. pancreatitis,										
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,										
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid										
CC	molecule is selected from the group of ribozymes consisting of										
CC	Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The										
CC	nucleic acid molecules further comprise at least five ribose residues, at										
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at										
CC	least three of the 5' terminal nucleotides and a 3' end modification of a										
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080										
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given										
CC	in the specification. The present sequence is that of a nucleic acid										
CC	molecule of the invention										
XX	Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;										
QY	Query Match 0.9%; Score 14.4; DB 1; Length 17;										
DB	Best Local Similarity 75.0%; Pred. No. 1.6e+02;										
DB	Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;										
QY	1234 CGGACGTTCTTCCCG 1249										
DB	2 CGGACGTCGCAUCCCG 17										

Best Local Similarity 93.8%; Pred. No. 1.6e+02;		Pred. No. 1.6e+02;		0; Mismatches 1; Indels 0; Gaps 0;							
Matches 15; Conservative 0;		0; Mismatches 1; Indels 0; Gaps 0;		0; Gaps 0;							
QY	1234 CGGACGTTCTTCCCG 1249										
DB	17 CGGACGTTCCATCCGG 2										
RESULT 243											
ABT38885/c											
ID	ABT38885 standard; DNA; 17 BP.										
XX	ABT38885;										
XX	ABT38885;										

RESULT 242	
ACN07603	
ID	ACN07603 standard; RNA; 17 BP.
XX	
AC	ACN07603;
XX	
DT	22-APR-2004 (first entry)
XX	
XX	WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 7606.
XX	
KW	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW	viricide; neuroprotective; antibacterial; replication; pancreatitis;
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;
KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;
KW	Amberzyme; Zinzyne; ss.
XX	
OS	West Nile Virus.
XX	
PN	WO200268637-A2.
XX	
PD	06-SEP-2002.
XX	
PF	19-OCT-2001; 2001WO-US048350.
XX	
PR	20-OCT-2000; 2000US-0242411P.
XX	
PA	(RIBO-) RIBOZYME PHARM INC.
PA	(BLAT/) BLATT L.
XX	(MCSW/) MCSWIGGEN J A.
PI	Blatt L, Mcswiggen JA;
XX	
DR	WPI; 2002-706994/76.
XX	
PT	New nucleic acid molecule that modulates replication of West Nile Virus
PT	(WNV), useful for treating a condition related to WNV infection e.g.
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX	
PS	Claim 23; SEQ ID NO 7606; 495pp; English.
XX	
CC	The invention relates to nucleic acid molecules that modulate replication
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for
CC	treating a condition related to WNV infection e.g. pancreatitis,
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
CC	molecule is selected from the group of ribozymes consisting of
CC	Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The
CC	nucleic acid molecules further comprise at least five ribose residues, at
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at
CC	least three of the 5' terminal nucleotides and a 3' end modification of a
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
CC	in the specification. The present sequence is that of a nucleic acid
CC	molecule of the invention
XX	
SQ	Sequence 17 BP; 2 A; 6 C; 6 G; 0 T; 3 U; 0 Other;
	Query Match 0.9%; Score 14.4; DB 1; Length 17;
	Best Local Similarity 75.0%; Pred. No. 1.6e+02;
	Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY	1234 CGGACGTTCTTCCGG 1249
DB	2 CGGACGUUCCAUCCGG 17
RESULT 243	
ABT38885/c	
ID	ABT38885 standard; DNA; 17 BP.
XX	
AC	ABT38885;
XX	



XX PF1281758-A2.  
XX 05-FEB-2003.  
XX 30-JUL-2002; 2002EP-00016874.  
XX 02-AUG-2001; 2001US-00922181.  
XX (AEOM-) AEOMICA INC.  
XX Shannon M, Gu Y, Nguyen C;  
XX WPI; 2003-423107/40.  
XX New zinc finger-containing proteins and nucleic acids, useful in  
PT manufacturing a medicament for treating or preventing a disorder  
PT associated with decreased or increased expression or activity of MD23,  
PT MD24, MD27 or MD212, e.g. cancer.  
XX Example 8; SEQ ID NO 1450; 103pp; English.  
XX The present invention relates to novel human zinc finger-containing  
CC proteins and their coding sequences: MD23, MD24, MD27, MD212. MD23 is  
CC encoded at chromosome 7q22.1, MD24 is encoded at chromosome 6p21.3-22.2,  
CC MD27 is encoded at chromosome 16p11.2 and MD212 is encoded at chromosome  
CC 15q26.1. The MD23, MD24, MD27, and MD212 sequences are useful in therapy,  
CC or in manufacturing a medicament for treating or preventing a disorder  
CC associated with decreased or increased expression or activity of MD23,  
CC MD24, MD27, or MD212, e.g. cancer or developmental disorders. The nucleic  
CC acids and proteins are also useful for diagnosing or monitoring a disease  
CC caused by altered expression of MD23, MD24, MD27, or MD212. The nucleic  
CC acids can also be used as probes to detect and characterize gross  
CC alterations in MD23, MD24, MD27, or MD212 genetic locus. The probes are  
CC useful in constructing microarrays for measuring gene expression. The  
CC proteins are useful as therapeutic agents for gene therapy or as  
CC vaccines. The present sequence was used to illustrate the invention.  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 929 CTGCTCGGATGAAG 944  
DB 17 CTGCTCGGCTGAAG 2  
RESULT 246  
ABZ61479/c  
ID ABZ61479 standard; RNA; 17 BP.  
XX ABZ61479;  
AC  
XX 21-MAR-2003 (first entry)  
DT  
XX Human H-Ras DNAzyme target #270.  
DE  
XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;  
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytosstatic; anti-HIV;  
KW anti-rheumatic; cancer; AIDS; ss.  
XX Homo sapiens.  
OS  
XX WO200297114-A2.  
PN  
XX 05-DEC-2002.  
PD  
XX 29-MAY-2002; 2002WO-US016840.  
PF  
XX 29-MAY-2001; 2001US-0294140P.  
PR 06-JUN-2001; 2001US-0296249P.

PR 10-SEP-2001; 2001US-0318471P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Mcswiggen J;  
XX WPI; 2003-140484/13.  
XX Novel short interfering RNA and enzymatic nucleic acid useful for  
PT treating cancer, modulates the expression of a nucleic acid encoding  
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences.  
XX Claim 58; Page 116; 185pp; English.  
XX The invention relates to a novel short interfering RNA (siRNA) nucleic  
CC acid molecule or an enzymatic nucleic acid molecule, that modulates  
CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,  
CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic  
CC acid molecule of the invention has cytostatic, anti-HIV, and anti-  
CC rheumatic activity. The nucleic acid molecules are useful for reducing  
CC HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic acids are  
CC also useful for treating breast, ovarian, colorectal, lung, prostate,  
CC bladder, or pancreatic cancer, and HIV infection, and AIDS. The sequences  
CC shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531, ABZ66520 - ABZ66524,  
CC ABZ66530 - ABZ66585 represent substrate/target sequences for the human  
CC ribozymes of the invention  
XX  
SQ Sequence 17 BP; 1 A; 5 C; 9 G; 0 T; 2 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1507 CCAGCTCCAGGCCCC 1522  
DB 17 CCAGCTGCAGGCCCC 2  
RESULT 247  
ACD59853  
ID ACD59853 standard; RNA; 17 BP.  
XX ACD59853;  
AC  
XX 24-SEP-2003 (first entry)  
DT  
XX HCV DNAzyme substrate sequence #1543.  
DE  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KW RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNAzyme; inozyme; zinzyme;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
XX Hepatitis C virus.  
OS  
XX WO200281494-A1.  
PN  
XX 17-OCT-2002.  
PD  
XX 26-MAR-2002; 2002WO-US009187.  
PF  
XX 26-MAR-2001; 2001US-00817879.  
PR 08-JUN-2001; 2001US-00877478.  
PR 08-JUN-2001; 2001US-0296876P.  
PR 24-OCT-2001; 2001US-0335059P.  
PR 05-DEC-2001; 2001US-0337055P.  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.



KW virus resistance; transgenic animals; Alzheimer's disease; schizophrenia;  
XX diagnosis.  
OS Homo sapiens.  
XX WO2003040369-A2.  
PN 15-MAY-2003.  
XX 17-SEP-2002; 2002WO-IB004219.  
PF 17-SEP-2001; 2001FR-00011981.  
PR (MOLE-) MOLECULAR ENGINES LAB.  
XX Telerman A, Anson R, Tuijnder M;  
PI WPI; 2003-441574/41.  
XX New nucleic acid encoding human prostate membrane-specific antigen,  
PT useful e.g. for treatment of tumors and viral infection, also related  
PT polypeptide and antibodies.  
XX Disclosure; Page 493; 771pp; French.  
XX The invention relates to the isolation of 6327 nucleotide sequences,  
CC fragments of at least 15 consecutive nucleotides of these nucleotides, a  
CC sequence having at least 80% identity, after optimal alignment, with the  
CC nucleotides, a sequence that hybridizes under stringent conditions with  
CC the nucleotides, or the complement, or corresponding RNA, of the  
CC nucleotides. The nucleotides are used as probes or primers for detecting,  
CC identifying, quantifying and/or amplifying nucleic acids, as in vitro  
CC sense and antisense sequences, of nucleotides involved in tumour  
CC suppression or reversion, apoptosis and or viral resistance, to produce  
CC recombinant polypeptides, and to prepare transgenic animals, as  
CC experimental models. The nucleotides (also vectors containing them and  
CC cells containing the vectors), the encoded polypeptides and antibodies  
CC (Ab) against the polypeptide are useful for prevention and/or treatment  
CC of viral infections or diseases characterized by development of tumours  
CC or cell degeneration (e.g. Alzheimer's disease or schizophrenia).  
CC Analysis of the expression of the nucleotides can be used for diagnosis  
CC and/or prognosis of these diseases. The nucleotides and polypeptides can  
CC also be used to screen for their specific interactive molecules,  
CC potentially useful for treating diseases associated with abnormal  
CC expression of the nucleotides.  
XX Sequence 17 BP; 7 A; 2 C; 5 G; 3 T; 0 U; 0 Other;  
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 154 ATCAGGGAAGTAAGTA 169  
Db 2 ATCAGGGAAGTAAGTA 17  
RESULT 250  
ADE30979  
ID ADE30979 standard; DNA; 17 BP.  
XX ADE30979;  
AC ADE30979;  
XX 29-JAN-2004 (first entry)  
DT XX Cholesterol homeostasis/adipogenesis related DNA seq id 366.  
DE XX expression vector; anorectic; antiarteriosclerotic; cardiant;  
XX antiidiabetic; elevated cholesterol; elevated lipid; adipogenesis;  
KW obesity; atherosclerosis; diabetes mellitus;  
KW coronary artery heart disease; cholesterol homeostasis; ss;  
KW differential expression.

OS Homo sapiens.  
XX US2003180764-A1.  
XX 25-SEP-2003.  
XX 08-JAN-2003; 2003US-00339793.  
PF 09-JAN-2002; 2002US-0347286P.  
PR (LYNX-) LYNX THERAPEUTICS INC.  
XX Shang J, Bowen B;  
PI WPI; 2003-830986/77.  
XX Polynucleotides differentially regulated in response to cholesterol and  
PT adipogenesis are useful to detect and treat associated conditions such as  
PT obesity, atherosclerosis, diabetes mellitus and coronary artery heart  
PT disease.  
XX Claim 8; SEQ ID NO 366; 59pp; English.  
XX The invention describes a composition comprising at least one expression  
CC vector comprising a polynucleotide of the invention. The composition has  
CC anorectic, antiarteriosclerotic, cardiant and antiidiabetic properties.  
CC The invention is used to detect and treat conditions associated with  
CC elevated cholesterol and lipid or during adipogenesis, particularly  
CC obesity, atherosclerosis, diabetes mellitus or coronary artery heart  
CC disease. This sequence represents a polynucleotide differentially  
CC expressed during cholesterol homeostasis and adipogenesis.  
XX Sequence 17 BP; 5 A; 9 C; 1 G; 2 T; 0 U; 0 Other;  
SQ Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 990 ACCAACACCCCTCCC 1005  
Db 2 ATCAACACCCCTCCC 17  
RESULT 251  
ABX95832  
ID ABX95832 standard; DNA; 17 BP.  
XX AC ABX95832;  
XX 24-JUL-2003 (first entry)  
DT XX Human Phe311Leu mutant Abl kinase, allele specific PCR primer F311T.  
DE XX Human; Abl kinase domain; tyrosine kinase activity; leukaemia;  
XX N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4-;  
KW (4-methyl-piperazin-1-ylmethyl)-benzamide; PCR; primer; ss.  
XX Homo sapiens.  
OS Synthetic.  
OS WO2003031608-A2.  
XX 17-APR-2003.  
XX 04-OCT-2002; 2002WO-EP011144.  
XX 05-OCT-2001; 2001US-0327389P.  
PR 12-OCT-2001; 2001US-0328740P.  
PR 11-JAN-2002; 2002US-0347351P.  
XX (NOVS ) NOVARTIS AG.  
PA (UYBO-) UNIV BORDEAUX 2 SEGALEN VICTOR.  
PA (UYMU-) UNIV TECH MUENCHEN.

```
PA (UYOR-) UNIV OREGON HEALTH SCI.
PA (UYHE-) UNIV HEIDELBERG.
PA (CHRU-) CHRU LILLE.
PA (MEDV-) MEDVET SCI PTY LTD.
XX
PI Barthe C, Branford S, Corbin A, Druker BJ, Duyster J, Hochhaus A;
PI Hughes T, Kreil S, Leguay T, Mahon F, Marit G, Mueller M;
PI Peschel C, Preudhomme C, Roche Lestienne C, Rudzki Z;
XX
XX WPI; 2003-363366/34.
XX
PT New isolated polypeptide having mutated native human Abl kinase domains,
PT useful for screening compounds that inhibit tyrosine kinase activity and
PT for diagnosing leukemias.
XX
PS Example 6; Page 34; 57pp; English.
XX
CC The present invention relates to mutated human Abl kinase domains that
CC are functional and resistant to inhibition of their tyrosine kinase
CC activity by N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4
CC -(4-methyl-piperazin-1-ylmethyl)-benzamide, or its salt. The mutant Abl
CC polypeptides are useful in screening for compounds that inhibit the
CC tyrosine kinase activity of such polypeptides. Polynucleotide sequences
CC encoding the mutant polypeptides are useful for the production of the
CC mutant polypeptides. The mutant polypeptides are also useful in the
CC diagnosis of leukaemias. The present sequence represents a PCR primer
CC used in the examples of the present invention
XX
SQ Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 635 CACCCGGAGCCCCAG 650
DB 1 CACCCGGAGCCCCCG 16
RESULT 252
ABX95833
ID ABX95833 standard; DNA; 17 BP.
XX
AC ABX95833;
XX
DT 24-JUL-2003 (first entry)
XX
DE Human Phe311Leu mutant Abl kinase, allele specific PCR primer F311C.
XX
KW Human; Abl kinase domain; tyrosine kinase activity; leukaemia;
KW N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4-;
KW (4-methyl-piperazin-1-ylmethyl)-benzamide; PCR; primer; ss.
XX
OS Homo sapiens.
OS Synthetic.
XX
PN WO2003031608-A2.
XX
PD 17-APR-2003.
XX
PF 04-OCT-2002; 2002WO-EP011144.
XX
PR 05-OCT-2001; 2001US-0327389P.
PR 12-OCT-2001; 2001US-0328740P.
PR 11-JAN-2002; 2002US-0347351P.
XX
XX (NOVS ) NOVARTIS AG.
PA (UYBO-) UNIV BORDEAUX 2 SEGALEN VICTOR.
PA (UYMU-) UNIV TECH MUENCHEN.
PA (UYOR-) UNIV OREGON HEALTH SCI.
PA (UYHE-) UNIV HEIDELBERG.
PA (CHRU-) CHRU LILLE.
PA (MEDV-) MEDVET SCI PTY LTD.
XX
Barthe C, Branford S, Corbin A, Druker BJ, Duyster J, Hochhaus A;
Hughes T, Kreil S, Leguay T, Mahon F, Marit G, Mueller M;
Peschel C, Preudhomme C, Roche Lestienne C, Rudzki Z;
WPI; 2003-363366/34.
New isolated polypeptide having mutated native human Abl kinase domains,
useful for screening compounds that inhibit tyrosine kinase activity and
for diagnosing leukemias.
Example 6; Page 34; 57pp; English.
The present invention relates to mutated human Abl kinase domains that
are functional and resistant to inhibition of their tyrosine kinase
activity by N-(4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl)-4
-(4-methyl-piperazin-1-ylmethyl)-benzamide, or its salt. The mutant Abl
polypeptides are useful in screening for compounds that inhibit the
tyrosine kinase activity of such polypeptides. Polynucleotide sequences
encoding the mutant polypeptides are useful for the production of the
mutant polypeptides. The mutant polypeptides are also useful in the
diagnosis of leukaemias. The present sequence represents a PCR primer
used in the examples of the present invention
Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 U; 0 Other;
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 1.6e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 635 CACCCGGAGCCCCAG 650
DB 1 CACCCGGAGCCCCCG 16
RESULT 253
ADL18587
ID ADL18587 standard; DNA; 17 BP.
XX
AC ADL18587;
XX
DT 06-MAY-2004 (first entry)
XX
DE RT-PCR primer HP6.
XX
KW DNA storage; DNA analysis; virus identification; bacteria identification;
KW reverse transcriptase; RT-PCR; primer; ss; HP6.
XX
OS Synthetic.
XX
PN US20031134312-A1.
XX
PD 17-JUL-2003.
XX
PF 15-NOV-2002; 2002US-00298255.
XX
PR 15-NOV-2001; 2001US-0336005P.
XX
XX (WHAT-) WHATMAN INC.
XX
XX Burgoyne LA;
XX
XX WPI; 2003-843261/78.
XX
XX New device comprising a filter layer comprising a dry solid medium
XX comprising a hydrophilic solid matrix, and an isolation layer, useful for
XX storing and analyzing a nucleic acid containing moiety.
XX
XX Example 1; SEQ ID NO 4; 14pp; English.
XX
XX The invention relates to a device for storage and analysis of a nucleic
XX acid containing a moiety in a biological sample, comprising a filter
XX layer comprising a dry solid medium comprising a hydrophilic solid
```

CC matrix, and an isolation layer comprising a dry solid medium comprising a  
CC neutral solid matrix attached to a composition comprising a detergent.  
CC Storing and analysing a nucleic acid containing a moiety in a biological  
CC sample comprises applying a biological sample to the filter layer,  
CC filtering the components of the biological sample through the filter  
CC layer to the isolation layer, retaining the nucleic acid components in  
CC the isolation layer while removing the non-nucleic acid components,  
CC drying the isolation layer, providing a primer and analysing the nucleic  
CC acid components using at least one primer. The device and method are  
CC useful for storing and analysing a nucleic acid containing a moiety in a  
CC biological sample. They are also useful for identifying known or unknown  
CC virions or bacteria contained in a fluid. This sequence represents a  
CC reverse transcriptase PCR (RT-PCR) primer used in the scope of the  
CC invention.

XX  
SQ Sequence 17 BP; 3 A; 10 C; 3 G; 1 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1508 CAGCCTCCAGGCCCC 1523  
|||||  
Db 1 CAGCCTCCAGGCCCC 16

RESULT 254  
ADM59611/c  
ID ADM59611 standard; RNA; 17 BP.

XX AC ADM59611;  
XX DT 03-JUN-2004 (first entry)

DE DE Hepatitis B virus (HBV) RNA target sequence #1745.  
KW Hepatitis B virus; HBV; ss; enzymatic nucleic acid; RNA cleavage;  
KW hepatitis B virus infection; hepatitis; hepatocellular carcinoma;  
KW cirrhosis; liver failure; lamivudine; interferon; genetic drift;  
KW virucide; hepatotropic; antiinflammatory; cytostatic.

XX OS Hepatitis B virus.  
XX PN US2004054156-A1.  
XX PD 18-MAR-2004.  
XX PF 15-JAN-2003; 2003US-00342902.  
XX PR 14-MAY-1992; 92US-00882712.  
XX PR 07-FEB-1994; 94US-00193627.  
XX PR 08-NOV-1999; 99US-00436430.  
XX PR 20-MAR-2000; 2000US-00531025.  
XX PR 09-AUG-2000; 2000US-00636385.  
XX PR 24-OCT-2000; 2000US-00696347.  
XX PR 08-JUN-2001; 2001US-00877478.

XX (DRAP/) DRAPER K.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
PA (MORR/) MORRISSEY D.

PI Draper K, Blatt L, Mcswiggen JA, Morrissey D;  
XX WPI; 2004-247781/23.

XX Novel enzymatic nucleic acid molecule such as DNazymes and inozymes  
PT specifically cleaving RNA derived from hepatitis B virus and comprising  
PT one or more binding arms, useful for treating hepatitis and cirrhosis.  
XX Disclosure; SEQ ID NO 1745; 122pp; English.

XX The invention relates to an enzymatic nucleic acid molecule that

CC specifically cleaves RNA derived from hepatitis B virus (HBV) and  
CC comprising one or more binding arms, without requiring the presence of a  
CC 2'-OH group within the molecule for activity. The nucleic acids are  
CC useful for treating hepatitis B virus infection, hepatitis,  
CC hepatocellular carcinoma, cirrhosis and liver failure, either alone or in  
CC combination with other therapies such as lamivudine and interferons. The  
CC nucleic acids are useful as diagnostic tools to examine genetic drift and  
CC mutations within diseased cells, for detecting the presence of HBV RNA in  
CC a cell, for the study of RNA and for down-regulating gene expression of  
CC target genes in bacterial, fungal, viral, plant or mammalian cells. This  
CC sequence represents an HBV RNA target sequence, used in the scope of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.

XX SQ Sequence 17 BP; 3 A; 0 C; 11 G; 0 T; 3 U; 0 Other;  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1519 CCCCCCACTCGCCCA 1534  
|||||  
Db 16 CCCCCCACTCGCCCA 1

RESULT 255  
ADI84297  
ID ADI84297 standard; RNA; 17 BP.

XX AC ADI84297;  
XX DT 03-JUN-2004 (first entry)

DE DE HCV DNzyme substrate sequence #1543.  
KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
KW HCV infection; type I interferon; DNzyme.

XX OS Hepatitis C virus.  
XX PN US2003125270-A1.  
XX PD 03-JUL-2003.  
XX PF 18-DEC-2000; 2000US-00740332.  
XX PR 18-DEC-2000; 2000US-00740332.

XX (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (ROBE/) ROBERTS E.  
PA (PAVC/) PAVCO P A.  
PA (MACE/) MACEJACK D.

XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
XX WPI; 2004-031273/03.

XX Enzymatic nucleic acid molecules which specifically cleave RNA derived  
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,  
PT especially in combination with type I interferon therapy.

XX Claim 1; SEQ ID NO 1543; 198pp; English.  
XX The invention relates to an enzymatic nucleic acid molecule which  
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which  
CC the binding arms of the enzymatic nucleic acid molecule comprises  
CC sequences complementary to any of the defined substrate sequences given  
CC in the specification. The nucleic acid molecule may be administered for  
CC the treatment of HCV infections, especially in combination with type I  
CC interferons. The present sequence represents a HCV DNzyme substrate  
CC sequence.



SQ	Sequence	17 BP; 2 A; 7 C; 4 G; 0 T; 4 U; 0 Other;	
XX	AC	ACN71763;	
XX	AC		
XX	DT	02-DEC-2004 (first entry)	
XX	DE	Human GDMPLP-1 probe SEQ ID NO:8665.	
XX	DE		
XX	KW	Human; ss; probe; myosin-like protein-1; hGDMPLP-1;	
XX	KW	hGDMPLP-1 agonist; hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;	
XX	KW	skeletal muscle function.	
XX	OS	Homo sapiens.	
XX	OS		
XX	PN	US2004137589-A1.	
XX	PN		
XX	PD	15-JUL-2004.	
XX	PD		
XX	PF	26-NOV-2003; 2003US-00723361.	
XX	PF		
XX	PR	26-MAY-2000; 2000US-0207456P.	
XX	PR	21-SEP-2000; 2000US-0234687P.	
XX	PR	27-SEP-2000; 2000US-0236359P.	
XX	PR	04-OCT-2000; 2000GB-00024263.	
XX	PR	30-JAN-2001; 2001WO-US000661.	
XX	PR	30-JAN-2001; 2001WO-US000662.	
XX	PR	30-JAN-2001; 2001WO-US000663.	
XX	PR	30-JAN-2001; 2001WO-US000664.	
XX	PR	30-JAN-2001; 2001WO-US000665.	
XX	PR	30-JAN-2001; 2001WO-US000666.	
XX	PR	30-JAN-2001; 2001WO-US000667.	
XX	PR	30-JAN-2001; 2001WO-US000668.	
XX	PR	30-JAN-2001; 2001WO-US000669.	
XX	PR	30-JAN-2001; 2001WO-US000670.	
XX	PR	05-FEB-2001; 2001US-0266860P.	
XX	PR	25-MAY-2001; 2001US-00866108.	
XX	PA	(GIYY/) GU Y.	
XX	PA	(JIYY/) JI Y.	
XX	PA	(PENN/) PENN S G.	
XX	PA	(HANZ/) HANZEL D K.	
XX	PA	(RANK/) RANK D.	
XX	PA	(CHEN/) CHEN W.	
XX	PA	(SHAN/) SHANNON M E.	
XX	PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;	
XX	PI	WPI; 2004-533378/51.	
XX	PT	Novel myosin-like protein-1, useful for treating or preventing disorder	
XX	PT	associated with decreased expression or activity of human genome-derived	
XX	PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle	
XX	PT	function.	
XX	PS	Disclosure; SEQ ID NO 8665; Opp; English.	
XX	CC	The invention relates to a novel polypeptide (I) comprising a sequence	
XX	CC	(S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully	
XX	CC	defined in the specification, a fragment of at least 8 amino acids of	
XX	CC	(S1), 95% deviation from (S1) which are conservative substitutions, and	
XX	CC	65% identity to (S1). A polypeptide of the invention acts as an agonist or	
XX	CC	antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A	
XX	CC	pharmaceutical composition of the invention is useful for treating or	
XX	CC	preventing a disorder associated with decreased expression or activity of	
XX	CC	hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.	
XX	CC	The present sequence represents a 17-mer nucleotide, used in the	
XX	CC	invention for scanning the sequence represented in ACN63103	
XX	XX	Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;	
XX	XX	Query Match 0.9%; Score 14.4; DB 1; Length 17;	
XX	XX	Best Local Similarity 93.8%; Pred. No. 1.6e+02;	
XX	XX	Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	

RESULT 256

AD185767/C

ID AD185767 standard; RNA; 17 BP.

XX AC

XX AC

XX AD185767;

XX AC

XX 03-JUN-2004 (first entry)

XX AC

XX HCV DNzyme substrate sequence #3013.

XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;

KW HCV infection; type I interferon; DNzyme.

XX Hepatitis C virus.

OS

XX US2003125270-A1.

XX PN

XX 03-JUL-2003.

XX 18-DEC-2000; 2000US-00740332.

XX PF

XX 18-DEC-2000; 2000US-00740332.

XX PR

XX (BLAT/) BLATT L.

PA (MCSW/) MCSWIGGEN J.

PA (ROBE/) ROBERTS E.

PA (PAVC/) PAVCO P A.

PA (MACE/) MACEJACK D.

XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;

XX WPI; 2004-031273/03.

XX Enzymatic nucleic acid molecules which specifically cleave RNA derived

XX from hepatitis C virus (HCV), useful for the treatment of HCV infections,

XX especially in combination with type I interferon therapy.

XX Claim 1; SEQ ID NO 3013; 198pp; English.

XX The invention relates to an enzymatic nucleic acid molecule which

XX specifically cleaves RNA derived from hepatitis C virus (HCV), in which

XX the binding arms of the enzymatic nucleic acid molecule comprises

XX sequences complementary to any of the defined substrate sequences given

XX in the specification. The nucleic acid molecule may be administered for

XX the treatment of HCV infections, especially in combination with type I

XX interferons. The present sequence represents a HCV DNzyme substrate

XX sequence.

XX Sequence 17 BP; 3 A; 5 C; 7 G; 0 T; 2 U; 0 Other;

XX Query Match 0.9%; Score 14.4; DB 1; Length 17;

XX Best Local Similarity 93.8%; Pred. No. 1.6e+02;

XX Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY	768	CACGCCATGTTCCAGC	783
Db	1	CACGCCAUGUCCGGC	16

RESULT 257

ACN71763

ID ACN71763 standard; DNA; 17 BP.

QY	768	CACGCCATGTTCCAGC	783
Db	16	CACGCCATGTTCCGGC	1



CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103

XX  
SQ Sequence 17 BP; 2 A; 3 C; 8 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 715 CCGCATCGTCCGAC 730  
Db 17 CCGCATCGTCCAC 2

RESULT 260  
ACN71450/c  
ID ACN71450 standard; DNA; 17 BP.  
XX AC ACN71450;  
XX  
XX  
DT 02-DEC-2004 (first entry)  
XX  
XX Human GDMPLP-1 probe SEQ ID NO:8352.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.

XX Homo sapiens.  
XX  
XX US2004137589-A1.  
XX  
XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.  
XX (JIY/) JI Y.  
XX (PENN/) PENN S G.  
XX (HANZ/) HANZEL D K.  
XX (RANK/) RANK D.  
XX (CHEN/) CHEN W.  
XX (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
PI WPI; 2004-533378/51.  
XX  
XX Novel myosin-like protein-1, useful for treating or preventing disorder

PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.

XX Disclosure; SEQ ID NO 8352; Opp; English.

XX The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103

XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1109 CACCTCCTCTGCTG 1124  
Db 17 CAGCTCCTCTGCTG 2

RESULT 261  
ACN71451/c  
ID ACN71451 standard; DNA; 17 BP.  
XX AC ACN71451;  
XX  
XX  
DT 02-DEC-2004 (first entry)  
XX  
XX Human GDMPLP-1 probe SEQ ID NO:8353.

XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.

XX Homo sapiens.  
XX  
XX US2004137589-A1.  
XX  
XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX 25-MAY-2001; 2001US-00866108.

XX (GUY/) GU Y.  
XX (JIY/) JI Y.  
XX (PENN/) PENN S G.  
XX (HANZ/) HANZEL D K.  
XX (RANK/) RANK D.

PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
XX  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
XX Disclosure; SEQ ID NO 8353; Opp; English.  
PS  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
XX Sequence 17 BP; 5 A; 3 C; 8 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1109 CACCTCTCTCTTGCTG 1124  
DB 16 CAGCTCTCTCTTGCTG 1  
RESULT 262  
ACN71765  
ID ACN71765 standard; DNA; 17 BP.  
XX  
XX ACN71765;  
AC  
DT 02-DEC-2004 (first entry)  
XX  
XX Human GDMLP-1 probe SEQ ID NO:8667.  
XX  
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;  
KW hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
XX Homo sapiens.  
OS  
XX US2004137589-A1.  
PN  
XX  
PD 15-JUL-2004.  
XX  
XX 26-NOV-2003; 2003US-00723361.  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
DR  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
XX Disclosure; SEQ ID NO 8667; Opp; English.  
PS  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
XX Sequence 17 BP; 9 A; 2 C; 6 G; 0 T; 0 U; 0 Other;  
SQ  
Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 1.6e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 274 AAGCCCAAGGAAGAA 289  
DB 1 AAGCCCAAGGAAGAA 16  
RESULT 263  
AAQ80949/C  
ID AAQ80949 standard; DNA; 18 BP.  
XX  
XX AAQ80949;  
AC  
XX 25-MAR-2003 (revised)  
DT 24-AUG-1995 (first entry)  
XX  
XX PCR primer to generate probe flanking the sCos-1 T7 promoter site.  
XX  
XX sequence sampled mapping; genomic analysis; complex genome mapping;  
KW cosmid library; Giardia lamblia; T7 promoter; ss.  
XX  
XX Synthetic.  
OS  
XX WO9429486-A1.  
PN  
XX 22-DEC-1994.  
PD  
XX 15-JUN-1994; 94WO-US006810.  
XX  
XX 15-JUN-1993; 93US-00078471.  
PR 07-SEP-1993; 93US-00117952.  
XX  
XX (SALK ) SALK INST BIOLOGICAL STUDIES.  
PA Evans GA, Smith MW;  
XX  
PI

XX WPI; 1995-036508/05.  
XX Sequencing complex genomes, present as fragments in a cosmid library - by  
PT sequencing end-specific nucleotides of each clone then correlating with  
PT spatial relationship of cosmid, esp. for mammalian chromosomes.

XX Example 3; Page 44; 128pp; English.

XX In a sequence-sample mapping procedure using a Giardia lamblia 20-genome  
XX equivalent cosmid library, each end of the genomic insert in a cosmid was  
CC detected as a vector/genomic chimera by hybridisation with probes  
CC flanking the T3 and T7 promoter sites of sCos-1. The 1046 bp T3 probe was  
CC amplified from sCos-1 with the primers AAQ80946 and AAQ80947 and the 1004  
CC bp T7 probe was amplified with primers AAQ80948 and AAQ80949. The T7  
CC probe was labelled with 35S- dATP and the T3 probe with 33P-dATP for dual  
CC -label hybridisations. Maps were constructed by determining an order of  
CC fragments with no gaps using a computer program. (Updated on 25-MAR-2003  
CC to correct PN field.)

XX Sequence 18 BP; 4 A; 2 C; 9 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1520 CCCCAACTCGCCCGAC 1535  
Db 18 CCTTAATCGCCCGAC 3

RESULT 264  
ADM06417  
ID ADM06417 standard; DNA; 18 BP.  
AC ADM06417;  
XX 20-MAY-2004 (first entry)  
XX Human PCR primer SEQ ID NO:5102.  
XX human; gene therapy; diagnostic marker; pharmaceutical; ss; PCR; primer.  
XX Homo sapiens.  
XX EPI347046-A1.  
XX 24-SEP-2003.  
XX 12-APR-2002; 2002EP-00008400.  
XX 22-MAR-2002; 2002JP-00137785.  
XX (REAS-) RES ASSOC BIOTECHNOLOGY.  
XX Isoqai T, Sugiyama T, Otsuki T, Wakamatsu A, Sato H, Ishii S;  
XX Yamamoto J, Isono Y, Hio Y, Otsuka K, Nagai K, Irie R, Tamechika I;  
XX Seki N, Yoshikawa T, Otsuka M, Nagahari K, Masuho Y;  
XX WPI; 2003-723558/69.  
XX New polynucleotides and polypeptides are useful in gene therapy, for  
XX developing a diagnostic marker or medicines for regulating their  
XX expression and activity, or as a target of gene therapy.

XX Example 8; SEQ ID NO 5102; 305pp; English.

XX The invention relates to a novel human polynucleotide and the encoded  
XX polypeptide. A polynucleotide of the invention may have a use in gene  
XX therapy. An oligonucleotide of the invention ADM06202-ADM06773 is useful  
XX as a primer for synthesizing the polynucleotide or as a probe for  
XX detecting the polynucleotide. The polynucleotides ADM01316-ADM03758 are  
XX useful in gene therapy, for developing a diagnostic marker or medicines

CC for regulating their expression and activity, or as a target of gene  
CC therapy. The proteins ADM03759-ADM06201 encoded by the polynucleotides  
CC are useful as pharmaceutical agents. The present sequence represents an  
CC oligonucleotide used in the invention.

XX Sequence 18 BP; 4 A; 3 C; 7 G; 4 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1094 GTGGAAGATGCTCAAC 1109  
Db 1 GTGGAAGATGCTCGAC 16

RESULT 265  
ADM92954  
ID ADM92954 standard; DNA; 18 BP.  
XX AC ADM92954;  
XX 03-JUN-2004 (first entry)  
XX SNP-containing cardiovascular associated gene primer #285.  
XX SNP; single nucleotide polymorphism; cardiovascular associated gene;  
XX allelic variation; atherosclerosis; ischemia; reperfusion; hypertension;  
XX restenosis; arterial inflammation; myocardial infarction; stroke; primer;  
XX ss.

XX Homo sapiens.  
XX WO2003057911-A2.  
XX 17-JUL-2003.  
XX 07-JAN-2003; 2003WO-EP000060.  
XX 08-JAN-2002; 2002EP-00000153.  
XX (FARB ) BAYER AG.  
XX Stropp U, Schwiers S, Kallabis H;  
XX WPI; 2003-577532/54.  
XX New isolated polynucleotides comprising single nucleotide polymorphisms  
XX of the cardiovascular gene, useful for assessing predisposition or  
XX susceptibility to a cardiovascular disease, e.g. atherosclerosis,  
XX restenosis or stroke.

XX Disclosure; Page 78; 187pp; English.

XX The invention relates an isolated polynucleotide (I) encoded by a  
XX cardiovascular associated (CA) gene, having allelic variation contained  
XX in a functional surrounding like full length cDNA for CA gene  
XX polypeptide, and with or without the CA gene promoter sequence. (I) is a  
XX polynucleotide comprising single nucleotide polymorphisms predicting  
XX cardiovascular disease. The polynucleotides are useful for assessing  
XX predisposition or susceptibility to a cardiovascular disease, e.g.  
XX atherosclerosis, ischemia/reperfusion, hypertension, restenosis, arterial  
XX inflammation, myocardial infarction, and stroke. These may also be used  
XX to predict personal medication schemes omitting adverse drug reactions,  
XX or as probes for detecting genetic polymorphisms and as templates for the  
XX recombinant production of normal or variant peptides/polypeptides encoded  
XX by the genes. This sequence corresponds to a PCR primer to amplify one of  
XX the genes of the invention.

XX Sequence 18 BP; 8 A; 5 C; 2 G; 3 T; 0 U; 0 Other;

Query Match 0.9%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
QY	1488 GTCACCAAGTAACGAG 1503	
Db	1 GTCACCAATTACGAG 16	
RESULT 266		
ADH71057/c		
ID	ADH71057 standard; DNA; 18 BP.	
XX	ADH71057;	
XX	25-MAR-2004 (first entry)	
XX	Human Vbeta point mutation PCR primer #10.	
XX	human; T-cell associated disease; Vbeta; autoimmune disease;	
KW	degenerative nervous system disease; graft versus host disease;	
KW	hypersensitivity disease; infectious disease; neoplastic disease;	
KW	Addison's disease; atrophic gastritis;	
KW	degenerative nervous system disease; multiple sclerosis;	
KW	Alzheimer's disease; hypersensitivity disease; type I hypersensitivity;	
KW	allergy; type II hypersensitivity; Goodpasture's syndrome;	
KW	type IV hypersensitivity; leprosy; infectious disease; viral infection;	
KW	HIV; fungal infection; Candida; parasitic infection; schistosoma;	
KW	filaria; bacterial infection; Mycobacterium; neoplastic disease;	
KW	lymphoproliferative disease; leukaemia; lymphoma; cancer; brain cancer;	
KW	breast cancer; ss; PCR; primer.	
XX		
OS	Homo sapiens.	
XX		
PN	US2002150891-A1.	
XX		
PD	17-OCT-2002.	
XX		
XX	05-MAR-1999; 99US-00263959.	
PF		
XX		
PR	19-SEP-1994; 94US-00309335.	
PR	19-SEP-1995; 95US-00531241.	
XX		
XX	(HOOD/) HOOD L E.	
PA	(ROWE/) ROWEN L.	
XX		
XX	Hood LE, Rowen L;	
PI		
XX		
XX	WPI; 2004-059052/06.	
DR		
XX		
PT	Kit for diagnosing and treating T-cell associated diseases e.g.	
PT	autoimmune, degenerative nervous system and infectious disease, comprises	
PT	nucleic acid primers specifically priming and allowing amplification of a	
PT	Vbeta gene.	
XX		
PS	Disclosure; SEQ ID NO 1251; 164pp; English.	
XX		
CC	The invention relates to a kit for diagnosing and treating T-cell	
CC	associated diseases which comprises a panel of nucleic acid primers	
CC	specifically priming and allowing amplification of each Vbeta gene,	
CC	VbetaRNA or cDNA. The kit is useful for diagnosing organ transplant	
CC	rejection and diagnosing and treating T-cell associated diseases	
CC	including autoimmune diseases, degenerative nervous system diseases,	
CC	graft versus host disease, hypersensitivity diseases, infectious diseases	
CC	and neoplastic diseases. Autoimmune diseases include Addison's disease,	
CC	atrophic gastritis. Degenerative nervous system diseases include multiple	
CC	sclerosis and Alzheimer's disease. Hypersensitivity diseases include Type	
CC	I hypersensitivities such as contact with allergens that lead to	
CC	allergies, Type II hypersensitivities such as those present in	
CC	Goodpasture's syndrome and type IV hypersensitivities such as those	
CC	manifested in leprosy. Infectious diseases include viral infections	
CC	caused by viruses such as HIV, fungal infections such as those caused by	
CC	the yeast genus Candida, parasitic infections such as those caused by	
CC	schistosomes, filaria and bacterial infections such as those caused by	
CC	Mycobacterium. Neoplastic diseases include lymphoproliferative diseases	
XX		
such as leukaemias, lymphomas and cancers such as cancer of the brain,		
CC	breast. The present sequence represents a Vbeta point mutation PCR	
CC	primer.	
XX		
SQ	Sequence 18 BP; 1 A; 4 C; 9 G; 4 T; 0 U; 0 Other;	
Query Match 0.9%; Score 14.4; DB 1; Length 18;		
Best Local Similarity 93.8%; Pred. No. 1.9e-02;		
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		
QY	634 TCACCCGGGAGCCCA 649	
Db	17 TCACCCGGGAGCCCA 2	
RESULT 267		
AAF47085		
ID	AAF47085 standard; DNA; 15 BP.	
XX	AAF47085;	
XX	30-MAR-2001 (first entry)	
DT	IGFBP3 oligonucleotide #505.	
DE		
XX	Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;	
KW	cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;	
KW	skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pteryiasis;	
KW	IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;	
KW	growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;	
KW	keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;	
KW	hyperneovascular condition; hyperplasia; kidney disease;	
KW	neovascular condition of the retina; ss.	
XX		
OS	Homo sapiens.	
XX		
PN	WO200078341-A1.	
XX		
PD	28-DEC-2000.	
XX		
XX	21-JUN-2000; 2000WO-AU000693.	
PF		
XX		
XX	21-JUN-1999; 99US-0140345P.	
PR		
XX	(MURD-) MURDOCH CHILDRENS RES INST.	
PA		
XX		
XX	Wright CJ, Werther GA, Edmondson SR;	
PI		
XX		
XX	WPI; 2001-041421/05.	
DR		
XX		
PT	Ameliorating the effects of a disorder, e.g. psoriasis, by administering	
PT	UV (ultra-violet) treatment (optional) and an antisense nucleic acid that	
PT	inhibits or reduces growth factor mediated cell proliferation and/or	
PT	inflammation.	
XX		
PS	Example 7; Page 47; 201pp; English.	
XX		
CC	The present invention relates to a method for ameliorating the effects of	
CC	skin disorders. The method comprises contacting the skin with an	
CC	antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1	
CC	receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of	
CC	inhibiting or reducing growth factor mediated cell proliferation,	
CC	inflammation and/or other disorders. The present sequence is an	
CC	oligonucleotide which can be used to design the antisense	
CC	oligonucleotides of the present invention (see AAF45151 and AAF45153-	
CC	F45161). The method is useful for ameliorating the effects of psoriasis,	
CC	ichthyosis, pteryiasis, ruba, pilaris, serborrhea, keloids, keratosis,	
CC	neoplasias, scleroderma, warts, benign growths, cancers of the skin, a	
CC	hyperneovascular condition such as a neovascular condition of the retina,	
CC	brain or skin, growth factor-mediated malignancies, other sclerotic	
CC	disease, kidney disease, hyperproliferation of the inside of blood	
CC	vessels or any other hyperplasia	
XX		

SQ Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 136 AGCTCCAGGAAATG 149  
 |||||  
 Db 2 AGCTCCAGGAAATG 15

RESULT 269  
 ABK25595/c  
 ID ABK25595 standard; DNA; 17 BP.  
 XX  
 AC ABK25595;  
 XX  
 DT DT  
 XX 09-APR-2002 (first entry)  
 XX  
 DE Stress tolerance conferring genome altering oligonucleotide #63.  
 XX  
 KW Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;  
 KW o-methyl modification; LNA modification; phosphorothioate linkage;  
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;  
 KW abiotic stress tolerance; improved nutritional value; glyphosate resistance;  
 KW amino acid over production; herbicide resistance; glyphosate resistance;  
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;  
 KW pyrophoric herbicide resistance; triazine resistance; disease resistance;  
 KW modified oil production; modified starch production; waxy starch;  
 KW altered floral morphology; male-sterile plant; albino mutant;  
 KW modified fatty acid content; reduced palmitate production; albino plant;  
 KW increased stearate production; reduced linolenic acid production;  
 KW photosynthetic process.  
 XX  
 OS Rucalyptus camaldulensis.  
 OS Synthetic.  
 XX  
 PN WO200192512-A2.  
 XX  
 PD 06-DEC-2001.  
 XX  
 PF 01-JUN-2001; 2001WO-US017672.  
 XX  
 PR 01-JUN-2000; 2000US-0208538P.  
 PR 30-OCT-2000; 2000US-024989P.  
 PR 27-MAR-2001; 2001US-00818875.  
 XX  
 PA (UYDE ) UNIV DELAWARE.  
 XX  
 PI Kmiec EB, Gamper HB, Rice MC, Kim J;  
 XX  
 DR WPI; 2002-106307/14.  
 XX  
 PT New oligonucleotides with modified nuclease-resistant termini, useful for  
 PT creating plants with desired phenotypes, e.g. stress tolerance, improved  
 PT nutritional value, herbicide or disease resistance, or modified oil  
 PT production.  
 XX  
 PS Claim 7; Page 100; 220pp; English.  
 XX  
 CC The invention relates to an oligonucleotide for targeted alteration of a  
 CC genetic sequence, which comprises a single-stranded oligonucleotide  
 CC having a DNA domain. The DNA domain has at least one mismatch with  
 CC respect to the genetic sequence to be altered and further comprises  
 CC chemical modifications of the oligonucleotide. The chemical modifications  
 CC consist of o-methyl modification, an LNA modification, two or more  
 CC phosphorothioate linkages on a terminus, or a combination of any two or  
 CC more of these modifications. The oligonucleotides are useful for  
 CC directing repair or alteration of plant genetic information. The  
 CC oligonucleotides are particularly useful for creating plants with desired  
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved  
 CC nutritional value (e.g. altering amino acid content of plants or  
 CC conferring amino acid over production), herbicide resistance (e.g.  
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide  
 CC resistance, pyrophoric herbicide resistance or triazine resistance),  
 CC disease resistance, modified oil production, modified starch production  
 CC (e.g. increased starch or production of waxy starch), altered floral

SQ Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 136 AGCTCCAGGAAATG 149  
 |||||  
 Db 1 AGCTCCAGGAAATG 14

RESULT 268  
 AAF47084  
 ID AAF47084 standard; DNA; 15 BP.  
 XX  
 AC AAF47084;  
 XX  
 DT 30-MAR-2001 (first entry)  
 XX  
 DE IGFBP3 oligonucleotide #504.  
 XX  
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;  
 KW cytoskeletal; dermatological; cardiant; virucide; ophthalmological; keloid;  
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;  
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;  
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;  
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;  
 KW hyperneovascular condition; hyperplasia; kidney disease;  
 KW neovascular condition of the retina; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN WO200078341-A1.  
 XX  
 PD 28-DEC-2000.  
 XX  
 PF 21-JUN-2000; 2000WO-AU000693.  
 XX  
 PR 21-JUN-1999; 99US-0140345P.  
 XX  
 PA (MURD-) MURDOCH CHILDRENS RES INST.  
 XX  
 PI Wraight CJ, Werther GA, Edmondson SR;  
 XX  
 DR WPI; 2001-041421/05.  
 XX  
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by administering  
 PT UV (ultra-violet) treatment (optional) and an antisense nucleic acid that  
 PT inhibits or reduces growth factor mediated cell proliferation and/or  
 PT inflammation.  
 XX  
 PS Example 7; Page 47; 201pp; English.  
 XX  
 CC The present invention relates to a method for ameliorating the effects of  
 CC skin disorders. The method comprises contacting the skin with an  
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1  
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of  
 CC inhibiting or reducing growth factor mediated cell proliferation,  
 CC inflammation and/or other disorders. The present invention is an  
 CC oligonucleotide which can be used to design the antisense  
 CC oligonucleotides of the present invention (see AAF45151 and AAF45153-  
 CC F45161). The method is useful for ameliorating the effects of psoriasis,  
 CC ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids, keratosis,  
 CC neoplasias, scleroderma, warts, benign growths, cancers of the skin, a  
 CC hyperneovascular condition such as a neovascular condition of the retina,  
 CC brain or skin, growth factor-mediated malignancies, other sclerotic  
 CC disease, kidney disease, hyperproliferation of the inside of blood  
 CC vessels or any other hyperplasia  
 XX  
 SQ Sequence 15 BP; 5 A; 4 C; 4 G; 2 T; 0 U; 0 Other;  
 Query Match 0.9%; Score 14; DB 1; Length 15;  
 Best Local Similarity 100.0%; Pred. No. 1.2e+02;

CC morphology (e.g. male-sterile plants) or modified fatty acid content  
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).  
CC The oligonucleotides are also useful for producing albino mutants for the  
CC analysis of photosynthetic processes. This sequence represents a genome  
CC altering oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1202 GGTCACACGGTGG 1215  
DB 14 GGTCACACGGTGG 1  
  
RESULT 270  
ABK25596  
ID ABK25596 standard; DNA; 17 BP.  
XX  
AC ABK25596;  
XX  
DT 09-APR-2002 (first entry)  
DE  
XX Stress tolerance conferring genome altering oligonucleotide #64.  
XX  
XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;  
KW o-methyl modification; DNA modification; phosphorothioate linkage;  
KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;  
KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;  
KW amino acid over production; herbicide resistance; glyphosate resistance;  
KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;  
KW porphyric herbicide resistance; triazine resistance; disease resistance;  
KW modified oil production; modified starch production; waxy starch;  
KW altered floral morphology; male-sterile plant; albino mutant;  
KW increased fatty acid content; reduced palmitate production; albino plant;  
KW modified stearate production; reduced linolenic acid production;  
KW photosynthetic process.  
XX  
XX Eucalyptus camaldulensis.  
OS Synthetic.  
XX  
XX WO200192512-A2.  
PN  
XX  
XX 06-DEC-2001.  
PD  
XX  
XX 01-JUN-2001; 2001WO-US017672.  
PF  
XX  
XX 01-JUN-2000; 2000US-0208538P.  
PR  
XX 30-OCT-2000; 2000US-0244989P.  
PR  
XX 27-MAR-2001; 2001US-00818875.  
PR  
XX  
XX (UYDE ) UNIV DELAWARE.  
PA  
XX  
XX Kmiec EB, Gamper HB, Rice MC, Kim J;  
PI  
XX  
XX WPI; 2002-106307/14.  
DR  
XX  
XX New oligonucleotides with modified nuclease-resistant termini, useful for  
PT creating plants with desired phenotypes, e.g. stress tolerance, improved  
PT nutritional value, herbicide or disease resistance, or modified oil  
PT production.  
PT  
XX Claim 7; Page 100; 220pp; English.  
PS  
XX  
XX The invention relates to an oligonucleotide for targeted alteration of a  
CC genetic sequence, which comprises a single-stranded oligonucleotide  
CC having a DNA domain. The DNA domain has at least one mismatch with  
CC respect to the genetic sequence to be altered and further comprises  
CC chemical modifications of the oligonucleotide. The chemical modifications  
CC consist of o-methyl modification, an INA modification, two or more  
CC phosphorothioate linkages on a terminus, or a combination of any two or

CC more of these modifications. The oligonucleotides are useful for  
CC directing repair or alteration of plant genetic information. The  
CC oligonucleotides are particularly useful for creating plants with desired  
CC phenotypes, e.g. environmental or abiotic stress tolerance, improved  
CC nutritional value (e.g. altering amino acid content of plants or  
CC conferring amino acid over production), herbicide resistance (e.g.  
CC glyphosate resistance, imidazolinone and sulphonylurea herbicide  
CC resistance, porphyric herbicide resistance or triazine resistance),  
CC disease resistance, modified oil production, modified starch production  
CC (e.g. increased starch or production of waxy starch), altered floral  
CC morphology (e.g. male-sterile plants) or modified fatty acid content  
CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).  
CC The oligonucleotides are also useful for producing albino mutants for the  
CC analysis of photosynthetic processes. This sequence represents a genome  
CC altering oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;  
  
Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
  
QY 1202 GGTCACACGGTGG 1215  
DB 4 GGTCACACGGTGG 17  
  
RESULT 271  
ACD59851  
ID ACD59851 standard; RNA; 17 BP.  
XX  
XX ACD59851;  
AC  
XX  
XX 24-SEP-2003 (first entry)  
DT  
XX HCV DNazyme substrate sequence #1541.  
DE  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KW RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; zinzyme;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer; replication;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
XX  
XX Hepatitis C virus.  
OS  
XX  
XX WO200281494-A1.  
PN  
XX  
XX 17-OCT-2002.  
PD  
XX  
XX 26-MAR-2002; 2002WO-US009187.  
PF  
XX  
XX 26-MAR-2001; 2001US-00817879.  
PR  
XX 08-JUN-2001; 2001US-00877478.  
PR  
XX 08-JUN-2001; 2001US-0296876P.  
PR  
XX 24-OCT-2001; 2001US-0335059P.  
PR  
XX 05-DEC-2001; 2001US-0337055P.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (NACE/) MACERJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEEP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.  
XX  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey J, Pavco P, Lee P;  
PI Draper K, Roberts E;  
XX



PT especially in combination with type I interferon therapy.  
 XX  
 PS Claim 1; SEQ ID NO 1541; 198pp; English.  
 CC The invention relates to an enzymatic nucleic acid molecule which specifically cleaves RNA derived from hepatitis C virus (HCV), in which the binding arms of the enzymatic nucleic acid molecule comprises sequences complementary to any of the defined substrate sequences given in the specification. The nucleic acid molecule may be administered for the treatment of HCV infections, especially in combination with type I interferons. The present sequence represents a HCV DNzyme substrate sequence.  
 XX  
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;  
 Query Match 0.9%; Score 14; DB 1; Length 17;  
 Best Local Similarity 71.4%; Pred. No. 1.8e+02;  
 Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
 QY 766 TCACGCCCATGTC 779  
 Db 4 UCCACGCCCAUGUUC 17  
 RESULT 273  
 ADN44286/c  
 ID ADN44286 standard; DNA; 17 BP.  
 XX  
 AC ADN44286;  
 XX  
 DT 15-JUL-2004 (first entry)  
 DE Mutant cell identification-related mutagenic oligonucleotide SeqID955.  
 XX  
 KW cell identification; oligonucleotide-directed sequence alteration;  
 KW selectable phenotype; transgenic plant; herbicide resistance;  
 KW sterile plant; abiotic stress tolerance; albino plant;  
 KW amino acid production; ss.  
 XX  
 OS Eucalyptus camaldulensis.  
 OS Synthetic.  
 XX  
 PN WO2004033708-A2.  
 XX  
 PD 22-APR-2004.  
 XX  
 PF 07-OCT-2003; 2003WO-US031862.  
 XX  
 PR 07-OCT-2002; 2002US-0416983P.  
 PR 07-MAR-2003; 2003US-0453360P.  
 XX  
 PA (UYDE ) UNIV DELAWARE.  
 PA (NAPR-) NAPRO BIO THERAPEUTICS INC.  
 XX  
 PI Kmiec EB, Van Brabant A;  
 XX  
 WPI; 2004-340941/31.  
 XX  
 PT Identifying a cell with a desired oligonucleotide-directed sequence alteration at a nucleic acid target site within the cell by identifying the desired sequence alteration in cells selected for the presence of a selectable phenotype.  
 PT  
 PS Example 25; SEQ ID NO 955; 303pp; English.  
 XX  
 CC This invention relates to a novel method of identifying a cell having a desired oligonucleotide-directed sequence alteration at a first nucleic acid target site within the cell. The method comprises identifying the desired sequence alteration in cells that have been selected for the presence of a selectable phenotype conferred by a concurrent oligonucleotide-directed sequence alteration at a second nucleic acid target site within the cells. The method is useful in identifying a cell having a desired oligonucleotide-directed sequence alteration at a first

DR WPI; 2003-229207/22.  
 XX  
 PT Novel compound useful for treating cirrhosis, liver failure,  
 PT hepatocellular carcinoma, or condition associated with hepatitis C virus infection.  
 XX  
 PS Claim 1; Page 261; 387pp; English.  
 CC The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of Hepatitis C virus (HCV) or Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense and enzymatic nucleic acids such as hammerhead ribozymes, DNzymes, inozymes, zinzymes, ambezymes, and G-cleaver ribozymes. Also disclosed are nucleic acid decoy molecules and aptamers that bind to HBV reverse transcriptase and/or HBV reverse transcriptase primer sequences, as well as oligonucleotides that specifically bind the Enhancer I region of HBV DNA. The nucleic acids may be used to modulate the expression of HBV genes and HBV viral replication. Also disclosed is a method for screening compounds and/or potential therapies directed against HBV, and compounds that modulate the expression and/or replication of HCV. The compounds and methods of the invention are useful for the treatment of degenerative and disease states related to HBV and HCV infection, replication and gene expression such as cirrhosis, liver failure, and hepatocellular carcinoma. The present sequence represents a substrate for one of the HCV DNzyme or minus strand DNzyme sequences disclosed in the present invention  
 XX  
 SQ Sequence 17 BP; 2 A; 7 C; 3 G; 0 T; 5 U; 0 Other;  
 Query Match 0.9%; Score 14; DB 1; Length 17;  
 Best Local Similarity 71.4%; Pred. No. 1.8e+02;  
 Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;  
 QY 766 TCACGCCCATGTC 779  
 Db 4 UCCACGCCCAUGUUC 17  
 RESULT 272  
 ADI84295  
 ID ADI84295 standard; RNA; 17 BP.  
 XX  
 AC ADI84295;  
 XX  
 DT 03-JUN-2004 (first entry)  
 DE HCV DNzyme substrate sequence #1541.  
 XX  
 KW ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;  
 KW HCV infection; type I interferon; DNzyme.  
 XX  
 OS Hepatitis C virus.  
 XX  
 PN US2003125270-A1.  
 XX  
 PD 03-JUL-2003.  
 XX  
 PF 18-DEC-2000; 2000US-00740332.  
 XX  
 PR 18-DEC-2000; 2000US-00740332.  
 XX  
 PA (BLAT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J.  
 PA (ROBE/) ROBERTS E.  
 PA (PAVC/) PAVCO P A.  
 PA (MACE/) MACEJACK D.  
 XX  
 PI Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;  
 XX  
 WPI; 2004-031273/03.  
 XX  
 PT Enzymatic nucleic acid molecules which specifically cleave RNA derived from hepatitis C virus (HCV), useful for the treatment of HCV infections,

CC nucleic acid target site within the cell. The method may be useful for  
CC the production of plants with herbicide resistance, male or female  
CC sterile plants, abiotic stress tolerance, albino plants or plants with  
CC altered amino acid production as well as for use in mammalian cell lines.  
CC The present sequence is that of a mutagenic oligonucleotide which was  
CC used in the exemplification of the invention.  
XX  
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1202 GGTCAACCGGTGG 1215  
Db 14 GGTCAACCGGTGG 1  
RESULT 274  
ADN44287  
ID ADN44287 standard; DNA; 17 BP.  
XX  
AC ADN44287;  
XX  
DT 15-JUL-2004 (first entry)  
XX  
DE Mutant cell identification-related mutagenic oligonucleotide SeqID956.  
XX  
KW cell identification; oligonucleotide-directed sequence alteration;  
KW selectable phenotype; transgenic plant; herbicide resistance;  
KW sterile plant; abiotic stress tolerance; albino plant;  
KW amino acid production; ss.  
XX  
OS Eucalyptus camaldulensis.  
OS Synthetic.  
PN WO2004033708-A2.  
XX  
PD 22-APR-2004.  
XX  
PF 07-OCT-2003; 2003WO-US031862.  
XX  
PR 07-OCT-2002; 2002US-0416983P.  
PR 07-MAR-2003; 2003US-0453360P.  
XX  
PA (UYDE ) UNIV DELAWARE.  
PA (NAPR-) NAPRO BIO THERAPEUTICS INC.  
XX  
PI Kmiec EB, Van Brabant A;  
XX  
DR WPI; 2004-340941/31.  
XX  
PT Identifying a cell with a desired oligonucleotide-directed sequence  
PT alteration at a nucleic acid target site within the cell by identifying  
PT the desired sequence alteration in cells selected for the presence of a  
PT selectable phenotype.  
XX  
PS Example 25; SEQ ID NO 956; 303pp; English.  
XX  
CC This invention relates to a novel method of identifying a cell having a  
CC desired oligonucleotide-directed sequence alteration at a first nucleic  
CC acid target site within the cell. The method comprises identifying the  
CC desired sequence alteration in cells that have been selected for the  
CC presence of a selectable phenotype conferred by a concurrent  
CC oligonucleotide-directed sequence alteration at a second nucleic acid  
CC target site within the cells. The method is useful in identifying a cell  
CC having a desired oligonucleotide-directed sequence alteration at a first  
CC nucleic acid target site within the cell. The method may be useful for  
CC the production of plants with herbicide resistance, male or female  
CC sterile plants, abiotic stress tolerance, albino plants or plants with  
CC altered amino acid production as well as for use in mammalian cell lines.  
CC The present sequence is that of a mutagenic oligonucleotide which was  
CC used in the exemplification of the invention.  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 U; 0 Other;  
Query Match 0.9%; Score 14; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 1.8e+02;  
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1202 GGTCAACCGGTGG 1215  
Db 4 GGTCAACCGGTGG 17  
RESULT 275  
AAT05231/C  
ID AAT05231 standard; DNA; 17 BP.  
XX  
AC AAT05231;  
XX  
DT 13-JUN-1996 (first entry)  
XX  
DE Hepatitis C virus antisense oligonucleotide A377 (17) .  
XX  
KW Inhibition; expression; hepatitis C virus; HCV; non-A; non-B; RNA;  
KW translation; in vivo; ex vivo; in vitro; treatment; prevention;  
KW infection; antisense; non coding; region; NCR; core region; ss.  
XX  
OS Synthetic.  
XX  
PN WO9530746-A1.  
XX  
PD 16-NOV-1995.  
XX  
PF 08-MAY-1995; 95WO-US005812.  
XX  
PR 10-MAY-1994; 94US-00240382.  
XX  
PA (GEHO ) GEN HOSPITAL CORP.  
XX  
PI Wakita T, Wands JR;  
XX  
DR WPI; 1995-404113/51.  
XX  
PT New anti-sense hepatitis C virus oligonucleotide(s) - used for  
PT inhibiting HCV RNA translation, for the treatment or prevention of HCV  
PT infection.  
XX  
PS Claim 1; Page 31; 50pp; English.  
XX  
CC The present oligonucleotide (ON) inhibits the expression of hepatitis C  
CC virus (HCV) RNA, specifically HCV type II protein synthesis is inhibited  
CC by about 50%. The ONs of the invention inhibit translation of HCV types I  
CC -V RNA in vivo, ex vivo or in vitro, and can therefore be used to treat  
CC or prevent HCV infection. The antisense ONs comprise 10-28 nucleotides  
CC complementary to the entire HCV 5'-non-coding and part of the core  
CC region. The A or S in the ONs name denotes antisense or sense, and the  
CC no. indicates the position of the 5'-end of the ON. The ON was tested at  
CC 10 fold molar excess to HCV RNA  
XX  
SQ Sequence 17 BP; 1 A; 1 C; 4 G; 11 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 222 CTCATAGAAAAACCAA 238  
Db 17 CTCAAAGAAAAACCAA 1  
RESULT 276  
AAX75009  
ID AAX75009 standard; RNA; 17 BP.  
XX

AC	AXX75009;
XX	
XX	28-JUL-1999 (first entry)
XX	
XX	Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #537.
XX	
XX	Vascular endothelial growth factor receptor; VEGF receptor; flt-1; flk-1;
KW	KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
KW	tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
KW	fms-like tyrosine kinase 1; kinase insert domain containing receptor;
KW	foetal liver kinase 1; ss.
XX	
XX	Mus sp.
OS	
XX	WO9715662-A2.
PN	
XX	01-MAY-1997.
PD	
XX	25-OCT-1996; 96WO-US017480.
XX	
XX	26-OCT-1995; 95US-0005974P.
PR	
PR	11-JAN-1996; 96US-00584040.
XX	
XX	(RIBO-) RIBOZYME PHARM INC.
PA	
PA	(CHIR-) CHIRON CORP.
XX	
PI	Pavco P, Mcswiggen J, Stinchcomb D, Escobedo J;
PI	
XX	WPI; 1997-259017/23.
DR	
XX	
XX	Nucleic acid molecule modulating VEGF receptor(s) gene expression or mRNA
PT	stability - useful for treating e.g. tumour angiogenesis, psoriasis,
PT	rheumatoid arthritis, etc., in a human patient.
XX	
XX	Claim 4; Page 171; 218pp; English.
PS	
XX	
XX	The present invention describes nucleic acid molecules which modulate the
XX	synthesis, expression and/or stability of a mRNA encoding 1 or more
CC	receptors of vascular endothelial growth factor (VEGF). A patient
CC	(preferably human) having a condition associated with the level of the
CC	fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
CC	receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
CC	angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can be
CC	treated by administering the nucleic acid molecule or the expression
CC	vector to the patient. AAX67275 to AAX75752 represent specific examples
CC	of nucleic acid molecules from the present invention
CC	
XX	
XX	Sequence 17 BP; 2 A; 8 C; 3 G; 0 T; 4 U; 0 Other;
XX	
XX	Best Match
XX	Best Local Similarity 0.8%; Score 13.8; DB 1; Length 17;
XX	Matches 11; Conservative 4; Mismatches 2; Indels 0; Gaps 0;
XX	
Qy	1112 CTCCTCTTGTCTGGAGC 1128
	: : : : : : :
	: : : : : : :
Db	1 CUCCCCCUUGCUAAGC 17
XX	
XX	
RESULT 277	
AA62812/c	
ID	AA62812 standard; RNA; 17 BP.
XX	
XX	AA62812;
AC	
XX	
XX	16-JUL-1999 (first entry)
DT	
XX	
DE	Delta-9 desaturase hamerhead ribozyme target SEQ ID NO:697.
XX	
KW	Maize; corn; Zea mays; delta-9 desaturase; GBS5; target; substrate;
KW	granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
KW	modulation; gene expression; transgenic plant; cleavage; canola plant;
KW	caffeine synthesis; coffee plant; nicotine production; tobacco;
KW	fruit ripening; flower pigmentation; lignin production; ss.

PR	11-DEC-1995;	95US-00570142.	PT	fluorophore.	
PR	28-DEC-1995;	95US-00583153.	XX		
PR	22-JAN-1996;	96US-00599455.	PS	Disclosure; Fig 1; 16pp; English.	
PR	26-APR-1996;	96US-00638524.	XX		
PR	03-SEP-1996;	96US-00708123.	CC	A method has been developed of separating and detecting tagged	
XX	(MILL-) MILLENNIUM PHARM INC.		CC	polynucleotides. The method comprises: providing a set of	
XX	Tartaglia LA, Tepper RI, Culpepper JA, White DW;		CC	polynucleotides, each tagged with a chromophore or fluorophore; resolving	
XX	WPI; 1997-310525/28.		CC	to separate one of the tagged polynucleotides from other tagged	
XX			CC	polynucleotides differing in length by a single nucleotide using an	
XX	Isolated Ob receptor genes and polypeptide(s) - useful to develop		CC	electrophoretic procedure capable of resolving tagged polynucleotides	
PT	products for diagnosis or treatment of body weight disorders, e.g.		CC	differing by a single nucleotide; and detecting the resolved tagged	
PT	obesity, cachexia, anorexia and bulimia.		CC	polynucleotides by means of the chromophore or fluorophore. The present	
XX	Example; Page 122; 265pp; English.		CC	invention also describes a method of determining the sequence of a	
XX			CC	polynucleotide by analysing tagged polynucleotide fragments generated by	
XX	Forward and reverse PCR primers (AAT69614 and AAT69615) are based on the		CC	polynucleotide sequencing technique which comprises: introducing the	
CC	3' sequence of mouse Ob receptor (OBR) cDNA clone famj5312 (see also		CC	tagged polynucleotide fragments into an electrophoretic medium;	
CC	AAT69590). They revealed a polymorphism on SSCP gels between C57Bl/6J		CC	separating the tagged polynucleotide fragments in the electrophoretic	
CC	genomic DNA and wild-derived Mus spretus strain SPRET/Bi DNA. The		CC	medium using an electrophoretic procedure capable of resolving the	
CC	polymorphism allowed the genetic mapping of famj5312 to murine chromosome		CC	polynucleotide fragments differing in length by a single nucleotide;	
CC	4, approx. 2.2 cm distal to the marker D4Mit9 and 4.6 cm proximal to the		CC	detecting the separated tagged polynucleotide fragments by means of the	
CC	marker D4Mit46. This mapping confirmed the results obtd. using another		CC	chromophore or fluorophore; and determining the polynucleotide sequence	
CC	primer pair (AAT69612-13) derived from famj5312		CC	from the polynucleotide fragments detected. The present sequence	
XX			CC	represents a DNA fragment used in an example for end-labeling the DNA	
XX			CC	fragment with a fluorescent tag	
SQ	Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;		SQ	Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;	
Query Match 0.8%; Score 13.8; DB 1; Length 17;			Query Match 0.8%; Score 13.8; DB 1; Length 17;		
Best Local Similarity 88.2%; Pred. No. 1.9e+02;			Best Local Similarity 88.2%; Pred. No. 1.9e+02;		
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	660	CACTACCTGCCCTTCAG 676	QY	1357 AAGCGCTGCAGGAATAC 1373	
Db	1	CACTATTGCCCTTCAG 17	Db	1 ATGCTCTGCAGGAATAC 17	
RESULT 279			RESULT 280		
AAV61074	AAV61074 standard; DNA; 17 BP.		AAV47411/c	AAV47411 standard; DNA; 17 BP.	
ID	AAV61074		ID	AAV47411	
XX			XX		
AC	AAV61074;		AC	AAV47411;	
XX			XX		
DT	09-DEC-1998 (first entry)		DT	10-NOV-1998 (first entry)	
XX			XX		
DE	Synthetic DNA fragment from US5821058.		DE	Antisense oligonucleotide 911, targeting adenosine A1 receptor.	
XX			XX		
XX	Electrophoretic analysis; DNA fragment; sequencing; chromophore;		KW	Secondary structure; mRNA; phosphorothioate backbone; G-protein;	
KW	fluorophore; tag; electrophoresis; primer; ss.		KW	bronchoconstriction; lung inflammation; asthma; pulmonary disease;	
XX			KW	allergy; emphysema; cystic fibrosis; ss.	
OS	Synthetic.		XX		
XX			OS	Synthetic.	
XX			OS	Homo sapiens.	
PN	US5821058-A.		XX		
XX			XX		
PD	13-OCT-1998.		FT	Key	Location/Qualifiers
XX			FT	modified_base	1..17
XX			FT	/*tag= a	
XX			FT	/note= "contains phosphorothioate internucleotide	
XX			FT	linkages"	
XX			XX		
PF	21-DEC-1994;	94US-00361176.	XX		
XX			PN	WO9823294-A1.	
PR	16-JAN-1984;	84US-00570973.	XX		
PR	02-JAN-1985;	85US-00689013.	XX		
PR	11-APR-1985;	85US-00722742.	PD	04-JUN-1998.	
PR	07-OCT-1987;	87US-00106232.	XX		
PR	21-FEB-1991;	91US-00660160.	PF	26-NOV-1997;	97WO-US022017.
PR	12-JUN-1992;	92US-00898019.	XX		
XX			PR	26-NOV-1996;	96US-00757024.
XX			XX		
PA	(CALY ) CALIFORNIA INST OF TECHNOLOGY.		XX		
XX			PA	(UYEC-) UNIV EAST CAROLINA.	
XX			XX		
PI	Hood LE, Connell CR, Hunkapiller MW, Smith LM, Hunkapiller TJ;		XX		
XX			XX	Nyce JW;	
XX	WPI; 1998-567653/48.		XX		
XX			DR	WPI; 1998-322464/28.	
XX			XX		
PT	Electrophoretic analysis of DNA fragments - tagged with chromophore or				

PT Treating respiratory disease with antisense sequences directed against  
PT adenosine or bradykinin receptors - with localised delivery to the  
PT respiratory system, suitable for long term treatment of asthma, adult  
PT respiratory distress syndrome etc.  
XX  
XX  
PS Claim 12; Page 8-24; 47pp; English.  
XX  
CC Sequences AAV46501-V47446 are anti-sense oligonucleotides that target the  
CC human adenosine A1 receptor, the design of which required the secondary  
CC structure of this targets mRNA. The adenosine receptor mRNA secondary  
CC structure was both analysed and used to construct antisense  
CC oligonucleotides containing a phosphorothioate backbone. Once the  
CC antisense molecules are created they can be used to target their  
CC antisense oligonucleotides containing a phosphorothioate backbone. The  
CC predetermined target, thus causing the gene product to decrease. The  
CC antisense oligonucleotides were targeted to specific mRNA regions  
CC containing either a junction between the intron and exon, or where they  
CC may overlap the initiation codon. The receptor is a member of the G-  
CC protein coupled family of cell surface receptors that have 7-  
CC transmembrane segments. These oligonucleotides can be used to treat or  
CC prevent conditions associated with bronchoconstriction and/or lung  
CC inflammation in humans or other animals e.g. asthma, pulmonary disease,  
CC allergy, emphysema and cystic fibrosis  
XX  
XX Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1530 GCCCAGCCTCTCCCGC 1546  
|||||  
DB 17 GCCCAGCCTGTGCCGC 1  
RESULT 281  
AAV46535/C  
ID AAV46535 standard; DNA; 17 BP.  
XX  
XX AAV46535;  
AC  
DT 10-NOV-1998 (first entry)  
XX  
XX Antisense oligonucleotide 35, targeting adenosine A1 receptor.  
DE  
XX Secondary structure; mRNA; phosphorothioate backbone; G-protein;  
KW bronchoconstriction; lung inflammation; asthma; pulmonary disease;  
KW allergy; emphysema; cystic fibrosis; ss.  
XX  
OS Synthetic.  
OS Homo sapiens.  
XX  
XX Key Location/Qualifiers  
FH modified\_base 1..17  
FT /\*tag= a  
FT /note= "contains phosphorothioate internucleotide  
linkages"  
FT  
XX  
XX WO9823294-A1.  
XX  
XX 04-JUN-1998.  
XX  
XX 26-NOV-1997; 97WO-US022017.  
XX  
XX 26-NOV-1996; 96US-00757024.  
XX  
XX (UYEC-) UNIV EAST CAROLINA.  
PA  
XX  
XX Nyce JW;  
PI  
XX  
XX WPI; 1998-322464/28.  
DR  
XX  
XX Treating respiratory disease with antisense sequences directed against  
PT adenosine or bradykinin receptors - with localised delivery to the

PT respiratory system, suitable for long term treatment of asthma, adult  
PT respiratory distress syndrome etc.  
XX  
XX  
PS Claim 12; Page 8-24; 47pp; English.  
XX  
CC Sequences AAV46501-V47446 are anti-sense oligonucleotides that target the  
CC human adenosine A1 receptor, the design of which required the secondary  
CC structure of this targets mRNA. The adenosine receptor mRNA secondary  
CC structure was both analysed and used to construct antisense  
CC oligonucleotides containing a phosphorothioate backbone. Once the  
CC antisense molecules are created they can be used to target their  
CC antisense oligonucleotides were targeted to specific mRNA regions  
CC containing either a junction between the intron and exon, or where they  
CC may overlap the initiation codon. The receptor is a member of the G-  
CC protein coupled family of cell surface receptors that have 7-  
CC transmembrane segments. These oligonucleotides can be used to treat or  
CC prevent conditions associated with bronchoconstriction and/or lung  
CC inflammation in humans or other animals e.g. asthma, pulmonary disease,  
CC allergy, emphysema and cystic fibrosis  
XX  
XX Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1530 GCCCAGCCTCTCCCGC 1546  
|||||  
DB 17 GCCCAGCCTGTGCCGC 1  
RESULT 282  
AAV94804  
ID AAV94804 standard; RNA; 17 BP.  
XX  
XX AAV94804;  
AC  
DT 24-FEB-1999 (first entry)  
XX  
XX Human IL-2 receptor g-chain substrate position 1385.  
DE  
XX  
XX Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;  
KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;  
KW autoimmune disease; psoriasis; allergy; inflammatory disease;  
KW graft rejection; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX WO9824913-A2.  
PN  
XX  
XX 11-JUN-1998.  
PD  
XX  
XX 02-DEC-1997; 97WO-US021748.  
PF  
XX  
XX 03-DEC-1996; 96US-00758306.  
PR  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Stinchcomb DT, Meswigen JA;  
PI  
XX  
XX WPI; 1998-333332/29.  
DR  
XX  
XX Ribozymes targeted to interleukin 2 - useful for treating e.g. cancer,  
PT autoimmune disease and allergies.  
PT  
XX  
XX Claim 4; Page 37; 61pp; English.  
PS  
XX  
XX The present sequence invention describes ribozymes targeted to modulate  
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA.  
CC AAV93889 to AAV94574 represent specifically claimed ribozymes, and  
CC AAV94575 to AAV95560 represent specifically claimed substrate sequences  
CC from the present invention. The ribozymes can be used for the treatment

CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy  
CC and other inflammatory conditions. The ribozymes are also used to induce  
CC tolerance in a recipient to alloantigen from a donor  
XX  
SQ Sequence 17 BP; 0 A; 10 C; 0 G; 0 T; 7 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.9e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
QY 693 CCTCATTCTCTTTCC 709  
DB 1 CCUCCUUCUUCUCC 17  
RESULT 283  
AAV92651/c  
ID AAV92651 standard; RNA; 17 BP.  
XX  
AC AAV92651;  
XX  
DT 18-FEB-1999 (first entry)  
DE Human A-Raf substrate position 2271.  
XX  
XX Human; c-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;  
KW target; substrate; catalyst; modulation; expression; Raf gene; delivery;  
KW screening; identification; synthesis; deprotection; purification; cancer;  
KW inflammation; psoriasis; non-hepatic ascites; infection; genetic drift;  
KW restenosis; rheumatoid arthritis; ss.  
XX  
OS Homo sapiens.  
XX  
XX WO9850530-A2.  
PN  
XX  
PD 12-NOV-1998.  
XX  
XX 05-MAY-1998; 98WO-US009249.  
XX  
XX 09-MAY-1997; 97US-0046059P.  
PR 09-JUN-1997; 97US-0049002P.  
PR 03-JUL-1997; 97US-0051718P.  
PR 22-AUG-1997; 97US-0056808P.  
PR 02-OCT-1997; 97US-0061321P.  
PR 02-OCT-1997; 97US-0061324P.  
PR 05-NOV-1997; 97US-0064866P.  
PR 19-DEC-1997; 97US-0068212P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
XX  
XX Jarvis T, Matulic-Adamic J, Reynolds M, Kisich K, Bellon L;  
PI Parry T, Beigelman L, Mcswiggen JA, Karpeisky A, Burgin A;  
PI Thompson J, Workman CT, Beaudry A, Sweedler D;  
XX  
XX WPI; 1999-009494/01.  
XX  
XX Identifying new catalytic nucleic acid that modulates selected processes  
PT - especially ribozymes that cleave Raf RNA for treating cancer,  
PT restenosis, and also new ribozymes and modified nucleoside triphosphates  
PT used as antiviral agents and synthons.  
XX  
XX Claim 177; Page 162; 259pp; English.  
XX  
XX A method has been developed for the identification of a nucleic acid  
CC capable of modulating a process in a biological system. The method  
CC comprises: (a) introducing into the system a random library of nucleic  
CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising  
CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC  
CC in systems where modulation has occurred and/or determining the sequence  
CC of at least part of the SBDs in such systems. Nucleic acid molecules with  
CC endonuclease activity and catalytic activity, from the present invention,  
CC are used to modulate gene expression in plant and mammalian cells and to  
CC cleave target nucleic acid, particularly for treating systemic diseases

CC caused by specific RNA, e.g. cancer, inflammation, psoriasis, non-hepatic  
CC ascites and infection. They may also be used to detect genetic drift and  
CC mutations in diseased cells and to determine c-raf RNA. Specifically NACs  
CC with RNA-cleaving activity that modulate expression of the Raf gene, are  
CC used to treat cancer, restenosis, psoriasis or rheumatoid arthritis, or  
CC generally any condition associated with the level of c-raf. Introduction  
CC of sugar/phosphate modifications increases stability against nuclease and  
CC activity. AAV90922 to AAV93877 represent NACs that can be used in the  
CC method, specifically for modulating the expression of a Raf gene  
XX  
SQ Sequence 17 BP; 2 A; 6 C; 4 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 328 AGCTGAGGAGCTCCCA 344  
DB 17 AGATGGAGGAGCTCCCA 1  
RESULT 284  
AAV53788/c  
ID AAV53788 standard; DNA; 17 BP.  
XX  
AC AAV53788;  
XX  
DT 05-JUL-1999 (first entry)  
DE Human adenosine A1 receptor antisense oligonucleotide fragment.  
XX  
XX Antisense oligonucleotide; multiple target; antisense treatment;  
KW impaired respiration; inflammation; lung disease;  
KW pulmonary vasoconstriction; inflammation; allergic rhinitis;  
KW acute asthma; allergy; asthma; impeded respiration;  
KW respiratory distress syndrome; pain; cystic fibrosis;  
KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;  
KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;  
KW colon cancer; breast cancer; lung cancer; pancreatic cancer;  
KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;  
KW prostate cancer; ss.  
XX  
XX Synthetic.  
XX WO9913886-A1.  
PN  
XX 25-MAR-1999.  
PD  
XX 17-SEP-1998; 98WO-US019419.  
XX  
XX 17-SEP-1997; 97US-0059160P.  
PR 09-JUN-1998; 98US-00093972.  
XX  
XX (UYEC-) UNIV EAST CAROLINA.  
XX  
XX Nyce JW;  
PI  
XX WPI; 1999-229400/19.  
DR  
XX New antisense oligonucleotides used in treatment of, e.g. pulmonary  
PT vasoconstriction.  
XX  
XX Disclosure; Page 41; 120pp; English.  
XX  
XX The specification describes antisense oligonucleotides (AAV52869-X55271)  
CC directed against at least 2 mRNAs selected from target genes, coding and  
CC non-coding regions of RNAs corresponding to target genes, gene initiation  
CC codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'-  
CC end and the juxta-section between coding and non-coding regions and all  
CC segments of RNAs encoding proteins associated with one or more diseases,  
CC conditions or mixtures. The antisense oligonucleotides may be derived  
CC from sequences AAV55272-74. These multiple target oligonucleotides  
CC (specifically AAV55180-271) can be used for the antisense treatment of

CC	diseases and conditions. Typical diseases and conditions are those	CC	from sequences AAX5272-74. These multiple target oligonucleotides
CC	associated with impaired respiration and inflammation, including lung	CC	(specifically AAX55180-271) can be used for the antisense treatment of
CC	asthma, pulmonary vasoconstriction, inflammation, allergic rhinitis,	CC	diseases and conditions. Typical diseases and conditions are those
CC	acute asthma, allergies, asthma, impeded respiration, respiratory	CC	associated with impaired respiration and inflammation, including lung
CC	distress syndrome, pain, cystic fibrosis, pulmonary hypertension,	CC	diseases, pulmonary vasoconstriction, inflammation, allergic rhinitis,
CC	pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary	CC	acute asthma, allergies, asthma, impeded respiration, respiratory
CC	disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.	CC	distress syndrome, pain, cystic fibrosis, pulmonary hypertension,
CC	colon cancer, breast cancer, lung cancer, pancreatic cancer,	CC	pulmonary vasoconstriction, emphysema, chronic obstructive pulmonary
CC	hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as	CC	disease (COPD), and cancers such as leukemias, lymphomas, carcinomas e.g.
CC	well as all types of cancers which may metastasize or have metastasized	CC	colon cancer, breast cancer, lung cancer, pancreatic cancer,
CC	to the lungs, including breast and prostate cancer	CC	hepatocellular carcinoma, kidney cancer, melanoma, hepatic metastases, as
XX		CC	well as all types of cancers which may metastasize or have metastasized
SQ	Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;	XX	to the lungs, including breast and prostate cancer
	Query Match 0.8%; Score 13.8; DB 1; Length 17;	SQ	Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;		Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		Best Local Similarity 88.2%; Pred. No. 1.9e+02;
QY	1530 GCCCAGCCTCTCCCGC 1546	QY	1530 GCCCAGCCTCTCCCGC 1546
DB	17 GCCCAGCCTGTGCCGC 1	DB	17 GCCCAGCCTGTGCCGC 1
RESULT 285		RESULT 286	
ID	AAX52912/c	ID	AAX3231/c
XX	AAX52912 standard; DNA; 17 BP.	XX	AAA3231 standard; DNA; 17 BP.
AC	AAX52912;	AC	AAA3231;
DT	05-JUL-1999 (first entry)	DT	28-JUL-2000 (first entry)
XX	Human adenosine A1 receptor antisense oligonucleotide fragment.	XX	Low adenosine antisense oligonucleotide SEQ ID NO:920.
XX	Antisense oligonucleotide; multiple target; antisense treatment;	XX	Human; adenosine receptor; low adenosine antisense oligonucleotide;
KW	impaired respiration; inflammation; lung disease;	KW	phosphorothioate; impaired respiration; inflammation; allergy;
KW	pulmonary vasoconstriction; inflammation; allergic rhinitis;	KW	allergic disease; bronchoconstriction; inhibitor; anti-inflammatory;
KW	acute asthma; allergy; asthma; impeded respiration;	KW	antiallergic; antiasthmatic; cytostatic; analgesic; impaired airway;
KW	respiratory distress syndrome; pain; cystic fibrosis;	KW	lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
KW	pulmonary hypertension; pulmonary vasoconstriction; emphysema;	KW	respiratory distress syndrome; pain; cystic fibrosis; emphysema;
KW	chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;	KW	pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
KW	colon cancer; breast cancer; lung cancer; pancreatic cancer;	KW	cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
KW	hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;	XX	Homo sapiens.
KW	prostate cancer; ss.	OS	
OS	Synthetic.	XX	
XX		XX	
PN	WO9913886-A1.	PN	WO200009525-A2.
XX		XX	
PD	25-MAR-1999.	PD	24-FEB-2000.
XX		XX	
PF	17-SEP-1998; 98WO-US019419.	PF	03-AUG-1999; 99WO-US017712.
XX		XX	
PR	17-SEP-1997; 97US-0059160P.	PR	03-AUG-1998; 98US-0095212P.
PR	09-JUN-1998; 98US-00093972.	XX	
XX		XX	
XX		PA	(UYEC-) UNIV EAST CAROLINA.
PA	(UYEC-) UNIV EAST CAROLINA.	XX	
XX		PI	Nyce JW;
PI	Nyce JW;	XX	
XX		XX	
XX		DR	WPI; 2000-205971/19.
XX		XX	
DR	WPI; 1999-229400/19.	XX	
XX		PT	New antisense oligonucleotides useful for treating e.g. pulmonary
XX		PT	vasoconstriction, inflammation, allergies, asthma, hypertension,
PT	New antisense oligonucleotides used in treatment of, e.g. pulmonary	PT	bronchitis, emphysema, respiratory distress syndrome, ischemia or
PT	vasoconstriction.	PT	cancers.
XX		XX	
XX		PS	Claim 18; Page 380; 1343pp; English.
PS	Disclosure; Page 28; 120pp; English.	XX	
XX		XX	
CC	The specification describes antisense oligonucleotides (AAX52869-X55271)	XX	The present invention describes a new composition comprising an antisense
CC	directed against at least 2 mRNAs selected from target genes, coding and	CC	oligonucleotide (ON) with low adenosine (up to 15%), which targets
CC	non-coding regions of RNAs corresponding to target genes, gene initiation	CC	nucleic acids involved in bronchoconstriction, allergies, and/or
CC	codons, genomic flanking regions, intron-exon borders, the 5'-end, the 3'	CC	inflammation. The ON can have antiinflammatory, antiallergic,
CC	-end and the juxta-section between coding and non-coding regions and all	CC	antiasthmatic, cytostatic and analgesic activities. The compositions are
CC	segments of RNAs encoding proteins associated with one or more diseases,	CC	useful for the treatment of diseases associated with inflammation,
CC	conditions or mixtures. The antisense oligonucleotides may be derived		

CC impaired airways, including lung disease and diseases whose secondary  
CC effects afflict the lungs of a subject. They can be used for treating  
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,  
CC impeded respiration, respiratory distress syndrome, pain, cystic  
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive  
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,  
CC carcinomas, and cancers which may metastasise to the lungs, including  
CC breast and prostate cancer. The reduction of the adenosine content of the  
CC ONS reduces side effects. The A-containing ONS break down with the  
CC release of deoxyadenosine which activates adenosine receptors causing  
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the  
CC nucleotide sequences given in the sequence listing from the present  
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185  
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ  
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to  
CC AAA33992) are specifically claimed ONS from the present invention. N.B.  
CC Sequences given in the disclosure of the present invention do not match  
CC up with their corresponding SEQ ID NO: sequences given in the sequence  
CC listing  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCACGCCCTCTCCCGC 1546  
Db 17 GCCACGCCCTGTGCCCC 1  
  
RESULT 287  
AAA32356/c  
ID AAA32356 standard; DNA; 17 BP.  
AC AAA32356;  
DT 28-JUL-2000 (first entry)  
XX Low adenosine antisense oligonucleotide SEQ ID NO:44.  
DE  
XX Human; adenosine receptor; low adenosine antisense oligonucleotide;  
KW phosphorothioate; impaired respiration; inflammation; allergy;  
KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;  
KW antiasthmatic; cytosstatic; analgesic; impaired airway;  
KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;  
KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;  
KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;  
KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200009525-A2.  
XX  
XX 24-FEB-2000.  
XX  
XX 03-AUG-1999; 99WO-US017712.  
XX  
XX 03-AUG-1998; 98US-0095212P.  
PR  
XX (UYEC-) UNIV EAST CAROLINA.  
XX  
XX Nyce JW;  
XX  
XX WPI; 2000-205971/18.  
DR  
XX New antisense oligonucleotides useful for treating e.g. pulmonary  
XX vasoconstriction, inflammation, allergies, asthma, hypertension,  
PT bronchitis, emphysema, respiratory distress syndrome, ischemia or  
PT cancers.  
PT  
XX Claim 18; Page 272; 1343pp; English.  
PS  
XX

CC The present invention describes a new composition comprising an antisense  
CC oligonucleotide (ON) with low adenosine (up to 15%), which targets  
CC nucleic acids involved in bronchoconstriction, allergies, and/or  
CC inflammation. The ON can have antiinflammatory, antiallergic,  
CC antiasthmatic, cytosstatic and analgesic activities. The compositions are  
CC useful for the treatment of diseases associated with inflammation,  
CC impaired airways, including lung disease and diseases whose secondary  
CC effects afflict the lungs of a subject. They can be used for treating  
CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies, asthma,  
CC impeded respiration, respiratory distress syndrome, pain, cystic  
CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive  
CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,  
CC carcinomas, and cancers which may metastasise to the lungs, including  
CC breast and prostate cancer. The reduction of the adenosine content of the  
CC ONS reduces side effects. The A-containing ONS break down with the  
CC release of deoxyadenosine which activates adenosine receptors causing  
CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the  
CC nucleotide sequences given in the sequence listing from the present  
CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last 185  
CC sequences are also called SEQ ID NO:1 to 185, but the sequences differ  
CC from the previously named sequences. SEQ ID NO:11 to 1680 (AAA32323 to  
CC AAA33992) are specifically claimed ONS from the present invention. N.B.  
CC Sequences given in the disclosure of the present invention do not match  
CC up with their corresponding SEQ ID NO: sequences given in the sequence  
CC listing  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCACGCCCTCTCCCGC 1546  
Db 17 GCCACGCCCTGTGCCCC 1  
  
RESULT 288  
AAZ57766/c  
ID AAZ57766 standard; DNA; 17 BP.  
XX  
AC AAZ57766;  
XX  
DT 05-APR-2000 (first entry)  
XX Hepatitis C virus antisense inhibitor oligonucleotide #21.  
DE  
XX Hepatitis C virus; HCV; antisense oligonucleotide; hepatotropic; ss;  
KW anti-inflammatory; translation inhibition; HCV infection; virucide.  
KW  
XX Hepatitis C virus.  
OS  
XX US6001990-A.  
XX  
XX 14-DEC-1999.  
PD  
XX 07-JUN-1995; 95US-00474700.  
PF  
XX 10-MAY-1994; 94US-00240382.  
PR  
XX (GEHO ) GEN HOSPITAL CORP.  
PA  
XX Moradpour D, Wands JR, Wakita T;  
PI  
XX WPI; 2000-104900/09.  
DR  
XX Antisense oligonucleotide to Hepatitis C virus RNA, useful for treating  
PT Hepatitis C virus infections.  
PT  
XX Claim 24; Col 25; 31pp; English.  
PS  
XX This sequence is an antisense oligonucleotide that hybridises to  
CC Hepatitis C virus (HCV) RNA, under physiological conditions. The  
CC



CC invention relates to HCV antisense oligonucleotides, and also for a  
CC vector comprising a nucleotide sequence which is transcribed in an animal  
CC cell to generate an antisense oligonucleotide. The oligonucleotides have  
CC virucide, hepatotropic and anti-inflammatory activity, and are useful for  
CC treating HCV infection by inhibiting translation of type I-V HCV RNA.  
CC Hepatitis C virus is a positive strand RNA virus, and is the major  
CC causative agent of post-transfusion hepatitis. Persistent HCV infection  
CC can lead to chronic hepatitis, cirrhosis, and hepatocellular carcinoma  
XX  
XX Sequence 17 BP; 1 A; 1 C; 4 G; 11 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 222 CTCATAGAAAAACAAA 238  
DB 17 CTCAAAGAAACCAAA 1  
RESULT 289  
AAA03590/c  
ID AAA03590 standard; DNA; 17 BP.  
XX AC AAA03590;  
XX AC  
XX 19-MAY-2000 (first entry)  
XX Human adenosine A1 receptor antisense oligonucleotide SEQ ID NO:874.  
DE Human; adenosine A1 receptor; antisense oligonucleotide; hypoxia;  
XX Human; adenosine A2a receptor; adenosine A3 receptor;  
KW phosphothioate; cardiopulmonary failure; renal failure; ischaemia;  
KW endotoxin release; ARDS; acute respiratory distress syndrome;  
KW cytoprotective; anti-allergic; anti-inflammatory; anti-hypoxic;  
KW supraventricular tachycardia; allergic rhinitis; acute inflammation;  
KW chronic obstructive pulmonary disease; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX WO9963938-A2.  
XX 16-DEC-1999.  
XX 08-JUN-1999; 99WO-US012775.  
XX 08-JUN-1998; 98US-0088501P.  
PR 09-JUN-1998; 98US-00093972.  
PR 09-JUN-1998; 98US-0088657P.  
XX (EPIG-) EPIGENESIS PHARM INC.  
XX Nyce JW, Hill JL;  
XX WPI; 2000-116433/10.  
XX Novel composition for treating or preventing e.g. cardiopulmonary and  
PT renal injury.  
XX Claim 17; Page 36; 252pp; English.  
XX The present invention describes a pharmaceutical composition, comprising  
CC at least one agent (I) that prevents, alleviates and/or inhibits  
CC adenosine-mediated cardiopulmonary and/or renal damage and/or failure.  
CC (I) is an adenosine A2a receptor agonist (Ia), or an oligonucleotide  
CC (Ib), containing less than 15% adenosine (A), that is antisense to target  
CC genes or corresponding RNA, to genomic flanking regions (i.e. 5' or 3',  
CC ends or segments between coding and non-coding sequences), or to all  
CC segments of mRNA encoding the adenosine A1, A2a, A2b or A3 receptors, and  
CC has A1, A2b or A3 agonist activity or A2a antagonist activity (or at  
CC least no agonist activity at this receptor). (I) may be a mixture of (Ia)  
CC and (Ib), and optionally also contains one or more surfactants. The

CC compositions are used to prevent, alleviate and/or treat adenosine  
CC receptor-mediated cardiac, lung and/or renal damage or failure  
CC (particularly where associated with ischaemia, toxin release and/or  
CC administration of drugs or imaging agents, e.g. adenosine for treating  
CC supraventricular tachycardia); (adult) respiratory distress syndrome  
CC (e.g. associated with sepsis); allergic rhinitis; chronic obstructive  
CC pulmonary disease; cardiopulmonary hypoxia associated with administration  
CC of stress-test agents, particularly where such conditions are associated  
CC with acute inflammation. AAA02717, AAA02719, AAA02721 and AAA02723 to  
CC AAA03715 represent specifically claimed phosphorothioate antisense  
CC oligonucleotides for use in the composition of the present invention.  
CC AAA02718, AAA02720, AAA02722 and AAA03716 to AAA03720 represent other  
CC phosphorothioate oligonucleotides used in the exemplification of the  
CC present invention  
XX  
XX Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1530 GCCCAGCCTCTCCCCGC 1546  
DB 17 GCCCAGCCTGTGCCGC 1  
RESULT 290  
AAA03660/c  
ID AAA03660 standard; DNA; 17 BP.  
XX AC AAA03660;  
XX 19-MAY-2000 (first entry)  
XX Human adenosine A1 receptor antisense oligonucleotide SEQ ID NO:944.  
DE Human; adenosine A1 receptor; antisense oligonucleotide; hypoxia;  
KW adenosine A2a receptor; adenosine A3 receptor; adenosine A3 receptor;  
KW phosphothioate; cardiopulmonary failure; renal failure; ischaemia;  
KW endotoxin release; ARDS; acute respiratory distress syndrome;  
KW cytoprotective; anti-allergic; anti-inflammatory; anti-hypoxic;  
KW supraventricular tachycardia; allergic rhinitis; acute inflammation;  
KW chronic obstructive pulmonary disease; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX WO9963938-A2.  
XX 16-DEC-1999.  
XX 08-JUN-1999; 99WO-US012775.  
XX 08-JUN-1998; 98US-0088501P.  
PR 09-JUN-1998; 98US-00093972.  
PR 09-JUN-1998; 98US-0088657P.  
XX (EPIG-) EPIGENESIS PHARM INC.  
XX Nyce JW, Hill JL;  
XX WPI; 2000-116433/10.  
XX Novel composition for treating or preventing e.g. cardiopulmonary and  
PT renal injury.  
XX Claim 17; Page 37; 252pp; English.  
XX The present invention describes a pharmaceutical composition, comprising  
CC at least one agent (I) that prevents, alleviates and/or inhibits  
CC adenosine-mediated cardiopulmonary and/or renal damage and/or failure.  
CC (I) is an adenosine A2a receptor agonist (Ia), or an oligonucleotide  
CC (Ib), containing less than 15% adenosine (A), that is antisense to target

CC genes or corresponding RNA, to genomic flanking regions (i.e. 5' or 3'  
CC ends or segments between coding and non-coding sequences), or to all  
CC segments of mRNA encoding the adenosine A1, A2a, A2b or A3 receptors, and  
CC has A1, A2b or A3 agonist activity or A2a antagonist activity (or at  
CC least no agonist activity at this receptor). (I) may be a mixture of (Ia)  
CC and (Ib), and optionally also contains one or more surfactants. The  
CC compositions are used to prevent, alleviate and/or treat adenosine  
CC receptor-mediated cardiac, lung and/or renal damage or failure  
CC (particularly where associated with ischaemia, toxin release and/or  
CC administration of drugs or imaging agents, e.g. adenosine for treating  
CC supraventricular tachycardia); (adult) respiratory distress syndrome  
CC (e.g. associated with sepsis); allergic rhinitis; chronic obstructive  
CC pulmonary disease; cardiopulmonary hypoxia associated with administration  
CC of stress-test agents, particularly where such conditions are associated  
CC with acute inflammation. AAA02717, AAA02719, AAA02721 and AAA02723 to  
CC AAA03715 represent specifically claimed phosphorothioate antisense  
CC oligonucleotides for use in the composition of the present invention.  
CC AAA02718, AAA02720, AAA02722 and AAA03716 to AAA03720 represent other  
CC phosphorothioate oligonucleotides used in the exemplification of the  
CC present invention  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCACGCCCTCTCCCGC 1546  
Db 17 GCCACGCCCTGTGCCGC 1

RESULT 291  
AAF19353/C  
ID AAF19353 standard; DNA; 17 BP.  
XX  
AC AAF19353;  
XX  
DT 14-MAR-2001 (first entry)  
XX  
DE Human adenosine A1 receptor polynucleotide fragment #920.  
XX

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;  
KW human; airway disorder; bronchoconstriction; lung inflammation;  
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;  
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cyostatic;  
KW respiratory obstruction; pulmonary obstruction; impeded respiration;  
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;  
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;  
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;  
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;  
KW cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200062736-A2.  
XX  
PD 26-OCT-2000.  
XX  
PF 24-MAR-2000; 2000WO-US008020.  
XX  
PR 06-APR-1999; 99US-0127958P.  
XX  
PA (UYEC-) UNIV EAST CAROLINA.  
PA (NYCE/) NYCE J W.  
XX  
XX Nyce JW;  
XX  
XX WPI; 2000-679539/66.  
XX  
XX Low adenosine (A) content antisense oligonucleotides which do not trigger  
PT adenosine receptors during metabolism, useful e.g. for treating cancers  
PT and respiratory obstructions.

XX Claim 14; Page 120; 1592pp; English.  
PS The present invention describes low adenosine (A) content antisense  
XX oligonucleotides and compositions (I) comprising them. In the antisense  
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.  
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,  
CC immunosuppressive, antiasthmatic, hypotensive and cyostatic activities.  
CC The antisense oligonucleotides and (I) can be used to down-regulate the  
CC expression and or activity of target polypeptides associated with  
CC lung/respiratory disorders and malignancies, such as stimulating and  
CC activating peptide factors and transmitters, transcription factors,  
CC immunoglobulins and antibodies, antibody receptors, cytokines and  
CC chemokines, endogenously produced specific and non-specific enzymes,  
CC binding proteins, adhesion molecules and their receptors, cytokine and  
CC chemokine receptors, adenosine receptors, bradykinin receptors, central  
CC nervous system (CNS) and peripheral nervous and non-nervous system  
CC receptors, CNS and peripheral nervous and non-nervous system peptide  
CC transmitters, defensins growth factors, vasoactive peptides and  
CC receptors, binding proteins and malignancy associated proteins. The  
CC antisense oligonucleotides may be used in this way to treat disorders  
CC including respiratory obstruction (especially pulmonary obstruction  
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or  
CC surfactant hypoproduction which are associated with a disease or  
CC condition selected from pulmonary vasoconstriction, inflammation,  
CC allergies, asthma, impeded respiration, respiratory distress syndrome  
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,  
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
CC fragments and antisense oligonucleotides used in the exemplification of  
CC the present invention  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCACGCCCTCTCCCGC 1546  
Db 17 GCCACGCCCTGTGCCGC 1

RESULT 292  
AAF18477/C  
ID AAF18477 standard; DNA; 17 BP.  
XX  
AC AAF18477;  
XX  
DT 14-MAR-2001 (first entry)  
XX  
DE Human adenosine A1 receptor polynucleotide fragment #44.  
XX

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;  
KW human; airway disorder; bronchoconstriction; lung inflammation;  
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;  
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cyostatic;  
KW respiratory obstruction; pulmonary obstruction; impeded respiration;  
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;  
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;  
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;  
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;  
KW cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200062736-A2.  
XX  
PD 26-OCT-2000.  
XX  
PF 24-MAR-2000; 2000WO-US008020.  
XX

PR 06-APR-1999; 99US-0127958P.  
XX (UYEC-) UNIV EAST CAROLINA.  
PA (NYCE/) NYCE J W.  
XX NYCE JW;  
XX WPI; 2000-679539/66.  
DR Low adenosine (A) content antisense oligonucleotides which do not trigger  
PT adenosine receptors during metabolism, useful e.g. for treating cancers  
PT and respiratory obstructions.  
XX Claim 14; Page 106; 1592pp; English.  
XX The present invention describes low adenosine (A) content antisense  
CC oligonucleotides and compositions (I) comprising them. In the antisense  
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.  
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,  
CC immunosuppressive, antiaesthetic, hypotensive and cytostatic activities.  
CC The antisense oligonucleotides and (I) can be used to down-regulate the  
CC expression and/or activity of target polypeptides associated with  
CC lung/respiratory disorders and malignancies, such as stimulating and  
CC activating peptide factors and transmitters, transcription factors,  
CC immunoglobulins and antibodies, antibody receptors, cytokines and  
CC chemokines, endogenously produced specific and non-specific enzymes,  
CC binding proteins, adhesion molecules and their receptors, cytokine and  
CC chemokine receptors, adenosine receptors, bradykinin receptors, central  
CC nervous system (CNS) and peripheral nervous and non-nervous system  
CC receptors, CNS and peripheral nervous and non-nervous system peptide  
CC transmitters, defensins, growth factors, vasoactive peptides and  
CC receptors, binding proteins and malignancy associated proteins. The  
CC antisense oligonucleotides may be used in this way to treat disorders  
CC including respiratory obstruction (especially pulmonary obstruction  
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies) and/or  
CC surfactant hypoproduction which are associated with a disease or  
CC condition selected from pulmonary vasoconstriction, inflammation,  
CC allergies, asthma, impeded respiration, respiratory distress syndrome  
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary  
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),  
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,  
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide  
CC fragments and antisense oligonucleotides used in the exemplification of  
CC the present invention  
XX Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1530 GCCAGCCTCTCCCGC 1546  
Db 17 GCCAGCCTGTGCCGC 1  
RESULT 293  
AAF02647  
ID AAF02647 standard; DNA; 17 BP.  
XX AAF02647;  
AC AAF02647;  
XX 16-FEB-2001 (first entry)  
DT DT  
DE Hammerhead ribozyme substrate #942.  
XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;  
KW interferon alpha; ss.  
XX Homo sapiens.  
XX OS  
XX PN W0200061729-A2.  
XX

PD 19-OCT-2000.  
XX 11-APR-2000; 2000WO-US009721.  
XX 12-APR-1999; 99US-0129390P.  
XX (RIBO-) RIBOZYME PHARM INC.  
XX Blatt L, Zwick M, Pavco P, Mcswiggen J;  
XX WPI; 2000-647423/62.  
XX Enzymatic and antisense nucleic acid inhibition of repressor genes,  
PT useful for producing e.g. granulocyte colony stimulating factor protein,  
PT interferon alpha and erythropoietin.  
XX Claim 37; Page 77; 164pp; English.  
XX The present invention relates to enzymatic and antisense nucleic acid  
CC molecules that act as inhibitors of the expression of repressor genes  
CC encoding the T2 Orphan receptor, EAR3/COUP-TF-1, the GATA transcription  
CC factor gene, IRF-2 and/or the CAAT Displacement Protein (CDP).  
CC Inhibition of the repressors removes prevents inhibition (and  
CC consequently increases expression of) genes involved in the production of  
CC erythropoietin, granulocyte colony stimulating factor protein and  
CC interferon alpha  
XX Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 116 CCAGACGGTCTCAGACA 132  
Db 1 CCAGACGTTCTCAGTCA 17  
RESULT 294  
ABK01885/C  
ID ABK01885 standard; RNA; 17 BP.  
XX ABK01885;  
AC ABK01885;  
XX 12-MAR-2002 (first entry)  
DT DT  
DE Human Nogo Zinzyne #207.  
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; Nogo; hammerhead ribozyme;  
KW DNazyme; inozyme; G-cleaver; amberyne; zinzyne; lymphoma; leukaemia;  
KW B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;  
KW human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;  
KW MCL; immunocytoma; IMC; immune thrombocytopaenia; stroke; dementia;  
KW inflammatory arthropathy; central nervous system injury;  
KW cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;  
KW chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;  
KW Parkinson's disease; ataxia; Huntington's disease;  
KW Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.  
XX Homo sapiens.  
XX OS  
XX Synthetic.  
XX W0200159103-A2.  
XX 16-AUG-2001.  
XX 09-FEB-2001; 2001WO-US004273.  
XX 11-FEB-2000; 2000US-0181797P.  
XX 28-FEB-2000; 2000US-0185516P.  
XX 06-MAR-2000; 2000US-0187128P.  
XX

XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J.  
PA (CHOW/) CHOWRIRA B M.  
XX  
XX Blatt L, Mcswiggen J, Chowrira BM;  
XX WPI; 2001-607195/69.  
XX  
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense  
PT constructs, which down regulate expression of a CD20 gene or neurite  
PT growth inhibitor gene useful for treating, e.g., lymphoma, leukemia, and  
PT central nervous system injury.  
XX  
XX Claim 88; Page 99; 200pp; English.  
XX  
XX The invention relates to a nucleic acid molecule which down regulates  
CC expression of a CD20 gene and a nucleic acid molecule which down  
CC regulates expression of a neurite growth inhibitor gene (NOGO). The  
CC nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a  
CC DNAzyme) an Inozyme (an endolytic nucleic acid cleaving an RNA molecule  
CC possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN motif) or  
CC an amberzyme (cleaving RNA with an NGN triplet), a zinyzyme (cleaving RNA  
CC with a YGY motif). The CD20-targeting nucleic acid is used to cleave RNA  
CC of CD20 in the presence of a divalent cation that is preferably Mg<sup>2+</sup>.  
CC Furthermore, it may be contacted with a cell to reduce CD20 activity of  
CC the cell and treat a patient having a condition associated with the level  
CC of CD20. The treatment may further comprise the use of one or more  
CC therapies. In particular, the CD20 targeting nucleic acid may be used to  
CC treat lymphoma, leukaemia, B-cell lymphoma, low-grade or follicular non-  
CC Hodgkin's lymphoma (NHL), bulky low-grade or follicular NHL, lymphocytic  
CC leukaemia, HIV (human immunodeficiency virus) associated NHL, mantle-cell  
CC lymphoma (MCL), immunocytoma (IMC), small B-cell lymphocytic lymphoma,  
CC immune thrombocytopaenia, and inflammatory arthropathy. The NOGO-  
CC targeting nucleic acid is used to cleave RNA of the NOGO gene in the  
CC presence of a divalent cation that is preferably Mg<sup>2+</sup>. Furthermore, the  
CC nucleic acid may be contacted with a cell to reduce NOGO activity of the  
CC cell and treat a patient having a condition associated with the level of  
CC NOGO. The treatment may further comprise the use of one or more  
CC therapies. In particular, the NOGO-targeting nucleic acid may be used to  
CC treat central nervous system (CNS) injury and cerebrovascular accident  
CC (CVA, stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),  
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),  
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob  
CC disease, muscular dystrophy, and/or other neurodegenerative disease  
CC states which respond to the modulation of NOGO expression. The present  
CC sequence is a zinyzyme molecule of the invention  
XX  
SQ Sequence 17 BP; 8 A; 1 C; 3 G; 0 T; 5 U; 0 Other;  
Query Match 0.8%; Score 13.6; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 1621 CAATAAACGTCTTGT 1637  
Db 17 CAATAAACGTCTTTT 1  
RESULT 295  
ABK01053/C  
ID ABK01053 standard; RNA; 17 BP.  
XX  
XX AC ABK01053;  
XX  
XX DT 12-MAR-2002 (first entry)  
XX  
XX DE Human NOGO Inozyme #323.  
XX  
XX Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;  
KW cerebroprotective; nootropic; neuroprotective; antiparkinsonian;  
KW muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1622 AATAAACTGCTCTTG 1638  
DB 17 ATTAATAACTGCTCTTTG 1

RESULT 296  
AAD20527  
ID AAD20527 standard; DNA; 17 BP.  
XX AC AAD20527;  
XX 03-JAN-2002 (first entry)  
XX Mouse Obr genomic DNA amplifying forward PCR primer #2.  
XX Mouse; obese receptor; Obr; anorectic; anabolic; body weight disorder;  
XX therapy; obesity; cachexia; anorexia; PCR primer; ss.  
XX Mus sp.  
XX US6287782-B1.  
XX 11-SEP-2001.  
XX 29-APR-1998; 98US-00069781.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2001-624489/72.

Identifying compounds for treating body weight disorder, e.g. obesity, anorexia or cachexia, comprises contacting cell expressing mammalian Ob receptor protein, JAK2 protein and mammalian SOCS-1 protein with test compound.  
Example; Col 62; 109pp; English.  
The patent discloses obese receptor (Obr) proteins and nucleic acids encoding them. Obr protein participates in the regulation of mammalian body weight. The invention also relates to a method of identifying therapeutic compounds for the treatment of a body weight disorder. The method involves contacting a cell that expresses a mammalian Obr protein, a JAK2 protein and a mammalian SOCS-1 protein with a test compound. The method is useful for identifying compounds which modulate Obr gene expression and gene product activity, which can be used as agents to control body weight particularly as therapeutic agents for treating body weight disorders, including obesity, cachexia and anorexia. The present DNA sequence is a forward PCR primer which is used for amplifying mouse Obr genomic DNA  
Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676

DB 1 CACTATTTCCTTCAG 17

RESULT 297  
AAD20529  
ID AAD20529 standard; DNA; 17 BP.  
XX AC AAD20529;  
XX 03-JAN-2002 (first entry)  
XX Mouse famj5312 Obr cDNA amplifying forward PCR primer.  
XX Mouse; obese receptor; Obr; anorectic; anabolic; body weight disorder;  
XX therapy; obesity; cachexia; anorexia; PCR primer; ss.  
XX Mus spretus.  
XX US6287782-B1.  
XX 11-SEP-2001.  
XX 29-APR-1998; 98US-00069781.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2001-624489/72.

Identifying compounds for treating body weight disorder, e.g. obesity, anorexia or cachexia, comprises contacting cell expressing mammalian Ob receptor protein, JAK2 protein and mammalian SOCS-1 protein with test compound.  
Example; Col 63; 109pp; English.  
The patent discloses obese receptor (Obr) proteins and nucleic acids encoding them. Obr protein participates in the regulation of mammalian body weight. The invention also relates to a method of identifying therapeutic compounds for the treatment of a body weight disorder. The method involves contacting a cell that expresses a mammalian Obr protein, a JAK2 protein and a mammalian SOCS-1 protein with a test compound. The method is useful for identifying compounds which modulate Obr gene expression and gene product activity, which can be used as agents to control body weight particularly as therapeutic agents for treating body weight disorders, including obesity, cachexia and anorexia. The present DNA sequence is a forward PCR primer which is used for amplifying mouse famj5312 Obr cDNA  
Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCCTTCAG 676  
DB 1 CACTATTTCCTTCAG 17

RESULT 298

AAAF79852	AAAF79852 standard; DNA; 17 BP.
XX	AAF79852;
XX	AAF79852;
XX	30-MAY-2001 (first entry)
DT	DNA sequencing method DNA fragment.
XX	DNA sequencing; sequence analysis; chromophore; fluorophore; ds.
XX	Synthetic.
OS	US6200748-B1.
XX	13-MAR-2001.
XX	07-JUN-1995; 95US-00484340.
XX	16-JAN-1984; 84US-00570973.
PR	02-JAN-1985; 85US-00689013.
PR	11-APR-1985; 85US-00722742.
PR	07-OCT-1987; 87US-00106232.
PR	21-FEB-1991; 91US-00660160.
PR	12-JUN-1992; 92US-00898019.
PR	21-DEC-1994; 94US-00361176.
XX	(CALY ) CALIFORNIA INST OF TECHNOLOGY.
PA	Smith LM, Hood LE, Hunkapiller MW, Hunkapiller TJ, Connell CR;
XX	WPI; 2001-256466/26.
XX	Novel duplex useful in sequencing reactions, comprising an
PT	oligonucleotide primer covalently coupled to a chromophore or fluorophore
PT	so as to allow chain extension by a polymerase, and a template.
XX	Disclosure; Fig 1A; 15pp; English.
XX	The present invention describes a duplex comprising a template and a
CC	primer joined to a chromophore or fluorophore to enable chain extension
CC	by a polymerase. Also described is a method of sequencing a nucleic acid
CC	using said primer, where the chromophore or fluorophore is used to
CC	determine the sequence of the oligonucleotide. This is useful in sequence
CC	analysis. The present sequence was used to demonstrate the method of the
CC	invention
XX	Sequence 17 BP; 5 A; 4 C; 4 G; 4 T; 0 U; 0 Other;
XX	Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	1357 AAGCGCTGCAGGAATAC 1373
Db	1 ATGCTCTGCAGGAATAC 17
RESULT 299	
AB146807/C	
ID	ABL46807 standard; RNA; 17 BP.
XX	AC ABL46807;
XX	27-JUN-2003 (first entry)
DT	Human GRID NCH ribozyme substrate oligonucleotide #261.
DE	Human; Grb2-related with Insert Domain; GRID; T-cell;
XX	co-stimulatory adaptor protein; tissue rejection; graft rejection;
KW	leukaemia; cytostatic; ss.
KW	Homo sapiens.
XX	

XX	WO200162911-A2.
XX	30-AUG-2001.
XX	23-FEB-2001; 2001WO-US005957.
PF	
XX	24-FEB-2000; 2000US-0184594P.
XX	(RIBO-) RIBOZYME PHARM INC.
PA	(GLAX ) GLAXO GROUP LTD.
XX	
XX	Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
PI	
XX	WPI; 2001-550088/61.
DR	
XX	New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT	(GRID) gene comprises using antisense and enzymatic nucleic acid
PT	molecules such as hammerhead ribozymes.
XX	
XX	Claim 4; Page 67; 108pp; English.
XX	
CC	The present invention relates to oligonucleotides that downregulate the
CC	expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC	a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC	for modulating the expression of GRID, to treat conditions such as
CC	tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC	administered in conjunction with other therapies such as radiation,
CC	chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC	used to illustrate the invention
XX	
SQ	Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
	Query Match            0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity   88.2%; Pred. No. 1.9e+02;
	Matches   15; Conservative   0; Mismatches   2; Indels   0; Gaps   0;
QY	1539 CTCCCCGCTCTGGATCC 1555
Db	17 CTCCCCGCTGTGAACC 1
RESULT 300	
AAD41482	
ID	AAD41482 standard; DNA; 17 BP.
XX	
AC	AAD41482;
XX	
DT	30-OCT-2002 (first entry)
XX	
DE	Mouse Ob receptor (ObR) gene amplifying forward PCR primer #2.
XX	
KW	Mouse; obese receptor; Obr; receptor; body weight disorder; obesity;
KW	cachexia; anorexia; anorectic; anabolic; immunomodulator; PCR; primer;
KW	ss.
XX	
OS	Mus sp.
XX	
FN	US6395498-B1.
XX	
PD	28-MAY-2002.
XX	
PP	28-MAY-1997; 97US-00864564.
XX	
XX	27-NOV-1995; 95US-00562663.
PR	04-DEC-1995; 95US-00566622.
PR	08-DEC-1995; 95US-00569485.
PR	11-DEC-1995; 95US-00570142.
PR	28-DEC-1995; 95US-00583153.
PR	22-JAN-1996; 96US-00599455.
PR	26-APR-1996; 96US-00638524.
PR	03-SEP-1996; 96US-00708123.
XX	

XX	WO200162911-A2.
XX	30-AUG-2001.
XX	23-FEB-2001; 2001WO-US005957.
PF	24-FEB-2000; 2000US-0184594P.
XX	(RIBO-) RIBOZYME PHARM INC.
XX	(GLAX ) GLAXO GROUP LTD.
XX	Jarvis T, Von Carlowitz I, Mcswiggen JA, Hamblin PA, Ellis JH;
PI	WPI; 2001-550088/61.
XX	New nucleic acid(s) for regulating the Grb2-related with Insert Domain
PT	(GRID) gene comprises using antisense and enzymatic nucleic acid
PT	molecules such as hammerhead ribozymes.
XX	Claim 4; Page 67; 108pp; English.
XX	The present invention relates to oligonucleotides that downregulate the
CC	expression of human Grb2-related with Insert Domain (GRID) gene. GRID is
CC	a T-cell co-stimulatory adaptor protein. The oligonucleotides are useful
CC	for modulating the expression of GRID, to treat conditions such as
CC	tissue/graft rejection and leukaemia. The oligonucleotides can also be
CC	administered in conjunction with other therapies such as radiation,
CC	chemotherapy and cyclosporin treatment. The present oligonucleotide was
CC	used to illustrate the invention
XX	Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	1539 CTCCTCGCTCTGGATCC 1555
Db	17 CTCCTCGCTGTGAACC 1
RESULT 300	
AAD41482	
ID	AAD41482 standard; DNA; 17 BP.
XX	AC AAD41482;
XX	30-OCT-2002 (first entry)
DE	Mouse Ob receptor (ObR) gene amplifying forward PCR primer #2.
KW	Mouse; obese receptor; Obr; receptor; body weight disorder; obesity;
KW	cachexia; anorexia; anorectic; anabolic; immunomodulator; PCR; primer;
KW	ss.
OS	Mus sp.
XX	USG395498-B1.
PD	28-MAY-2002.
XX	28-MAY-1997; 97US-00864564.
XX	27-NOV-1995; 95US-00562663.
PR	04-DEC-1995; 95US-00566622.
PR	08-DEC-1995; 95US-00569485.
PR	11-DEC-1995; 95US-00570142.
PR	28-DEC-1995; 95US-00583153.
PR	22-JAN-1996; 96US-00599455.
PR	26-APR-1996; 96US-00638524.
PR	03-SEP-1996; 96US-00708123.
XX	

XX Identifying candidate therapeutic agents for treating body weight  
PT disorders, comprises contacting test compound with cell expressing  
PT mammalian obese receptor and reporter protein, and measuring expression  
PT of reporter protein.  
XX  
XX Example; Col 121; 110pp; English.  
XX  
XX The present invention relates to novel obese (Ob) receptor (OBR) proteins  
CC and polynucleotides encoding them. The invention relates to a method of  
CC identifying candidate therapeutic agents to treat body weight disorder.  
CC The method involves providing a cell which expresses a mammalian OBR on  
CC the cell surface, binds leptin, the cell harbouring a reporter construct  
CC comprising a sequence encoding a reporter protein, contacting the cell  
CC with a test compound and measuring the expression of the reporter protein  
CC in the presence of the test compound. The method is useful to identify an  
CC agent, preferably a small molecule or antibody for the treatment of body  
CC weight disorders such as obesity, cachexia, and anorexia. The present DNA  
CC sequence is a PCR primer which is used for amplifying mouse OBR genomic  
CC DNA. This sequence is used in the exemplification of the invention  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
  
RESULT 302  
AAD42341  
ID AAD42341 standard; DNA; 17 BP.  
XX  
AC AAD42341;  
DT  
DT 04-NOV-2002 (first entry)  
XX  
DE Mouse obesity receptor (Obr) gene amplifying forward primer #3.  
XX  
KW Obesity receptor; Obr; body weight disorder; therapy; food intake;  
KW anorexia; cachexia; acquired immune deficiency syndrome; cytostatic;  
KW AIDS-related wasting; cancer-related wasting; metabolic; anti-HIV;  
KW immunomodulator; human immunodeficiency virus; mouse; PCR; primer; ss.  
XX  
OS Mus sp.  
XX  
XX US6403552-B1.  
XX  
XX 11-JUN-2002.  
XX  
XX 09-JUN-1998; 98US-00094410.  
XX  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX  
XX (MILL-) MILLENNIUM PHARM INC.  
XX  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2002-536045/57.  
XX  
XX Increasing food intake in a mammal having a low body weight disorder such  
PT as anorexia, involves administering to the mammal a soluble polypeptide

PA (MILL-) MILLENNIUM PHARM INC.  
PI Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2002-535640/57.  
XX  
XX Identifying candidate therapeutic agents for treating body weight  
PT disorders, comprises contacting test compound with cell expressing  
PT mammalian obese receptor and reporter protein, and measuring expression  
PT of reporter protein.  
XX  
XX Example; Col 119; 110pp; English.  
XX  
XX The present invention relates to novel obese (Ob) receptor (OBR) proteins  
CC and polynucleotides encoding them. The invention relates to a method of  
CC identifying candidate therapeutic agents to treat body weight disorder.  
CC The method involves providing a cell which expresses a mammalian OBR on  
CC the cell surface, binds leptin, the cell harbouring a reporter construct  
CC comprising a sequence encoding a reporter protein, contacting the cell  
CC with a test compound and measuring the expression of the reporter protein  
CC in the presence of the test compound. The method is useful to identify an  
CC agent, preferably a small molecule or antibody for the treatment of body  
CC weight disorders such as obesity, cachexia, and anorexia. The present DNA  
CC sequence is a PCR primer which is used for amplifying mouse OBR genomic  
CC DNA. This sequence is used in the exemplification of the invention  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
  
RESULT 301  
AAD41484  
ID AAD41484 standard; DNA; 17 BP.  
XX  
AC AAD41484;  
DT  
DT 30-OCT-2002 (first entry)  
XX  
DE Mouse Ob receptor (Obr) gene amplifying forward PCR primer #3.  
XX  
XX Mouse; obese receptor; Obr; receptor; body weight disorder; obesity;  
KW cachexia; anorexia; anorectic; anabolic; immunomodulator; PCR; primer;  
KW ss.  
XX  
XX Mus sp.  
XX  
XX US6395498-B1.  
XX  
XX 28-MAY-2002.  
XX  
XX 28-MAY-1997; 97US-00864564.  
XX  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX  
XX (MILL-) MILLENNIUM PHARM INC.  
XX  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2002-535640/57.  
XX  
XX

PT comprising the extracellular domain of an obesity receptor protein.  
XX Example; Col 63; 114pp; English.  
PS  
CC The invention relates to obesity receptor (Obr) protein and its  
CC corresponding nucleic acid. The invention also relates to a method for  
CC the diagnosis and treatment of body weight disorders. The method is  
CC useful for increasing food intake in a mammal having a disorder  
CC characterised by low body weight, where the disorder is anorexia,  
CC cachexia, acquired immunodeficiency syndrome (AIDS)-related wasting or  
CC cancer-related wasting. The present sequence is a PCR primer used for  
CC amplifying mouse Obr gene.  
XX of the invention  
CC  
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 660 CACTACCTGCCCTTCAG 676  
DB 1 CACTATTGCGCCTTCAG 17  
RESULT 303  
AAD42339  
ID AAD42339 standard; DNA; 17 BP.  
XX  
XX AAD42339;  
XX  
XX 04-NOV-2002 (first entry)  
XX  
XX Mouse obesity receptor (Obr) gene amplifying forward primer #2.  
DE  
XX  
XX Obesity receptor; Obr; body weight disorder; therapy; food intake;  
KW anorexia; cachexia; acquired immune deficiency syndrome; cytostatic;  
KW AIDS-related wasting; cancer-related wasting; metabolic; anti-HIV;  
KW immunomodulator; human immunodeficiency virus; mouse; PCR; primer; ss.  
XX  
XX Mus sp.  
XX  
XX US6403552-B1.  
XX  
XX 11-JUN-2002.  
XX  
XX 09-JUN-1998; 98US-00094410.  
XX  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX  
XX (MILL-) MILLENIUM PHARM INC.  
XX  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2002-536045/57.  
XX  
XX Increasing food intake in a mammal having a low body weight disorder such  
PT as anorexia, involves administering to the mammal a soluble polypeptide  
PT comprising the extracellular domain of an obesity receptor protein.  
PT  
XX Example; Col 62; 114pp; English.  
PS  
XX The invention relates to obesity receptor (Obr) protein and its  
CC corresponding nucleic acid. The invention also relates to a method for  
CC the diagnosis and treatment of body weight disorders. The method is

CC useful for increasing food intake in a mammal having a disorder  
CC characterised by low body weight, where the disorder is anorexia,  
CC cachexia, acquired immunodeficiency syndrome (AIDS)-related wasting or  
CC cancer-related wasting. The present sequence is a PCR primer used for  
CC amplifying mouse Obr gene  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 660 CACTACCTGCCCTTCAG 676  
DB 1 CACTATTGCGCCTTCAG 17  
RESULT 304  
ABN01903/c  
ID ABN01903 standard; DNA; 17 BP.  
XX  
XX ABN01903;  
XX  
XX 29-MAY-2002 (first entry)  
XX  
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1895.  
DE  
XX  
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
XX Homo sapiens.  
XX  
XX WO200192524-A2.  
XX  
XX 06-DEC-2001.  
PD  
XX  
XX 25-MAY-2001; 2001WO-US016981.  
PF  
XX  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
PA  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
PT  
XX  
XX Disclosure; SEQ ID NO 1895; 214pp; English.  
PS  
XX  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1



CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 93 GAGAGTGGCAGGTCTCT 109  
DB 17 GAGAGAGCCAGGTCTCT 1  
  
RESULT 305  
ABN07493/C  
ID ABN07493 standard; DNA; 17 BP.  
XX  
AC ABN07493;  
DT  
XX 29-MAY-2002 (first entry)  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7485.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX  
PN W0200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
XX (AEOM-) AEOMICA INC.  
XX  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPT; 2002-179446/23.  
XX  
XX New polypeptide, for raising antibodies that recognise hGDMPLP-1 proteins,  
PT

PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption/ionisation, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 7485; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 4 A; 3 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCCAGCCTCTCCCGC 1546  
DB 17 GTCCAGCCTCTCTCGC 1  
  
RESULT 306  
ABN08576  
ID ABN08576 standard; DNA; 17 BP.  
XX  
AC ABN08576;  
XX  
XX 29-MAY-2002 (first entry)  
XX  
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8568.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX  
PN W0200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.

PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PA (AEOM-) AEOMICA INC.  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX Disclosure; SEQ ID NO 8568; 214pp; English.  
PS The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterize and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 292 AGGATGCCCTAAATGAG 308  
DB 1 AGGATGACCTGAATGAG 17  
RESULT 307  
ABN09695/c  
ID ABN09695 standard; DNA; 17 BP.  
XX AC ABN09695;  
XX 29-MAY-2002 (first entry)  
DT Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9687.  
XX Human, genome-derived myosin-like protein 1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX W0200192524-A2.  
PN 06-DEC-2001.  
XX 25-MAY-2001; 2001WO-US016981.  
PF 26-MAY-2000; 2000US-0207456P.  
XX

PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00242423.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX (AEOM-) AEOMICA INC.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
PI WPI; 2002-179446/23.  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX Disclosure; SEQ ID NO 9687; 214pp; English.  
PS The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterize and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;  
SQ  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 93 GAGAGTGGGCGAGTCCT 109  
DB 17 GAGAGTGGGCGAGTCCT 1  
RESULT 308  
ABN08671  
ID ABN08671 standard; DNA; 17 BP.  
XX AC ABN08671;  
XX 29-MAY-2002 (first entry)  
DT Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8663.  
XX Human, genome-derived myosin-like protein 1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW

skkeletal muscle disorder; amplicon; screening; ss.

Homo sapiens.

WO200192524-A2.

06-DEC-2001.

25-MAY-2001; 2001WO-US016981.

26-MAY-2000; 2000US-0207456P.

21-SEP-2000; 2000US-0234687P.

27-SEP-2000; 2000US-0236359P.

04-OCT-2000; 2000GB-00024263.

30-JAN-2001; 2001WO-US000661.

30-JAN-2001; 2001WO-US000662.

30-JAN-2001; 2001WO-US000663.

30-JAN-2001; 2001WO-US000664.

30-JAN-2001; 2001WO-US000665.

30-JAN-2001; 2001WO-US000666.

30-JAN-2001; 2001WO-US000667.

30-JAN-2001; 2001WO-US000668.

30-JAN-2001; 2001WO-US000669.

30-JAN-2001; 2001WO-US000670.

05-FEB-2001; 2001US-0266860P.

(AEOM-) AEOMICA INC.

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

WPI; 2002-179446/23.

New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins, or as specific biomolecule capture probes for surface-enhanced laser desorption ionization, comprises human myosin-like protein hGDMPLP-1.

Disclosure; SEQ ID NO 8663; 214pp; English.

The present invention describes a human genome-derived myosin-like protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1 can be used in gene therapy and vaccine production. The hGDMPLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMPLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequence

Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 270 GAAGAGCCAGAGAA 286

Db 1 GAGGAGCCAGAGGA 17

RESULT 309

ABN09696/c

ID ABN09696 standard; DNA; 17 BP.

AC ABN09696;

XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9688.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;

XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US016981.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 30-JAN-2001; 2001WO-US000670.

XX 05-FEB-2001; 2001US-0266860P.

(AEOM-) AEOMICA INC.

Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

WPI; 2002-179446/23.

New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins, or as specific biomolecule capture probes for surface-enhanced laser desorption ionization, comprises human myosin-like protein hGDMPLP-1.

Disclosure; SEQ ID NO 9688; 214pp; English.

The present invention describes a human genome-derived myosin-like protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-1 can be used in gene therapy and vaccine production. The hGDMPLP-1 nucleic acids can be used as probes to detect, characterise and quantify hGDMPLP-1 nucleic acids in samples, as amplification substrates, to provide initial substrates for the recombinant engineering of hGDMPLP-1 protein variants having desired phenotypic improvements, and for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be used as immunogens to raise antibodies that specifically recognise hGDMPLP-1 proteins, as standards in assays used to determine the concentration and/or amount specifically of hGDMPLP proteins, as specific biomolecule capture probes for surface-enhanced laser desorption ionisation, as therapeutic supplement in patients having specific deficiency in hGDMPLP-1 production, and in vaccines or for replacement therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a disorder associated with the expression of hGDMPLP-1, in particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22. The present sequence represents an oligomer used in the screening of the hGDMPLP-1 sequence in the exemplification of the present invention. N.B. The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequence

Sequence 17 BP; 2 A; 8 C; 4 G; 3 T; 0 U; 0 Other;

CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 91 GGGAGAGTGGGCGAGTCC 107  
Db 17 GGGAGAGTGGGCGAGTCC 1  
  
RESULT 311  
ABN09697/C  
ID ABN09697 standard; DNA; 17 BP.  
XX  
AC ABN09697;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:7355.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 9689; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-

CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMPLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX  
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 92 GGAGAGTGGGCGAGTCC 108  
Db 17 GGAGAGTGGGCGAGTCC 1  
  
RESULT 310  
ABN09697/C  
ID ABN09697 standard; DNA; 17 BP.  
XX  
AC ABN09697;  
XX  
DT 29-MAY-2002 (first entry)  
XX  
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9689.  
XX  
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200192524-A2.  
XX  
PD 06-DEC-2001.  
XX  
PF 25-MAY-2001; 2001WO-US016981.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX  
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMPLP-1.  
XX  
PS Disclosure; SEQ ID NO 9689; 214pp; English.  
XX  
CC The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMPLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMPLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMPLP-1

XX WPI; 2002-179446/23.  
XX New polypeptide, for raising antibodies that recognize hGDMLP-1 proteins,  
PT or as specific biomolecule capture probes for surface-enhanced laser  
PT desorption ionization, comprises human myosin-like protein hGDMLP-1.  
XX Disclosure; SEQ ID NO 8664; 214pp; English.  
XX The present invention describes a human genome-derived myosin-like  
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of hGDMLP-  
CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, and for  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 271 AAGAAGCCCAAGAGAG 287  
Db 1 AGGAAGCCCAAGAGAG 17

RESULT 313  
ABN08669  
ID ABN08669 standard; DNA; 17 BP.  
XX AC ABN08669;  
XX DT 29-MAY-2002 (first entry)  
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8661.  
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN WO200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001US-0266860P.  
XX PA (AEOM-) ASOMICA INC.  
XX GU Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

CC 1 can be used in gene therapy and vaccine production. The hGDMLP-1  
CC nucleic acids can be used as probes to detect, characterise and quantify  
CC hGDMLP-1 nucleic acids in samples, as amplification substrates, to  
CC provide initial substrates for the recombinant engineering of hGDMLP-1  
CC protein variants having desired phenotypic improvements, and for  
CC expressing the proteins. The hGDMLP-1 proteins or polypeptides may be  
CC used as immunogens to raise antibodies that specifically recognise hGDMLP  
CC -1 proteins, as standards in assays used to determine the concentration  
CC and/or amount specifically of hGDMLP proteins, as specific biomolecule  
CC capture probes for surface-enhanced laser desorption/ionisation, as  
CC therapeutic supplement in patients having specific deficiency in hGDMLP-1  
CC production, and in vaccines or for replacement therapy. The  
CC polynucleotide sequences encoding hGDMLP-1 may be used for diagnosing a  
CC disorder associated with the expression of hGDMLP-1, in particular heart  
CC and skeletal muscle disorders. hGDMLP-1 is localised to chromosome 22.  
CC The present sequence represents an oligomer used in the screening of the  
CC hGDMLP-1 sequence in the exemplification of the present invention. N.B.  
CC The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequence  
XX SQ Sequence 17 BP; 8 A; 4 C; 5 G; 0 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAAGAAGCCCAAGAGAA 286  
Db 1 GAAGAAGCCCAAGAGAA 17

RESULT 312  
ABN08672  
ID ABN08672 standard; DNA; 17 BP.  
XX AC ABN08672;  
XX DT 29-MAY-2002 (first entry)  
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8664.  
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX OS Homo sapiens.  
XX PN WO200192524-A2.  
XX PD 06-DEC-2001.  
XX PF 25-MAY-2001; 2001WO-US016981.  
XX PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001US-0266860P.

XX PA (AEOM-) ASOMICA INC.  
XX GU Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

PR	30-JAN-2001;	2001WO-US000665.	
PR	30-JAN-2001;	2001WO-US000666.	
PR	30-JAN-2001;	2001WO-US000667.	
PR	30-JAN-2001;	2001WO-US000668.	
PR	30-JAN-2001;	2001WO-US000669.	
PR	30-JAN-2001;	2001WO-US000670.	
PR	05-FEB-2001;	2001US-0266860P.	
XX	(AEOM-) AEOMICA INC.		
PA			
XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;		
XX	WPI; 2002-179446/23.		
XX	New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,		
PT	or as specific biomolecule capture probes for surface-enhanced laser		
PT	desorption ionization, comprises human myosin-like protein hGDMPLP-1.		
XX	Disclosure; SEQ ID NO 8661; 214pp; English.		
XX	The present invention describes a human genome-derived myosin-like		
CC	protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-		
CC	1 can be used in gene therapy and vaccine production. The hGDMPLP-1		
CC	nucleic acids can be used as probes to detect, characterize and quantify		
CC	hGDMPLP-1 nucleic acids in samples, as amplification substrates, to		
CC	provide initial substrates for the recombinant engineering of hGDMPLP-1		
CC	protein variants having desired phenotypic improvements, and for		
CC	expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be		
CC	used as immunogens to raise antibodies that specifically recognise hGDMPLP		
CC	-1 proteins, as standards in assays used to determine the concentration		
CC	and/or amount specifically of hGDMPLP proteins, as specific biomolecule		
CC	capture probes for surface-enhanced laser desorption ionisation, as		
CC	therapeutic supplement in patients having specific deficiency in hGDMPLP-1		
CC	production, and in vaccines or for replacement therapy. The		
CC	polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a		
CC	disorder associated with the expression of hGDMPLP-1, in particular heart		
CC	and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.		
CC	The present sequence represents an oligomer used in the screening of the		
CC	hGDMPLP-1 sequence in the exemplification of the present invention. N.B.		
CC	The sequence data for this patent did not form part of the printed		
CC	specification, but was obtained in electronic format directly from WIPO		
CC	at ftp.wipo.int/pub/published_pct_sequence		
XX	Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;		
SQ			
Query Match	0.8%;	Score 13.8; DB 1; Length 17;	
Best Local Similarity	88.2%;	Pred. No. 1.9e+02;	
Matches	15; Conservative	0; Mismatches 2; Indels 0; Gaps 0;	
QY	268 TAGAAGAGCCCAAG 284		
DB	1 TGGAGGAGCCCAAG 17		
RESULT 314			
ABN02651/c			
ID	ABN02651 standard; DNA; 17 BP.		
XX	ABN02651;		
AC			
XX	29-MAY-2002 (first entry)		
DT			
XX	Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2643.		
DE			
XX	Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;		
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;		
KW	skeletal muscle disorder; amplicon; screening; ss.		
XX			
OS	Homo sapiens.		
XX			
XX	WO200192524-A2.		
FN			
XX	06-DEC-2001.		
PD			
XX	25-MAY-2001; 2001WO-US016981.		
PF			
XX	26-MAY-2000; 2000US-0207456P.		
PR	21-SEP-2000; 2000US-0234687P.		
PR	27-SEP-2000; 2000US-0236359P.		
PR	04-OCT-2000; 2000GB-00024263.		
PR	30-JAN-2001; 2001WO-US000661.		
PR	30-JAN-2001; 2001WO-US000662.		
PR	30-JAN-2001; 2001WO-US000663.		
PR	30-JAN-2001; 2001WO-US000664.		
PR	30-JAN-2001; 2001WO-US000665.		
PR	30-JAN-2001; 2001WO-US000666.		
PR	30-JAN-2001; 2001WO-US000667.		
PR	30-JAN-2001; 2001WO-US000668.		
PR	30-JAN-2001; 2001WO-US000669.		
PR	30-JAN-2001; 2001WO-US000670.		
PR	05-FEB-2001; 2001US-0266860P.		
XX	(AEOM-) AEOMICA INC.		
PA			
XX	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;		
PI			
XX	WPI; 2002-179446/23.		
DR			
XX	New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,		
PT	or as specific biomolecule capture probes for surface-enhanced laser		
PT	desorption ionization, comprises human myosin-like protein hGDMPLP-1.		
XX	Disclosure; SEQ ID NO 2643; 214pp; English.		
PS			
XX	The present invention describes a human genome-derived myosin-like		
CC	protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-		
CC	1 can be used in gene therapy and vaccine production. The hGDMPLP-1		
CC	nucleic acids can be used as probes to detect, characterize and quantify		
CC	hGDMPLP-1 nucleic acids in samples, as amplification substrates, to		
CC	provide initial substrates for the recombinant engineering of hGDMPLP-1		
CC	protein variants having desired phenotypic improvements, and for		
CC	expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be		
CC	used as immunogens to raise antibodies that specifically recognise hGDMPLP		
CC	-1 proteins, as standards in assays used to determine the concentration		
CC	and/or amount specifically of hGDMPLP proteins, as specific biomolecule		
CC	capture probes for surface-enhanced laser desorption ionisation, as		
CC	therapeutic supplement in patients having specific deficiency in hGDMPLP-1		
CC	production, and in vaccines or for replacement therapy. The		
CC	polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a		
CC	disorder associated with the expression of hGDMPLP-1, in particular heart		
CC	and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.		
CC	The present sequence represents an oligomer used in the screening of the		
CC	hGDMPLP-1 sequence in the exemplification of the present invention. N.B.		
CC	The sequence data for this patent did not form part of the printed		
CC	specification, but was obtained in electronic format directly from WIPO		
CC	at ftp.wipo.int/pub/published_pct_sequence		
XX	Sequence 17 BP; 1 A; 4 C; 8 G; 4 T; 0 U; 0 Other;		
SQ			
Query Match	0.8%;	Score 13.8; DB 1; Length 17;	
Best Local Similarity	88.2%;	Pred. No. 1.9e+02;	
Matches	15; Conservative	0; Mismatches 2; Indels 0; Gaps 0;	
QY	268 TAGAAGAGCCCAAG 284		
DB	1 TGGAGGAGCCCAAG 17		
RESULT 314			
ABN02651/c			
ID	ABN02651 standard; DNA; 17 BP.		
XX	ABN02651;		
AC			
XX	29-MAY-2002 (first entry)		
DT			
XX	Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:2643.		
DE			
XX	Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;		
KW	muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;		
KW	skeletal muscle disorder; amplicon; screening; ss.		
XX			
OS	Homo sapiens.		
XX			
XX	WO200192524-A2.		
FN			
XX	06-DEC-2001.		
PD			
XX	845 CTTCGACGACCGCCAA 861		
QY			
DB	17 CTGCGACGACCGCCAA 1		
RESULT 315			
ABN08668			
ID	ABN08668 standard; DNA; 17 BP.		
XX	ABN08668;		
AC			
XX	29-MAY-2002 (first entry)		
DT			
XX			

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8660.  
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;  
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;  
KW skeletal muscle disorder; amplicon; screening; ss.  
XX Homo sapiens.  
XX WO200192524-A2.  
XX 06-DEC-2001.  
XX 25-MAY-2001; 2001WO-US016981.  
XX 26-MAY-2000; 2000US-0207456P.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 05-FEB-2001; 2001US-0266860P.  
XX (ABOM-) ABOMICA INC.  
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;  
XX WPI; 2002-179446/23.  
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1 proteins,  
XX or as specific biomolecule capture probes for surface-enhanced laser  
XX desorption/ionization, comprises human myosin-like protein hGDMPLP-1.  
XX Disclosure; SEQ ID NO 8660; 214pp; English.  
XX The present invention describes a human genome-derived myosin-like  
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of hGDMPLP-  
XX 1 can be used in gene therapy and vaccine production. The hGDMPLP-1  
XX nucleic acids can be used as probes to detect, characterize and quantify  
XX hGDMPLP-1 nucleic acids in samples, as amplification substrates, to  
XX provide initial substrates for the recombinant engineering of hGDMPLP-1  
XX protein variants having desired phenotypic improvements, and for  
XX expressing the proteins. The hGDMPLP-1 proteins or polypeptides may be  
XX used as immunogens to raise antibodies that specifically recognise hGDMPLP  
XX -1 proteins, as standards in assays used to determine the concentration  
XX and/or amount specifically of hGDMPLP proteins, as specific biomolecule  
XX capture probes for surface-enhanced laser desorption/ionisation, as  
XX therapeutic supplement in patients having specific deficiency in hGDMPLP-1  
XX production, and in vaccines or for replacement therapy. The  
XX polynucleotide sequences encoding hGDMPLP-1 may be used for diagnosing a  
XX disorder associated with the expression of hGDMPLP-1, in particular heart  
XX and skeletal muscle disorders. hGDMPLP-1 is localised to chromosome 22.  
XX The present sequence represents an oligomer used in the screening of the  
XX hGDMPLP-1 sequence in the exemplification of the present invention. N.B.  
XX The sequence data for this patent did not form part of the printed  
XX specification, but was obtained in electronic format directly from WIPO  
XX at ftp.wipo.int/pub/published\_pct\_sequence  
XX Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;  
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX 267 CTAGAAGAGCAAGAA 283  
XX |||||  
OY 267 CTAGAAGAGCAAGAA 283

Db 1 CTGGAGGAGCCCAAGAA 17  
RESULT 316  
ABQ63736  
ID ABQ63736 standard; DNA; 17 BP.  
XX  
XX AC ABQ63736;  
XX  
XX 20-AUG-2002 (first entry)  
XX  
XX DE Human KTOM1a portion (ABQ63232) probe # 449.  
XX  
XX Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytosstatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
XX OS Homo sapiens.  
XX  
XX WO200224750-A2.  
XX  
XX 28-MAR-2002.  
XX  
XX 21-SEP-2001; 2001WO-US029656.  
XX  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.  
XX 30-JAN-2001; 2001WO-US000661.  
XX 30-JAN-2001; 2001WO-US000662.  
XX 30-JAN-2001; 2001WO-US000663.  
XX 30-JAN-2001; 2001WO-US000664.  
XX 30-JAN-2001; 2001WO-US000665.  
XX 30-JAN-2001; 2001WO-US000666.  
XX 30-JAN-2001; 2001WO-US000667.  
XX 30-JAN-2001; 2001WO-US000668.  
XX 30-JAN-2001; 2001WO-US000669.  
XX 30-JAN-2001; 2001WO-US000670.  
XX 23-MAY-2001; 2001US-00864761.  
XX 28-AUG-2001; 2001US-0315676P.  
XX  
XX (ABOM-) ABOMICA INC.  
XX  
XX Zhang J;  
XX  
XX WPI; 2002-479509/51.  
XX  
XX New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
XX acids encoding the protein, useful for treating subjects having defects  
XX in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
XX e.g., liver or bone.  
XX  
XX Example 2; Page 216; 418pp; English.  
XX  
XX The invention relates to a novel isolated nucleic acid encoding human  
XX KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the  
XX invention has cytosstatic activity. The nucleotide may have a use in gene  
XX therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
XX monitor a disease caused by altered expression of human KTOM1.  
XX Compositions comprising the nucleic acids, proteins or antibodies may be  
XX used to treat subjects having defects in KTOM1 which can manifest as  
XX cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
XX heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
XX function. The sequence represents a probe used in the invention to scan  
XX the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX  
XX Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;  
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
XX 524 CGACTCCCTGCTGGAGA 540  
OY 524 CGACTCCCTGCTGGAGA 540

Qy 522 ATCGACTCCCTGCTGGA 538  
Db 1 ATCTACTCCAGCTGGA 17

RESULT 318  
ABQ63732  
ID ABQ63732 standard; DNA; 17 BP.  
XX  
AC ABQ63732;  
XX  
DT 20-AUG-2002 (first entry)  
XX  
DE Human KTOM1a portion (ABQ63232) probe # 445.  
XX  
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200224750-A2.  
XX  
PD 28-MAR-2002.  
XX  
PF 21-SEP-2001; 2001WO-US029656.  
XX  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 28-AUG-2001; 2001US-0315676P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhang J;  
XX  
XX WPI; 2002-479509/51.  
XX  
DR New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX  
PS Example 2; Page 216; 418pp; English.  
XX  
CC The invention relates to a novel isolated nucleic acid encoding human  
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the  
CC invention has cytostatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX  
SQ Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Db 1 ATCTACTCCAGCTGGA 17

RESULT 317  
ABQ63734  
ID ABQ63734 standard; DNA; 17 BP.  
XX  
AC ABQ63734;  
XX  
DT 20-AUG-2002 (first entry)  
XX  
DE Human KTOM1a portion (ABQ63232) probe # 447.  
XX  
KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200224750-A2.  
XX  
PD 28-MAR-2002.  
XX  
PF 21-SEP-2001; 2001WO-US029656.  
XX  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 23-MAY-2001; 2001US-00864761.  
PR 28-AUG-2001; 2001US-0315676P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhang J;  
XX  
XX WPI; 2002-479509/51.  
XX  
DR New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX  
PS Example 2; Page 216; 418pp; English.  
XX  
CC The invention relates to a novel isolated nucleic acid encoding human  
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the  
CC invention has cytostatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX  
SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;



Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 521 CATCGACTCCCTGCTGG 537  
|||||  
Db 1 CATCTACTCCAGCTGG 17

RESULT 320  
ABQ63735  
ID ABQ63735 standard; DNA; 17 BP.  
XX AC ABQ63735;  
XX DT 20-AUG-2002 (first entry)  
XX DE Human KTOM1a portion (ABQ63232) probe # 448.  
XX KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX OS Homo sapiens.  
XX PN WO200224750-A2.  
XX PD 28-MAR-2002.  
XX PF 21-SEP-2001; 2001WO-US029656.  
XX PR 21-SEP-2000; 2000US-0234687P.  
XX PR 27-SEP-2000; 2000US-0236359P.  
XX PR 04-OCT-2000; 2000GB-00024263.  
XX PR 30-JAN-2001; 2001WO-US000661.  
XX PR 30-JAN-2001; 2001WO-US000662.  
XX PR 30-JAN-2001; 2001WO-US000663.  
XX PR 30-JAN-2001; 2001WO-US000664.  
XX PR 30-JAN-2001; 2001WO-US000665.  
XX PR 30-JAN-2001; 2001WO-US000666.  
XX PR 30-JAN-2001; 2001WO-US000667.  
XX PR 30-JAN-2001; 2001WO-US000668.  
XX PR 30-JAN-2001; 2001WO-US000669.  
XX PR 30-JAN-2001; 2001WO-US000670.  
XX PR 23-MAY-2001; 2001US-00864761.  
XX PR 28-AUG-2001; 2001US-0315676P.  
XX PA (ABOM-) ABOMICA INC.  
XX PI Zhang J;  
XX DR WPI; 2002-479509/51.  
XX PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX PS Example 2; Page 216; 418pp; English.  
XX CC The invention relates to a novel isolated nucleic acid encoding human  
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the  
CC invention has cytostatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX SQ Sequence 17 BP; 3 A; 6 C; 4 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Qy 520 GCATCGACTCCCTGCTG 536  
|||||  
Db 1 GCATCTACTCCAGCTG 17

RESULT 319  
ABQ63733  
ID ABQ63733 standard; DNA; 17 BP.  
XX AC ABQ63733;  
XX DT 20-AUG-2002 (first entry)  
XX DE Human KTOM1a portion (ABQ63232) probe # 446.  
XX KW Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;  
KW gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;  
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.  
XX OS Homo sapiens.  
XX PN WO200224750-A2.  
XX PD 28-MAR-2002.  
XX PF 21-SEP-2001; 2001WO-US029656.  
XX PR 21-SEP-2000; 2000US-0234687P.  
XX PR 27-SEP-2000; 2000US-0236359P.  
XX PR 04-OCT-2000; 2000GB-00024263.  
XX PR 30-JAN-2001; 2001WO-US000661.  
XX PR 30-JAN-2001; 2001WO-US000662.  
XX PR 30-JAN-2001; 2001WO-US000663.  
XX PR 30-JAN-2001; 2001WO-US000664.  
XX PR 30-JAN-2001; 2001WO-US000665.  
XX PR 30-JAN-2001; 2001WO-US000666.  
XX PR 30-JAN-2001; 2001WO-US000667.  
XX PR 30-JAN-2001; 2001WO-US000668.  
XX PR 30-JAN-2001; 2001WO-US000669.  
XX PR 30-JAN-2001; 2001WO-US000670.  
XX PR 23-MAY-2001; 2001US-00864761.  
XX PR 28-AUG-2001; 2001US-0315676P.  
XX PA (ABOM-) ABOMICA INC.  
XX PI Zhang J;  
XX DR WPI; 2002-479509/51.  
XX PT New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic  
PT acids encoding the protein, useful for treating subjects having defects  
PT in KTOM1 which can manifest as cancer of the kidney, or as a disorder of  
PT e.g., liver or bone.  
XX PS Example 2; Page 216; 418pp; English.  
XX CC The invention relates to a novel isolated nucleic acid encoding human  
CC KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the  
CC invention has cytostatic activity. The nucleotide may have a use in gene  
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or  
CC monitor a disease caused by altered expression of human KTOM1.  
CC Compositions comprising the nucleic acids, proteins or antibodies may be  
CC used to treat subjects having defects in KTOM1 which can manifest as  
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,  
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta  
CC function. The sequence represents a probe used in the invention to scan  
CC the nt 1-1001 portion of human KTOM1a (ABQ63232)  
XX SQ Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;		0.8%; Score 13.8; DB 1; Length 17;	
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	523 TCGACTCCCTGCTGGAG 539	526 ACTCCCTGCTGGAGAAC 542	
Db	1 TCTACTCCCGAGCTGGAG 17	1 ACTCCAGCTGGAGACC 17	
RESULT 321			
ABQ63738			
ID	ABQ63738 standard; DNA; 17 BP.		
XX	AC ABQ63738;		
XX	20-AUG-2002 (first entry)		
DE	Human KTOM1a portion (ABQ63232) probe # 451.		
XX	Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;		
KW	gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;		
KW	kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.		
XX	Homo sapiens.		
XX	WO200224750-A2.		
XX	28-MAR-2002.		
XX	21-SEP-2001; 2001WO-US029656.		
XX	21-SEP-2000; 2000US-0234687P.		
PR	27-SEP-2000; 2000US-0236359P.		
PR	04-OCT-2000; 2000GB-00024263.		
PR	30-JAN-2001; 2001WO-US000661.		
PR	30-JAN-2001; 2001WO-US000662.		
PR	30-JAN-2001; 2001WO-US000663.		
PR	30-JAN-2001; 2001WO-US000664.		
PR	30-JAN-2001; 2001WO-US000665.		
PR	30-JAN-2001; 2001WO-US000666.		
PR	30-JAN-2001; 2001WO-US000667.		
PR	30-JAN-2001; 2001WO-US000668.		
PR	30-JAN-2001; 2001WO-US000669.		
PR	30-JAN-2001; 2001WO-US000670.		
PR	23-MAY-2001; 2001US-00864761.		
PR	28-AUG-2001; 2001US-0315676P.		
XX	(AEOM-) AEOMICA INC.		
PA	Zhang J;		
PI	WPI; 2002-479509/51.		
XX	New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic		
PT	acids encoding the protein, useful for treating subjects having defects		
PT	in KTOM1 which can manifest as cancer of the kidney, or as a disorder of		
PT	e.g., liver or bone.		
XX	Example 2; Page 216; 418pp; English.		
XX	The invention relates to a novel isolated nucleic acid encoding human		
XX	KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the		
CC	invention has cytostatic activity. The nucleotide may have a use in gene		
CC	therapy. The KTOM1 nucleic acids may be used to diagnose, treat or		
CC	monitor a disease caused by altered expression of human KTOM1.		
CC	Compositions comprising the nucleic acids, proteins or antibodies may be		
CC	used to treat subjects having defects in KTOM1 which can manifest as		
CC	cancer of the kidney, as well as a disorder of liver, bone marrow, brain,		
CC	heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta		
CC	function. The sequence represents a probe used in the invention to scan		
CC	the nt 1-1001 portion of human KTOM1a (ABQ63232)		
XX	Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 U; 0 Other;		
XX			

Best Local Similarity 88.2%; Pred. No. 1.9e+02;		0.8%; Score 13.8; DB 1; Length 17;	
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;			
QY	526 ACTCCCTGCTGGAGAAC 542	526 ACTCCCTGCTGGAGAAC 542	
Db	1 ACTCCAGCTGGAGACC 17	1 ACTCCAGCTGGAGACC 17	
RESULT 322			
ABQ64165			
ID	ABQ64165 standard; DNA; 17 BP.		
XX	AC ABQ64165;		
XX	20-AUG-2002 (first entry)		
DE	Human KTOM1a portion (ABQ63232) probe # 878.		
XX	Human; KTOM1a; KTOM1; kidney tumour overexpressed membrane; cytostatic;		
KW	gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;		
KW	kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.		
XX	Homo sapiens.		
XX	WO200224750-A2.		
XX	28-MAR-2002.		
XX	21-SEP-2001; 2001WO-US029656.		
XX	21-SEP-2000; 2000US-0234687P.		
PR	27-SEP-2000; 2000US-0236359P.		
PR	04-OCT-2000; 2000GB-00024263.		
PR	30-JAN-2001; 2001WO-US000661.		
PR	30-JAN-2001; 2001WO-US000662.		
PR	30-JAN-2001; 2001WO-US000663.		
PR	30-JAN-2001; 2001WO-US000664.		
PR	30-JAN-2001; 2001WO-US000665.		
PR	30-JAN-2001; 2001WO-US000666.		
PR	30-JAN-2001; 2001WO-US000667.		
PR	30-JAN-2001; 2001WO-US000668.		
PR	30-JAN-2001; 2001WO-US000669.		
PR	30-JAN-2001; 2001WO-US000670.		
PR	23-MAY-2001; 2001US-00864761.		
PR	28-AUG-2001; 2001US-0315676P.		
XX	(AEOM-) AEOMICA INC.		
PA	Zhang J;		
PI	WPI; 2002-479509/51.		
XX	New human kidney tumor overexpressed membrane (KTOM1) protein and nucleic		
PT	acids encoding the protein, useful for treating subjects having defects		
PT	in KTOM1 which can manifest as cancer of the kidney, or as a disorder of		
PT	e.g., liver or bone.		
XX	Example 2; Page 272; 418pp; English.		
XX	The invention relates to a novel isolated nucleic acid encoding human		
XX	KTOM1 (kidney tumour overexpressed membrane) protein. The protein of the		
CC	invention has cytostatic activity. The nucleotide may have a use in gene		
CC	therapy. The KTOM1 nucleic acids may be used to diagnose, treat or		
CC	monitor a disease caused by altered expression of human KTOM1.		
CC	Compositions comprising the nucleic acids, proteins or antibodies may be		
CC	used to treat subjects having defects in KTOM1 which can manifest as		
CC	cancer of the kidney, as well as a disorder of liver, bone marrow, brain,		
CC	heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta		
CC	function. The sequence represents a probe used in the invention to scan		
CC	the nt 1-1001 portion of human KTOM1a (ABQ63232)		
XX	Sequence 17 BP; 2 A; 6 C; 5 G; 4 T; 0 U; 0 Other;		
XX			

XX Query Match 0.8%; Score 13.8; DB 1; Length 17;  
SQ Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1203 GTCACACGGTGGCTTC 1219  
Db 1 GTCACACCTGTGGCTGC 17

RESULT 323  
ABV79503  
ID ABV79503 standard; DNA; 17 BP.  
XX  
AC ABV79503;  
XX  
DT 03-JAN-2003 (first entry)  
XX  
DE Human HTPL scanning oligonucleotide SEQ ID 749.  
XX  
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1229046-A2.  
XX  
PD 07-AUG-2002.  
XX  
PF 28-JAN-2002; 2002EP-00001167.  
XX  
PR 30-JAN-2001; 2001WO-US000663.  
XX  
PR 30-JAN-2001; 2001WO-US000664.  
XX  
PR 30-JAN-2001; 2001WO-US000665.  
XX  
PR 30-JAN-2001; 2001WO-US000667.  
XX  
PR 30-JAN-2001; 2001WO-US000668.  
XX  
PR 30-JAN-2001; 2001WO-US000669.  
XX  
PR 23-MAY-2001; 2001US-00864761.  
XX  
PR 09-OCT-2001; 2001US-0327898P.  
XX  
PA (AEOM-) ABOMICA INC.  
XX  
PI Zhan J;  
XX  
PI WPI; 2002-676582/73.  
XX  
DR Novel isolated human testis expressed Patched like protein (HTPL), useful  
PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX  
PS Example 2; Page 162; 718pp; English.  
XX  
PS The present invention relates to human testis expressed Patched like  
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC important in regulating male germ cell development, and the HTPL gene was  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention

XX Query Match 0.8%; Score 13.8; DB 1; Length 17;  
SQ Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 522 ATCGACTCCCTGCTCGA 538  
Db 1 AGCGACTCACTGCTGGA 17

RESULT 324  
ABV79992  
ID ABV79992 standard; DNA; 17 BP.  
XX  
AC ABV79992;  
XX  
DT 03-JAN-2003 (first entry)  
XX  
DE Human HTPL scanning oligonucleotide SEQ ID 1238.  
XX  
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
PN EP1229046-A2.  
XX  
PD 07-AUG-2002.  
XX  
PF 28-JAN-2002; 2002EP-00001167.  
XX  
PR 30-JAN-2001; 2001WO-US000663.  
XX  
PR 30-JAN-2001; 2001WO-US000664.  
XX  
PR 30-JAN-2001; 2001WO-US000665.  
XX  
PR 30-JAN-2001; 2001WO-US000667.  
XX  
PR 30-JAN-2001; 2001WO-US000668.  
XX  
PR 30-JAN-2001; 2001WO-US000669.  
XX  
PR 23-MAY-2001; 2001US-00864761.  
XX  
PR 09-OCT-2001; 2001US-0327898P.  
XX  
PA (AEOM-) ABOMICA INC.  
XX  
PI Zhan J;  
XX  
PI WPI; 2002-676582/73.  
XX  
DR Novel isolated human testis expressed Patched like protein (HTPL), useful  
PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX  
PS Example 2; Page 226; 718pp; English.  
XX  
PS The present invention relates to human testis expressed Patched like  
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC important in regulating male germ cell development, and the HTPL gene was  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,  
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention

CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 4 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1273 TCTTTGACTCTGATCCC 1289  
||| ||||| ||||| |||||  
Db 1 TCTGTGACTGTGATCCC 17  
RESULT 325  
ABV79502  
ID ABV79502 standard; DNA; 17 BP.  
XX  
AC ABV79502;  
XX  
DT 03-JAN-2003 (first entry)  
XX  
DE Human HTPL scanning oligonucleotide SEQ ID 748.  
XX  
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;  
KW human testis expressed Patched like protein; testis; adrenal; liver;  
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;  
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.  
XX  
OS Homo sapiens.  
XX  
XN EPI229046-A2.  
XX  
PD 07-AUG-2002.  
XX  
PF 28-JAN-2002; 2002EP-00001167.  
XX  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 23-MAY-2001; 2001US-00864761.  
PR 09-OCT-2001; 2001US-0327898P.  
XX  
PA (AEOM-) AEOMICA INC.  
XX  
PI Zhan J;  
XX  
XX WPI; 2002-676582/73.  
XX  
PT Novel isolated human testis expressed Patched like protein (HTPL), useful  
PT for identifying agonist and antagonist and specific binding partners, and  
PT for treating subjects having defects in HTPL.  
XX  
PS Example 2; Page 161; 718pp; English.  
XX  
XX The present invention relates to human testis expressed Patched like  
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL  
CC has two isoforms, with a few single base pair differences between the  
CC two. One of the single base pair changes introduces a premature stop  
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL  
CC shares an overall structure organisation with the Patched protein. The  
CC shared structural features strongly imply that HTPL plays a role similar  
CC to that of Patched, and is a potential tumour suppressor. HTPL is  
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are  
CC important in regulating male germ cell development, and the HTPL gene was  
CC useful for diagnosing a disorder caused by mutation in HTPL, and in  
CC therapy and manufacture of a medicament for treatment or prevention of  
CC such disorder associated with decreased expression or activity of human  
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and  
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,

CC skeletal muscle or colon function. HTPL proteins and nucleic acids are  
CC clinically useful diagnostic markers and potential therapeutic agents for  
CC male infertility and cancer. The present oligonucleotide was used in an  
CC example from the invention  
XX  
SQ Sequence 17 BP; 3 A; 6 C; 5 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 521 CATGACTCCCTGCTGG 537  
||| ||||| ||||| |||||  
Db 1 CAGCGACTCACTGCTGG 17  
RESULT 326  
ABK18229  
ID ABK18229 standard; RNA; 17 BP.  
XX  
AC ABK18229;  
XX  
DT 09-APR-2002 (first entry)  
XX  
DE Human ERG hammerhead ribozyme target sequence, Seq ID No 876.  
XX  
KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;  
KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;  
KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
KW tumour angiogenesis; diabetic retinopathy; macular degeneration;  
KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;  
KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;  
KW amberzyme.  
XX  
OS Homo sapiens.  
XX  
XN WO200188124-A2.  
XX  
PD 22-NOV-2001.  
XX  
PF 16-MAY-2001; 2001WO-US015866.  
XX  
PR 16-MAY-2000; 2000US-00572021.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (GLAX ) GLAXO GROUP LTD.  
XX  
PI Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;  
XX  
XX WPI; 2002-082995/11.  
XX  
PT Novel polynucleotide which down regulates expression of Ets-related gene,  
PT useful for treating cancer, diabetic retinopathy, macular degeneration,  
PT arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
XX  
PS Claim 4; Page 74; 149pp; English.  
XX  
XX The invention relates to a nucleic acid molecule (I) which down regulates  
CC expression of an Ets-related gene (ERG). (I) is useful for treating  
CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,  
CC tumour angiogenesis, diabetic retinopathy, macular degeneration,  
CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge  
CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu  
CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
CC treating a patient having a condition associated with the level of ERG  
CC by contacting cells of the patient with (I) under conditions suitable for  
CC the treatment. The method comprises the use of one or more therapies  
CC under conditions suitable for the treatment. Leukaemia or tumour  
CC angiogenesis is treated by administering (I) to the patient in  
CC conjunction with one or more of other therapies such as radiation or

CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and  
 CC diseases related to the expression of ERG, and as diagnostic tool to  
 CC examine genetic drift and mutations within diseased cells or to detect  
 CC the presence of ERG RNA in a cell. (I) is useful for specifically  
 CC targeting genes that share homology with ERG gene or ERG fusion genes.  
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and  
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and  
 CC related PCR primers of the invention  
 XX  
 SQ Sequence 17 BP; 2 A; 12 C; 2 G; 0 T; 1 U; 0 Other;  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 Qy 1504 GCCCAGCCTCCAGGCC 1520  
 Db 1 GCCCCACCCGCCGCC 17  
 RESULT 327  
 ABK19135  
 ID ABK19135 standard; RNA; 17 BP.  
 AC  
 AC ABK19135;  
 DT 09-APR-2002 (first entry)  
 XX Human ERG Amberzyme target sequence Seq ID No 1782.  
 DE Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;  
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;  
 KW vulnary; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;  
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;  
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;  
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;  
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;  
 KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNazyme; inozyme;  
 KW amberzyme.  
 XX  
 OS Homo sapiens.  
 XX  
 XX WO200188124-A2.  
 XX  
 XX 22-NOV-2001.  
 XX  
 XX 16-MAY-2001; 2001WO-US015866.  
 XX  
 XX 16-MAY-2000; 2000US-00572021.  
 XX  
 XX (RIBO-) RIBOZYME PHARM INC.  
 XX (GLAX) GLAXO GROUP LTD.  
 XX  
 XX Jarvis T, Von Carlowitz I, Mcswiggen JA, McLaughlin F, Randi AM;  
 XX WPI; 2002-082995/11.  
 XX  
 XX Novel polynucleotide which down regulates expression of Ets-related gene,  
 XX useful for treating cancer, diabetic retinopathy, macular degeneration,  
 XX arthritis, psoriasis, verruca vulgaris and Sturge Weber syndrome.  
 XX  
 XX Claim 4; Page 120; 149pp; English.  
 XX  
 XX The invention relates to a nucleic acid molecule (I) which down regulates  
 XX expression of an Ets-related gene (ERG). (I) is useful for treating  
 XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,  
 XX tumour angiogenesis, diabetic retinopathy, macular degeneration,  
 XX neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca  
 XX vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge  
 XX Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu

CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for  
 CC treating a patient having a condition associated with the level of ERG,  
 CC by contacting cells of the patient with (I) under conditions suitable for  
 CC the treatment. The method comprises the use of one or more therapies  
 CC under conditions suitable for the treatment. Leukaemia or tumour  
 CC angiogenesis is treated by administering (I) to the patient in  
 CC conjunction with one or more of other therapies such as radiation or  
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a  
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of  
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent  
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and  
 CC diseases related to the expression of ERG, and as diagnostic tool to  
 CC examine genetic drift and mutations within diseased cells or to detect  
 CC the presence of ERG RNA in a cell. (I) is useful for specifically  
 CC targeting genes that share homology with ERG gene or ERG fusion genes.  
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and  
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and  
 CC related PCR primers of the invention  
 XX  
 SQ Sequence 17 BP; 10 A; 3 C; 3 G; 0 T; 1 U; 0 Other;  
 Query Match 0.8%; Score 13.8; DB 1; Length 17;  
 Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
 Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
 Qy 218 GACTTCTCATAGAAAAA 234  
 Db 1 GACUCACAGAGAAAAA 17  
 RESULT 328  
 AAD38269  
 ID AAD38269 standard; DNA; 17 BP.  
 XX  
 AC AAD38269;  
 XX  
 DT 10-SEP-2002 (first entry)  
 XX Mouse Ob receptor genomic DNA amplifying forward PCR primer #2.  
 DE Mouse; Ob receptor; OBR; leptin; body weight disorder; drug screening;  
 KW gene therapy; obesity; cachexia; anorexia; anorectic; anabolic; PCR;  
 KW primer; ss.  
 XX  
 XX Mus sp.  
 XX  
 XX US6380363-B1.  
 XX  
 XX 30-APR-2002.  
 XX  
 XX 19-AUG-1998; 98US-00137132.  
 XX  
 XX 27-NOV-1995; 95US-00562663.  
 XX 04-DEC-1995; 95US-00566622.  
 XX 08-DEC-1995; 95US-00569485.  
 XX 11-DEC-1995; 95US-00570142.  
 XX 28-DEC-1995; 95US-00583153.  
 XX 22-JAN-1996; 96US-00599455.  
 XX 26-APR-1996; 96US-00638524.  
 XX 03-SEP-1996; 96US-00708123.  
 XX 28-MAY-1997; 97US-00864564.  
 XX  
 XX (TART/) TARTAGLIA L A.  
 XX (TEPP/) TEPPER R I.  
 XX (CULP/) CULPEPPER J A.  
 XX (WHIT/) WHITE D W.  
 XX  
 XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
 XX WPI; 2002-413726/44.  
 XX  
 XX Antibodies which selectively bind mammalian Ob receptors and inhibits the  
 XX binding of leptin to the mammalian Ob receptor, useful for diagnosing and

```

PT treating weight disorders.
XX Example; Col 62; 108pp; English.
XX The present invention relates to novel antibodies which selectively bind
CC mammalian Ob receptors (ObR) and inhibit the binding of leptin to the
CC mammalian Ob receptor. ObR sequences are novel receptor proteins that
CC participate in the control of mammalian body weight. The antibodies of
CC the invention may be used to detect of Ob receptor in a biological sample
CC and utilised as a part of diagnostic or prognostic technique in which
CC patients may be tested for abnormal amounts of Ob receptors. They may be
CC utilised in conjunction with, for example, compound screening schemes for
CC the evaluation of the effect of test compounds on expression and/or
CC activity of the Ob receptor gene product. The antibodies can be used in
CC conjunction with the gene therapy techniques, for example, to evaluate
CC the normal and/or engineered Ob receptor-expressing cells prior to their
CC introduction into the patient. They may be used in the method for the
CC inhibition of abnormal Ob receptor activity and can be used for drug
CC screening, clinical trial monitoring and/or the treatment of body weight
CC disorders including but not limited to obesity, cachexia and anorexia.
CC The present DNA sequence is a PCR primer which is used for amplifying
CC mouse ObR genomic DNA. This sequence is used in the exemplification of
CC the invention
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTGCCCTTCAG 17

RESULT 329
AAD38271
ID AAD38271 standard; DNA; 17 BP.
XX AAD38271;
AC AAD38271;
XX 10-SEP-2002 (first entry)
XX Mouse Ob receptor genomic DNA amplifying forward PCR primer #3.
XX Mouse; Ob receptor; ObR; leptin; body weight disorder; drug screening;
KW gene therapy; obesity; cachexia; anorexia; anorectic; anabolic; PCR;
KW primer; ss.
XX Mus sp.
XX US6380363-B1.
XX 30-APR-2002.
XX 19-AUG-1998; 98US-00137132.
XX 27-NOV-1995; 95US-00562663.
PR 04-DEC-1995; 95US-00566622.
PR 08-DEC-1995; 95US-00569485.
PR 11-DEC-1995; 95US-00570142.
PR 28-DEC-1995; 95US-00583153.
PR 22-JAN-1996; 96US-00599455.
PR 26-APR-1996; 96US-00638524.
PR 03-SEP-1996; 96US-00708123.
PR 28-MAY-1997; 97US-00864564.
XX (TART/) TARTAGLIA L A.
XX (TEPP/) TEPPER R I.
PA (CULP/) CULPEPPER J A.
PA (WHIT/) WHITE D W.
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;

```

```

XX WPI; 2002-413726/44.
XX Antibodies which selectively bind mammalian Ob receptors and inhibits the
PT binding of leptin to the mammalian Ob receptor, useful for diagnosing and
PT treating weight disorders.
XX Example; Col 62; 108pp; English.
XX The present invention relates to novel antibodies which selectively bind
CC mammalian Ob receptors (ObR) and inhibit the binding of leptin to the
CC mammalian Ob receptor. ObR sequences are novel receptor proteins that
CC participate in the control of mammalian body weight. The antibodies of
CC the invention may be used to detect of Ob receptor in a biological sample
CC and utilised as a part of diagnostic or prognostic technique in which
CC patients may be tested for abnormal amounts of Ob receptors. They may be
CC utilised in conjunction with, for example, compound screening schemes for
CC the evaluation of the effect of test compounds on expression and/or
CC activity of the Ob receptor gene product. The antibodies can be used in
CC conjunction with the gene therapy techniques, for example, to evaluate
CC the normal and/or engineered Ob receptor-expressing cells prior to their
CC introduction into the patient. They may be used in the method for the
CC inhibition of abnormal Ob receptor activity and can be used for drug
CC screening, clinical trial monitoring and/or the treatment of body weight
CC disorders including but not limited to obesity, cachexia and anorexia.
CC The present DNA sequence is a PCR primer which is used for amplifying
CC mouse ObR genomic DNA. This sequence is used in the exemplification of
CC the invention
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACCTGCCTTCAG 676
Db 1 CACTATTGCCCTTCAG 17

RESULT 330
ACN05936/C
ID ACN05936 standard; RNA; 17 BP.
XX ACN05936;
AC ACN05936;
XX 22-APR-2004 (first entry)
XX WNV Amberzyme substrate SEQ ID NO 5939.
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;
KW encephalitis; myocarditis; meningitis; infection; hepatitis;
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
KW Amberzyme; Zinzyne; ss.
XX West Nile Virus.
OS WO200268637-A2.
XX 06-SEP-2002.
XX 19-OCT-2001; 2001WO-US048350.
XX 20-OCT-2000; 2000US-0242411P.
XX (RIBO-) RIBOZYME PHARM INC.
PA (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J A.
XX Blatt L, Mcswiggen JA;
XX WPI; 2002-706994/76.

```

XX New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 5939; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 6 A; 4 C; 4 G; 0 T; 3 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. NO. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 1226 TTCTGACTCGACGCTTC 1242  
Db 17 TTCTGAGTCGACATTC 1  
  
RESULT 331  
ACN08391  
ID ACN08391 standard; RNA; 17 BP.  
XX  
AC ACN08391;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8394.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 8394; 495pp; English.  
XX

CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 0 A; 9 C; 0 G; 0 T; 8 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. NO. 1.9e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
  
Qy 488 CTCGCCCTTCTACTTCT 504  
Db 1 CUCUCCCUCCUCCUUCU 17  
  
RESULT 332  
ACN15008  
ID ACN15008 standard; RNA; 17 BP.  
XX  
AC ACN15008;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Amberzyme substrate SEQ ID NO 15011.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 15011; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The

CC	nucleic acid molecules further comprise at least five ribose residues, at	XX	Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at	SQ	0.8%; Score 13.8; DB 1; Length 17;
CC	least three of the 5' terminal nucleotides and a 3' end modification of a		Query Match
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080		Best Local Similarity 88.2%; Pred. NO. 1.9e+02;
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given		Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
CC	in the specification. The present sequence is that of a nucleic acid		
CC	molecule of the invention		
XX		QY	1228 CTGACTCGGAGTTCCT 1244
SQ	Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;	Db	17 CTGAGTCGACATTCCT 1
	Query Match		
	Best Local Similarity 58.8%; Pred. NO. 1.9e+02;		
	Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;		
QY	1227 TCTGACTCGGAGTTCCT 1243		
Db	1 UCUGAGUCGACAUCC 17		
RESULT 333			
ACN00398/c			
ID	ACN00398 standard; RNA; 17 BP.		
XX			
AC	ACN00398;		
XX			
DT	22-APR-2004 (first entry)		
XX			
DE	WNV Hammerhead Ribozyme substrate SEQ ID NO 388.		
XX			
KW	WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;		
KW	virucide; neuroprotective; antibacterial; replication; pancreatitis;		
KW	encephalitis; myocarditis; meningitis; infection; hepatitis;		
KW	liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;		
KW	Amberzyme; Zinzyme; ss.		
XX			
OS	West Nile Virus.		
XX			
PN	WO200268637-A2.		
XX			
PD	06-SEP-2002.		
XX			
PF	19-OCT-2001; 2001WO-US048350.		
XX			
PR	20-OCT-2000; 2000US-0242411P.		
XX			
PA	(RIBO-) RIBOZYME PHARM INC.		
PA	(BLAT/) BLATT L.		
PA	(MCSW/) MCSWIGGEN J A.		
XX			
PI	Blatt L, Mcswiggen JA;		
XX			
DR	WPI; 2002-706994/76.		
XX			
XX	New nucleic acid molecule that modulates replication of West Nile Virus		
PT	(WNV), useful for treating a condition related to WNV infection e.g.		
PT	pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.		
XX			
PS	Claim 23; SEQ ID NO 388; 495pp; English.		
XX			
CC	The invention relates to nucleic acid molecules that modulate replication		
CC	of the West Nile Virus (WNV). The nucleic acid molecules are useful for		
CC	treating a condition related to WNV infection e.g. pancreatitis,		
CC	encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,		
CC	liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid		
CC	molecule is selected from the group of ribozymes consisting of		
CC	Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The		
CC	nucleic acid molecules further comprise at least five ribose residues, at		
CC	least ten 2'-O-methyl modifications, phosphorothioate linkages on at		
CC	least three of the 5' terminal nucleotides and a 3' end modification of a		
CC	3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080		
CC	are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given		
CC	in the specification. The present sequence is that of a nucleic acid		
CC	molecule of the invention		
XX			
SQ	Sequence 17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;		
	Query Match		
	Best Local Similarity 52.9%; Pred. NO. 1.9e+02;		
	Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;		



```
Qy 1229 TGACTCGGACGTTCTT 1245
Db 1 UGAGUCGACAUCCU 17

RESULT 335
ACN15009
ID ACN15009 standard; RNA; 17 BP.
AC ACN15009;
XX
XX
DT 22-APR-2004 (first entry)
XX
XX WNV minus strand Amberzyme substrate SEQ ID NO 15012.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 15012; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 3 A; 5 C; 4 G; 0 T; 5 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 58.8%; Pred. No. 1.9e+02;
XX Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 1228 CTGACTCGGACGTTCTT 1244
Db 1 CUGAGUCGACAUCCU 17

RESULT 336
ACN06460/c
ID ACN06460 standard; RNA; 17 BP.
AC ACN06460;
XX
XX
DT 22-APR-2004 (first entry)
XX
XX WNV Amberzyme substrate SEQ ID NO 6463.
XX
XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;
XX virucide; neuroprotective; antibacterial; replication; pancreatitis;
XX encephalitis; myocarditis; meningitis; infection; hepatitis;
XX liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNAzyme;
XX Amberzyme; Zinzyme; ss.
XX
XX West Nile Virus.
XX
XX WO200268637-A2.
XX
XX 06-SEP-2002.
XX
XX 19-OCT-2001; 2001WO-US048350.
XX
XX 20-OCT-2000; 2000US-0242411P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J A.
XX
XX Blatt L, Mcswiggen JA;
XX
XX WPI; 2002-706994/76.
XX
XX New nucleic acid molecule that modulates replication of West Nile Virus
XX (WNV), useful for treating a condition related to WNV infection e.g.
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.
XX
XX Claim 23; SEQ ID NO 6463; 495pp; English.
XX
XX The invention relates to nucleic acid molecules that modulate replication
XX of the West Nile Virus (WNV). The nucleic acid molecules are useful for
XX treating a condition related to WNV infection e.g. pancreatitis,
XX encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,
XX liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid
XX molecule is selected from the group of ribozymes consisting of
XX Hammerhead, Inozyme, G-cleaver, DNAzyme, Amberzyme and Zinzyme. The
XX nucleic acid molecules further comprise at least five ribose residues, at
XX least ten 2'-O-methyl modifications, phosphorothioate linkages on at
XX least three of the 5' terminal nucleotides and a 3' end modification of a
XX 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080
XX are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given
XX in the specification. The present sequence is that of a nucleic acid
XX molecule of the invention
XX
XX Sequence 17 BP; 8 A; 1 C; 8 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
Qy 489 TCGCCCTTCTACTCTG 505
Db 17 TCTCCCTTCTCTCTG 1

RESULT 337
ACN01953/c
ID ACN01953 standard; RNA; 17 BP.
XX
XX ACN01953;
XX
XX 22-APR-2004 (first entry)
XX
XX WNV Inozyme substrate SEQ ID NO 1943.
```

XX WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PF New nucleic acid molecule that modulates replication of West Nile Virus  
PR (WNV), useful for treating a condition related to WNV infection e.g.  
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 1943; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 5 G; 0 T; 3 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1227 TCTGACTCGGACGTTCC 1243  
DB 17 TCTGACTCGGACATTCC 1  
RESULT 338  
ACN08392  
XX ACN08392 standard; RNA; 17 BP.  
XX ACN08392;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8395.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX

OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
PA (RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76.  
XX  
PF New nucleic acid molecule that modulates replication of West Nile Virus  
PR (WNV), useful for treating a condition related to WNV infection e.g.  
XX pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
PS Claim 23; SEQ ID NO 8395; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3', inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX  
SQ Sequence 17 BP; 0 A; 8 C; 1 G; 0 T; 8 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.9e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;  
QY 489 TCGCCCTCTTACTTCTG 505  
DB 1 UCUCUCCUCCUCCUCCUG 17  
RESULT 339  
ACN11835/C  
XX ACN11835 standard; RNA; 17 BP.  
XX ACN11835;  
XX  
DT 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Inozyme substrate SEQ ID NO 11838.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyme; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268637-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX

PI Blatt L, Mcswiggen JA;  
XX  
XX WPI; 2002-706994/76.  
XX  
PT New nucleic acid molecule that modulates replication of West Nile Virus  
PT (WNV), useful for treating a condition related to WNV infection e.g.  
PT pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.  
XX  
XX Claim 23; SEQ ID NO 5388; 495pp; English.  
XX  
CC The invention relates to nucleic acid molecules that modulate replication  
CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for  
CC treating a condition related to WNV infection e.g. pancreatitis,  
CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,  
CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid  
CC molecule is selected from the group of ribozymes consisting of  
CC Hammerhead, Inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyne. The  
CC nucleic acid molecules further comprise at least five ribose residues, at  
CC least three 2'-O-methyl modifications, phosphorothioate linkages on at  
CC least three of the 5' terminal nucleotides and a 3' end modification of a  
CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080  
CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given  
CC in the specification. The present sequence is that of a nucleic acid  
CC molecule of the invention  
XX

QY 1232 CTCGGACGTTTCCTCCG 1248  
Db 17 CGCGGACGTTCCATCCG 1

RESULT 341  
ACN08973  
ID ACN08973 standard; RNA; 17 BP.  
XX  
AC ACN08973;  
XX  
XX 22-APR-2004 (first entry)  
XX  
DE WNV minus strand Hammerhead Ribozyme substrate SEQ ID NO 8976.  
XX  
KW WNV; West Nile Virus; antiinflammatory; cytostatic; hepatotropic;  
KW virucide; neuroprotective; antibacterial; replication; pancreatitis;  
KW encephalitis; myocarditis; meningitis; infection; hepatitis;  
KW liver failure; cancer; cirrhosis; Hammerhead; Inozyme; DNazyme;  
KW Amberzyme; Zinzyne; ss.  
XX  
OS West Nile Virus.  
XX  
PN WO200268537-A2.  
XX  
PD 06-SEP-2002.  
XX  
PF 19-OCT-2001; 2001WO-US048350.  
XX  
PR 20-OCT-2000; 2000US-0242411P.  
XX  
XX (RIBO-) RIBOZYME PHARM INC.  
PA (BLATT/) BLATT L.  
PA (MCSW/) MCSWIGGEN J A.  
XX  
PI Blatt L, Mcswiggen JA;  
XX  
DR WPI; 2002-706994/76..  
XX

New nucleic acid molecule that modulates replication of West Nile Virus (WNV), useful for treating a condition related to WNV infection e.g. pancreatitis, meningitis, hepatocellular carcinoma or cirrhosis.

XX Claim 23; SEQ ID NO 8976; 495pp; English.

XX The invention relates to nucleic acid molecules that modulate replication

CC of the West Nile Virus (WNV). The nucleic acid molecules are useful for

CC treating a condition related to WNV infection e.g. pancreatitis,

CC encephalitis, myocarditis, meningitis, neurologic infection, hepatitis,

CC liver failure, hepatocellular carcinoma or cirrhosis. The nucleic acid

CC molecule is selected from the group of ribozymes consisting of

CC Hammerhead, inozyme, G-cleaver, DNazyme, Amberzyme and Zinzyme. The

CC nucleic acid molecules further comprise at least five ribose residues, at

CC least ten 2'-O-methyl modifications, phosphorothioate linkages on at

CC least three of the 5' terminal nucleotides and a 3' end modification of a

CC 3'-3' inverted abasic moiety. Nucleic acid molecules SEQ ID NO 1 to 37080

CC are claimed; however, SEQ ID NO 2194-2206 and 17502-17514 are not given

CC in the specification. The present sequence is that of a nucleic acid

CC molecule of the invention

XX

XX Sequence 17 BP; 3 A; 4 C; 4 G; 0 T; 6 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 52.9%; Pred. No. 1.9e+02;

Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1226 TTCTGACTCGGCGTTC 1242

DB 1 UUCUGAGUGGCAUUC 17

RESULT 342

ABT34420/c

ID ABT34420 standard; DNA; 17 BP.

XX

AC ABT34420;

XX

DT 12-JUN-2003 (first entry)

XX

DE Tumour suppression related human fukutin oligo SEQ ID No 57.

XX

XX Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;

XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;

KW human fukutin; ds.

XX

OS Homo sapiens.

XX

XX WO2003025175-A2.

XX

XX 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004208.

XX

XX 17-SEP-2001; 2001FR-00011978.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

XX

XX Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-313353/30.

XX

XX New isolated nucleic acid, useful for treating viral diseases associated

XX with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

PT

XX Disclosure; Page 40; 720pp; French.

XX

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,

XX given in the specification, a sequence containing at least 15 consecutive

CC nucleotides from the 17 mer sequence, a sequence with, after optimal

CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that

CC hybridizes to them under highly stringent conditions, or the complement

CC of any of them, or the corresponding RNA. The novel isolated nucleic

CC acids of the invention are useful as probes and primers for detecting,

CC

CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

CC component of a gene chip, in vitro as (anti)sense reagents, and for

CC production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and

CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in

CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and

CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression

CC related human fukutin oligonucleotide of the invention

XX

XX Sequence 17 BP; 4 A; 7 C; 2 G; 4 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 CTGGGAAGAGTGTAAAGC 390

DB 17 CTGGGAAGAGTGTGATC 1

RESULT 343

ABT37737

ID ABT37737 standard; DNA; 17 BP.

XX

AC ABT37737;

XX

DT 12-JUN-2003 (first entry)

XX

DE Tumour suppression related human fukutin oligo SEQ ID No 3374.

XX

XX Cytostatic; virucide; neuroprotective; nontropic; neuroleptic; gene chip;

XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;

KW human fukutin; ds.

XX

OS Homo sapiens.

XX

XX WO2003025175-A2.

XX

XX 27-MAR-2003.

XX

PF 17-SEP-2002; 2002WO-IB004208.

XX

XX 17-SEP-2001; 2001FR-00011978.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

XX

XX Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-313353/30.

XX

XX New isolated nucleic acid, useful for treating viral diseases associated

XX with tumors and cell degeneration, also related polypeptides, antibodies

PT and transfected cells.

PT

XX Disclosure; Page 428; 720pp; French.

XX

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,

XX given in the specification, a sequence containing at least 15 consecutive

CC nucleotides from the 17 mer sequence, a sequence with, after optimal

CC alignment, at least 80 % identity to the 17 mer sequence, a sequence that

CC hybridizes to them under highly stringent conditions, or the complement

CC of any of them, or the corresponding RNA. The novel isolated nucleic

CC acids of the invention are useful as probes and primers for detecting,

CC identifying, quantifying and/or amplifying a nucleic acid, e.g. as one

CC component of a gene chip, in vitro as (anti)sense reagents, and for

CC

CC production of recombinant polypeptides. Any of the nucleic acids,  
CC polypeptides, vectors containing the nucleic acids, cells containing the  
CC vector or antibodies directed against the polypeptides are useful for  
CC preparation of pharmaceuticals for prevention and/or treatment of viral  
CC diseases that are characterised by development of tumours or cell  
CC degeneration, specifically cancer but also Alzheimer's disease and  
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in  
CC patient samples is useful for diagnosis and/or prognosis of these  
CC diseases. The polypeptides can also be used to generate antibodies, and  
CC both the polypeptide and antibodies are useful as components of protein  
CC chips. The nucleic acid sequences of the invention can be used in gene  
CC therapy. This polynucleotide sequence represents a tumour suppression  
CC related human fukutin oligonucleotide of the invention  
XX  
SQ Sequence 17 BP; 3 A; 4 C; 4 G; 6 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 359 GACCATGATGCCCTCT 375  
Db 1 GATCATGATGCCCTCT 17  
RESULT 344  
ID ACA06296 standard; RNA; 17 BP.  
AC ACA06296;  
AC ACA06296;  
DT 03-JUN-2003 (first entry)  
XX  
DE NFKB sub-unit modulating inozyme substrate #115.  
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
KW allergic airway inflammation; inflammatory bowel disease; infection; as.  
XX  
OS Homo sapiens.  
XX  
XX US2002177568-A1.  
XX  
XX 28-NOV-2002.  
XX  
XX 23-MAY-2001; 2001US-00864785.  
XX  
XX 07-DEC-1992; 92US-00987132.  
XX  
XX 18-MAY-1994; 94US-00245466.  
XX  
XX 15-AUG-1994; 94US-00291932.  
XX  
XX 23-DEC-1996; 96US-00777916.  
XX  
XX (STIN//) STINCHOMB D T.  
XX (MCSW//) MCSWIGGEN J.  
XX (DRAP//) DRAPER K G.  
XX  
XX Stinchcomb DT, Mcswiggen J, Draper KG;  
XX  
XX WPI; 2003-340953/32.  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
XX a sequence encoding a subunit of nuclear factor kappa B useful for  
XX treating cancer, inflammatory disorders and autoimmune diseases.  
PT

XX Claim 3; Page 29; 72pp; English.  
XX  
XX The invention describes an enzymatic nucleic acid molecule (I) which down  
CC regulates expression of a sequence encoding a subunit of nuclear factor  
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne  
CC cancer and is useful for down-regulating REL-A activity in a cell, for  
CC treating a patient having a condition associated with the level of REL-A.  
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
CC antisense nucleic acid molecules are useful for treating breast, lung,  
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
CC multidrug resistant cancer. The method involves use of other drug  
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
CC gencitabine or radiation therapy. The enzymatic and antisense nucleic  
CC acid molecules are also useful for treating inflammatory disease such as  
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
CC rejection, gene therapy applications, ischaemia/reperfusion injury  
CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
CC infection. This sequence represents the substrate of a novel enzymatic  
CC nucleic acid molecule  
XX  
SQ Sequence 17 BP; 6 A; 9 C; 0 G; 0 T; 2 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 988 CCACCAACACCCCTCC 1004

Db 1 CCACCAACACCCCTCC 17

RESULT 345

ACA07700

ID ACA07700 standard; RNA; 17 BP.

XX ACA07700;

AC ACA07700;

DT 03-JUN-2003 (first entry)

XX NFKB sub-unit modulating zinzyme substrate #99.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;  
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;  
KW allergic airway inflammation; inflammatory bowel disease; infection; as.

XX Homo sapiens.

XX OS

XX US2002177568-A1.

XX 28-NOV-2002.

XX

XX 23-MAY-2001; 2001US-00864785.

XX 07-DEC-1992; 92US-00987132.

XX 18-MAY-1994; 94US-00245466.

PR

PR	15-AUG-1994;	94US-00291932.	
PR	23-DEC-1996;	96US-00777916.	
XX			
PA	(STIN/) STINCHCOMB D T.		
PA	(MCSW/) MCSWIGGEN J.		
PA	(DRAP/) DRAPER K G.		
XX			
PI	Stinchcomb DT, Mcswiggen J, Draper KG;		
XX			
DR	WPI; 2003-340953/32.		
XX			
PT	Novel enzymatic nucleic acid molecules which down regulates expression of		
PT	a sequence encoding a subunit of nuclear factor kappa B useful for		
PT	treating cancer, inflammatory disorders and autoimmune diseases.		
XX			
XX	Claim 3; Page 39; 72pp; English.		
XX			
CC	The invention describes an enzymatic nucleic acid molecule (I) which down		
CC	regulates expression of a sequence encoding a subunit of nuclear factor		
CC	kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme		
CC	configuration. The enzymatic nucleic acid molecule is adapted to treat		
CC	cancer and is useful for down-regulating REL-A activity in a cell, for		
CC	treating a patient having a condition associated with the level of REL-A.		
CC	(I) is useful for cleaving RNA comprising a sequence of REL-A gene, in		
CC	the presence of a divalent cation, especially Mg <sup>2+</sup> . The enzymatic and		
CC	antisense nucleic acid molecules are useful for treating breast, lung,		
CC	prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,		
CC	cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or		
CC	multidrug resistant cancer. The method involves use of other drug		
CC	therapies such as monoclonal antibodies, REL-A-specific inhibitors or		
CC	chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,		
CC	cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,		
CC	gemcitabine or radiation therapy. The enzymatic and antisense nucleic		
CC	acid molecules are also useful for treating inflammatory disease such as		
CC	rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,		
CC	obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft		
CC	rejection, gene therapy applications, ischaemia/reperfusion injury		
CC	(central nervous system (CNS) and myocardial), glomerulonephritis,		
CC	sepsis, allergic airway inflammation, inflammatory bowel disease or		
CC	infection. This sequence represents the substrate of a novel enzymatic		
CC	nucleic acid molecule		
XX			
SQ	Sequence 17 BP; 4 A; 7 C; 5 G; 0 T; 1 U; 0 Other;		
	Query Match 0.8%; Score 13.8; DB 1; Length 17;		
	Best Local Similarity 82.4%; Pred. No. 1.9e+02;		
	Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;		
QY	1502 AGGCCCCAGCTCCAGG 1518		
Db	1 AGACCCCGCCGCGAGG 17		
	:     :		
	RESULT 346		
ACA07701			
ID	ACA07701 standard; RNA; 17 BP.		
XX			
AC	ACA07701;		
XX			
DT	03-JUN-2003 (first entry)		
XX			
DE	NFKB sub-unit modulating zinzyme substrate #100.		
XX			
KW	Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;		
KW	G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;		
KW	lung cancer; prostate cancer; colorectal cancer; brain cancer;		
KW	oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;		
KW	cervical cancer; head and neck cancer; ovarian cancer; melanoma;		
KW	lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;		
KW	chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;		
KW	cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;		
KW	gemcitabine; radiation therapy; inflammatory bowel disease; asthma; diabetes;		
KW	rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;		

KW	gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;		
KW	transplant/graft rejection; reperfusion injury; glomerulonephritis;		
XX	allergic airway inflammation; inflammatory bowel disease; infection; ss.		
XX			
OS	Homo sapiens.		
XX			
PN	US2002177568-A1.		
XX			
PD	28-NOV-2002.		
XX			
PF	23-MAY-2001; 2001US-00864785.		
XX			
PR	07-DEC-1992; 92US-00987132.		
PR	18-MAY-1994; 94US-00245466.		
PR	15-AUG-1994; 94US-00291932.		
PR	23-DEC-1996; 96US-00777916.		
XX			
XX	(STIN/) STINCHCOMB D T.		
PA	(MCSW/) MCSWIGGEN J.		
PA	(DRAP/) DRAPER K G.		
XX			
PI	Stinchcomb DT, Mcswiggen J, Draper KG;		
XX			
DR	WPI; 2003-340953/32.		
XX			
PT	Novel enzymatic nucleic acid molecules which down regulates expression of		
PT	a sequence encoding a subunit of nuclear factor kappa B useful for		
PT	treating cancer, inflammatory disorders and autoimmune diseases.		
XX			
XX	Claim 3; Page 39; 72pp; English.		
XX			
CC	The invention describes an enzymatic nucleic acid molecule (I) which down		
CC	regulates expression of a sequence encoding a subunit of nuclear factor		
CC	kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme		
CC	configuration. The enzymatic nucleic acid molecule is adapted to treat		
CC	cancer and is useful for down-regulating REL-A activity in a cell, for		
CC	treating a patient having a condition associated with the level of REL-A.		
CC	(I) is useful for cleaving RNA comprising a sequence of REL-A gene, in		
CC	the presence of a divalent cation, especially Mg <sup>2+</sup> . The enzymatic and		
CC	antisense nucleic acid molecules are useful for treating breast, lung,		
CC	prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,		
CC	cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or		
CC	multidrug resistant cancer. The method involves use of other drug		
CC	therapies such as monoclonal antibodies, REL-A-specific inhibitors or		
CC	chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,		
CC	cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,		
CC	gemcitabine or radiation therapy. The enzymatic and antisense nucleic		
CC	acid molecules are also useful for treating inflammatory disease such as		
CC	rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,		
CC	obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft		
CC	rejection, gene therapy applications, ischaemia/reperfusion injury		
CC	(central nervous system (CNS) and myocardial), glomerulonephritis,		
CC	sepsis, allergic airway inflammation, inflammatory bowel disease or		
CC	infection. This sequence represents the substrate of a novel enzymatic		
CC	nucleic acid molecule		
XX			
SQ	Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;		
	Query Match 0.8%; Score 13.8; DB 1; Length 17;		
	Best Local Similarity 82.4%; Pred. No. 1.9e+02;		
	Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;		
QY	1506 CCCAGCCTCCAGGCCCC 1522		
Db	1 CCCAGCCGCGAGGCCUC 17		
	:     :		
	RESULT 347		
ACA08217			
ID	ACA08217 standard; RNA; 17 BP.		
XX			
AC	ACA08217;		
XX			

03-JUN-2003 (first entry)  
NFKB sub-unit modulating DNzyme substrate #24.  
Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
lung cancer; prostate cancer; colorectal cancer; brain cancer;  
oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
transplant/graft rejection; reperfusion injury; glomerulonephritis;  
allergic airway inflammation; inflammatory bowel disease; infection; ss.  
XX  
OS Homo sapiens.  
XX  
XX US2002177568-A1.  
XX  
XX 28-NOV-2002.  
XX  
XX 23-MAY-2001; 2001US-00864785.  
XX  
XX 07-DEC-1992; 92US-00987132.  
XX  
XX 18-MAY-1994; 94US-00245466.  
XX  
XX 15-AUG-1994; 94US-00291932.  
XX  
XX 23-DEC-1996; 96US-00777916.  
XX  
XX (STIN/) STINCHCOMB D T.  
XX  
XX (MCSW/) MCSWIGGEN J.  
XX  
XX (DRAP/) DRAPER K G.  
XX  
XX Stinchcomb DT, Mcswiggen J, Draper KG;  
XX  
XX WPI; 2003-340953/32.  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
XX a sequence encoding a subunit of nuclear factor kappa B useful for  
XX treating cancer, inflammatory disorders and autoimmune diseases.  
XX  
XX Claim 3; Page 43; 72pp; English.  
XX  
XX The invention describes an enzymatic nucleic acid molecule (I) which down  
XX regulates expression of a sequence encoding a subunit of nuclear factor  
XX kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne  
XX configuration. The enzymatic nucleic acid molecule is adapted to treat  
XX cancer and is useful for down-regulating REL-A activity in a cell, for  
XX treating a patient having a condition associated with the level of REL-A.  
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
XX the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
XX antisense nucleic acid molecules are useful for treating breast, lung,  
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
XX multidrug resistant cancer. The method involves use of other drug  
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
XX gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
XX acid molecules are also useful for treating inflammatory disease such as  
XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
XX rejection, gene therapy applications, ischaemia/reperfusion injury  
XX (central nervous system (CNS) and myocardial), glomerulonephritis,  
XX sepsis, allergic airway inflammation, inflammatory bowel disease or  
XX infection. This sequence represents the substrate of a novel enzymatic  
XX nucleic acid molecule  
XX  
XX Sequence 17 BP; 6 A; 9 C; 0 G; 0 T; 2 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
QY 989 CACCAACAACCCCTCCC 1005  
DB 1 CAACACAACCCCUCC 17  
RESULT 348  
ACA06298  
ID ACA06298 standard; RNA; 17 BP.  
AC ACA06298;  
XX  
XX 03-JUN-2003 (first entry)  
XX  
XX NFKB sub-unit modulating inozyme substrate #117.  
XX  
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
XX G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
XX lung cancer; prostate cancer; colorectal cancer; brain cancer;  
XX oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
XX cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
XX lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
XX chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
XX cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
XX gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
XX rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
XX gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
XX transplant/graft rejection; reperfusion injury; glomerulonephritis;  
XX allergic airway inflammation; inflammatory bowel disease; infection; ss.  
XX  
XX Homo sapiens.  
XX  
XX US2002177568-A1.  
XX  
XX 28-NOV-2002.  
XX  
XX 23-MAY-2001; 2001US-00864785.  
XX  
XX 07-DEC-1992; 92US-00987132.  
XX  
XX 18-MAY-1994; 94US-00245466.  
XX  
XX 15-AUG-1994; 94US-00291932.  
XX  
XX 23-DEC-1996; 96US-00777916.  
XX  
XX (STIN/) STINCHCOMB D T.  
XX  
XX (MCSW/) MCSWIGGEN J.  
XX  
XX (DRAP/) DRAPER K G.  
XX  
XX Stinchcomb DT, Mcswiggen J, Draper KG;  
XX  
XX WPI; 2003-340953/32.  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
XX a sequence encoding a subunit of nuclear factor kappa B useful for  
XX treating cancer, inflammatory disorders and autoimmune diseases.  
XX  
XX Claim 3; Page 29; 72pp; English.  
XX  
XX The invention describes an enzymatic nucleic acid molecule (I) which down  
XX regulates expression of a sequence encoding a subunit of nuclear factor  
XX kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne  
XX configuration. The enzymatic nucleic acid molecule is adapted to treat  
XX cancer and is useful for down-regulating REL-A activity in a cell, for  
XX treating a patient having a condition associated with the level of REL-A.  
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
XX the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
XX antisense nucleic acid molecules are useful for treating breast, lung,  
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
XX multidrug resistant cancer. The method involves use of other drug  
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,

CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,  
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
CC acid molecules are also useful for treating inflammatory disease such as  
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes  
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
CC rejection, gene therapy applications, ischaemia/reperfusion injury  
CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
CC infection. This sequence represents the substrate of a novel enzymatic  
CC nucleic acid molecule  
XX  
SQ Sequence 17 BP; 6 A; 8 C; 1 G; 0 T; 2 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
  
QY 992 CAACAACCCCTCCAGG 1008  
Db 1 CAACAACCCCTCCAGG 17  
|||||||: |||  
1 CAACAACCCCTCCAGG 17  
  
RESULT 349  
ACA06394  
ID ACA06394 standard; RNA; 17 BP.  
AC ACA06394;  
XX  
XX  
DT 03-JUN-2003 (first entry)  
XX  
DE NFKB sub-unit modulating inozyme substrate #213.  
XX  
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
XX G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
XX lung cancer; prostate cancer; colorectal cancer; brain cancer;  
XX oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
XX cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
XX lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
XX chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
XX cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;  
XX gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
XX rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
XX gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
XX transplant/graft rejection; reperfusion injury; glomerulonephritis;  
XX allergic airway inflammation; inflammatory bowel disease; infection; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX US2002177568-A1.  
PN  
XX  
XX 28-NOV-2002.  
PD  
XX  
XX 23-MAY-2001; 2001US-00864785.  
PF  
XX  
XX 07-DEC-1992; 92US-00987132.  
PR  
XX 18-MAY-1994; 94US-00245466.  
PR  
XX 15-AUG-1994; 94US-00291932.  
PR  
XX 23-DEC-1996; 96US-00777916.  
PR  
XX  
XX (STIN)/ STINCHOMB D T.  
PA  
XX (MCSW)/ MCSWIGGEN J.  
PA  
XX (DRAP)/ DRAPER K G.  
PA  
XX  
XX Stinchcomb DT, Mcswiggen J, Draper KG;  
PI  
XX WPI; 2003-340953/32.  
DR  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
PT a sequence encoding a subunit of nuclear factor kappa B useful for  
PT treating cancer, inflammatory disorders and autoimmune diseases.  
XX  
XX Claim 3; Page 30; 72pp; English.  
PS  
XX

CC The invention describes an enzymatic nucleic acid molecule (I) which down  
CC regulates expression of a sequence encoding a subunit of nuclear factor  
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne  
CC configuration. The enzymatic nucleic acid molecule is adapted to treat  
CC cancer and is useful for down-regulating REL-A activity in a cell, for  
CC treating a patient having a condition associated with the level of REL-A.  
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
CC the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
CC antisense nucleic acid molecules are useful for treating breast, lung,  
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
CC multidrug resistant cancer. The method involves use of other drug  
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,  
CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic  
CC acid molecules are also useful for treating inflammatory disease such as  
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
CC rejection, gene therapy applications, ischaemia/reperfusion injury  
CC (central nervous system (CNS) and myocardial), glomerulonephritis,  
CC sepsis, allergic airway inflammation, inflammatory bowel disease or  
CC infection. This sequence represents the substrate of a novel enzymatic  
CC nucleic acid molecule  
XX  
SQ Sequence 17 BP; 4 A; 8 C; 4 G; 0 T; 1 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1501 CAGGCCCCAGCTCCAG 1517  
Db 1 CAGGCCCCAGCTCCAG 17  
|||||||: |||  
1 CAGGCCCCAGCTCCAG 17  
  
RESULT 350  
ACA06396  
ID ACA06396 standard; RNA; 17 BP.  
AC ACA06396;  
XX  
XX  
DT 03-JUN-2003 (first entry)  
XX  
XX NFKB sub-unit modulating inozyme substrate #215.  
DE  
XX  
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;  
XX G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;  
XX lung cancer; prostate cancer; colorectal cancer; brain cancer;  
XX oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
XX cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
XX lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
XX chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
XX cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;  
XX gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
XX rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
XX gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
XX transplant/graft rejection; reperfusion injury; glomerulonephritis;  
XX allergic airway inflammation; inflammatory bowel disease; infection; ss.  
XX  
XX Homo sapiens.  
OS  
XX  
XX US2002177568-A1.  
PN  
XX  
XX 28-NOV-2002.  
PD  
XX  
XX 23-MAY-2001; 2001US-00864785.  
PF  
XX  
XX 07-DEC-1992; 92US-00987132.  
PR  
XX 18-MAY-1994; 94US-00245466.  
PR  
XX 15-AUG-1994; 94US-00291932.  
PR  
XX 23-DEC-1996; 96US-00777916.  
PR  
XX  
XX (STIN)/ STINCHOMB D T.  
PA  
XX (MCSW)/ MCSWIGGEN J.  
PA  
XX (DRAP)/ DRAPER K G.  
PA  
XX  
XX Stinchcomb DT, Mcswiggen J, Draper KG;  
PI  
XX WPI; 2003-340953/32.  
DR  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
PT a sequence encoding a subunit of nuclear factor kappa B useful for  
PT treating cancer, inflammatory disorders and autoimmune diseases.  
XX  
XX Claim 3; Page 30; 72pp; English.  
PS  
XX



PA (STIN/) STINCHOMB D T.  
PA (MCSW/) MCSWIGGEN J.  
PA (DRAP/) DRAPER K G.  
XX Stinchcomb DT, Mcswiggen J, Draper KG;  
XX WPI; 2003-340953/32.  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
XX a sequence encoding a subunit of nuclear factor kappa B useful for  
XX treating cancer, inflammatory disorders and autoimmune diseases.  
XX Claim 3; Page 30; 72pp; English.  
XX  
XX The invention describes an enzymatic nucleic acid molecule (I) which down  
XX regulates expression of a sequence encoding a subunit of nuclear factor  
XX kappa B (NFkB), where (I) is an inozyme, zinczyme, G-cleaver or amberzyme  
XX configuration. The enzymatic nucleic acid molecule is adapted to treat  
XX cancer and is useful for down-regulating REL-A activity in a cell, for  
XX treating a patient having a condition associated with the level of REL-A.  
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
XX the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
XX antisense nucleic acid molecules are useful for treating breast, lung,  
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
XX multidrug resistant cancer. The method involves use of other drug  
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
XX gencitabine or radiation therapy. The enzymatic and antisense nucleic  
XX acid molecules are also useful for treating inflammatory disease such as  
XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
XX rejection, gene therapy applications, ischaemia/reperfusion injury  
XX (central nervous system (CNS) and myocardial), glomerulonephritis,  
XX sepsis, allergic airway inflammation, inflammatory bowel disease or  
XX infection. This sequence represents the substrate of a novel enzymatic  
XX nucleic acid molecule  
XX  
XX Sequence 17 BP; 2 A; 9 C; 4 G; 0 T; 2 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;  
XX Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
XX Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
XX  
XX Qy 1505 CCCGAGCTCCAGGCC 1521  
XX |||||:|||||  
XX 1 CCCGAGCTCCAGGCC 17  
XX  
XX RESULT 351  
XX ACA06517 standard; RNA; 17 BP.  
XX  
XX AC A06517;  
XX  
XX 03-JUN-2003 (first entry)  
XX  
XX NFKB sub-unit modulating inozyme substrate #336.  
XX  
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinczyme;  
XX G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;  
XX lung cancer; prostate cancer; colorectal cancer; brain cancer;  
XX oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;  
XX cervical cancer; head and neck cancer; ovarian cancer; melanoma;  
XX lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;  
XX chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;  
XX cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;  
XX gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;  
XX rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;  
XX gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;  
XX transplant/graft rejection; reperfusion injury; glomerulonephritis;  
XX allergic airway inflammation; inflammatory bowel disease; infection; ss.

XX Homo sapiens.  
XX US2002177568-A1.  
XX 28-NOV-2002.  
XX  
XX 23-MAY-2001; 2001US-00864785.  
XX  
XX 07-DEC-1992; 92US-00987132.  
XX 18-MAY-1994; 94US-00245466.  
XX 15-AUG-1994; 94US-00291932.  
XX 23-DEC-1996; 96US-00777916.  
XX  
XX (STIN/) STINCHOMB D T.  
XX (MCSW/) MCSWIGGEN J.  
XX (DRAP/) DRAPER K G.  
XX Stinchcomb DT, Mcswiggen J, Draper KG;  
XX WPI; 2003-340953/32.  
XX  
XX Novel enzymatic nucleic acid molecules which down regulates expression of  
XX a sequence encoding a subunit of nuclear factor kappa B useful for  
XX treating cancer, inflammatory disorders and autoimmune diseases.  
XX Claim 3; Page 32; 72pp; English.  
XX  
XX The invention describes an enzymatic nucleic acid molecule (I) which down  
XX regulates expression of a sequence encoding a subunit of nuclear factor  
XX kappa B (NFkB), where (I) is an inozyme, zinczyme, G-cleaver or amberzyme  
XX configuration. The enzymatic nucleic acid molecule is adapted to treat  
XX cancer and is useful for down-regulating REL-A activity in a cell, for  
XX treating a patient having a condition associated with the level of REL-A.  
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in  
XX the presence of a divalent cation, especially Mg<sup>2+</sup>. The enzymatic and  
XX antisense nucleic acid molecules are useful for treating breast, lung,  
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,  
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or  
XX multidrug resistant cancer. The method involves use of other drug  
XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or  
XX chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,  
XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,  
XX gencitabine or radiation therapy. The enzymatic and antisense nucleic  
XX acid molecules are also useful for treating inflammatory disease such as  
XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,  
XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft  
XX rejection, gene therapy applications, ischaemia/reperfusion injury  
XX (central nervous system (CNS) and myocardial), glomerulonephritis,  
XX sepsis, allergic airway inflammation, inflammatory bowel disease or  
XX infection. This sequence represents the substrate of a novel enzymatic  
XX nucleic acid molecule  
XX  
XX Sequence 17 BP; 2 A; 11 C; 3 G; 0 T; 1 U; 0 Other;  
XX  
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;  
XX Best Local Similarity 82.4%; Pred. No. 1.9e+02;  
XX Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;  
XX  
XX Qy 1505 CCCGAGCTCCAGGCC 1521  
XX |||||:|||||  
XX 1 CCCGAGCTCCAGGCC 17  
XX  
XX RESULT 352  
XX ADA99701 standard; DNA; 17 BP.  
XX  
XX ID ADA99701  
XX  
XX AC ADA99701;  
XX  
XX 20-NOV-2003 (first entry)  
XX  
XX Human MD23 scanning oligonucleotide SEQ ID 690.



(RIBO-) RIBOZYME PHARM INC.  
PA (BLAT/) BLATT J.  
PA (MACE/) MACEJAK D.  
PA (MCSW/) MCSWIGGEN J.  
PA (MORR/) MORRISSEY D.  
PA (PAVC/) PAVCO P.  
PA (LEBP/) LEE P.  
PA (DRAP/) DRAPER K.  
PA (ROBE/) ROBERTS E.

Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
Draper K, Roberts E;  
WPI; 2003-229207/22.

Novel compound useful for treating cirrhosis, liver failure,  
hepatocellular carcinoma, or condition associated with hepatitis C virus  
infection.

Claim 1; Page 245; 387pp; English.

The present invention relates to nucleic acid molecules which modulate  
the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
inozymes, zinzymes, amberzymes, and G-cleaver ribozymes. Also disclosed  
are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
transcriptase and/or HBV reverse transcriptase primer sequences, as well  
as oligonucleotides that specifically bind the Enhancer I region of HBV  
DNA. The nucleic acids may be used to modulate the expression of HBV  
genes and HBV viral replication. Also disclosed is a method for screening  
compounds and/or potential therapies directed against HBV, and compounds  
that modulate the expression and/or replication of HCV. The compounds and  
methods of the invention are useful for the treatment of degenerative and  
disease states related to HBV and HCV infection, replication and gene  
expression such as cirrhosis, liver failure, and hepatocellular  
carcinoma. The present sequence represents a substrate for one of the HCV  
DNzyme or minus strand DNzyme sequences disclosed in the present  
invention

Sequence 17 BP; 2 A; 1 C; 7 G; 0 T; 7 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 1.9e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1400 TGTGGATGTTGCTTTTG 1416  
DB 1 UGUUGGAUGAUGCUGUUG 17  
:::|:::|:::|:::|:::|

RESULT 356  
ACD61087  
ID ACD61087 standard; RNA; 17 BP.  
XX AC ACD61087;  
XX AC AC  
XX DT DT  
XX XX  
XX 24-SEP-2003 (first entry)  
DE HCV DNzyme substrate sequence #2161.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;  
KW RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNzyme; inozyme; zinzyme;  
KW amberzyme; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
OS Hepatitis C virus.  
XX  
XX WO200281494-A1.

XX RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
XX Hepatitis C virus.  
OS  
XX WO200281494-A1.  
PN  
XX 17-OCT-2002.  
PD  
XX 26-MAR-2002; 2002WO-US009187.  
PF  
XX 26-MAR-2001; 2001US-00817879.  
PR  
XX 08-JUN-2001; 2001US-00877478.  
PR  
XX 08-JUN-2001; 2001US-0296876P.  
PR  
XX 24-OCT-2001; 2001US-0335059P.  
PR  
XX 05-DEC-2001; 2001US-0337055P.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX (BLAT/) BLATT L.  
PA  
XX (MACE/) MACEJAK D.  
PA  
XX (MCSW/) MCSWIGGEN J.  
PA  
XX (MORR/) MORRISSEY D.  
PA  
XX (PAVC/) PAVCO P.  
PA  
XX (LEEP/) LEE P.  
PA  
XX (DRAP/) DRAPER K.  
PA  
XX (ROBE/) ROBERTS E.  
PA  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
PI  
XX WPI; 2003-229207/22.  
DR  
XX Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
PT  
XX Claim 1; Page 272; 387pp; English.  
PS  
XX The present invention relates to nucleic acid molecules which modulate  
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV, and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNazyme or minus strand DNazyme sequences disclosed in the present  
XX invention  
SQ Sequence 17 BP; 3 A; 5 C; 2 G; 0 T; 7 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 52.8%; Pred. No. 1.9e+02;  
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;  
QY 689 GAGGCTTCACTTCTTCT 705  
DB 1 GAUGACUCACUUCUUCU 17  
RESULT 357  
ACD62816/C  
ID ACD62816 standard; RNA; 17 BP.  
XX  
XX ACD62816;  
AC  
XX AC  
XX AC  
DT 24-SEP-2003 (first entry)  
XX  
DE HCV minus strand DNazyme substrate sequence #735.  
XX  
XX Nucleic acid molecule; Hepatitis C virus; HCV; Hepatitis B virus; HBV;

XX RNA stability; RNA expression; RNA synthesis; antisense;  
KW enzymatic nucleic acid; hammerhead ribozyme; DNazyme; inozyme; zinzyme;  
KW amberyne; G-cleaver ribozyme; decoy molecule; aptamer;  
KW HBV reverse transcriptase; Enhancer I region; viral replication;  
KW degenerative; disease state; HBV infection; HCV infection; cirrhosis;  
KW liver failure; hepatocellular carcinoma; hepatotropic; cytostatic;  
KW virucide; antiinflammatory; substrate; ss.  
XX Hepatitis C virus.  
OS  
XX WO200281494-A1.  
PN  
XX 17-OCT-2002.  
PD  
XX 26-MAR-2002; 2002WO-US009187.  
PF  
XX 26-MAR-2001; 2001US-00817879.  
PR  
XX 08-JUN-2001; 2001US-00877478.  
PR  
XX 08-JUN-2001; 2001US-0296876P.  
PR  
XX 24-OCT-2001; 2001US-0335059P.  
PR  
XX 05-DEC-2001; 2001US-0337055P.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX (BLAT/) BLATT L.  
PA  
XX (MACE/) MACEJAK D.  
PA  
XX (MCSW/) MCSWIGGEN J.  
PA  
XX (MORR/) MORRISSEY D.  
PA  
XX (PAVC/) PAVCO P.  
PA  
XX (LEEP/) LEE P.  
PA  
XX (DRAP/) DRAPER K.  
PA  
XX (ROBE/) ROBERTS E.  
PA  
XX Blatt L, Macejak D, Mcswiggen J, Morrissey D, Pavco P, Lee P;  
PI Draper K, Roberts E;  
PI  
XX WPI; 2003-229207/22.  
DR  
XX Novel compound useful for treating cirrhosis, liver failure,  
PT hepatocellular carcinoma, or condition associated with hepatitis C virus  
PT infection.  
PT  
XX Claim 1; Page 288; 387pp; English.  
PS  
XX The present invention relates to nucleic acid molecules which modulate  
XX the synthesis, expression and/or stability of Hepatitis C virus (HCV) or  
CC Hepatitis B virus (HBV) RNA. The nucleic acid molecules include antisense  
CC and enzymatic nucleic acids such as hammerhead ribozymes, DNazymes,  
CC inozymes, zinzymes, amberyne, and G-cleaver ribozymes. Also disclosed  
CC are nucleic acid decoy molecules and aptamers that bind to HBV reverse  
CC transcriptase and/or HBV reverse transcriptase primer sequences, as well  
CC as oligonucleotides that specifically bind the Enhancer I region of HBV  
CC DNA. The nucleic acids may be used to modulate the expression of HBV  
CC genes and HBV viral replication. Also disclosed is a method for screening  
CC compounds and/or potential therapies directed against HBV, and compounds  
CC that modulate the expression and/or replication of HCV. The compounds and  
CC methods of the invention are useful for the treatment of degenerative and  
CC disease states related to HBV and HCV infection, replication and gene  
CC expression such as cirrhosis, liver failure, and hepatocellular  
CC carcinoma. The present sequence represents a substrate for one of the HCV  
CC DNazyme or minus strand DNazyme sequences disclosed in the present  
XX invention  
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 0 T; 2 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 769 ACGCATGTTCCAGCCC 785  
DB 17 ACGCATGTTCCGCTC 1

KW	diagnosis.
XX	Homo sapiens.
OS	WO2003040369-A2.
PN	15-MAY-2003.
XX	17-SEP-2002; 2002WO-IB004219.
PF	17-SEP-2001; 2001FR-00011981.
PR	(MOLE-) MOLECULAR ENGINES LAB.
PA	Telerman A, Amson R, Tuijnder M;
PI	WPI; 2003-441574/41.
XX	New nucleic acid encoding human prostate membrane-specific antigen,
PT	useful e.g. for treatment of tumors and viral infection, also related
PP	polypeptide and antibodies.
XX	Disclosure; Page 37; 77lpp; French.
CC	The invention relates to the isolation of 6327 nucleotide sequences,
CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC	sequence having at least 80% identity, after optimal alignment, with the
CC	nucleotides, a sequence that hybridizes under stringent conditions with
CC	the nucleotides, or the complement, or corresponding RNA, of the
CC	nucleotides. The nucleotides are used as probes or primers for detecting,
CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC	sense and antisense sequences, of nucleotides involved in tumour
CC	suppression or reversion, apoptosis and or viral resistance, to produce
CC	recombinant polypeptides, and to prepare transgenic animals, as
CC	experimental models. The nucleotides (also vectors containing them and
CC	cells containing the vectors), the encoded polypeptides and antibodies
CC	(Ab) against the polypeptide are useful for prevention and/or treatment
CC	of viral infections or diseases characterized by development of tumours
CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC	Analysis of the expression of the nucleotides can be used for diagnosis
CC	and/or prognosis of these diseases. The nucleotides and polypeptides can
CC	also be used to screen for their specific interactive molecules,
CC	potentially useful for treating diseases associated with abnormal
CC	expression of the nucleotides.
XX	Sequence 17 BP; 2 A; 10 C; 2 G; 3 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	91 GGGAGAGTGGCAGGTC 107
DB	17 GGGAGGTGGCAGATC 1
RESULT 360	
ID	ADI47981 standard; DNA; 17 BP.
XX	AC ADI47981;
DT	15-APR-2004 (first entry)
XX	Human tumour suppression/reversion-related DNA sequence SeqID484.
DE	tumour suppression; tumour reversion; apoptosis; virus resistance;
XX	cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW	primer; PCR; gene chip; antisense; viral disease; tumour;
KW	cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
OS	Homo sapiens.
XX	

  

KW	diagnosis.
XX	Homo sapiens.
OS	WO2003040369-A2.
PN	15-MAY-2003.
XX	17-SEP-2002; 2002WO-IB004219.
PF	17-SEP-2001; 2001FR-00011981.
PR	(MOLE-) MOLECULAR ENGINES LAB.
PA	Telerman A, Amson R, Tuijnder M;
PI	WPI; 2003-441574/41.
XX	New nucleic acid encoding human prostate membrane-specific antigen,
PT	useful e.g. for treatment of tumors and viral infection, also related
PP	polypeptide and antibodies.
XX	Disclosure; Page 37; 77lpp; French.
CC	The invention relates to the isolation of 6327 nucleotide sequences,
CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC	sequence having at least 80% identity, after optimal alignment, with the
CC	nucleotides, a sequence that hybridizes under stringent conditions with
CC	the nucleotides, or the complement, or corresponding RNA, of the
CC	nucleotides. The nucleotides are used as probes or primers for detecting,
CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC	sense and antisense sequences, of nucleotides involved in tumour
CC	suppression or reversion, apoptosis and or viral resistance, to produce
CC	recombinant polypeptides, and to prepare transgenic animals, as
CC	experimental models. The nucleotides (also vectors containing them and
CC	cells containing the vectors), the encoded polypeptides and antibodies
CC	(Ab) against the polypeptide are useful for prevention and/or treatment
CC	of viral infections or diseases characterized by development of tumours
CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC	Analysis of the expression of the nucleotides can be used for diagnosis
CC	and/or prognosis of these diseases. The nucleotides and polypeptides can
CC	also be used to screen for their specific interactive molecules,
CC	potentially useful for treating diseases associated with abnormal
CC	expression of the nucleotides.
XX	Sequence 17 BP; 2 A; 10 C; 2 G; 3 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	91 GGGAGAGTGGCAGGTC 107
DB	17 GGGAGGTGGCAGATC 1
RESULT 360	
ID	ADI47981 standard; DNA; 17 BP.
XX	AC ADI47981;
DT	15-APR-2004 (first entry)
XX	Human tumour suppression/reversion-related DNA sequence SeqID484.
DE	tumour suppression; tumour reversion; apoptosis; virus resistance;
XX	cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW	primer; PCR; gene chip; antisense; viral disease; tumour;
KW	cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
OS	Homo sapiens.
XX	

  

KW	diagnosis.
XX	Homo sapiens.
OS	WO2003040369-A2.
PN	15-MAY-2003.
XX	17-SEP-2002; 2002WO-IB004219.
PF	17-SEP-2001; 2001FR-00011981.
PR	(MOLE-) MOLECULAR ENGINES LAB.
PA	Telerman A, Amson R, Tuijnder M;
PI	WPI; 2003-441574/41.
XX	New nucleic acid encoding human prostate membrane-specific antigen,
PT	useful e.g. for treatment of tumors and viral infection, also related
PP	polypeptide and antibodies.
XX	Disclosure; Page 37; 77lpp; French.
CC	The invention relates to the isolation of 6327 nucleotide sequences,
CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC	sequence having at least 80% identity, after optimal alignment, with the
CC	nucleotides, a sequence that hybridizes under stringent conditions with
CC	the nucleotides, or the complement, or corresponding RNA, of the
CC	nucleotides. The nucleotides are used as probes or primers for detecting,
CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC	sense and antisense sequences, of nucleotides involved in tumour
CC	suppression or reversion, apoptosis and or viral resistance, to produce
CC	recombinant polypeptides, and to prepare transgenic animals, as
CC	experimental models. The nucleotides (also vectors containing them and
CC	cells containing the vectors), the encoded polypeptides and antibodies
CC	(Ab) against the polypeptide are useful for prevention and/or treatment
CC	of viral infections or diseases characterized by development of tumours
CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC	Analysis of the expression of the nucleotides can be used for diagnosis
CC	and/or prognosis of these diseases. The nucleotides and polypeptides can
CC	also be used to screen for their specific interactive molecules,
CC	potentially useful for treating diseases associated with abnormal
CC	expression of the nucleotides.
XX	Sequence 17 BP; 2 A; 10 C; 2 G; 3 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.

KW	diagnosis.
XX	Homo sapiens.
OS	WO2003040369-A2.
PN	15-MAY-2003.
XX	17-SEP-2002; 2002WO-IB004219.
PF	17-SEP-2001; 2001FR-00011981.
PR	(MOLE-) MOLECULAR ENGINES LAB.
PA	Telerman A, Amson R, Tuijnder M;
PI	WPI; 2003-441574/41.
XX	New nucleic acid encoding human prostate membrane-specific antigen,
PT	useful e.g. for treatment of tumors and viral infection, also related
PP	polypeptide and antibodies.
XX	Disclosure; Page 37; 77lpp; French.
CC	The invention relates to the isolation of 6327 nucleotide sequences,
CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC	sequence having at least 80% identity, after optimal alignment, with the
CC	nucleotides, a sequence that hybridizes under stringent conditions with
CC	the nucleotides, or the complement, or corresponding RNA, of the
CC	nucleotides. The nucleotides are used as probes or primers for detecting,
CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC	sense and antisense sequences, of nucleotides involved in tumour
CC	suppression or reversion, apoptosis and or viral resistance, to produce
CC	recombinant polypeptides, and to prepare transgenic animals, as
CC	experimental models. The nucleotides (also vectors containing them and
CC	cells containing the vectors), the encoded polypeptides and antibodies
CC	(Ab) against the polypeptide are useful for prevention and/or treatment
CC	of viral infections or diseases characterized by development of tumours
CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC	Analysis of the expression of the nucleotides can be used for diagnosis
CC	and/or prognosis of these diseases. The nucleotides and polypeptides can
CC	also be used to screen for their specific interactive molecules,
CC	potentially useful for treating diseases associated with abnormal
CC	expression of the nucleotides.
XX	Sequence 17 BP; 2 A; 10 C; 2 G; 3 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	91 GGGAGAGTGGCAGGTC 107
DB	17 GGGAGGTGGCAGATC 1
RESULT 360	
ID	ADI47981 standard; DNA; 17 BP.
XX	ADI47981;
AC	15-APR-2004 (first entry)
DT	Human tumour suppression/reversion-related DNA sequence SeqID484.
XX	tumour suppression; tumour reversion; apoptosis; virus resistance;
KW	cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW	primer; PCR; gene chip; antisense; viral disease; tumour;
KW	cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
OS	Homo sapiens.
XX	

  

KW	diagnosis.
XX	Homo sapiens.
OS	WO2003040369-A2.
PN	15-MAY-2003.
XX	17-SEP-2002; 2002WO-IB004219.
PF	17-SEP-2001; 2001FR-00011981.
PR	(MOLE-) MOLECULAR ENGINES LAB.
PA	Telerman A, Amson R, Tuijnder M;
PI	WPI; 2003-441574/41.
XX	New nucleic acid encoding human prostate membrane-specific antigen,
PT	useful e.g. for treatment of tumors and viral infection, also related
PP	polypeptide and antibodies.
XX	Disclosure; Page 37; 77lpp; French.
CC	The invention relates to the isolation of 6327 nucleotide sequences,
CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC	sequence having at least 80% identity, after optimal alignment, with the
CC	nucleotides, a sequence that hybridizes under stringent conditions with
CC	the nucleotides, or the complement, or corresponding RNA, of the
CC	nucleotides. The nucleotides are used as probes or primers for detecting,
CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC	sense and antisense sequences, of nucleotides involved in tumour
CC	suppression or reversion, apoptosis and or viral resistance, to produce
CC	recombinant polypeptides, and to prepare transgenic animals, as
CC	experimental models. The nucleotides (also vectors containing them and
CC	cells containing the vectors), the encoded polypeptides and antibodies
CC	(Ab) against the polypeptide are useful for prevention and/or treatment
CC	of viral infections or diseases characterized by development of tumours
CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC	Analysis of the expression of the nucleotides can be used for diagnosis
CC	and/or prognosis of these diseases. The nucleotides and polypeptides can
CC	also be used to screen for their specific interactive molecules,
CC	potentially useful for treating diseases associated with abnormal
CC	expression of the nucleotides.
XX	Sequence 17 BP; 2 A; 10 C; 2 G; 3 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY	91 GGGAGAGTGGCAGGTC 107
DB	17 GGGAGGTGGCAGATC 1
RESULT 360	
ID	ADI47981 standard; DNA; 17 BP.
XX	ADI47981;
AC	15-APR-2004 (first entry)
DT	Human tumour suppression/reversion-related DNA sequence SeqID484.
XX	tumour suppression; tumour reversion; apoptosis; virus resistance;
KW	cytostatic; virucide; neuroprotective; nontropic; neuroleptic; probe;
KW	primer; PCR; gene chip; antisense; viral disease; tumour;
KW	cell degeneration; cancer; Alzheimer's disease; schizophrenia; ds; human.
OS	Homo sapiens.
XX	

  

KW	diagnosis.
XX	Homo sapiens.
OS	WO2003040369-A2.
PN	15-MAY-2003.
XX	17-SEP-2002; 2002WO-IB004219.
PF	17-SEP-2001; 2001FR-00011981.
PR	(MOLE-) MOLECULAR ENGINES LAB.
PA	Telerman A, Amson R, Tuijnder M;
PI	WPI; 2003-441574/41.
XX	New nucleic acid encoding human prostate membrane-specific antigen,
PT	useful e.g. for treatment of tumors and viral infection, also related
PP	polypeptide and antibodies.
XX	Disclosure; Page 37; 77lpp; French.
CC	The invention relates to the isolation of 6327 nucleotide sequences,
CC	fragments of at least 15 consecutive nucleotides of these nucleotides, a
CC	sequence having at least 80% identity, after optimal alignment, with the
CC	nucleotides, a sequence that hybridizes under stringent conditions with
CC	the nucleotides, or the complement, or corresponding RNA, of the
CC	nucleotides. The nucleotides are used as probes or primers for detecting,
CC	identifying, quantifying and/or amplifying nucleic acids, as in vitro
CC	sense and antisense sequences, of nucleotides involved in tumour
CC	suppression or reversion, apoptosis and or viral resistance, to produce
CC	recombinant polypeptides, and to prepare transgenic animals, as
CC	experimental models. The nucleotides (also vectors containing them and
CC	cells containing the vectors), the encoded polypeptides and antibodies
CC	(Ab) against the polypeptide are useful for prevention and/or treatment
CC	of viral infections or diseases characterized by development of tumours
CC	or cell degeneration (e.g. Alzheimer's disease or schizophrenia).
CC	Analysis of the expression of the nucleotides can be used for diagnosis
CC	and/or prognosis of these diseases. The nucleotides and polypeptides can
CC	also be used to screen for their specific interactive molecules,
CC	potentially useful for treating diseases associated with abnormal
CC	expression of the nucleotides.
XX	Sequence 17 BP; 2 A; 10 C; 2 G; 3 T; 0 U; 0 Other;
SQ	Query Match 0.8%; Score 13.8; DB 1; Length 17;
	Best Local Similarity 88.2%; Pred.

PN WO2003025177-A2.  
XX  
PD 27-MAR-2003.  
XX  
PF 17-SEP-2002; 2002WO-IB004523.  
XX  
PR 17-SEP-2001; 2001FR-00011980.  
XX  
PA (MOLE-) MOLECULAR ENGINES LAB.  
XX  
PI Telerman A, Amson R, Tuijnder M;  
XX  
DR WPI; 2003-313354/30.  
XX  
XX New isolated nucleic acid, useful for treating viral diseases associated  
PT with tumors and cell degeneration, also related polypeptides, antibodies  
PT and transfected cells.  
PT  
PS Disclosure; SEQ ID NO 484; 30pp; French.  
XX  
XX This invention relates to novel isolated nucleic acid sequences involved  
CC in the phenomena of tumour suppression, tumour reversion, apoptosis  
CC and/or resistance to viruses. The invention may be useful for the  
CC development of compounds with a cytostatic, virucide, neuroprotective,  
CC neurotropic or neuroleptic activity. The DNA sequences may be useful as  
CC probes and primers for detecting, indentifying, quantifying and/or  
CC amplifying nucleic acid, for example as one component of a gene chip, in  
CC vitro as antisense reagents and for production of recombinant  
CC polypeptides. The invention may therefore be useful for preparation of  
CC pharmaceuticals for prevention and/or treatment of viral diseases that  
CC are characterised by development of tumours or cell degeneration,  
CC specifically cancer but also Alzheimer's disease and schizophrenia. The  
CC present sequence is that of a nucleic acid sequence of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences  
XX  
SQ Sequence 17 BP; 5 A; 4 C; 2 G; 6 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1551 GATCCTGCACTCTAACA 1567  
Db 1 GATCCTGTACTCTAATA 17  
  
RESULT 361  
ABZ94171/c  
ID ABZ94171 standard; DNA; 17 BP.  
XX  
AC ABZ94171;  
XX  
XX 17-OCT-2003 (first entry)  
DT  
DE Human adenosine A1 receptor antisense fragment no.34.  
XX  
XX Human; antisense; lung dysfunction; nasal airway dysfunction;  
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;  
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;  
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;  
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
KW lung inflammation; respiratory disease; ds.  
XX  
OS Homo sapiens.  
XX  
XX WO200285308-A2.  
PN  
XX 31-OCT-2002.  
PD  
XX 23-APR-2002; 2002WO-US013135.  
PF  
XX

PR 24-APR-2001; 2001US-0286137P.  
XX  
PA (EPIG-) EPIGENESIS PHARM INC.  
XX  
PI Nyce JW, Li Y, Sandrasagra A, Katz E, Pabalan J, Aguilar D;  
PI Miller S, Tang L, Shahabuddin S;  
XX  
DR WPI; 2003-229219/22.  
XX  
XX Pharmaceutical composition for treating ailments associated with impaired  
PT respiration, has oligo(s) antisense to specific gene(s) or its  
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
PT ubiqunone.  
XX  
PS Disclosure; SEQ ID NO 9413; 872pp; English.  
XX  
XX The invention relates to a novel pharmaceutical composition, which has a  
CC first active agent comprising an oligonucleotide antisense to the  
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
CC junctions of genes encoding a polypeptide associated with lung and/or  
CC nasal airway dysfunction and a second active agent comprising an  
CC antiinflammatory steroid and ubiqunone. A composition of the invention  
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive, have a  
CC immunosuppressive, and cytostatic activity. The composition may have a  
CC use in antisense gene therapy. The composition is useful for treating or  
CC preventing a respiratory, lung or malignant disease or condition, also  
CC for enhancing the prophylactic or therapeutic respiratory effect of an  
CC antiinflammatory steroid in a subject, for reducing or depleting levels  
CC of, or reducing sensitivity to adenosine, reducing levels of ubiqunone or  
CC receptor, producing bronchodilation, increasing levels of ubiqunone or  
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
CC lung inflammation, lung allergies, or a respiratory disease or condition.  
CC Note: The sequence data for this patent is not represented in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/publishedpct\_sequences  
XX  
SQ Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
  
QY 1530 GCCCAGCCTCTCCCGC 1546  
Db 17 GCCCAGCCTGTGCCGC 1  
  
RESULT 362  
ABZ95047/c  
ID ABZ95047 standard; DNA; 17 BP.  
XX  
AC ABZ95047;  
XX  
XX 17-OCT-2003 (first entry)  
DT  
DE Human adenosine A1 receptor antisense fragment no.910.  
XX  
XX Human; antisense; lung dysfunction; nasal airway dysfunction;  
KW antiinflammatory steroid; ubiqunone; antiinflammatory; antiallergic;  
KW antiasthmatic; hypotensive; immunosuppressive; cytostatic; gene therapy;  
KW antisense gene therapy; respiratory; lung; adenosine sensitivity;  
KW adenosine receptor; bronchodilation; bronchoconstriction; lung allergy;  
KW lung inflammation; respiratory disease; ds.  
XX  
OS Homo sapiens.  
XX  
XX WO200285308-A2.  
PN  
XX 31-OCT-2002.  
PD  
XX 23-APR-2002; 2002WO-US013135.  
PF  
XX

PR 24-APR-2001; 2001US-0286137P.  
XX (EPIC-) EPIGENESIS PHARM INC.  
XX  
XX Nyce JW, Li Y, Sandasaqra A, Katz E, Pabalan J, Aguilar D;  
PI Miller S, Tang L, Shahabuddin S;  
PI  
XX WPI; 2003-229219/22.  
XX  
XX Pharmaceutical composition for treating ailments associated with impaired  
PT respiration, has oligo(s) antisense to specific gene(s) or its  
PT corresponding RNAs, and glucocorticoid or non-glucocorticoid steroid or  
PT ubiquinone.  
XX  
XX Disclosure; SEQ ID NO 10289; 872pp; English.  
XX  
XX The invention relates to a novel pharmaceutical composition, which has a  
CC first active agent comprising an oligonucleotide antisense to the  
CC initiation codon, coding region, 5' or 3' end genomic flanking regions,  
CC 5' and 3' intron-exon junctions, or regions within 2-10 nucleotides of  
CC junctions of genes encoding a polypeptide associated with lung and/or  
CC nasal airway dysfunction and a second active agent comprising an  
CC antiinflammatory steroid and ubiquinone. A composition of the invention  
CC has antiinflammatory, antiallergic, antiasthmatic, hypotensive,  
CC immunosuppressive, and cytostatic activity. The composition may have a  
CC use in antisense gene therapy. The composition is useful for treating or  
CC preventing a respiratory, lung or malignant disease or condition, also  
CC for enhancing the prophylactic or therapeutic respiratory effect of an  
CC antiinflammatory steroid in a subject, for reducing or depleting levels  
CC of, or reducing sensitivity to adenosine, reducing levels of adenosine  
CC receptor, producing bronchodilation, increasing levels of ubiquinone or  
CC lung surfactant in a subject's tissue, or treating bronchoconstriction,  
CC lung inflammation, lung allergies, or a respiratory disease or condition.  
CC Note: The sequence data for this patent is not represented in the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pt\_sequences  
XX  
XX Sequence 17 BP; 2 A; 5 C; 9 G; 1 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1530 GCCAGCCTCTCCCGC 1546  
Db ||||| |  
17 GCCAGCCTGTGCCGC 1  
RESULT 363  
ADL48005  
ID ADL48005 standard; RNA; 17 BP.  
XX  
XX ADL48005;  
AC  
XX  
XX 20-MAY-2004 (first entry)  
DT  
XX  
XX Human IKK-gamma substrate sequence #515.  
DE  
XX  
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;  
KW substrate; ds.  
XX  
XX Unidentified.  
OS  
XX  
XX WO200281628-A2.  
PN  
XX

PD 17-OCT-2002.  
XX  
XX 03-APR-2002; 2002WO-US010512.  
PF  
XX  
XX 05-APR-2001; 2001US-00827395.  
PR  
XX 29-MAY-2001; 2001US-0294412P.  
PR  
XX 28-AUG-2001; 2001US-0315315P.  
PR  
XX (RIBO-) RIBOZYME PHARM INC.  
PA  
XX  
XX Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;  
PI WPI; 2003-058513/05.  
XX  
XX Novel enzymatic nucleic acid that down-regulates expression of neurite  
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or  
PT protein kinase PKR genes, for treating cancer and inflammatory disease.  
XX  
XX Claim 59; SEQ ID NO 1538; 317pp; English.  
PS  
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)  
CC that down regulate the expression or inhibit the function of a receptor  
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),  
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the  
CC invention are useful for treating: cerebrovascular accident, central  
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,  
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,  
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune  
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic  
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The  
CC nucleic acids of the invention are also useful for down-regulating the  
CC expression of a target gene and as a diagnostic tool to examine genetic  
CC drifts and mutations within diseased cells or to detect the presence of a  
CC target RNA in a cell. The present RNA sequence represents a human IKK-  
CC gamma substrate sequence.  
XX  
XX Sequence 17 BP; 3 A; 6 C; 3 G; 0 T; 5 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 58.8%; Pred. No. 1.9e+02;  
Matches 10; Conservative 5; Mismatches 2; Indels 0; Gaps 0;  
QY 697 ACTTCTTCTTCCCAAG 713  
Db ||::: |::: |||||  
1 ACUCUGCUGUCCCAAG 17  
RESULT 364  
ADL50256/c  
ID ADL50256 standard; RNA; 17 BP.  
XX  
XX ADL50256;  
AC  
XX  
XX 20-MAY-2004 (first entry)  
DT  
XX  
XX Human PKR substrate sequence #1370.  
DE  
XX  
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;  
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;  
KW protein kinase PKR; cerebrovascular accident;  
KW central nervous system injury; CNS injury; spinal cord injury; cancer;  
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;  
KW restenosis; asthma; Crohn's disease; diabetes; obesity;  
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;  
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;  
KW allergy; asthma; allergic rhinitis; atopic dermatitis; human PKR;  
KW substrate; ds.  
XX  
XX Unidentified.  
OS  
XX  
XX WO200281628-A2.  
PN  
XX

```
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
PS Claim 59; SEQ ID NO 3789; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human PKR
CC substrate sequence.
XX
SQ Sequence 17 BP; 8 A; 6 C; 1 G; 0 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1400 TGTGGATGTTGCTTTG 1416
DB 17 TGTGGATGTTGCTTTG 1
RESULT 365
ADL48380
ID ADL48380 standard; RNA; 17 BP.
XX
AC ADL48380;
XX
XX 20-MAY-2004 (first entry)
DE Human IKK-gamma substrate sequence #890.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis; Human IKK-gamma;
KW substrate; ds.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
```

```
PD 17-OCT-2002.
XX
PF 03-APR-2002; 2002WO-US010512.
XX
PR 05-APR-2001; 2001US-00827395.
PR 29-MAY-2001; 2001US-0294412P.
PR 28-AUG-2001; 2001US-0315315P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Blatt L, Chowrira B, Haeberli P, Mcswiggen J, Fosnaugh K;
XX WPI; 2003-058513/05.
DR
XX
XX Novel enzymatic nucleic acid that down-regulates expression of neurite
PT growth inhibitor receptor, prostaglandin D2 receptor, IkappaB kinase or
PT protein kinase PKR genes, for treating cancer and inflammatory disease.
PT
XX
PS Claim 59; SEQ ID NO 1913; 317pp; English.
XX
XX The invention comprises nucleic acids (e.g. antisense oligonucleotides)
CC that down regulate the expression or inhibit the function of a receptor
CC for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),
CC IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the
CC invention are useful for treating: cerebrovascular accident, central
CC nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,
CC lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,
CC restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune
CC disease, lupus, multiple sclerosis, transplant/graft rejection,
CC ischaemia/reperfusion injury, glomerulonephritis, sepsis, and allergic
CC conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The
CC nucleic acids of the invention are also useful for down-regulating the
CC expression of a target gene and as a diagnostic tool to examine genetic
CC drifts and mutations within diseased cells or to detect the presence of a
CC target RNA in a cell. The present RNA sequence represents a human IKK-
CC gamma substrate sequence.
XX
SQ Sequence 17 BP; 2 A; 6 C; 3 G; 0 T; 6 U; 0 Other;
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.9e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
QY 698 CTTCTTCTTTCCTCAAGT 714
DB 1 CUUCUGCUGUCCCAAGU 17
RESULT 366
ADM09485
ID ADM09485 standard; RNA; 17 BP.
XX
AC ADM09485;
XX
XX 20-MAY-2004 (first entry)
DE Human NOGO receptor amberzyme substrate sequence #40.
XX
XX antisense oligonucleotide; neurite growth inhibitor; NOGO;
KW prostaglandin D2 receptor; PTGDR; IkappaB kinase; IKK;
KW protein kinase PKR; cerebrovascular accident;
KW central nervous system injury; CNS injury; spinal cord injury; cancer;
KW melanoma; lymphoma; glioma; inflammatory disease; rheumatoid arthritis;
KW restenosis; asthma; Crohn's disease; diabetes; obesity;
KW autoimmune disease; lupus; multiple sclerosis; transplant rejection;
KW graft rejection; ischaemia; reperfusion; glomerulonephritis; sepsis;
KW allergy; asthma; allergic rhinitis; atopic dermatitis;
KW NOGO receptor amberzyme; substrate; ss.
XX
OS Unidentified.
XX
XX WO200281628-A2.
XX
```



PA	(CARL/) CARLOWITZ I V.	PA	17-OCT-2002.
PA	(MCSW/) MCSWIGGEN J.	XX	
PA	(HAMB/) HAMBELIN P A.	PF	03-APR-2002; 2002WO-US010512.
PA	(ELLI/) ELLIS J H.	XX	
XX		PR	05-APR-2001; 2001US-00827395.
PI	Jarvis T, Carlowitz IV, Mcswiggen J, Hamblin PA, Ellis JH;	PR	29-MAY-2001; 2001US-0294412P.
XX		PR	28-AUG-2001; 2001US-0315315P.
XX		XX	
XX	WPI; 2003-829646/77.	XX	(RIBO-) RIBOZYME PHARM INC.
XX		XX	
XX	New nucleic acid molecule that down-regulates expression of Grb2-related	XX	
XX	with insert domain (GRID) gene, useful for treating a condition	XX	
XX	associated with the level of GRID, e.g. tissue/graft rejection and	XX	
XX	leukemia.	XX	
XX		XX	
XX	Claim 4; SEQ ID NO 440; 74pp; English.	XX	
XX		XX	
XX	The invention relates to a nucleic acid molecule that down-regulates	XX	
XX	expression of Grb2-related with insert domain (GRID) gene, e.g. a	XX	
XX	hammerhead ribozyme, NCH ribozyme, G-cleaver ribozyme, Zinzyme, DNazyme,	XX	
XX	amberzyme, inozyme or hairpin ribozyme. Also include are a mammalian cell	XX	
XX	including the novel nucleic acid molecule, reducing GRID activity in a	XX	
XX	cell by contacting the cell with the novel nucleic acid molecule,	XX	
XX	treating a patient having a condition associated with the level of GRID	XX	
XX	(e.g. tissue/graft rejection or leukaemia) by contacting the cell with	XX	
XX	the novel nucleic acid molecule, cleaving RNA of a GRID gene by	XX	
XX	contacting the cell with the novel nucleic acid molecule, an expression	XX	
XX	vector comprising a nucleic acid sequences (encoding at least the novel	XX	
XX	nucleic acid molecule in a manner that allows its expression), a	XX	
XX	mammalian cell including the expression vector and an enzymatic nucleic	XX	
XX	acid molecule that cleaves RNA derived from a GRID gene. The nucleic acid	XX	
XX	molecule is useful for treating a condition associated with the level of	XX	
XX	GRID, e.g. tissue/graft rejection and leukaemia. The present sequence is	XX	
XX	a target region for the enzymatic nucleic acids of the invention.	XX	
XX		XX	
SQ	Sequence 17 BP; 3 A; 4 C; 8 G; 0 T; 2 U; 0 Other;		
	Query Match 0.8%; Score 13.8; DB 1; Length 17;		
	Best Local Similarity 88.2%; Pred. No. 1.9e+02;		
	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;		
QY	1539 CTCCTCCGCTCTGGATCC 1555		
Db			
	17 CTCCTCCGCTCTGGAAC 1		
	RESULT 368		
	ABD18019/C		
ID	ABD18019 standard; DNA; 17 BP.		
XX			
AC	ABD18019;		
XX			
DT	29-JUL-2004 (first entry)		
XX			
DE	Human adenosine A1 receptor oligonucleotide fragment 34.		
XX			
XX	Human; antiseize; bronchoconstriction; allergy; hyposecretion; pain;		
XX	respiratory tract inflammation; adenosine sensitivity; lung; cancer;		
XX	surfactant depletion; antiallergic; antiinflammatory; antiasthmatic;		
XX	analgesic; hypotensive; immunosuppressive; cytostatic; cystic fibrosis;		
XX	beta-adrenergic agonist; respiratory disease; pulmonary vasoconstriction;		
XX	respiratory distress syndrome; allergic rhinitis; pulmonary hypertension;		
XX	emphysema; chronic obstructive pulmonary disease; cancer; bronchitis;		
XX	pulmonary transplantation rejection; ds.		
XX			
OS	Homo sapiens.		
XX			
PN	WO200285309-A2.		
XX			
PD	31-OCT-2002.		
XX			
PF	23-APR-2002; 2002WO-US013143.		
XX			
XX	24-APR-2001; 2001US-0286036P.		

---

PD	17-OCT-2002.	PA	17-OCT-2002.
XX		XX	
PF	03-APR-2002; 2002WO-US010512.	XX	
XX		XX	
PR	05-APR-2001; 2001US-00827395.	XX	
PR	29-MAY-2001; 2001US-0294412P.	XX	
PR	28-AUG-2001; 2001US-0315315P.	XX	
XX		XX	
XX	(RIBO-) RIBOZYME PHARM INC.	XX	
XX		XX	
XX	Blatt L, Chowrira B, Haerberli P, Mcswiggen J, Fosnaugh K;	XX	
XX		XX	
XX	WPI; 2003-058513/05.	XX	
XX		XX	
XX	Novel enzymatic nucleic acid that down-regulates expression of neurite	XX	
XX	growth inhibitor receptor, prostaglandin D2 receptor, ikappaB kinase or	XX	
XX	protein kinase PKR genes, for treating cancer and inflammatory disease.	XX	
XX		XX	
XX	Claim 9; SEQ ID NO 880; 317pp; English.	XX	
XX		XX	
XX	The invention comprises nucleic acids (e.g. antisense oligonucleotides)	XX	
XX	that down regulate the expression or inhibit the function of a receptor	XX	
XX	for a neurite growth inhibitor, NOGO, prostaglandin D2 receptor (PTGDR),	XX	
XX	IkappaB kinase (IKK), or protein kinase PKR. The nucleic acids of the	XX	
XX	invention are useful for treating: cerebrovascular accident, central	XX	
XX	nervous system (CNS) injury, spinal cord injury, cancer (e.g. melanoma,	XX	
XX	lymphoma or glioma), inflammatory disease (e.g. rheumatoid arthritis,	XX	
XX	restenosis or asthma), Crohn's disease, diabetes, obesity, autoimmune	XX	
XX	disease, lupus, multiple sclerosis, transplant/graft rejection,	XX	
XX	ischemia/reperfusion injury, glomerulonephritis, sepsis, and allergic	XX	
XX	conditions (e.g. asthma, allergic rhinitis or atopic dermatitis). The	XX	
XX	nucleic acids of the invention are also useful for down-regulating the	XX	
XX	expression of a target gene and as a diagnostic tool to examine genetic	XX	
XX	drifts and mutations within diseased cells or to detect the presence of a	XX	
XX	target RNA in a cell. The present RNA sequence represents a human NOGO	XX	
XX	receptor amberzyme substrate sequence.	XX	
XX		XX	
SQ	Sequence 17 BP; 2 A; 7 C; 5 G; 0 T; 3 U; 0 Other;		
	Query Match 0.8%; Score 13.8; DB 1; Length 17;		
	Best Local Similarity 70.6%; Pred. No. 1.9e+02;		
	Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;		
QY	1117 CCTGTGCTGGAGCAGCTG 1133		
Db			
	1 CCCUCCUGGAGCAGCUG 17		
	RESULT 367		
	ADM54165/C		
ID	ADM54165 standard; mRNA; 17 BP.		
XX			
AC	ADM54165;		
XX			
DT	03-JUN-2004 (first entry)		
XX			
DE	Human GRID mRNA substrate sequence #440.		
XX			
XX	Human; ss; GRID; Grb2-related with insert domain; hammerhead ribozyme;		
XX	NCH ribozyme; G-cleaver ribozyme; Zinzyme; DNazyme; amberzyme; inozyme;		
XX	hairpin ribozyme; tissue rejection; graft rejection; leukaemia.		
XX			
OS	Homo sapiens.		
XX			
PN	US2003134806-A1.		
XX			
PD	17-JUL-2003.		
XX			
PF	23-FEB-2001; 2001US-00792818.		
XX			
PR	10-FEB-2000; 2000US-0181594P.		
XX			
PA	(JARV/) JARVIS T.		



AC ADG63002;  
XX 11-MAR-2004 (first entry)  
XX Mouse genomic DNA amplifying famj5312-derived forward PCR primer #3.  
DE Obese receptor gene; ObR gene; body weight regulation; diagnosis;  
XX prognosis; body weight disorder; obesity; cachexia; anorexia; bulimia;  
KW AIDS-related wasting; cancer-related wasting;  
KW acquired immune deficiency syndrome; therapy; murine; PCR; primer; ss.  
XX Mus sp.  
OS US2002182676-A1.  
XX 05-DEC-2002.  
XX 19-FEB-2002; 2002US-00079625.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2004-050987/05.  
XX New nucleic acid encoding an Ob receptor protein is useful to provide  
XX treatment for weight disorders, particularly anorexia, cachexia, bulimia,  
XX AIDS-related wasting or cancer-related wasting, or obesity.  
XX Example 8; SEQ ID NO 27; 112pp; English.  
XX The present invention relates to the identification and characterisation  
XX of nucleotides that encode obese receptor (ObR), a receptor protein that  
XX participates in mammalian body weight regulation. The invention is useful  
XX for diagnosis and prognosis of body weight disorders including obesity,  
XX cachexia, anorexia, bulimia, AIDS (acquired immune deficiency syndrome)-  
XX related and cancer-related wasting. The present sequence is mouse genomic  
XX DNA amplifying famj5312-derived PCR primer. This primer is used in the  
XX exemplification of the invention.  
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
RESULT 371  
ADG63000  
ID ADG63000 standard; DNA; 17 BP.  
XX AC ADG63000;  
XX 11-MAR-2004 (first entry)  
XX Mouse genomic DNA amplifying famj5312-derived forward PCR primer #2.  
DE Obese receptor gene; ObR gene; body weight regulation; diagnosis;  
XX prognosis; body weight disorder; obesity; cachexia; anorexia; bulimia;  
KW AIDS-related wasting; cancer-related wasting;  
KW acquired immune deficiency syndrome; therapy; murine; PCR; primer; ss.  
XX Mus sp.  
OS US2002182676-A1.  
XX 05-DEC-2002.  
XX 19-FEB-2002; 2002US-00079625.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2004-050987/05.  
XX New nucleic acid encoding an Ob receptor protein is useful to provide  
XX treatment for weight disorders, particularly anorexia, cachexia, bulimia,  
XX AIDS-related wasting or cancer-related wasting, or obesity.  
XX Example 8; SEQ ID NO 27; 112pp; English.  
XX The present invention relates to the identification and characterisation  
XX of nucleotides that encode obese receptor (ObR), a receptor protein that  
XX participates in mammalian body weight regulation. The invention is useful  
XX for diagnosis and prognosis of body weight disorders including obesity,  
XX cachexia, anorexia, bulimia, AIDS (acquired immune deficiency syndrome)-  
XX related and cancer-related wasting. The present sequence is mouse genomic  
XX DNA amplifying famj5312-derived PCR primer. This primer is used in the  
XX exemplification of the invention.  
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
RESULT 371  
ADG63000  
ID ADG63000 standard; DNA; 17 BP.  
XX AC ADG63000;  
XX 11-MAR-2004 (first entry)  
XX Mouse genomic DNA amplifying famj5312-derived forward PCR primer #2.  
DE Obese receptor gene; ObR gene; body weight regulation; diagnosis;  
XX prognosis; body weight disorder; obesity; cachexia; anorexia; bulimia;  
KW AIDS-related wasting; cancer-related wasting;  
KW acquired immune deficiency syndrome; therapy; murine; PCR; primer; ss.  
XX Mus sp.  
OS US2002182676-A1.  
XX 05-DEC-2002.  
XX 19-FEB-2002; 2002US-00079625.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2004-050987/05.  
XX New nucleic acid encoding an Ob receptor protein is useful to provide  
XX treatment for weight disorders, particularly anorexia, cachexia, bulimia,  
XX AIDS-related wasting or cancer-related wasting, or obesity.  
XX Example 8; SEQ ID NO 27; 112pp; English.  
XX The present invention relates to the identification and characterisation  
XX of nucleotides that encode obese receptor (ObR), a receptor protein that  
XX participates in mammalian body weight regulation. The invention is useful  
XX for diagnosis and prognosis of body weight disorders including obesity,  
XX cachexia, anorexia, bulimia, AIDS (acquired immune deficiency syndrome)-  
XX related and cancer-related wasting. The present sequence is mouse genomic  
XX DNA amplifying famj5312-derived PCR primer. This primer is used in the  
XX exemplification of the invention.  
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
RESULT 371  
ADG63000  
ID ADG63000 standard; DNA; 17 BP.  
XX AC ADG63000;  
XX 11-MAR-2004 (first entry)  
XX Mouse genomic DNA amplifying famj5312-derived forward PCR primer #2.  
DE Obese receptor gene; ObR gene; body weight regulation; diagnosis;  
XX prognosis; body weight disorder; obesity; cachexia; anorexia; bulimia;  
KW AIDS-related wasting; cancer-related wasting;  
KW acquired immune deficiency syndrome; therapy; murine; PCR; primer; ss.  
XX Mus sp.  
OS US2002182676-A1.  
XX 05-DEC-2002.  
XX 19-FEB-2002; 2002US-00079625.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2004-050987/05.  
XX New nucleic acid encoding an Ob receptor protein is useful to provide  
XX treatment for weight disorders, particularly anorexia, cachexia, bulimia,  
XX AIDS-related wasting or cancer-related wasting, or obesity.  
XX Example 8; SEQ ID NO 25; 112pp; English.  
XX The present invention relates to the identification and characterisation  
XX of nucleotides that encode obese receptor (ObR), a receptor protein that  
XX participates in mammalian body weight regulation. The invention is useful  
XX for diagnosis and prognosis of body weight disorders including obesity,  
XX cachexia, anorexia, bulimia, AIDS (acquired immune deficiency syndrome)-  
XX related and cancer-related wasting. The present sequence is mouse genomic  
XX DNA amplifying famj5312-derived PCR primer. This primer is used in the  
XX exemplification of the invention.  
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
RESULT 372  
ADK98279/C  
ID ADK98279 standard; DNA; 17 BP.  
XX AC ADK98279;  
XX 06-MAY-2004 (first entry)  
XX Primer of the invention #3999.  
XX human; single nucleotide polymorphism; SNP; ss; primer.  
XX Synthetic.  
XX JP2003259875-A.  
XX 16-SEP-2003.  
XX 08-MAR-2002; 2002JP-00064373.  
XX

KW AIDS-related wasting; cancer-related wasting;  
KW acquired immune deficiency syndrome; therapy; murine; PCR; primer; ss.  
XX Mus sp.  
XX US2002182676-A1.  
XX 05-DEC-2002.  
XX 19-FEB-2002; 2002US-00079625.  
XX 27-NOV-1995; 95US-00562663.  
XX 04-DEC-1995; 95US-00566622.  
XX 08-DEC-1995; 95US-00569485.  
XX 11-DEC-1995; 95US-00570142.  
XX 28-DEC-1995; 95US-00583153.  
XX 22-JAN-1996; 96US-00599455.  
XX 26-APR-1996; 96US-00638524.  
XX 03-SEP-1996; 96US-00708123.  
XX 28-MAY-1997; 97US-00864564.  
XX (MILL-) MILLENNIUM PHARM INC.  
XX Tartaglia LA, Tepper RI, Culpepper JA, White DW;  
XX WPI; 2004-050987/05.  
XX New nucleic acid encoding an Ob receptor protein is useful to provide  
XX treatment for weight disorders, particularly anorexia, cachexia, bulimia,  
XX AIDS-related wasting or cancer-related wasting, or obesity.  
XX Example 8; SEQ ID NO 25; 112pp; English.  
XX The present invention relates to the identification and characterisation  
XX of nucleotides that encode obese receptor (ObR), a receptor protein that  
XX participates in mammalian body weight regulation. The invention is useful  
XX for diagnosis and prognosis of body weight disorders including obesity,  
XX cachexia, anorexia, bulimia, AIDS (acquired immune deficiency syndrome)-  
XX related and cancer-related wasting. The present sequence is mouse genomic  
XX DNA amplifying famj5312-derived PCR primer. This primer is used in the  
XX exemplification of the invention.  
XX Sequence 17 BP; 3 A; 6 C; 2 G; 6 T; 0 U; 0 Other;  
SQ Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 660 CACTACCTGCCCTTCAG 676  
Db 1 CACTATTGCCCTTCAG 17  
RESULT 372  
ADK98279/C  
ID ADK98279 standard; DNA; 17 BP.  
XX AC ADK98279;  
XX 06-MAY-2004 (first entry)  
XX Primer of the invention #3999.  
XX human; single nucleotide polymorphism; SNP; ss; primer.  
XX Synthetic.  
XX JP2003259875-A.  
XX 16-SEP-2003.  
XX 08-MAR-2002; 2002JP-00064373.  
XX

```
PR 08-MAR-2002; 2002JP-00064373.
XX (KAGA-) KAGAKU GIJUTSU SHINKO JIGYODAN.
XX WPI; 2004-093977/10.
XX Novel polynucleotide useful for PCR amplification along with two DNA
PT fragment from another set of sequences, or for detecting single
PT nucleotide polymorphism in human gene.
XX Claim 2; SEQ ID NO 7308; 2627pp; Japanese.
XX The present invention relates to a polynucleotide isolated from a human
CC gene and is useful for detecting a single nucleotide polymorphism in a
CC human gene or for diagnosing of disease. The invention enables the
CC detection of a single nucleotide polymorphism in a human gene. The
CC present sequence represents a primer of the invention.
XX Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 666 CTGCCCTTCAGCCTGCC 682
DB ||||| ||||| ||||| |||||
17 CTGCATTTCAGCCTGCC 1

RESULT 373
AD184915
ID AD184915 standard; RNA; 17 BP.
XX
AC AD184915;
XX
DT 03-JUN-2004 (first entry)
XX
DE HCV DNazyme substrate sequence #2161.
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.
XX Hepatitis C virus.
XX
XX US2003125270-A1.
PN
XX
PD 03-JUL-2003.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 2161; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.
XX
XX Sequence 17 BP; 2 A; 1 C; 7 G; 1 T; 6 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.9e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1400 TGTCGATGTTGCTTTTG 1416
DB :|||:|||:|
1 UGUGGAUGATGCUUG 17

CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.
XX
XX Sequence 17 BP; 3 A; 5 C; 2 G; 0 T; 7 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.9e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
XX
QY 689 GAGGCTCACTTCTTCT 705
DB ||||| :|||:|||:|
1 GAUGACUCACUUCUUCU 17

RESULT 374
AD183386
ID AD183386 standard; RNA; 17 BP.
XX
AC AD183386;
XX
DT 03-JUN-2004 (first entry)
XX
DE HCV DNazyme substrate sequence #632.
XX
XX ss; enzymatic nucleic acid; RNA cleavage; hepatitis C virus; HCV;
KW HCV infection; type I interferon; DNazyme.
XX Hepatitis C virus.
XX
XX US2003125270-A1.
PN
XX
PD 03-JUL-2003.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX 18-DEC-2000; 2000US-00740332.
XX
XX (BLAT/) BLATT L.
PA (MCSW/) MCSWIGGEN J.
PA (ROBE/) ROBERTS E.
PA (PAVC/) PAVCO P A.
PA (MACE/) MACEJACK D.
XX
XX Blatt L, Mcswiggen J, Roberts E, Pavco PA, Macejack D;
PI WPI; 2004-031273/03.
XX
XX Enzymatic nucleic acid molecules which specifically cleave RNA derived
PT from hepatitis C virus (HCV), useful for the treatment of HCV infections,
PT especially in combination with type I interferon therapy.
XX
XX Claim 1; SEQ ID NO 632; 198pp; English.
XX
XX The invention relates to an enzymatic nucleic acid molecule which
CC specifically cleaves RNA derived from hepatitis C virus (HCV), in which
CC the binding arms of the enzymatic nucleic acid molecule comprises
CC sequences complementary to any of the defined substrate sequences given
CC in the specification. The nucleic acid molecule may be administered for
CC the treatment of HCV infections, especially in combination with type I
CC interferons. The present sequence represents a HCV DNazyme substrate
CC sequence.
XX
XX Sequence 17 BP; 2 A; 1 C; 7 G; 1 T; 6 U; 0 Other;
SQ
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 1.9e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1400 TGTCGATGTTGCTTTTG 1416
DB :|||:|||:|
1 UGUGGAUGATGCUUG 17
```

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCGAGTCTCT 109  
DB 17 GAGAGAGGCCAGTCTCT 1

RESULT 376  
ACN71759  
ID ACN71759 standard; DNA; 17 BP.  
XX AC ACN71759;  
XX 02-DEC-2004 (first entry)  
DT Human GDMPLP-1 probe SEQ ID NO:8661.  
DE  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX Homo sapiens.  
OS  
XX US2004137589-A1.  
PN  
XX 15-JUL-2004.  
PD  
XX 26-NOV-2003; 2003US-00723361.  
PF  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001WO-US000670.  
PR 25-MAY-2001; 2001US-00866108.  
XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PI (PENN/) PENN S G.  
XX (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
XX (SHAN/) SHANNON M E.  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
DR  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
XX associated with decreased expression or activity of human genome-derived  
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
XX function.  
XX Disclosure; SEQ ID NO 8661; Opp; English.  
PS The invention relates to a novel polypeptide (I) comprising a sequence  
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1); 95% deviation from (S1) which are conservative substitutions, and  
CC (S1); 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A

RESULT 375  
ACN64993/c  
ID ACN64993 standard; DNA; 17 BP.  
XX AC ACN64993;  
XX 02-DEC-2004 (first entry)  
DT Human GDMPLP-1 probe SEQ ID NO:1895.  
DE  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX Homo sapiens.  
OS  
XX US2004137589-A1.  
PN  
XX 15-JUL-2004.  
PD  
XX 26-NOV-2003; 2003US-00723361.  
PF  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 05-FEB-2001; 2001WO-US000670.  
PR 25-MAY-2001; 2001US-00866108.  
XX (GUY/) GU Y.  
PA (JIY/) JI Y.  
PI (PENN/) PENN S G.  
XX (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
XX (SHAN/) SHANNON M E.  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
DR  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
XX associated with decreased expression or activity of human genome-derived  
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
XX function.  
XX Disclosure; SEQ ID NO 1895; Opp; English.  
PS The invention relates to a novel polypeptide (I) comprising a sequence  
XX (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1); 95% deviation from (S1) which are conservative substitutions, and  
CC (S1); 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as a agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63102  
XX  
SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 U; 0 Other;

CC	pharmaceutical composition of the invention is useful for treating or	PS	Disclosure; SEQ ID NO 9687; Opp; English.
CC	preventing a disorder associated with decreased expression or activity of	XX	
CC	hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.	CC	The invention relates to a novel polypeptide (I) comprising a sequence
CC	The present sequence represents a 17-mer nucleotide, used in the	CC	(S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
CC	invention for scanning the sequence represented in ACN63103	CC	defined in the specification, a fragment of at least 8 amino acids of
XX		CC	(S1), 95% deviation from (S1) which are conservative substitutions, and
SQ	Sequence 17 BP; 7 A; 2 C; 7 G; 1 T; 0 U; 0 Other;	CC	65% identity to (S1). A polypeptide of the invention acts as an agonist or
		CC	antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
Query Match	0.8%; Score 13.8; DB 1; Length 17;	CC	pharmaceutical composition of the invention is useful for treating or
Best Local Similarity	88.2%; Pred. No. 1.9e+02;	CC	preventing a disorder associated with decreased expression or activity of
Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;	CC	hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
OY	268 TAGAAGACCCCAAGAAG 284	CC	The present sequence represents a 17-mer nucleotide, used in the
Db	1 TGGAGGAGCCCAAGAAG 17	CC	invention for scanning the sequence represented in ACN63103
		XX	
RESULT 377		SQ	Sequence 17 BP; 3 A; 7 C; 4 G; 3 T; 0 U; 0 Other;
ACN72785/c			
ID	ACN72785 standard; DNA; 17 BP.	Query Match	0.8%; Score 13.8; DB 1; Length 17;
XX		Best Local Similarity	88.2%; Pred. No. 1.9e+02;
AC	ACN72785;	Matches	15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX		OY	93 GAGAGTGGCGAGGTCCT 109
DT	02-DEC-2004 (first entry)	Db	
XX			17 GAGAGTGGCGCAGTCCT 1
DE	Human GDMLP-1 probe SEQ ID NO:9687.		
XX		RESULT 378	
XX	Human, ss; probe; myosin-like protein-1; hGDMLP-1;	ACN72787/c	
KW	hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;	ID	ACN72787 standard; DNA; 17 BP.
KW	skeletal muscle function.	XX	
OS	Homo sapiens.	AC	ACN72787;
XX		XX	
PN	US2004137589-A1.	DT	02-DEC-2004 (first entry)
XX		XX	
PD	15-JUL-2004.	DE	Human GDMLP-1 probe SEQ ID NO:9689.
XX		XX	
PF	26-NOV-2003; 2003US-00723361.	XX	Human, ss; probe; myosin-like protein-1; hGDMLP-1;
XX		KW	hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
PR	26-MAY-2000; 2000US-0207456P.	KW	skeletal muscle function.
PR	21-SEP-2000; 2000US-0234687P.	XX	
PR	27-SEP-2000; 2000US-0236359P.	OS	Homo sapiens.
PR	04-OCT-2000; 2000GB-00024263.	XX	
PR	30-JAN-2001; 2001WO-US000661.	XX	US2004137589-A1.
PR	30-JAN-2001; 2001WO-US000662.	PD	15-JUL-2004.
PR	30-JAN-2001; 2001WO-US000663.	XX	
PR	30-JAN-2001; 2001WO-US000664.	XX	26-NOV-2003; 2003US-00723361.
PR	30-JAN-2001; 2001WO-US000665.	XX	
PR	30-JAN-2001; 2001WO-US000666.	XX	26-MAY-2000; 2000US-0207456P.
PR	30-JAN-2001; 2001WO-US000667.	PR	21-SEP-2000; 2000US-0234687P.
PR	30-JAN-2001; 2001WO-US000668.	PR	27-SEP-2000; 2000US-0236359P.
PR	30-JAN-2001; 2001WO-US000669.	PR	04-OCT-2000; 2000GB-00024263.
PR	30-JAN-2001; 2001WO-US000670.	PR	30-JAN-2001; 2001WO-US000661.
PR	05-FEB-2001; 2001US-0266860P.	PR	30-JAN-2001; 2001WO-US000662.
PR	25-MAY-2001; 2001US-00866108.	PR	30-JAN-2001; 2001WO-US000663.
XX		PR	30-JAN-2001; 2001WO-US000664.
PA	(GUY/) GU Y.	PR	30-JAN-2001; 2001WO-US000665.
PA	(JIY/) JI Y.	PR	30-JAN-2001; 2001WO-US000666.
PA	(PENN/) PENN S G.	PR	30-JAN-2001; 2001WO-US000667.
PA	(HANZ/) HANZEL D K.	PR	30-JAN-2001; 2001WO-US000668.
PA	(RANK/) RANK D.	PR	30-JAN-2001; 2001WO-US000669.
PA	(CHEN/) CHEN W.	PR	30-JAN-2001; 2001WO-US000670.
PA	(SHAN/) SHANNON M E.	PR	05-FEB-2001; 2001US-0266860P.
XX		PR	25-MAY-2001; 2001US-00866108.
XX		XX	
PI	Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;	XX	(GUY/) GU Y.
XX		PA	(JIY/) JI Y.
XX		PA	(PENN/) PENN S G.
DR	WPI; 2004-533378/51.	PA	(HANZ/) HANZEL D K.
XX		PA	(RANK/) RANK D.
XX		PA	(CHEN/) CHEN W.
PT	Novel myosin-like protein-1, useful for treating or preventing disorder	PA	(SHAN/) SHANNON M E.
PT	associated with decreased expression or activity of human genome-derived	XX	
PT	myosin-like protein-1 such as disorder of heart and/or skeletal muscle	XX	
PT	function.	XX	
XX		XX	

XX  
DR WPI; 2004-533378/51.  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
XX Disclosure; SEQ ID NO 9689; Opp; English.  
XX  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 91 GGGAGAGTGGCGAGGTC 107  
|||||||  
DB 17 GGGAGAGTGGCGCAGTC 1  
RESULT 379  
ACN71758  
ID ACN71758 standard; DNA; 17 BP.  
XX  
AC ACN71758;  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMPLP-1 probe SEQ ID NO:8660.  
XX  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
XX Homo sapiens.  
XX US2004137589-A1.  
XX 15-JUL-2004.  
XX 26-NOV-2003; 2003US-00723361.  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 25-MAY-2001; 2001US-00866108.  
XX (GUY/) GU Y.

PA (JIYX/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
XX WPI; 2004-533378/51.  
DR  
XX Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
XX Disclosure; SEQ ID NO 8660; Opp; English.  
XX  
XX The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 7 A; 3 C; 6 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 267 CTAGAAGAAGCCCAAGAA 283  
|||||||  
DB 1 CTGGAGAGCCCAAGAA 17  
RESULT 380  
ACN71761  
ID ACN71761 standard; DNA; 17 BP.  
XX  
AC ACN71761;  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMPLP-1 probe SEQ ID NO:8663.  
XX  
XX Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
XX Homo sapiens.  
XX US2004137589-A1.  
XX 15-JUL-2004.  
XX 26-NOV-2003; 2003US-00723361.  
XX 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.

```
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0268860P.
PR 25-MAY-2001; 2001US-00866108.
XX
PA (GUY/) GU Y.
PA (JIY/) JI Y.
PA (PENN/) PENN S G.
PA (HANZ/) HANZEL D K.
PA (RANK/) RANK D.
PA (CHEN/) CHEN W.
PA (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 8663; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 9% deviation from (SI) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as an agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63103
XX
XX Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 270 GAAGAGCCCAAGAGAA 286
DB 1 GAGAGAGCCCAAGAGGA 17
XX
XX RESULT 381
XX ACN65741/C
XX ID ACN65741 standard; DNA; 17 BP.
XX
XX ACN65741;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMLP-1 probe SEQ ID NO:2643.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
XX US2004137589-A1.
XX
XX 15-JUL-2004.
XX
XX 26-NOV-2003; 2003US-00723361.
XX
XX 26-MAY-2000; 2000US-0207456P.
XX
XX 21-SEP-2000; 2000US-0234687P.
XX
PR 27-SEP-2000; 2000US-0236359P.
PR 04-OCT-2000; 2000GB-00024263.
PR 30-JAN-2001; 2001WO-US000661.
PR 30-JAN-2001; 2001WO-US000662.
PR 30-JAN-2001; 2001WO-US000663.
PR 30-JAN-2001; 2001WO-US000664.
PR 30-JAN-2001; 2001WO-US000665.
PR 30-JAN-2001; 2001WO-US000666.
PR 30-JAN-2001; 2001WO-US000667.
PR 30-JAN-2001; 2001WO-US000668.
PR 30-JAN-2001; 2001WO-US000669.
PR 30-JAN-2001; 2001WO-US000670.
PR 05-FEB-2001; 2001US-0268860P.
PR 25-MAY-2001; 2001US-00866108.
XX
XX (GUY/) GU Y.
XX (JIY/) JI Y.
XX (PENN/) PENN S G.
XX (HANZ/) HANZEL D K.
XX (RANK/) RANK D.
XX (CHEN/) CHEN W.
XX (SHAN/) SHANNON M E.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;
XX
XX WPI; 2004-533378/51.
XX
XX Novel myosin-like protein-1, useful for treating or preventing disorder
XX associated with decreased expression or activity of human genome-derived
XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle
XX function.
XX
XX Disclosure; SEQ ID NO 2643; Opp; English.
XX
XX The invention relates to a novel polypeptide (I) comprising a sequence
XX (S1) of myosin-like protein-1 (hGDMLP-1) having 2568 amino acids fully
XX defined in the specification, a fragment of at least 8 amino acids of
XX (S1), 9% deviation from (SI) which are conservative substitutions, and
XX 65% identity to (S1). A polypeptide of the invention acts as a agonist or
XX antagonist of hGDMLP-1, or as an inhibitor of hGDMLP-1 activity. A
XX pharmaceutical composition of the invention is useful for treating or
XX preventing a disorder associated with decreased expression or activity of
XX hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.
XX The present sequence represents a 17-mer nucleotide, used in the
XX invention for scanning the sequence represented in ACN63102
XX
XX Sequence 17 BP; 1 A; 4 C; 8 G; 4 T; 0 U; 0 Other;
XX
XX Query Match 0.8%; Score 13.8; DB 1; Length 17;
XX Best Local Similarity 88.2%; Pred. No. 1.9e+02;
XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 845 CTTCCAGCACCCGCCAA 861
DB 17 CTGCCAGGACCCGCCAA 1
XX
XX RESULT 382
XX ACN70453
XX ID ACN70453 standard; DNA; 17 BP.
XX
XX ACN70453;
XX
XX 02-DEC-2004 (first entry)
XX
XX Human GDMLP-1 probe SEQ ID NO:7355.
XX
XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;
XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;
XX skeletal muscle function.
XX
XX Homo sapiens.
XX
```





RESULT 384  
ACN71762  
ID ACN71762 standard; DNA; 17 BP.  
XX  
AC ACN71762;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:8664.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUYV/) GU Y.  
PA (JIYV/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANKZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
DR WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 8664; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or  
CC preventing a disorder associated with decreased expression or activity of  
CC hGDMPLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103  
XX  
SQ Sequence 17 BP; 8 A; 2 C; 7 G; 0 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
Qy 271 AAGAAGCCCAAGAGAG 287  
Db 1 AGGAGCCCAAGAGAG 17  
RESULT 385  
ACN71666  
ID ACN71666 standard; DNA; 17 BP.  
XX  
AC ACN71666;  
XX  
DT 02-DEC-2004 (first entry)  
XX  
DE Human GDMLP-1 probe SEQ ID NO:8568.  
XX  
KW Human; ss; probe; myosin-like protein-1; hGDMPLP-1;  
KW hGDMPLP-1 agonist hGDMPLP antagonist; hGDMPLP inhibitor; heart disorder;  
KW skeletal muscle function.  
XX  
OS Homo sapiens.  
XX  
PN US2004137589-A1.  
XX  
PD 15-JUL-2004.  
XX  
PF 26-NOV-2003; 2003US-00723361.  
XX  
PR 26-MAY-2000; 2000US-0207456P.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
PR 30-JAN-2001; 2001WO-US000661.  
PR 30-JAN-2001; 2001WO-US000662.  
PR 30-JAN-2001; 2001WO-US000663.  
PR 30-JAN-2001; 2001WO-US000664.  
PR 30-JAN-2001; 2001WO-US000665.  
PR 30-JAN-2001; 2001WO-US000666.  
PR 30-JAN-2001; 2001WO-US000667.  
PR 30-JAN-2001; 2001WO-US000668.  
PR 30-JAN-2001; 2001WO-US000669.  
PR 30-JAN-2001; 2001WO-US000670.  
PR 05-FEB-2001; 2001US-0266860P.  
PR 25-MAY-2001; 2001US-00866108.  
XX  
PA (GUYV/) GU Y.  
PA (JIYV/) JI Y.  
PA (PENN/) PENN S G.  
PA (HANKZ/) HANZEL D K.  
PA (RANK/) RANK D.  
PA (CHEN/) CHEN W.  
PA (SHAN/) SHANNON M E.  
XX  
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;  
DR WPI; 2004-533378/51.  
XX  
PT Novel myosin-like protein-1, useful for treating or preventing disorder  
PT associated with decreased expression or activity of human genome-derived  
PT myosin-like protein-1 such as disorder of heart and/or skeletal muscle  
PT function.  
XX  
PS Disclosure; SEQ ID NO 8568; Opp; English.  
XX  
CC The invention relates to a novel polypeptide (I) comprising a sequence  
CC (S1) of myosin-like protein-1 (hGDMPLP-1) having 2568 amino acids fully  
CC defined in the specification, a fragment of at least 8 amino acids of  
CC (S1), 95% deviation from (S1) which are conservative substitutions, and  
CC 65% identity to (S1). A polypeptide of the invention acts as an agonist or  
CC antagonist of hGDMPLP-1, or as an inhibitor of hGDMPLP-1 activity. A  
CC pharmaceutical composition of the invention is useful for treating or

CC preventing a disorder associated with decreased expression or activity of  
CC hGDMLP-1, such as a disorder of heart and/or skeletal muscle function.  
CC The present sequence represents a 17-mer nucleotide, used in the  
CC invention for scanning the sequence represented in ACN63103

SQ Sequence 17 BP; 6 A; 2 C; 6 G; 3 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 1.9e+02;

Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 292 AGGATGCCCTAAATGAG 308

Db 1 AGGATGACCTGAATGAG 17

RESULT 386

ACN72786/C

ID ACN72786 standard; DNA; 17 BP.

XX AC

XX AC

XX AC

DT 02-DEC-2004 (first entry)

XX Human GDMLP-1 probe SEQ ID NO:9688.

XX Human; ss; probe; myosin-like protein-1; hGDMLP-1;

XX hGDMLP-1 agonist hGDMLP antagonist; hGDMLP inhibitor; heart disorder;

XX skeletal muscle function.

XX Homo sapiens.

XX US2004137589-A1.

XX 15-JUL-2004.

XX 26-NOV-2003; 2003US-00723361.

XX 26-MAY-2000; 2000US-0207456P.

XX 21-SEP-2000; 2000US-0234687P.

XX 27-SEP-2000; 2000US-0236359P.

XX 04-OCT-2000; 2000GB-00024263.

XX 30-JAN-2001; 2001WO-US000661.

XX 30-JAN-2001; 2001WO-US000662.

XX 30-JAN-2001; 2001WO-US000663.

XX 30-JAN-2001; 2001WO-US000664.

XX 30-JAN-2001; 2001WO-US000665.

XX 30-JAN-2001; 2001WO-US000666.

XX 30-JAN-2001; 2001WO-US000667.

XX 30-JAN-2001; 2001WO-US000668.

XX 30-JAN-2001; 2001WO-US000669.

XX 05-FEB-2001; 2001WO-US000670.

XX 25-MAY-2001; 2001US-0266860P.

XX (GUY/) GU Y.

XX (JIY/) JI Y.

XX (PENN/) PENN S G.

XX (HANZ/) HANZEL D K.

XX (RANK/) RANK D.

XX (CHEN/) CHEN W.

XX (SHAN/) SHANNON M E.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank D, Chen W, Shannon ME;

XX WPI; 2004-533378/51.

XX Novel myosin-like protein-1, useful for treating or preventing disorder

XX associated with decreased expression or activity of human genome-derived

XX myosin-like protein-1 such as disorder of heart and/or skeletal muscle

XX function.

XX Disclosure; SEQ ID NO 9688; Opp; English.

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC drugs to treat diseases related to PER1 activity. (I) is useful for  
CC therapeutic purposes. A recombinant non-human organism transformed or  
CC transfected with (I) can be used for studying expression of the PER1  
CC isogenes in vivo, for in vivo screening and testing of drugs targeted  
CC against PER1 protein, and for testing the efficacy of therapeutic agents  
CC and compounds for disorders associated with circadian rhythm regulation.  
CC The present sequence represents an allele specific oligonucleotide primer  
CC for human PER1, which is used in the exemplification of the present  
CC invention  
XX  
SQ Sequence 15 BP; 1 A; 3 C; 8 G; 2 T; 0 U; 1 Other;  
Query Match 0.8%; Score 13.6; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.3e+02;  
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1500 CCAGGCCCGCCT 1513  
DB 14 YCAGGCCCGCCT 1  
RESULT 388  
AAS95535  
ID AAS95535 standard; DNA; 15 BP.  
XX  
AC AAS95535;  
XX  
DT 14-FEB-2002 (first entry)  
XX  
DE Human IL8RB gene allele-specific oligonucleotide probe #11.  
XX  
KW Human; interleukin 8 receptor beta; IL8RB; ss; antiinflammatory; probe;  
KW haplotyping; haplotype pair; single nucleotide polymorphism; genotyping;  
KW gene therapy; drug screening; chronic obstructive pulmonary disease;  
KW inflammatory disease; sequencing primer; PCR primer.  
XX  
OS Homo sapiens.  
XX  
PN WO200179221-A2.  
XX  
PD 25-OCT-2001.  
XX  
PF 12-APR-2001; 2001WO-US011942.  
XX  
PR 12-APR-2000; 2000US-0196734P.  
XX  
PA (GENA-) GENAISSANCE PHARM INC.  
XX  
PI Bentivegna SC, Chew A, Choi JY, Denton RR, Nandabalan K;  
XX  
DR WPI; 2002-055250/07.  
XX  
PT New polymorphic variants comprising interleukin-8 receptor beta (IL8RB)  
PT isogene, useful in expressing IL8RB protein for use in screening for  
PT candidate drugs to treat diseases related to IL8RB activity, e.g.  
PT inflammatory disorders.  
PS  
PS Claim 16; Page 13; 74pp; English.  
XX  
XX The invention relates to single nucleotide polymorphisms in the human  
XX interleukin 8 receptor beta (IL8RB) gene. A method for haplotyping the  
XX IL8RB gene in an individual comprises identifying the nucleotide at one  
XX or more polymorphic sites and determining whether one of the copies of  
XX the gene is defined by one of the IL8RB haplotypes given in the  
XX specification or whether both copies are defined by a haplotype pair.  
XX This method is useful in genotyping, whereby all possible haplotype pairs  
XX can be assigned to specific genotypes. An association between a trait and  
XX a haplotype or haplotype pair of the IL8RB gene can be identified by  
XX comparing the frequency of the haplotype or haplotype pair in a  
XX population exhibiting the trait with the frequency of the haplotype or  
XX haplotype pair in a reference population, where a higher haplotype  
XX frequency in the trait population indicates the trait is associated with  
XX the haplotype or haplotype pair. IL8RB and its corresponding DNA are used

CC for studying the expression and function of IL8RB, for use in screening  
CC for candidate drugs to treat diseases related to IL8RB activity, such as  
CC chronic obstructive pulmonary disease and other inflammatory disorders.  
CC The sequences are also useful for studying the effect of variation on the  
CC biological activity of IL8RB as well as on the binding affinity of  
CC candidate drugs targeting IL8RB. Sequences AAS95525-AAS95579 represent  
CC allele-specific oligonucleotide probes, sequencing primers and PCR  
CC primers used to detect IL8RB gene polymorphisms  
XX  
SQ Sequence 15 BP; 5 A; 4 C; 4 G; 1 T; 0 U; 1 Other;  
Query Match 0.8%; Score 13.6; DB 1; Length 15;  
Best Local Similarity 92.9%; Pred. No. 1.3e+02;  
Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;  
QY 197 CAACGGGGTGAAC 210  
DB 1 CAACGGGGTGAAC 14  
RESULT 389  
AAT54903  
ID AAT54903 standard; RNA; 15 BP.  
XX  
AC AAT54903;  
XX  
DT 25-MAR-2003 (revised)  
DT 07-APR-1997 (first entry)  
XX  
DE Mouse relA hammerhead ribozyme target sequence (nt. position 1250).  
XX  
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;  
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;  
KW intercellular adhesion molecule; rel A; tumour necrosis factor;  
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;  
KW translocation; chronic myelogenous leukaemia; CML; cancer;  
KW Philadelphia chromosome; inflammation; autoimmunity disease;  
KW atherosclerosis; myocardial infarction; stroke; restenosis;  
KW transplant rejection; rheumatoid arthritis; psoriasis;  
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;  
KW human immunodeficiency virus; acquired immune deficiency syndrome; AIDS;  
ss.  
XX  
OS Mus musculus.  
XX  
PN WO9523225-A2.  
XX  
PD 31-AUG-1995.  
XX  
PF 23-FEB-1995; 95WO-IB000156.  
XX  
XX 23-FEB-1994; 94US-00201109.  
XX 29-MAR-1994; 94US-00218934.  
PR 04-APR-1994; 94US-00222795.  
PR 07-APR-1994; 94US-00224483.  
PR 15-APR-1994; 94US-00227958.  
PR 15-APR-1994; 94US-00228041.  
PR 18-MAY-1994; 94US-00245736.  
PR 06-JUL-1994; 94US-00271280.  
PR 15-AUG-1994; 94US-00291932.  
PR 16-AUG-1994; 94US-00291433.  
PR 17-AUG-1994; 94US-00292620.  
PR 19-AUG-1994; 94US-00293520.  
PR 02-SEP-1994; 94US-00300000.  
PR 08-SEP-1994; 94US-00303039.  
PR 23-SEP-1994; 94US-00311486.  
PR 23-SEP-1994; 94US-00311749.  
PR 28-SEP-1994; 94US-00314397.  
PR 03-OCT-1994; 94US-00316771.  
PR 07-OCT-1994; 94US-00319492.  
PR 11-OCT-1994; 94US-00321993.  
PR 04-NOV-1994; 94US-00334847.  
PR 10-NOV-1994; 94US-00337608.

```
PR 28-NOV-1994; 94US-00345516.
PR 16-DEC-1994; 94US-00357577.
PR 23-DEC-1994; 94US-00363233.
PR 30-JAN-1995; 95US-00380734.
XX (RIBO-) RIBOZYME PHARM INC.
PA Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
XX Grimm S, Karpeisky A, Kisich K, Matulic-Adamic J, Mcswiggen JA;
PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D, Thompson JD;
PI Tracz D, Usman N, Wincott PE, Woolf T;
XX WPI; 1995-351090/45.
DR Ribozymes having modified bases and methods for producing them - for use
XX in inhibiting disease related genes.
XX Claim 2; Page 226; 407pp; English.
XX The present sequence represents a preferred target sequence for an
CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves rRNA at the
CC nucleotide base position indicated in the DE line. The rRNA gene product
CC is a subunit of the transcriptional regulator NF-kappaB and is implicated
CC specifically in the induction of inflammatory responses. Regions of the
CC mRNA that do not form secondary folding structures and that contain
CC potential hammerhead and hairpin ribozyme cleavage sites were identified
CC by computer analysis. Ribozymes directed against these mRNA sequences
CC were designed and synthesised with modifications that improve their
CC nuclease resistance. The ribozymes are designed to cleave the target
CC sequences and thereby inhibit rRNA expression, making them potentially
CC useful for treating rheumatoid arthritis, restenosis and asthma as well
CC as for increasing tolerance to transplanted tissues. The potential
CC immunosuppressive properties of a ribozyme that cleaves rRNA means
CC that uses are limited to local delivery, acute indications or ex vivo
CC treatment. (Updated on 25-MAR-2003 to correct PI field.)
XX SQ Sequence 15 BP; 2 A; 8 C; 3 G; 0 T; 2 U; 0 Other;
SQ Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.4e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
QY 1507 CCAGCCTCCAGGCC 1521
DB 1 CCAGCCUCCAGGCUC 15
RESULT 390
AAV31969/c
ID AAV31969 standard; DNA; 15 BP.
XX AC AAV31969;
XX 21-AUG-1998 (first entry)
XX Peptide nucleic acid probe 112.
XX Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;
XX ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.
XX Synthetic.
XX Mycobacterium sp.
XX Key Location/Qualifiers
XX modified_base 1..15
XX /tag= a
XX /note= "This sequence contains a polyamide backbone
XX instead of a deoxyribose backbone"
XX WO9815648-A1.
XX 16-APR-1998.
XX Stender H, Lund K, Mollerup TA;
XX
```

```
PF 03-OCT-1997; 97WO-DK000425.
XX 04-OCT-1996; 96DK-00001096.
PR 18-OCT-1996; 96DK-00001156.
PR 05-MAY-1997; 97DK-00000512.
XX (DAKO-) DAKO AS.
XX Stender H, Lund K, Mollerup TA;
XX WPI; 1998-240831/21.
XX Peptide nucleic acid probes for detection of ribosomal nucleic acid of
XX mycobacteria - allow differentiation between species of tuberculosis
XX complex and others and can penetrate cell membranes without pretreatment.
XX Claim 22; Page 67; 106pp; English.
XX This is the nucleotide sequence of the peptide nucleic acid (PNA) probe
XX used in the method of the invention, to detect ribosomal nucleic acid of
XX mycobacteria. The probes are used, in situ or in vitro, for detection of
XX the Mycobacterium tuberculosis complex (MTC), specifically M.
XX tuberculosis, and especially in sputum samples, but also in other body
XX fluids, biopsy specimens, foods, soil, air and water. Particularly, they
XX are used to diagnose, stage or monitor infection, or for identification
XX of drug-resistant strains (which generally have mutations in rRNA)
XX SQ Sequence 15 BP; 2 A; 3 C; 1 G; 9 T; 0 U; 0 Other;
SQ Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 177 AAGGAATTCAAAAT 191
DB 15 AAGGAATTCAAAAT 1
RESULT 391
AAV31970/c
ID AAV31970 standard; DNA; 15 BP.
XX AC AAV31970;
XX 21-AUG-1998 (first entry)
XX Peptide nucleic acid probe 113.
XX Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;
XX ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.
XX Synthetic.
XX Mycobacterium sp.
XX Key Location/Qualifiers
XX modified_base 1..15
XX /tag= a
XX /note= "This sequence contains a polyamide backbone
XX instead of a deoxyribose backbone"
XX WO9815648-A1.
XX 16-APR-1998.
XX 03-OCT-1997; 97WO-DK000425.
XX 04-OCT-1996; 96DK-00001096.
PR 18-OCT-1996; 96DK-00001156.
PR 05-MAY-1997; 97DK-00000512.
XX (DAKO-) DAKO AS.
XX Stender H, Lund K, Mollerup TA;
XX
```

XX This is the nucleotide sequence of the peptide nucleic acid (PNA) probe  
CC used in the method of the invention, to detect ribosomal nucleic acid of  
CC mycobacteria. The probes are used, in situ or in vitro, for detection of  
CC the Mycobacterium tuberculosis complex (MTC), specifically M.  
CC tuberculosis, and especially in sputum samples, but also in other body  
CC fluids, biopsy specimens, foods, soil, air and water. Particularly, they  
CC are used to diagnose, stage or monitor infection, or for identification  
CC of drug-resistant strains (which generally have mutations in rRNA)  
XX  
SQ Sequence 15 BP; 2 A; 2 C; 2 G; 9 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 177 AAGGAAATTCAAAAT 191  
DB 15 AAGGAAATTCAAAAT 1  
RESULT 393  
AAV31967/C  
ID AAV31967 standard; DNA; 15 BP.  
XX  
AC AAV31967;  
XX  
DT 21-AUG-1998 (first entry)  
XX  
DE Peptide nucleic acid probe 110.  
XX  
KW Peptide nucleic acid; PNA; probe; hybridisation; mycobacteria;  
KW ribosomal nucleic acid; rRNA; drug-resistant strain; mutation; ss.  
XX  
OS Synthetic.  
OS Mycobacterium sp.  
XX  
PH Key Location/Qualifiers  
FT modified\_base 1..15  
FT /\*tag= a  
FT /note= "This sequence contains a polyamide backbone  
FT instead of a deoxyribose backbone"  
XX  
PN WO9815648-A1.  
XX  
PD 16-APR-1998.  
XX  
XX 03-OCT-1997; 97WO-DK000425.  
XX  
XX 04-OCT-1996; 96DK-00001096.  
XX  
XX 18-OCT-1996; 96DK-00001156.  
XX  
XX 05-MAY-1997; 97DK-00000512.  
XX  
XX (DAKO-) DAKO AS.  
XX  
XX Stender H, Lund K, Mollerup TA;  
XX  
XX WPI; 1998-240831/21.  
XX  
XX Peptide nucleic acid probes for detection of ribosomal nucleic acid of  
XX mycobacteria - allow differentiation between species of tuberculosis  
XX complex and others and can penetrate cell membranes without pretreatment.  
XX  
XX Claim 22; Page 67; 106pp; English.

XX This is the nucleotide sequence of the peptide nucleic acid (PNA) probe  
CC used in the method of the invention, to detect ribosomal nucleic acid of  
CC mycobacteria. The probes are used, in situ or in vitro, for detection of  
CC the Mycobacterium tuberculosis complex (MTC), specifically M.  
CC tuberculosis, and especially in sputum samples, but also in other body  
CC fluids, biopsy specimens, foods, soil, air and water. Particularly, they  
CC are used to diagnose, stage or monitor infection, or for identification  
CC of drug-resistant strains (which generally have mutations in rRNA)  
XX  
SQ Sequence 15 BP; 2 A; 2 C; 2 G; 9 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 177 AAGGAAATTCAAAAT 191  
DB 15 AAGGAAATTCAAAAT 1  
RESULT 393  
AAV31967/C  
ID AAV31967 standard; DNA; 15 BP.  
XX  
AC AAV31967;  
XX  
DT 21-MAY-1999 (first entry)  
XX  
DE Tag sequence of a transcript increased in colorectal cancer.  
XX  
KW Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;  
KW diagnosis; prognosis; treatment; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO9853319-A2.  
XX  
PD 26-NOV-1998.  
XX  
PF 20-MAY-1998; 98WO-US010277.  
XX  
PR 21-MAY-1997; 97US-0047352P.  
XX  
PA (UYJO ) UNIV JOHNS HOPKINS.  
XX  
PI Vogelstein B, Kinzler KW;  
XX  
DR WPI; 1999-070161/06.  
XX  
XX Use of isolated gene transcripts - useful for developing products for the  
XX diagnosis, prognosis and treatment of cancers, particularly colon and  
XX pancreatic cancer.  
XX  
XX Claim 2; Page 31; 120pp; English.  
XX  
XX AAX30947-31815 represent tag sequences of transcripts that are  
XX differentially expressed in colorectal cancer, in pancreatic cancer, or  
XX in both. The tag sequences can be used to identify genes by matching the  
XX tag to a gen data base member, or by using the tag sequences as probes to  
XX isolate unidentified genes from cDNA libraries. The tag sequences can  
XX also be used in a method for diagnosing colon or pancreatic cancer in a  
XX sample suspected of being neoplastic. The method comprises comparing the  
XX level of at least one transcript in a first sample of a tissue to a  
XX second sample, where the first sample is a colonic tissue suspected of  
XX being neoplastic and the second sample is a normal human colonic tissue.  
XX The transcript is identified by a tag selected from AAX30947-31815. The  
XX methods of the invention can be used in the diagnosis, prognosis and  
XX treatment of cancer  
XX  
SQ Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 15;  
Best Local Similarity 93.3%; Pred. No. 1.4e+02;

```
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 807 GCTCAGCAGGCCATG 821
Db 15 GCCCAGCAGGCCATG 1
RESULT 394
AAX31728/c
ID AAX31728 standard; DNA; 15 BP.
XX
XX
AC AAX31728;
XX
XX 21-MAY-1999 (first entry)
XX
XX Transcript tag sequence increased in pancreatic and colorectal cancer.
XX
XX Tag sequence; colorectal cancer; pancreatic cancer; colon cancer;
XX diagnosis; prognosis; treatment; ss.
XX
XX Homo sapiens.
XX
XX W09853319-A2.
XX
XX 26-NOV-1998.
XX
XX 20-MAY-1998; 98WO-US010277.
XX
XX 21-MAY-1997; 97US-0047352P.
XX
XX (UYJO ) UNIV JOHNS HOPKINS.
XX
XX Vogelstein B, Kinzler KW;
XX
XX WPI; 1999-070161/06.
XX
XX Use of isolated gene transcripts - useful for developing products for the
XX diagnosis, prognosis and treatment of cancers, particularly colon and
XX pancreatic cancer.
XX
XX Disclosure; Page 73; 120pp; English.
XX
XX AAX30947-31815 represent tag sequences of transcripts that are
XX differentially expressed in colorectal cancer, in pancreatic cancer, or
XX in both. The tag sequences can be used to identify genes by matching the
XX tag to a gen data base member, or by using the tag sequences as probes to
XX isolate unidentified genes from cDNA libraries. The tag sequences can
XX also be used in a method for diagnosing colon or pancreatic cancer in a
XX sample suspected of being neoplastic. The method comprises comparing the
XX level of at least one transcript in a first sample of a tissue to a
XX second sample, where the first sample is a colonic tissue suspected of
XX being neoplastic and the second sample is a normal human colonic tissue.
XX The transcript is identified by a tag selected from AAX30947-31815. The
XX methods of the invention can be used in the diagnosis, prognosis and
XX treatment of cancer
XX
XX Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 807 GCTCAGCAGGCCATG 821
Db 15 GCCCAGCAGGCCATG 1
RESULT 395
AAF50848
ID AAF50848 standard; DNA; 15 BP.
XX
XX AAF50848;
AC
XX
```

```
DT 30-MAR-2001 (first entry)
XX
XX IGF-I oligonucleotide #1808.
XX
XX Antisense therapy; antiproliferative; antiinflammatory; antiporiatic;
XX cytostatic; dermatological; cardiac; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrheas; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.
XX
XX Homo sapiens.
XX
XX W0200078341-A1.
XX
XX 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU000693.
XX
XX 21-JUN-1999; 99US-0140345P.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wraight CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by administering
XX UV (ultra-violet) treatment (optional) and an antisenese nucleic acid that
XX inhibits or reduces growth factor mediated cell proliferation and/or
XX inflammation.
XX
XX Example 8; Page 72; 201pp; English.
XX
XX The present invention relates to a method for ameliorating the effects of
XX skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and AAF45153-
XX F45161). The method is useful for ameliorating the effects of psoriasis,
XX ichthyosis, ptyriasis, ruba, pilaris, serborrheas, keloids, keratosis,
XX neoplasias, scleroderma, warts, benign growths, cancers of the skin, a
XX hyperneovascular condition such as a neovascular condition of the retina,
XX brain or skin, growth factor-mediated malignancies, other sclerotic
XX disease, kidney disease, hyperproliferation of the inside of blood
XX vessels or any other hyperplasia
XX
XX Sequence 15 BP; 4 A; 3 C; 6 G; 2 T; 0 U; 0 Other;
Query Match 0.8%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 532 TGCTGGAGACGACC 546
Db 1 TGCTGGAGACGACC 15
RESULT 396
ABK32682/c
ID ABK32682 standard; DNA; 15 BP.
XX
XX ABK32682;
XX
XX 23-APR-2002 (first entry)
XX
XX Human colorectal and pancreatic cancer SAGE tag #49.
XX
```

KW	Human; colon cancer; colorectal cancer; pancreatic cancer; SAGE tag;	XX	New human nucleic acid containing specific SAGE tags, useful as
KW	serial analysis of gene expression; diagnostic; prognostic; probe;	PT	diagnostic markers for cancer, also derived probes.
KW	cancer marker; ss.	XX	Disclosure; Col 25; 161pp; English.
OS	Homo sapiens.	PS	
XX	US6333152-B1.	XX	The invention relates to an isolated, purified human nucleic acid (I)
XX	25-DEC-2001.	CC	that has the same sequence as a mRNA found in humans and is a SAGE
PD		CC	(serial analysis of gene expression) tag comprising a single stranded
XX	20-MAY-1998; 98US-00081646.	CC	probe containing at least 10 consecutive nucleotides. SAGE tags, are
PF		CC	diagnostic and prognostic markers of cancer, especially of the colon and
XX	20-MAY-1998; 98US-00081646.	CC	pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer
PR		CC	SAGE tags of the invention
XX	(UYJO ) UNIV JOHNS HOPKINS.	XX	Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;
XX	Vogelstein B, Kinzler KW, Zhang L, Zhou W;	Query Match	0.8%; Score 13.4; DB 1; Length 15;
PI		Best Local Similarity	93.3%; Pred. No. 1.4e+02;
XX	WPI; 2002-153821/20.	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;	
DR			
XX	New human nucleic acid containing specific SAGE tags, useful as	QY	807 GCTCAGCAGGCCATG 821
PT	diagnostic markers for cancer, also derived probes.	DB	15 GCCCAGCAGGCCATG 1
XX	Disclosure; Col 87; 161pp; English.		
PS		RESULT 398	
XX	The invention relates to an isolated, purified human nucleic acid (I)	ABX01805	
CC	that has the same sequence as a mRNA found in humans and is a SAGE	ID	ABX01805 standard; RNA; 15 BP.
CC	(serial analysis of gene expression) tag comprising a single stranded	XX	ABX01805;
CC	probe containing at least 10 consecutive nucleotides. SAGE tags, are	AC	
CC	diagnostic and prognostic markers of cancer, especially of the colon and	XX	23-DEC-2002 (first entry)
CC	pancreas. ABK31900-ABK32770 represent human colon and pancreatic cancer	DT	
CC	SAGE tags of the invention	XX	Hepatitis C virus (HCV) ribozyme related RNA sequence #74.
XX	Sequence 15 BP; 1 A; 5 C; 6 G; 3 T; 0 U; 0 Other;	DE	
SQ		XX	Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;
		KW	HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;
		KW	liver failure; hepatocellular carcinoma; HCV infection; drug therapy;
		KW	type I interferon; interferon alpha; interferon beta; cytostatic; ss;
		KW	interferon gamma; consensus interferon; hepatotropic; antiinflammatory.
		XX	Unidentified.
		OS	
		XX	US2002082225-A1.
		PN	
		XX	27-JUN-2002.
		PD	
		XX	23-MAR-1999; 99US-00274553.
		PF	
		XX	23-MAR-1999; 99US-00274553.
		PR	
		XX	(BLAT/) BLATT L.
		PA	(MCSW/) MCSWIGGEN J A.
		PA	(ROBE/) ROBERTS B.
		PA	(PAVC/) PAVCO P A.
		PA	(MACE/) MACEJACK D.
		XX	Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;
		PI	
		XX	WPI; 2002-617759/66.
		XX	New ribozymes targeting RNA derived from hepatitis C virus inhibit viral
		PT	replication and are useful to treat hepatitis C virus infections and
		PT	cirrhosis, liver failure or hepatocellular carcinoma.
		XX	Disclosure; SEQ ID NO 1587; 80pp; English.
		PS	
		XX	The present invention relates to enzymatic nucleic acids which
		CC	specifically cleave RNA derived from Hepatitis C virus (HCV). The
		CC	enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin
		CC	(HP) motif where the binding arms comprise sequences complementary to one
		CC	of the substrate sequences defined in the specification. The HCV
		CC	ribozymes are useful for modulating the expression and/or replication of



CC HCV. They can be used to treat cirrhosis, liver failure and/or  
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating  
 CC a condition associated with HCV infection in conjunction with one or more  
 CC other drug therapies, particularly type I interferon, especially  
 CC interferon alpha, beta or gamma or consensus interferon. The present  
 CC sequence represents a RNA sequence of unknown function. Note: The present  
 CC sequence is given in the sequence data but is not mentioned elsewhere in  
 CC the specification. The complete sequence data for this patent was  
 CC obtained in electronic format directly from the USPTO web site at  
 CC seqdata.uspto.gov/psipdsIDEntry.html  
 XX  
 SQ Sequence 15 BP; 3 A; 8 C; 3 G; 0 T; 1 U; 0 Other;  
 Query Match 0.8%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. No. 1.4e+02;  
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 1509 AGCTCCAGGCCCC 1523  
 Db 1 AGCCUCCAGGCCCC 15  
 RESULT 399  
 ID ABX01804  
 AC ABX01804 standard; RNA; 15 BP.  
 AC ABX01804;  
 XX  
 DT 23-DEC-2002 (first entry)  
 XX  
 DE Hepatitis C virus (HCV) ribozyme related RNA sequence #73.  
 XX  
 KW Enzymatic nucleic acid; RNA cleavage; Hepatitis C virus infection;  
 KW HCV ribozyme; HCV expression; HCV replication; cirrhosis; virucide;  
 KW liver failure; hepatocellular carcinoma; HCV infection; drug therapy;  
 KW type I interferon; interferon alpha; interferon beta; cytostatic; ss;  
 KW interferon gamma; consensus interferon; hepatotropic; antiinflammatory.  
 XX  
 OS Unidentified.  
 XX  
 PN US2002082225-A1.  
 XX  
 PD 27-JUN-2002.  
 XX  
 PF 23-MAR-1999; 99US-00274553.  
 XX  
 PR 23-MAR-1999; 99US-00274553.  
 XX  
 PA (BLATT/) BLATT L.  
 PA (MCSW/) MCSWIGGEN J A.  
 PA (ROBE/) ROBERTS B.  
 PA (FAVC/) FAVCO P A.  
 PA (MACE/) MACEJACK D.  
 XX  
 PI Blatt L, Mcswiggen JA, Roberts B, Pavco PA, Macejack D;  
 XX  
 DR WPI; 2002-617759/66.  
 XX  
 PT New ribozymes targeting RNA derived from hepatitis C virus inhibit viral  
 PT replication and are useful to treat hepatitis C virus infections and  
 PT cirrhosis, liver failure or hepatocellular carcinoma.  
 XX  
 PS Disclosure; SEQ ID NO 1586; 80pp; English.  
 XX  
 CC The present invention relates to enzymatic nucleic acids which  
 CC specifically cleave RNA derived from Hepatitis C virus (HCV). The  
 CC enzymatic nucleic acid or ribozyme is in a hammerhead (HH) or hairpin  
 CC (HP) motif where the binding arms comprise sequences complementary to one  
 CC of the substrate sequences defined in the specification. The HCV  
 CC ribozymes are useful for modulating the expression and/or replication of  
 CC HCV. They can be used to treat cirrhosis, liver failure and/or  
 CC hepatocellular carcinoma. The HCV ribozymes are also useful for treating  
 CC a condition associated with HCV infection in conjunction with one or more

CC other drug therapies, particularly type I interferon, especially  
 CC interferon alpha, beta or gamma or consensus interferon. The present  
 CC sequence represents a RNA sequence of unknown function. Note: The present  
 CC sequence is given in the sequence data but is not mentioned elsewhere in  
 CC the specification. The complete sequence data for this patent was  
 CC obtained in electronic format directly from the USPTO web site at  
 CC seqdata.uspto.gov/psipdsIDEntry.html  
 XX  
 SQ Sequence 15 BP; 3 A; 8 C; 3 G; 0 T; 1 U; 0 Other;  
 Query Match 0.8%; Score 13.4; DB 1; Length 15;  
 Best Local Similarity 86.7%; Pred. No. 1.4e+02;  
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;  
 QY 1508 CAGCTCCAGGCCCC 1522  
 Db 1 CAGCCUCCAGGCCCC 15  
 RESULT 400  
 ID AAV70490  
 XX AAV70490 standard; DNA; 16 BP.  
 AC AAV70490;  
 XX  
 DT 08-APR-1999 (first entry)  
 XX  
 DE Sequence ID# 68 from patent specification WO9850403.  
 XX  
 KW Nucleic acid detection; nucleic acid characterisation; hybridisation;  
 KW infection; disease; cancer; forensic; paternity; multiplexing; ss.  
 XX  
 OS Unidentified.  
 XX  
 PN WO9850403-A1.  
 XX  
 PD 12-NOV-1998.  
 XX  
 PF 05-MAY-1998; 98WO-US003194.  
 XX  
 PR 05-MAY-1997; 97US-00851588.  
 PR 19-SEP-1997; 97US-00934097.  
 PR 03-MAR-1998; 98US-00034205.  
 XX  
 PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
 XX  
 PI Dong F, Lyamichiev VI, Prudent JR, Fors L, Neri BP, Brow MAD;  
 PI Anderson TA, Dahlberg JE;  
 XX  
 DR WPI; 1998-610317/51.  
 XX  
 PT Detection and characterisation of nucleic acid sequences - by mixing a  
 PT folded target and one or more probes to form a probe/folded target  
 PT complex and detecting and characterising the complexes.  
 XX  
 PS Disclosure; Page 180; 279pp; English.  
 XX  
 CC The invention relates to methods and compositions of detection and  
 CC characterisation of nucleic acid sequences and sequence changes. One  
 CC method of detection and characterisation comprises: (a) providing: (i) a  
 CC folded target having a DNA sequence comprising at least 1 double stranded  
 CC region and at least 1 single stranded region; and (ii) at least 1 probe  
 CC complementary to at least a portion of the folded target; and (b) mixing  
 CC the target and probes so that the probe hybridises to form a probe  
 CC /folded target complex. Also provided are methods for determination of  
 CC structure formation in nucleic acid targets; for analysing folded nucleic  
 CC acids targets; and for analysis of nucleic acid structures. The methods  
 CC can be used for the detection and characterisation of nucleic acid  
 CC sequences to detect the presence of pathogenic nucleic acid sequences  
 CC indicative of an infection, the presence of variants or alleles of  
 CC mammalian genes associated with disease and cancers, and the  
 CC identification of the source of nucleic acids found in forensic samples,  
 CC as well as in paternity determinations. The methods allow simultaneous

CC	analysis of both strands (e.g. the sense and antisense strands) and are	CC	as well as in paternity determinations. The methods allow simultaneous
CC	ideal for high-level multiplexing. The products produced are amenable to	CC	analysis of both strands (e.g. the sense and antisense strands) and are
CC	qualitative, quantitative and positional analysis. The methods may be	CC	ideal for high-level multiplexing. The products produced are amenable to
CC	performed in solution or in the solid phase (e.g. on a solid support).	CC	qualitative, quantitative and positional analysis. The methods may be
CC	The methods are powerful in that they allow for analysis of longer	CC	performed in solution or in the solid phase (e.g. on a solid support).
CC	fragments of nucleic acid than current methodologies. The present	CC	The methods are powerful in that they allow for analysis of longer
CC	sequence represents the sequence no:68 in the specification for which no	CC	fragments of nucleic acid than current methodologies. The present
CC	information is provided	CC	sequence represents the sequence no:67 in the specification for which no
XX		CC	information is provided
SQ	Sequence 16 BP; 3 A; 8 C; 4 G; 1 T; 0 U; 0 Other;	SQ	Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;
	Query Match 0.8%; Score 13.4; DB 1; Length 16;		Query Match 0.8%; Score 13.4; DB 1; Length 16;
	Best Local Similarity 93.3%; Pred. No. 1.7e+02;		Best Local Similarity 93.3%; Pred. No. 1.7e+02;
	Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;		Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY	1508 CAGCCTCCAGGCCCC 1522	QY	1508 CAGCCTCCAGGCCCC 1522
DB		DB	
	2 CAGCCTCCAGGCCCC 16		2 CAGCCTCCAGGCCCC 16
RESULT 401		RESULT 402	
AAV70489		AAV70489	
ID	AAV70489 standard; DNA; 16 BP.	ID	AAV70489 standard; DNA; 16 BP.
XX		XX	
AC	AAV70489;	AC	AAV70489;
XX		XX	
DT	08-APR-1999 (first entry)	DT	24-MAR-1999 (first entry)
XX		XX	
DE	Sequence ID# 67 from patent specification WO9850403.	DE	Triple helix third strand of dystrophin gene nucleotides 4480-4495.
XX		XX	
KW	Nucleic acid detection; nucleic acid characterisation; hybridisation;	KW	Triplex formation; DNA detection; triple helix; identification; bacteria;
XX	infection; disease; cancer; forensic; paternity; multiplexing; ss.	KW	oncogene; virus; ss.
OS	Unidentified.	OS	Synthetic.
XX		OS	Homo sapiens.
PN	WO9850403-A1.	XX	
XX		PN	US5861244-A.
PD	12-NOV-1998.	XX	
XX		PD	19-JAN-1999.
PF	05-MAY-1998; 98WO-US003194.	XX	
XX		PF	22-DEC-1993; 93US-00173489.
PR	05-MAY-1997; 97US-00851588.	PR	29-OCT-1992; 92US-00968436.
PR	19-SEP-1997; 97US-00934097.	XX	
PR	03-MAR-1998; 98US-00034205.	XX	
XX		XX	
PA	(THIR-) THIRD WAVE TECHNOLOGIES INC.	PA	(PROF-) PROFILE DIAGNOSTIC SCI INC.
XX		XX	
PI	Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;	PI	Hepburn AG, Wang C;
PI	Anderson TA, Dahlberg JE;	XX	
XX		XX	
DR	WPI; 1998-610317/51.	DR	WPI; 1999-130384/11.
XX		XX	
PT	Detection and characterisation of nucleic acid sequences - by mixing a	PT	Assay of genetic sequences based on triplex formation from double
PT	folded target and one or more probes to form a probe/folded target	PT	stranded analyte - and hybrid of anchor and reporter sequences, with
PT	complex and detecting and characterising the complexes.	PT	reporter released if triplex formation occurs, used e.g. to identify
XX		PT	bacteria.
XX		XX	
PS	Disclosure; Page 180; 279pp; English.	PS	Disclosure; Col 15-16; 168pp; English.
XX		XX	
CC	The invention relates to methods and compositions of detection and	XX	
CC	characterisation of nucleic acid sequences and sequence changes. One	CC	The present sequence represents a polynucleotide that is able to form a
CC	method of detection and characterisation comprises: (a) providing: (i) a	CC	triplex helix with a double stranded sequence. Cytosine bases in the
CC	folded target having a DNA sequence comprising at least 1 double stranded	CC	present can be replaced with 5-methylcytosine for increased triplex
CC	region and at least 1 single stranded region; and (ii) at least 1 probe	CC	stability. The present sequence is used in the assay of the invention,
CC	complementary to at least a portion of the folded target; and (b) mixing	CC	where it can be part of the anchor DNA or reporter DNA sequence. The
CC	the target and probes so that the probe hybridises to form a probe	CC	assay comprises adding a sample containing double-stranded DNA test
CC	/folded target complex. Also provided are methods for determination of	CC	sequences to an aqueous medium containing at least one complex of anchor
CC	structure formation in nucleic acid targets; for analysing folded nucleic	CC	DNA, attached to a solid support, and reporter DNA, where either a part
CC	acids targets; and for analysis of nucleic acid structures. The methods	CC	of the anchor DNA or reporter DNA is designed to form a triplex-strand
CC	can be used for the detection and characterisation of nucleic acid	CC	structure with part of the test sequence. Triplex formation results in
CC	sequences to detect the presence of pathogenic nucleic acid sequences	CC	displacement of the reporter DNA which is detected as an indication of
CC	indicative of an infection, the presence of variants or alleles of	CC	the presence of the DNA test sequence. The method is used to detect DNA
CC	mammalian genes associated with disease and cancers, and the	CC	sequences, particularly for identification of bacteria (by detecting
CC	identification of the source of nucleic acids found in forensic samples,	CC	genes for ribosomal RNA) in clinical samples, but also detection of
		CC	oncogenes and Hepatitis B virus

XX SQ Sequence 16 BP; 0 A; 4 C; 1 G; 11 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 271 AAGAAGCCAGAGA 285  
Db 15 AAGAAGCAAGAAGA 1

RESULT 403  
ABL46101  
ID ABL46101 standard; DNA; 16 BP.  
XX AC ABL46101;  
XX DT 26-APR-2002 (first entry)  
XX DE Hepatitis C virus PCR primer SEQ ID NO:68.  
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;  
KW characterisation; identification; nucleic acid structure; diagnosis;  
KW PCR primer; probe; ss.  
XX OS Hepatitis C virus.  
OS Synthetic.  
XX WO200198537-A2.  
XX PN 27-DEC-2001.  
XX PD 15-JUN-2001; 2001WO-US019401.  
XX PF 17-JUN-2000; 2000US-0212308P.  
XX PR 15-JUN-2001; 2001US-00212308.  
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX LYamichev V, Allawi H, Dong F, Neri BP, Vener IT;  
XX WPI; 2002-049698/06.  
XX DR Identifying oligonucleotides hybridizing to nucleic acids containing  
XX secondary structure, useful in clinical diagnosis, comprises identifying  
XX primers that interact with the target to form an extension product under  
XX amplification conditions.  
XX Example 8; Page 370; 409pp; English.  
XX The present invention describes a method for identifying oligonucleotides  
XX with desired hybridisation properties to nucleic acid targets containing  
XX secondary structure. The method comprises amplifying a target nucleic  
XX acid having at least one accessible and one inaccessible site. Primers  
XX that form an extension product are identified as the oligonucleotides  
XX which can interact with the folded target nucleic acid. Oligonucleotides  
XX from the present invention can be used in novel detection methods for  
XX clinical diagnostic purposes, including the detection and identification  
XX of pathogenic organisms (e.g. HIV). The method allows the ability to  
XX rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
XX sequences used in the exemplification of the present invention  
XX SQ Sequence 16 BP; 3 A; 8 C; 4 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1508 CAGCCTCCAGGACCC 1522  
Db 2 CAGCCTCCAGGACCC 16

RESULT 404  
ABL46100  
ID ABL46100 standard; DNA; 16 BP.  
XX AC ABL46100;  
XX DT 26-APR-2002 (first entry)  
XX DE Hepatitis C virus PCR primer SEQ ID NO:67.  
XX KW Nucleic acid accessible hybridisation site; detection; hybridisation;  
KW characterisation; identification; nucleic acid structure; diagnosis;  
KW PCR primer; probe; ss.  
XX OS Hepatitis C virus.  
OS Synthetic.  
XX WO200198537-A2.  
XX PN 27-DEC-2001.  
XX PD 15-JUN-2001; 2001WO-US019401.  
XX PF 17-JUN-2000; 2000US-0212308P.  
XX PR 15-JUN-2001; 2001US-00212308.  
XX PA (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX LYamichev V, Allawi H, Dong F, Neri BP, Vener IT;  
XX WPI; 2002-049698/06.  
XX DR Identifying oligonucleotides hybridizing to nucleic acids containing  
XX secondary structure, useful in clinical diagnosis, comprises identifying  
XX primers that interact with the target to form an extension product under  
XX amplification conditions.  
XX Example 8; Page 370; 409pp; English.  
XX The present invention describes a method for identifying oligonucleotides  
XX with desired hybridisation properties to nucleic acid targets containing  
XX secondary structure. The method comprises amplifying a target nucleic  
XX acid having at least one accessible and one inaccessible site. Primers  
XX that form an extension product are identified as the oligonucleotides  
XX which can interact with the folded target nucleic acid. Oligonucleotides  
XX from the present invention can be used in novel detection methods for  
XX clinical diagnostic purposes, including the detection and identification  
XX of pathogenic organisms (e.g. HIV). The method allows the ability to  
XX rapidly analyse nucleic acid structures. ABL46034 to ABL46367 represent  
XX sequences used in the exemplification of the present invention  
XX SQ Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 1508 CAGCCTCCAGGACCC 1522  
Db 2 CAGCCTCCAGGACCC 16

RESULT 405  
ADK82290  
ID ADK82290 standard; DNA; 16 BP.  
XX AC ADK82290;  
XX DT 03-JUN-2004 (first entry)  
XX DE Nucleic acid analysis method associated oligonucleotide seqid 67.  
XX

XX 18-JUL-2000; 2000US-00402618.  
XX 05-MAY-1997; 97US-00851588.  
XX 19-SEP-1997; 97US-00934097.  
XX 03-MAR-1998; 98US-00034205.  
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;  
XX Anderson TA, Dahlberg JE;  
XX WPI; 2004-256067/24.  
XX Analyzing nucleic acids, comprises mixing target nucleic acid such as  
XX hepatitis C virus nucleic acid, bridging oligonucleotide, second  
XX oligonucleotide and cleavage agent to form cleavage structure.  
XX Disclosure; SEQ ID NO 68; 143pp; English.  
XX The invention describes a method of analysing nucleic acids comprising  
XX providing a target nucleic acid, e.g. hepatitis C virus nucleic acid  
XX having non-contiguous single-stranded regions (NCSR) separated by an  
XX intervening region, a bridging oligonucleotide capable of binding to the  
XX first and second NCSR; a second oligonucleotide binding to a portion of  
XX the first NCSR and a cleavage agent, and mixing the contents to form a  
XX cleavage structure. The method is useful for analysing nucleic acids,  
XX e.g. hepatitis C virus nucleic acid useful for clinical diagnostic  
XX purposes and detection and identification of pathogenic microorganisms  
XX such as hepatitis C virus. This sequence represents an oligonucleotide  
XX associated with the nucleic acid analysis method of the invention.  
XX Sequence 16 BP; 3 A; 8 C; 4 G; 1 T; 0 U; 0 Other;  
XX Query Match 0.8%; Score 13.4; DB 1; Length 16;  
XX Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
Db |||||||||  
2 CAGCCTCCAGGCCCC 16  
RESULT 407  
ADM80152/C  
ID ADM80152 standard; DNA; 16 BP.  
XX  
XX ADM80152;  
XX  
XX 03-JUN-2004 (first entry)  
XX DE Linker peptide encoding DNA SEQ ID NO:11.  
XX ds; gene; in vitro diagnosis; virus-related disease; HIV-1; HIV-2;  
XX linker.  
XX Synthetic.  
XX Key Location/Qualifiers  
XX CDS 2..16  
FT /\*tag= a  
FT /partial  
FT /note= "No start/stop codon given"  
XX  
XX FR2844519-A1.  
XX  
XX 19-MAR-2004.  
XX  
XX 17-SEP-2002; 2002FR-00011485.  
XX  
XX 17-SEP-2002; 2002FR-00011485.  
XX (INMR ) BIO MERIEUX.  
XX

KW nucleic acid analysis; hepatitis C virus;  
KW non-contiguous single-stranded region; NCSR; cleavage structure;  
KW clinical; diagnostic; microorganism detection;  
KW microorganism identification; ss.  
XX Synthetic.  
OS  
XX US6709815-B1.  
PN  
XX 23-MAR-2004.  
PD  
XX 18-JUL-2000; 2000US-00402618.  
PF  
XX 05-MAY-1997; 97US-00851588.  
PR  
XX 19-SEP-1997; 97US-00934097.  
PR  
XX 03-MAR-1998; 98US-00034205.  
PR  
XX (THIR-) THIRD WAVE TECHNOLOGIES INC.  
XX  
XX Dong F, Lyamichev VI, Prudent JR, Fors L, Neri BP, Brow MAD;  
XX Anderson TA, Dahlberg JE;  
XX WPI; 2004-256067/24.  
XX Analyzing nucleic acids, comprises mixing target nucleic acid such as  
XX hepatitis C virus nucleic acid, bridging oligonucleotide, second  
XX oligonucleotide and cleavage agent to form cleavage structure.  
XX Disclosure; SEQ ID NO 67; 143pp; English.  
XX The invention describes a method of analysing nucleic acids comprising  
XX providing a target nucleic acid, e.g. hepatitis C virus nucleic acid  
XX having non-contiguous single-stranded regions (NCSR) separated by an  
XX intervening region, a bridging oligonucleotide capable of binding to the  
XX first and second NCSR; a second oligonucleotide binding to a portion of  
XX the first NCSR and a cleavage agent, and mixing the contents to form a  
XX cleavage structure. The method is useful for analysing nucleic acids,  
XX e.g. hepatitis C virus nucleic acid useful for clinical diagnostic  
XX purposes and detection and identification of pathogenic microorganisms  
XX such as hepatitis C virus. This sequence represents an oligonucleotide  
XX associated with the nucleic acid analysis method of the invention.  
XX Sequence 16 BP; 4 A; 8 C; 3 G; 1 T; 0 U; 0 Other;  
XX Query Match 0.8%; Score 13.4; DB 1; Length 16;  
XX Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1522  
Db |||||||||  
2 CAGCCTCCAGGCCCC 16  
RESULT 406  
ADK82291  
ID ADK82291 standard; DNA; 16 BP.  
XX  
XX ADK82291;  
XX  
XX 03-JUN-2004 (first entry)  
XX DE Nucleic acid analysis method associated oligonucleotide seqid 68.  
XX  
XX nucleic acid analysis; hepatitis C virus;  
XX non-contiguous single-stranded region; NCSR; cleavage structure;  
XX clinical; diagnostic; microorganism detection;  
XX microorganism identification; ss.  
XX Synthetic.  
OS  
XX US6709815-B1.  
PN  
XX 23-MAR-2004.  
PD

XX Letourneur O;  
XX WPI; 2004-259482/25.  
DR P-PSDB; ADM80153.  
XX  
PT New recombinant DNA encoding chimeric protein, useful for in vitro  
PT diagnosis of viral infections, comprises sequences encoding epitopic  
PT regions, a linker and a binding region.  
XX  
PS Claim 5; SEQ ID NO 11; 33pp; French.  
XX  
XX The invention relates to a novel recombinant DNA (I) encoding a  
CC recombinant chimeric protein (II). The protein consists of at least two  
CC nucleotide fragments, each encoding an epitopic region of at least one  
CC microorganism; at least one sequence encoding a linker, and at least one  
CC sequence encoding a binding region. The DNA and/or protein are used for  
CC in vitro diagnosis, especially of virus-related diseases, specifically  
CC HIV-1 or -2 infections. The protein is easy to purify and synthesize, and  
CC has strong immunoreactivity with sera from virus-infected subjects. The  
CC present sequence encodes a linker of the recombinant chimeric peptide of  
CC the invention.  
XX  
SQ Sequence 16 BP; 2 A; 5 C; 6 G; 3 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 476 CCTGAACCGAGCTC 490  
Db 15 CCTGAACCGAGCTC 1  
RESULT 408  
ADR32381  
ID ADR32381 standard; DNA; 16 BP.  
XX  
AC ADR32381;  
XX  
DT 04-NOV-2004 (first entry)  
XX  
XX E. coli nicking agent target DNA #26.  
DE  
XX ss; nicking agent; assay panel; diagnosis; expression pattern;  
KW DNA fingerprinting; nosocomial infection; microbiological assay;  
KW bacterial contamination; genome mapping; bioremediation.  
XX  
XX Escherichia coli.  
OS  
XX WO2004067765-A2.  
PN  
XX 12-AUG-2004.  
PD  
XX 29-JAN-2004; 2004WO-US002720.  
XX  
PF 29-JAN-2003; 2003US-0443811P.  
XX  
PR (KECK-) KECK GRADUATE INST.  
XX  
PA Van Ness J, Galas DJ, Van Ness LK;  
XX  
PI WPI; 2004-581010/56.  
XX  
DR Identifying nucleic acid sample source, useful for identifying bacterial  
PT strains involved in nosocomial infections, comprises treating the nucleic  
PT acid sample with components comprising a nicking agent under nicking  
PT conditions.  
XX  
XX Example 1; Page 65; 238pp; English.  
PS  
XX The invention relates to a method of treating a nucleic acid sample with  
CC components under nicking conditions, where the components comprise a

CC nicking agent, and the conditions cause the nicking agent to nick the  
CC nucleic acid sample to thus produce a family of initiating  
CC oligonucleotide fragments, and subjecting one or more members of the  
CC family of initiating oligonucleotide fragments to a characterization  
CC process to thus provide results. The method is useful for creating an  
CC assay panel of diagnostic oligonucleotides that can identify any organism  
CC or individual. The method is useful for characterizing other DNA  
CC molecules e.g., cDNA, and for characterizing cDNA expression patterns.  
CC The method, kit or composition is useful for identifying the source  
CC organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,  
CC non-human animal or human. The method is particularly useful for rapidly  
CC fingerprinting DNA to identifying prokaryotic and eukaryotic species.  
CC subspecies, and especially strains or individuals of the subspecies. It  
CC is especially useful for identifying different bacterial strains involved  
CC in e.g., nosocomial infections. Furthermore, the method is useful for  
CC diagnosing bacterial disease in plants and humans, monitoring for  
CC bacterial content and/or contamination in the environment, monitoring for  
CC food for bacterial contamination, monitoring manufacturing processes for  
CC bacterial contamination, monitoring quality assurance/quality control of  
CC laboratory tests involving microbiological assays, tracing bacterial  
CC contamination and/or outbreaks of bacterial infections, genome mapping,  
CC monitoring bioremediation sites, and for monitoring agricultural sites  
CC for test crops, bacteria and recombinant molecules. This sequence  
CC corresponds to nucleic acid used in the method of the invention.  
XX  
SQ Sequence 16 BP; 4 A; 1 C; 4 G; 7 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
Qy 501 TTCTGGATGAATGGT 515  
Db 1 TTCTGGATGAATGGT 15  
RESULT 409  
ADR32430  
ID ADR32430 standard; DNA; 16 BP.  
XX  
AC ADR32430;  
XX  
DT 04-NOV-2004 (first entry)  
XX  
XX E. coli fingerprint oligonucleotide #12.  
DE  
XX ss; nicking agent; assay panel; diagnosis; expression pattern;  
KW DNA fingerprinting; nosocomial infection; microbiological assay;  
KW bacterial contamination; genome mapping; bioremediation.  
XX  
XX Escherichia coli.  
OS  
XX WO2004067765-A2.  
PN  
XX 12-AUG-2004.  
PD  
XX 29-JAN-2004; 2004WO-US002720.  
XX  
PF 29-JAN-2003; 2003US-0443811P.  
XX  
PR (KECK-) KECK GRADUATE INST.  
XX  
PA Van Ness J, Galas DJ, Van Ness LK;  
XX  
PI WPI; 2004-581010/56.  
XX  
DR Identifying nucleic acid sample source, useful for identifying bacterial  
PT strains involved in nosocomial infections, comprises treating the nucleic  
PT acid sample with components comprising a nicking agent under nicking  
PT conditions.  
XX  
XX Example 1; Page 70; 238pp; English.  
PS  
XX

CC The invention relates to a method of treating a nucleic acid sample with  
CC components under nicking conditions, where the components comprise a  
CC nicking agent, and the conditions cause the nicking agent to nick the  
CC nucleic acid sample to thus produce a family of initiating  
CC oligonucleotide fragments, and subjecting one or more members of the  
CC family of initiating oligonucleotide fragments to a characterization  
CC process to thus provide results. The method is useful for creating an  
CC assay panel of diagnostic oligonucleotides that can identify any organism  
CC or individual. The method is useful for characterizing other DNA  
CC molecules e.g., cDNA, and for characterizing cDNA expression patterns.  
CC The method, kit or composition is useful for identifying the source  
CC organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,  
CC non-human animal or human. The method is particularly useful for rapidly  
CC fingerprinting DNA to identifying prokaryotic and eukaryotic species,  
CC subspecies, and especially strains or individuals of the subspecies. It  
CC is especially useful for identifying different bacterial strains involved  
CC in e.g., nosocomial infections. Furthermore, the method is useful for  
CC diagnosing bacterial disease in plants and humans, monitoring for  
CC bacterial content and/or contamination in the environment, monitoring  
CC food for bacterial contamination, monitoring manufacture/quality control of  
CC bacterial contamination, monitoring microbiological assays, tracing bacterial  
CC laboratory tests involving microbiological assays, tracing bacterial  
CC contamination and/or outbreaks of bacterial infections, genome mapping,  
CC monitoring bioremediation sites, and for monitoring agricultural sites  
CC for test crops, bacteria and recombinant molecules. This sequence  
CC corresponds to nucleic acid used in the method of the invention.

XX  
SQ Sequence 16 BP; 4 A; 1 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 501 TTCTGGATGATGGT 515  
|||||  
Db 1 TTCTGGATGATGTT 15

RESULT 410

AD33575  
ID AD33575 standard; DNA; 16 BP.

XX  
AC AD33575;

DT 04-NOV-2004 (first entry)

XX E. coli strain K12 detection oligonucleotide K12-558515.

XX ss; nicking agent; assay panel; diagnosis; expression pattern;  
KW DNA fingerprinting; nosocomial infection; microbiological assay;  
KW bacterial contamination; genome mapping; bioremediation.

XX Escherichia coli.

OS WO2004067765-A2.

XX 12-AUG-2004.

XX 29-JAN-2004; 2004WO-US002720.

XX 29-JAN-2003; 2003US-0443811P.

XX (KECK-) KECK GRADUATE INST.

XX Van Ness J, Galas DJ, Van Ness LK;

XX WPT; 2004-581010/56.

XX Identifying nucleic acid sample source, useful for identifying bacterial  
XX strains involved in nosocomial infections, comprises treating the nucleic  
XX acid sample with components comprising a nicking agent under nicking  
XX conditions.

PS Example 2; Page 94; 238pp; English.

XX The invention relates to a method of treating a nucleic acid sample with  
CC components under nicking conditions, where the components comprise a  
CC nicking agent, and the conditions cause the nicking agent to nick the  
CC nucleic acid sample to thus produce a family of initiating  
CC oligonucleotide fragments, and subjecting one or more members of the  
CC family of initiating oligonucleotide fragments to a characterization  
CC process to thus provide results. The method is useful for creating an  
CC assay panel of diagnostic oligonucleotides that can identify any organism  
CC or individual. The method is useful for characterizing other DNA  
CC molecules e.g., cDNA, and for characterizing cDNA expression patterns.  
CC The method, kit or composition is useful for identifying the source  
CC organism of a nucleic acid sample e.g., bacterium, fungus, virus, plant,  
CC non-human animal or human. The method is particularly useful for rapidly  
CC fingerprinting DNA to identifying prokaryotic and eukaryotic species,  
CC subspecies, and especially strains or individuals of the subspecies. It  
CC is especially useful for identifying different bacterial strains involved  
CC in e.g., nosocomial infections. Furthermore, the method is useful for  
CC diagnosing bacterial disease in plants and humans, monitoring for  
CC bacterial content and/or contamination in the environment, monitoring  
CC food for bacterial contamination, monitoring manufacture/quality control of  
CC bacterial contamination, monitoring microbiological assays, tracing bacterial  
CC laboratory tests involving microbiological assays, tracing bacterial  
CC contamination and/or outbreaks of bacterial infections, genome mapping,  
CC monitoring bioremediation sites, and for monitoring agricultural sites  
CC for test crops, bacteria and recombinant molecules. This sequence  
CC corresponds to an oligonucleotide used in the method of the invention to  
CC detect an E. coli strain K12 sequence.

XX  
SQ Sequence 16 BP; 4 A; 1 C; 4 G; 7 T; 0 U; 0 Other;

Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 501 TTCTGGATGATGGT 515  
|||||  
Db 1 TTCTGGATGATGTT 15

RESULT 411

AD69939/c  
ID AD69939 standard; DNA; 16 BP.

XX  
AC AD69939;

DT 04-NOV-2004 (first entry)

DE Human survivin gene modulatory oligonucleotide #7.

XX ss; antiangiogenic; cytostatic; antiarteriosclerotic; antipsoriatic;  
KW anti-diabetic; ophthalmologic; antiarthritic; anti-rheumatic;  
KW antiasthmatic; anti-allergic; anti-inflammatory; dermatological; anti-HIV;  
KW virucide; survivin antagonist; apoptosis inhibitor;  
KW cellular proliferation inhibitor; survivin; gene expression;  
KW abnormal angiogenesis; chemotherapeutic agent; busulfan; myleran;  
KW carboplatin; paraplatin; Taxol; doxorubicin; adriamycin; atherosclerosis;  
KW psoriasis; diabetic retinopathy; rheumatoid arthritis; asthma; warts;  
KW allergic dermatitis; cancer; tumour; sarcoma; glioma; carcinoma;  
KW melanoma; osteosarcoma; Ewing's sarcoma; chondrosarcoma;  
KW malignant fibrous histiocytoma; fibrosarcoma; Kaposi's sarcoma;  
KW Paclitaxel; Docetaxel.

OS Homo sapiens.

OS Synthetic.

XX Key Location/Qualifiers

FT modified\_base 1..16

FT /tag= b

FT /mod\_base= OTHER

FT /note= "OTHER = phosphorothioate internucleotide

FT linkages, all locked nucleic acid (LNA) residues are 5'-

FT modified\_base methyl cytosine residues"  
FT 1. .4  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER = beta-D-oxy-locked nucleic acid but  
FT optionally DNA nucleotides, optionally phosphate  
FT internucleotide linkages"  
FT modified\_base  
FT 13. .16  
FT /\*tag= C  
FT /mod\_base= OTHER  
FT /note= "OTHER = beta-D-oxy-locked nucleic acid but  
FT optionally DNA nucleotides, optionally phosphate  
FT internucleotide linkages"  
XX WO2004069991-A2.  
XX  
XX 19-AUG-2004.  
XX  
XX 10-FEB-2004; 2004WO-DK000096.  
XX  
XX 10-FEB-2003; 2003DK-00000183.  
XX 18-NOV-2003; 2003DK-00001708.  
XX (SANT-) SANTARIS PHARMA AS.  
XX Hansen B, Thru CA, Petersen KD, Westergaard M, Wissenbach M;  
XX WPI; 2004-625494/60.  
XX  
XX New locked nucleic acid containing oligomeric compound capable of  
XX modulating survivin expression, useful for treating cancer such as breast  
XX carcinoma, lung carcinoma, etc.  
XX  
XX Claim 1; SEQ ID NO 8; 122pp; English.  
XX  
XX The invention relates to an oligomeric compound (I) capable of modulating  
XX survivin expression, having 8-50 nucleotides and/or nucleotide analogues,  
XX where the compound comprises a subsequence of at least 8 nucleotides or  
XX nucleotide analogues, where the subsequence is located within a sequence  
XX chosen from one of 143 sequences given in the specification. (I) is  
XX useful for treating a mammal suffering from or susceptible from a disease  
XX caused by abnormal angiogenesis, by administering (I) containing one or  
XX more LNA units that are targeted to survivin. (I) is useful as a  
XX medicament and for the manufacture of a medicament for the treatment of  
XX cancer, in combination with chemotherapeutic agent such as busulfan  
XX (myleran), carboplatin (paraplatin), Taxol, doxorubicin (adriamycin),  
XX etc. (I) or a conjugate (II) containing (I) is useful in the preparation  
XX of a medicament for the treatment of atherosclerosis, psoriasis, diabetic  
XX retinopathy, rheumatoid arthritis, asthma, warts and allergic dermatitis.  
XX (I), (II) or a pharmaceutical (III) containing (I) is useful for treating  
XX cancer in the form of a solid tumour, sarcoma, glioma or carcinoma chosen  
XX from malignant melanoma, basal cell carcinoma, ovarian carcinoma, breast  
XX carcinoma, non-small cell lung cancer, renal cell carcinoma, bladder  
XX carcinoma, recurrent superficial bladder cancer, stomach carcinoma,  
XX prostatic carcinoma, pancreatic carcinoma, lung carcinoma, cervical  
XX carcinoma, cervical dysplasia, laryngeal papillomatosis, colon carcinoma,  
XX colorectal carcinoma and carcinoma tumours. The malignant melanoma is  
XX chosen from superficial spreading melanoma, nodular melanoma, lentigo  
XX maligna melanoma, acral melanoma, amelanotic melanoma, and desmoplastic  
XX melanoma. The sarcoma is chosen from osteosarcoma, Ewing's sarcoma,  
XX chondrosarcoma, malignant fibrous histiocytoma, fibrosarcoma and Kaposi's  
XX sarcoma. The treatment further involves administration of a  
XX chemotherapeutic agent such as taxanes, preferably Taxol, Paclitaxel or  
XX Docetaxel. (I), (II) or (III) is also useful for preventing or limiting  
XX apoptosis or for preventing cellular proliferation. This sequence  
XX corresponds to an antisense oligonucleotide targeted to the human  
XX survivin gene.  
XX  
XX SQ Sequence 16 BP; 1 A; 3 C; 1 G; 11 T; 0 U; 0 Other;  
Query Match 0.8%; Score 13.4; DB 1; Length 16;  
Best Local Similarity 93.3%; Pred. No. 1.7e+02;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 278 CAAGAAGAGAAAGA 292  
||| |||||  
Db 16 CAATAGAGAGAAAGA 2

Search completed: September 13, 2005, 10:42:46  
Job time : 10 secs





GenCore version 5.1.6  
Copyright (c) 1993 - 2005 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:46:55 ; Search time 10 Seconds  
(without alignments)  
3.440 Million cell updates/sec

Title: us-10-828-394-1

Perfect score: 1643

Sequence: 1 gaattccgcgcgtgaccgag.....taaaactgtctgtgagctg 1643

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 0.5

Searched: 497 seqs, 10470 residues

Total number of hits satisfying chosen parameters: 994

Minimum DB seq length: 8

Maximum DB seq length: 50

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 497 summaries

Database : rnpdb.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	25	1.5	25	1	US-10-717-597-1314
2	25	1.5	25	1	US-10-717-597-1315
3	25	1.5	25	1	US-10-717-597-1316
4	25	1.5	25	1	US-10-717-597-1317
5	25	1.5	25	1	US-10-717-597-1318
6	25	1.5	25	1	US-10-717-597-1319
7	25	1.5	25	1	US-10-717-597-1320
8	25	1.5	25	1	US-10-717-597-1321
9	25	1.5	25	1	US-10-717-597-1322
10	25	1.5	25	1	US-10-717-597-1323
11	25	1.5	25	1	US-10-717-597-1324
12	25	1.5	25	1	US-10-717-597-1325
13	25	1.5	25	1	US-10-717-597-1326
14	25	1.5	25	1	US-10-717-597-1327
15	25	1.5	25	1	US-10-717-597-1328
16	25	1.5	25	1	US-10-717-597-1329
17	25	1.5	25	1	US-10-717-597-1330
18	25	1.5	25	1	US-10-956-157-25934
19	25	1.5	25	1	US-10-956-157-25935
20	25	1.5	25	1	US-10-956-157-25936
21	25	1.5	25	1	US-10-956-157-25937
22	25	1.5	25	1	US-10-956-157-25938
23	25	1.5	25	1	US-10-956-157-25939
24	25	1.5	25	1	US-10-956-157-25940
25	25	1.5	25	1	US-10-956-157-25941
26	25	1.5	25	1	US-10-956-157-25942
27	25	1.5	25	1	US-10-956-157-25943
28	25	1.5	25	1	US-10-956-157-25944
29	25	1.5	25	1	US-10-956-157-25945
30	25	1.5	25	1	US-10-956-157-25946
31	25	1.5	25	1	US-10-956-157-25947
32	25	1.5	25	1	US-10-956-157-25948
33	25	1.5	25	1	US-10-956-157-25949

Sequence 25950, A	1	US-10-956-157-25950	25	1.5	34
Sequence 25951, A	1	US-10-956-157-25951	25	1.5	35
Sequence 25952, A	1	US-10-956-157-25952	25	1.5	36
Sequence 25953, A	1	US-10-956-157-25953	25	1.5	37
Sequence 25954, A	1	US-10-956-157-25954	25	1.5	38
Sequence 25955, A	1	US-10-956-157-25955	25	1.5	39
Sequence 25956, A	1	US-10-956-157-25956	25	1.5	40
Sequence 122144, A	1	US-10-956-157-122144	25	1.5	41
Sequence 127897, A	1	US-10-956-157-127897	25	1.5	42
Sequence 131009, A	1	US-10-956-157-131009	25	1.5	43
Sequence 134947, A	1	US-10-956-157-134947	25	1.5	44
Sequence 135244, A	1	US-10-956-157-135244	25	1.5	45
Sequence 139926, A	1	US-10-956-157-139926	25	1.5	46
Sequence 140752, A	1	US-10-956-157-140752	25	1.5	47
Sequence 141327, A	1	US-10-956-157-141327	25	1.5	48
Sequence 146594, A	1	US-10-956-157-146594	25	1.5	49
Sequence 146923, A	1	US-10-956-157-146923	25	1.5	50
Sequence 156812, A	1	US-10-956-157-156812	25	1.5	51
Sequence 158656, A	1	US-10-956-157-158656	25	1.5	52
Sequence 159440, A	1	US-10-956-157-159440	25	1.5	53
Sequence 168291, A	1	US-10-956-157-168291	25	1.5	54
Sequence 172467, A	1	US-10-956-157-172467	25	1.5	55
Sequence 174696, A	1	US-10-956-157-174696	25	1.5	56
Sequence 174708, A	1	US-10-956-157-174708	25	1.5	57
Sequence 174902, A	1	US-10-956-157-174902	25	1.5	58
Sequence 176821, A	1	US-10-956-157-176821	25	1.5	59
Sequence 178550, A	1	US-10-956-157-178550	25	1.5	60
Sequence 178867, A	1	US-10-956-157-178867	25	1.5	61
Sequence 186901, A	1	US-10-956-157-186901	25	1.5	62
Sequence 186902, A	1	US-10-956-157-186902	25	1.5	63
Sequence 186903, A	1	US-10-956-157-186903	25	1.5	64
Sequence 186908, A	1	US-10-956-157-186908	25	1.5	65
Sequence 186914, A	1	US-10-956-157-186914	25	1.5	66
Sequence 188008, A	1	US-10-956-157-188008	25	1.5	67
Sequence 188038, A	1	US-10-956-157-188038	25	1.5	68
Sequence 189641, A	1	US-10-956-157-189641	25	1.5	69
Sequence 191487, A	1	US-10-956-157-191487	25	1.5	70
Sequence 193107, A	1	US-10-956-157-193107	25	1.5	71
Sequence 193726, A	1	US-10-956-157-193726	25	1.5	72
Sequence 194937, A	1	US-10-956-157-194937	25	1.5	73
Sequence 195328, A	1	US-10-956-157-195328	25	1.5	74
Sequence 195368, A	1	US-10-956-157-195368	25	1.5	75
Sequence 196424, A	1	US-10-956-157-196424	25	1.5	76
Sequence 197173, A	1	US-10-956-157-197173	25	1.5	77
Sequence 206442, A	1	US-10-956-157-206442	25	1.5	78
Sequence 208499, A	1	US-10-956-157-208499	25	1.5	79
Sequence 212934, A	1	US-10-956-157-212934	25	1.5	80
Sequence 215054, A	1	US-10-956-157-215054	25	1.5	81
Sequence 216983, A	1	US-10-956-157-216983	25	1.5	82
Sequence 218349, A	1	US-10-956-157-218349	25	1.5	83
Sequence 218350, A	1	US-10-956-157-218350	25	1.5	84
Sequence 218351, A	1	US-10-956-157-218351	25	1.5	85
Sequence 219734, A	1	US-10-956-157-219734	25	1.5	86
Sequence 220245, A	1	US-10-956-157-220245	25	1.5	87
Sequence 221279, A	1	US-10-956-157-221279	25	1.5	88
Sequence 222407, A	1	US-10-956-157-222407	25	1.5	89
Sequence 225352, A	1	US-10-956-157-225352	25	1.5	90
Sequence 228789, A	1	US-10-956-157-228789	25	1.5	91
Sequence 229316, A	1	US-10-956-157-229316	25	1.5	92
Sequence 230136, A	1	US-10-956-157-230136	25	1.5	93
Sequence 230317, A	1	US-10-956-157-230317	25	1.5	94
Sequence 231573, A	1	US-10-956-157-231573	25	1.5	95
Sequence 231724, A	1	US-10-956-157-231724	25	1.5	96
Sequence 231783, A	1	US-10-956-157-231783	25	1.5	97
Sequence 232704, A	1	US-10-956-157-232704	25	1.5	98
Sequence 233030, A	1	US-10-956-157-233030	25	1.5	99
Sequence 233762, A	1	US-10-956-157-233762	25	1.5	100
Sequence 235882, A	1	US-10-956-157-235882	25	1.5	101
Sequence 236817, A	1	US-10-956-157-236817	25	1.5	102
Sequence 237638, A	1	US-10-956-157-237638	25	1.5	103
Sequence 238337, A	1	US-10-956-157-238337	25	1.5	104
Sequence 243092, A	1	US-10-956-157-243092	25	1.5	105
Sequence 243092, A	1	US-10-956-157-243092	25	1.5	106

107	25	1.5	25	1	US-10-956-157-252760	Sequence 252760,	180	21	1.3	21	1	US-09-967-726A-12	Sequence 12, Appl
108	25	1.5	25	1	US-10-956-157-253138	Sequence 253138,	181	21	1.3	21	1	US-10-270-871-14	Sequence 14, Appl
109	25	1.5	25	1	US-10-956-157-255424	Sequence 255424,	182	21	1.3	21	1	US-10-080-794-3	Sequence 3, Appl
110	25	1.5	25	1	US-10-956-157-255957	Sequence 255957,	183	21	1.3	21	1	US-10-080-794-4	Sequence 4, Appl
111	25	1.5	25	1	US-10-956-157-256203	Sequence 256203,	184	21	1.3	21	1	US-10-080-794-5	Sequence 5, Appl
112	25	1.5	25	1	US-10-956-157-261789	Sequence 261789,	185	21	1.3	21	1	US-10-080-794-6	Sequence 6, Appl
113	25	1.5	25	1	US-10-956-157-266662	Sequence 266662,	186	21	1.3	21	1	US-10-080-794-7	Sequence 7, Appl
114	25	1.5	25	1	US-10-956-157-268124	Sequence 268124,	187	21	1.3	21	1	US-10-080-794-8	Sequence 8, Appl
115	25	1.5	25	1	US-10-956-157-269972	Sequence 269972,	188	21	1.3	21	1	US-10-080-794-9	Sequence 9, Appl
116	25	1.5	25	1	US-10-956-157-273702	Sequence 273702,	189	21	1.3	21	1	US-10-080-794-10	Sequence 10, Appl
117	25	1.5	25	1	US-10-956-157-274079	Sequence 274079,	190	21	1.3	21	1	US-10-080-794-11	Sequence 11, Appl
118	25	1.5	25	1	US-10-956-157-274264	Sequence 274264,	191	21	1.3	21	1	US-10-080-794-12	Sequence 12, Appl
119	25	1.5	25	1	US-10-956-157-274647	Sequence 274647,	192	21	1.3	21	1	US-10-380-124-6	Sequence 6, Appl
120	25	1.5	25	1	US-10-956-157-279222	Sequence 279222,	193	21	1.3	21	1	US-10-383-864-27	Sequence 27, Appl
121	25	1.5	25	1	US-10-956-157-281215	Sequence 281215,	194	21	1.3	21	1	US-10-383-864-28	Sequence 28, Appl
122	25	1.5	25	1	US-10-956-157-285427	Sequence 285427,	195	21	1.3	21	1	US-10-646-391A-3	Sequence 3, Appl
123	25	1.5	25	1	US-10-956-157-285561	Sequence 285561,	196	21	1.3	21	1	US-10-646-391A-4	Sequence 4, Appl
124	25	1.5	25	1	US-10-956-157-285688	Sequence 285688,	197	21	1.3	21	1	US-10-646-391A-5	Sequence 5, Appl
125	25	1.5	25	1	US-10-956-157-285832	Sequence 285832,	198	21	1.3	21	1	US-10-646-391A-6	Sequence 6, Appl
126	25	1.5	25	1	US-10-956-157-291738	Sequence 291738,	199	21	1.3	21	1	US-10-646-391A-7	Sequence 7, Appl
127	25	1.5	25	1	US-10-956-157-292100	Sequence 292100,	200	21	1.3	21	1	US-10-646-391A-8	Sequence 8, Appl
128	25	1.5	25	1	US-10-956-157-292272	Sequence 292272,	201	21	1.3	21	1	US-10-646-391A-9	Sequence 9, Appl
129	25	1.5	25	1	US-10-956-157-297166	Sequence 297166,	202	21	1.3	21	1	US-10-646-391A-10	Sequence 10, Appl
130	25	1.5	25	1	US-10-956-157-302171	Sequence 302171,	203	21	1.3	21	1	US-10-646-391A-11	Sequence 11, Appl
131	25	1.5	25	1	US-10-956-157-316681	Sequence 316681,	204	21	1.3	21	1	US-10-646-391A-12	Sequence 12, Appl
132	25	1.5	25	1	US-10-956-157-317598	Sequence 317598,	205	21	1.3	21	1	US-10-646-391A-20	Sequence 20, Appl
133	24	1.5	25	1	US-10-956-157-287991	Sequence 287991,	206	21	1.3	21	1	US-10-646-391A-21	Sequence 21, Appl
134	23	1.4	25	1	US-10-719-956-187214	Sequence 187214,	207	21	1.3	21	1	US-10-646-391A-22	Sequence 22, Appl
135	23	1.4	23	1	US-10-080-794-16	Sequence 16, Appl	208	21	1.3	21	1	US-10-646-391A-23	Sequence 23, Appl
136	23	1.4	23	1	US-10-080-794-17	Sequence 17, Appl	209	21	1.3	21	1	US-10-646-391A-25	Sequence 25, Appl
137	23	1.4	23	1	US-10-380-124-5	Sequence 5, Appl	210	21	1.3	21	1	US-10-646-391A-36	Sequence 36, Appl
138	23	1.4	23	1	US-10-646-436-57	Sequence 57, Appl	211	21	1.3	21	1	US-10-646-391A-37	Sequence 37, Appl
139	23	1.4	23	1	US-10-646-436-60	Sequence 60, Appl	212	21	1.3	21	1	US-10-646-391A-38	Sequence 38, Appl
140	23	1.4	23	1	US-10-646-436-63	Sequence 63, Appl	213	21	1.3	21	1	US-10-646-391A-39	Sequence 39, Appl
141	23	1.4	23	1	US-10-646-436-66	Sequence 66, Appl	214	21	1.3	21	1	US-10-646-391A-40	Sequence 40, Appl
142	23	1.4	25	1	US-10-956-157-291041	Sequence 291041,	215	21	1.3	21	1	US-10-646-391A-41	Sequence 41, Appl
143	22	1.3	22	1	US-10-980-850-34	Sequence 34, Appl	216	21	1.3	21	1	US-10-646-436-1	Sequence 1, Appl
144	22	1.3	25	1	US-10-956-157-167169	Sequence 167169,	217	21	1.3	21	1	US-10-646-436-2	Sequence 2, Appl
145	22	1.3	25	1	US-10-956-157-167170	Sequence 167170,	218	21	1.3	21	1	US-10-646-436-3	Sequence 3, Appl
146	22	1.3	25	1	US-10-956-157-167171	Sequence 167171,	219	21	1.3	21	1	US-10-646-436-4	Sequence 4, Appl
147	22	1.3	25	1	US-10-956-157-228788	Sequence 228788,	220	21	1.3	21	1	US-10-646-436-5	Sequence 5, Appl
148	22	1.3	25	1	US-10-956-157-279365	Sequence 279365,	221	21	1.3	21	1	US-10-646-436-6	Sequence 6, Appl
149	21	1.8	25	1	US-10-719-900-56804	Sequence 56804, A	222	21	1.3	21	1	US-10-646-436-58	Sequence 58, Appl
150	21	1.8	25	1	US-10-719-900-417945	Sequence 417945,	223	21	1.3	21	1	US-10-646-436-59	Sequence 59, Appl
151	21	1.8	25	1	US-10-719-900-417946	Sequence 417946,	224	21	1.3	21	1	US-10-646-436-61	Sequence 61, Appl
152	21	1.8	25	1	US-10-719-900-815718	Sequence 815718,	225	21	1.3	21	1	US-10-646-436-62	Sequence 62, Appl
153	21	1.8	25	1	US-10-719-900-892165	Sequence 892165,	226	21	1.3	21	1	US-10-646-436-64	Sequence 64, Appl
154	21	1.8	25	1	US-10-909-189-31760	Sequence 31760, A	227	21	1.3	21	1	US-10-646-436-65	Sequence 65, Appl
155	21	1.8	25	1	US-10-719-956-30749	Sequence 30749, A	228	21	1.3	21	1	US-10-828-394-4	Sequence 4, Appl
156	21	1.8	25	1	US-10-719-956-187213	Sequence 187213,	229	21	1.3	21	1	US-10-828-394-5	Sequence 5, Appl
157	21	1.8	25	1	US-10-719-956-374026	Sequence 374026,	230	21	1.3	21	1	US-10-828-394-6	Sequence 6, Appl
158	21	1.8	25	1	US-10-719-956-501381	Sequence 501381,	231	21	1.3	21	1	US-10-828-394-7	Sequence 7, Appl
159	21	1.8	25	1	US-10-719-956-612442	Sequence 612442,	232	21	1.3	21	1	US-10-828-394-8	Sequence 8, Appl
160	21	1.3	21	1	US-09-944-326-3	Sequence 3, Appl	233	21	1.3	21	1	US-10-828-394-9	Sequence 9, Appl
161	21	1.3	21	1	US-09-944-326-4	Sequence 4, Appl	234	21	1.3	21	1	US-10-828-394-10	Sequence 10, Appl
162	21	1.3	21	1	US-09-944-326-5	Sequence 5, Appl	235	21	1.3	21	1	US-10-828-394-11	Sequence 11, Appl
163	21	1.3	21	1	US-09-944-326-6	Sequence 6, Appl	236	21	1.3	21	1	US-10-828-394-12	Sequence 12, Appl
164	21	1.3	21	1	US-09-944-326-7	Sequence 7, Appl	237	21	1.3	21	1	US-10-828-394-13	Sequence 13, Appl
165	21	1.3	21	1	US-09-944-326-8	Sequence 8, Appl	238	21	1.3	21	1	US-10-828-395-4	Sequence 4, Appl
166	21	1.3	21	1	US-09-944-326-9	Sequence 9, Appl	239	21	1.3	21	1	US-10-828-395-5	Sequence 5, Appl
167	21	1.3	21	1	US-09-944-326-10	Sequence 10, Appl	240	21	1.3	21	1	US-10-828-395-6	Sequence 6, Appl
168	21	1.3	21	1	US-09-944-326-11	Sequence 11, Appl	241	21	1.3	21	1	US-10-828-395-7	Sequence 7, Appl
169	21	1.3	21	1	US-09-944-326-12	Sequence 12, Appl	242	21	1.3	21	1	US-10-828-395-8	Sequence 8, Appl
170	21	1.3	21	1	US-09-459-749D-14	Sequence 14, Appl	243	21	1.3	21	1	US-10-828-395-9	Sequence 9, Appl
171	21	1.3	21	1	US-09-967-726A-3	Sequence 3, Appl	244	21	1.3	21	1	US-10-828-395-10	Sequence 10, Appl
172	21	1.3	21	1	US-09-967-726A-4	Sequence 4, Appl	245	21	1.3	21	1	US-10-828-395-11	Sequence 11, Appl
173	21	1.3	21	1	US-09-967-726A-5	Sequence 5, Appl	246	21	1.3	21	1	US-10-828-395-12	Sequence 12, Appl
174	21	1.3	21	1	US-09-967-726A-6	Sequence 6, Appl	247	21	1.3	21	1	US-10-828-395-13	Sequence 13, Appl
175	21	1.3	21	1	US-09-967-726A-7	Sequence 7, Appl	248	20.8	1.3	25	1	US-10-719-900-695781	Sequence 695781, A
176	21	1.3	21	1	US-09-967-726A-8	Sequence 8, Appl	249	20.2	1.2	25	1	US-10-719-900-56803	Sequence 56803, A
177	21	1.3	21	1	US-09-967-726A-9	Sequence 9, Appl	250	20.2	1.2	25	1	US-10-719-900-452919	Sequence 452919, A
178	21	1.3	21	1	US-09-967-726A-10	Sequence 10, Appl	251	20.2	1.2	25	1	US-10-719-900-815717	Sequence 815717, A
179	21	1.3	21	1	US-09-967-726A-11	Sequence 11, Appl	252	20.2	1.2	25	1	US-10-719-900-892166	Sequence 892166, A

253	20.2	1.2	25	1	US-10-809-189-31758	Sequence 31758, A	C 326	20	1.2	20	1	US-10-380-124-80	Sequence 80, Appl
254	20.2	1.2	25	1	US-10-956-157-271151	Sequence 271151, A	327	20	1.2	20	1	US-10-980-850-17	Sequence 17, Appl
255	20.2	1.2	25	1	US-10-719-956-30750	Sequence 30750, A	C 328	20	1.2	20	1	US-10-980-850-18	Sequence 18, Appl
256	20.2	1.2	25	1	US-10-719-956-70566	Sequence 70566, A	C 329	20	1.2	20	1	US-10-980-850-33	Sequence 33, Appl
257	20.2	1.2	25	1	US-10-719-956-355802	Sequence 355802, A	C 330	20	1.2	21	1	US-10-646-391A-28	Sequence 28, Appl
258	20.2	1.2	25	1	US-10-719-956-374027	Sequence 374027, A	C 331	20	1.2	21	1	US-10-646-436-9	Sequence 9, Appl
259	20.2	1.2	25	1	US-10-719-956-501380	Sequence 501380, A	C 332	19.4	1.2	21	1	US-09-459-749D-13	Sequence 13, Appl
260	20.2	1.2	25	1	US-10-719-956-517912	Sequence 517912, A	C 333	19.4	1.2	21	1	US-10-270-871-13	Sequence 13, Appl
261	20.2	1.2	25	1	US-10-719-956-604881	Sequence 604881, A	C 334	19	1.2	19	1	US-10-646-391A-42	Sequence 42, Appl
262	20.2	1.2	25	1	US-10-719-956-612441	Sequence 612441, A	C 335	19	1.2	19	1	US-10-646-391A-43	Sequence 43, Appl
263	20	1.2	20	1	US-10-380-124-14	Sequence 14, Appl	C 336	19	1.2	19	1	US-10-646-436-67	Sequence 67, Appl
264	20	1.2	20	1	US-10-380-124-15	Sequence 15, Appl	C 337	19	1.2	19	1	US-10-646-436-68	Sequence 68, Appl
265	20	1.2	20	1	US-10-380-124-16	Sequence 16, Appl	C 338	19	1.2	19	1	US-10-828-394-16	Sequence 16, Appl
266	20	1.2	20	1	US-10-380-124-17	Sequence 17, Appl	C 339	19	1.2	19	1	US-10-828-394-17	Sequence 17, Appl
267	20	1.2	20	1	US-10-380-124-18	Sequence 18, Appl	C 340	19	1.2	19	1	US-10-828-394-18	Sequence 18, Appl
268	20	1.2	20	1	US-10-380-124-19	Sequence 19, Appl	C 341	19	1.2	19	1	US-10-828-395-16	Sequence 16, Appl
269	20	1.2	20	1	US-10-380-124-20	Sequence 20, Appl	C 342	19	1.2	19	1	US-10-828-395-17	Sequence 17, Appl
270	20	1.2	20	1	US-10-380-124-21	Sequence 21, Appl	C 343	19	1.2	19	1	US-10-828-395-18	Sequence 18, Appl
271	20	1.2	20	1	US-10-380-124-22	Sequence 22, Appl	C 344	19	1.2	21	1	US-10-646-391A-29	Sequence 29, Appl
272	20	1.2	20	1	US-10-380-124-23	Sequence 23, Appl	C 345	19	1.2	21	1	US-10-646-436-10	Sequence 10, Appl
273	20	1.2	20	1	US-10-380-124-24	Sequence 24, Appl	C 346	18	1.1	18	1	US-10-380-124-4	Sequence 4, Appl
274	20	1.2	20	1	US-10-380-124-25	Sequence 25, Appl	C 347	17.8	1.1	21	1	US-09-967-726A-15	Sequence 15, Appl
275	20	1.2	20	1	US-10-380-124-26	Sequence 26, Appl	C 348	17.8	1.1	21	1	US-10-080-794-15	Sequence 15, Appl
276	20	1.2	20	1	US-10-380-124-27	Sequence 27, Appl	C 349	17.8	1.1	21	1	US-10-751-736-11047	Sequence 11047, A
277	20	1.2	20	1	US-10-380-124-28	Sequence 28, Appl	C 350	16.8	1.0	20	1	US-10-921-868A-37	Sequence 37, Appl
278	20	1.2	20	1	US-10-380-124-29	Sequence 29, Appl	C 351	16.8	1.0	21	1	US-10-786-720-3371	Sequence 3371, Ap
279	20	1.2	20	1	US-10-380-124-30	Sequence 30, Appl	C 352	16.8	1.0	21	1	US-10-786-720-4073	Sequence 4073, Ap
280	20	1.2	20	1	US-10-380-124-31	Sequence 31, Appl	C 353	16.8	1.0	21	1	US-10-786-720-4811	Sequence 4811, Ap
281	20	1.2	20	1	US-10-380-124-32	Sequence 32, Appl	C 354	16.8	1.0	21	1	US-10-751-736-24026	Sequence 24026, A
282	20	1.2	20	1	US-10-380-124-33	Sequence 33, Appl	C 355	16.8	1.0	21	1	US-10-911-318-81	Sequence 81, Appl
283	20	1.2	20	1	US-10-380-124-34	Sequence 34, Appl	C 356	16	1.0	16	1	US-09-294-121A-97	Sequence 97, Appl
284	20	1.2	20	1	US-10-380-124-35	Sequence 35, Appl	C 357	16	1.0	16	1	US-09-899-082A-97	Sequence 97, Appl
285	20	1.2	20	1	US-10-380-124-36	Sequence 36, Appl	C 358	16	1.0	16	1	US-09-899-302-97	Sequence 97, Appl
286	20	1.2	20	1	US-10-380-124-37	Sequence 37, Appl	C 359	16	1.0	16	1	US-09-899-044-97	Sequence 97, Appl
287	20	1.2	20	1	US-10-380-124-38	Sequence 38, Appl	C 360	16	1.0	16	1	US-10-822-711-97	Sequence 97, Appl
288	20	1.2	20	1	US-10-380-124-39	Sequence 39, Appl	C 361	16	1.0	20	1	US-10-160-787-84	Sequence 84, Appl
289	20	1.2	20	1	US-10-380-124-40	Sequence 40, Appl	C 362	16	1.0	20	1	US-10-160-787-137	Sequence 137, App
290	20	1.2	20	1	US-10-380-124-41	Sequence 41, Appl	C 363	15.8	1.0	19	1	US-10-646-391A-24	Sequence 24, Appl
291	20	1.2	20	1	US-10-380-124-42	Sequence 42, Appl	C 364	15.8	1.0	19	1	US-10-646-391A-26	Sequence 26, Appl
292	20	1.2	20	1	US-10-380-124-43	Sequence 43, Appl	C 365	15.8	1.0	19	1	US-10-646-391A-27	Sequence 27, Appl
293	20	1.2	20	1	US-10-380-124-44	Sequence 44, Appl	C 366	15.8	1.0	19	1	US-10-646-436-7	Sequence 7, Appl
294	20	1.2	20	1	US-10-380-124-45	Sequence 45, Appl	C 367	15.8	1.0	19	1	US-10-846-436-8	Sequence 8, Appl
295	20	1.2	20	1	US-10-380-124-46	Sequence 46, Appl	C 368	15.8	1.0	19	1	US-10-667-271-1001	Sequence 1001, App
296	20	1.2	20	1	US-10-380-124-47	Sequence 47, Appl	C 369	15.8	1.0	19	1	US-09-866-108-8666	Sequence 8666, Ap
297	20	1.2	20	1	US-10-380-124-48	Sequence 48, Appl	C 370	15.4	0.9	17	1	US-09-780-533A-170	Sequence 170, App
298	20	1.2	20	1	US-10-380-124-49	Sequence 49, Appl	C 371	15.4	0.9	17	1	US-09-740-332-1542	Sequence 1542, Ap
299	20	1.2	20	1	US-10-380-124-50	Sequence 50, Appl	C 372	15.4	0.9	17	1	US-09-740-332-3013	Sequence 3013, Ap
300	20	1.2	20	1	US-10-380-124-51	Sequence 51, Appl	C 373	15.4	0.9	17	1	US-09-817-879-1542	Sequence 1542, Ap
301	20	1.2	20	1	US-10-380-124-52	Sequence 52, Appl	C 374	15.4	0.9	17	1	US-09-817-879-3013	Sequence 3013, Ap
302	20	1.2	20	1	US-10-380-124-53	Sequence 53, Appl	C 375	15.4	0.9	17	1	US-10-669-841-4135	Sequence 4135, Ap
303	20	1.2	20	1	US-10-380-124-54	Sequence 54, Appl	C 376	15.4	0.9	17	1	US-10-669-841-4135	Sequence 4135, Ap
304	20	1.2	20	1	US-10-380-124-55	Sequence 55, Appl	C 377	15.4	0.9	17	1	US-10-669-841-5606	Sequence 5606, Ap
305	20	1.2	20	1	US-10-380-124-56	Sequence 56, Appl	C 378	15.4	0.9	17	1	US-10-723-361-8666	Sequence 8666, Ap
306	20	1.2	20	1	US-10-380-124-57	Sequence 57, Appl	C 379	15.4	0.9	17	1	US-10-828-394-19	Sequence 19, Appl
307	20	1.2	20	1	US-10-380-124-58	Sequence 58, Appl	C 380	15.4	0.9	17	1	US-10-828-395-19	Sequence 19, Appl
308	20	1.2	20	1	US-10-380-124-59	Sequence 59, Appl	C 381	15	0.9	15	1	US-10-758-451-883	Sequence 883, App
309	20	1.2	20	1	US-10-380-124-60	Sequence 60, Appl	C 382	15	0.9	17	1	US-09-740-332-3014	Sequence 3014, Ap
310	20	1.2	20	1	US-10-380-124-61	Sequence 61, Appl	C 383	15	0.9	17	1	US-09-817-879-3014	Sequence 3014, Ap
311	20	1.2	20	1	US-10-380-124-62	Sequence 62, Appl	C 384	15	0.9	17	1	US-10-669-841-5607	Sequence 5607, Ap
312	20	1.2	20	1	US-10-380-124-63	Sequence 63, Appl	C 385	14.8	0.9	18	1	US-10-497-692-11	Sequence 11, Appl
313	20	1.2	20	1	US-10-380-124-64	Sequence 64, Appl	C 386	14.4	0.9	17	1	US-09-866-108-8352	Sequence 8352, Ap
314	20	1.2	20	1	US-10-380-124-65	Sequence 65, Appl	C 387	14.4	0.9	17	1	US-09-866-108-8353	Sequence 8353, Ap
315	20	1.2	20	1	US-10-380-124-66	Sequence 66, Appl	C 388	14.4	0.9	17	1	US-09-866-108-8665	Sequence 8665, Ap
316	20	1.2	20	1	US-10-380-124-67	Sequence 67, Appl	C 389	14.4	0.9	17	1	US-09-866-108-8667	Sequence 8667, Ap
317	20	1.2	20	1	US-10-380-124-68	Sequence 68, Appl	C 390	14.4	0.9	17	1	US-09-866-108-10037	Sequence 10037, A
318	20	1.2	20	1	US-10-380-124-69	Sequence 69, Appl	C 391	14.4	0.9	17	1	US-09-866-108-10038	Sequence 10038, A
319	20	1.2	20	1	US-10-380-124-70	Sequence 70, Appl	C 392	14.4	0.9	17	1	US-09-928-412-7	Sequence 7, Appl
320	20	1.2	20	1	US-10-380-124-71	Sequence 71, Appl	C 393	14.4	0.9	17	1	US-09-780-533A-171	Sequence 171, App
321	20	1.2	20	1	US-10-380-124-72	Sequence 72, Appl	C 394	14.4	0.9	17	1	US-09-877-478-1745	Sequence 1745, Ap
322	20	1.2	20	1	US-10-380-124-73	Sequence 73, Appl	C 395	14.4	0.9	17	1	US-09-740-332-1543	Sequence 1543, Ap
323	20	1.2	20	1	US-10-380-124-74	Sequence 74, Appl	C 396	14.4	0.9	17	1	US-09-817-879-1543	Sequence 1543, Ap
324	20	1.2	20	1	US-10-380-124-75	Sequence 75, Appl	C 397	14.4	0.9	17	1	US-10-298-255-4	Sequence 4, Appl
325	20	1.2	20	1	US-10-380-124-78	Sequence 78, Appl	C 398	14.4	0.9	17	1	US-10-238-700-2912	Sequence 2912, Ap



; APPLICANT: Wyeth  
; APPLICANT: Burczynski, Michael E.  
; APPLICANT: Twine, Natalie C.  
; APPLICANT: Dörner, Andrew J.  
; APPLICANT: Trepicchio, William L.  
; APPLICANT: Slonim, Donna K.  
; APPLICANT: Stover, Jennifer A.  
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS  
; FILE REFERENCE: AM101080L  
; CURRENT APPLICATION NUMBER: US/10/717,597  
; CURRENT FILING DATE: 2003-11-21  
; PRIOR APPLICATION NUMBER: US 60/459,782  
; PRIOR FILING DATE: 2003-04-03  
; PRIOR APPLICATION NUMBER: US 60/427,982  
; PRIOR FILING DATE: 2002-11-21  
; NUMBER OF SEQ ID NOS: 4904  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1315  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-717-597-1315

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1177 AAGCGAAGACCACTACTCTGCG 1201  
Db 1 AAGCGAAGACCACTACTCTGCG 25  
|||||

RESULT 3  
US-10-717-597-1316  
; Sequence 1316, Application US/10717597  
; Publication No. US20040110221A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Burczynski, Michael E.  
; APPLICANT: Twine, Natalie C.  
; APPLICANT: Dörner, Andrew J.  
; APPLICANT: Trepicchio, William L.  
; APPLICANT: Slonim, Donna K.  
; APPLICANT: Stover, Jennifer A.  
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS  
; FILE REFERENCE: AM101080L  
; CURRENT APPLICATION NUMBER: US/10/717,597  
; CURRENT FILING DATE: 2003-11-21  
; PRIOR APPLICATION NUMBER: US 60/459,782  
; PRIOR FILING DATE: 2003-04-03  
; PRIOR APPLICATION NUMBER: US 60/427,982  
; PRIOR FILING DATE: 2002-11-21  
; NUMBER OF SEQ ID NOS: 4904  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1316  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-717-597-1316

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1196 TCTCGGGTCACCACTGCTTCC 1220  
Db 1 TCTCGGGTCACCACTGCTTCC 25  
|||||

RESULT 4  
US-10-717-597-1317  
; Sequence 1317, Application US/10717597  
; Publication No. US20040110221A1

; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Burczynski, Michael E.  
; APPLICANT: Twine, Natalie C.  
; APPLICANT: Dörner, Andrew J.  
; APPLICANT: Trepicchio, William L.  
; APPLICANT: Slonim, Donna K.  
; APPLICANT: Stover, Jennifer A.  
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS  
; FILE REFERENCE: AM101080L  
; CURRENT APPLICATION NUMBER: US/10/717,597  
; CURRENT FILING DATE: 2003-11-21  
; PRIOR APPLICATION NUMBER: US 60/459,782  
; PRIOR FILING DATE: 2003-04-03  
; PRIOR APPLICATION NUMBER: US 60/427,982  
; PRIOR FILING DATE: 2002-11-21  
; NUMBER OF SEQ ID NOS: 4904  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1317  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-717-597-1317

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1256 TGAGGTGGTCGTGAAGCTCTTTGAC 1280  
Db 1 TGAGGTGGTCGTGAAGCTCTTTGAC 25  
|||||

RESULT 5  
US-10-717-597-1318  
; Sequence 1318, Application US/10717597  
; Publication No. US20040110221A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Burczynski, Michael E.  
; APPLICANT: Twine, Natalie C.  
; APPLICANT: Dörner, Andrew J.  
; APPLICANT: Trepicchio, William L.  
; APPLICANT: Slonim, Donna K.  
; APPLICANT: Stover, Jennifer A.  
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS  
; FILE REFERENCE: AM101080L  
; CURRENT APPLICATION NUMBER: US/10/717,597  
; CURRENT FILING DATE: 2003-11-21  
; PRIOR APPLICATION NUMBER: US 60/459,782  
; PRIOR FILING DATE: 2003-04-03  
; PRIOR APPLICATION NUMBER: US 60/427,982  
; PRIOR FILING DATE: 2002-11-21  
; NUMBER OF SEQ ID NOS: 4904  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 1318  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-717-597-1318

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1262 GGTCTGAAGCTCTTTGACTCTGAT 1286  
Db 1 GGTCTGAAGCTCTTTGACTCTGAT 25  
|||||

RESULT 6  
US-10-717-597-1319  
; Sequence 1319, Application US/10717597

```
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1319
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1319

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1268 GAAGCTCTTTGACTCTGATCCCATC 1292
Db 1 GAAGCTCTTTGACTCTGATCCCATC 25

RESULT 7
US-10-717-597-1320
; Sequence 1320, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1320
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1320

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1274 CTTTGACTCTGATCCCATCACTGTG 1298
Db 1 CTTTGACTCTGATCCCATCACTGTG 25

RESULT 8
US-10-717-597-1321
```

```
; Sequence 1321, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1321
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1321

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1397 AGATGTGGATGTTGCTTTTGACCT 1421
Db 1 AGATGTGGATGTTGCTTTTGACCT 25

RESULT 9
US-10-717-597-1322
; Sequence 1322, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1322
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1322

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1470 CCAGAGAGAGCTCTGCACGTCACCA 1494
Db 1 CCAGAGAGAGCTCTGCACGTCACCA 25

RESULT 10
```

```

RESULT 13
US-10-717-597-1326
; Sequence 1326, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dornier, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCES: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIORITY APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIORITY APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1326
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1326

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1556  TGCACCTTAACACTCGACTCTGCTG 1580
Db      1      TGCACCTTAACACTCGACTCTGCTG 25

```

```
RESULT 14
US-10-717-597-1327
; Sequence 1327, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1327
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1327

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1562 CTAACACTCGACTCTGCTGCTCATG 1586
DB 1 CTAACACTCGACTCTGCTGCTCATG 25

RESULT 15
US-10-717-597-1328
; Sequence 1328, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1328

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1563 TAACACTCGACTCTGCTGCTCATGG 1587
DB 1 TAACACTCGACTCTGCTGCTCATGG 25
```

```
RESULT 16
US-10-717-597-1329
; Sequence 1329, Application US/10717597
; Publication No. US20040110221A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Burczynski, Michael E.
; APPLICANT: Twine, Natalie C.
; APPLICANT: Dörner, Andrew J.
; APPLICANT: Trepicchio, William L.
; APPLICANT: Slonim, Donna K.
; APPLICANT: Stover, Jennifer A.
; TITLE OF INVENTION: METHODS FOR DIAGNOSING RCC AND OTHER SOLID TUMORS
; FILE REFERENCE: AM101080L
; CURRENT APPLICATION NUMBER: US/10/717,597
; CURRENT FILING DATE: 2003-11-21
; PRIOR APPLICATION NUMBER: US 60/459,782
; PRIOR FILING DATE: 2003-04-03
; PRIOR APPLICATION NUMBER: US 60/427,982
; PRIOR FILING DATE: 2002-11-21
; NUMBER OF SEQ ID NOS: 4904
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1329
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-717-597-1329

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1564 AACACTCGACTCTGCTGCTCATGGG 1588
DB 1 AACACTCGACTCTGCTGCTCATGGG 25

RESULT 17
US-10-956-157-25933
; Sequence 25933, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25933
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25933

Query Match          1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 494 CTTCTACTTCTGGATGAATGGTGAC 518
DB 1 CTTCTACTTCTGGATGAATGGTGAC 25

RESULT 18
US-10-956-157-25934
; Sequence 25934, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
```



```
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25934
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25934

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 493 CCTTCTACTTCTGGATGAATGGTGA 517
      |||||||
Db 1 CCTTCTACTTCTGGATGAATGGTGA 25

RESULT 19
US-10-956-157-25935
; Sequence 25935, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25935
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25935

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 495 TTCTACTTCTGGATGAATGGTGACC 519
      |||||||
Db 1 TTCTACTTCTGGATGAATGGTGACC 25

RESULT 20
US-10-956-157-25936
; Sequence 25936, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25936
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25936
```

```
Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 300 CTAATGAGACCAAGGAATCAGAGA 324
      |||||||
Db 1 CTAATGAGACCAAGGAATCAGAGA 25

RESULT 21
US-10-956-157-25937
; Sequence 25937, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25937
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25937

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 301 TAAATGAGACCAAGGAATCAGAGAC 325
      |||||||
Db 1 TAAATGAGACCAAGGAATCAGAGAC 25

RESULT 22
US-10-956-157-25938
; Sequence 25938, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25938
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25938

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 281 GAAGAGAGAAAGAGATGCCCTAAAT 305
      |||||||
Db 1 GAAGAGAGAAAGAGATGCCCTAAAT 25

RESULT 23
US-10-956-157-25939
; Sequence 25939, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25939
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25939

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 282 AAGAAGAAAGAGGATGCCCTAAATG 306
|||||
Db 1 AAGAAGAAAGAGGATGCCCTAAATG 25

RESULT 24
US-10-956-157-25940
; Sequence 25940, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25940
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25940

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 284 GAAGAAGAGGATGCCCTAAATGAG 308
|||||
Db 1 GAAGAAGAGGATGCCCTAAATGAG 25

RESULT 25
US-10-956-157-25941
; Sequence 25941, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25941
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25941

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 284 GAAGAAGAGGATGCCCTAAATGAG 308
|||||
Db 1 GAAGAAGAGGATGCCCTAAATGAG 25

RESULT 26
US-10-956-157-25942
; Sequence 25942, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25942
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25942

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 283 AGAAGAAAGAGGATGCCCTAAATGA 307
|||||
Db 1 AGAAGAAAGAGGATGCCCTAAATGA 25

RESULT 27
US-10-956-157-25943
; Sequence 25943, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25943
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25943

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAAGAGGATGCCCTAAA 304
|||||
Db 1 AGAAGAAAGAGGATGCCCTAAA 25

RESULT 28
US-10-956-157-25944
; Sequence 25944, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
```

```

Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 285 AAGAAGAGGATGCCCTAAATGAGA 309
|||||
Db 1 AAGAAGAGGATGCCCTAAATGAGA 25

RESULT 26
US-10-956-157-25942
; Sequence 25942, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25942
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25942

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 283 AGAAGAAAGAGGATGCCCTAAATGA 307
|||||
Db 1 AGAAGAAAGAGGATGCCCTAAATGA 25

RESULT 27
US-10-956-157-25943
; Sequence 25943, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25943
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25943

Query Match
Best Local Similarity 1.5%; Score 25; DB 1; Length 25;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 280 AGAAGAAAGAGGATGCCCTAAA 304
|||||
Db 1 AGAAGAAAGAGGATGCCCTAAA 25

RESULT 28
US-10-956-157-25944
; Sequence 25944, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
```

```
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25944
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25944

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 279 AAGAAGAAGAAAGAGGATGCCCTAA 303
      |||||
Db 1 AAGAAGAAGAAAGAGGATGCCCTAA 25

RESULT 29
US-10-956-157-25945
; Sequence 25945, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25945
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25945

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 492 CCCTTCTACTTCTGGATGAATGGTG 516
      |||||
Db 1 CCCTTCTACTTCTGGATGAATGGTG 25

RESULT 30
US-10-956-157-25946
; Sequence 25946, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25946
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25946

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 492 CCCTTCTACTTCTGGATGAATGGTG 516
      |||||
Db 1 CCCTTCTACTTCTGGATGAATGGTG 25

RESULT 31
US-10-956-157-25947
; Sequence 25947, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25947
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25947

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 286 AGAAGAGGATGCCCTAAATGAGAC 310
      |||||
Db 1 AGAAGAGGATGCCCTAAATGAGAC 25

RESULT 32
US-10-956-157-25948
; Sequence 25948, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25948
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25948

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 278 CAAGAAGAGAAAGAGGATGCCCTA 302
      |||||
Db 1 CAAGAAGAGAAAGAGGATGCCCTA 25

RESULT 33
US-10-956-157-25949
; Sequence 25949, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

```
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 496 TCTACTTCTGGATGAATGGTGACCG 520
      |||||
Db 1 TCTACTTCTGGATGAATGGTGACCG 25

RESULT 31
US-10-956-157-25947
; Sequence 25947, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25947
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25947

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 286 AGAAGAGGATGCCCTAAATGAGAC 310
      |||||
Db 1 AGAAGAGGATGCCCTAAATGAGAC 25

RESULT 32
US-10-956-157-25948
; Sequence 25948, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 25948
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-25948

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 278 CAAGAAGAGAAAGAGGATGCCCTA 302
      |||||
Db 1 CAAGAAGAGAAAGAGGATGCCCTA 25

RESULT 33
US-10-956-157-25949
; Sequence 25949, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
```

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25949  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25949

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1066 AATACACGAGCTGCTAAAGTCCTA 1090  
|||||  
Db 1 AATACACGAGCTGCTAAAGTCCTA 25

RESULT 34  
US-10-956-157-25950  
; Sequence 25950, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25950  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25950

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 299 CCTAAATGAGACCGAGGAATCAGAG 323  
|||||  
Db 1 CCTAAATGAGACCGAGGAATCAGAG 25

RESULT 35  
US-10-956-157-25951  
; Sequence 25951, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25951  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25951

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1048 CTGAGAGTTGACCAGGAATACAA 1072  
|||||  
Db 1 CTGAGAGTTGACCAGGAATACAA 25

RESULT 36  
US-10-956-157-25952  
; Sequence 25952, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25952  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25952

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1064 GAAATACACGAGCTGCTAAAGTCC 1088  
|||||  
Db 1 GAAATACACGAGCTGCTAAAGTCC 25

RESULT 37  
US-10-956-157-25953  
; Sequence 25953, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25953  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25953

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1063 GGAATACACGAGCTGCTAAAGTC 1087  
|||||  
Db 1 GGAATACACGAGCTGCTAAAGTC 25

RESULT 38  
US-10-956-157-25954  
; Sequence 25954, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081);  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25954  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25954

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1067 ATACAAGAGCTGCTAAAGTCTTAC 1091  
Db 1 ATACAAGAGCTGCTAAAGTCTTAC 25

## RESULT 39

US-10-956-157-25955  
; Sequence 25955, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25955  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25955

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 398 GAAACAGACCTGCATGAAGTCTTAC 422  
Db 1 GAAACAGACCTGCATGAAGTCTTAC 25

## RESULT 40

US-10-956-157-25956  
; Sequence 25956, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 25956  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-25956

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 304 ATGAGACCAGGGGAATCAGAGACAAA 328  
Db 1 ATGAGACCAGGGGAATCAGAGACAAA 25

## RESULT 41

US-10-956-157-122144  
; Sequence 122144, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 122144  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-122144

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 850 AGACCCGCCCAACAGATTTCATCG 874  
Db 1 AGACCCGCCCAACAGATTTCATCG 25

## RESULT 42

US-10-956-157-127897  
; Sequence 127897, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 127897  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-127897

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 411 ATGAAGTTCTACGACGCGTCTGCA 435  
Db 1 ATGAAGTTCTACGACGCGTCTGCA 25

## RESULT 43

US-10-956-157-131009  
; Sequence 131009, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 131009  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-131009

; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 131009  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-131009

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 561 ATGCTGGATGTCATGCAGGACCACT 585  
|||||

Db 1 ATGCTGGATGTCATGCAGGACCACT 25  
|||||

## RESULT 44

US-10-956-157-134947  
; Sequence 134947, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 134947  
; LENGTH: 25  
; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-134947

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 334 AGGAGTCCCGAGTGTCGAATGA 358  
|||||

Db 1 AGGAGTCCCGAGTGTCGAATGA 25  
|||||

## RESULT 45

US-10-956-157-135244  
; Sequence 135244, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 135244  
; LENGTH: 25  
; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-135244

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 292 AGGATGCCCTAAATGAGACCAGGA 316

Db 1 AGGATGCCCTAAATGAGACCAGGA 25  
|||||

## RESULT 46

US-10-956-157-139926  
; Sequence 139926, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 139926  
; LENGTH: 25  
; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-139926

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 307 AGACCAGGGAATCAGACAAAGCT 331  
|||||

Db 1 AGACCAGGGAATCAGACAAAGCT 25  
|||||

## RESULT 47

US-10-956-157-140752  
; Sequence 140752, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 140752  
; LENGTH: 25  
; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-140752

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 875 AGAAGCGCAGATGACCCGACTGTG 899  
|||||

Db 1 AGAAGCGCAGATGACCCGACTGTG 25  
|||||

## RESULT 48

US-10-956-157-141327  
; Sequence 141327, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 141327  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-141327

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1299 ACGTCCCTGTAGAGTCTCCAGCA 1323  
Db 1 ACGTCCCTGTAGAGTCTCCAGCA 25

## RESULT 49

US-10-956-157-146594  
; Sequence 146594, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 146594  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-146594

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 889 ACCGGACTGTGTCCGGGAGATCCG 913  
Db 1 ACCGGACTGTGTCCGGGAGATCCG 25

## RESULT 50

US-10-956-157-146923  
; Sequence 146923, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 146923  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-146923

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 544 ACCGGCAGCAGCACATGCTGGA 568  
|||||

Db 1 ACCGGCAGCAGCACATGCTGGA 25

## RESULT 51

US-10-956-157-156812  
; Sequence 156812, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 156812  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-156812

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1379 AAAGCACCCGGGAGGTGAGATGTG 1403  
Db 1 AAAGCACCCGGGAGGTGAGATGTG 25

## RESULT 52

US-10-956-157-158656  
; Sequence 158656, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 158656  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-158656

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1083 AAGTCCTACCAGTGGGAAGATGCTCA 1107  
Db 1 AAGTCCTACCAGTGGGAAGATGCTCA 25

## RESULT 53

US-10-956-157-159440  
; Sequence 159440, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 159440  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-159440

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1071 AACGAGCTGCTAAAGTCTACCACT 1095  
|||||  
Db 1 AACGAGCTGCTAAAGTCTACCACT 25

## RESULT 54

US-10-956-157-168291  
; Sequence 168291, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 168291  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-168291

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 182 AATTCAAAATGCTGTCACCGGGGTG 206  
|||||  
Db 1 AATTCAAAATGCTGTCACCGGGGTG 25

## RESULT 55

US-10-956-157-172467  
; Sequence 172467, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 172467  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-172467

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1140 CAGTTTAACTGGGTGTCCTCCGGCTGG 1164  
|||||  
Db 1 CAGTTTAACTGGGTGTCCTCCGGCTGG 25

## RESULT 56

US-10-956-157-174696  
; Sequence 174696, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 174696  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-174696

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 462 CAGCTTGAGGAGTTCCTGAACACAGA 486  
|||||  
Db 1 CAGCTTGAGGAGTTCCTGAACACAGA 25

## RESULT 57

US-10-956-157-174708  
; Sequence 174708, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 174708  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-174708

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 780 CAGCCCTTCCTTGAGATGATACACG 804  
|||||  
Db 1 CAGCCCTTCCTTGAGATGATACACG 25

## RESULT 58

US-10-956-157-174902  
; Sequence 174902, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805





; SEQ ID NO 186902  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-186902

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1602 CTCCTGCATGCAACTAATTCAATAA 1626  
|||||  
Db 1 CTCCTGCATGCAACTAATTCAATAA 25

## RESULT 64

US-10-956-157-186903  
; Sequence 186903, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 186903  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-186903

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1602 CTCCTGCATGCAACTAATTCAATAA 1626  
|||||  
Db 1 CTCCTGCATGCAACTAATTCAATAA 25

## RESULT 65

US-10-956-157-186908  
; Sequence 186908, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 186908  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-186908

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1482 CTGCAGTCACCAAGTAACCAAGCC 1506  
|||||  
Db 1 CTGCAGTCACCAAGTAACCAAGCC 25

## RESULT 66

US-10-956-157-186914  
; Sequence 186914, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 186914  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-186914

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1038 CTCCAGTCGCTGAGAGGTTGACCA 1062  
|||||  
Db 1 CTCCAGTCGCTGAGAGGTTGACCA 25

## RESULT 67

US-10-956-157-188008  
; Sequence 188008, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 188008  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-188008

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 78 CTGCTGCTGACCTGGGAGAGTGGGC 102  
|||||  
Db 1 CTGCTGCTGACCTGGGAGAGTGGGC 25

## RESULT 68

US-10-956-157-188038  
; Sequence 188038, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:

; APPLICANT: Wyeth  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 188038

```

; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-188038

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 407 CTGCATGAAGTTCTACGACGCTC 431
      |||||
Db 1 CTGCATGAAGTTCTACGACGCTC 25

RESULT 69
US-10-956-157-189641
; Sequence 189641, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 189641
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-189641

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 976 CTGTGGACTGTTCCACCACCAACCC 1000
      |||||
Db 1 CTGTGGACTGTTCCACCACCAACCC 25

RESULT 70
US-10-956-157-191487
; Sequence 191487, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 191487
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-191487

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 884 CGATGACCGGACTGTGTGCGCGGAG 908
      |||||
Db 1 CGATGACCGGACTGTGTGCGCGGAG 25

RESULT 71
```

```

US-10-956-157-193107
; Sequence 193107, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193107
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-193107

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 490 CGCCCTTCTACTTCTGGATGAATGG 514
      |||||
Db 1 CGCCCTTCTACTTCTGGATGAATGG 25

RESULT 72
US-10-956-157-193726
; Sequence 193726, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 193726
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-193726

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 341 CCCAGGAGTGTGCAATGAGACCATG 365
      |||||
Db 1 CCCAGGAGTGTGCAATGAGACCATG 25

RESULT 73
US-10-956-157-194937
; Sequence 194937, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 194937
; LENGTH: 25
```

```
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-194937

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 390 CCTGCTGAAACAGACCTGCATGA 414
      |||||
Db 1 CCTGCTGAAACAGACCTGCATGA 25

RESULT 74
US-10-956-157-195328
; Sequence 195328, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195328
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-195328

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 854 CCCGCCAACAGAAATTCATACGAGAA 878
      |||||
Db 1 CCCGCCAACAGAAATTCATACGAGAA 25

RESULT 75
US-10-956-157-195368
; Sequence 195368, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 195368
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-195368

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1467 CCCCAGAGAGAGCTCTGCACGTCA 1491
      |||||
Db 1 CCCCAGAGAGAGCTCTGCACGTCA 25

RESULT 76
US-10-956-157-196424
```

```
; Sequence 196424, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 196424
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-196424

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 590 CCGCGGTCGACGATCATAGACGAG 614
      |||||
Db 1 CCGCGGTCGACGATCATAGACGAG 25

RESULT 77
US-10-956-157-199713
; Sequence 199713, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 199713
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-199713

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 106 TCCTGGGGACCGACGCGTCTCAGA 130
      |||||
Db 1 TCCTGGGGACCGACGCGTCTCAGA 25

RESULT 78
US-10-956-157-206442
; Sequence 206442, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 206442
; LENGTH: 25
; TYPE: DNA
```

```

; ORGANISM: Probe Sequence
US-10-956-157-206442

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 782 GCCCTTCCTTGAGATGATACACGAG 806
      |||||
Db 1 GCCCTTCCTTGAGATGATACACGAG 25

RESULT 79
US-10-956-157-208499
; Sequence 208499, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 208499
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-208499

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1121 GCTGGAGCAGCTGACGAGCAGTTT 1145
      |||||
Db 1 GCTGGAGCAGCTGACGAGCAGTTT 25

RESULT 80
US-10-956-157-212934
; Sequence 212934, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 212934
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-212934

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1364 GCAGGAATACCGCAAAAGCACCGG 1388
      |||||
Db 1 GCAGGAATACCGCAAAAGCACCGG 25

RESULT 81
US-10-956-157-215054
; Sequence 215054, Application US/10956157

```

```

; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 215054
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-215054

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 GCAGACGCACATGCTGGATGTCATG 575
      |||||
Db 1 GCAGACGCACATGCTGGATGTCATG 25

RESULT 82
US-10-956-157-216983
; Sequence 216983, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 216983
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-216983

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 247 GCAAGACACTGCTCAGCAACCTAGA 271
      |||||
Db 1 GCAAGACACTGCTCAGCAACCTAGA 25

RESULT 83
US-10-956-157-218349
; Sequence 218349, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 218349
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence

```

## US-10-956-157-218349

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1596 GAATTGCTCTGCGATGCAACTAATT 1620  
|||||  
Db 1 GAATTGCTCTGCGATGCAACTAATT 25

## RESULT 84

US-10-956-157-218350  
; Sequence 218350, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 218350

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-218350

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1596 GAATTGCTCTGCGATGCAACTAATT 1620  
|||||  
Db 1 GAATTGCTCTGCGATGCAACTAATT 25

## RESULT 85

US-10-956-157-218351  
; Sequence 218351, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 218351

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-218351

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1596 GAATTGCTCTGCGATGCAACTAATT 1620  
|||||  
Db 1 GAATTGCTCTGCGATGCAACTAATT 25

## RESULT 86

US-10-956-157-219734  
; Sequence 219734, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 219734

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-219734

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1311 GAAGTCTCCAGGAAGAACCTTAAT 1335  
|||||  
Db 1 GAAGTCTCCAGGAAGAACCTTAAT 25

## RESULT 87

US-10-956-157-220245  
; Sequence 220245, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 220245

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-220245

Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 941 GAAGGACCAGTGTGACAAGTGGCGG 965  
|||||  
Db 1 GAAGGACCAGTGTGACAAGTGGCGG 25

## RESULT 88

US-10-956-157-221279  
; Sequence 221279, Application US/10956157  
; Publication No. US20050118625A1

## ; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 221279

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

## US-10-956-157-221279

```

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1588 GAAGAACAGAAATTCCTCTGCATGC 1612
Db 1 GAAGAACAGAAATTCCTCTGCATGC 25

RESULT 89
US-10-956-157-221280
; Sequence 221280, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 221280
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-221280

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1588 GAAGAACAGAAATTCCTCTGCATGC 1612
Db 1 GAAGAACAGAAATTCCTCTGCATGC 25

RESULT 90
US-10-956-157-222407
; Sequence 222407, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 222407
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-222407

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1325 GAACCCCTAAATTTATGGACACGCTG 1349
Db 1 GAACCCCTAAATTTATGGACACGCTG 25

RESULT 91
US-10-956-157-225352
; Sequence 225352, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:

```

```

; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 225352
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-225352

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1355 GAAAGCGCTGCAGGAATACCGCAA 1379
Db 1 GAAAGCGCTGCAGGAATACCGCAA 25

RESULT 92
US-10-956-157-228789
; Sequence 228789, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 228789
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228789

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1571 GACTCTGCTGCTCATGGGAAGAACA 1595
Db 1 GACTCTGCTGCTCATGGGAAGAACA 25

RESULT 93
US-10-956-157-229312
; Sequence 229312, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 229312
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-229312

```

```
Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 119 GAGGCTCTCAGCAATGAGTCCAG 143
      |||||
Db 1 GAGGCTCTCAGCAATGAGTCCAG 25

RESULT 94
US-10-956-157-230136
; Sequence 230136, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 230136
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-230136

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 404 GACCTGCATGAAGTTCTACGACGC 428
      |||||
Db 1 GACCTGCATGAAGTTCTACGACGC 25

RESULT 95
US-10-956-157-230317
; Sequence 230317, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 230317
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-230317

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1185 GACCAGTACTATCTCGGGGTACCA 1209
      |||||
Db 1 GACCAGTACTATCTCGGGGTACCA 25

RESULT 96
US-10-956-157-231573
; Sequence 231573, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
```

```
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 231573
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-231573

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 135 GAGCTCCAGGAAATGTCCAATCAGG 159
      |||||
Db 1 GAGCTCCAGGAAATGTCCAATCAGG 25

RESULT 97
US-10-956-157-231724
; Sequence 231724, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 231724
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-231724

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1074 GAGCTGCTAAAGTCTCTACCAGTGG 1098
      |||||
Db 1 GAGCTGCTAAAGTCTCTACCAGTGG 25

RESULT 98
US-10-956-157-231783
; Sequence 231783, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 231783
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-231783

Query Match      1.5%; Score 25; DB 1; Length 25;
```



```

Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1137 GAGCAGTTTAACTGGGTGTCCTCCGC 1161
      |||||
Db 1 GAGCAGTTTAACTGGGTGTCCTCCGC 25

RESULT 99
US-10-956-157-232704
; Sequence 232704, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 232704
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-232704

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1341 GAGACCGTGGCGGAGAAAGCCCTGC 1365
      |||||
Db 1 GAGACCGTGGCGGAGAAAGCCCTGC 25

RESULT 100
US-10-956-157-233030
; Sequence 233030, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233030
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-233030

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 321 GAGACAAAGCTGAAGAGCTCCAG 345
      |||||
Db 1 GAGACAAAGCTGAAGAGCTCCAG 25

RESULT 101
US-10-956-157-233762
; Sequence 233762, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William

```

```

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 233762
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-233762

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 966 GAGATCTTGTCTGTGGACTGTTCAC 990
      |||||
Db 1 GAGATCTTGTCTGTGGACTGTTCAC 25

RESULT 102
US-10-956-157-235882
; Sequence 235882, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 235882
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-235882

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 468 GAGGAGTTCTCTGAACACGAGCTCGC 492
      |||||
Db 1 GAGGAGTTCTCTGAACACGAGCTCGC 25

RESULT 103
US-10-956-157-236817
; Sequence 236817, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 236817
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-236817

Query Match 1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 468 GAGGAGTTCTCTGAACACGAGCTCGC 492
      |||||
Db 1 GAGGAGTTCTCTGAACACGAGCTCGC 25

```

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 43 GAGCATGATGAGACTCTGCTGCT 67  
|||||  
Db 1 GAGCATGATGAGACTCTGCTGCT 25

## RESULT 104

US-10-956-157-237638  
; Sequence 237638, Application US/10956157  
; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 237638

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-237638

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 794 GATGATACACGAGGCTCAGCAGGCC 818  
|||||

Db 1 GATGATACACGAGGCTCAGCAGGCC 25

## RESULT 105

US-10-956-157-238337

; Sequence 238337, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 238337

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-238337

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 506 GATGAATGGTGACCGCATCGACTCC 530  
|||||

Db 1 GATGAATGGTGACCGCATCGACTCC 25

## RESULT 106

US-10-956-157-243092

; Sequence 243092, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH

; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 243092

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-243092

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 416 GTTCTACGCACGCGTCTGCAGAGT 440  
|||||

Db 1 GTTCTACGCACGCGTCTGCAGAGT 25

## RESULT 107

US-10-956-157-252760

; Sequence 252760, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 252760

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-252760

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1044 GTCGCTGAGAGTTGACACAGAAAT 1068  
|||||

Db 1 GTCGCTGAGAGTTGACACAGAAAT 25

## RESULT 108

US-10-956-157-253138

; Sequence 253138, Application US/10956157

; Publication No. US20050118625A1

; GENERAL INFORMATION:

; APPLICANT: Wyeth

; APPLICANT: Mounts, William

; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)

; CURRENT APPLICATION NUMBER: US/10/956,157

; CURRENT FILING DATE: 2004-10-04

; NUMBER OF SEQ ID NOS: 319805

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 253138

; LENGTH: 25

; TYPE: DNA

; ORGANISM: Probe Sequence

US-10-956-157-253138

Query Match 1.5%; Score 25; DB 1; Length 25;

Best Local Similarity 100.0%; Pred. No. 72;

Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 596 GTCCAGCATCATGACGAGCTCTTC 620  
|||||  
Db 1 GTCCAGCATCATGACGAGCTCTTC 25  
|||||

RESULT 109  
US-10-956-157-255424  
; Sequence 255424, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 255424  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-255424

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1394 GTGAGATGTGGATGTGCTTTTGCA 1418  
|||||  
Db 1 GTGAGATGTGGATGTGCTTTTGCA 25  
|||||

RESULT 110  
US-10-956-157-255957  
; Sequence 255957, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 255957  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-255957

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 383 GTGTAAGCCCTGCCTGAAACAGACC 407  
|||||  
Db 1 GTGTAAGCCCTGCCTGAAACAGACC 25  
|||||

RESULT 111  
US-10-956-157-256203  
; Sequence 256203, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES

; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 256203  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-256203

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 348 GTGTGCAATGAGACCAATGATGGCCC 372  
|||||  
Db 1 GTGTGCAATGAGACCAATGATGGCCC 25  
|||||

RESULT 112  
US-10-956-157-261789  
; Sequence 261789, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 261789  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-261789

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1259 GGTGTCGTGAAGCTCTTTGACTCT 1283  
|||||  
Db 1 GGTGTCGTGAAGCTCTTTGACTCT 25  
|||||

RESULT 113  
US-10-956-157-266662  
; Sequence 266662, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 266662  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-266662

Query Match 1.5%: Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 566 GGATGTCATGCAGGACCACTTCAG 590  
|||  
Db 1 GGATGTCATGCAGGACCACTTCAG 25

```

RESULT 114
US-10-956-157-268124
; Sequence 268124, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Wyeth
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 268124
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-268124

```

```

RESULT 115
US-10-956-157-269972
; Sequence 269972, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 269972
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-269972

```

RESULT 116  
US-10-956-157-273702  
; Sequence 273702, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)

```

; CURRENT APPLICATION NUMBER: US/10/956,157
;
; CURRENT FILING DATE: 2004-10-04
;
; NUMBER OF SEQ ID NOS: 319805
;
; SOFTWARE: PatentIn version 3.2
;
; SEQ ID NO 273702
;
; LENGTH: 25
;
; TYPE: DNA
;
; ORGANISM: Probe Sequence
US-10-956-157-273702

```

```

RESULT 117
US-10-956-157-274079
; Sequence 274079, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274079
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274079

```

```

RESULT 118
US-10-956-157-274264
; Sequence 274264, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wveth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 274264
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-274264

```

Db 1 GGCAGAACCACTACTATCTGCGGG 25  
|||||  
RESULT 119  
US-10-956-157-274647  
; Sequence 274647, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 274647  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-274647  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 20 GCGGTGCAAGACTCCAGATTGGA 44  
|||||  
Db 1 GCGGTGCAAGACTCCAGATTGGA 25  
|||||  
RESULT 120  
US-10-956-157-279222  
; Sequence 279222, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 279222  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-279222  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 1295 TGTGACGGTCCCTGTAGAAGTCTCC 1319  
|||||  
Db 1 TGTGACGGTCCCTGTAGAAGTCTCC 25  
|||||  
RESULT 121  
US-10-956-157-281215  
; Sequence 281215, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157

; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 281215  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-281215  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 150 TCCAATCAGGGAAGTAAGTACGTCA 174  
|||||  
Db 1 TCCAATCAGGGAAGTAAGTACGTCA 25  
|||||  
RESULT 122  
US-10-956-157-285427  
; Sequence 285427, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 285427  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-285427  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 52 TGAAGACTCTGCTGCTGTTGTGGG 76  
|||||  
Db 1 TGAAGACTCTGCTGCTGTTGTGGG 25  
|||||  
RESULT 123  
US-10-956-157-285561  
; Sequence 285561, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; CURRENT APPLICATION NUMBER: US/10/956.157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 285561  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-285561  
Query Match 1.5%; Score 25; DB 1; Length 25;  
Best Local Similarity 100.0%; Pred. No. 72;  
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Qy 351 TGCATGAGACCATGATGCGCCTCT 375  
|||||

```
Db      1  TGCATGAGACCATGATGGCCCTCT 25

RESULT 124
US-10-956-157-285688
; Sequence 285688, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 285688
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-285688

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      256  TGCTCAGCAACCTAGAGAAGCCAA 280
          |||||
Db      1  TGCTCAGCAACCTAGAGAAGCCAA 25

RESULT 125
US-10-956-157-287832
; Sequence 287832, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287832
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287832

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      960  TGCCGGGAGATCTGTGTGGACT 984
          |||||
Db      1  TGCCGGGAGATCTGTGTGGACT 25

RESULT 126
US-10-956-157-291738
; Sequence 291738, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
```

```
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291738
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-291738

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1002  TCCAGGCTAAGCTGCGGGGAGC 1026
          |||||
Db      1  TCCAGGCTAAGCTGCGGGGAGC 25

RESULT 127
US-10-956-157-292100
; Sequence 292100, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 292100
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-292100

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1264  TCGTGAAGCTCTTGACTCTGATCC 1288
          |||||
Db      1  TCGTGAAGCTCTTGACTCTGATCC 25

RESULT 128
US-10-956-157-292272
; Sequence 292272, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 292272
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-292272

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1569  TCGACTCTCTGCTCATGGGAAGAA 1593
          |||||
Db      1  TCGACTCTCTGCTCATGGGAAGAA 25
```

```

RESULT 129
US-10-956-157-297166
; Sequence 297166, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 297166
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-297166

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1171 TCACGCAAGGCGAAGACCAAGTACTA 1195
Db      1 TCACGCAAGGCGAAGACCAAGTACTA 25

RESULT 130
US-10-956-157-302171
; Sequence 302171, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 302171
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-302171

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      871 TACGAGAAGGCGACATGACCGGAC 895
Db      1 TACGAGAAGGCGACATGACCGGAC 25

RESULT 131
US-10-956-157-316681
; Sequence 316681, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805

```

```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 316681
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-316681

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1244 TTCGGGTGTCACGTGAGGTGTCGTG 1268
Db      1 TTCGGGTGTCACGTGAGGTGTCGTG 25

RESULT 132
US-10-956-157-317598
; Sequence 317598, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 317598
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-317598

Query Match      1.5%; Score 25; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 72;
Matches 25; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1240 TTCCTCCGGTGTCACTGAGGTGT 1264
Db      1 TTCCTCCGGTGTCACTGAGGTGT 25

RESULT 133
US-10-956-157-287991
; Sequence 287991, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 287991
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-287991

Query Match      1.5%; Score 24; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 90;
Matches 24; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      8 GCCGCTGACCGAGCGGTGCAAGA 31
Db      2 GCCGCTGACCGAGCGGTGCAAGA 25

```

```
RESULT 134
US-10-719-956-187214
; Sequence 187214, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 187214
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-187214

Query Match          1.4%; Score 23.4; DB 1; Length 25;
Best Local Similarity 96.0%; Pred. No. 1e+02;
Matches 24; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 969 ATCTGCTGTGGACTGTTCCACCA 993
Db 1 ATCTGCTGTGGACTGTTCCACCA 25

RESULT 135
US-10-080-794-16
; Sequence 16, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR FILING DATE: 2001-08-10
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 16
; LENGTH: 23
; TYPE: DNA
; ORGANISM: HUMAN
US-10-080-794-16

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 177 AAGAAATTCAAAATGCTGTCAA 199
Db 1 AAGAAATTCAAAATGCTGTCAA 23

RESULT 136
US-10-080-794-17/c
; Sequence 17, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
```

```
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 17
; LENGTH: 23
; TYPE: DNA
; ORGANISM: HUMAN
US-10-080-794-17

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 957 AAGTCCGGGAGATCTTGTCGT 979
Db 23 AAGTCCGGGAGATCTTGTCGT 1

RESULT 137
US-10-380-124-5/c
; Sequence 5, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 5
; LENGTH: 23
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
US-10-380-124-5

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 789 CTTGAGATGATACACGAGGCTCA 811
Db 23 CTTGAGATGATACACGAGGCTCA 1

RESULT 138
US-10-646-436-57
; Sequence 57, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
```



```

; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 57
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-57

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 480 AACGAGCTCGCCCTTCTACTT 502
      |||||
Db 1 AACGAGCTCGCCCTTCTACTT 23

RESULT 139
US-10-646-436-60
; Sequence 60, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 60
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-60

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 711 AAGTCCCGCATCGTCGCGAGCTT 733
      |||||
Db 1 AAGTCCCGCATCGTCGCGAGCTT 23

RESULT 140
US-10-646-436-63
; Sequence 63, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 63
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-63

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 711 AAGTCCCGCATCGTCGCGAGCTT 733
      |||||
Db 1 AAGTCCCGCATCGTCGCGAGCTT 23

RESULT 141
US-10-646-436-66
; Sequence 66, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 66
; LENGTH: 23
; TYPE: DNA
; ORGANISM: human
US-10-646-436-66

Query Match          1.4%; Score 23; DB 1; Length 23;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCATATAAACTGCTT 1635
      |||||
Db 1 AACTAATTCATATAAACTGCTT 23

RESULT 142
US-10-956-157-291041
; Sequence 291041, Application US/10956157
; Publication No. US20050118625A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 291041
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-291041

Query Match      1.4%; Score 23; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 23; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1114 CCTCCTTGCTGGAGCAGCTGAAC 1136
        |||||||
Db       3 CCTCCTTGCTGGAGCAGCTGAAC 25

RESULT 143
US-10-980-850-34/c
; Sequence 34, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; PRIOR FILING DATE: 2003-11-03
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 34
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Reverse Primer for OAS1
US-10-980-850-34

Query Match      1.3%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1072 ACGAGCTGCTAAAGTCCTACCA 1093
        |||||||
Db       22 ACGAGCTGCTAAAGTCCTACCA 1

RESULT 144
US-10-956-157-167169
; Sequence 167169, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167169
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228788
; Sequence 228788, Application US/10956157
```

```
; ORGANISM: Probe Sequence
US-10-956-157-167169

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1622 AATAAACTGCTCTGTGAGCTG 1643
        |||||||
Db       1 AATAAACTGCTCTGTGAGCTG 22

RESULT 145
US-10-956-157-167170
; Sequence 167170, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167170
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-167170

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1622 AATAAACTGCTCTGTGAGCTG 1643
        |||||||
Db       1 AATAAACTGCTCTGTGAGCTG 22

RESULT 146
US-10-956-157-167171
; Sequence 167171, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 167171
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-167171

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1622 AATAAACTGCTCTGTGAGCTG 1643
        |||||||
Db       1 AATAAACTGCTCTGTGAGCTG 22

RESULT 147
US-10-956-157-228788
; Sequence 228788, Application US/10956157
```

```

; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 228788
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-228788

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1571 GACTCTGCTGCTCATGGAGA 1592
Db      1 GACTCTGCTGCTCATGGAGA 22

RESULT 148
US-10-956-157-279365
; Sequence 279365, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth
; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; TITLE OF INVENTION: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 279365
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-279365

Query Match      1.3%; Score 22; DB 1; Length 25;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1400 TGTGATGTTGCTTTTGACCT 1421
Db      1 TGTGATGTTGCTTTTGACCT 22

RESULT 149
US-10-719-900-56804
; Sequence 56804, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 56804
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-56804

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1269 AACCTCTTTGACTCTGATCCCATCA 1293
Db      1 AAGCTGTTTGACTCTGACCCCATCA 25

RESULT 150
US-10-719-900-417945
; Sequence 417945, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 417945
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-417945

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1133 GAACGACGAGTTTAACCTGGGTGTC 1157
Db      1 GAACGACGAGTTCACTGGGTGTC 25

RESULT 151
US-10-719-900-417946
; Sequence 417946, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 417946
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-417946

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1133 GAACGACGAGTTTAACCTGGGTGTC 1157
Db      1 GAACGACGAGTTGAACCTGGGTGTC 25

RESULT 152
US-10-719-900-815718
; Sequence 815718, Application US/10719900
; Publication No. US20050026164A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 815718
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-815718

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1245 TCCGGTGTCACTGAGGTGGTGGTGA 1269
      ||| ||||| ||||| ||||| |||||
Db 1 TCCGTGTCACTGAGGTGGTGGTGA 25

RESULT 153
US-10-719-900-892165
; Sequence 892165, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 892165
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-892165

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1149 TGGGTGTCCGGTGCACAACTCA 1173
      ||| ||||| ||||| ||||| |||||
Db 1 TGGGTGTCCAGCTGGGCTAACCTCA 25

RESULT 154
US-10-809-189-31760
; Sequence 31760, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 1999-09-15
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSEQ for Windows Version 4.0

; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 187213
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-187213

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1120 TGCTGGAGCAGCTGAACGAGCAGTT 1144
      ||||| ||||| ||||| ||||| |||||
Db 25 TGCTGGACAGCTGAACGACCAGTT 1

RESULT 156
US-10-719-956-187213
; Sequence 187213, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2003-11-20
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 187213
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-187213

Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 969 ATCTTGCTGTGGACTGTTCCACCA 993
      ||||| ||||| ||||| ||||| |||||
Db 1 ATCTTGCTGTGCACCTGTTCCACCA 25
```

```
RESULT 157
US-10-719-956-374026/c
; Sequence 374026, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 374026
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-374026
Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 975 TCTGTGGACTGTTCCACCAACACC 999
Db 25 TCTGTGGACTGTTCCACCAACATC 1

RESULT 158
US-10-719-956-501381
; Sequence 501381, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 501381
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-501381
Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1266 GTGAAGCTCTTTGACTCTGATCCCA 1290
Db 1 GTGAAGCTGTTTGACTCTGACCCCA 25

RESULT 159
US-10-719-956-612442/c
; Sequence 612442, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002-11-20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 612442
```

```
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-612442
Query Match      1.3%; Score 21.8; DB 1; Length 25;
Best Local Similarity 92.0%; Pred. No. 1.4e+02;
Matches 23; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1149 TGGGTGTCGCGGTGCGCAACCTCA 1173
Db 25 TGGGTGTCGCGGTGCGCTAACCTCA 1

RESULT 160
US-09-944-326-3/c
; Sequence 3, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; CURRENT FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-09-944-326-3
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 16 CCGAGGCGGTGCAAGACTCCA 36
Db 21 CCGAGGCGGTGCAAGACTCCA 1

RESULT 161
US-09-944-326-4/c
; Sequence 4, Application US/09944326
; Patent No. US20020128220A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY
; FILE REFERENCE: UBC.P-020-2
; CURRENT APPLICATION NUMBER: US/09/944,326
; CURRENT FILING DATE: 2001-08-30
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; NUMBER OF SEQ ID NOS: 14
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
```

; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-4

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68  
|||||  
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 162  
US-09-944-326-5/c  
; Sequence 5, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC.P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 5  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-5

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134  
|||||  
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 163  
US-09-944-326-6/c  
; Sequence 6, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC.P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 6  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN

; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-6

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 316 AATCAGACAAAGCTGAAGG 336  
|||||  
Db 21 AATCAGACAAAGCTGAAGG 1

RESULT 164  
US-09-944-326-7/c  
; Sequence 7, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC.P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 7  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-7

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535  
|||||  
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 165  
US-09-944-326-8/c  
; Sequence 8, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC.P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 8  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN

US-09-944-326-8

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 716 CCGCATCGTCCGAGCTTGAT 736  
Db 21 CCGCATCGTCCGAGCTTGAT 1

RESULT 166

US-09-944-326-9/c  
; Sequence 9, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 9  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-9

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 916 ACAACTCCACGGGCTGCTGC 936  
Db 21 ACAACTCCACGGGCTGCTGC 1

RESULT 167

US-09-944-326-10/c  
; Sequence 10, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 10  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-10

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 168

US-09-944-326-11/c  
; Sequence 11, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 11  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-11

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1316 CTCGAGGAAGAACCCCTAAATT 1336  
Db 21 CTCGAGGAAGAACCCCTAAATT 1

RESULT 169

US-09-944-326-12/c  
; Sequence 12, Application US/09944326  
; Patent No. US20020128220A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
; FILE REFERENCE: UBC P-020-2  
; CURRENT APPLICATION NUMBER: US/09/944,326  
; CURRENT FILING DATE: 2001-08-30  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; NUMBER OF SEQ ID NOS: 14  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 12  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-12

```
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCGGCCAGC 1536
Db 21 AGGCCCCCAACTCGGCCAGC 1

RESULT 170
US-09-459-749D-14
; Sequence 14, Application US/09459749D
; Patent No. US20020136716A1
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/09/459,749D
; CURRENT FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer bind
; OTHER INFORMATION: synthetic sense primer based on porcine clusterin
US-09-459-749D-14

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AAGCCAAGAGAAGAAAGAGG 294
Db 1 AAGCCAAGAGAAGAAAGAGG 21

RESULT 171
US-09-967-726A-3/c
; Sequence 3, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-3

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGGCGTGCAAGACTCCA 36
Db 21 CCGAGGCGTGCAAGACTCCA 1

US-09-967-726A-3
```

```
RESULT 172
US-09-967-726A-4/c
; Sequence 4, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-4

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 173
US-09-967-726A-5/c
; Sequence 5, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; TITLE OF INVENTION: Oligonucleotides
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-5

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAAT 134
Db 21 GACCAGACGGTCTCAGACAAAT 1

RESULT 174
US-09-967-726A-6/c
; Sequence 6, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
```



```
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      316 AATCAGAGACAAAGCTGAAGG 336
Db      21 AATCAGAGACAAAGCTGAAGG 1
|||||

RESULT 175
US-09-967-726A-7/c
; Sequence 7, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      515 TGACCGCATCGACTCCCTGCT 535
Db      21 TGACCGCATCGACTCCCTGCT 1
|||||

RESULT 176
US-09-967-726A-8/c
; Sequence 8, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
```

```
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-8

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      716 CCGCATCGTCCGAGCTTGAT 736
Db      21 CCGCATCGTCCGAGCTTGAT 1
|||||

RESULT 177
US-09-967-726A-9/c
; Sequence 9, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      916 ACAACTCCAGGGCTGCCTGC 936
Db      21 ACAACTCCAGGGCTGCCTGC 1
|||||

RESULT 178
US-09-967-726A-10/c
; Sequence 10, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-10

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 179
US-09-967-726A-11/c
; Sequence 11, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-11

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCGAGGAGAACCCCTAAATT 1336
Db 21 CTCGAGGAGAACCCCTAAATT 1

RESULT 180
US-09-967-726A-12/c
; Sequence 12, Application US/09967726A
; Publication No. US20030158130A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Zellweger, Tobias
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
; FILE REFERENCE: UBC.P-022
; CURRENT APPLICATION NUMBER: US/09/967,726A
; CURRENT FILING DATE: 2001-09-28
; NUMBER OF SEQ ID NOS: 15
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-09-967-726A-12

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCAGC 1536
Db 21 AGGCCCCCAACTCCGCCAGC 1

RESULT 181
US-10-270-871-14
; Sequence 14, Application US/10270871
; Publication No. US20030162702A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Millis, Albert J. T.
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration
; FILE REFERENCE: 0794.016A
; CURRENT APPLICATION NUMBER: US/10/270,871
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: US/09/459,749D
; PRIOR FILING DATE: 1999-12-10
; PRIOR APPLICATION NUMBER: 60/111,856
; PRIOR FILING DATE: 1998-12-11
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 14
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:primer_bind
; FEATURE:
; OTHER INFORMATION: synthetic sense primer based on porcine clusterin
US-10-270-871-14

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 274 AAGCCCAAGAGAGAAAGAGG 294
Db 1 AAGCCCAAGAGAGAAAGAGG 21

RESULT 182
US-10-080-794-3/c
; Sequence 3, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
; CURRENT APPLICATION NUMBER: US/10/080,794
; CURRENT FILING DATE: 2002-02-22
; PRIOR APPLICATION NUMBER: 60/121,726
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-3

Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGCGGTGCAAGACTCCA 36
Db 21 CCGAGCGGTGCAAGACTCCA 1

RESULT 183
US-10-080-794-4/c
```

Sequence 4, Application US/10080794  
Publication No. US20030166591A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
APPLICANT: Monia, Brett P.  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
FILE REFERENCE: UBC P-020-3  
CURRENT APPLICATION NUMBER: US/10/080,794  
CURRENT FILING DATE: 2002-02-22  
PRIOR APPLICATION NUMBER: 60/121,726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913,325  
PRIOR FILING DATE: 2001-08-10  
PRIOR APPLICATION NUMBER: 09/944,326  
PRIOR FILING DATE: 2001-08-30  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 4  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:  
OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-4

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 48 ATGATGAAGACTGCTGCTG 68  
Db 21 ATGATGAAGACTGCTGCTG 1

RESULT 184  
US-10-080-794-5/c  
Sequence 5, Application US/10080794  
Publication No. US20030166591A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
APPLICANT: Monia, Brett P.  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
FILE REFERENCE: UBC P-020-3  
CURRENT APPLICATION NUMBER: US/10/080,794  
CURRENT FILING DATE: 2002-02-22  
PRIOR APPLICATION NUMBER: 60/121,726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913,325  
PRIOR FILING DATE: 2001-08-10  
PRIOR APPLICATION NUMBER: 09/944,326  
PRIOR FILING DATE: 2001-08-30  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 5  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:  
OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-5

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 114 GACCAGACGGTCTCAGACAAAT 134  
Db 21 GACCAGACGGTCTCAGACAAAT 1

RESULT 185  
US-10-080-794-6/c  
Sequence 6, Application US/10080794  
Publication No. US20030166591A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
APPLICANT: Monia, Brett P.  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
FILE REFERENCE: UBC P-020-3  
CURRENT APPLICATION NUMBER: US/10/080,794  
CURRENT FILING DATE: 2002-02-22  
PRIOR APPLICATION NUMBER: 60/121,726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913,325  
PRIOR FILING DATE: 2001-08-10  
PRIOR APPLICATION NUMBER: 09/944,326  
PRIOR FILING DATE: 2001-08-30  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 6  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:  
OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-6

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 316 AATCAGAGACAAAGCTGAAGG 336  
Db 21 AATCAGAGACAAAGCTGAAGG 1

RESULT 186  
US-10-080-794-7/c  
Sequence 7, Application US/10080794  
Publication No. US20030166591A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
APPLICANT: Monia, Brett P.  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
FILE REFERENCE: UBC P-020-3  
CURRENT APPLICATION NUMBER: US/10/080,794  
CURRENT FILING DATE: 2002-02-22  
PRIOR APPLICATION NUMBER: 60/121,726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913,325  
PRIOR FILING DATE: 2001-08-10  
PRIOR APPLICATION NUMBER: 09/944,326  
PRIOR FILING DATE: 2001-08-30  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 7  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:

```
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 187
US-10-080-794-8/c
; Sequence 8, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT FILING DATE: 2002-02-22
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-8

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCCGAGCTTGAT 736
Db 21 CCGCATCGTCCGAGCTTGAT 1

RESULT 188
US-10-080-794-9/c
; Sequence 9, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT FILING DATE: 2002-02-22
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
```

```
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCACGGGCTGCCTGC 936
Db 21 ACAACTCCACGGGCTGCCTGC 1

RESULT 189
US-10-080-794-10/c
; Sequence 10, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT FILING DATE: 2002-02-22
; PRIOR FILING DATE: 1999-02-26
; PRIOR APPLICATION NUMBER: 09/913,325
; PRIOR FILING DATE: 2001-08-10
; PRIOR APPLICATION NUMBER: 09/944,326
; PRIOR FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-10

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGTGGAGCAGCTGAA 1135
Db 21 CTCCTTGTGGAGCAGCTGAA 1

RESULT 190
US-10-080-794-11/c
; Sequence 11, Application US/10080794
; Publication No. US20030166591A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Rennie, Paul S.
; APPLICANT: Miyake, Hideaki
; APPLICANT: Nelson, Colleen
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
; FILE REFERENCE: UBC.P-020-3
; CURRENT FILING DATE: 2001-08-30
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: HUMAN
; FEATURE:
; OTHER INFORMATION: antisense TRPM-2 ODN
US-10-080-794-11
```

; CURRENT FILING DATE: 2002-02-22  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; PRIOR APPLICATION NUMBER: 09/944,326  
; PRIOR FILING DATE: 2001-08-30  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 11  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-11

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1316 CTCGAGGAAGACCTAAATT 1336  
Db 21 CTCGAGGAAGACCTAAATT 1

RESULT 191  
US-10-080-794-12/c  
; Sequence 12, Application US/10080794  
; Publication No. US20030166591A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; APPLICANT: Monia, Brett P.  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
; TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS  
; FILE REFERENCE: USC P-020-3  
; CURRENT APPLICATION NUMBER: US/10/080,794  
; CURRENT FILING DATE: 2002-02-22  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; PRIOR APPLICATION NUMBER: 09/944,326  
; PRIOR FILING DATE: 2001-08-30  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 12  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-12

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1516 AGGCCCCCAACTCCGCCAGC 1536  
Db 21 AGGCCCCCAACTCCGCCAGC 1

RESULT 192  
US-10-380-124-6  
; Sequence 6, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 6  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: PCR Probe  
US-10-380-124-6

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 766 TCCACGCCATGTTCCAGCCCT 786  
Db 1 TCCACGCCATGTTCCAGCCCT 21

RESULT 193  
US-10-383-864-27  
; Sequence 27, Application US/10383864  
; Publication No. US20040081976A1  
; GENERAL INFORMATION:  
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE  
; APPLICANT: SIDRANSKY, David  
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES  
; FILE REFERENCE: JHU1860-1  
; CURRENT APPLICATION NUMBER: US/10/383,864  
; CURRENT FILING DATE: 2003-07-25  
; PRIOR APPLICATION NUMBER: US 60/362,577  
; PRIOR FILING DATE: 2002-03-07  
; NUMBER OF SEQ ID NOS: 127  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 27  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial sequence  
; FEATURE:  
; OTHER INFORMATION: PCR primer  
US-10-383-864-27

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 994 ACAACCCCTCCAGGCTAAGC 1014  
Db 1 ACAACCCCTCCAGGCTAAGC 21

RESULT 194  
US-10-383-864-28/c  
; Sequence 28, Application US/10383864  
; Publication No. US20040081976A1  
; GENERAL INFORMATION:  
; APPLICANT: THE JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE  
; APPLICANT: SIDRANSKY, David  
; TITLE OF INVENTION: GENOMIC SCREEN FOR EPIGENETICALLY SILENCED TUMOR SUPPRESSOR GENES  
; FILE REFERENCE: JHU1860-1  
; CURRENT APPLICATION NUMBER: US/10/383,864  
; CURRENT FILING DATE: 2003-07-25  
; PRIOR APPLICATION NUMBER: US 60/362,577  
; PRIOR FILING DATE: 2002-03-07  
; NUMBER OF SEQ ID NOS: 127  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 28  
; LENGTH: 21  
; TYPE: DNA

```
; ORGANISM: Artificial sequence
; FEATURE:
; OTHER INFORMATION: PCR primer
US-10-383-864-28

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1334 ATTTATGGAGACCGTGGCGGA 1354
      |||||
Db 21 ATTTATGGAGACCGTGGCGGA 1

RESULT 195
US-10-646-391A-3/c
; Sequence 3, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 3
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-3

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 16 CCGAGGCGTGCAAGACTCCA 36
      |||||
Db 21 CCGAGGCGTGCAAGACTCCA 1

RESULT 196
US-10-646-391A-4/c
; Sequence 4, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-4

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
      |||||
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 198
US-10-646-391A-6/c
; Sequence 6, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-6

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
      |||||
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 197
US-10-646-391A-5/c
; Sequence 5, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-5

Query Match          1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
      |||||
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 198
US-10-646-391A-6/c
; Sequence 6, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-6
```

```

; ORGANISM: human
US-10-646-391A-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 316 AATCAGAGACAAAGCTGAAGG 336
      |||||
Db 21 AATCAGAGACAAAGCTGAAGG 1

RESULT 199
US-10-646-391A-7/c
; Sequence 7, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 515 TGACCGCATCGACTCCCTGCT 535
      |||||
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 200
US-10-646-391A-8/c
; Sequence 8, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-8

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 716 CCGCATCGTCGGCAGCTTGAT 736
      |||||
Db 21 CCGCATCGTCGGCAGCTTGAT 1

RESULT 201
US-10-646-391A-9/c
; Sequence 9, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 916 ACAACTCCACGGCTGCTGC 936
      |||||
Db 21 ACAACTCCACGGCTGCTGC 1

RESULT 202
US-10-646-391A-10/c
; Sequence 10, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-646-391A-10

```

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTCTGAGAGAGCTGAA 1135  
Db 21 CTCCTTCTGAGAGAGCTGAA 1

RESULT 203  
US-10-646-391A-11/c  
; Sequence 11, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 11  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-646-391A-11

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCAGAGAGAACCTTAATT 1336  
Db 21 CTCAGAGAGAACCTTAATT 1

RESULT 204  
US-10-646-391A-12/c  
; Sequence 12, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 12  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-646-391A-12

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCACTCCGCCGAGC 1536  
Db 21 AGGCCCCCACTCCGCCGAGC 1

RESULT 205  
US-10-646-391A-20  
; Sequence 20, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 20  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-20

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 81.0%; Pred. No. 1.2e+02;  
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACTT 502  
Db 1 CCAGAGCTCGCCCTTCTACTT 21

RESULT 206  
US-10-646-391A-21/c  
; Sequence 21, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 21  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: artificial  
; FEATURE:



```

; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-21

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 480 AACGAGCTCGCCCTTCTAC 500
    |||||
Db 21 AACGAGCTCGCCCTTCTAC 1

RESULT 207
US-10-646-391A-22
; Sequence 22, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 22
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-22

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1100 GATGCTCAACACCTCTCTT 1120
    ||:|||||:|||||:|||||
Db 1 GAUGCUCACACCTCTCTT 21

RESULT 208
US-10-646-391A-23/c
; Sequence 23, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 23
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-23/c

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCATATAAACTGTC 1633
    |||||
Db 21 AACTAATTCATATAAACTGTC 1

RESULT 210
US-10-646-391A-36
; Sequence 36, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-36

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCATATAAACTGTC 1633
    |||||
Db 21 AACTAATTCATATAAACTGTC 1

```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 36
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-36

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGTCGCCCTTCTACT 502
      |||||:||||:|:||||
Db 1 CCAGAGCUGCCCUUACUACTT 21

RESULT 211
US-10-646-391A-37/c
; Sequence 37, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 37
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-37

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 480 AACGAGCTCGCCCTTCTAC 500
      |||||:||||:|:||||
Db 21 AACGAGCTCGCCCTTCTAC 1

RESULT 212
US-10-646-391A-38
; Sequence 38, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 38
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-38

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 711 AGTCCCGCATCGTCGCAGC 731
      |||||:||||:|:||||
Db 21 AGTCCCGCATCGTCGCAGC 1

RESULT 214
US-10-646-391A-40
; Sequence 40, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39/c
; Sequence 39, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCCCGCATCGTCGCAGCTT 733
      |||||:||||:|:||||
Db 1 GUCCCGCAUGGUGCCGAGCTT 21

RESULT 213
US-10-646-391A-39/c
; Sequence 39, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; PRIOR FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 39
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-39

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCCCGCATCGTCGCAGCTT 733
      |||||:||||:|:||||
Db 1 GUCCCGCAUGGUGCCGAGCTT 21
```

```

; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 40
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
; US-10-646-391A-40

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 1.2e+02;
Matches 15; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

Qy 1615 CTAATTCAATAAAAGTCTT 1635
Db 1 CUAUAUCAAAUAAACUGCTT 21

RESULT 215
US-10-646-391A-41/c
; Sequence 41, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC.P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 41
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
; US-10-646-391A-41

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1613 AACTAATTCAATAAAAGTGC 1633
Db 21 AACTAATTCAATAAAAGTGC 1

RESULT 216
US-10-646-436-1
; Sequence 1, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios

```

```

; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
; US-10-646-436-1

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 482 CCAGAGCTCGCCCTTCTACTT 502
Db 1 CCAGAGCUCGCCCUUCUACTT 21

RESULT 217
US-10-646-436-2/c
; Sequence 2, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efstathios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC.P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
; US-10-646-436-2

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 480 AACAGAGCTCGCCCTTCTAC 500
Db 21 AACAGAGCTCGCCCTTCTAC 1

RESULT 218
US-10-646-436-3
; Sequence 3, Application US/10646436
; Publication No. US20040096882A1

```



```
Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATTAATAAACTGTC 1633
DB 21 AACTAATTCATTAATAAACTGTC 1

RESULT 222
US-10-646-436-58
; Sequence 58, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC-P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 58
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-58

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 81.0%; Pred. No. 1.2e+02;
Matches 17; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGTCGCGCCTTCTACTT 502
DB 1 CCAGAGTCGCGCCUUCUACTT 21

RESULT 223
US-10-646-436-59/c
; Sequence 59, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC-P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 59
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-59

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1613 AACTAATTCATTAATAAACTGTC 1633
DB 21 AACTAATTCATTAATAAACTGTC 1

RESULT 224
US-10-646-436-61
; Sequence 61, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC-P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 61
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-61

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 18; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 713 GTCCCGCATGTCGCGAGCTT 733
DB 1 GUCCCGCAUCGCGCCGAGCTT 21

RESULT 225
US-10-646-436-62/c
; Sequence 62, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Beraldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC-P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 62
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-62
```



```
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-5

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCTG 68
Db 21 ATGATGAAGACTCTGCTGCTG 1

RESULT 230
US-10-828-394-6/c
; Sequence 6, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 114 GACCAGACGGTCTCAGACAAT 134
Db 21 GACCAGACGGTCTCAGACAAT 1

RESULT 231
US-10-828-394-7/c
; Sequence 7, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21

; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-8/c

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 233
US-10-828-394-9/c
; Sequence 9, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC.P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-9

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCCGACGCTTGAT 736
Db 21 CCGCATCGTCCGACGCTTGAT 1
```

```
Db 21 CCGCATCGTCCGACGCTGAT 1
|||||
RESULT 234
US-10-828-394-10/c
; Sequence 10, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-10
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCAGCGGCTGCCTGC 936
|||||
Db 21 ACAACTCCAGCGGCTGCCTGC 1
|||||

RESULT 235
US-10-828-394-11/c
; Sequence 11, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 11
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-11
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGGACGAGCTGAA 1135
|||||
Db 21 CTCCTTGCTGGACGAGCTGAA 1
|||||

RESULT 236
US-10-828-394-12/c
; Sequence 12, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; CURRENT APPLICATION NUMBER: US/10/828,395
; PRIOR FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; CURRENT APPLICATION NUMBER: US 60/464,159
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-12
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCGACG 1536
|||||
Db 21 AGGCCCCCAACTCCGCCGACG 1
|||||

RESULT 237
US-10-828-394-13/c
; Sequence 13, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; CURRENT APPLICATION NUMBER: US/10/828,394
; PRIOR FILING DATE: 2004-04-19
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-394-13
Query Match 1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1516 AGGCCCCCAACTCCGCCGACG 1536
|||||
Db 21 AGGCCCCCAACTCCGCCGACG 1
|||||

RESULT 238
US-10-828-395-4/c
; Sequence 4, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
```



```
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 4
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-4

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      16 CCGAGGGCTGCAAGACTCCA 36
Db      21 CCGAGGGCTGCAAGACTCCA 1

RESULT 239
US-10-828-395-5/c
; Sequence 5, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 5
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-5

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      48 ATGATGAAGACTCTGCTGCTG 68
Db      21 ATGATGAAGACTCTGCTGCTG 1

RESULT 240
US-10-828-395-6/c
; Sequence 6, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
```

```
; SEQ ID NO 6
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-6

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      114 GACCAGACGGTCTCAGACAAT 134
Db      21 GACCAGACGGTCTCAGACAAT 1

RESULT 241
US-10-828-395-7/c
; Sequence 7, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-7

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      316 AATCAGAGACAAAGCTGAAGG 336
Db      21 AATCAGAGACAAAGCTGAAGG 1

RESULT 242
US-10-828-395-8/c
; Sequence 8, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC.P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-8
```

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 515 TGACCGCATCGACTCCCTGCT 535  
Db 21 TGACCGCATCGACTCCCTGCT 1

RESULT 243  
US-10-828-395-9/c  
; Sequence 9, Application US/10828395  
; Publication No. US20040224914A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
; FILE REFERENCE: UBC P-032  
; CURRENT APPLICATION NUMBER: US/10/828,395  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: US 60/464,160  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 9  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-395-9

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 716 CCGCATCGTCCGCGAGCTTGAT 736  
Db 21 CCGCATCGTCCGCGAGCTTGAT 1

RESULT 244  
US-10-828-395-10/c  
; Sequence 10, Application US/10828395  
; Publication No. US20040224914A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
; FILE REFERENCE: UBC P-032  
; CURRENT APPLICATION NUMBER: US/10/828,395  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: US 60/464,160  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 10  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-395-10

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 916 ACAACTCCACGGGCTGCCTGC 936  
Db 21 ACAACTCCACGGGCTGCCTGC 1

RESULT 245  
US-10-828-395-11/c  
; Sequence 11, Application US/10828395  
; Publication No. US20040224914A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
; FILE REFERENCE: UBC P-032  
; CURRENT APPLICATION NUMBER: US/10/828,395  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: US 60/464,160  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 11  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-395-11

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1115 CTCCTTGCTGGAGCAGCTGAA 1135  
Db 21 CTCCTTGCTGGAGCAGCTGAA 1

RESULT 246  
US-10-828-395-12/c  
; Sequence 12, Application US/10828395  
; Publication No. US20040224914A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
; FILE REFERENCE: UBC P-032  
; CURRENT APPLICATION NUMBER: US/10/828,395  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: US 60/464,160  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 12  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-395-12

Query Match 1.3%; Score 21; DB 1; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.2e+02;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1316 CTCAGGAAGAACCCCTAAATT 1336  
Db 21 CTCAGGAAGAACCCCTAAATT 1

```

RESULT 247
US-10-828-395-13/c
; Sequence 13, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: URC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 13
; LENGTH: 21
; TYPE: DNA
; ORGANISM: human
US-10-828-395-13

Query Match      1.3%; Score 21; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1516 AGGCCCCCAACTCGCCGAGC 1536
Db 21 AGGCCCCCAACTCGCCGAGC 1

RESULT 248
US-10-719-900-695781/c
; Sequence 695781, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 695781
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-695781

Query Match      1.3%; Score 20.8; DB 1; Length 25;
Best Local Similarity 91.7%; Pred. No. 1.8e+02;
Matches 22; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 565 TGCATGTCATGCAGGACCTCTCA 588
Db 25 TGCATGTCATGCAGGACCTCTCA 2

RESULT 249
US-10-719-900-56803
; Sequence 56803, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20

```

```

; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 56803
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-56803

Query Match      1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1269 AAGCTCTTTGACTCTGATCCCATCA 1293
Db 1 AAGCTGTTTGACACTGACCCCATCA 25

RESULT 250
US-10-719-900-452919
; Sequence 452919, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 452919
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-452919

Query Match      1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1137 GAGCAGTTTAACTGGGTGTCGCCGC 1161
Db 1 GACCAGTTCAACTGGGTGTCGCCAGC 25

RESULT 251
US-10-719-900-815717
; Sequence 815717, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10/719,900
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 815717
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-815717

Query Match      1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1245 TCCGGTGTCACTGAGGTGTCGTGA 1269

```

```
Db 1 TCCCGTGTCACTCAGGTGGTGA 25
|||||
RESULT 252
US-10-719-900-892166
; Sequence 892166, Application US/10719900
; Publication No. US20050026164A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Mouse
; FILE REFERENCE: 3528.1
; CURRENT APPLICATION NUMBER: US/10719,900
; PRIOR FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,808
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 982914
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 892166
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-719-900-892166

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1149 TGGGTGTCGGGTGGCAACCTCA 1173
|||||
Db 1 TGGGTGTCGGGTGGCTAACCTCA 25
|||||

RESULT 253
US-10-809-189-31758
; Sequence 31758, Application US/10809189
; Publication No. US20050048531A1
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/10/809,189
; CURRENT FILING DATE: 2004-03-25
; PRIOR APPLICATION NUMBER: US/09/396,196
; PRIOR FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 31758
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-10-809-189-31758

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1171 TCACGGAAGCGAAGACCACTACTA 1195
|||||
Db 1 TCACACAGGCGAAGACCACTACTA 25
|||||

RESULT 254
US-10-956-157-271151
; Sequence 271151, Application US/10956157
; Publication No. US20050118625A1
; GENERAL INFORMATION:
; APPLICANT: Wyeth

; APPLICANT: Mounts, William
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH
; FILE REFERENCE: 031896-043000 (AM 101081)
; CURRENT APPLICATION NUMBER: US/10/956,157
; CURRENT FILING DATE: 2004-10-04
; NUMBER OF SEQ ID NOS: 319805
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 271151
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Probe Sequence
US-10-956-157-271151

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1588 GAAGAACAGAAATTGCTCCTGCATGC 1612
|||||
Db 1 GGAAGACAGAAATTGCTCCTGCATGC 25
|||||

RESULT 255
US-10-719-956-30750/c
; Sequence 30750, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 30750
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-30750

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02;
Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1120 TGCTGGAGCAGCTGAACGAGCAGTT 1144
|||||
Db 25 TGCTGGACAGCAGACGACCAGTT 1
|||||

RESULT 256
US-10-719-956-70566/c
; Sequence 70566, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 70566
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-70566

Query Match 1.2%; Score 20.2; DB 1; Length 25;
```

```
Best Local Similarity 88.0%; Pred. No. 2e+02; Mismatches 0; Indels 3; Gaps 0;
Matches 22; Conservative 0;

Qy 951 TGTGACAAAGTCCGGGAGATCTTCT 975
Db 25 TGTGAGAAAGTGCCCAAGAGATCTTGT 1

RESULT 257
US-10-719-956-355802/c
; Sequence 355802, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 355802
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-355802

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02; Mismatches 0; Indels 3; Gaps 0;
Matches 22; Conservative 0;

Qy 898 TGTGCGGGAGATCCGCCACAATC 922
Db 25 TGTGCAAGGAGATCCGCCATACTC 1

RESULT 258
US-10-719-956-374027/c
; Sequence 374027, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 374027
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-374027

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02; Mismatches 0; Indels 3; Gaps 0;
Matches 22; Conservative 0;

Qy 975 TCTGTGACTGTTCCACCAACAAC 999
Db 25 TCTGTGACTGTACCAACACATC 1

RESULT 259
US-10-719-956-501380
; Sequence 501380, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 501380
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-501380

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02; Mismatches 0; Indels 3; Gaps 0;
Matches 22; Conservative 0;

Qy 1266 GTGAAGCTCTTTGACTCTGATCCCA 1290
Db 1 GTGAAGCTGTTTCACTCTGACCCCA 25

RESULT 260
US-10-719-956-517912
; Sequence 517912, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 517912
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-517912

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02; Mismatches 0; Indels 3; Gaps 0;
Matches 22; Conservative 0;

Qy 897 GTGTGCGGGAGATCCGCCACAATC 921
Db 1 GTGTGCAAGGAGATCCGCCATACT 25

RESULT 261
US-10-719-956-604881/c
; Sequence 604881, Application US/10719956
; Publication No. US20040146910A1
; GENERAL INFORMATION:
; APPLICANT: Xue Mei Zhou
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat
; FILE REFERENCE: 3527.1
; CURRENT APPLICATION NUMBER: US/10/719,956
; CURRENT FILING DATE: 2003-11-20
; PRIOR APPLICATION NUMBER: 60/427,836
; PRIOR FILING DATE: 2002 11 20
; NUMBER OF SEQ ID NOS: 699466
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1
; SEQ ID NO 604881
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-10-719-956-604881

Query Match 1.2%; Score 20.2; DB 1; Length 25;
Best Local Similarity 88.0%; Pred. No. 2e+02; Mismatches 0; Indels 3; Gaps 0;
Matches 22; Conservative 0;
```

Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 778 TCCAGCCCTTCCTTGAGATGATACA 802  
||||| ||||||| ||||||| |||  
Db 25 TCCAGCCCTTCCTTGAGTTGATCA 1

RESULT 262  
US-10-719-956-612441/c  
; Sequence 612441, Application US/10719956  
; Publication No. US20040146910A1  
; GENERAL INFORMATION:  
; APPLICANT: Xue Mei Zhou  
; TITLE OF INVENTION: Methods of Genetic Analysis of Rat  
; FILE REFERENCE: 3527.1  
; CURRENT APPLICATION NUMBER: US/10/719,956  
; CURRENT FILING DATE: 2003-11-20  
; PRIOR APPLICATION NUMBER: 60/427,836  
; PRIOR FILING DATE: 2002 11 20  
; NUMBER OF SEQ ID NOS: 699466  
; SOFTWARE: Microarray Probe Sequence Listing Generator V 1.1  
; SEQ ID NO 612441  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Rattus norvegicus  
US-10-719-956-612441

Query Match 1.2%; Score 20.2; DB 1; Length 25;

Best Local Similarity 88.0%; Pred. No. 2e+02; Mismatches 3; Indels 0; Gaps 0;

Matches 22; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1149 TGGGTGTCCCGGTGGCAACCTCA 1173  
||||| ||||||| ||||||| |||  
Db 25 TGGGTGTCCCGGTGGCTAACCTCA 1

RESULT 263  
US-10-380-124-14/c  
; Sequence 14, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 14  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-14

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.3e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 13 TGACCGAGCGGTGCAAGAC 32  
||||| ||||||| ||||||| |||  
Db 20 TGACCGAGCGGTGCAAGAC 1

RESULT 264  
US-10-380-124-15/c  
; Sequence 15, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia

; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 15  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-15

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.3e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 21 GCGTGCAAGACTCCAGAAT 40  
||||| ||||||| ||||||| |||  
Db 20 GCGTGCAAGACTCCAGAAT 1

RESULT 265  
US-10-380-124-16/c  
; Sequence 16, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 16  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-16

Query Match 1.2%; Score 20; DB 1; Length 20;

Best Local Similarity 100.0%; Pred. No. 1.3e+02; Mismatches 0; Indels 0; Gaps 0;

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 39 ATTGGAGGCATGATGAAGAC 58  
||||| ||||||| ||||||| |||  
Db 20 ATTGGAGGCATGATGAAGAC 1

RESULT 266  
US-10-380-124-17/c  
; Sequence 17, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 17  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-17

```
Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 77 GCTGCTGCTGACCTGGGAGA 96
Db 20 GCTGCTGCTGACCTGGGAGA 1

RESULT 267
US-10-380-124-18/c
; Sequence 18, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-18

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 101 GCAGTCTCTGGGGACCAGA 120
Db 20 GCAGTCTCTGGGGACCAGA 1

RESULT 268
US-10-380-124-19/c
; Sequence 19, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 19
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-19

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 122 GGTCTCAGACATGAGCTCC 141
Db 20 GGTCTCAGACATGAGCTCC 1

RESULT 269
US-10-380-124-20/c
; Sequence 20, Application US/10380124
```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-22

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 201 GGGGTGAACAGATAAAGAC 220
Db 20 GGGGTGAACAGATAAAGAC 1

RESULT 272
US-10-380-124-23/c
; Sequence 23, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 23
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-23

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 281 GAAGAAGAAAGAGATGCC 300
Db 20 GAAGAAGAAAGAGATGCC 1

RESULT 273
US-10-380-124-24/c
; Sequence 24, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-24

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 286 AGAAGAGAGATGCCCTAAAT 305
Db 20 AGAAGAGAGATGCCCTAAAT 1

RESULT 274
US-10-380-124-25/c
; Sequence 25, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-25

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 298 CCTTAATGAGACCGGAA 317
Db 20 CCTTAATGAGACCGGAA 1

RESULT 275
US-10-380-124-26/c
; Sequence 26, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 26
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-26

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 307 AGACCGAGGAATCAGAGACA 326
Db 20 AGACCGAGGAATCAGAGACA 1

RESULT 276
US-10-380-124-27/c
; Sequence 27, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
```



; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 27  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-27

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 324 ACAAGCTGAAGGAGCTCCC 343  
Db 20 ACAAGCTGAAGGAGCTCCC 1

RESULT 277  
US-10-380-124-28/c  
; Sequence 28, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 28  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-28

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 359 GACCATGATGCCCTCTGGG 378  
Db 20 GACCATGATGCCCTCTGGG 1

RESULT 278  
US-10-380-124-29/c  
; Sequence 29, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 29  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-29

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 364 TGATGCCCTCTCGGAAGAG 383  
Db 20 TGATGCCCTCTCGGAAGAG 1

RESULT 279  
US-10-380-124-30/c  
; Sequence 30, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 30  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-30

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 380 AGAGTGAAGCCCTGCCTGA 399  
Db 20 AGAGTGAAGCCCTGCCTGA 1

RESULT 280  
US-10-380-124-31/c  
; Sequence 31, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 31  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-31

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 407 CTGCATGAAGTTCTACGCAC 426  
Db 20 CTGCATGAAGTTCTACGCAC 1

RESULT 281  
US-10-380-124-32/c  
; Sequence 32, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier

; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 32  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-32

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 443 CTCAGGCTGGTTGGCGCC 462  
Db 20 CTCAGGCTGGTTGGCGCC 1

RESULT 282  
US-10-380-124-33/c  
; Sequence 33, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 33  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-33

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 444 TCAGGCTGGTTGGCGCCA 463  
Db 20 TCAGGCTGGTTGGCGCCA 1

RESULT 283  
US-10-380-124-34/c  
; Sequence 34, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 34  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-34

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 455 TGGCCGCCAGCTTGAGGAGT 474  
Db 20 TGGCCGCCAGCTTGAGGAGT 1

RESULT 284  
US-10-380-124-35/c  
; Sequence 35, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 35  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-35

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 482 CCAGAGCTCGCCCTTCTACT 501  
Db 20 CCAGAGCTCGCCCTTCTACT 1

RESULT 285  
US-10-380-124-36/c  
; Sequence 36, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; APPLICANT: Susan M. Freier  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 36  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-36

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 492 CCCTTCTACTCTGGATGAA 511  
Db 20 CCCTTCTACTTCTGGATGAA 1

RESULT 286  
US-10-380-124-37/c  
; Sequence 37, Application US/10380124  
; Publication No. US20040053874A1

```

; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 37
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-37

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 517 ACCGATCGACTCCCTGCTG 536
Db 20 ACCGATCGACTCCCTGCTG 1

RESULT 287
US-10-380-124-38/c
; Sequence 38, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 38
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-38

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 533 GCTGGAGAACCGCGGAGC 552
Db 20 GCTGGAGAACCGCGGAGC 1

RESULT 288
US-10-380-124-39/c
; Sequence 39, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 39
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence

```

```

; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-39

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 551 GCAGCGCACATGCTGGATG 570
Db 20 GCAGCGCACATGCTGGATG 1

RESULT 289
US-10-380-124-40/c
; Sequence 40, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 40
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-40

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 553 AGACGCGACATGCTGGATGC 572
Db 20 AGACGCGACATGCTGGATGC 1

RESULT 290
US-10-380-124-41/c
; Sequence 41, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 41
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-41

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 565 TGGATGTCATGCAGGACCAC 584
Db 20 TGGATGTCATGCAGGACCAC 1

```

```
RESULT 291
US-10-380-124-42/c
; Sequence 42, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-42

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 567 GATGTCATGCAGACCACTT 586
Db 20 GATGTCATGCAGACCACTT 1

RESULT 292
US-10-380-124-43/c
; Sequence 43, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-43

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 604 TCATAGCAGCTCTTCCAG 623
Db 20 TCATAGCAGCTCTTCCAG 1

RESULT 293
US-10-380-124-44/c
; Sequence 44, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
```

```
; SEQ ID NO 44
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-44

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 608 AGACGAGCTCTTCCAGACA 627
Db 20 AGACGAGCTCTTCCAGACA 1

RESULT 294
US-10-380-124-45/c
; Sequence 45, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 45
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-45

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 613 AGCTCTTCCAGCAGGTTTC 632
Db 20 AGCTCTTCCAGCAGGTTTC 1

RESULT 295
US-10-380-124-46/c
; Sequence 46, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 46
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-46

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 690 AGGCCTCACTTCTTCTTCC 709
```

```

; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 49
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-49

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      776 GTTCCAGCCCTTCCTTGAGA 795
Db      20 GTTCCAGCCCTTCCTTGAGA 1

RESULT 299
US-10-380-124-50/c
; Sequence 50, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 50
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-50

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      783 CCCTTCCTTGATGATACA 802
Db      20 CCCTTCCTTGATGATACA 1

RESULT 300
US-10-380-124-51/c
; Sequence 51, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 51
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-51

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      775 TGTTCAGCCCTTCCTTGAG 794
Db      20 TGTTCAGCCCTTCCTTGAG 1

RESULT 298
US-10-380-124-49/c
; Sequence 49, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
US-10-380-124-49

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      721 TCGTCCGAGCTTGATGCC 740
Db      20 TCGTCCGAGCTTGATGCC 1

RESULT 297
US-10-380-124-48/c
; Sequence 48, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 48
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-48

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      721 TCGTCCGAGCTTGATGCC 740
Db      20 TCGTCCGAGCTTGATGCC 1

RESULT 296
US-10-380-124-47/c
; Sequence 47, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-47

Query Match      1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      721 TCGTCCGAGCTTGATGCC 740
Db      20 TCGTCCGAGCTTGATGCC 1

```

```
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 820 TGGACATCCACTTCCACAGC 839
Db 20 TGGACATCCACTTCCACAGC 1

RESULT 301
US-10-380-124-52/c
; Sequence 52, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-54

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 893 GACTGTGTGCCGGGAGATCC 912
Db 20 GACTGTGTGCCGGGAGATCC 1

RESULT 304
US-10-380-124-55/c
; Sequence 55, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-55

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 894 ACTGTGTGCCGGGAGATCCG 913
Db 20 ACTGTGTGCCGGGAGATCCG 1

RESULT 305
US-10-380-124-56/c
; Sequence 56, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 56
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-56
```

---

```
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 820 TGGACATCCACTTCCACAGC 839
Db 20 TGGACATCCACTTCCACAGC 1

RESULT 301
US-10-380-124-52/c
; Sequence 52, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-52

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 848 CCAGCACCCGCCAACAGAAAT 867
Db 20 CCAGCACCCGCCAACAGAAAT 1

RESULT 302
US-10-380-124-53/c
; Sequence 53, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 53
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-53

Query Match 1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 853 ACCCGCAACAGAAATTCATA 872
Db 20 ACCCGCAACAGAAATTCATA 1

RESULT 303
US-10-380-124-54/c
; Sequence 54, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
```

OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-56

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 906 GAGATCGCGCACACTCCAC 925  
DB 20 GAGATCGCGCACACTCCAC 1

RESULT 306

US-10-380-124-57/c  
; Sequence 57, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 57  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-57

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 928 GCTGCTCGCGATGAAGAC 947  
DB 20 GCTGCTCGCGATGAAGAC 1

RESULT 307  
US-10-380-124-58/c  
; Sequence 58, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 58  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-58

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 967 AGATCTGTCTGTGACTGT 986  
DB 20 AGATCTGTCTGTGACTGT 1

RESULT 308

US-10-380-124-59/c  
; Sequence 59, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1009 CTAAGCTGCGCGGAGCTC 1028  
DB 20 CTAAGCTGCGCGGAGCTC 1

RESULT 309  
US-10-380-124-60/c  
; Sequence 60, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 60  
; LENGTH: 20  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; OTHER INFORMATION: Antisense Oligonucleotide  
US-10-380-124-60

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1022 GGAGCTCGACGATCCTCC 1041  
DB 20 GGAGCTCGACGATCCTCC 1

RESULT 310  
US-10-380-124-61/c  
; Sequence 61, Application US/10380124  
; Publication No. US20040053874A1  
; GENERAL INFORMATION:  
; APPLICANT: Isis Pharmaceuticals, Inc.  
; APPLICANT: Brett P. Monia  
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION  
; FILE REFERENCE: RTS-0156  
; CURRENT APPLICATION NUMBER: US/10/380,124  
; CURRENT FILING DATE: 2003-03-10  
; NUMBER OF SEQ ID NOS: 90  
; SEQ ID NO 61

Query Match 1.2%; Score 20; DB 1; Length 20;  
Best Local Similarity 100.0%; Pred. No. 1.3e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1022 GGAGCTCGACGATCCTCC 1041  
DB 20 GGAGCTCGACGATCCTCC 1

```
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-61

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1083 AAGTCTACCACTGAGAGAT 1102
DB 20 AAGTCTACCACTGAGAGAT 1

RESULT 311
US-10-380-124-62/c
/ Sequence 62, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/10/380,124
/ CURRENT FILING DATE: 2003-03-10
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 62
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-62

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1091 CCAGTGAAGATGCTCAACA 1110
DB 20 CCAGTGAAGATGCTCAACA 1

RESULT 312
US-10-380-124-63/c
/ Sequence 63, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/10/380,124
/ CURRENT FILING DATE: 2003-03-10
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 63
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-63

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1113 TCCTCTTGTGAGAGAGCT 1132
DB 20 TCCTCTTGTGAGAGAGCT 1132
```

```
DB 20 TCCTCTTGTGAGAGAGCT 1

RESULT 313
US-10-380-124-64/c
/ Sequence 64, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/10/380,124
/ CURRENT FILING DATE: 2003-03-10
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 64
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-64

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1121 GCTGAGCAGCTGACGAGC 1140
DB 20 GCTGAGCAGCTGACGAGC 1

RESULT 314
US-10-380-124-65/c
/ Sequence 65, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/10/380,124
/ CURRENT FILING DATE: 2003-03-10
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 65
/ LENGTH: 20
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-65

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1148 CTGGGTCTCCCGGCTGGCAA 1167
DB 20 CTGGGTCTCCCGGCTGGCAA 1

RESULT 315
US-10-380-124-66/c
/ Sequence 66, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freier
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
```



```

; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 66
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-66

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1182 GAAGACGAGTACTATCTGCG 1201
DB 20 GAAGACGAGTACTATCTGCG 1

RESULT 316
US-10-380-124-67/c
; Sequence 67, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 67
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-67

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1194 TATCTGCGGTCACCAACGCT 1213
DB 20 TATCTGCGGTCACCAACGCT 1

RESULT 317
US-10-380-124-68/c
; Sequence 68, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 68
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-68

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1275 TTTGACTCTGATCCCATCAC 1294
DB 20 TTTGACTCTGATCCCATCAC 1

RESULT 319
US-10-380-124-70/c
; Sequence 70, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-70

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 CGGTCCCTGTAGAGTCTCC 1319
DB 20 CGGTCCCTGTAGAGTCTCC 1

RESULT 320
US-10-380-124-71/c
; Sequence 71, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
```

```

Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1216 CTCCCACTTCTGACTCG 1235
DB 20 CTCCCACTTCTGACTCG 1

RESULT 318
US-10-380-124-69/c
; Sequence 69, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 69
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-69

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1275 TTTGACTCTGATCCCATCAC 1294
DB 20 TTTGACTCTGATCCCATCAC 1

RESULT 319
US-10-380-124-70/c
; Sequence 70, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 70
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-70

Query Match
Best Local Similarity 1.2%; Score 20; DB 1; Length 20;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1300 CGGTCCCTGTAGAGTCTCC 1319
DB 20 CGGTCCCTGTAGAGTCTCC 1

RESULT 320
US-10-380-124-71/c
; Sequence 71, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
```

```
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 71
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-10-380-124-71

Query Match
1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1332 AATTATGAGACCGTGGC 1351
DB 20 AATTATGAGACCGTGGC 1

RESULT 321
US-10-380-124-72/C
; Sequence 72, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 72
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-10-380-124-72

Query Match
1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1398 GATGTGATGTGCTTTGC 1417
DB 20 GATGTGATGTGCTTTGC 1

RESULT 322
US-10-380-124-73/C
; Sequence 73, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 73
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-10-380-124-73/C
```

```
US-10-380-124-73

Query Match
1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1545 GCTCTGATCCTGCACCTCA 1564
DB 20 GCTCTGATCCTGCACCTCA 1

RESULT 323
US-10-380-124-74/C
; Sequence 74, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 74
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-10-380-124-74

Query Match
1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1600 TGCTCTGCATGCACTAAT 1619
DB 20 TGCTCTGCATGCACTAAT 1

RESULT 324
US-10-380-124-75/C
; Sequence 75, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RTS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 75
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
;
US-10-380-124-75

Query Match
1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1615 CTAATTCATAAACAATGCT 1634
DB 20 CTAATTCATAAACAATGCT 1

RESULT 325
US-10-380-124-76/C
```

```
; Sequence 78, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RFS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 78
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-78

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      979 TGGACTGTTCCACCAACAC 998
DB      20 TGGACTGTTCCACCAACAC 1

RESULT 326
US-10-380-124-80/c
; Sequence 80, Application US/10380124
; Publication No. US20040053874A1
; GENERAL INFORMATION:
; APPLICANT: Isis Pharmaceuticals, Inc.
; APPLICANT: Brett P. Monia
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
; FILE REFERENCE: RFS-0156
; CURRENT APPLICATION NUMBER: US/10/380,124
; CURRENT FILING DATE: 2003-03-10
; NUMBER OF SEQ ID NOS: 90
; SEQ ID NO 80
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-380-124-80

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1383 CACCGGAGAGGTGATGT 1402
DB      20 CACCGGAGAGGTGATGT 1

RESULT 327
US-10-980-850-17
; Sequence 17, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; PRIOR FILING DATE: 2003-11-03
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 17
```

```
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Forward Primer for CLU
US-10-980-850-17

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      762 AACTTCCACGCCATGTTCCA 781
DB      1 AACTTCCACGCCATGTTCCA 20

RESULT 328
US-10-980-850-18/c
; Sequence 18, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; PRIOR FILING DATE: 2003-11-03
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 18
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Reverse Primer for CLU
US-10-980-850-18

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      870 ATACGAGAAGCGACGATGA 889
DB      20 ATACGAGAAGCGACGATGA 1

RESULT 329
US-10-980-850-33
; Sequence 33, Application US/10980850
; Publication No. US20050152908A1
; GENERAL INFORMATION:
; APPLICANT: Liew, Choong-Chin
; APPLICANT: Liew, Choong-Chin
; TITLE OF INVENTION: LIVER CANCER BIOMARKERS
; FILE REFERENCE: 4231/2072
; CURRENT APPLICATION NUMBER: US/10/980,850
; CURRENT FILING DATE: 2004-11-03
; PRIOR APPLICATION NUMBER: US 60/516,853
; PRIOR FILING DATE: 2003-11-03
; NUMBER OF SEQ ID NOS: 46
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Forward Primer for OAS1
US-10-980-850-33

Query Match          1.2%; Score 20; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 977 TGTGACTGTTCCACCAACA 996  
Db 1 TGTGACTGTTCCACCAACA 20

## RESULT 330

US-10-646-391A-28  
; Sequence 28, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: USC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; PRIOR FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 28  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-28

Query Match 1.2%; Score 20; DB 1; Length 21;  
Best Local Similarity 75.0%; Pred. No. 1.4e+02;  
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCT 67  
Db 1 AUGAUGAAGACUCUCUGCT 20

## RESULT 331

US-10-646-436-9  
; Sequence 9, Application US/10646436  
; Publication No. US20040096882A1  
; GENERAL INFORMATION:  
; APPLICANT: Jansen, Burkhard  
; APPLICANT: Gleave, Martin  
; APPLICANT: Signsevsky, Maxim  
; APPLICANT: Beraldi, Eliana  
; APPLICANT: Trougakos, Ioannis  
; APPLICANT: Gonos, Efethios  
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins  
; FILE REFERENCE: USC.P-030  
; CURRENT APPLICATION NUMBER: US/10/646,436  
; PRIOR FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 9  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-436-9

Query Match 1.2%; Score 20; DB 1; Length 21;  
Best Local Similarity 75.0%; Pred. No. 1.4e+02;  
Matches 15; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 48 ATGATGAAGACTCTGCTGCT 67  
Db 1 AUGAUGAAGACUCUCUGCT 20

## RESULT 332

US-09-459-749D-13  
; Sequence 13, Application US/09459749D  
; Patent No. US20020136716A1  
; GENERAL INFORMATION:  
; APPLICANT: Millie, Albert J. T.  
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration  
; FILE REFERENCE: 0794.016A  
; CURRENT APPLICATION NUMBER: US/09/459,749D  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: 60/111,856  
; PRIOR FILING DATE: 1998-12-11  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 13  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:primer\_bind  
; OTHER INFORMATION: synthetic antisense primer based on murine clusterin  
US-09-459-749D-13

Query Match 1.2%; Score 19.4; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 271 AAGAGCCCAAGAGAGAAAG 291  
Db 1 AAGAGCCCAAGAGAGAAAG 21

## RESULT 333

US-10-270-871-13  
; Sequence 13, Application US/10270871  
; Publication No. US20030162702A1  
; GENERAL INFORMATION:  
; APPLICANT: Millie, Albert J. T.  
; TITLE OF INVENTION: Compositions and Methods For Altering Cell Migration  
; FILE REFERENCE: 0794.016A  
; CURRENT APPLICATION NUMBER: US/10/270,871  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: US/09/459,749D  
; PRIOR FILING DATE: 1999-12-10  
; PRIOR APPLICATION NUMBER: 60/111,856  
; PRIOR FILING DATE: 1998-12-11  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 13  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Description of Artificial Sequence:primer\_bind  
; OTHER INFORMATION: synthetic antisense primer based on murine clusterin  
US-10-270-871-13

Query Match 1.2%; Score 19.4; DB 1; Length 21;  
Best Local Similarity 95.2%; Pred. No. 1.6e+02;  
Matches 20; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 271 AAGAGCCCAAGAGAGAAAG 291

Db 1 AGGAGCCAGAGAGAGAG 21

RESULT 334

US-10-646-391A-42  
; Sequence 42, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 42  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-42

Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 73.7%; Pred. No. 1.4e+02;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Oy 48 ATGATGAAGACTCTGCTGC 66

Db 1 AUGAGAGAGACUCCUCG 19

RESULT 335

US-10-646-391A-43/c  
; Sequence 43, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 43  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-43

Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 100.0%; Pred. No. 1.4e+02;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
Oy 48 ATGATGAAGACTCTGCTGC 66  
Db 19 ATGATGAAGACTCTGCTGC 1

RESULT 336

US-10-646-436-67  
; Sequence 67, Application US/10646436  
; Publication No. US20040096882A1  
; GENERAL INFORMATION:  
; APPLICANT: Jansen, Burkhard  
; APPLICANT: Gleave, Martin  
; APPLICANT: Signaevsky, Maxim  
; APPLICANT: Beraldi, Eliana  
; APPLICANT: Trougakos, Ioannis  
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins  
; FILE REFERENCE: UBC P-030  
; CURRENT APPLICATION NUMBER: US/10/646,436  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 67  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-436-67

Query Match 1.2%; Score 19; DB 1; Length 19;  
Best Local Similarity 73.7%; Pred. No. 1.4e+02;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

Oy 48 ATGATGAAGACTCTGCTGC 66

Db 1 AUGAGAGAGACUCCUCG 19

RESULT 337

US-10-646-436-68/c  
; Sequence 68, Application US/10646436  
; Publication No. US20040096882A1  
; GENERAL INFORMATION:  
; APPLICANT: Jansen, Burkhard  
; APPLICANT: Gleave, Martin  
; APPLICANT: Signaevsky, Maxim  
; APPLICANT: Beraldi, Eliana  
; APPLICANT: Trougakos, Ioannis  
; APPLICANT: Ginos, Efstrachios  
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins  
; FILE REFERENCE: UBC P-030  
; CURRENT APPLICATION NUMBER: US/10/646,436  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 68  
; LENGTH: 19  
; TYPE: RNA

```

; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi fo rhuman clusterin
US-10-646-436-68
```

```
Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      48 ATGATGAAGACTGCTGTC 66
Db      19 ATGATGAAGACTGCTGTC 1
```

```
RESULT 338
US-10-828-394-16
; Sequence 16, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC-P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-10-828-394-16
```

```
Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      482 CCAGAGCTGCGCCCTTCTAC 500
Db      1 CCAGAGCTGCGCCCTTCTAC 19
```

```
RESULT 339
US-10-828-394-17
; Sequence 17, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC-P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-394-17
```

```
Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1100 GATGCTCAACACCTCTCC 1118
Db      1 GAUGCUCACACCCUCCUCC 19
```

```
RESULT 340
US-10-828-394-18
; Sequence 18, Application US/10828394
; Publication No. US20040220131A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders
; FILE REFERENCE: UBC-P-033
; CURRENT APPLICATION NUMBER: US/10/828,394
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-394-18
```

```
Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.4e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1615 CTATTCAATPAAACTGTC 1633
Db      1 CUAUUCACAAUAAACUGUC 19
```

```
RESULT 341
US-10-828-395-16
; Sequence 16, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 16
; LENGTH: 19
; TYPE: DNA
; ORGANISM: human
US-10-828-395-16
```

```
Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      482 CCAGAGCTGCGCCCTTCTAC 500
Db      1 CCAGAGCTGCGCCCTTCTAC 19
```

```
RESULT 342
US-10-828-395-17
```

```
Sequence 17, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 17
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-395-17

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 78.9%; Pred. No. 1.4e+02;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      1100 GATGCTCAACACCTCTCTCC 1118
DB      1 GAUGCUCAACACCCUCCUCC 19

RESULT 343
US-10-828-395-18
; Sequence 18, Application US/10828395
; Publication No. US20040224914A1
; GENERAL INFORMATION:
; APPLICANT: Jackson, John
; APPLICANT: Burt, Helen
; APPLICANT: Springate, Christopher
; APPLICANT: Gleave, Martin
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders
; FILE REFERENCE: UBC-P-032
; CURRENT APPLICATION NUMBER: US/10/828,395
; CURRENT FILING DATE: 2004-04-19
; PRIOR APPLICATION NUMBER: US 60/464,159
; PRIOR FILING DATE: 2003-04-18
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 18
; LENGTH: 19
; TYPE: RNA
; ORGANISM: human
US-10-828-395-18

Query Match          1.2%; Score 19; DB 1; Length 19;
Best Local Similarity 68.4%; Pred. No. 1.4e+02;
Matches 13; Conservative 6; Mismatches 0; Indels 0; Gaps 0;

QY      1615 CTAATTCATTAATAACTGTC 1633
DB      1 CUAUUCUCAAUAAAACUCUC 19

RESULT 344
US-10-646-436-10/c
; Sequence 29, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Gleave, Martin
; APPLICANT: Jansen, Burkhard
US-10-646-436-10/c

TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC-P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 29
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-391A-29

Query Match          1.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      48 ATGATGAAGACTCTGCTGC 66
DB      19 ATGATGAAGACTCTGCTGC 1

RESULT 345
US-10-646-436-10/c
; Sequence 10, Application US/10646436
; Publication No. US20040096882A1
; GENERAL INFORMATION:
; APPLICANT: Jansen, Burkhard
; APPLICANT: Gleave, Martin
; APPLICANT: Signaevsky, Maxim
; APPLICANT: Betaldi, Eliana
; APPLICANT: Trougakos, Ioannis
; APPLICANT: Gonos, Efsthios
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins
; FILE REFERENCE: UBC-P-030
; CURRENT APPLICATION NUMBER: US/10/646,436
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 10
; LENGTH: 21
; TYPE: DNA
; ORGANISM: artificial
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-10

Query Match          1.2%; Score 19; DB 1; Length 21;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      48 ATGATGAAGACTCTGCTGC 66
DB      19 ATGATGAAGACTCTGCTGC 1

RESULT 346
US-10-380-124-4
```

```
/ Sequence 4, Application US/10380124
/ Publication No. US20040053874A1
/ GENERAL INFORMATION:
/ APPLICANT: Isis Pharmaceuticals, Inc.
/ APPLICANT: Brett P. Monia
/ APPLICANT: Susan M. Freiler
/ TITLE OF INVENTION: ANTISENSE MODULATION OF CLUSTERIN EXPRESSION
/ FILE REFERENCE: RTS-0156
/ CURRENT APPLICATION NUMBER: US/10/380,124
/ CURRENT FILING DATE: 2003-03-10
/ NUMBER OF SEQ ID NOS: 90
/ SEQ ID NO 4
/ LENGTH: 18
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: PCR Primer
US-10-380-124-4
```

```
Query Match 1.1%; Score 18; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.6e+02;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY 746 TCCGTACGAGCCCTGAA 763
Db 1 TCCGTACGAGCCCTGAA 18
```

```
RESULT 347
US-09-967-726A-15/C
/ Sequence 15, Application US/09967726A
/ Publication No. US20030158130A1
/ GENERAL INFORMATION:
/ APPLICANT: Gleave, Martin
/ APPLICANT: Rennie, Paul S.
/ APPLICANT: Miyake, Hideaki
/ APPLICANT: Nelson, Colleen
/ APPLICANT: Zellweger, Tobias
/ TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2
/ TITLE OF INVENTION: Oligonucleotides
/ FILE REFERENCE: UBC.P-022
/ CURRENT APPLICATION NUMBER: US/09/967,726A
/ CURRENT FILING DATE: 2001-09-28
/ NUMBER OF SEQ ID NOS: 15
/ SOFTWARE: PatentIn version 3.1
/ SEQ ID NO 15
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: Artificial
/ FEATURE:
/ OTHER INFORMATION: 2 base mismatch primer from human TRPM-2
US-09-967-726A-15
```

```
Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 48 ATGATGAAGACTGCTGCTG 68
Db 21 ATGATAAATCTCTGCTGCTG 1
```

```
RESULT 348
US-10-080-794-15/C
/ Sequence 15, Application US/10080794
/ Publication No. US20030166591A1
/ GENERAL INFORMATION:
/ APPLICANT: Gleave, Martin
/ APPLICANT: Rennie, Paul S.
/ APPLICANT: Miyake, Hideaki
/ APPLICANT: Nelson, Colleen
/ APPLICANT: Monia, Brett P.
/ TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE
```

```
/ TITLE OF INVENTION: HAVING 2'-O-(2-METHOXY)ETHYL MODIFICATIONS
/ FILE REFERENCE: UBC.P-020-3
/ CURRENT APPLICATION NUMBER: US/10/080,794
/ CURRENT FILING DATE: 2002-02-22
/ PRIOR APPLICATION NUMBER: 60/121,726
/ PRIOR FILING DATE: 1999-02-26
/ PRIOR APPLICATION NUMBER: 09/913,325
/ PRIOR FILING DATE: 2001-08-10
/ PRIOR APPLICATION NUMBER: 09/944,326
/ PRIOR FILING DATE: 2001-08-30
/ NUMBER OF SEQ ID NOS: 19
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 15
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: HUMAN
US-10-080-794-15
```

```
Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 48 ATGATGAAGACTGCTGCTG 68
Db 21 ATGATAAATCTCTGCTGCTG 1
```

```
RESULT 349
US-10-751-736-11047
/ Sequence 11047, Application US/10751736
/ Publication No. US20040265230A1
/ GENERAL INFORMATION:
/ APPLICANT: Wylech
/ APPLICANT: Martinez, Robert
/ APPLICANT: Brown, Eugene
/ APPLICANT: Liu, Wei
/ TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON
/ TITLE OF INVENTION: CANCERS
/ FILE REFERENCE: AM100927 (031896-002000)
/ CURRENT APPLICATION NUMBER: US/10/751,736
/ CURRENT FILING DATE: 2003-01-06
/ PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000
/ PRIOR FILING DATE: 2003-01-06
/ NUMBER OF SEQ ID NOS: 54873
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 11047
/ LENGTH: 21
/ TYPE: DNA
/ ORGANISM: homo sapiens
US-10-751-736-11047
```

```
Query Match 1.1%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 2.3e+02;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 35 CAGAAATGGAGCATGATGAA 55
Db 1 CAGTAATGGAGCATGATGAA 21
```

```
RESULT 350
US-10-921-868A-37/C
/ Sequence 37, Application US/10921868A
/ Publication No. US20050118251A1
/ GENERAL INFORMATION:
/ APPLICANT: Nagata, Leslie P.
/ APPLICANT: Wong, Jonathan P.
/ TITLE OF INVENTION: NOVEL DNA-BASED VACCINE AGAINST THE ENCEPHALITIS ALPHAVIRUSES
/ FILE REFERENCE: NEL-0001/DV1
/ CURRENT APPLICATION NUMBER: US/10/921,868A
/ CURRENT FILING DATE: 2004-08-20
/ PRIOR APPLICATION NUMBER: 10/023,649
/ PRIOR FILING DATE: 2001-12-21
```



PRIOR APPLICATION NUMBER: 60/256,948  
PRIOR FILING DATE: 2000-12-21  
NUMBER OF SEQ ID NOS: 49  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 37  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: DNA Primer  
US-10-921-868A-37

Query Match 1.0%; Score 16.8; DB 1; Length 20;  
Best Local Similarity 90.0%; Pred. No. 2.5e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 524 CGACTCCCTGCTGGAGAAGC 543  
DB 20 CGACACGCTGCTGGAGAAGC 1

RESULT 351  
US-10-786-720-3371/c  
Sequence 3371, Application US/10786720  
Publication No. US20040191818A1  
GENERAL INFORMATION:  
APPLICANT: Wyeth  
APPLICANT: O'Toole, Margot  
APPLICANT: Liu, Wei  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE  
FILE REFERENCE: 031896-023000 (AM101331L)  
CURRENT APPLICATION NUMBER: US/10/786,720  
CURRENT FILING DATE: 2004-02-26  
NUMBER OF SEQ ID NOS: 2135  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 3371  
LENGTH: 21  
TYPE: RNA  
ORGANISM: RNAI-sense strand  
US-10-786-720-3371

Query Match 1.0%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 583 ACTTCAGCCGCGCTCCAGC 602  
DB 20 ACTTCAGCCGCTCCAGC 1

RESULT 352  
US-10-786-720-4073/c  
Sequence 4073, Application US/10786720  
Publication No. US20040191818A1  
GENERAL INFORMATION:  
APPLICANT: Wyeth  
APPLICANT: O'Toole, Margot  
APPLICANT: Liu, Wei  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE  
FILE REFERENCE: 031896-023000 (AM101331L)  
CURRENT APPLICATION NUMBER: US/10/786,720  
CURRENT FILING DATE: 2004-02-26  
NUMBER OF SEQ ID NOS: 21135  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 4073  
LENGTH: 21  
TYPE: RNA  
ORGANISM: RNAI-sense strand  
US-10-786-720-4073

Query Match 1.0%; Score 16.8; DB 1; Length 21;

Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 583 ACTTCAGCCGCGCTCCAGC 602  
DB 20 ACTTCAGCCGCTCCAGC 1

RESULT 353  
US-10-786-720-4811/c  
Sequence 4811, Application US/10786720  
Publication No. US20040191818A1  
GENERAL INFORMATION:  
APPLICANT: Wyeth  
APPLICANT: O'Toole, Margot  
APPLICANT: Liu, Wei  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING AUTOIMMUNE  
FILE REFERENCE: 031896-023000 (AM101331L)  
CURRENT APPLICATION NUMBER: US/10/786,720  
CURRENT FILING DATE: 2004-02-26  
NUMBER OF SEQ ID NOS: 21135  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 4811  
LENGTH: 21  
TYPE: RNA  
ORGANISM: RNAI-sense strand  
US-10-786-720-4811

Query Match 1.0%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 583 ACTTCAGCCGCGCTCCAGC 602  
DB 20 ACTTCAGCCGCTCCAGC 1

RESULT 354  
US-10-751-736-24026/c  
Sequence 24026, Application US/10751736  
Publication No. US20040265230A1  
GENERAL INFORMATION:  
APPLICANT: Wyeth  
APPLICANT: Martinez, Robert  
APPLICANT: Brown, Eugene  
APPLICANT: Liu, Wei  
TITLE OF INVENTION: COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING COLON  
FILE REFERENCE: AM100927 (031896-002000)  
CURRENT APPLICATION NUMBER: US/10/751,736  
CURRENT FILING DATE: 2003-01-06  
PRIOR APPLICATION NUMBER: US Provisional Application 60/438,000  
PRIOR FILING DATE: 2003-01-06  
NUMBER OF SEQ ID NOS: 54873  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 24026  
LENGTH: 21  
TYPE: RNA  
ORGANISM: RNAI  
US-10-751-736-24026

Query Match 1.0%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 136 AGCTCAGAGAAATGTCAT 155  
DB 20 AGCTCAGAGAAATGTCAT 1

RESULT 355  
US-10-911-318-81/c

/ Sequence 81, Application US/10911318  
/ Publication No. US20050130186A1  
/ GENERAL INFORMATION:  
/ APPLICANT: We Gene Technologies, Inc.  
/ TITLE OF INVENTION: MENINGITIS DETECTION CHIP AND FABRICATION METHOD THEREOF AND  
/ TITLE OF INVENTION: METHOD OF DETECTING MENINGITIS AND PRIMER SET FOR MENINGITIS  
/ TITLE OF INVENTION: DETECTION  
/ FILE REFERENCE: 12333-US-PA  
/ CURRENT APPLICATION NUMBER: US/10/911,318  
/ CURRENT FILING DATE: 2004-08-03  
/ PRIOR APPLICATION NUMBER: TW 92135134  
/ PRIOR FILING DATE: 2003-12-12  
/ NUMBER OF SEQ ID NOS: 134  
/ SOFTWARE: PatentIn version 3.3  
/ SEQ ID NO 81  
/ LENGTH: 21  
/ TYPE: DNA  
/ ORGANISM: artificial sequence  
/ FEATURE:  
/ OTHER INFORMATION: Primer  
US-10-911-318-81

Query Match 1.0%; Score 16.8; DB 1; Length 21;  
Best Local Similarity 90.0%; Pred. No. 2.8e+02;  
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1281 TCTGATCCCATCACTGTGAC 1300  
Db 21 TCTGATCCCATCACTGTGAC 2

RESULT 356  
US-09-294-121A-97/C  
/ Sequence 97, Application US/09294121A  
/ Patent No. US20020069422A1  
/ GENERAL INFORMATION:  
/ APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;  
/ APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO  
/ TITLE OF INVENTION: PROCESS FOR TYPING OF HCV  
/ TITLE OF INVENTION: ISOLATES  
/ NUMBER OF SEQUENCES: 97  
/ CORRESPONDENCE ADDRESS:  
/ ADDRESSEE: BIERMAN & MUSERLIAN  
/ STREET: 600 THIRD AVENUE  
/ CITY: NEW YORK  
/ STATE: NEW YORK  
/ COUNTRY: USA  
/ ZIP: 10016  
/ COMPUTER READABLE FORM:  
/ MEDIUM TYPE: floppy disk  
/ COMPUTER: IBM PC compatible  
/ OPERATING SYSTEM: PC-DOS/MS-DOS  
/ SOFTWARE: ASCII  
/ CURRENT APPLICATION DATA:  
/ APPLICATION NUMBER: US/09/294,121A  
/ FILING DATE:  
/ CLASSIFICATION:  
/ PRIOR APPLICATION DATA:  
/ APPLICATION NUMBER: 08/256,568  
/ FILING DATE: 18-JUL-1994  
/ APPLICATION NUMBER: PCT/EP93/03325  
/ FILING DATE: 26-NOV-1993  
/ PRIOR APPLICATION DATA:  
/ APPLICATION NUMBER: EP/93/402,129.6  
/ FILING DATE: 31-AUG-1993  
/ PRIOR APPLICATION DATA:  
/ APPLICATION NUMBER: EP/92/403,222.0  
/ FILING DATE: 27-NOV-1992  
/ ATTORNEY/AGENT INFORMATION:  
/ NAME: CHARLES A. MUSERLIAN  
/ REGISTRATION NUMBER: 19,683  
/ REFERENCE/DOCKET NUMBER: 410.004  
/ TELECOMMUNICATION INFORMATION:

/ TELEPHONE: (212) 661-8000  
/ TELEFAX: (212) 661-8002  
/ INFORMATION FOR SEQ ID NO: 97:  
/ SEQUENCE CHARACTERISTICS:  
/ LENGTH: 16 base pairs  
/ TYPE: nucleic acid  
/ STRANDEDNESS: single  
/ TOPOLOGY: linear  
/ MOLECULE TYPE: CDNA  
/ HYPOTHETICAL: NO  
/ ANTI-SENSE: YES  
US-09-294-121A-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1508 CAGCTTCAGGCCCCC 1523  
Db 16 CAGCTTCAGGCCCCC 1

RESULT 357  
US-09-899-082A-97/C  
/ Sequence 97, Application US/09899082A  
/ Patent No. US2002010638A1  
/ GENERAL INFORMATION:  
/ APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;  
/ APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO  
/ TITLE OF INVENTION: PROCESS FOR TYPING OF HCV  
/ TITLE OF INVENTION: ISOLATES  
/ NUMBER OF SEQUENCES: 97  
/ CORRESPONDENCE ADDRESS:  
/ ADDRESSEE: BIERMAN & MUSERLIAN  
/ STREET: 600 THIRD AVENUE  
/ CITY: NEW YORK  
/ STATE: NEW YORK  
/ COUNTRY: USA  
/ ZIP: 10016  
/ COMPUTER READABLE FORM:  
/ MEDIUM TYPE: floppy disk  
/ COMPUTER: IBM PC compatible  
/ OPERATING SYSTEM: PC-DOS/MS-DOS  
/ SOFTWARE: ASCII  
/ CURRENT APPLICATION DATA:  
/ APPLICATION NUMBER: US/09/899,082A  
/ FILING DATE: 06-JUL-2001  
/ CLASSIFICATION: <Unknown>  
/ PRIOR APPLICATION DATA:  
/ APPLICATION NUMBER: US/09/378,900  
/ FILING DATE: <Unknown>  
/ APPLICATION NUMBER: 08/256,568  
/ FILING DATE: 18-JUL-1994  
/ APPLICATION NUMBER: PCT/EP93/03325  
/ FILING DATE: 26-NOV-1993  
/ APPLICATION NUMBER: EP/93/402,129.6  
/ FILING DATE: 31-AUG-1993  
/ APPLICATION NUMBER: EP/92/403,222.0  
/ FILING DATE: 27-NOV-1992  
/ ATTORNEY/AGENT INFORMATION:  
/ NAME: CHARLES A. MUSERLIAN  
/ REGISTRATION NUMBER: 19,683  
/ REFERENCE/DOCKET NUMBER: 410.004  
/ TELECOMMUNICATION INFORMATION:  
/ TELEPHONE: (212) 661-8000  
/ TELEFAX: (212) 661-8002  
/ INFORMATION FOR SEQ ID NO: 97:  
/ SEQUENCE CHARACTERISTICS:  
/ LENGTH: 16 base pairs  
/ TYPE: nucleic acid  
/ STRANDEDNESS: single  
/ TOPOLOGY: linear  
/ MOLECULE TYPE: CDNA

HYPOTHETICAL: NO  
ANTI-SENSE: YES  
SEQUENCE DESCRIPTION: SEQ ID NO: 97:  
US-09-899-0824-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523

DB 16 CAGCCTCCAGGCCCC 1

RESULT 358  
US-09-899-302-97/c  
; Sequence 97, Application US/09899302  
; Patent No. US20020168626A1  
; GENERAL INFORMATION:  
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;  
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO  
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV  
; TITLE OF INVENTION: ISOLATES  
; NUMBER OF SEQUENCES: 97  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BIERMAN & MUSERLIAN  
; STREET: 600 THIRD AVENUE  
; CITY: NEW YORK  
; STATE: NEW YORK  
; COUNTRY: USA  
; ZIP: 10016  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: ASCII  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/899,302  
; FILING DATE:  
; CLASSIFICATION:  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/378,900  
; FILING DATE:  
; APPLICATION NUMBER: 08/256,568  
; FILING DATE: 18-JUL-1994  
; APPLICATION NUMBER: PCT/EP93/03325  
; FILING DATE: 26-NOV-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: EP/93/402,129.6  
; FILING DATE: 31-AUG-1993  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: EP/92/403,222.0  
; FILING DATE: 27-NOV-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: CHARLES A. MUSERLIAN  
; REGISTRATION NUMBER: 19,683  
; REFERENCE/DOCKET NUMBER: 410,004  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 661-8000  
; TELEFAX: (212) 661-8002  
; INFORMATION FOR SEQ ID NO: 97:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 16 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: YES  
US-09-899-302-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1508 CAGCCTCCAGGCCCC 1523  
DB 16 CAGCCTCCAGGCCCC 1

RESULT 359  
US-09-899-044-97/c  
; Sequence 97, Application US/09899044  
; Publication No. US20030036053A1  
; GENERAL INFORMATION:  
; APPLICANT: MAERTENS, GEERT; STUYVER, LIEVEN;  
; APPLICANT: ROSSAU, RUDI; VAN HEUVERSWYN, HUGO  
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV  
; TITLE OF INVENTION: ISOLATES  
; NUMBER OF SEQUENCES: 97  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: BIERMAN & MUSERLIAN  
; STREET: 600 THIRD AVENUE  
; CITY: NEW YORK  
; STATE: NEW YORK  
; COUNTRY: USA  
; ZIP: 10016  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: ASCII  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/899,044  
; FILING DATE: 06-JUL-2001  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: 09/378,900  
; FILING DATE: <Unknown>  
; APPLICATION NUMBER: PCT/EP93/03325  
; FILING DATE: 26-NOV-1993  
; APPLICATION NUMBER: EP/93/402,129.6  
; FILING DATE: 31-AUG-1993  
; APPLICATION NUMBER: EP/92/403,222.0  
; FILING DATE: 27-NOV-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: CHARLES A. MUSERLIAN  
; REGISTRATION NUMBER: 19,683  
; REFERENCE/DOCKET NUMBER: 410,004  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: (212) 661-8000  
; TELEFAX: (212) 661-8002  
; INFORMATION FOR SEQ ID NO: 97:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 16 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: YES  
; SEQUENCE DESCRIPTION: SEQ ID NO: 97:  
US-09-899-044-97

Query Match 1.0%; Score 16; DB 1; Length 16;  
Best Local Similarity 100.0%; Pred. No. 1.9e+02;  
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1508 CAGCCTCCAGGCCCC 1523  
DB 16 CAGCCTCCAGGCCCC 1

RESULT 360  
US-10-822-711-97/c  
; Sequence 97, Application US/10822711

```
; Publication No. US20040191768A1
; GENERAL INFORMATION:
; APPLICANT: MAERTENS, GEBERT; STUYVER, LIEVEN;
; ROSSAU, RUDI; VAN HEUVERSWAN, HUGO
; TITLE OF INVENTION: PROCESS FOR TYPING OF HCV
; ISOLATES
; NUMBER OF SEQUENCES: 97
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: BIERMAN & MUSERLIAN
; STREET: 600 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10016
; COMPUTER READABLE FORM:
; MEDIUM TYPE: floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/822,711
; FILING DATE: 13-Apr-2004
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/09/899,082A
; FILING DATE: 06-Jul-2001
; APPLICATION NUMBER: US/09/378,900
; FILING DATE: <Unknown>
; APPLICATION NUMBER: 08/256,568
; FILING DATE: 18-Jul-1994
; APPLICATION NUMBER: PCT/EP93/03325
; FILING DATE: 26-Nov-1993
; APPLICATION NUMBER: EP/93/402,129.6
; FILING DATE: 31-Aug-1993
; APPLICATION NUMBER: EP/92/403,222.0
; FILING DATE: 27-Nov-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: CHARLES A. MUSERLIAN
; REGISTRATION NUMBER: 19,683
; REFERENCE/DOCKET NUMBER: 410.004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 661-8000
; TELEFAX: (212) 661-8002
; INFORMATION FOR SEQ ID NO: 97:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHEICAL: NO
; ANTI-SENSE: YES
; SEQUENCE DESCRIPTION: SEQ ID NO: 97:
US-10-822-711-97

Query Match      1.0%; Score 16; DB 1; Length 16;
Best Local Similarity 100.0%; Pred. No. 1.9e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1508 CAGCCTCAGGCCCC 1523
DB      16 CAGCCTCAGGCCCC 1

RESULT 361
US-10-160-787-84/c
; Sequence 84, Application US/10160787
; Publication No. US20030225256A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PCTAIRE PROTEIN KINASE 2 EXPRESSION
; FILE REFERENCE: RTS-0204
; CURRENT APPLICATION NUMBER: US/10/160,787
```

```
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 84
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-10-160-787-84

Query Match      1.0%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1583 CATGGGAAGAACGAA 1598
DB      17 CATGGGAAGAACGAA 2

RESULT 362
US-10-160-787-137
; Sequence 137, Application US/10160787
; Publication No. US20030225256A1
; GENERAL INFORMATION:
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF PCTAIRE PROTEIN KINASE 2 EXPRESSION
; FILE REFERENCE: RTS-0204
; CURRENT APPLICATION NUMBER: US/10/160,787
; CURRENT FILING DATE: 2002-05-31
; NUMBER OF SEQ ID NOS: 141
; SEQ ID NO 137
; LENGTH: 20
; TYPE: DNA
; ORGANISM: H. sapiens
; FEATURE:
US-10-160-787-137

Query Match      1.0%; Score 16; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 3e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1583 CATGGGAAGAACGAA 1598
DB      4 CATGGGAAGAACGAA 19

RESULT 363
US-10-646-391A-24
; Sequence 24, Application US/10646391A
; Publication No. US20040082534A1
; GENERAL INFORMATION:
; APPLICANT: Janssen, Burthard
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels
; FILE REFERENCE: UBC-P-035
; CURRENT APPLICATION NUMBER: US/10/646,391A
; CURRENT FILING DATE: 2003-08-21
; PRIOR APPLICATION NUMBER: US 60/405,193
; PRIOR FILING DATE: 2002-08-21
; PRIOR APPLICATION NUMBER: US 60/319,748
; PRIOR FILING DATE: 2002-12-02
; PRIOR APPLICATION NUMBER: US 60/408,152
; PRIOR FILING DATE: 2002-09-03
; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 43
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 24
; LENGTH: 19
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
```

## US-10-646-391A-24

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 2.8e+02;  
Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATTAATAACTGCT 1634

Db 1 UAATTCACAAACACUGUTT 19

## RESULT 364

US-10-646-391A-26

Sequence 26, Application US/10646391A  
Publication No. US20040082534A1

GENERAL INFORMATION:

APPLICANT: Jansen, Martin

APPLICANT: Jansen, Burkhard

TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels

FILE REFERENCE: UBC-P-035

CURRENT APPLICATION NUMBER: US/10/646,391A

CURRENT FILING DATE: 2003-08-21

PRIOR APPLICATION NUMBER: US 60/405,193

PRIOR FILING DATE: 2002-08-21

PRIOR APPLICATION NUMBER: US 60/319,748

PRIOR FILING DATE: 2002-12-02

PRIOR APPLICATION NUMBER: US 60/408,152

PRIOR FILING DATE: 2002-09-03

PRIOR APPLICATION NUMBER: US 60/473,387

PRIOR FILING DATE: 2003-05-20

NUMBER OF SEQ ID NOS: 43

SOFTWARE: PatentIn version 3.2

SEQ ID NO 26

LENGTH: 19

TYPE: DNA

ORGANISM: artificial

FEATURE:

OTHER INFORMATION: RNAi for human clusterin

US-10-646-391A-26

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 2.8e+02;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATTAATAACTGCT 1634

Db 1 UAATTCACAAACACUGUTT 19

## RESULT 365

US-10-646-391A-27/c

Sequence 27, Application US/10646391A  
Publication No. US20040082534A1

GENERAL INFORMATION:

APPLICANT: Jansen, Martin

APPLICANT: Jansen, Burkhard

TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels

FILE REFERENCE: UBC-P-035

CURRENT APPLICATION NUMBER: US/10/646,391A

CURRENT FILING DATE: 2003-08-21

PRIOR APPLICATION NUMBER: US 60/405,193

PRIOR FILING DATE: 2002-08-21

PRIOR APPLICATION NUMBER: US 60/319,748

PRIOR FILING DATE: 2002-12-02

PRIOR APPLICATION NUMBER: US 60/408,152

PRIOR FILING DATE: 2002-09-03

PRIOR APPLICATION NUMBER: US 60/473,387

PRIOR FILING DATE: 2003-05-20

NUMBER OF SEQ ID NOS: 43

SOFTWARE: PatentIn version 3.2

SEQ ID NO 27

LENGTH: 19

TYPE: DNA

ORGANISM: artificial

FEATURE:

OTHER INFORMATION: RNAi for human clusterin

US-10-646-391A-27

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 89.5%; Pred. No. 2.8e+02;  
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1614 ACTAATTCATTAATAACTGCT 1632

Db 19 AATAATTCACAAACACUGTT 1

## RESULT 366

US-10-646-436-7

Sequence 7, Application US/10646436  
Publication No. US20040096882A1

GENERAL INFORMATION:

APPLICANT: Jansen, Martin

APPLICANT: Jansen, Burkhard

APPLICANT: Signaevsky, Maxim

APPLICANT: Beraldi, Eliana

APPLICANT: Trougakos, Ioannis

APPLICANT: Gonos, Efethachios

TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins

FILE REFERENCE: UBC-P-030

CURRENT APPLICATION NUMBER: US/10/646,436

CURRENT FILING DATE: 2003-08-21

PRIOR APPLICATION NUMBER: US 60/405,193

PRIOR FILING DATE: 2002-08-21

PRIOR APPLICATION NUMBER: US 60/408,152

PRIOR FILING DATE: 2002-09-03

PRIOR APPLICATION NUMBER: US 60/473,387

PRIOR FILING DATE: 2003-05-20

NUMBER OF SEQ ID NOS: 68

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 19

TYPE: DNA

ORGANISM: artificial

FEATURE:

OTHER INFORMATION: RNAi for human clusterin

US-10-646-436-7

Query Match 1.0%; Score 15.8; DB 1; Length 19;  
Best Local Similarity 63.2%; Pred. No. 2.8e+02;

Matches 12; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1616 TAATTCATTAATAACTGCT 1634

Db 1 UAATTCACAAACACUGUTT 19

## RESULT 367

US-10-646-436-8/c

Sequence 8, Application US/10646436  
Publication No. US20040096882A1

GENERAL INFORMATION:

APPLICANT: Jansen, Martin

APPLICANT: Jansen, Burkhard

APPLICANT: Signaevsky, Maxim

APPLICANT: Beraldi, Eliana

APPLICANT: Trougakos, Ioannis

APPLICANT: Gonos, Efethachios

TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins

FILE REFERENCE: UBC-P-030

CURRENT APPLICATION NUMBER: US/10/646,436

CURRENT FILING DATE: 2003-08-21

PRIOR APPLICATION NUMBER: US 60/405,193

PRIOR FILING DATE: 2002-08-21

PRIOR APPLICATION NUMBER: US 60/408,152

PRIOR FILING DATE: 2002-09-03

```

; PRIOR APPLICATION NUMBER: US 60/473,387
; PRIOR FILING DATE: 2003-05-20
; NUMBER OF SEQ ID NOS: 68
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 8
; LENGTH: 19
; TYPE: DNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: RNAi for human clusterin
US-10-646-436-8

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1614 ACTAATTCATAAAGTGT 1632
      19 AATATTCAACAAACTGT 1

RESULT 368
US-10-667-271-305
; Sequence 305, Application US/10667271
; Publication No. US20040209831A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Beigelman, Leonid
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis C Virus (HCV)
; FILE REFERENCE: 400/129 (MBH02-763B)
; CURRENT APPLICATION NUMBER: US/10/667,271
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT / US03/05043
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT / US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: USSN 60/401,104
; PRIOR FILING DATE: 2002-08-05
; PRIOR APPLICATION NUMBER: USSN 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: USSN 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: USSN 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: USSN 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: USSN 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: USSN 60/409,293
; PRIOR FILING DATE: 2002-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1705
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 305
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Target Sequence/siNA sense re
US-10-667-271-305

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 2.8e+02;
Matches 16; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY      222 CTCATAGAAAAACCAACG 240
      1:||||| ||||| |||||
```

```

DB      1 CUCAAGAAAAACCAACG 19

RESULT 369
US-10-667-271-1001/C
; Sequence 1001, Application US/10667271
; Publication No. US20040209831A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics
; APPLICANT: McSwiggen, James
; APPLICANT: Macejak, Dennis
; APPLICANT: Beigelman, Leonid
; APPLICANT: Morrissey, David
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Hepatitis C Virus (HCV)
; FILE REFERENCE: 400/129 (MBH02-763B)
; CURRENT APPLICATION NUMBER: US/10/667,271
; CURRENT FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/444,853
; PRIOR FILING DATE: 2003-05-23
; PRIOR APPLICATION NUMBER: PCT / US03/05043
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: PCT / US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: USSN 60/401,104
; PRIOR FILING DATE: 2002-08-05
; PRIOR APPLICATION NUMBER: USSN 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: USSN 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: USSN 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: USSN 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: USSN 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: USSN 60/409,293
; PRIOR FILING DATE: 2002-09-09
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 1705
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 1001
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-667-271-1001

Query Match      1.0%; Score 15.8; DB 1; Length 19;
Best Local Similarity 89.5%; Pred. No. 2.8e+02;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      222 CTCATAGAAAAACCAACG 240
      19 CTCAGAAAAACCAACG 1

RESULT 370
US-09-866-108-8666
; Sequence 8666, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: ABOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
```

CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Acomica Sequence Listing Engine  
SEQ ID NO 8666  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8666

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 273 GAGCCAGAGAGAGAA 289  
DB 1 GAGCCAGAGAGAGAA 17

RESULT 371  
US-09-780-533A-170/c  
Sequence 170, Application US/09780533A  
Publication No. US20030060611A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Blatt, Larry  
APPLICANT: McSwigen, Jim  
APPLICANT: Chowrita, Bharat  
APPLICANT: Haeblerl, Pete  
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
FILE REFERENCE: MBH00,878-A (400/011)  
CURRENT APPLICATION NUMBER: US/09/780,533A  
CURRENT FILING DATE: 2001-02-09  
PRIOR APPLICATION NUMBER: US 60/181,797  
PRIOR FILING DATE: 2000-02-11  
NUMBER OF SEQ ID NOS: 6679  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 170  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-780-533A-170

Query Match 0.9%; Score 15.4; DB 1; Length 17;

Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;  
QY 1619 TTCAATAAACTGCTT 1635  
DB 17 TTCAATAAACTGCTT 1

RESULT 372  
US-09-740-332-1542  
Sequence 1542, Application US/09740332  
Publication No. US20030125270A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals Inc.  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection  
FILE REFERENCE: RPI 400/003  
CURRENT APPLICATION NUMBER: US/09/740,332  
CURRENT FILING DATE: 2001-03-26  
NUMBER OF SEQ ID NOS: 9704  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1542  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial sequence  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-1542

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 2.4e+02;  
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY 766 TCACGCCCATGTTCCAG 782  
DB 1 UCACGCCCATGTTCCAG 17

RESULT 373  
US-09-740-332-3013/c  
Sequence 3013, Application US/09740332  
Publication No. US20030125270A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals Inc.  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to Hepatitis C Virus Infection  
FILE REFERENCE: RPI 400/003  
CURRENT APPLICATION NUMBER: US/09/740,332  
CURRENT FILING DATE: 2001-03-26  
NUMBER OF SEQ ID NOS: 9704  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3013  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial sequence  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-09-740-332-3013

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 767 CCAGCCATGTTCCAGC 783  
DB 17 CCAGCCATGTTCCAGC 1

RESULT 374

```
US-09-817-879-1542
; Sequence 1542, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1542
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1542

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.4e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      766 TCCACGCCCATGTTCCAG 782
Db      1 UCCACGCCCAUGUCCGG 17

RESULT 375
US-09-817-879-3013/c
; Sequence 3013, Application US/09817879
; Publication No. US2003017131A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3013
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3013

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      767 CCACGCCATGTTCCAGC 783
Db      17 CCACGCCATGTTCCGGC 1

RESULT 376
US-10-669-841-4135
; Sequence 4135, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Dennis, Macejak
; APPLICANT: James, MCSwiigen
; APPLICANT: David, Morrissey
```

```
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/04205 (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4135
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4135

Query Match      0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.4e+02;
Matches 12; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      766 TCCACGCCCATGTTCCAG 782
Db      1 UCCACGCCCAUGUCCGG 17

RESULT 377
US-10-669-841-5606/c
; Sequence 5606, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Elisabeth, Roberts
; APPLICANT: Dennis, Macejak
; APPLICANT: James, MCSwiigen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; FILE REFERENCE: 400/04205 (MBH02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
```



PRIOR FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: US 60/296,876  
PRIOR FILING DATE: 2001-06-08  
PRIOR APPLICATION NUMBER: US 60/335,059  
PRIOR FILING DATE: 2001-10-24  
PRIOR APPLICATION NUMBER: US 60/337,055  
PRIOR FILING DATE: 2001-12-05  
PRIOR APPLICATION NUMBER: US 60/358,580  
PRIOR FILING DATE: 2002-02-20  
PRIOR APPLICATION NUMBER: US 60/363,124  
PRIOR FILING DATE: 2002-03-11  
PRIOR APPLICATION NUMBER: US 09/817,879  
PRIOR FILING DATE: 2001-03-26  
PRIOR APPLICATION NUMBER: US 09/740,332  
PRIOR FILING DATE: 2000-12-18  
PRIOR APPLICATION NUMBER: US 09/611,931  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 09/504,321  
PRIOR FILING DATE: 2000-02-15  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 16207  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5606  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-5606

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 767 CCAGCCATGTTCCAGC 783  
Db 17 CCAGCCATGTTCCAGC 1

RESULT 378  
US-10-723-361-8666  
Sequence 8666, Application US/10723361  
Publication No. US20040137589A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wenheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
FILE REFERENCE: PB0105  
CURRENT APPLICATION NUMBER: US/10/723,361  
CURRENT FILING DATE: 2003-11-26  
PRIOR APPLICATION NUMBER: US 09/866,108  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30

PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 8666  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-723-361-8666

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 273 GAAGCCAGAGAGAA 289  
Db 1 GAAGCCAGAGAGAA 17

RESULT 379  
US-10-828-394-19/c  
Sequence 19, Application US/10828394  
Publication No. US20040220131A1  
GENERAL INFORMATION:  
APPLICANT: Jackson, John  
APPLICANT: Burt, Helen  
APPLICANT: Springate, Christopher  
APPLICANT: Gleave, Martin  
TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders  
FILE REFERENCE: UBC.P-033  
CURRENT APPLICATION NUMBER: US/10/828,394  
CURRENT FILING DATE: 2004-04-19  
PRIOR APPLICATION NUMBER: US 60/464,159  
PRIOR FILING DATE: 2003-04-18  
NUMBER OF SEQ ID NOS: 23  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 19  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial  
FEATURE:  
OTHER INFORMATION: clusterin targeted siRNA  
US-10-828-394-19

Query Match 0.9%; Score 15.4; DB 1; Length 17;  
Best Local Similarity 94.1%; Pred. No. 2.4e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1616 TAATTCATAAACTGT 1632  
Db 17 TAATTCATCAAACTGT 1

RESULT 380  
US-10-828-395-19/c  
Sequence 19, Application US/10828395  
Publication No. US20040224914A1  
GENERAL INFORMATION:  
APPLICANT: Jackson, John  
APPLICANT: Burt, Helen  
APPLICANT: Springate, Christopher  
APPLICANT: Gleave, Martin  
TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
FILE REFERENCE: UBC.P-032  
CURRENT APPLICATION NUMBER: US/10/828,395  
CURRENT FILING DATE: 2004-04-19  
PRIOR APPLICATION NUMBER: US 60/464,159  
PRIOR FILING DATE: 2003-04-18

```
; PRIOR APPLICATION NUMBER: US 60/464,160
; PRIOR FILING DATE: 2003-04-18
; NUMBER OF SEQ ID NOS: 23
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 19
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial
; FEATURE:
; OTHER INFORMATION: clusterin targeted siRNA sequence
US-10-828-395-19
```

```
Query Match          0.9%; Score 15.4; DB 1; Length 17;
Best Local Similarity 94.1%; Pred. No. 2.4e+02;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1616 TAATTCATAAACTGT 1632
Db       17  TAATTCACAAACTGT 1
```

```
RESULT 381
US-10-758-451-883/C
; Sequence 883, Application US/10758451
; Publication No. US20050014711A1
; GENERAL INFORMATION:
; APPLICANT: East Carolina University
; TITLE OF INVENTION: COMPOSITION, FORMULATION & METHOD FOR PREVENTION & TREATMENT OF D
; TITLE OF INVENTION: AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICTION, ALLERGY (IES)
; TITLE OF INVENTION: INFLAMMATION
; FILE REFERENCE: 30775-706.301
; CURRENT APPLICATION NUMBER: US/10/758,451
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: 09/093,972
; PRIOR FILING DATE: 1998-06-09
; NUMBER OF SEQ ID NOS: 996
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 883
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-758-451-883
```

```
Query Match          0.9%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      1531 CCCAGCCTCTCCCG 1545
Db       15  CCCAGCCTCTCCCG 1
```

```
RESULT 382
US-09-740-332-3014/C
; Sequence 3014, Application US/09740332
; Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740,332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3014
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
```

```
US-09-740-332-3014
```

```
Query Match          0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      766 TCCAGCCCATGTTCC 780
Db       15  TCCAGCCCATGTTCC 1
```

```
RESULT 383
US-09-817-879-3014/C
; Sequence 3014, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Hepatitis C Virus Infection
; FILE REFERENCE: MBHB00-801-P
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3014
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-3014
```

```
Query Match          0.9%; Score 15; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.6e+02;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
QY      766 TCCAGCCCATGTTCC 780
Db       15  TCCAGCCCATGTTCC 1
```

```
RESULT 384
US-10-669-841-5607/C
; Sequence 5607, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sinna Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
; TITLE OF INVENTION: VIRUS REPLICATION
; FILE REFERENCE: 400/042US (MBHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
```

PRIOR FILING DATE: 2002-03-11  
PRIOR APPLICATION NUMBER: US 09/817,879  
PRIOR FILING DATE: 2001-03-26  
PRIOR APPLICATION NUMBER: US 09/740,332  
PRIOR FILING DATE: 2000-12-18  
PRIOR APPLICATION NUMBER: US 09/611,931  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 09/504,321  
PRIOR FILING DATE: 2000-02-15  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 16207  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 5607  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-5607

Query Match 0.9%; Score 15; DB 1; Length 17;  
Best Local Similarity 100.0%; Pred. No. 2.6e+02;  
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 766 TCCACGCCATGTTCC 780  
|||  
Db 15 TCCACGCCATGTTCC 1

RESULT 385  
US-10-497-692-11  
Sequence 11, Application US/10497692  
Publication No. US2005004056A1  
GENERAL INFORMATION:  
APPLICANT: Weise, Martin  
APPLICANT: Eulenbery, Karsten  
APPLICANT: Fritsch, Rudiger  
APPLICANT: Hader, Thomas  
APPLICANT: Bronner, Gunter  
APPLICANT: Steernagel, Arnd  
TITLE OF INVENTION: PTP10D, Tec protein tyrosine kinase and ETRP homologous proteins  
FILE REFERENCE: 2923-632  
CURRENT FILING DATE: 2004-06-04  
PRIOR APPLICATION NUMBER: US/10/497,692  
PRIOR FILING DATE: 2002-12-04  
PRIOR APPLICATION NUMBER: PCT/EP02/13744  
PRIOR FILING DATE: 2002-01-02  
PRIOR APPLICATION NUMBER: EP 01 000 010.5  
PRIOR FILING DATE: 2002-01-02  
PRIOR APPLICATION NUMBER: EP 01 129 138.2  
PRIOR FILING DATE: 2001-12-07  
PRIOR APPLICATION NUMBER: EP 01 128 844.6  
PRIOR FILING DATE: 2001-12-04  
NUMBER OF SEQ ID NOS: 20  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 11  
LENGTH: 18  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: mouse PTPRB reverse primer  
US-10-497-692-11

Query Match 0.9%; Score 14.8; DB 1; Length 18;  
Best Local Similarity 88.9%; Pred. No. 3.1e+02;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 764 CTTCCAGCCATGTTCCA 781  
|||  
|||

Db 1 CTTCCAGCCATGTTCCA 18

RESULT 386  
US-09-866-108-8352/c  
Sequence 8352, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE  
FILE REFERENCE: A60MICA-7  
CURRENT APPLICATION NUMBER: US/09/866,108  
CURRENT FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00662  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Acomica Sequence Listing Engine  
SEQ ID NO 8352  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-8352

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1109 CACCTCTCTGCTG 1124  
|||  
Db 17 CAGCTCTCTGCTG 2

RESULT 387  
US-09-866-108-8353/c  
Sequence 8353, Application US/09866108  
Patent No. US20020048800A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang

```

; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-8353

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1109 CACCTCCTCTGCTG 1124
Db      16 CAGCTCCTCTGCTG 1

RESULT 388
US-09-866-108-8665
; Sequence 8665, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```

; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-866-108-8665

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      273 GAAGCCAAAGAGA 288
Db      2 GAAGCCAAAGAGA 17

RESULT 389
US-09-866-108-8667
; Sequence 8667, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: A60MICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8667

```

```

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 274 AACCCAGAGAGAGAA 289

Db 1 AACCCAGAGAGAGAA 16

```

RESULT 390
US-09-866-108-10037/C
; Sequence 10037, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOWICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8667

```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 10037
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-10037

```

```

Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

QY 715 CCCGATGTCGCGAG 730

Db 17 CCCGATGTCGCGAG 2

```

RESULT 391
US-09-866-108-10038/C
; Sequence 10038, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOWICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO: 15752

```

```
/ SOFTWARE: Aecomica Sequence Listing Engine
/ SEQ ID NO 10038
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-09-866-108-10038
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      715 CCCGCATCGTCCGACG 730
Db      16 CCCGCATCGTCCACAG 1
```

```
RESULT 392
US-09-928-412-7
/ Sequence 7, Application US/09928412
/ Patent No. US20020123623A1
/ GENERAL INFORMATION:
/ APPLICANT: KAWAKOKA, Akiyoshi
/ APPLICANT: EBINUMA, Hiroyasu
/ TITLE OF INVENTION: TRANSCRIPTION FACTOR CONTROLLING PHENYLPROPANOIC
/ FILE REFERENCE: 4859-0027-0
/ CURRENT FILING DATE: 2001-08-14
/ PRIOR APPLICATION NUMBER: US/09/928,412
/ PRIOR FILING DATE: EARLIER FILING DATE: 1998-03-31
/ PRIOR APPLICATION NUMBER: EARLIER APPLICATION NUMBER: JP 10-125171
/ PRIOR FILING DATE: EARLIER FILING DATE: 1998-03-31
/ NUMBER OF SEQ ID NOS: 13
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 7
/ LENGTH: 17
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence:Synthetic DNA
US-09-928-412-7
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1104 CTCACACCTCCCTCT 1119
Db      2 CTCACACCTCTCTCT 17
```

```
RESULT 393
US-09-780-533A-171/c
/ Sequence 171, Application US/09780533A
/ Publication No. US2003006011A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Blatt, Larry
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Chowiriza, Bharat
/ APPLICANT: Haberli, Pete
/ TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene
/ FILE REFERENCE: MBH00,878-A (400/011)
/ CURRENT FILING DATE: US/09/780,533A
/ PRIOR APPLICATION NUMBER: 2001-02-09
/ PRIOR APPLICATION NUMBER: US 60/181,797
/ PRIOR FILING DATE: 2000-02-11
/ NUMBER OF SEQ ID NOS: 6679
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 171
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
```

```
US-09-780-533A-171
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1619 TTCATATAAACTGTCT 1634
Db      16 TTCATATAAACTGTCT 1
```

```
RESULT 394
US-09-877-478-1745/c
/ Sequence 1745, Application US/09877478
/ Publication No. US20030068301A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Draper, Kenneth
/ APPLICANT: Blatt, Larry
/ APPLICANT: McSwiggen, Jim
/ APPLICANT: Morrissey, Dave
/ TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
/ FILE REFERENCE: MBH00-845-H (400/029)
/ CURRENT FILING DATE: US/09/877,478
/ PRIOR FILING DATE: 2001-12-31
/ PRIOR APPLICATION NUMBER: US 07/882,712
/ PRIOR FILING DATE: 1992-05-14
/ PRIOR APPLICATION NUMBER: US 09/531,025
/ PRIOR FILING DATE: 2000-03-20
/ PRIOR APPLICATION NUMBER: US 09/636,385
/ PRIOR FILING DATE: 2000-08-09
/ PRIOR APPLICATION NUMBER: US 09/696,347
/ PRIOR FILING DATE: 2000-10-24
/ PRIOR APPLICATION NUMBER: US 08/193,627
/ PRIOR FILING DATE: 1994-02-07
/ PRIOR APPLICATION NUMBER: US 08/433,993
/ PRIOR FILING DATE: 1995-05-04
/ PRIOR APPLICATION NUMBER: US 08/434,504
/ PRIOR FILING DATE: 1995-05-04
/ PRIOR APPLICATION NUMBER: US 09/436,430
/ PRIOR FILING DATE: 1999-11-08
/ NUMBER OF SEQ ID NOS: 6586
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 1745
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Hepatitis B virus
US-09-877-478-1745
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY      1519 CCCCAACTCCGCCCA 1534
Db      16 CCCCAACTCTCCCA 1
```

```
RESULT 395
US-09-740-332-1543
/ Sequence 1543, Application US/09740332
/ Publication No. US20030125270A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals Inc.
/ TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
/ FILE REFERENCE: RPI 400/003
/ CURRENT FILING DATE: US/09/740,332
/ PRIOR APPLICATION NUMBER: 2001-03-26
/ NUMBER OF SEQ ID NOS: 9704
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 1543
/ LENGTH: 17
```

```
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1543
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      768 CACGCCATGTTCCAGC 783
Db      1 CACGCCAUGUCCGCGC 16
```

```
RESULT 396
US-09-817-879-1543
Sequence 1543, Application US/09817879
Publication No. US2003017111A1
```

```
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
FILE REFERENCE: MHB00-801-F
CURRENT APPLICATION NUMBER: US/09/817,879
CURRENT FILING DATE: 2001-03-26
NUMBER OF SEQ ID NOS: 9703
SOFTWARE: Patentin version 3.0
SEQ ID NO 1543
LENGTH: 17
TYPE: RNA
ORGANISM: artificial sequence
FEATURE:
NAME/KEY: misc_feature
LOCATION:
OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1543
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 3e+02;
Matches 12; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      768 CACGCCATGTTCCAGC 783
Db      1 CACGCCAUGUCCGCGC 16
```

```
RESULT 397
US-10-298-255-4
Sequence 4, Application US/10298255
Publication No. US20030134312A1
```

```
GENERAL INFORMATION:
APPLICANT: BURGONE, LEIGH A.
TITLE OF INVENTION: METHODS AND MATERIALS FOR DETECTING GENETIC MATERIAL
FILE REFERENCE: 45858-56064
CURRENT APPLICATION NUMBER: US/10/298,255
CURRENT FILING DATE: 2002-11-15
PRIOR APPLICATION NUMBER: 60/336,005
PRIOR FILING DATE: 2001-11-15
NUMBER OF SEQ ID NOS: 7
SOFTWARE: Patentin Ver. 2.1
SEQ ID NO 4
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-10-298-255-4
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
```

```
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy      1508 CAGCCTCCAGGCCCC 1523
Db      1 CAGCCTCAGAGAGCCCC 16
```

```
RESULT 398
US-10-238-700-2912/c
Sequence 2912, Application US/10238700
Publication No. US20030153521A1
```

```
GENERAL INFORMATION:
APPLICANT: McSwiggen, James
TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level
FILE REFERENCE: 400/057 (MHB01-1158-A)
CURRENT APPLICATION NUMBER: US/10/238,700
CURRENT FILING DATE: 2002-09-18
PRIOR APPLICATION NUMBER: PCT/US 02/16840
PRIOR FILING DATE: 2002-05-29
PRIOR APPLICATION NUMBER: US 60/318,471
PRIOR FILING DATE: 2001-09-10
NUMBER OF SEQ ID NOS: 4666
SOFTWARE: Patentin version 3.0
SEQ ID NO 2912
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-10-238-700-2912
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      1507 CCAGCTCCAGGCCCC 1522
Db      17 CCAGCTCAGAGCCCC 2
```

```
RESULT 399
US-10-339-793-366
Sequence 366, Application US/10339793
Publication No. US20030180764A1
```

```
GENERAL INFORMATION:
APPLICANT: Lynx Therapeutics, Inc.
APPLICANT: Shang, Jin
APPLICANT: Bowen, Benjamin
TITLE OF INVENTION: GENES AFFECTED BY CHOLESTEROL TREATMENT AND DURING ADIPOGENESIS
FILE REFERENCE: 37-000310US
CURRENT APPLICATION NUMBER: US/10/339,793
CURRENT FILING DATE: 2003-01-08
NUMBER OF SEQ ID NOS: 443
SOFTWARE: Patentin version 3.1
SEQ ID NO 366
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-339-793-366
```

```
Query Match          0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy      990 ACCAACACCCCTCCC 1005
Db      2 ATCAACACCCCTCCC 17
```

```
RESULT 400
US-10-342-902-1745/c
Sequence 1745, Application US/10342902
Publication No. US20040054156A1
GENERAL INFORMATION:
```

```
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Diaper, Kenneth
/ APPLICANT: Blatt, Larry
/ APPLICANT: McSwigen, Jim
/ APPLICANT: Morrissey, Dave
/ TITLE OF INVENTION: Method and Reagent for Inhibiting Hepatitis B Virus Replication
/ FILE REFERENCE: 400/075 (MEHB00-845-1)
/ CURRENT APPLICATION NUMBER: US/10/342,902
/ PRIOR FILING DATE: 2003-01-15
/ PRIOR APPLICATION NUMBER: US 09/877,478
/ PRIOR FILING DATE: 2001-06-08
/ PRIOR APPLICATION NUMBER: US 09/531,025
/ PRIOR FILING DATE: 2000-03-20
/ PRIOR APPLICATION NUMBER: US 09/636,385
/ PRIOR FILING DATE: 2000-08-09
/ PRIOR APPLICATION NUMBER: US 09/696,347
/ PRIOR FILING DATE: 2000-10-24
/ PRIOR APPLICATION NUMBER: US 08/193,627
/ PRIOR FILING DATE: 1994-02-07
/ PRIOR APPLICATION NUMBER: US 07/882,712
/ PRIOR FILING DATE: 1992-05-14
/ PRIOR APPLICATION NUMBER: US 09/436,430
/ PRIOR FILING DATE: 1999-11-08
/ NUMBER OF SEQ ID NOS: 6592
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 1745
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Hepatitis B virus
US-10-342-902-1745
```

```
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1519 CCCCCAATCGGCCCA 1534
Db 16 CCCCCAATCGGCCCA 1
```

```
RESULT 401
US-10-138-674-8431/c
/ Sequence 8431, Application US/10138674
/ Publication No. US20040077565A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwigen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MEHB00-876-N (400/049)
/ CURRENT APPLICATION NUMBER: US/10/138,674
/ CURRENT FILING DATE: 2002-05-03
/ NUMBER OF SEQ ID NOS: 20822
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 8431
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-138-674-8431
```

```
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1545 GCTCTGATCCTGCAC 1560
Db 17 GCTCTGATCCTGCAC 2
```

RESULT 402

```
US-10-287-949A-8431/c
/ Sequence 8431, Application US/10287949A
/ Publication No. US20040102389A1
/ GENERAL INFORMATION:
/ APPLICANT: Ribozyme Pharmaceuticals, Inc.
/ APPLICANT: Pavco, Pam
/ APPLICANT: McSwigen, Jim
/ APPLICANT: Stinchcomb, Dan
/ APPLICANT: Escobedo, Jaime
/ TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
/ TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
/ FILE REFERENCE: MEHB00-876-N (400/049)
/ CURRENT APPLICATION NUMBER: US/10/287,949A
/ CURRENT FILING DATE: 2003-04-11
/ NUMBER OF SEQ ID NOS: 20822
/ SOFTWARE: PatentIn version 3.0
/ SEQ ID NO 8431
/ LENGTH: 17
/ TYPE: RNA
/ ORGANISM: Homo sapiens
US-10-287-949A-8431
```

```
Query Match 0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 1545 GCTCTGATCCTGCAC 1560
Db 17 GCTCTGATCCTGCAC 2
```

```
RESULT 403
US-10-669-841-1745/c
/ Sequence 1745, Application US/10669841
/ Publication No. US20040127446A1
/ GENERAL INFORMATION:
/ APPLICANT: Sirna Therapeutics, Inc.
/ APPLICANT: Lawrence, Blatt
/ APPLICANT: Dennis, Macejak
/ APPLICANT: James, McSwigen
/ APPLICANT: David, Morrissey
/ APPLICANT: Pamela, Pavco
/ APPLICANT: Patrice, Lee
/ APPLICANT: Kenneth, Draper
/ APPLICANT: Elisabeth, Roberts
/ TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPAT
/ TITLE OF INVENTION: VIRUS REPLICATION
/ FILE REFERENCE: 400/042US (MEHB02-249-E)
/ CURRENT APPLICATION NUMBER: US/10/669,841
/ CURRENT FILING DATE: 2003-09-23
/ PRIOR APPLICATION NUMBER: PCT/US02/09187
/ PRIOR FILING DATE: 2002-03-26
/ PRIOR APPLICATION NUMBER: US 60/296,876
/ PRIOR FILING DATE: 2001-06-08
/ PRIOR APPLICATION NUMBER: US 60/335,059
/ PRIOR FILING DATE: 2001-10-24
/ PRIOR APPLICATION NUMBER: US 60/337,055
/ PRIOR FILING DATE: 2001-12-05
/ PRIOR APPLICATION NUMBER: US 60/358,580
/ PRIOR FILING DATE: 2002-02-20
/ PRIOR APPLICATION NUMBER: US 60/363,124
/ PRIOR FILING DATE: 2002-03-11
/ PRIOR APPLICATION NUMBER: US 09/817,879
/ PRIOR FILING DATE: 2001-03-26
/ PRIOR APPLICATION NUMBER: US 09/740,332
/ PRIOR FILING DATE: 2000-12-18
/ PRIOR APPLICATION NUMBER: US 09/611,931
/ PRIOR FILING DATE: 2000-07-07
/ PRIOR APPLICATION NUMBER: US 09/504,321
/ Remaining Prior Application data removed - See File Wrapper or PALM.
/ NUMBER OF SEQ ID NOS: 16207
/ SOFTWARE: PatentIn version 3.0
```



SEQ ID NO 1745  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Hepatitis B virus  
US-10-669-841-1745

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1;

Oy 1519 CCCCCCTCCGCCA 1534  
Db 16 CCCCCACTCTCCCA 1

RESULT 404  
US-10-669-841-4136  
Sequence 4136, Application US/10669841  
Publication No. US20040127446A1

GENERAL INFORMATION:  
APPLICANT: Sirna Therapeutics, Inc.  
APPLICANT: Lawrence, Blat  
APPLICANT: Dennis, Macejak  
APPLICANT: James, McSwigen  
APPLICANT: David, Morrissey  
APPLICANT: Pamela, Pavco  
APPLICANT: Patricia, Lee  
APPLICANT: Kenneth, Draper  
APPLICANT: Elisabeth, Roberts  
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEP  
TITLE OF INVENTION: VIRUS REPLICATION  
FILE REFERENCE: 400/04205 (HMB02-249-E)  
CURRENT FILING DATE: 2003-09-23  
PRIOR APPLICATION NUMBER: PCT/US02/09187  
PRIOR FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: US 60/296,876  
PRIOR FILING DATE: 2001-06-08  
PRIOR APPLICATION NUMBER: US 60/335,059  
PRIOR FILING DATE: 2001-10-24  
PRIOR APPLICATION NUMBER: US 60/337,055  
PRIOR FILING DATE: 2001-12-05  
PRIOR APPLICATION NUMBER: US 60/358,580  
PRIOR FILING DATE: 2002-02-20  
PRIOR APPLICATION NUMBER: US 60/363,124  
PRIOR FILING DATE: 2002-03-11  
PRIOR APPLICATION NUMBER: US 09/817,879  
PRIOR FILING DATE: 2001-03-26  
PRIOR APPLICATION NUMBER: US 09/740,332  
PRIOR FILING DATE: 2000-12-18  
PRIOR APPLICATION NUMBER: US 09/611,931  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 09/504,321  
PRIOR FILING DATE: 2000-02-15  
Remaining Prior Application data removed - See file wrapper or PALM.  
NUMBER OF SEQ ID NOS: 16207  
SOFTWARE: Patentin version 3.0  
SEQ ID NO 4136  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-4136

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 75.0%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;  
Matches 12; Conservative 3; Mismatches 1;

Oy 768 CACGCATGTTCCAGC 783  
Db 1 CACGCATGTTCCAGC 16

RESULT 405  
US-10-723-361-8352/C  
Sequence 8352, Application US/10723361  
Publication No. US20040137589A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
FILE REFERENCE: PB0105  
CURRENT FILING DATE: 2003-11-26  
PRIOR APPLICATION NUMBER: US/10/723,361  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 09/866,108  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263,6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
Remaining Prior Application data removed - See file wrapper or PALM.  
NUMBER OF SEQ ID NOS: 15755  
SOFTWARE: Aecmica Sequence Listing Engine  
SEQ ID NO 8352  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-723-361-8352

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1;

Oy 1109 CACCTCCTCTGCTG 1124  
Db 17 CACCTCCTCTGCTG 2

RESULT 406  
US-10-723-361-8353/C  
Sequence 8353, Application US/10723361  
Publication No. US20040137589A1  
GENERAL INFORMATION:  
APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
FILE REFERENCE: PB0105

```

; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8353
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8353
```

```

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservativity 0; Mismatches 1; Indels 0; Gaps 0;

QY      1109 CACCTCCTCTTGCTG 1124
Db      16 CAGCTCCTCTTGCTG 1
```

```

RESULT 407
US-10-723-361-8665
; Sequence 8665, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```

; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8665
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8665
```

```

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservativity 0; Mismatches 1; Indels 0; Gaps 0;

QY      273 GAAGCCAAAGAAGA 288
Db      2 GAAGCCAAAGAAGA 17
```

```

RESULT 408
US-10-723-361-8667
; Sequence 8667, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8667
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8667
```

```

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 3e+02;
Matches 15; Conservativity 0; Mismatches 1; Indels 0; Gaps 0;

QY      274 AAGCCAAAGAAGA 289
Db      1 AAGCCAAAGAAGA 16
```

```
RESULT 409
US-10-723-361-10037/C
; Sequence 10037, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10037
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10037

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Beat Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      715 CCCGATCGTCCGAC 730
DB      17 CCCGATCGTCCACAG 2

RESULT 410
US-10-723-361-10038/C
; Sequence 10038, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharron G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
```

```
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See file wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 10038
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-10038

Query Match      0.9%; Score 14.4; DB 1; Length 17;
Beat Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      715 CCCGATCGTCCGAC 730
DB      16 CCCGATCGTCCACAG 1

RESULT 411
US-10-712-633-3472/C
; Sequence 3472, Application US/10712633
; Publication No. US20040220128A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pamela
; APPLICANT: Sandberg, Jennifer
; APPLICANT: Gordon, Galad
; APPLICANT: McSwiggan, James
; APPLICANT: Stinchcomb, Dan
; TITLE OF INVENTION: NUCLEIC ACID BASED MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACT
; TITLE OF INVENTION: RECEPTOR FOR THE TREATMENT OF ANGIOGENESIS RELATED DISEASES AND
; FILE REFERENCE: MHHB02-325PCT (400/047)
; CURRENT APPLICATION NUMBER: US/10/712,633
; CURRENT FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 09/708,690
; PRIOR FILING DATE: 2000-11-07
; PRIOR APPLICATION NUMBER: US 09/870,161
; PRIOR FILING DATE: 2001-05-29
; PRIOR APPLICATION NUMBER: US 60/334,461
; PRIOR FILING DATE: 2001-11-30
; PRIOR APPLICATION NUMBER: US 10/138,674
; PRIOR FILING DATE: 2002-05-03
; NUMBER OF SEQ ID NOS: 5989
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3472
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
```

US-10-712-633-3472

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;  
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1545 GCTCTGATCTCTGCAC 1560

Db 17 GCTCTGCATCTCTGCAC 2

RESULT 412

US-10-724-270-1591/c

; Sequence 1591, Application US/10724270  
; Publication No. US20050080031A1  
; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; TITLE OF INVENTION: Nucleic Acid Treatment of Diseases or Conditions Related to Level

; FILE REFERENCE: 400/046-US (MBH02-326-A)

; CURRENT FILING DATE: 2003-11-26

; PRIOR APPLICATION NUMBER: PCT/US02/16840

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 60/318,471

; PRIOR FILING DATE: 2001-09-10

; PRIOR APPLICATION NUMBER: US 60/296,249

; PRIOR FILING DATE: 2001-06-06

; PRIOR APPLICATION NUMBER: US 60/294,140

; PRIOR FILING DATE: 2001-05-29

; PRIOR APPLICATION NUMBER: US 10/238,700

; PRIOR FILING DATE: 2002-09-10

; PRIOR APPLICATION NUMBER: US 10/163,552

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 10/157,580

; PRIOR FILING DATE: 2002-05-29

; PRIOR APPLICATION NUMBER: US 10/693,059

; PRIOR FILING DATE: 2002-10-23

; PRIOR APPLICATION NUMBER: US 10/444,853

; PRIOR FILING DATE: 2003-05-23

; PRIOR APPLICATION NUMBER: US 10/417,012

; PRIOR FILING DATE: 2003-04-16

; Remaining Prior Application data removed - See file wrapper or PALM.

; NUMBER OF SEQ ID NOS: 6810

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 1591

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-10-724-270-1591

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1507 CCAGCTCCAGCCCC 1522

Db 17 CCAGCTCCAGCCCC 2

RESULT 413

US-11-016-291-4

; Sequence 4, Application US/11016291  
; Publication No. US20050095641A1  
; GENERAL INFORMATION:

; APPLICANT: BURGONE, LEIGH A.

; TITLE OF INVENTION: METHODS AND MATERIALS FOR DETECTING GENETIC MATERIAL

; FILE REFERENCE: 45858-56064

; CURRENT APPLICATION NUMBER: US/11/016,291

; CURRENT FILING DATE: 2004-12-17

; PRIOR APPLICATION NUMBER: 60/336,005

; PRIOR FILING DATE: 2001-11-15

; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4

; LENGTH: 17

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE: OTHER INFORMATION: Description of Artificial Sequence: Primer

US-11-016-291-4

Query Match 0.9%; Score 14.4; DB 1; Length 17;  
Best Local Similarity 93.8%; Pred. No. 3e+02; 1; Indels 0; Gaps 0;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1508 CAGCTCCAGAGCCCC 1523

Db 1 CAGCTCCAGAGCCCC 16

RESULT 414

US-09-263-959-1251/c

; Sequence 1251, Application US/09263959  
; Patent No. US20020150891A1  
; GENERAL INFORMATION:

; APPLICANT: Hood, Leroy E.

; APPLICANT: Koop, Ben F.

; TITLE OF INVENTION: DIAGNOSTIC AND THERAPEUTIC COMPOSITIONS AND METHODS WHICH UTI

; NUMBER OF SEQUENCES: 1279

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Seed and Berry LLP

; STREET: 6300 Columbia Center, 701 Fifth Avenue

; CITY: Seattle

; STATE: Washington

; COUNTRY: US

; ZIP: 98104-7092

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; OPERATING SYSTEM: IBM PC compatible

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/263,959

; FILING DATE: 05-MAR-1999

; CLASSIFICATION:

; ATTORNEY/AGENT INFORMATION:

; NAME: McMaisters, David D.

; REGISTRATION NUMBER: 33,963

; REFERENCE/DOCKET NUMBER: 920010.426C2

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (206) 622-4900

; TELEFAX: (206) 682-6031

; INFORMATION FOR SEQ ID NO: 1251:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 18 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-09-263-959-1251

Query Match 0.9%; Score 14.4; DB 1; Length 18;  
Best Local Similarity 93.8%; Pred. No. 3.3e+02;

Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 634 TCACCGGAGAGCCCCA 649

Db 17 TCACCGGAGAGCCCCA 2

RESULT 415

US-10-108-260A-5102

; Sequence 5102, Application US/10108260A  
; Publication No. US20040005560A1

```

; GENERAL INFORMATION:
; APPLICANT: HELIX RESEARCH INSTITUTE
; TITLE OF INVENTION: No. US20040005560A1el full length cDNA
; FILE REFERENCE: H1-A0106
; CURRENT APPLICATION NUMBER: US/10/108,260A
; CURRENT FILING DATE: 2002-03-27
; NUMBER OF SEQ ID NOS: 5458
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 5102
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: an artificially synthesized p
US-10-108-260A-5102

Query Match      0.9%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1094 GTGCAAGTCTCCAC 1109
DB      1 GTGCAAGTCTCCAC 16

RESULT 416
US-10-758-451-884/c
; Sequence 884, Application US/10758451
; Publication No. US20050014711A1
; GENERAL INFORMATION:
; APPLICANT: East Carolina University
; TITLE OF INVENTION: COMPOSITION, FORMULATION & METHOD FOR PREVENTION & TREATMENT OF D
; TITLE OF INVENTION: AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICION, ALLERGY (IES)
; FILE REFERENCE: 30775-706.301
; CURRENT APPLICATION NUMBER: US/10/758,451
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: 09/093,972
; PRIOR FILING DATE: 1998-06-09
; NUMBER OF SEQ ID NOS: 996
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 884
; LENGTH: 14
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-758-451-884

Query Match      0.9%; Score 14; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 2.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1532 CCAGCCTCTCCCG 1545
DB      14 CCAGCCTCTCCCG 1

RESULT 417
US-09-930-423-9
; Sequence 9, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 17
; TYPE: RNA
```

```

; ORGANISM: Homo Sapiens
US-09-930-423-9

Query Match      0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1531 CCCAGCCTCTCCCG 1544
DB      1 CCCAGCCTCTCCCG 14

RESULT 418
US-09-930-423-359
; Sequence 359, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 359
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-359

Query Match      0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1531 CCCAGCCTCTCCCG 1544
DB      3 CCCAGCCTCTCCCG 16

RESULT 419
US-09-930-423-360
; Sequence 360, Application US/09930423
; Publication No. US20030092003A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blact, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: MBHB00,918-A 400/027
; CURRENT APPLICATION NUMBER: US/09/930,423
; CURRENT FILING DATE: 2001-08-15
; NUMBER OF SEQ ID NOS: 4553
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo Sapiens
US-09-930-423-360

Query Match      0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1531 CCCAGCCTCTCCCG 1544
DB      2 CCCAGCCTCTCCCG 15

RESULT 420
US-09-740-332-1541
; Sequence 1541, Application US/09740332
```

```
/ Publication No. US20030125270A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740.332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-1541

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      766 TCCAGCGCCATGTTTC 779
      :|||||:|:|
Db      4 UCCAGCGCCAUUGUC 17

RESULT 421
US-09-745-237A-9
; Sequence 9, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745.237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 9
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-9

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1531 CCCAGCCTCTCCCC 1544
      :|||||:|:|
Db      1 CCCAGCCUCUCCCC 14

RESULT 422
US-09-745-237A-359
; Sequence 359, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745.237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 359
```

```
/ LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-359

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1531 CCCAGCCTCTCCCC 1544
      :|||||:|:|
Db      3 CCCAGCCUCUCCCC 16

RESULT 423
US-09-745-237A-360
; Sequence 360, Application US/09745237A
; Publication No. US20030143708A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745.237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 360
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-360

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 3.2e+02;
Matches 12; Conservative 2; Mismatches 0; Indels 0; Gaps 0;

QY      1531 CCCAGCCTCTCCCC 1544
      :|||||:|:|
Db      2 CCCAGCCUCUCCCC 15

RESULT 424
US-09-817-879-1541
; Sequence 1541, Application US/09817879
; Publication No. US20030171311A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817.879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1541
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-1541

Query Match          0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      766 TCCAGCGCCATGTTTC 779
      :|||||:|:|
Db      4 UCCAGCGCCAUUGUC 17
```

```
RESULT 425
US-10-307-005-955/c
; Sequence 955, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; TITLE OF INVENTION: Using Modified Single Stranded Oligonucleotides
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; PRIOR FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedmann macro Napro4
; SEQ ID NO 955
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Eucalyptus camaldulensis
US-10-307-005-955

Query Match      0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1202 GGTCCACGCGGTGG 1215
Db      14 GGTCCACGCGGTGG 1

RESULT 426
US-10-307-005-956
; Sequence 956, Application US/10307005
; Publication No. US20030236208A1
; GENERAL INFORMATION:
; APPLICANT: University of Delaware
; APPLICANT: Eric B. Kmiec
; APPLICANT: Howard B. Gamper
; APPLICANT: Michael C. Rice
; APPLICANT: Jungsup Kim
; TITLE OF INVENTION: Targeted Chromosomal Genomic Alterations in Plants
; TITLE OF INVENTION: Using Modified Single Stranded Oligonucleotides
; FILE REFERENCE: Napro/009 PCT
; CURRENT APPLICATION NUMBER: US/10/307,005
; PRIOR FILING DATE: 2002-11-26
; PRIOR APPLICATION NUMBER: PCT/US01/17672
; PRIOR FILING DATE: 2001-06-01
; PRIOR APPLICATION NUMBER: US 60/208,538
; PRIOR FILING DATE: 2000-06-01
; PRIOR APPLICATION NUMBER: US 60/244,989
; PRIOR FILING DATE: 2000-10-30
; PRIOR APPLICATION NUMBER: US 09/818,875
; PRIOR FILING DATE: 2001-03-27
; NUMBER OF SEQ ID NOS: 2717
; SOFTWARE: Friedmann macro Napro4
; SEQ ID NO 956
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Eucalyptus camaldulensis
US-10-307-005-956
```

```
Query Match      0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      1202 GGTCCACGCGGTGG 1215
Db      4 GGTCCACGCGGTGG 17

RESULT 427
US-10-669-841-4134
; Sequence 4134, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggen
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patricia, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA
; FILE REFERENCE: 400/042US (MEHB02-249-E)
; CURRENT APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4134
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4134

Query Match      0.9%; Score 14; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 3.2e+02;
Matches 10; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY      766 TCCACGCCATGTC 779
Db      4 UCCACGCCAUGUC 17

RESULT 428
```

```
US-09-866-108-1895/c
; Sequence 1895, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1895
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-1895

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      93 GAGAGTGGGCGAGTCTT 109
Db      17 GAGAGAGCGCCAGTCTT 1

RESULT 429
US-09-866-108-2643/c
; Sequence 2643, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
```

```
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 2643
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-2643

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      845 CTTCAGCACCCTCCCAA 861
Db      17 CTGCAGAGCACCCTCCCAA 1

RESULT 430
US-09-866-108-7355
; Sequence 7355, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
```



```
;; PRIOR FILING DATE: 2000-09-27
;; PRIOR APPLICATION NUMBER: PCT/US01/00666
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00667
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00664
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00669
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00665
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO: 7355
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-7355
```

```
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 270 GAAGAGCCAGAGAA 286
Db 1 GAAGAGCCAGAGAA 17
```

```
RESULT 431
US-09-866-108-7485/c
; Sequence 7485, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
```

```
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00668
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00663
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00662
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00661
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: PCT/US01/00670
;; PRIOR FILING DATE: 2001-01-30
;; PRIOR APPLICATION NUMBER: US 60/234,687
;; PRIOR FILING DATE: 2000-09-21
;; PRIOR APPLICATION NUMBER: US 60/266,860
;; PRIOR FILING DATE: 2001-02-05
;; NUMBER OF SEQ ID NOS: 15752
;; SOFTWARE: Aecomica Sequence Listing Engine
;; SEQ ID NO: 7485
;; LENGTH: 17
;; TYPE: DNA
;; ORGANISM: Homo sapiens
US-09-866-108-7485
```

```
Query Match 0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY 1530 GCCAGCCTCTCCCGC 1546
Db 17 GTCCAGCCTCTCTCCGC 1
```

```
RESULT 432
US-09-866-108-8568
; Sequence 8568, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEWICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
```

```
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8568
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8568

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      292 AGGATGCCCTTAATGAG 308
Db      1 AGGATGACCTGAATGAG 17

RESULT 433
US-09-866-108-8660
; Sequence 8660, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8660
; LENGTH: 17
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
US-09-866-108-8660

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      267 CTGAGAGAGCCCAAGAA 283
Db      1 CTGAGAGAGCCCAAGAA 17

RESULT 434
US-09-866-108-8661
; Sequence 8661, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; CURRENT FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aecomica Sequence Listing Engine
; SEQ ID NO 8661
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8661

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      268 TAGAGAGAGCCCAAGAG 284
Db      1 TGAGAGAGCCCAAGAG 17
```

```
RESULT 435
US-09-866-108-8663
; Sequence 8663, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8663
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8663

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      270 GAAGAAGCCAGAGAGAA 286
DB      1 GAAGAAGCCAGAGAGAA 17
```

```
RESULT 436
US-09-866-108-8664
; Sequence 8664, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
```

```
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8664
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-8664

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      271 AAGAAGCCAGAGAGAG 287
DB      1 AAGAAGCCAGAGAGAG 17
```

```
RESULT 437
US-09-866-108-9687/C
; Sequence 9687, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT FILING DATE: 2001-05-25
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: US 60/207,456
```

```
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9687
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9687
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      93 GGAGGTGGGCGAGTCCT 109
Db      17 GGAGGTGGGCGAGTCCT 1
```

```
RESULT 438
US-09-866-108-9688/c
; Sequence 9688, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, Wensheng
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
```

```
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00661
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00670
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 60/234,687
; PRIOR FILING DATE: 2000-09-21
; PRIOR APPLICATION NUMBER: US 60/266,860
; PRIOR FILING DATE: 2001-02-05
; NUMBER OF SEQ ID NOS: 15752
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9688
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-866-108-9688
```

```
Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      92 GGAGGTGGGCGAGTCCT 108
Db      17 GGAGGTGGGCGAGTCCT 1
```

```
RESULT 439
US-09-866-108-9689/c
; Sequence 9689, Application US/09866108
; Patent No. US20020048800A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, Wensheng
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: MYOSIN-LIKE GENE EXPRESSED IN HUMAN HEART AND MUSCLE
; FILE REFERENCE: AEOMICA-7
; CURRENT APPLICATION NUMBER: US/09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00662
; PRIOR FILING DATE: 2001-01-30
```

PRIOR APPLICATION NUMBER: PCT/US01/00661  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00670  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 60/234,687  
PRIOR FILING DATE: 2000-09-21  
PRIOR APPLICATION NUMBER: US 60/266,860  
PRIOR FILING DATE: 2001-02-05  
NUMBER OF SEQ ID NOS: 15752  
SOFTWARE: Aecomica Sequence Listing Engine  
SEQ ID NO 9689  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-09-866-108-9689

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 91 GCGAGAGTGGCGAGCTC 107  
DB 17 GCGAGAGTGGCGAGCTC 1

RESULT 440  
US-09-776-291A-4/c  
Sequence 4, Application US/09776291A  
Patent No. US2002013046A1  
GENERAL INFORMATION:  
APPLICANT: SMITH, Lloyd W.  
APPLICANT: HOOD, Leroy E.  
APPLICANT: HUNKAPILLER, Michael W.  
APPLICANT: HUNKAPILLER, Tim J.  
APPLICANT: CONNELL, Charles R.  
TITLE OF INVENTION: AUTOMATED DNA SEQUENCING TECHNIQUE  
FILE REFERENCE: 243132000106  
CURRENT APPLICATION NUMBER: US/09/776,291A  
CURRENT FILING DATE: 2001-02-02  
PRIOR APPLICATION NUMBER: 08/484,340  
PRIOR FILING DATE: 1995-06-07  
PRIOR APPLICATION NUMBER: 08/361,176  
PRIOR FILING DATE: 1994-12-21  
PRIOR APPLICATION NUMBER: 07/898,019  
PRIOR FILING DATE: 1992-06-12  
PRIOR APPLICATION NUMBER: 07/660,160  
PRIOR FILING DATE: 1991-02-21  
PRIOR APPLICATION NUMBER: 07/106,232  
PRIOR FILING DATE: 1987-10-07  
PRIOR APPLICATION NUMBER: 06/722,742  
PRIOR FILING DATE: 1985-04-11  
PRIOR APPLICATION NUMBER: 06/689,013  
PRIOR FILING DATE: 1985-01-02  
PRIOR APPLICATION NUMBER: 06/570,973  
PRIOR FILING DATE: 1984-01-16  
NUMBER OF SEQ ID NOS: 7  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 4  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: synthetic construct  
US-09-776-291A-4

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1357 AAGCGCTGCAGGATAC 1373  
DB 17 ATGCTCTGCAGGATAC 1

RESULT 441  
US-09-864-785-115  
Sequence 115, Application US/09864785  
Patent No. US2002017568A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Draper, Ken  
APPLICANT: McSwigen, Jim  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
FILE REFERENCE: 400/022 (MEHB00-812-D)  
CURRENT APPLICATION NUMBER: US/09/864,785  
CURRENT FILING DATE: 2001-05-23  
NUMBER OF SEQ ID NOS: 3929  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 115  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-115

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 3.3e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 988 CCACCACACCCCTCC 1004  
DB 1 CCACCACACCCCTCC 17

RESULT 442  
US-09-864-785-117  
Sequence 117, Application US/09864785  
Patent No. US2002017568A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Draper, Ken  
APPLICANT: McSwigen, Jim  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
FILE REFERENCE: 400/022 (MEHB00-812-D)  
CURRENT APPLICATION NUMBER: US/09/864,785  
CURRENT FILING DATE: 2001-05-23  
NUMBER OF SEQ ID NOS: 3929  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 117  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-117

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 3.3e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 992 CAACAACCCCTCCAG 1008  
DB 1 CAACAACCCCTCCAG 17

RESULT 443  
US-09-864-785-213  
Sequence 213, Application US/09864785  
Patent No. US20020177568A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.

```
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 213
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-213
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1501 CAGGCCCGCAGCTCCAG 1517
Db      1 CAGACCCCGCAGCTCCAG 17
```

```
RESULT 444
US-09-864-785-215
; Sequence 215, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 215
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-215
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1505 CCCGAGCTCCAGGCC 1521
Db      1 CCCGAGCTCCAGGCC 17
```

```
RESULT 445
US-09-864-785-336
; Sequence 336, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
```

```
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 336
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-336
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1505 CCCGAGCTCCAGGCC 1521
Db      1 CCCGAGCTCCAGGCC 17
```

```
RESULT 446
US-09-864-785-1519
; Sequence 1519, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1519
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
US-09-864-785-1519
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 3.3e+02;
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1502 AGGCCCGCAGCTCCAG 1518
Db      1 AGACCCCGCAGCTCCAG 17
```

```
RESULT 447
US-09-864-785-1520
; Sequence 1520, Application US/09864785
; Patent No. US2002017568A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Draper, Ken
; APPLICANT: McSwigen, Jim
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of NF-Kappa B
; FILE REFERENCE: 400/022 (MBHB00-812-D)
; CURRENT APPLICATION NUMBER: US/09/864,785
; CURRENT FILING DATE: 2001-05-23
; NUMBER OF SEQ ID NOS: 3929
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 1520
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
```

FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-1520

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 3.3e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 1506 CCCAGCTCCAGGCCCC 1522  
|||||:|||||  
DB 1 CCCAGCTCCAGGCTCC 17

RESULT 448  
US-09-864-785-2036  
Sequence 2036, Application US/09864785  
Patent No. US20020177568A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Stinchcomb, Dan  
APPLICANT: Draper, Ken  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Relate  
FILE REFERENCE: 400/022 (MBH00-812-D)  
CURRENT APPLICATION NUMBER: US/09/864,785  
NUMBER OF SEQ ID NOS: 3929  
SOFTWARE: Patent in version 3.0  
SEQ ID NO 2036  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
US-09-864-785-2036

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 82.4%; Pred. No. 3.3e+02;  
Matches 14; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

OY 969 CACCAACACCCCTCCC 1005  
|||||:|||||  
DB 1 CACCAACACCCCTCCC 17

RESULT 449  
US-09-961-077-687/C  
Sequence 687, Application US/09961077  
Publication No. US20030014775A1  
GENERAL INFORMATION:  
APPLICANT: Zwick, Michael G.  
Edington, Brent E.  
McSwiggen, James A.  
Merlo, Patricia Ann Owens  
Guo, Lining  
Skokut, Thomas A.  
Young, Scott A.  
Folkerts, Otto  
Merlo, Donald J.  
TITLE OF INVENTION: COMPOSITION AND METHODS FOR  
MODULATION OF GENE EXPRESSION  
IN PLANTS  
NUMBER OF SEQUENCES: 1263  
CORRESPONDENCE ADDRESS:  
ADDRESSER: Lyon & Lyon  
STREET: 633 West Fifth Street  
Suite 4700  
CITY: Los Angeles  
STATE: California  
COUNTRY: U.S.A.  
ZIP: 90071-2066  
COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 MB  
Storage  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: IBM P.C. DOS 5.0  
SOFTWARE: Word Perfect 5.1  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/961,077  
FILING DATE: 21-Sep-2001  
CLASSIFICATION: <Unknown>  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/679,645  
FILING DATE: July 12, 1996  
APPLICATION NUMBER: 60/001,135  
FILING DATE: July 13, 1995  
APPLICATION NUMBER: 08/300,726  
FILING DATE: September 2, 1994  
ATTORNEY/AGENT INFORMATION:  
NAME: Warburg, Richard J.  
REGISTRATION NUMBER: 32,327  
REFERENCE/DOCKET NUMBER: 219/247  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (213) 489-1600  
TELEFAX: (213) 955-0440  
TELEX: 67-3510  
INFORMATION FOR SEQ ID NO: 687:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
SEQUENCE DESCRIPTION: SEQ ID NO: 687:  
US-09-961-077-687

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1213 TGGCTTCCACACTTCT 1229  
|||||:|||||  
DB 17 TGGCTGCCACACTTCT 1

RESULT 450  
US-09-780-533A-1053/C  
Sequence 1053, Application US/09780533A  
Publication No. US20030060611A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Blatt, Larry  
APPLICANT: McSwiggen, Jim  
APPLICANT: Chowrita, Bharat  
APPLICANT: Haederil, Pete  
TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
FILE REFERENCE: MBH00,878-A (400/011)  
CURRENT APPLICATION NUMBER: US/09/780,533A  
CURRENT FILING DATE: 2001-02-09  
PRIOR APPLICATION NUMBER: US 60/181,797  
NUMBER OF SEQ ID NOS: 6679  
PRIORITY FILING DATE: 2000-02-11  
SOFTWARE: Patent in version 3.0  
SEQ ID NO 1053  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-09-780-533A-1053

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 1622 AATAAACTGCTCTTG 1638  
|||||:|||||  
DB 17 AATAAACTGCTCTTG 1

RESULT 451  
US-09-780-533A-1885/C  
; Sequence 1885, Application US/09780533A  
; Publication No. US2003006011A1  
; GENERAL INFORMATION:  
; APPLICANT: Ribozyme Pharmaceuticals, Inc.  
; APPLICANT: Blatt, Larry  
; APPLICANT: McSwiggen, Jim  
; APPLICANT: Chowitza, Bharat  
; APPLICANT: Haebertli, Peter  
; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO Gene  
; FILE REFERENCE: MHB00, 878-A (400/011)  
; CURRENT APPLICATION NUMBER: US/09/780, 533A  
; CURRENT FILING DATE: 2001-02-09  
; PRIOR APPLICATION NUMBER: US 60/181,797  
; PRIOR FILING DATE: 2000-02-11  
; NUMBER OF SEQ ID NOS: 6679  
; SOFTWARE: PatentIn version 3.0  
; SEQ ID NO 1885  
; LENGTH: 17  
; TYPE: RNA  
; ORGANISM: Homo sapiens  
US-09-780-533A-1885

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1621 CAATAAACTGCTCTGT 1637  
Db 17 CATTAACCTGCTCTTT 1

RESULT 452  
US-09-093-972C-874/C  
; Sequence 874, Application US/09093972C  
; Publication No. US20030087845A1  
; GENERAL INFORMATION:  
; APPLICANT: Nyce, Jonathan W.  
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
; BRONCHOCONSTRICITION, ALLERGY (IES) & INFLAMMATION  
; NUMBER OF SEQUENCES: 996  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
; STREET: 7 Clarke Drive  
; CITY: Cranbury  
; STATE: New Jersey  
; COUNTRY: USA  
; ZIP: 08512  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/093, 972C  
; FILING DATE: 09-Jun-1998  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/472, 527  
; FILING DATE: 7-June-1995  
; APPLICATION NUMBER: US 08/757, 024  
; FILING DATE: 26-11-1996  
; APPLICATION NUMBER: US 08/472, 527  
; FILING DATE: 7-June-1995  
; APPLICATION NUMBER: US 09/016, 464  
; FILING DATE: 30-January-1998  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Amzel, Viviana  
; REGISTRATION NUMBER: 30, 930

REFERENCE/DOCKET NUMBER: EPI-00672  
TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 609-409-3035  
; TELEFAX: 413-254-9245  
; TELEEX: <Unknown>  
; INFORMATION FOR SEQ ID NO: 874:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: DNA (genomic)  
; SEQUENCE DESCRIPTION: SEQ ID NO: 874:  
US-09-093-972C-874

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1530 GCCCAGCCTCTCCCGC 1546  
Db 17 GCCCAGCCTGTGCCCG 1

RESULT 453  
US-09-093-972C-944/C  
; Sequence 944, Application US/09093972C  
; Publication No. US20030087845A1  
; GENERAL INFORMATION:  
; APPLICANT: Nyce, Jonathan W.  
; TITLE OF INVENTION: COMPOSITION, FORMULATIONS & METHOD FOR PREVENTION  
; & TREATMENT OF DISEASES & CONDITIONS ASSOCIATED WITH  
; BRONCHOCONSTRICITION, ALLERGY (IES) & INFLAMMATION  
; NUMBER OF SEQUENCES: 996  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: EPIGENESIS PHARMACEUTICALS, INC.  
; STREET: 7 Clarke Drive  
; CITY: Cranbury  
; STATE: New Jersey  
; COUNTRY: USA  
; ZIP: 08512  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: floppy disk  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.30  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/09/093, 972C  
; FILING DATE: 09-Jun-1998  
; CLASSIFICATION: <Unknown>  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 08/472, 527  
; FILING DATE: 7-June-1995  
; APPLICATION NUMBER: US 08/757, 024  
; FILING DATE: 26-11-1996  
; APPLICATION NUMBER: US 08/472, 527  
; FILING DATE: 7-June-1995  
; APPLICATION NUMBER: US 09/016, 464  
; FILING DATE: 30-January-1998  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Amzel, Viviana  
; REGISTRATION NUMBER: 30, 930  
; REFERENCE/DOCKET NUMBER: EPI-00672  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 609-409-3035  
; TELEFAX: 413-254-9245  
; TELEEX: <Unknown>  
; INFORMATION FOR SEQ ID NO: 944:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 17 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear





```
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: RPI 400/003
; CURRENT APPLICATION NUMBER: US/09/740.332
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9704
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3012
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-740-332-3012

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      769 AGCCCATGTTCCAGCCC 785
Db      17  ACGCCATGTTCCGGCTC 1

RESULT 459
US-09-792-818-440/c
; Sequence 440, Application US/09792818
; Publication No. US20030134806a1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Jarvis, Thale
; APPLICANT: Von Carlowitz, Ira
; APPLICANT: McSwiggen, Jim
; APPLICANT: Hamblin, Paul
; APPLICANT: Ellis, Jonathan
; TITLE OF INVENTION: Method and Reagent for the Inhibition of Grb-2-related with Inse
; TITLE OF INVENTION: (GRID) Gene
; FILE REFERENCE: MBH00-901-A (400/013)
; CURRENT APPLICATION NUMBER: US/09/792,818
; CURRENT FILING DATE: 2001-02-23
; NUMBER OF SEQ ID NOS: 2304
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 440
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-792-818-440

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1539 CTCCCCGCTCTGATCC 1555
Db      17  CTCCCCGCTGTGGAACC 1

RESULT 460
US-09-745-237A-57/c
; Sequence 57, Application US/09745237A
; Publication No. US20030143708a1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Blatt, Larry
; APPLICANT: McSwiggen, Jim
; TITLE OF INVENTION: Method and Reagent for the Treatment of Alzheimer's Disease
; FILE REFERENCE: 400/007 (MBH00-918-A)
; CURRENT APPLICATION NUMBER: US/09/745,237A
; CURRENT FILING DATE: 2002-04-15
; NUMBER OF SEQ ID NOS: 4550
; SOFTWARE: PatentIn version 3.0
```

```
; SEQ ID NO 57
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-745-237A-57

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      643 AGCCCCAGATACCTAC 659
Db      17  AGCCCCAGATGCTTC 1

RESULT 461
US-09-817-879-632
; Sequence 632, Application US/09817879
; Publication No. US20030171311a1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 632
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-632

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 3.3e+02;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY      1400 TGTGATGTTGCTTTTG 1416
Db      1  TUGGAGUGAUGCUGUG 17

RESULT 462
US-09-817-879-2161
; Sequence 2161, Application US/09817879
; Publication No. US20030171311a1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals Inc.
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; FILE REFERENCE: MBH00-801-F
; CURRENT APPLICATION NUMBER: US/09/817,879
; CURRENT FILING DATE: 2001-03-26
; NUMBER OF SEQ ID NOS: 9703
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2161
; LENGTH: 17
; TYPE: RNA
; ORGANISM: artificial sequence
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-09-817-879-2161

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

QY 689 GAGGCTTCATCTTCT 705  
DB 1 GAUGACUCACUCCUCCU 17

## RESULT 463

US-09-817-879-3012/C  
Sequence 3012, Application US/09817879  
Publication No. US20030171311A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals Inc.  
TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to  
TITLE OF INVENTION: Hepatitis C Virus Infection  
FILE REFERENCE: MH800-801-F  
CURRENT FILING DATE: 2001-03-26  
NUMBER OF SEQ ID NOS: 9703  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3012  
LENGTH: 17  
TYPE: RNA  
ORGANISM: artificial sequence  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-09-817-879-3012

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 769 AGCCATGTTCCAGCC 785  
DB 17 AGCCATGTTCCAGCTC 1

## RESULT 464

US-10-079-625-25  
Sequence 25, Application US/10079625  
Publication No. US20020182676A1  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
APPLICANT: White, David W.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/079,625  
FILING DATE: 2002-FEB-19  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/864,564  
FILING DATE: 28-MAY-1997  
APPLICATION NUMBER: 08/708,123  
FILING DATE: 03-SEP-1996  
APPLICATION NUMBER: 08/638,524  
FILING DATE: 26-APR-1996

APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153  
FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Melkiohn, Ph.D., Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/019002  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 25:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-10-079-625-25

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 CACTACTGCCCCCTCAG 676  
DB 1 CACTATTGCCCTTCAG 17

## RESULT 465

US-10-079-625-27  
Sequence 27, Application US/10079625  
Publication No. US20020182676A1  
GENERAL INFORMATION:  
APPLICANT: Tartaglia, Louis A.  
APPLICANT: Tepper, Robert I.  
APPLICANT: Culpepper, Janice A.  
APPLICANT: White, David W.  
TITLE OF INVENTION: THE OB RECEPTOR AND METHODS FOR  
TITLE OF INVENTION: THE DIAGNOSIS AND TREATMENT OF BODY WEIGHT DISORDERS,  
TITLE OF INVENTION: INCLUDING OBESITY AND CACHEXIA  
NUMBER OF SEQUENCES: 50  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Fish & Richardson, P.C.  
STREET: 225 Franklin Street  
CITY: Boston  
STATE: MA  
COUNTRY: US  
ZIP: 02110-2804  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Diskette  
COMPUTER: IBM Compatible  
OPERATING SYSTEM: Windows95  
SOFTWARE: FastSeq for Windows Version 2.0  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/10/079,625  
FILING DATE: 2002-FEB-19  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: 08/864,564  
FILING DATE: 28-MAY-1997  
APPLICATION NUMBER: 08/708,123  
FILING DATE: 03-SEP-1996  
APPLICATION NUMBER: 08/638,524  
FILING DATE: 26-APR-1996

APPLICATION NUMBER: 08/599,455  
FILING DATE: 22-JAN-1996  
APPLICATION NUMBER: 08/583,153  
FILING DATE: 28-DEC-1995  
APPLICATION NUMBER: 08/570,142  
FILING DATE: 11-DEC-1995  
APPLICATION NUMBER: 08/569,485  
FILING DATE: 08-DEC-1995  
APPLICATION NUMBER: 08/566,622  
FILING DATE: 04-DEC-1995  
APPLICATION NUMBER: 08/562,663  
FILING DATE: 27-NOV-1995  
ATTORNEY/AGENT INFORMATION:  
NAME: Melkilejohn, Ph.D., Anita L.  
REGISTRATION NUMBER: 35,283  
REFERENCE/DOCKET NUMBER: 07334/019002  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 617-542-5070  
TELEFAX: 617-542-8906  
TELEX: 200154  
INFORMATION FOR SEQ ID NO: 27:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 17 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: DNA  
US-10-079-625-27

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 CACTACGCGCCTCAG 676  
Db 1 CACTATTGCCCCCTCAG 17

RESULT 466  
US-10-060-756A-748  
Sequence 748, Application US/10060756A  
Publication No. US20030046717A1  
GENERAL INFORMATION:  
APPLICANT: Zhang, Jian  
TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN  
FILE REFERENCE: PB0177  
CURRENT APPLICATION NUMBER: US/10/060,756A  
PRIOR FILING DATE: 2002-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 09/864,761  
PRIOR FILING DATE: 2001-05-23  
PRIOR APPLICATION NUMBER: US 60/327,898  
PRIOR FILING DATE: 2001-10-09  
NUMBER OF SEQ ID NOS: 4804  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 748  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-060-756A-748

Query Match 0.8%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 521 CACGACTCCTGCTGG 537  
Db 1 CAGGACTCCTGCTGG 17

RESULT 467  
US-10-060-756A-749  
Sequence 749, Application US/10060756A  
Publication No. US20030046717A1  
GENERAL INFORMATION:  
APPLICANT: Zhang, Jian  
TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN  
FILE REFERENCE: PB0177  
CURRENT APPLICATION NUMBER: US/10/060,756A  
PRIOR FILING DATE: 2002-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: US 09/864,761  
PRIOR FILING DATE: 2001-05-23  
PRIOR APPLICATION NUMBER: US 60/327,898  
PRIOR FILING DATE: 2001-10-09  
NUMBER OF SEQ ID NOS: 4804  
SOFTWARE: Aeomica Sequence Listing Engine  
SEQ ID NO 749  
LENGTH: 17  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-060-756A-749

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 522 ATGACCTCCCTGCTGA 538  
Db 1 AGCGACTCCTGCTGA 17

RESULT 468  
US-10-060-756A-1238  
Sequence 1238, Application US/10060756A  
Publication No. US20030046717A1  
GENERAL INFORMATION:  
APPLICANT: Zhang, Jian  
TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN  
FILE REFERENCE: PB0177  
CURRENT APPLICATION NUMBER: US/10/060,756A  
PRIOR FILING DATE: 2002-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00663  
PRIOR FILING DATE: 2001-01-30

```

: PRIOR APPLICATION NUMBER: US 09/864,761
: PRIOR FILING DATE: 2001-05-23
: PRIOR APPLICATION NUMBER: US 60/327,898
: PRIOR FILING DATE: 2001-10-09
: NUMBER OF SEQ ID NOS: 4804
: SOFTWARE: Acemica Sequence Listing Engine
: SEQ ID NO 1238
: LENGTH: 17
: TYPE: DNA
: ORGANISM: Homo sapiens
: US-10-060-756A-1238

```

Query Match	0.8%	Score 13.8	DB 1	Length 17
Best Local	88.2%	Pred. No. 3.3e+02		
Matches 15	Conservative 0	Mismatches 2	Indels 0	Gaps 0

QY	1273	TCTTTGACTCTGATCCC	1289
Db	1	TCTGTGACTGTGATCCC	17

```

RESULT 469
US-10-156-306-2719/c
; Sequence 2719, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCS4199en, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related
; TITLE OF INVENTION: Levels of IKK-Gamma and PKR
; FILE REFERENCE: MBH01-664-A (400/050)
; CURRENT FILING DATE: 2002-05-28
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2719
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-2719

```

Query Match	0.8%	Score 13.6	DB 1	Length 17
Best Local Similarity	88.2%	Pred: No. 3.3e+02		
Matches 15; Conservative	0;	Mismatches 2;	Indels 0;	Gaps 0

```

Qy      1400 TGTGATGTTGCTTTG 1416
          |||||
Db      17  TGTGATGTTGATTCG 1

```

```

RESULT 470
US-10-156-306-5069
; Sequence 5069, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKK-gamma and PKR
; FILE REFERENCE: MEMB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5069
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5069

```

Query Match	0.84	Score 13.8	DB 1	length 17
Similarity	58.8%	Pred. No. 3.3e+02		
Matches 10; Conservative	5	Mismatches 2	Indels 0	Gaps 0

QY 697 ACTTCTTCTTTCCCAAG 713  
||::||:|:|||||  
Db 1 ACUUCUGCUGUCCCAAG 17

```

RESULT 471
US-10-156-306-5948
; Sequence 5948, Application US/10156306
; Publication No. US20030119017A1
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: MCSwiggan, James
; TITLE OF INVENTION: Enzymatic Nucleic Acid Treatment of Diseases or Conditions Related to
; TITLE OF INVENTION: Levels of IKR-Gamma and PKR
; FILE REFERENCE: MBHB01-664-A (400/050)
; CURRENT APPLICATION NUMBER: US/10/156,306
; CURRENT FILING DATE: 2002-05-28
; NUMBER OF SEQ ID NOS: 8013
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 5948
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-10-156-306-5948

```

Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	52.9%;	Pred. No. 3.3e+02;		
Matches	9;	Conservative	6;	Mismatches 2;
				Indels 0;
				Gaps 0

**QY** 698 CTTCCTTCCCAAGT 714  
|::|::|::|::|:  
**Db** 1 CUUCUGCUGUCCCAAGU 17

```

      RESULT 472
      US-10-430-882-880
      ; Sequence 880, Application US/10430882
      ; Publication No. US20030203870A1
      ; GENERAL INFORMATION:
      ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
      ; APPLICANT: Lawrence Blatt
      ; APPLICANT: James McSwiggen
      ; APPLICANT: Bharat Chowitra
      ; APPLICANT: Peter Haeblerli
      ; TITLE OF INVENTION: Method and Reagent for the Inhibition of NOGO and NOGO Receptor C
      ; FILE REFERENCE: MBHB0-878-H (400/112)
      ; CURRENT APPLICATION NUMBER: US/10/430,882
      ; CURRENT FILING DATE: 2003-05-06
      ; PRIOR APPLICATION NUMBER: 09/827,395
      ; PRIOR FILING DATE: 2001-04-05
      ; PRIOR APPLICATION NUMBER: 09/780,533
      ; PRIOR FILING DATE: 2001-02-09
      ; PRIOR APPLICATION NUMBER: PCT/US01/04273
      ; PRIOR FILING DATE: 2001-02-09
      ; PRIOR APPLICATION NUMBER: 60/181,797
      ; PRIOR FILING DATE: 2000-02-11
      ; PRIOR APPLICATION NUMBER: PCT/US02/10512
      ; PRIOR FILING DATE: 2002-04-03
      ; NUMBER OF SEQ ID NOS: 2617
      ; SOFTWARE: PatentIn version 3.0
      ; SEQ ID NO 880
      ; LENGTH: 17
      ; TYPE: RNA
      ; ORGANISM: Homo sapiens
      ; US-10-430-882-880

```

Query Match	0.8%;	Score 13.8;	DB 1;	Length 17;
Best Local Similarity	70.6%;	Pred. No. 3.3e+02;		
Matches 12; Conservative	3;	Mismatches 2;	Indels 0;	Gaps 0
QY 1117 CCTTGCTGAGACAGCTG 1133				
: :             :				

QY 1117 CCTGCTGGAGCAGCTG 1133  
||:|||||||:|



PRIOR APPLICATION NUMBER: 60/197,769  
PRIOR FILING DATE: 2000-04-14  
PRIOR APPLICATION NUMBER: 60/150,713  
PRIOR FILING DATE: 1999-08-31  
NUMBER OF SEQ ID NOS: 5586  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 564  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-712-672-564

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 98.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 101 GCAGGTCTGGGGGACC 117  
DB 17 GCAGGCCGAGGGGACC 1

RESULT 478  
US-10-712-672-1193  
Sequence 1193, Application US/10712672  
Publication No. US20040102413A1  
GENERAL INFORMATION:  
APPLICANT: Ribozyme Pharmaceuticals, Inc.  
APPLICANT: Chowitra, Bharat  
APPLICANT: McSwiggen, Jim  
APPLICANT: Stinchcomb, Dan  
TITLE OF INVENTION: Method and Reagent for the Inhibition of Telomerase Enzyme  
FILE REFERENCE: MHB00-882-C (400/019)  
CURRENT FILING DATE: 2003-11-13  
PRIOR APPLICATION NUMBER: US/09/653,225  
PRIOR FILING DATE: 2000-08-31  
PRIOR APPLICATION NUMBER: 60/197,769  
PRIOR FILING DATE: 2000-04-14  
PRIOR APPLICATION NUMBER: 60/150,713  
PRIOR FILING DATE: 1999-08-31  
NUMBER OF SEQ ID NOS: 5586  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 1193  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Homo sapiens  
US-10-712-672-1193

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 70.6%; Pred. No. 3.3e+02;  
Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 1321 GGAAGACCCCTAATT 1337  
DB 1 GGAAGACCCCACTUU 17

RESULT 479  
US-10-669-841-3225  
Sequence 3225, Application US/10669841  
Publication No. US20040127446A1  
GENERAL INFORMATION:  
APPLICANT: Sirta Therapeutics, Inc.  
APPLICANT: Lawrence, Blact  
APPLICANT: Dennis, Macejak  
APPLICANT: James, McSwiggen  
APPLICANT: David, Morrissey  
APPLICANT: Pamela, Pavco  
APPLICANT: Patrice, Lee  
APPLICANT: Kenneth, Draper  
APPLICANT: Elisabeth, Roberts  
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA  
TITLE OF INVENTION: VIRUS REPLICATION

FILE REFERENCE: 400/042US (MHB02-249-E)  
CURRENT APPLICATION NUMBER: US/10/669,841  
CURRENT FILING DATE: 2003-09-23  
PRIOR APPLICATION NUMBER: PCT/US02/09187  
PRIOR FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: US 60/296,876  
PRIOR FILING DATE: 2001-06-08  
PRIOR APPLICATION NUMBER: US 60/335,059  
PRIOR FILING DATE: 2001-10-24  
PRIOR APPLICATION NUMBER: US 60/337,055  
PRIOR FILING DATE: 2001-12-05  
PRIOR APPLICATION NUMBER: US 60/358,580  
PRIOR FILING DATE: 2002-02-20  
PRIOR APPLICATION NUMBER: US 60/363,124  
PRIOR FILING DATE: 2002-03-11  
PRIOR APPLICATION NUMBER: US 09/817,879  
PRIOR FILING DATE: 2001-03-26  
PRIOR APPLICATION NUMBER: US 09/740,332  
PRIOR FILING DATE: 2000-12-18  
PRIOR APPLICATION NUMBER: US 09/611,931  
PRIOR FILING DATE: 2000-07-07  
PRIOR APPLICATION NUMBER: US 09/504,321  
PRIOR FILING DATE: 2000-02-15  
Remaining Prior Application data removed - See File Wrapper or PALM.  
NUMBER OF SEQ ID NOS: 16207  
SOFTWARE: PatentIn version 3.0  
SEQ ID NO 3225  
LENGTH: 17  
TYPE: RNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid  
FEATURE:  
NAME/KEY: misc\_feature  
LOCATION:  
OTHER INFORMATION: oligonucleotide substrate  
US-10-669-841-3225

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 47.1%; Pred. No. 3.3e+02;  
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

OY 1400 TGTGATGTCCTTG 1416  
DB 1 UGUGAUGAUGCUCUG 17

RESULT 480  
US-10-669-841-4754  
Sequence 4754, Application US/10669841  
Publication No. US20040127446A1  
GENERAL INFORMATION:  
APPLICANT: Sirta Therapeutics, Inc.  
APPLICANT: Lawrence, Blact  
APPLICANT: Dennis, Macejak  
APPLICANT: James, McSwiggen  
APPLICANT: David, Morrissey  
APPLICANT: Pamela, Pavco  
APPLICANT: Patrice, Lee  
APPLICANT: Kenneth, Draper  
APPLICANT: Elisabeth, Roberts  
TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPA  
TITLE OF INVENTION: VIRUS REPLICATION  
FILE REFERENCE: 400/042US (MHB02-249-E)  
CURRENT APPLICATION NUMBER: US/10/669,841  
CURRENT FILING DATE: 2003-09-23  
PRIOR APPLICATION NUMBER: PCT/US02/09187  
PRIOR FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: US 60/296,876  
PRIOR FILING DATE: 2001-06-08  
PRIOR APPLICATION NUMBER: US 60/335,059  
PRIOR FILING DATE: 2001-10-24  
PRIOR APPLICATION NUMBER: US 60/337,055

```

; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4754
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-4754
```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 3.3e+02;
Matches 9; Conservative 6; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      689 GAGGCGTCACTTCTTCT 705
Db      1 GAUGACUCACUCUCUCU 17
```

```

RESULT 481
; US-10-669-841-5605/c
; Sequence 5605, Application US/10669841
; Publication No. US20040127446A1
; GENERAL INFORMATION:
; APPLICANT: Sirta Therapeutics, Inc.
; APPLICANT: Lawrence, Blact
; APPLICANT: Dennis, Macejak
; APPLICANT: James, McSwiggan
; APPLICANT: David, Morrissey
; APPLICANT: Pamela, Pavco
; APPLICANT: Patrice, Lee
; APPLICANT: Kenneth, Draper
; APPLICANT: Elisabeth, Roberts
; TITLE OF INVENTION: OLIGONUCLEOTIDE MEDIATED INHIBITION OF HEPATITIS B VIRUS AND HEPV
; FILE REFERENCE: 400/042US (MHB02-249-E)
; CURRENT FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US/10/669,841
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PCT/US02/09187
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: US 60/296,876
; PRIOR FILING DATE: 2001-06-08
; PRIOR APPLICATION NUMBER: US 60/335,059
; PRIOR FILING DATE: 2001-10-24
; PRIOR APPLICATION NUMBER: US 60/337,055
; PRIOR FILING DATE: 2001-12-05
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 09/817,879
; PRIOR FILING DATE: 2001-03-26
; PRIOR APPLICATION NUMBER: US 09/740,332
; PRIOR FILING DATE: 2000-12-18
; PRIOR APPLICATION NUMBER: US 09/611,931
```

```

; PRIOR FILING DATE: 2000-07-07
; PRIOR APPLICATION NUMBER: US 09/504,321
; PRIOR FILING DATE: 2000-02-15
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 16207
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5605
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Nucleic Acid
; NAME/KEY: misc_feature
; LOCATION:
; OTHER INFORMATION: oligonucleotide substrate
US-10-669-841-5605
```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      769 ACGCCATGTTCCAGCCC 785
Db      17 ACGCCATGTTCCGCGTC 1
```

```

RESULT 482
; US-10-723-361-1895/c
; Sequence 1895, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART ANT
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; PRIOR FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 1895
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-1895

Query Match      0.8%; Score 13.8; DB 1; Length 17;
```



Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 93 GAGAGTGGCAGGCTCT 109  
Db 17 GAGAGAGCCAGGCTCT 1

## RESULT 483

US-10-723-361-2643/c  
; Sequence 2643, Application US/10723361  
; Publication No. US20040137589A1

## GENERAL INFORMATION:

APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
FILE REFERENCE: PB0105  
CURRENT FILING DATE: 2003-11-26  
PRIOR APPLICATION NUMBER: US 09/866,108  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aecmca Sequence Listing Engine  
; SEQ ID NO 2643  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-723-361-2643

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 845 CTTCCGACACCGCCCA 861  
Db 17 CTGCCAGACCGCCCA 1

## RESULT 484

US-10-723-361-7355  
; Sequence 7355, Application US/10723361  
; Publication No. US20040137589A1

## GENERAL INFORMATION:

APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng

APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
FILE REFERENCE: PB0105  
CURRENT FILING DATE: 2003-11-26  
PRIOR APPLICATION NUMBER: US 09/866,108  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00669  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00665  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00668  
PRIOR FILING DATE: 2001-01-30  
; Remaining Prior Application data removed - See File Wrapper or PALM.  
; NUMBER OF SEQ ID NOS: 15755  
; SOFTWARE: Aecmca Sequence Listing Engine  
; SEQ ID NO 7355  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-723-361-7355

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 270 GAGAGGCCAGAGAA 286  
Db 1 GAGAGGCCAGAGAA 17

## RESULT 485

US-10-723-361-7485/c  
; Sequence 7485, Application US/10723361  
; Publication No. US20040137589A1

## GENERAL INFORMATION:

APPLICANT: GU, Yizhong  
APPLICANT: JI, Yonggang  
APPLICANT: PENN, Sharon G.  
APPLICANT: HANZEL, David K.  
APPLICANT: RANK, David R.  
APPLICANT: CHEN, Wensheng  
APPLICANT: SHANNON, Mark  
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN  
FILE REFERENCE: PB0105  
CURRENT FILING DATE: 2003-11-26  
PRIOR APPLICATION NUMBER: US 09/866,108  
PRIOR FILING DATE: 2001-05-25  
PRIOR APPLICATION NUMBER: US 60/207,456  
PRIOR FILING DATE: 2000-05-26  
PRIOR APPLICATION NUMBER: GB 24263.6  
PRIOR FILING DATE: 2000-10-04  
PRIOR APPLICATION NUMBER: US 60/236,359  
PRIOR FILING DATE: 2000-09-27  
PRIOR APPLICATION NUMBER: PCT/US01/00666  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00667  
PRIOR FILING DATE: 2001-01-30  
PRIOR APPLICATION NUMBER: PCT/US01/00664  
PRIOR FILING DATE: 2001-01-30

```

; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 7485
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-7485
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      1530 GCCCAGCCTCTCCCGC 1546
Db       17  GTCCAGCCTCTCTCGC 1
```

```

RESULT 486
US-10-723-361-8568
; Sequence 8568, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8568
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8568
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      292 AGATGCCCTTAATGAG 308
Db       1  AGATGACCTGAATGAG 17
```

```

RESULT 487
US-10-723-361-8660
; Sequence 8660, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263,6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 8660
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-8660
```

```
Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

```
QY      267 CTGAGAGACCCAGAA 283
Db       1  CTGAGAGACCCAGAA 17
```

```

RESULT 488
US-10-723-361-8661
; Sequence 8661, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
```

```

CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
SOFTWARE: Aecomica Sequence Listing Engine
NUMBER OF SEQ ID NOS: 15755
US-10-723-361-8661
ORGANISM: Homo sapiens
TYPE: DNA
LENGTH: 17

```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Oy      268 TAGAAGCCAGAG 284
Db      1 TGGAGAGCCAGAG 17

```

```

RESULT 489
US-10-723-361-8663
Sequence 8663, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark
TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665

```

```

PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 8663
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-8663

```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Oy      270 GAGAGCCAGAG 286
Db      1 GAGAGCCAGAG 17

```

```

RESULT 490
US-10-723-361-8664
Sequence 8664, Application US/10723361
Publication No. US20040137589A1
GENERAL INFORMATION:
APPLICANT: GU, Yizhong
APPLICANT: JI, Yonggang
APPLICANT: PENN, Sharon G.
APPLICANT: HANZEL, David K.
APPLICANT: RANK, David R.
APPLICANT: CHEN, Wensheng
APPLICANT: SHANNON, Mark

```

```

TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
FILE REFERENCE: PB0105
CURRENT APPLICATION NUMBER: US/10/723,361
CURRENT FILING DATE: 2003-11-26
PRIOR APPLICATION NUMBER: US 09/866,108
PRIOR FILING DATE: 2001-05-25
PRIOR APPLICATION NUMBER: US 60/207,456
PRIOR FILING DATE: 2000-05-26
PRIOR APPLICATION NUMBER: GB 24263,6
PRIOR FILING DATE: 2000-10-04
PRIOR APPLICATION NUMBER: US 60/236,359
PRIOR FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: PCT/US01/00666
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00667
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00664
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00669
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00665
PRIOR FILING DATE: 2001-01-30
PRIOR APPLICATION NUMBER: PCT/US01/00668
PRIOR FILING DATE: 2001-01-30
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 15755
SOFTWARE: Aecomica Sequence Listing Engine
SEQ ID NO 8664
LENGTH: 17
TYPE: DNA
ORGANISM: Homo sapiens
US-10-723-361-8664

```

```

US-10-723-361-8664

```

```

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

Oy      271 AAGAGCCAGAG 287
Db      1 AGGAGCCAGAG 17

```

```
RESULT 491
US-10-723-361-9687/c
; Sequence 9687, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9687
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9687

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      93 GAGAGTGGGCGAGTCT 109
Db      17 GAGAGTGGGCGAGTCT 1

RESULT 492
US-10-723-361-9688/c
; Sequence 9688, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
```

```
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9688
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9688

Query Match      0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY      92 GAGAGTGGGCGAGTCC 108
Db      17 GAGAGTGGGCGAGTCC 1

RESULT 493
US-10-723-361-9689/c
; Sequence 9689, Application US/10723361
; Publication No. US20040137589A1
; GENERAL INFORMATION:
; APPLICANT: GU, Yizhong
; APPLICANT: JI, Yonggang
; APPLICANT: PENN, Sharon G.
; APPLICANT: HANZEL, David K.
; APPLICANT: RANK, David R.
; APPLICANT: CHEN, Wensheng
; APPLICANT: SHANNON, Mark
; TITLE OF INVENTION: HUMAN MYOSIN-LIKE POLYPEPTIDE EXPRESSED PREDOMINANTLY IN HEART AN
; FILE REFERENCE: PB0105
; CURRENT APPLICATION NUMBER: US/10/723,361
; CURRENT FILING DATE: 2003-11-26
; PRIOR APPLICATION NUMBER: US 09/866,108
; PRIOR FILING DATE: 2001-05-25
; PRIOR APPLICATION NUMBER: US 60/207,456
; PRIOR FILING DATE: 2000-05-26
; PRIOR APPLICATION NUMBER: GB 24263.6
; PRIOR FILING DATE: 2000-10-04
; PRIOR APPLICATION NUMBER: US 60/236,359
; PRIOR FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: PCT/US01/00666
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
```

```

; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 15755
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 9689
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-723-361-9689

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      91 GCGAGAGTGGCGAGCTC 107
Db      17 GCGAGAGTGGCGAGCTC 1

RESULT 494
US-10-758-451-944/C
; Sequence 944, Application US/10758451
; Publication No. US20050014711A1
; GENERAL INFORMATION:
; APPLICANT: East Carolina University
; TITLE OF INVENTION: COMPOSITION, FORMULATION & METHOD FOR PREVENTION & TREATMENT OF D
; TITLE OF INVENTION: AND CONDITIONS ASSOCIATED WITH BRONCHOCONSTRICITION, ALLERGY (IES)
; FILE REFERENCE: INFLAMMATION
; FILE REFERENCE: 30775-706.301
; CURRENT APPLICATION NUMBER: US/10/758,451
; CURRENT FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: 09/093,972
; PRIOR FILING DATE: 1998-06-09
; NUMBER OF SEQ ID NOS: 996
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 944
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-758-451-944

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1530 GCCCAGCCTCTCCCGC 1546
Db      17 GCCCAGCCTGTGCCGC 1

RESULT 495
US-10-890-776A-748
; Sequence 748, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/890,776A
; CURRENT FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: US 10/060,756
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
```

```

; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 748
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-748

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      521 CATGACTCCTCTCTGG 537
Db      1 CAGCGACTCACTGCTGG 17

RESULT 496
US-10-890-776A-749
; Sequence 749, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
; FILE REFERENCE: PB0177
; CURRENT APPLICATION NUMBER: US/10/890,776A
; CURRENT FILING DATE: 2004-07-14
; PRIOR APPLICATION NUMBER: US 10/060,756
; PRIOR FILING DATE: 2002-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00663
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00664
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00665
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00667
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00668
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: PCT/US01/00669
; PRIOR FILING DATE: 2001-01-30
; PRIOR APPLICATION NUMBER: US 09/864,761
; PRIOR FILING DATE: 2001-05-23
; PRIOR APPLICATION NUMBER: US 60/327,898
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4809
; SOFTWARE: Aeomica Sequence Listing Engine
; SEQ ID NO 749
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-890-776A-749

Query Match          0.8%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 3.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      522 ATCGACTCCCTCTGGA 538
Db      1 ACCGACTCACTCTGGA 17

RESULT 497
US-10-890-776A-1238
; Sequence 1238, Application US/10890776A
; Publication No. US20050129683A1
; GENERAL INFORMATION:
; APPLICANT: Zhang, Jian
; TITLE OF INVENTION: HUMAN TESTIS EXPRESSED PATCHED LIKE PROTEIN
```

FILE REFERENCE: PB0177  
; CURRENT APPLICATION NUMBER: US/10/890,776A  
; CURRENT FILING DATE: 2004-07-14  
; PRIOR APPLICATION NUMBER: US 10/060,756  
; PRIOR FILING DATE: 2002-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00663  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00664  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00665  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00667  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00668  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: PCT/US01/00669  
; PRIOR FILING DATE: 2001-01-30  
; PRIOR APPLICATION NUMBER: US 09/864,761  
; PRIOR FILING DATE: 2001-05-23  
; PRIOR APPLICATION NUMBER: US 60/327,898  
; PRIOR FILING DATE: 2001-10-09  
; NUMBER OF SEQ ID NOS: 4809  
; SOFTWARE: Aecomica Sequence Listing Engine  
; SEQ ID NO: 1238  
; LENGTH: 17  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-890-776A-1238

Query Match 0.8%; Score 13.8; DB 1; Length 17;  
Best Local Similarity 88.2%; Pred. No. 3.3e+02;  
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1273 TCTTGACTGTGATCCC 1289  
Db 1 TCTGTGACTGTGATCCC 17

Search completed: September 13, 2005, 10:47:07  
Job time : 12 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 13, 2005, 10:53:12 ; Search time 0.001 Seconds  
(without alignments)  
824.786 Million cell updates/sec

Title: us-10-828-394-1

Perfect score: 1643  
Sequence: 1 gaattccgcgcgtgaccgag.....taaacgtctgtgacgtg 1643

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 8 segs, 251 residues

Total number of hits satisfying chosen parameters: 16

Minimum DB seq length: 8  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 5000 summaries

Database : rctdb:\*

Pred. NO. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	47	2.9	48	1	H93557
2	40.2	2.4	46	1	T74174
3	39	2.4	39	1	BF39449
4	39	2.4	39	1	BF342092
5	39	2.4	40	1	T71848
6	16	1.0	48	1	H93557
7	12.8	0.8	39	1	BF39449
8	12.8	0.8	39	1	BF342092
9	12.8	0.8	46	1	T74174
10	12.6	0.8	40	1	T71848
11	11.4	0.7	13	1	CM020522
12	11.4	0.7	14	1	CF278327
13	11	0.7	12	1	CN752857
14	9	0.5	12	1	CN752857
15	8.2	0.5	13	1	CM020522
16	8.2	0.5	14	1	CF278327

## ALIGNMENTS

RESULT 1  
H93557 48 bp mRNA linear EST 01-DEC-1995  
LOCUS H93557  
DEFINITION yv1d11.r1 Soares fetal liver spleen INFIS Homo sapiens cDNA clone IMAGE:242709.5' similar to gb:U14723 CLUSTERIN PRECURSOR (HUMAN);  
mRNA sequence.  
H93557  
VERSION H93557.1 GI:1099885  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

## REFERENCE

Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
1 (bases 1 to 48)  
Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M., Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M., Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F., Trevaaskis, E., Waterston, R., Williamson, A., Wohlmann, P. and Wilson, R.

## TITLE

The Mashu-Merck EST Project  
Unpublished (1995)  
Contact: Wilson RK  
Washington University School of Medicine  
444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu

High quality sequence starts: 1  
High quality sequence stops: 1  
Source: IMAGE Consortium, LNL  
This clone is available royalty-free through LNL; contact the IMAGE Consortium (info@image.lnl.gov) for further information.  
Trace considered overall poor quality  
Seq primer: M13RP1  
High quality sequence stop: 1.  
Location/Qualifiers

## FEATURES

source

/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:3791842"  
/db\_xref="taxon:9606"  
/clone="IMAGE:242709"  
/sex="male"  
/dev stage="20 week-post conception fetus"  
/lab host="DH10B (ampicillin resistant)"  
/clone\_lib="Soares fetal liver spleen INFIS"

/note="Organ: Liver and Spleen; Vector: p773D (Pharmacia) with a modified polylinker; Site\_1: Pac I; Site\_2: Eco RI; 1st strand cDNA was primed with a Pac I - oligo(dT) primer (5' AACGTGAAGAATTAATTAAGATCTTTTCTTTTCTTTT 3'), double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Pac I and cloned into the Pac I and Eco RI sites of the modified p773 vector. Library went through one round of normalization. Library constructed by Bento Soares and M. Fatima Bernaldo."

Query Match 2.9%; Score 47; DB 1; Length 48;  
Best Local Similarity 97.9%; Pred. No. 0.54; Indels 0; Gaps 0;  
Matches 47; Conservative 0; Mismatches 1;

QY 1136 CGAGCAGTTTAACTGGTGTCCCGGCTGCAACCTCAGCAAGGCGA 1183

Db 1 CGAGCAGTTTAACTGGTGTCCCGGCTGCAACCTCAGCAAGGCGA 48

RESULT 2  
T74174 46 bp mRNA linear EST 02-MAR-1995  
LOCUS T74174  
DEFINITION y60b12.s1 StrataGene liver (#937224) Homo sapiens cDNA clone IMAGE:85053' similar to gb:U14723 CLUSTERIN PRECURSOR (HUMAN);  
mRNA sequence.

## ACCESSION

VERSION T74174  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.  
REFERENCE  
1 (bases 1 to 46)  
Hillier, L., Lennon, G., Becker, M., Bernaldo, M.F., Chapelli, B., Chisoe, S., Dietrich, N., Dubuque, T., Favello, A., Gish, W., Hawkins, M., Hultman, M., Kucaba, T., Le, M., Le, N., Marra, M., Moore, B., Morris, M., Parsons, J., Prange, C., Rifkin, L., Rohlfing, T., Scheinberg, K., Soares, M.B., Tan, F., Thierry-Mieg, J., Trevaaskis, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R.

TITLE	and Marra, M.
JOURNAL	Generation and analysis of 280,000 human expressed sequence tags
GENOME	Genome Res. 6 (9), 807-828 (1996)
PUBMED	97044478
COMMENT	8889549
	Contact: Wilson RK

TITLE	and Mairra,M.
JOURNAL	Generation and Analysis of 280,000 human expressed sequence tags
MEDLINE	Genome Res. 6 (9), 807-828 (1996)
PUBMED	97044478
COMMENT	8889549
	Contact: Wilson RK
	Washington University School of Medicine
	444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
	Tel: 314 286 1800
	Fax: 314 286 1810
	Email: est@watson.wustl.edu
	High quality sequence starts: 1
	High quality sequence stops: 1
	Source: IMAGE Consortium, LNL
	This clone is available royalty-free through LNL ; contact the
	IMAGE Consortium (info@image.lnl.gov) for further information.
	Trace considered overall poor quality
	Seq primer: ~21m13
	High quality sequence stop: 1.
FEATURES	Location/Qualifiers
source	1..46

```

/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:502112"
/db_xref="taxon:9606"
/clone="IMAGE:85055"
/sex="male"
/dev_string="49 years old"
/lab_host="SOLR cells (kanamycin resistant)"
/clone_idb="Stratagene liver #937224"
/notes="Organ: liver; Vector: pBluscript SK; Site: 1: EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer: Oligo dt. Hepatectomy from normal male caucasian. Averta insert size: 1.1 kb; Uni-ZAP XR Vector; -5' adaptor sequence: 5' GAATTCGGCAGCAG 3' -3' adaptor sequence: 5' CTCGAGTCTTTTTTTTTTTT 3'"

```

Query Match	2.4%	Score 40.2	DB 1	Length 46
Best Local Similarity	91.3%	Pred. No. 1.1		
Matches 42	Conservative 0	Mismatches 4	Indels 0	Gaps 0
Oy	1553	TCTGTGACTCTAACACTGCTCTGCTCTATGGAAGAAACAGAA	1598	
Ob	46	TCTGTGAGCGCTAAACCCGAGCTCTGCTCTCTATGGAAGAAACAGAA	1	

RESULT 3					
BF339449	BF339449	39 bp	mRNA	linear	EST 22-NOV-2
LOCUS	602039103F1	NCI	CGAP Brn64 Homo sapiens	cDNA clone	IMAGE:4186752
DEFINITION					

ACCESSION 5', mRNA sequence.  
 VERSION BF339449  
 KEYWORDS BF339449.1 GI:11285904  
 SOURCE EST.  
 ORGANISM Homo sapiens (human)

ORGANISM  
Homo sapiens  
Eukaryota, Metazoa, Chordata, Craniata, Vertebrata, Euteleostomi,  
Mammalia, Eutheria, Primates, Catarrhini, Homiidae, Homo.  
1 (bases 1 to 39)  
REFERENCE  
NIN-MGC <http://mgc.ncl.nih.gov/>.  
AUTHORS  
National Institutes of Health, Mammalian Gene Collection (MGC)  
TITLE  
Unpublished (1999)  
JOURNAL  
Contact: Robert Strusberg, Ph.D.  
COMMENT

Email: [cgapds-remail.nih.gov](mailto:cgapds-remail.nih.gov)  
Tissue Procurement: David N. Louis, M.D.  
cDNA Library Preparation: Life Technologies, Inc.  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/BLNI at: <http://image.lnl.gov>  
plate: LHAM9508 row: f column: 01  
High quality sequence stop: 38.

**FEATURES**  
**source**

```

/organism="Homo sapiens"
/mol_type="rRNA"
/db_xref="taxon:9606"
/clone="IMAGE:4186752"
/tissue_type="glioblastoma with EGFR amplification"
/lab_host="DH10B (T1 phage-resistant)"
/clone_lib="NCI CGAP Brn64"
/note="Organ: brain; Vector: pCMV-SPORT6; Site_1: NCI1; Site_2: SalI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.57 kb. Constructed by Life Technologies. Note: this is a NCI CGAP Library."

```

Query Match	2.4%	Score 39	DB 1	Length 39
Best Local Similarity	100.0%	Pred. No. 1.2		
Matches 39; Conservative 0;		Mismatches 0;		Indels 0;
		Gaps 0;		
QY	416	GTTCCTACGACGCGCTCTGCAGAAAGTGGCTCAGGCGTGGT	454	
db	1	GTTCCTACGACGCGCTCTGCAGAAAGTGGCTCAGGCGTGGT	39	

RESULT_4									
BP342092									
LOCUS	BP342092	39 bp	mRNA	linear	EST 22-NOV-2000				
DEFINITION	602012848P1 NCI CGAP_Brn64 Homo sapiens cDNA clone IMAGE:4148962 5' mRNA sequence.								
ACCESSION	BF342092								
VERSION	BF342092.1	GI:11286842							
KEYWORDS	EST.								
SOURCE	Homo sapiens (human)								
ORGANISM	Homo sapiens								

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 39)  
NIH-WGC <http://mgc.ncbi.nlm.nih.gov/>.  
National Institutes of Health, Mammalian Gene Collection (MGC)  
Unpublished (1999)  
Contact: Robert Strausberg, Ph.D.

Email: [cgabbs-r@mail.nih.gov](mailto:cgabbs-r@mail.nih.gov)  
Tissue Procurement: David N. Louis, M.D.  
cDNA Library Preparation: Life Technologies, Inc.  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)  
DNA Sequencing by: Incyte Genomics, Inc.  
Clone distribution: MGC clone distribution information can be  
found through the I.M.A.G.E. Consortium/LNL at:  
<http://image.lnl.gov>  
Plate: L14M9409 row: 0 column: 11  
High quality sequence stop: 37.

FEATURES	source	Location/Qualifiers
1..39		
		/organism="Homo sapiens"
		/mol_type="mRNA"
		/db_xref="taxon:9606"
		/clone="IMAGE:4148962"
		/tissue_type="Glioblastoma with EGFR amplification"
		/lab_host="DH10B (T1 phage-resistant)"
		/clone_id="NCI_CGAP-Brn64"
		/note="Organ: brain; Vector: PCWV-SPORE6; Site 1: NotI; Site 2: SalI; Cloned unidirectionally. Primer: Oligo dT. Average insert size 1.57 kb. Constructed by Life Technologies. Note: this is a NCI_CGAP Library."

	Query Match	2.4%	Score 39;	DB 1;	Length 39;
	Best Local Similarity	100.0%;	Pred.No. 1,2;	Mismatches	
	Matches 39; Conservative	0;	Indels	0;	Gaps
OY		416	GTCTACGCAAGCGCTGCAGAAGTGCTCAGGCTTGGT		454
Ob		1	GTCTTACGCAAGCGCTTCGAGAAGTGCTCAGGCTTGGT		39



RESULT 5  
LOCUS T71848/c  
DEFINITION T71848 40 bp mRNA linear EST 01-MAR-1995  
yc64e6.6.1 StrataGene liver (#937224) Homo sapiens cDNA clone  
IMAGE:85474 3' similar to gb:xl4723 CLUSTERIN PRECURSOR (HUMAN);  
mRNA sequence.  
ACCESSION T71848  
VERSION T71848.1 GI:686369  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 40)  
AUTHORS Hallier, L., Lennon, G., Becker, M., Bonaldo, M.F., Chiappelli, B.,  
Chisoe, S., Dietrich, N., Dubuque, T., Favello, A., Gish, M.,  
Hawkins, M., Hultman, M., Kucaba, T., Lacy, M., Le, M., Le, N.,  
Mardis, E., Moore, B., Morris, M., Parsons, J., Prange, C., Rifkin, L.,  
Rohlfing, T., Schellenberg, K., Soares, M.B., Tan, F., Thierly-Meg, J.,  
Trevaekis, E., Underwood, K., Wohlmann, P., Waterston, R., Wilson, R.  
and Marra, M.  
TITLE Generation and analysis of 280,000 human expressed sequence tags  
JOURNAL Genome Res. 6 (9), 807-828 (1996)  
MEDLINE 97044478  
PUBMED 8889549  
COMMENT Contact: Wilson RK  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu  
Insert Size: 26  
High quality sequence starts: 1 High quality sequence stops: 1  
Source: IMAGE Consortium, LNL This clone is available royalty-free  
through LNL; contact the IMAGE Consortium (info@image.llnl.gov)  
for further information. Trace considered overall poor quality  
Seq primer: -21m3  
High quality sequence stop: 1.  
Location/Qualifiers  
1..40  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:502531"  
/db\_xref="taxon:9606"  
/clone="IMAGE:85474"  
/sex="male"  
/dev\_stage="49 years old"  
/lab\_host="SOLR cells (kanamycin resistant)"  
/clone\_lib="StrataGene liver (#937224)"  
/note="Organ: liver; Vector: pBlueScript SK; Site: 1;  
EcoRI; Site 2: XhoI; Cloned unidirectionally. Primer:  
Oligo dT. Hepatectomy from normal male caucasian. Average  
insert size: 1.1 kb; Uni-ZAP XR Vector; ~5' adaptor  
sequence: 5' GAATTCGGCAGAG 3' ~3' adaptor sequence: 5'  
CTCAGCTTTTCTTTTCTTTT 3'."

Query Match 2.4%; Score 39; DB 1; Length 40;  
Best Local Similarity 97.5%; Pred. No. 1.2;  
Matches 39; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1512 CTCGAGGCCCACTCGCGCCAGCTCCCGCTGG 1551  
|||||  
Db 40 CTCGAGGCCCACTCGCGCCAGCTCCCGCTGG 1

RESULT 6  
LOCUS H93557/c  
DEFINITION H93557 48 bp mRNA linear EST 01-DEC-1995  
yv14d11.r1 Soares fetal liver spleen INFLS Homo sapiens cDNA clone  
IMAGE:242709 5' similar to gb:xl4723 CLUSTERIN PRECURSOR (HUMAN);  
mRNA sequence.  
ACCESSION H93557  
VERSION H93557.1 GI:1099885

KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 48)  
AUTHORS Hallier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M.,  
Holman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M.,  
Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F.,  
Trevaekis, E., Waterston, R., Williamson, A., Wohlmann, P. and  
Wilson, R.  
TITLE The WashU-Merck EST Project  
JOURNAL Unpublished (1995)  
COMMENT Contact: Wilson RK  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu  
High quality sequence starts: 1  
High quality sequence stops: 1  
Source: IMAGE Consortium, LNL  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
Trace considered overall poor quality  
Seq primer: M13RPI  
High quality sequence stop: 1.  
Location/Qualifiers  
1..48  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:3791842"  
/db\_xref="taxon:9606"  
/clone="IMAGE:242709"  
/sex="male"  
/dev\_stage="20 week-post conception fetus"  
/lab\_host="DH10B (ampicillin resistant)"  
/clone\_lib="Soares fetal liver spleen INFLS"  
/note="Organ: Liver and Spleen; Vector: pTZ19 (Pharmacia)  
with a modified polylinker; Site 1: Pac I; Site 2: Eco RI;  
1st strand cDNA was primed with a Pac I - oligo(dT) primer  
15' AACTGGAAGATTAAATTAAGATCTTTTCTTTT 3';  
double-stranded cDNA was ligated to Eco RI adaptors  
(Pharmacia), digested with Pac I and cloned into the Pac I  
and Eco RI sites of the modified pTZ19 vector. Library  
went through one round of normalization. Library  
constructed by Bento Soares and M. Patricia Bonaldo."

Query Match 1.0%; Score 16; DB 1; Length 48;  
Best Local Similarity 66.7%; Pred. No. 9;  
Matches 22; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 627 AGGTTCTTACCCGGAGCCCGAGATACCTAC 659  
|||||  
Db 36 AGGTTTNCACCGCGACACCCAGTTAACTGC 4

RESULT 7  
LOCUS BF339449/c  
DEFINITION BF339449 39 bp mRNA linear EST 22-NOV-2000  
602039103f1 NCI CGAP\_Brn64 Homo sapiens cDNA clone IMAGE:4186752  
5', mRNA sequence.  
ACCESSION BF339449  
VERSION BF339449.1 GI:11285904  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
REFERENCE 1 (bases 1 to 39)  
AUTHORS NIH-MGC http://mgc.nci.nih.gov/.  
TITLE National Institutes of Health, Mammalian Gene Collection (MGC)  
JOURNAL Unpublished (1999)



Db 3 CTGTTTCCATGACGACGAGCTCGGTTTAGCGTCA 43

RESULT 10  
T71848 40 bp mRNA linear EST 01-MAR-1995  
LOCUS T71848  
DEFINITION y646406.g1 StrataGene liver (#937224) Homo sapiens cDNA clone  
IMAGE:85474.3 similar to gb:U14723 CLUSTERIN PRECURSOR (HUMAN);  
mRNA sequence.  
T71848  
T71848.1 GI:686369  
EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.  
REFERENCE  
AUTHORS Hallier L., Lennon G., Becker M., Bonaldo M.F., Chiappelli B.,  
Chissee S., Dietrich N., Dubague T., Favello A., Gish W.,  
Hawkins M., Hultman M., Kucaba T., Lacy M., Le M., Le N.,  
Mavdis E., Moore B., Morris M., Parsons J., Prange C., Rifkin L.,  
Rohlfing T., Schellenberg K., Soares M.B., Tan F., Thierry-Mieg J.,  
Trevaekis E., Underwood K., Wohlmann P., Waterston R., Wilson R.  
and Marra M.  
TITLE Generation and analysis of 280,000 human expressed sequence tags  
JOURNAL Genome Res. 6 (9), 807-828 (1996)  
MEDLINE 97044478  
PUBMED 8889549  
COMMENT Contact: Wilson RK  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: est@watson.wustl.edu  
Insert Size: 26  
High quality sequence starts: 1 High quality sequence stops: 1  
Source: IMAGE Consortium, LNL This clone is available royalty-free  
through LNL; contact the IMAGE Consortium (infoimage.lnl.gov)  
for further information. Trace considered overall poor quality  
Seq primer: -21m13  
High quality sequence stop: 1.  
Location/Qualifiers  
1..40  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="GDB:502531"  
/db\_xref="taxon:9606"  
/clone="IMAGE:85474"  
/sex="male"  
/dev\_stage="49 years old"  
/lab\_host="SOLR cells (kanamycin resistant)"  
/clone\_lib="StrataGene liver (#937224)"  
/note="Organ: liver; Vector: pBluescript SK; Site: 1;  
EcorI; Site: 2; XhoI; Cloned unidirectionally. Primer:  
Oligo dt. Hepatectomy from normal male caucasian. Average  
insert size: 1.1 kb, Uni-ZAP XR Vector; ~5' adaptor  
sequence: 5' GAATTCGCGACGAG 3' ~3' adaptor sequence: 5'  
CTGAGTTTCTTTTCTTTT 3'"

Query Match 0.8%; Score 12.6; DB 1; Length 40;  
Best Local Similarity 58.3%; Pred. No. 11; Indels 0; Gaps 0;  
Matches 21; Conservative 0; Mismatches 15;

OY 84 CTGACCTGGAGAGTGGCAGGCTCTGGGGGACGAG 119  
DB 2 CAGAGCGGAGAGCGCTGGCGGAGTTTGGGGCGCTG 37

RESULT 11  
LOCUS CM020522 13 bp mRNA linear GSS 28-SEP-2004  
DEFINITION GC0792 TIGEM gene trap library Mus musculus cDNA clone m4.E4.D08,

ACCESSION CM020522  
VERSION CM020522.1 GI:52789782  
KEYWORDS GSS.  
SOURCE Mus musculus (house mouse)  
ORGANISM Mus musculus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE  
AUTHORS Cobellis G., Nicolson G., Marra E., Barbaisi M., Sardiello M., Di  
Giorgio F.P., Iovino N., Zollo M., Balabio A. and Cortese R.  
TITLE Tagging genes with cassette-exchange sites  
JOURNAL Unpublished (2004)  
COMMENT Contact: TIGEM  
107  
TIGEM  
Via P. Castellino, 111, 80131 NAPOLI, ITALY  
Tel: +390816132205  
Fax: +390815790919  
Email: cobellis@tigem.it  
Sequence tag generated by 5' RACE of total RNA from gene trap ES  
cell line. ES cell lines harboring insertion mutation of target  
gene are available upon request from TIGEM. Annotation information  
available from TIGEM  
Class: Gene Trap.

FEATURES  
source  
1..13  
Location/Qualifiers  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="129 Ola"  
/db\_xref="taxon:10090"  
/clone="m4.E4.D08"  
/sex="male"  
/cell\_type="Embryonic stem cell"  
/cell\_line="E14"  
/clone\_lib="TIGEM gene trap library"  
/note="Vector: pRL1p1"

Query Match 0.7%; Score 11.4; DB 1; Length 13;  
Best Local Similarity 92.3%; Pred. No. 14;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1498 AACGAGGCCCGAG 1510  
DB 13 AACGAGGCCCGAG 1

RESULT 12  
CF278327/c 14 bp mRNA linear EST 14-AUG-2003  
LOCUS 14ETL--04-D06.b1 Rice etiolated leaf plasmid cDNA library (14ETL)  
DEFINITION Oryza sativa (Japonica cultivar-group) cDNA clone 14ETL--04-D06,  
mRNA sequence.  
CF278327  
CF278327.1 GI:33655713  
EST.  
ACCESSION Oryza sativa (Japonica cultivar-group)  
VERSION Oryza sativa (Japonica cultivar-group)  
KEYWORDS Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
Euphorbiaceae; Oryzae; Oryza.  
SOURCE Oryza sativa (Japonica cultivar-group)  
ORGANISM Oryza sativa (Japonica cultivar-group)  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;  
Euphorbiaceae; Oryzae; Oryza.  
REFERENCE  
AUTHORS Kim J.S., Jun K.M., Cheong P.J., Kim M.J., Lee T.H., Shin Y.C.,  
Song S.I., Kim U.K., Kim Y.-K. and Nahm B.H.  
TITLE Large-scale Sequencing Analysis of Rice ESTs  
JOURNAL Unpublished (2003)  
COMMENT Contact: Nahm B.H.  
Genomics and Genetics Institute, GreenGene Biotech Inc., Division  
of Bioscience and Bioinformatics, Myongji University  
Yongin, Kyonggi, Korea  
Tel: 82 31 330 6193  
Fax: 82 31 321 6355  
Email: bhnam@gbio.com, bhnam@bio.myongji.ac.kr.

FEATURES  
source

## Location/Qualifiers

1. .14  
/organism="Oryza sativa (japonica cultivar-group)"  
/mol\_type="mRNA"  
/cultivar="Nackdong"  
/db\_xref="taxon:39947"  
/clone="14ETL--04-D06"  
/tissue\_type="leaf"  
/dev\_stage="14 days after germination"  
/lab\_host="E.coli DH108"  
/clone\_lib="Rice etiolated leaf plasmid cDNA library (14ETL)"  
/note="Vector: pCR4-TOPO, Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.7%; Score 11.4; DB 1; Length 14;  
Best Local Similarity 92.3%; Pred. No. 14;  
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 272 AGAAGCAGAG 284

Db 14 AGAAGCAGAG 2

## RESULT 13

CN752857/c

LOCUS APHL3JD-VII-F11 APHL3JD Acyrthosiphon pisum cDNA clone 12 bp mRNA linear EST 19-MAY-2004

DEFINITION APHL3JD-VII-F11 APHL3JD Acyrthosiphon pisum cDNA clone.

ACCESSION CN752857

VERSION CN752857.1 GI:47517854

KEYWORDS EST.

SOURCE Acyrthosiphon pisum (pea aphid)

ORGANISM Acyrthosiphon pisum (pea aphid)

Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes;

Aphidoidea; Aphididae; Macrosiphini; Acyrthosiphon.

1 (bases 1 to 12)

Hunter, W., Martinez-Torres, D., Rabhe, Y., Sabater-Munoz, B.,

Stern, D., Tagu, D. and Wincker, P.

An expressed sequence tags database for the pea aphid Acyrthosiphon

pisum

Unpublished (2004)

Contact: D. Tagu

INRA Rennes

UMR BIO3P, BP 35327, F-35653 Le Rheu Cedex France

Tel: +33.2.23.48.51.65

Fax: +33.2.23.48.51.50

Risk of contamination by bacterial sequences from obligatory

(Buchnera) or facultative endosymbionts.

PCR Primers

FORWARD: GCCGCATTAAGTGGTATAGCA

Plate: VII row: F column: 11.

Location/Qualifiers

1. .12

/organism="Acyrthosiphon pisum"

/mol\_type="mRNA"

/cultivar="yr2"

/db\_xref="taxon:7029"

/clone="APHL3JD-VII-F11"

/tissue\_type="head"

/dev\_stage="third instar nymph (I3)"

/lab\_host="TOP10"

/clone\_lib="APHL3JD"

/note="Vector: pDNR-LIB; Site 1: SfiI; Site 2: SfiI; Sample name: APHL3JD; Plant growth place: INRA-Rennes, UMR BIO3P, BP 35327, 35653 Le Rheu cedex, France; Soil conditions: peat; Sowing date: 18/01/2003; Harvesting date: 03/02/2003; Stress date: no stress; Description: aphids inoculated on one-week old *Vicia faba* germinations under non sterile conditions; experimental condition: long photoperiod (16-hr light/8-hr dark at 18 C)"

Query Match 0.7%; Score 11; DB 1; Length 12;  
Best Local Similarity 100.0%; Pred. No. 14;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 279 AAGAGAGAA 289

Db 11 AAGAGAGAA 1

## RESULT 14

CN752857

LOCUS APHL3JD-VII-F11 APHL3JD Acyrthosiphon pisum cDNA clone 12 bp mRNA linear EST 19-MAY-2004

DEFINITION APHL3JD-VII-F11 APHL3JD Acyrthosiphon pisum cDNA clone.

ACCESSION CN752857

VERSION CN752857.1 GI:47517854

KEYWORDS EST.

SOURCE Acyrthosiphon pisum (pea aphid)

ORGANISM Acyrthosiphon pisum (pea aphid)

Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;

Neoptera; Paraneoptera; Hemiptera; Sternorrhyncha; Aphidiformes;

Aphidoidea; Aphididae; Macrosiphini; Acyrthosiphon.

1 (bases 1 to 12)

Hunter, W., Martinez-Torres, D., Rabhe, Y., Sabater-Munoz, B.,

Stern, D., Tagu, D. and Wincker, P.

An expressed sequence tags database for the pea aphid Acyrthosiphon

pisum

Unpublished (2004)

Contact: D. Tagu

INRA Rennes

UMR BIO3P, BP 35327, F-35653 Le Rheu Cedex France

Tel: +33.2.23.48.51.65

Fax: +33.2.23.48.51.50

Risk of contamination by bacterial sequences from obligatory

(Buchnera) or facultative endosymbionts.

PCR Primers

FORWARD: GCCGCATTAAGTGGTATAGCA

Plate: VII row: F column: 11.

Location/Qualifiers

1. .12

/organism="Acyrthosiphon pisum"

/mol\_type="mRNA"

/cultivar="yr2"

/db\_xref="taxon:7029"

/clone="APHL3JD-VII-F11"

/tissue\_type="head"

/dev\_stage="third instar nymph (I3)"

/lab\_host="TOP10"

/clone\_lib="APHL3JD"

/note="Vector: pDNR-LIB; Site 1: SfiI; Site 2: SfiI; Sample name: APHL3JD; Plant growth place: INRA-Rennes, UMR BIO3P, BP 35327, 35653 Le Rheu cedex, France; Soil conditions: peat; Sowing date: 18/01/2003; Harvesting date: 03/02/2003; Stress date: no stress; Description: aphids inoculated on one-week old *Vicia faba* germinations under non sterile conditions; experimental condition: long photoperiod (16-hr light/8-hr dark at 18 C)"

Query Match 0.5%; Score 9; DB 1; Length 12;  
Best Local Similarity 100.0%; Pred. No. 17;  
Matches 9; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 698 CTCTCTCT 706

Db 3 CTCTCTCT 11

## RESULT 15

CW020522

LOCUS GCU792 TIGEM gene trap library Mus musculus cDNA clone m4.B4.D08, mRNA sequence.

DEFINITION GCU792 TIGEM gene trap library Mus musculus cDNA clone m4.B4.D08, mRNA sequence.

ACCESSION CW020522 GI:52789782  
 VERSION CW020522.1  
 KEYWORDS GSS.  
 SOURCE Mus musculus (house mouse)  
 ORGANISM Mus musculus  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 13)  
 Cobellis G., Nicolaus G., Marra, E., Barbaisi M., Sardiello, M., Di Giorgio, F.P., Iovino, N., Zollo, M., Ballibio, A. and Cortese, R.  
 Tagging genes with cassette-exchange sites  
 Unpublished (2004)  
 CONTACT: TIGEM  
 107  
 TIGEM  
 via P. Castellino, 111, 80131 NAPOLI, ITALY  
 Tel: +390816132205  
 Fax: +390815790919  
 Email: cobellis@tigem.it  
 Sequence tag generated by 5' RACE of total RNA from gene trap ES cell line. ES cell lines harboring insertion mutation of target gene are available upon request from TIGEM. Annotation information available from TIGEM  
 Class: Gene Trap.  
 Location/Qualifiers  
 1..13  
 /organism="Mus musculus"  
 /mol\_type="mRNA"  
 /strain="129 Ola"  
 /db\_xref="taxon:10090"  
 /clone="m4.E4.D08"  
 /sex="male"  
 /cell\_type="Embryonic stem cell"  
 /cell\_line="E14"  
 /clone\_lib="TIGEM gene trap library"  
 /note="Vector: pFLP1"

Query Match 0.5%; Score 8.2; DB 1; Length 13;  
 Best Local Similarity 76.9%; Pred. No. 18;  
 Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 443 CTCAGCCTGGTT 455  
 |||||  
 1 CTGGACCTGGTT 13

RESULT 16  
 CF278327 14 bp mRNA linear EST 14-AUG-2003  
 LOCUS 14FTL--04-D06.b1 Rice etiolated leaf plasmid cDNA library (14FTL)  
 DEFINITION Oryza sativa (japonica cultivar-group) cDNA clone 14FTL--04-D06, mRNA sequence.  
 ACCESSION CF278327  
 VERSION CF278327.1 GI:33655713  
 KEYWORDS EST.  
 SOURCE Oryza sativa (japonica cultivar-group)  
 ORGANISM Oryza sativa (japonica cultivar-group)  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Ehrhartoideae; Oryzaceae; Oryza.  
 1 (bases 1 to 14)  
 Kim, J.S., Jun, K.W., Cheong, P.J., Kim, M.J., Lee, T.H., Shin, Y.C., Song, S.I., Kim, J.K., Kim, Y.-K. and Nam, B.H.  
 Large-scale Sequencing Analysis of Rice ESTs  
 Unpublished (2003)  
 CONTACT: Nahm B.H.  
 Genomics and Genetics Institute, Greengene Biotech Inc., Division of Bioscience and Bioinformatics, Myongji University  
 Yongin, Kyeonggi, Korea  
 Tel: 82 31 330 6193  
 Fax: 82 31 321 6355  
 Email: bhnahm@gbio.com, bhnahm@bio.myongji.ac.kr.  
 Location/Qualifiers

FEATURES

source  
 1..14  
 /organism="Oryza sativa (japonica cultivar-group)"  
 /mol\_type="mRNA"  
 /cultivar="Nackdong"  
 /db\_xref="taxon:39947"  
 /clone="14FTL--04-D06"  
 /issue\_type="leaf"  
 /dev\_stage="14 days after germination"  
 /lab\_host="E.coli DH10B"  
 /clone\_lib="Rice etiolated leaf plasmid cDNA library (14FTL)"  
 /note="Vector: pCR4-TOPO; Site 1: EcoRI; mRNA was capped with oligoribonucleotides and then used as templates for RT-PCR."

Query Match 0.5%; Score 8.2; DB 1; Length 14;  
 Best Local Similarity 76.9%; Pred. No. 18;  
 Matches 10; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 697 ACTTCTTCTTCC 709  
 |||||  
 1 ACTTCTTCTTCC 13

Search completed: September 13, 2005, 10:53:12  
 Job time : 0.001 secs

***This Page Blank (uspto)***

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

## OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 15:23:21 ; Search time 128 Seconds  
(without alignments)  
268.452 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21  
Sequence: 1 cagcagcagagcttcacatc 21

Scoring table: IDENTITY\_NUC  
Gapop 10.0, Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 1209694

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

## Database :

Issued Patents NA: \*  
1: /cgn2\_6/ptodata/1/ina/5A\_COMB.seq: \*  
2: /cgn2\_6/ptodata/1/ina/5B\_COMB.seq: \*  
3: /cgn2\_6/ptodata/1/ina/6A\_COMB.seq: \*  
4: /cgn2\_6/ptodata/1/ina/6B\_COMB.seq: \*  
5: /cgn2\_6/ptodata/1/ina/PCCTS\_COMB.seq: \*  
6: /cgn2\_6/ptodata/1/ina/backfiles1.seq: \*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

## SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	17.8	84.8	50	US-09-485-632B-15	Sequence 15, Appl
2	16.2	77.1	32	US-09-410-935B-6	Sequence 6, Appl
3	16.2	77.1	32	US-09-784-403A-6	Sequence 6, Appl
4	16	76.2	25	US-09-396-196G-7759	Sequence 7759, Ap
5	15.4	73.3	45	US-07-885-688A-7	Sequence 7, Appl
6	15.2	72.4	22	US-09-823-549-46	Sequence 46, Appl
7	14.8	70.5	20	US-10-007-010-43	Sequence 43, Appl
8	14.8	70.5	31	US-08-467-603-35	Sequence 35, Appl
9	14.8	70.5	31	US-08-466-793-35	Sequence 35, Appl
10	14.8	70.5	31	US-08-491-861A-35	Sequence 35, Appl
11	14.8	70.5	31	US-09-374-671A-35	Sequence 35, Appl
12	14.6	69.5	25	US-09-396-196G-10991	Sequence 10991, A
13	14.6	69.5	25	US-09-396-196G-74836	Sequence 74836, A
14	14.6	69.5	44	US-09-110-959A-11	Sequence 11, Appl
15	14.2	67.6	20	US-09-205-860-3	Sequence 163, App
16	14.2	67.6	20	US-09-657-452A-163	Sequence 57, Appl
17	14.2	67.6	24	US-09-360-545-57	Sequence 57, Appl
18	14.2	67.6	25	US-09-396-196G-103491	Sequence 103491,
19	14.2	67.6	30	US-09-130-663-10	Sequence 10, Appl
20	14.2	67.6	30	US-09-432-335-10	Sequence 10, Appl
21	14.2	67.6	30	US-09-254-023B-20	Sequence 20, Appl
22	14.2	67.6	30	US-09-614-023-10	Sequence 10, Appl
23	14.2	67.6	47	US-09-422-978-3015	Sequence 3015, Ap
24	13.8	65.7	18	US-09-256-496-15	Sequence 15, Appl
25	13.8	65.7	25	US-09-396-196G-35606	Sequence 35606, A
26	13.8	65.7	25	US-09-396-196G-44424	Sequence 44424, A
27	13.8	65.7	25	US-09-396-196G-44425	Sequence 44425, A

28	13.8	65.7	25	4	US-09-396-196G-44426	Sequence 44426, A
29	13.8	65.7	25	4	US-09-396-196G-44427	Sequence 44427, A
30	13.8	65.7	25	4	US-09-396-196G-108268	Sequence 108268,
31	13.8	65.7	28	4	US-09-887-145-35	Sequence 35, Appl
32	13.8	65.7	30	4	US-09-586-216C-19	Sequence 19, Appl
33	13.8	65.7	37	2	US-08-467-603-54	Sequence 54, Appl
34	13.8	65.7	37	2	US-08-466-793-54	Sequence 54, Appl
35	13.8	65.7	37	2	US-08-491-861A-54	Sequence 54, Appl
36	13.8	65.7	37	2	US-09-374-671A-54	Sequence 54, Appl
37	13.8	65.7	41	4	US-09-586-216C-4	Sequence 87, Appl
38	13.6	64.8	20	3	US-09-517-467B-87	Sequence 4550, Ap
39	13.6	64.8	20	4	US-09-196-452A-4550	Sequence 6, Appl
40	13.6	64.8	23	3	US-09-489-085A-6	Sequence 7746, Ap
41	13.6	64.8	25	4	US-09-396-196G-7746	Sequence 10990, A
42	13.6	64.8	25	4	US-09-396-196G-10990	Sequence 68315, A
43	13.6	64.8	25	4	US-09-396-196G-68315	Patent No. 5463174
44	13.6	64.8	27	6	5463174-1	Patent No. 5463174
45	13.6	64.8	27	6	5463174-1	

## ALIGNMENTS

RESULT 1  
US-09-485-632B-15/c  
Sequence 15, Application US/09485632B  
Patent No. 6605280  
GENERAL INFORMATION:  
APPLICANT: No. 6605280ick, Daniela  
APPLICANT: Dinarello, Charles  
APPLICANT: Rubinstein, Menachem  
APPLICANT: Kim, Soo Hyun  
TITLE OF INVENTION: Interleukin-18 Binding Proteins, their Preparation and  
TITLE OF INVENTION: Use  
FILE REFERENCE: 20993-001  
CURRENT APPLICATION NUMBER: US/09/485,632B  
CURRENT FILING DATE: 2000-10-12  
PRIOR APPLICATION NUMBER: IL98/00379  
PRIOR FILING DATE: 1998-08-13  
PRIOR APPLICATION NUMBER: 125463  
PRIOR FILING DATE: 1998-07-22  
PRIOR APPLICATION NUMBER: 122134  
PRIOR FILING DATE: 1997-11-06  
PRIOR APPLICATION NUMBER: 121869  
PRIOR FILING DATE: 1997-09-29  
PRIOR APPLICATION NUMBER: 121639  
PRIOR FILING DATE: 1997-08-27  
PRIOR APPLICATION NUMBER: 121554  
PRIOR FILING DATE: 1997-08-14  
NUMBER OF SEQ ID NOS: 15  
SOFTWARE: PatentIn Ver. 2.0  
SEQ ID NO 15  
LENGTH: 50  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Chemically synthesized  
US-09-485-632B-15  
Query Match 84.8%; Score 17.8; DB 4; Length 50;  
Best Local Similarity 90.5%; Pred. No. 80;  
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGCTTCATCAT 21  
DB 42 CAGCAGCAGAGCTTCATCAT 22  
RESULT 2  
US-09-410-935B-6  
Sequence 6, Application US/09410935B  
Patent No. 6504083  
GENERAL INFORMATION:

```

; APPLICANT: Barbour, Eric
; APPLICANT: Euclaire Meyer, Terry
; APPLICANT: Eid Saad, Mohammed
; TITLE OF INVENTION: No. 6504083e1 Maize Promoters
; FILE REFERENCE: 5718-72
; CURRENT APPLICATION NUMBER: US/09/410,935B
; CURRENT FILING DATE: 1999-10-04
; PRIOR APPLICATION NUMBER: US 60/107,201
; PRIOR FILING DATE: 1998-11-05
; PRIOR APPLICATION NUMBER: US 60/103,294
; PRIOR FILING DATE: 1998-10-06
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Gene specific primer 1 for Gos-2
US-09-410-935B-6
```

```

Query Match          77.1%; Score 16.2; DB 4; Length 32;
Best Local Similarity 85.7%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```

QY      1 CAGCAGCAGAGTCTTCATCAT 21
        |||||
Db      3 CAGCACCAGAGTCTCTCAGCAT 23
```

```

RESULT 3
US-09-784-403A-6
; Sequence 6, Application US/097844403A
; Patent No. 6670467
; GENERAL INFORMATION:
; APPLICANT: Barbour, Eric
; APPLICANT: Euclaire Meyer, Terry
; APPLICANT: Eid Saad, Mohammed
; TITLE OF INVENTION: No. 6670467e1 Maize Promoters
; FILE REFERENCE: 35718/208067
; CURRENT APPLICATION NUMBER: US/09/784,403A
; CURRENT FILING DATE: 2001-02-15
; PRIOR APPLICATION NUMBER: US 60/107,201
; PRIOR FILING DATE: 1998-11-05
; PRIOR APPLICATION NUMBER: US 60/103,294
; PRIOR FILING DATE: 1998-10-06
; PRIOR APPLICATION NUMBER: 09/410,935
; PRIOR FILING DATE: 1999-10-04
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Gene specific primer 1 for Gos-2
US-09-784-403A-6
```

```

Query Match          77.1%; Score 16.2; DB 4; Length 32;
Best Local Similarity 85.7%; Pred. No. 3.9e+02;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

```

QY      1 CAGCAGCAGAGTCTTCATCAT 21
        |||||
Db      3 CAGCACCAGAGTCTCTCAGCAT 23
```

```

RESULT 4
US-09-396-196G-7759/c
; Sequence 7759, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Miltmann
```

```

; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396,196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7759
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-7759

Query Match          76.2%; Score 16; DB 4; Length 25;
Best Local Similarity 100.0%; Pred. No. 4.6e+02;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```

QY      2 AGCAGCAGAGTCTTCA 17
        |||||
Db      16 AGCAGCAGAGTCTTCA 1
```

```

RESULT 5
US-07-885-689A-7
; Sequence 7, Application US/07885689A
; Patent No. 5366876
; GENERAL INFORMATION:
; APPLICANT: Cho, Joong M.
; APPLICANT: Lee, Tae H.
; APPLICANT: Chung, Hyun H.
; APPLICANT: Lee, Yong B.
; APPLICANT: Lee, Tae G.
; APPLICANT: Park, Young W.
; APPLICANT: Han, Kyu B.
; TITLE OF INVENTION: Method for Production of Bovine Growth
; TITLE OF INVENTION: Hormone Using a Synthetic Gene.
; NUMBER OF SEQUENCES: 38
; CORRESPONDENCE ADDRESS:
; ADDRESS: Birch, Stewart, Kolash & Birch
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/885,689A
; FILING DATE: 19-MAY-1992
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Svensson, Leonard R.
; REGISTRATION NUMBER: 30,350
; REFERENCE/DOCKET NUMBER: 377-144P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-241-1300
; TELEFAX: 703-241-2848
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 45 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHEICAL: NO
; FEATURE:
```



NAME/KEY: -  
LOCATION: 1.45  
OTHER INFORMATION: /label= oligonucleotide  
OTHER INFORMATION: /note= "U7 oligonucleotide portion of synthetic  
OTHER INFORMATION: BGH gene, Figure 1."  
US-07-885-689A-7

Query Match 73.3%; Score 15.4; DB 1; Length 45;  
Best Local Similarity 94.1%; Pred. No. 9.2e+02;  
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 4 CAGCAGAGTTCATCA 20  
DB 21 CAGCAGAGTTCACCA 37

## RESULT 6

US-09-823-549-46  
Sequence 46, Application US/09823549  
Patent No. 6664442  
GENERAL INFORMATION:  
APPLICANT: McConlogue, Lisa C  
APPLICANT: Games, Kate D.  
APPLICANT: Yednock, Theodore A.  
APPLICANT: Hua, Tan  
APPLICANT: Messersmith, Elizabeth  
APPLICANT: Baird, Frederique  
TITLE OF INVENTION: SCREENING MARKERS AND METHODS FOR NEURODEGENERATIVE DISORDERS  
FILE REFERENCE: 015270-009110US  
CURRENT APPLICATION NUMBER: US/09/823,549  
CURRENT FILING DATE: 2001-03-30  
PRIOR FILING DATE: 2000-03-30  
NUMBER OF SEQ ID NOS: 85  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 46  
LENGTH: 22  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: IL-12 p40, #1 forward primer  
US-09-823-549-46

Query Match 72.4%; Score 15.2; DB 4; Length 22;  
Best Local Similarity 85.0%; Pred. No. 1e+03;  
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 1 CAGCAGAGTTCATCA 20  
DB 2 CAGCAGAGTTCATCA 21

## RESULT 7

US-10-007-010-43  
Sequence 43, Application US/10007010  
Patent No. 6828151  
GENERAL INFORMATION:  
APPLICANT: Alexander H. Borchers  
APPLICANT: Kenneth W. Dobie  
TITLE OF INVENTION: ANTISENSE MODULATION OF HCK EXPRESSION  
FILE REFERENCE: RTS-0345  
CURRENT APPLICATION NUMBER: US/10/007,010  
CURRENT FILING DATE: 2001-12-04  
NUMBER OF SEQ ID NOS: 87  
SEQ ID NO 43  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Antisense Oligonucleotide  
US-10-007-010-43

Query Match 70.5%; Score 14.8; DB 4; Length 20;

Best Local Similarity 88.9%; Pred. No. 1.5e+03;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 3 GCACAGAGTTCATCA 20  
DB 1 GCTCAGAGTTCATCA 18

## RESULT 8

US-08-467-603-35/C  
Sequence 35, Application US/08467603  
Patent No. 5843672  
GENERAL INFORMATION:  
APPLICANT: Morgenstern, Jay P.  
APPLICANT: Kanieczny, Andriy  
APPLICANT: Bizindaukas, Christine B.  
APPLICANT: Brauer, Andrew W.  
TITLE OF INVENTION: Allergenic Proteins and  
TITLE OF INVENTION: Peptides from Dog  
TITLE OF INVENTION: Dander and Uses Therefor  
NUMBER OF SEQUENCES: 104  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: LATITE & COCKFIELD  
STREET: 60 State Street, suite 510  
CITY: Boston  
STATE: MA  
COUNTRY: USA  
ZIP: 02109  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: ASCII-text  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/467,603  
FILING DATE:  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/156,549  
FILING DATE:  
APPLICATION NUMBER: 07/999,712  
FILING DATE: 31-Dec-92  
ATTORNEY/AGENT INFORMATION:  
NAME: Mandragoras, Amy E.  
REGISTRATION NUMBER: 36,207  
REFERENCE/DOCKET NUMBER: IMI-026CP (IPC-048CP)  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: (617) 227-7400  
TELEFAX: (617) 227-5941  
INFORMATION FOR SEQ ID NO: 35:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 31 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-467-603-35

Query Match 70.5%; Score 14.8; DB 2; Length 31;  
Best Local Similarity 88.9%; Pred. No. 1.6e+03;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 2 AGCAGAGGTTTCATC 19  
DB 24 AGCAGAGGTTTCATC 7

## RESULT 9

US-08-466-793-35/C  
Sequence 35, Application US/08466793  
Patent No. 5891716  
GENERAL INFORMATION:  
APPLICANT: Morgenstern, Jay P.

```

; APPLICANT: Kanieczny, Andrzej
; APPLICANT: Bizindaukas, Christine B.
; APPLICANT: Brauer, Andrew W.
; TITLE OF INVENTION: Allergenic Proteins and
; TITLE OF INVENTION: Peptides from Dog
; TITLE OF INVENTION: Dander and Uses Therefor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, suite 510
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII-text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,793
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/156,549
; FILING DATE: 22-NOV-1993
; APPLICATION NUMBER: 07/999,712
; FILING DATE: 31-Dec-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Mandragouras, Amy E.
; REGISTRATION NUMBER: 36,207
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 227-5941
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-466-793-35

Query Match 70.5%; Score 14.8; DB 2; Length 31;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 AGAGCAGAGCTCTTCATC 19
Db 24 AGAGCAGAGGCTCTTCATC 7

RESULT 10
; US-08-491-861A-35/c
; Sequence 35, Application US/08491861A
; Patent No. 5939283
; GENERAL INFORMATION:
; APPLICANT: Morgenstern, Jay P.
; APPLICANT: Kanieczny, Andrzej
; APPLICANT: Bizindaukas, Christine B.
; APPLICANT: Brauer, Andrew W.
; TITLE OF INVENTION: Allergenic Proteins and Peptides from Dog
; TITLE OF INVENTION: Dander and Uses Therefor
; NUMBER OF SEQUENCES: 104
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD, LLP
; STREET: 28 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:

```

```

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII-text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/491,861A
; FILING DATE: 27-OCT-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/999,712
; FILING DATE: 31-Dec-92
; ATTORNEY/AGENT INFORMATION:
; NAME: Mandragouras, Amy E.
; REGISTRATION NUMBER: 36,207
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (617) 227-7400
; TELEFAX: (617) 742-4214
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 31 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-491-861A-35

Query Match 70.5%; Score 14.8; DB 2; Length 31;
Best Local Similarity 88.9%; Pred. No. 1.6e+03;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 AGAGCAGAGCTCTTCATC 19
Db 24 AGAGCAGAGGCTCTTCATC 7

RESULT 11
; US-09-374-671A-35/c
; Sequence 35, Application US/09374671A
; Patent No. 6489118
; GENERAL INFORMATION:
; APPLICANT: Morgenstern, Jay P.
; APPLICANT: Kanieczny, Andrzej
; APPLICANT: Bizindaukas, Christine B.
; APPLICANT: Brauer, Andrew W.
; TITLE OF INVENTION: Allergenic Protein and Peptides from Dog
; TITLE OF INVENTION: Dander and Uses Therefor
; NUMBER OF SEQUENCES: 109
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Amy E. Mandragouras
; STREET: 28 State Street
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII Text
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/374,671A
; FILING DATE: 16-Aug-1999
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/156,549
; FILING DATE: 1993-NOV-22
; APPLICATION NUMBER: US 07/999,712
; FILING DATE: 1992-DEC-31
; ATTORNEY/AGENT INFORMATION:
; NAME: DiGiorgio, Jeanne M.
; REGISTRATION NUMBER: 41,710
; REFERENCE/DOCKET NUMBER: IMI-026C2CNCPPA
; TELECOMMUNICATION INFORMATION:

```

TELEPHONE: (617) 227-7400  
TELEFAX: (617) 742-4214  
INFORMATION FOR SEQ ID NO: 35:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 31 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
SEQUENCE DESCRIPTION: SEQ ID NO: 35:  
US-09-374-671A-35

Query Match 70.5%; Score 14.8; DB 4; Length 31;  
Best Local Similarity 88.9%; Pred. No. 1.6e+03;  
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGCTCTTCATC 19  
DB 24 AGCAGCAGAGCTCTTCATC 7

RESULT 12  
US-09-396-196G-10991  
Sequence 10991, Application US/09396196G  
Patent No. 6821724  
GENERAL INFORMATION:  
APPLICANT: Michael Miltmann  
APPLICANT: David Mack  
APPLICANT: David Lockhart  
APPLICANT: Affymetrix, Inc.  
TITLE OF INVENTION: Methods of Genetic Analysis  
FILE REFERENCE: 3101.1  
CURRENT APPLICATION NUMBER: US/09/396,196G  
CURRENT FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: 60/100,678  
PRIOR FILING DATE: 1998-09-17  
NUMBER OF SEQ ID NOS: 127806  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 10991  
LENGTH: 25  
TYPE: DNA  
ORGANISM: Mus musculus  
US-09-396-196G-10991

Query Match 69.5%; Score 14.6; DB 4; Length 25;  
Best Local Similarity 81.0%; Pred. No. 1.9e+03;  
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGCTCTTCATC 21  
DB 3 CAGCAGCAGAGCTCTTCATC 23

RESULT 13  
US-09-396-196G-74836  
Sequence 74836, Application US/09396196G  
Patent No. 6821724  
GENERAL INFORMATION:  
APPLICANT: Michael Miltmann  
APPLICANT: David Mack  
APPLICANT: David Lockhart  
APPLICANT: Affymetrix, Inc.  
TITLE OF INVENTION: Methods of Genetic Analysis  
FILE REFERENCE: 3101.1  
CURRENT APPLICATION NUMBER: US/09/396,196G  
CURRENT FILING DATE: 1999-09-15  
PRIOR APPLICATION NUMBER: 60/100,678  
PRIOR FILING DATE: 1998-09-17  
NUMBER OF SEQ ID NOS: 127806  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 74836  
LENGTH: 25  
TYPE: DNA

ORGANISM: mus musculus  
US-09-396-196G-74836

Query Match 69.5%; Score 14.6; DB 4; Length 25;  
Best Local Similarity 81.0%; Pred. No. 1.9e+03;  
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGCTCTTCATC 21  
DB 4 CAGCAGCAGAGCTCTTCATC 24

RESULT 14  
US-09-110-959A-11  
Sequence 11, Application US/09110959A  
Patent No. 6268197  
GENERAL INFORMATION:  
APPLICANT: Schuelin, Martin  
APPLICANT: Outtrup, Helle  
APPLICANT: Jorgensen, Per Lina  
APPLICANT: Bjornvad, Made Bakelund  
TITLE OF INVENTION: Alkaline Xyloglucanase  
FILE REFERENCE: 5206.200-US  
CURRENT APPLICATION NUMBER: US/09/110,959A  
CURRENT FILING DATE: 1998-07-07  
PRIOR APPLICATION NUMBER: 0822/97  
PRIOR FILING DATE: 1997-07-07  
PRIOR APPLICATION NUMBER: 1213/97  
PRIOR FILING DATE: 1997-10-24  
PRIOR APPLICATION NUMBER: 60/054,039  
PRIOR FILING DATE: 1997-07-28  
PRIOR APPLICATION NUMBER: 60/063,694  
PRIOR FILING DATE: 1997-10-28  
NUMBER OF SEQ ID NOS: 14  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 11  
LENGTH: 44  
TYPE: DNA  
ORGANISM: Bacillus sp.  
US-09-110-959A-11

Query Match 69.5%; Score 14.6; DB 3; Length 44;  
Best Local Similarity 81.0%; Pred. No. 2.1e+03;  
Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGCTCTTCATC 21  
DB 12 CAGCAGCGCGCGCTTCATC 32

RESULT 15  
US-09-205-860-3  
Sequence 3, Application US/09205860  
Patent No. 5981732  
GENERAL INFORMATION:  
APPLICANT: Lex M. Cowseert  
TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION  
FILE REFERENCE: RTS-0031  
CURRENT APPLICATION NUMBER: US/09/205,860  
CURRENT FILING DATE: 1998-12-04  
NUMBER OF SEQ ID NOS: 87  
SEQ ID NO 3  
LENGTH: 20  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: PCR Primer  
US-09-205-860-3

Query Match 67.6%; Score 14.2; DB 2; Length 20;  
Best Local Similarity 84.2%; Pred. No. 2.8e+03;  
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTCATC 19  
Db 2 CAGCAGCAGAGTCTTCACC 20

Search completed: September 3, 2005, 16:22:35  
Job time : 131 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using bw model

Run on: September 3, 2005, 15:24:25 ; Search time 603 Seconds  
(without alignments)  
228.072 Million cell updates/sec

Title: US-10-828-394-5  
Perfect score: 21  
Sequence: 1 cagcagcagcagcttcacat 21

Scoring table: IDENTITY\_NUC  
Gapop 10.0, Gapext 1.0

Searched: 7338684 seqs, 3274456166 residues  
Total number of hits satisfying chosen parameters: 8349320

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Listing first 45 summaries

Database :

Published Applications NA:\*

- 1: /cgn2\_6/ptodata/1/pubpna/US07\_PUBCOMB.seq:\*
- 2: /cgn2\_6/ptodata/1/pubpna/PCT\_NEW\_PUB.seq:\*
- 3: /cgn2\_6/ptodata/1/pubpna/US06\_NEW\_PUB.seq:\*
- 4: /cgn2\_6/ptodata/1/pubpna/US07\_NEW\_PUB.seq:\*
- 5: /cgn2\_6/ptodata/1/pubpna/PCTUS\_PUBCOMB.seq:\*
- 6: /cgn2\_6/ptodata/1/pubpna/US08\_NEW\_PUB.seq:\*
- 7: /cgn2\_6/ptodata/1/pubpna/US08\_PUBCOMB.seq:\*
- 8: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*
- 9: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*
- 10: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*
- 11: /cgn2\_6/ptodata/1/pubpna/US09\_PUBCOMB.seq:\*
- 12: /cgn2\_6/ptodata/1/pubpna/US09\_NEW\_PUB.seq:\*
- 13: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 14: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 15: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 16: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 17: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 18: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 19: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 20: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 21: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 22: /cgn2\_6/ptodata/1/pubpna/US10\_PUBCOMB.seq:\*
- 23: /cgn2\_6/ptodata/1/pubpna/US11\_NEW\_PUB.seq:\*
- 24: /cgn2\_6/ptodata/1/pubpna/US11\_NEW\_PUB.seq:\*
- 25: /cgn2\_6/ptodata/1/pubpna/US60\_NEW\_PUB.seq:\*
- 26: /cgn2\_6/ptodata/1/pubpna/US60\_PUBCOMB.seq:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	21	100.0	21	9 US-09-944-326-4	Sequence 4, Appli
2	21	100.0	21	10 US-09-967-726A-4	Sequence 4, Appli
3	21	100.0	21	16 US-10-080-794-4	Sequence 4, Appli
4	21	100.0	21	18 US-10-646-391A-4	Sequence 4, Appli
5	21	100.0	21	20 US-10-828-394-5	Sequence 5, Appli
6	21	100.0	21	20 US-10-828-395-5	Sequence 5, Appli
7	21	100.0	23	18 US-10-646-436-66	Sequence 66, Appli

C	8	20	95.2	21	18	US-10-646-391A-28	Sequence 28, Appli
C	9	20	95.2	21	18	US-10-646-436-9	Sequence 9, Appli
C	10	20	95.2	25	21	US-10-956-157-236817	Sequence 236817, Appli
C	11	19	90.5	19	18	US-10-646-391A-42	Sequence 42, Appli
C	12	19	90.5	19	18	US-10-646-391A-43	Sequence 43, Appli
C	13	19	90.5	19	18	US-10-646-436-67	Sequence 67, Appli
C	14	19	90.5	19	18	US-10-646-436-68	Sequence 68, Appli
C	15	19	90.5	21	18	US-10-646-391A-29	Sequence 29, Appli
C	16	19	90.5	21	18	US-10-646-436-10	Sequence 10, Appli
C	17	17.8	84.8	21	10	US-09-967-726A-15	Sequence 15, Appli
C	18	17.8	84.8	21	16	US-10-080-794-15	Sequence 16, Appli
C	19	17.8	84.8	50	11	US-09-790-338A-17	Sequence 17, Appli
C	20	17.8	84.8	50	18	US-10-434-583-15	Sequence 15, Appli
C	21	17	81.0	25	21	US-10-956-157-285427	Sequence 285427, Appli
C	22	16.4	78.1	25	22	US-10-719-956-187913	Sequence 187913, Appli
C	23	16.4	78.1	25	22	US-10-719-956-217934	Sequence 217934, Appli
C	24	16.2	77.1	25	21	US-10-956-157-174230	Sequence 174230, Appli
C	25	16.2	77.1	32	14	US-10-278-355-6	Sequence 6, Appli
C	26	16.2	77.1	32	18	US-10-690-034-6	Sequence 6, Appli
C	27	16	76.2	25	21	US-10-809-189-7759	Sequence 7759, Appli
C	28	15.8	75.2	25	22	US-10-719-956-190997	Sequence 190997, Appli
C	29	15.8	75.2	25	22	US-10-719-956-190998	Sequence 190998, Appli
C	30	15.4	73.3	25	22	US-10-719-956-539340	Sequence 539340, Appli
C	31	15.4	73.3	25	22	US-10-719-956-562252	Sequence 562252, Appli
C	32	15.4	73.3	25	22	US-10-719-956-599108	Sequence 599108, Appli
C	33	15.4	73.3	25	22	US-10-719-956-678358	Sequence 678358, Appli
C	34	15.2	72.4	22	9	US-09-823-549-46	Sequence 46, Appli
C	35	15.2	72.4	22	20	US-10-685-992-46	Sequence 46, Appli
C	36	15.2	72.4	25	21	US-10-719-900-79840	Sequence 79840, Appli
C	37	15.2	72.4	25	21	US-10-719-900-99916	Sequence 99916, Appli
C	38	15.2	72.4	25	21	US-10-719-900-516755	Sequence 516755, Appli
C	39	15.2	72.4	25	21	US-10-719-900-859600	Sequence 859600, Appli
C	40	15.2	72.4	25	22	US-10-719-956-74777	Sequence 74777, Appli
C	41	15.2	72.4	25	22	US-10-719-956-483005	Sequence 483005, Appli
C	42	14.8	70.5	20	15	US-10-007-010-43	Sequence 43, Appli
C	43	14.8	70.5	21	9	US-09-944-326-2	Sequence 1, Appli
C	44	14.8	70.5	21	9	US-09-944-326-1	Sequence 2, Appli
C	45	14.8	70.5	21	10	US-09-967-726A-1	Sequence 1, Appli

## ALIGNMENTS

RESULT 1  
US-09-944-326-4  
Sequence 4, Application US/09944326  
Patent No. US20020128220A1  
GENERAL INFORMATION:  
APPLICANT: Gleave, Martin  
APPLICANT: Rennie, Paul S.  
APPLICANT: Miyake, Hideaki  
APPLICANT: Nelson, Colleen  
TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY  
FILE REFERENCE: UBC.P-020-2  
CURRENT APPLICATION NUMBER: US/09/944.326  
CURRENT FILING DATE: 2001-08-30  
PRIOR APPLICATION NUMBER: 60/121.726  
PRIOR FILING DATE: 1999-02-26  
PRIOR APPLICATION NUMBER: 09/913.325  
PRIOR FILING DATE: 2001-08-10  
NUMBER OF SEQ ID NOS: 14  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 4  
LENGTH: 21  
TYPE: DNA  
ORGANISM: HUMAN  
FEATURE:  
OTHER INFORMATION: antisense TRPM-2 ODN  
US-09-944-326-4  
Query Match 100.0%; Score 21; DB 9; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 2

US-09-967-726A-4  
; Sequence 4, Application US/09967726A  
; Publication No. US20030158130A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; APPLICANT: Zellweger, Tobias  
; TITLE OF INVENTION: Chemo- and Radiation-Sensitization of Cancer by Antisense TRPM-2  
; FILE REFERENCE: UBC.P-022  
; CURRENT APPLICATION NUMBER: US/09/967,726A  
; CURRENT FILING DATE: 2001-09-28  
; NUMBER OF SEQ ID NOS: 15  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 4  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-09-967-726A-4

Query Match 100.0%; Score 21; DB 10; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 3

US-10-080-794-4  
; Sequence 4, Application US/10080794  
; Publication No. US2003016591A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Rennie, Paul S.  
; APPLICANT: Miyake, Hideaki  
; APPLICANT: Nelson, Colleen  
; APPLICANT: Morita, Brett P.  
; TITLE OF INVENTION: TRPM-2 ANTISENSE THERAPY USING AN OLIGONUCLEOTIDE  
; FILE REFERENCE: UBC.P-020-3  
; CURRENT APPLICATION NUMBER: US/10/080,794  
; CURRENT FILING DATE: 2002-02-22  
; PRIOR APPLICATION NUMBER: 60/121,726  
; PRIOR FILING DATE: 1999-02-26  
; PRIOR APPLICATION NUMBER: 09/913,325  
; PRIOR FILING DATE: 2001-08-10  
; PRIOR APPLICATION NUMBER: 09/944,326  
; PRIOR FILING DATE: 2001-08-30  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: HUMAN  
; FEATURE:  
; OTHER INFORMATION: antisense TRPM-2 ODN  
US-10-080-794-4

Query Match 100.0%; Score 21; DB 16; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 4

US-10-646-391A-4  
; Sequence 4, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 4  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-646-391A-4

Query Match 100.0%; Score 21; DB 18; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 5

US-10-828-394-5  
; Sequence 5, Application US/10828394  
; Publication No. US20040220131A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; TITLE OF INVENTION: Method for Treatment of Cancerous Angiogenic Disorders  
; FILE REFERENCE: UBC.P-033  
; CURRENT APPLICATION NUMBER: US/10/828,394  
; CURRENT FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 5  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-394-5

Query Match 100.0%; Score 21; DB 20; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
|||  
Db 1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 6

US-10-828-395-5  
; Sequence 5, Application US/10828395  
; Publication No. US20040224914A1  
; GENERAL INFORMATION:  
; APPLICANT: Jackson, John  
; APPLICANT: Burt, Helen  
; APPLICANT: Springate, Christopher  
; APPLICANT: Gleave, Martin  
; TITLE OF INVENTION: Method for Treatment of Angiogenic Disorders  
; FILE REFERENCE: UBC.P-032  
; CURRENT APPLICATION NUMBER: US/10/828,395  
; PRIOR FILING DATE: 2004-04-19  
; PRIOR APPLICATION NUMBER: US 60/464,159  
; PRIOR FILING DATE: 2003-04-18  
; PRIOR APPLICATION NUMBER: US 60/464,160  
; NUMBER OF SEQ ID NOS: 23  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 5  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: human  
US-10-828-395-5

Query Match      100.0%; Score 21; DB 20; Length 21;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1 CAGCAGCAGAGTCTTCATCAT 21  
Db      1 CAGCAGCAGAGTCTTCATCAT 21

## RESULT 7

US-10-646-436-66/c  
; Sequence 66, Application US/10646436  
; Publication No. US20040096882A1  
; GENERAL INFORMATION:  
; APPLICANT: Jansen, Burkhard  
; APPLICANT: Gleave, Martin  
; APPLICANT: Signaevsky, Maxim  
; APPLICANT: Beraldi, Eliana  
; APPLICANT: Trougakos, Ioannis  
; APPLICANT: Gonos, Efsthios  
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins  
; FILE REFERENCE: UBC.P-030  
; CURRENT APPLICATION NUMBER: US/10/646,436  
; PRIOR FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 66  
; LENGTH: 23  
; TYPE: DNA  
; ORGANISM: human  
US-10-646-436-66

Query Match      100.0%; Score 21; DB 18; Length 23;  
Best Local Similarity 100.0%; Pred. No. 3.5;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      1 CAGCAGCAGAGTCTTCATCAT 21  
Db      23 CAGCAGCAGAGTCTTCATCAT 3

## RESULT 8

## US-10-646-391A-28/c

; Sequence 28, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; PRIOR FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 28  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-28

Query Match      95.2%; Score 20; DB 18; Length 21;  
Best Local Similarity 100.0%; Pred. No. 10;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      2 AGCAGCAGAGTCTTCATCAT 21  
Db      20 AGCAGCAGAGTCTTCATCAT 1

## RESULT 9

US-10-646-436-9/c  
; Sequence 9, Application US/10646436  
; Publication No. US20040096882A1  
; GENERAL INFORMATION:  
; APPLICANT: Jansen, Burkhard  
; APPLICANT: Gleave, Martin  
; APPLICANT: Signaevsky, Maxim  
; APPLICANT: Beraldi, Eliana  
; APPLICANT: Trougakos, Ioannis  
; APPLICANT: Gonos, Efsthios  
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins  
; FILE REFERENCE: UBC.P-030  
; CURRENT APPLICATION NUMBER: US/10/646,436  
; PRIOR FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 9  
; LENGTH: 21  
; TYPE: DNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-436-9

Query Match      95.2%; Score 20; DB 18; Length 21;  
Best Local Similarity 100.0%; Pred. No. 10;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY      2 AGCAGCAGAGTCTTCATCAT 21

Db 20 AGCAGCAGAGCTTCATCAT 1

RESULT 10  
US-10-956-157-236817/c  
; Sequence 236817, Application US/10956157  
; Publication No. US20050118625A1  
; GENERAL INFORMATION:  
; APPLICANT: Wyeth  
; APPLICANT: Mounts, William  
; TITLE OF INVENTION: NUCLEIC ACID ARRAYS FOR DETECTING GENE EXPRESSION ASSOCIATED WITH  
; FILE REFERENCE: HUMAN OSTEOARTHRITIS AND HUMAN PROTEASES  
; FILE REFERENCE: 031896-043000 (AM 101081)  
; PRIOR APPLICATION NUMBER: US/10/956,157  
; CURRENT FILING DATE: 2004-10-04  
; NUMBER OF SEQ ID NOS: 319805  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 236817  
; LENGTH: 25  
; TYPE: DNA  
; ORGANISM: Probe Sequence  
US-10-956-157-236817

Query Match 95.2%; Score 20; DB 21; Length 25;  
Best Local Similarity 100.0%; Pred. No. 11;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGCTTCATCAT 21  
Db 25 AGCAGCAGAGCTTCATCAT 6

RESULT 11  
US-10-646-391A-42/c  
; Sequence 42, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleeave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 42  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-42

Query Match 90.5%; Score 19; DB 18; Length 19;  
Best Local Similarity 100.0%; Pred. No. 31;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGCTTCATCAT 21  
Db 19 GCAGCAGAGCTTCATCAT 1

RESULT 12  
US-10-646-391A-43

; Sequence 43, Application US/10646391A  
; Publication No. US20040082534A1  
; GENERAL INFORMATION:  
; APPLICANT: Gleeave, Martin  
; APPLICANT: Jansen, Burkhard  
; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels  
; FILE REFERENCE: UBC.P-035  
; CURRENT APPLICATION NUMBER: US/10/646,391A  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/319,748  
; PRIOR FILING DATE: 2002-12-02  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 43  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 43  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-391A-43

Query Match 90.5%; Score 19; DB 18; Length 19;  
Best Local Similarity 73.7%; Pred. No. 31;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGCTTCATCAT 21  
Db 1 GCAGCAGAGCTTCATCAT 19

RESULT 13  
US-10-646-436-67/c  
; Sequence 67, Application US/10646436  
; Publication No. US20040096882A1  
; GENERAL INFORMATION:  
; APPLICANT: Jansen, Burkhard  
; APPLICANT: Gleeave, Martin  
; APPLICANT: Signaevsky, Maxim  
; APPLICANT: Beraldi, Eliana  
; APPLICANT: Trougakos, Ioannis  
; APPLICANT: Gonos, Efethaios  
; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins  
; FILE REFERENCE: UBC.P-030  
; CURRENT APPLICATION NUMBER: US/10/646,436  
; CURRENT FILING DATE: 2003-08-21  
; PRIOR APPLICATION NUMBER: US 60/405,193  
; PRIOR FILING DATE: 2002-08-21  
; PRIOR APPLICATION NUMBER: US 60/408,152  
; PRIOR FILING DATE: 2002-09-03  
; PRIOR APPLICATION NUMBER: US 60/473,387  
; PRIOR FILING DATE: 2003-05-20  
; NUMBER OF SEQ ID NOS: 68  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 67  
; LENGTH: 19  
; TYPE: RNA  
; ORGANISM: artificial  
; FEATURE:  
; OTHER INFORMATION: RNAi for human clusterin  
US-10-646-436-67

Query Match 90.5%; Score 19; DB 18; Length 19;  
Best Local Similarity 100.0%; Pred. No. 31;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGCTTCATCAT 21



DB 19 GCAGCAGAGTCTTCATCAT 1

RESULT 14

US-10-646-436-68

; Sequence 68, Application US/10646436

; Publication No. US20040096882A1

; GENERAL INFORMATION:

; APPLICANT: Jansen, Burkhard

; APPLICANT: Gleave, Martin

; APPLICANT: Signaevsky, Maxim

; APPLICANT: Beraldi, Eliana

; APPLICANT: Trougakos, Ioannis

; APPLICANT: Gonos, Efstrathios

; TITLE OF INVENTION: RNAi Probes Targeting Cancer-Related Proteins

; FILE REFERENCE: UBC.P-030

; CURRENT APPLICATION NUMBER: US/10/646,436

; PRIOR FILING DATE: 2003-08-21

; PRIOR APPLICATION NUMBER: US 60/405,193

; PRIOR FILING DATE: 2002-08-21

; PRIOR APPLICATION NUMBER: US 60/408,152

; PRIOR FILING DATE: 2002-09-03

; PRIOR APPLICATION NUMBER: US 60/473,387

; PRIOR FILING DATE: 2003-05-20

; NUMBER OF SEQ ID NOS: 68

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 68

; LENGTH: 19

; TYPE: RNA

; ORGANISM: artificial

; FEATURE:

; OTHER INFORMATION: RNAi for human clusterin

US-10-646-436-68

Query Match 90.5%; Score 19; DB 18; Length 19;

Best Local Similarity 73.7%; Pred. No. 31;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21

DB 1 GCAGCAGAGUCUCCAUCAU 19

RESULT 15

US-10-646-391A-29

; Sequence 29, Application US/10646391A

; Publication No. US20040082534A1

; GENERAL INFORMATION:

; APPLICANT: Gleave, Martin

; APPLICANT: Jansen, Burkhard

; TITLE OF INVENTION: Treatment of Melanoma by Reduction in Clusterin Levels

; FILE REFERENCE: UBC.P-035

; CURRENT APPLICATION NUMBER: US/10/646,391A

; PRIOR FILING DATE: 2003-08-21

; PRIOR APPLICATION NUMBER: US 60/405,193

; PRIOR FILING DATE: 2002-08-21

; PRIOR APPLICATION NUMBER: US 60/319,748

; PRIOR FILING DATE: 2002-12-02

; PRIOR APPLICATION NUMBER: US 60/408,152

; PRIOR FILING DATE: 2002-09-03

; PRIOR APPLICATION NUMBER: US 60/473,387

; PRIOR FILING DATE: 2003-05-20

; NUMBER OF SEQ ID NOS: 43

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 29

; LENGTH: 21

; TYPE: DNA

; ORGANISM: artificial

; FEATURE:

; OTHER INFORMATION: RNAi for human clusterin

US-10-646-391A-29

Query Match 90.5%; Score 19; DB 18; Length 21;

Best Local Similarity 73.7%; Pred. No. 31;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21

DB 1 GCAGCAGAGUCUCCAUCAU 19

Search completed: September 3, 2005, 16:32:54  
Job time : 609 secs

***This Page Blank (uspto)***

GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 14:43:21; Search time 1859 Seconds  
(without alignments)  
547.369 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21

Sequence: 1 cagcagcagagctctcatcat 21

Scoring table: IDENTITY NUC  
Gapop 10.0, Gapext 1.0

Searched: 4708233 seqs, 24227607955 residues  
Total number of hits satisfying chosen parameters: 1839042

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database :

GenEmbl:\*  
1: gb\_ba:\*  
2: gb\_hng:\*  
3: gb\_in:\*  
4: gb\_cm:\*  
5: gb\_ov:\*  
6: gb\_pac:\*  
7: gb\_ph:\*  
8: gb\_pl:\*  
9: gb\_pr:\*  
10: gb\_ro:\*  
11: gb\_srs:\*  
12: gb\_sy:\*  
13: gb\_un:\*  
14: gb\_vl:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	length	DB ID	Description
1	21	100.0	21	6	CQ786615 Sequence
2	21	100.0	23	6	CQ786178 Sequence
3	20	95.2	21	6	CQ786121 Sequence
4	20	95.2	21	6	CQ786639 Sequence
5	19	90.5	19	6	CQ786179 Sequence
6	19	90.5	19	6	CQ786180 Sequence
7	19	90.5	19	6	CQ786653 Sequence
8	19	90.5	19	6	CQ786654 Sequence
9	19	90.5	21	6	CQ786122 Sequence
10	19	90.5	21	6	CQ786640 Sequence
11	17.8	84.8	50	6	AR374192 Sequence
12	16.2	77.1	32	6	AR274120 Sequence
13	16.2	77.1	32	6	AR444937 Sequence
14	16.2	77.1	48	6	A76301 Sequence
15	16.2	77.1	48	6	E01067 DNA Sequence
16	15.4	73.3	39	6	A08489 B.taurus ge
17	15.4	73.3	39	6	A12568 fragment of
18	15.4	73.3	45	6	A05116 Oligonucleo
19	15.2	72.4	22	6	AR439728 Sequence

20	15.2	72.4	22	6	AX268965 Sequence
21	14.8	70.5	21	6	CQ786613 Sequence
22	14.8	70.5	27	6	AX118356 Sequence
23	14.8	70.5	31	6	AR070079 Sequence
24	14.8	70.5	31	6	AR258163 Sequence
25	14.8	70.5	31	6	AX670795 Sequence
26	14.6	69.5	48	6	A76303 Sequence
27	14.4	68.6	30	6	BD186389 Peptides
28	14.4	68.6	39	6	BD186389 Peptides
29	14.4	68.6	39	6	A08490 Oligonucleo
30	14.4	68.6	39	6	A08491 Oligonucleo
31	14.4	68.6	39	6	A12569 Fragment of
32	14.2	67.6	39	6	A12570 Fragment of
33	14.2	67.6	20	6	AR085567 Sequence
34	14.2	67.6	22	6	AR221110 Sequence
35	14.2	67.6	22	6	AX697095 Sequence
36	14.2	67.6	24	6	AR221229 Sequence
37	14.2	67.6	26	6	AX697096 Sequence
38	14.2	67.6	30	6	A70102 Sequence
39	14.2	67.6	30	6	AR148235 Sequence
40	14.2	67.6	30	6	AR204084 Sequence
41	14.2	67.6	30	6	BD077090 Lipocallin
42	14.2	67.6	38	6	CQ817644 Sequence
43	14.2	67.6	38	6	CQ817645 Sequence
44	14.2	67.6	38	6	CQ867639 Sequence
45	14.2	67.6	38	6	CQ867640 Sequence
			47	6	AR291280 Sequence

#### ALIGNMENTS

RESULT 1  
LOCUS CQ786615 21 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 4 from Patent WO2004018675.  
ACCESSION CQ786615  
VERSION CQ786615.1 GI:45721635  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE 1  
AUTHORS Jansen, B.  
TITLES Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 4 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source location/Qualifiers  
1..21  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

#### ORIGIN

Query Match 100.0%; Score 21; DB 6; Length 21;  
Best Local Similarity 100.0%; Pred. No. 49;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGCTTTCATCAT 21  
|||||  
1 CAGCAGCAGAGCTTTCATCAT 21

RESULT 2  
LOCUS CQ786178 23 bp DNA linear PAT 24-MAR-2004  
DEFINITION Sequence 66 from Patent WO2004018676.  
ACCESSION CQ786178  
VERSION CQ786178.1 GI:45721281  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

REFERENCE 1 Mammalia; Eutheria; Primates; Catarrhini; Homiidae; Homo.  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 66 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source 1..23  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
ORIGIN  
Query Match 100.0%; Score 21; DB 6; Length 23;  
Best Local Similarity 100.0%; Pred. No. 49;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGCTTTCATCAT 21  
23 CAGCAGCAGAGCTTTCATCAT 3  
Db 23 CAGCAGCAGAGCTTTCATCAT 3  
RESULT 3  
CQ786121/c 21 bp DNA linear PAT 24-MAR-2004  
LOCUS Sequence 9 from Patent WO2004018676.  
CQ786121  
CQ786121.1 GI:45721224  
VERSION  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 9 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source 1..21  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Rnai for human clusterin"  
ORIGIN  
Query Match 95.2%; Score 20; DB 6; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 2 AGCAGCAGAGCTTTCATCAT 21  
20 AGCAGCAGAGCTTTCATCAT 1  
Db 20 AGCAGCAGAGCTTTCATCAT 1  
RESULT 4  
CQ786639/c 21 bp DNA linear PAT 24-MAR-2004  
LOCUS Sequence 28 from Patent WO2004018675.  
CQ786639  
CQ786639.1 GI:45721659  
VERSION  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B.  
TITLE Treatment of melanoma by reduction in clusterin levels  
JOURNAL Patent: WO 2004018675-A 28 04-MAR-2004;  
The University of British Columbia (CA); Gleave, Martin E. (CA)  
FEATURES  
source 1..21  
location/Qualifiers

/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Rnai for human clusterin"  
ORIGIN  
Query Match 95.2%; Score 20; DB 6; Length 21;  
Best Local Similarity 100.0%; Pred. No. 1.5e+02;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 2 AGCAGCAGAGCTTTCATCAT 21  
20 AGCAGCAGAGCTTTCATCAT 1  
Db 20 AGCAGCAGAGCTTTCATCAT 1  
RESULT 5  
CQ786179/c 19 bp RNA linear PAT 24-MAR-2004  
LOCUS Sequence 67 from Patent WO2004018676.  
CQ786179  
CQ786179.1 GI:45721282  
VERSION  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 67 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source 1..19  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Rnai for human clusterin"  
ORIGIN  
Query Match 90.5%; Score 19; DB 6; Length 19;  
Best Local Similarity 100.0%; Pred. No. 4.5e+02;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 3 GCAGCAGAGCTTTCATCAT 21  
19 GCAGCAGAGCTTTCATCAT 1  
Db 19 GCAGCAGAGCTTTCATCAT 1  
RESULT 6  
CQ786180 19 bp RNA linear PAT 24-MAR-2004  
LOCUS Sequence 68 from Patent WO2004018676.  
CQ786180  
CQ786180.1 GI:45721283  
VERSION  
KEYWORDS  
SOURCE synthetic construct  
ORGANISM synthetic construct  
other sequences; artificial sequences.  
REFERENCE 1  
AUTHORS Jansen,B., Gleave,M.E., Signaevsky,M., Beraldi,E., Trougakos,I. and Gonos,E.  
TITLE Rnai probes targeting cancer-related proteins  
JOURNAL Patent: WO 2004018676-A 68 04-MAR-2004;  
The University of British Columbia (CA)  
FEATURES  
source 1..19  
/organism="synthetic construct"  
/mol\_type="unassigned RNA"  
/db\_xref="taxon:32630"  
/note="Rnai for human clusterin"  
ORIGIN  
Query Match 90.5%; Score 19; DB 6; Length 19;



Unclassified.  
1 (bases 1 to 50)  
REFERENCE Novick,D., Dinaarello,C., Rubinstein,M. and Kilm,S.H.  
AUTHORS Interleukin-18 binding proteins, their preparation and use for  
TITLE blocking the activity of IL-18  
JOURNAL Patent: US 6605280-A 15 12-AUG-2003;  
FEATURES Location/Qualifiers  
SOURCE 1..50  
/organism="unknown"  
/mol\_type="genomic DNA"

ORIGIN  
Query Match 84.8%; Score 17.8; DB 6; Length 50;  
Best Local Similarity 90.5%; Pred. No. 1.6e+03;  
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
Db 42 CAGCAGCAGAGTCTTCATCAT 22

RESULT 12  
AR274120 AR274120 32 bp DNA linear PAT 10-APR-2003  
LOCUS Sequence 6 from patent US 6504083.  
DEFINITION AR274120  
ACCESSION AR274120  
VERSION AR274120.1 GI:29706097  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 32)  
AUTHORS Barbour,E., Meyer,T.E.C. and Saad,M.E.  
TITLE Maize Gcs-2 promoters  
JOURNAL Patent: US 6504083-A 6 07-JAN-2003;  
FEATURES Location/Qualifiers  
SOURCE 1..32  
/organism="unknown"  
/mol\_type="genomic DNA"

ORIGIN  
Query Match 77.1%; Score 16.2; DB 6; Length 32;  
Best Local Similarity 85.7%; Pred. No. 9.6e+03;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
Db 3 CAGCAGCAGAGTCTTCATCAT 23

RESULT 13  
AR444937 AR444937 32 bp DNA linear PAT 20-FEB-2004  
LOCUS Sequence 6 from patent US 6670467.  
DEFINITION AR444937  
ACCESSION AR444937  
VERSION AR444937.1 GI:42672814  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE 1 (bases 1 to 32)  
AUTHORS Barbour,E., Meyer,T.E.C. and Saad,M.E.  
TITLE Maize promoters  
JOURNAL Patent: US 6670467-A 6 30-DEC-2003;  
FEATURES Location/Qualifiers  
SOURCE 1..32  
/organism="unknown"  
/mol\_type="genomic DNA"

ORIGIN  
Query Match 77.1%; Score 16.2; DB 6; Length 32;  
Best Local Similarity 85.7%; Pred. No. 9.6e+03;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
Db 3 CAGCAGCAGAGTCTTCATCAT 23

RESULT 14  
A76301 A76301/c 48 bp DNA linear PAT 19-OCT-1999  
LOCUS Sequence 7 from Patent WO9319173.  
DEFINITION A76301  
ACCESSION A76301  
VERSION A76301.1 GI:6088388  
KEYWORDS  
SOURCE unidentified  
ORGANISM unidentified  
REFERENCE 1 (bases 1 to 48)  
AUTHORS Maegerl,H.  
TITLE DNA CODING FOR APHRODISIN  
JOURNAL Patent: WO 9319173-A 7 30-SEP-1993;  
FEATURES FORSSMANN WOLFF GEORG (DE)  
SOURCE Location/Qualifiers  
1..48  
/organism="unidentified"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32644"  
1..>48  
/note="unnamed protein product"  
/codon\_start=1  
/protein\_id="CAB58600.1"  
/db\_xref="GI:6088389"  
/translation="MWKILALVFSIAHA"

ORIGIN  
Query Match 77.1%; Score 16.2; DB 6; Length 48;  
Best Local Similarity 85.7%; Pred. No. 9.3e+03;  
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21  
Db 21 CAGCAGCAGAGTCTTCATCAT 1

RESULT 15  
E01067/c 48 bp DNA linear PAT 29-SEP-1997  
LOCUS DNA sequence coding for human pancreas-2 signal peptide.  
DEFINITION E01067  
ACCESSION E01067  
VERSION E01067.1 GI:2169326  
KEYWORDS JP 1987000276-A/9.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
TITLE Mammalia; Euteleia; Primates; Catarrhini; Homnidae; Homo.  
AUTHORS Takiguchi,H., Furukawa,H. and Tani,T.  
JOURNAL PRODUCTION OF PANCREAS ELASTASE  
Patent: JP 1987000276-A 9 06-JAN-1987;  
SANKYO CO LTD NIPPON SODA CO LTD, NISSAN CHEM IND LTD, TOYO SODA  
MFG CO LTD  
OS homo sapiens (human)  
PN JP 1987000276-A/9  
PD 06-JAN-1987  
PI 25-JUN-1985 JP 1985138494  
PT TAKIGUCHI HIROSHI, FURUKAWA HIDEHIKO, TANI TOKIO PC  
C12N9/66,A61K35/74,A61K37/54,C12N15/00//C07H21/04,(C12N9/66, PC  
C12R1:19),  
PC (C12N15/00,C12R1:19);  
CC strandedness: Double;  
CC topology: Linear;  
CC hypothetical: No;  
CC anti-sense: No;  
CC \*source: tissue\_type=pancreas;

FH	Key	Location/Qualifiers
FH	sig_peptide	1..48
FT		/product='human pancreas elastase-2 signal
FT		peptide'.

FEATURES

source

1..48

/organism='Homo sapiens'

/mol\_type='genomic DNA'

/db\_xref='taxon:9606'

ORIGIN

Query Match 77.1%; Score 16.2; DB 6; Length 48;

Best Local Similarity 85.7%; Pred. No. 9.3e+03;

Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1 CAGCAGCAGAGTCTTCATCAT 21

|||||

DB 21 CAGCAGCAGAGGTCTTCATCAT 1

Search completed: September 3, 2005, 15:29:38

Job time : 1864 secs

**This Page Blank (uspto)**





XX SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 100.0%; Score 21; DB 3; Length 21;  
Best Local Similarity 100.0%; Pred. No. 8.2;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGTCTTCATCAT 21  
DB 1 CAGCAGCAGAGTCTTCATCAT 21  
RESULT 2  
ACF36398  
ID ACF36398 standard; DNA; 21 BP.  
AC ACF36398;  
XX ACF36398;  
DT 18-DEC-2003 (first entry)  
XX TRPM-2 antisense oligonucleotide.  
DE TRPM-2 antisense oligonucleotide.  
XX TRPM-2: testosterone-repressed prostate message-2; cytostatic; androgen;  
KM prostate cancer; anti-apoptotic protein; antisense; ss.  
XX Synthetic.  
OS Homo sapiens.  
XX WO2003072591-A1.  
XX PD 04-SEP-2003.  
XX PF 20-FEB-2003; 2003WO-US005305.  
XX PR 22-FEB-2002; 2002US-00080794.  
XX PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX PI Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP;  
DR WPI; 2003-689981/65.  
XX PT New modified antisense oligonucleotide, useful particularly for treating  
PT prostate cancer, inhibits the testosterone-repressed prostate message-2.  
XX PS Claim 1; Page 25; 44pp; English.  
XX CC The invention relates to a compound consisting of an oligonucleotide with  
CC a phosphorothioate backbone throughout in which: (a) sugars on  
CC nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the  
CC remaining residues 5-17 are 2'-deoxy; and (b) the cytosines at  
CC positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence  
CC ACF36398 (I) is used: (a) to delay progression of androgen-sensitive  
CC prostate cancer cells to the androgen-independent state, in vivo or in  
CC vitro; (b) to treat prostate cancer (after initially withdrawing  
CC androgens to induce apoptosis); and (c) to increase sensitivity of cancer  
CC cells (prostatic, renal, non-small cell lung, urothelial transitional,  
CC ovarian and some breast cancer cells) that express abnormal levels of  
CC TRPM-2 to chemotherapy or radiation. The modifications present in (I)  
CC increase stability in vivo and activity (both in vivo or in vitro) and  
CC result in a synergistic increase in effect when (I) is used with  
CC chemotherapeutic agents or other antisense oligonucleotides directed  
CC against other antiapoptotic genes. The present sequence represents a  
CC specific example of an anti-apoptotic protein TRPM-2 (testosterone-  
CC repressed prostate message-2) antisense oligonucleotide  
XX SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 100.0%; Score 21; DB 10; Length 21;  
Best Local Similarity 100.0%; Pred. No. 8.2;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGTCTTCATCAT 21

DB 1 CAGCAGCAGAGTCTTCATCAT 21  
RESULT 3  
ADM83069  
ID ADM83069 standard; DNA; 21 BP.  
XX ADM83069;  
XX 03-JUN-2004 (first entry)  
XX Human TRPM-2 antisense oligonucleotide #4.  
XX Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity;  
KM radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;  
KM lung cancer; renal cell carcinoma; RCC; antisense gene therapy; human;  
XX antisense; ss.  
XX Homo sapiens.  
OS Synthetic.  
XX Key Location/Qualifiers  
FT modified\_base 1..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "Phosphorothioate backbone"  
XX US2003158130-A1.  
XX PD 21-AUG-2003.  
XX PF 28-SEP-2001; 2001US-00967726.  
XX PR 25-FEB-2000; 2000WO-US004875.  
XX PR 28-SEP-2000; 2000US-0236301P.  
XX PR 10-AUG-2001; 2001US-00913325.  
XX PA (GLEA/) GLEAVE M.  
PA (RENN/) RENNIE P S.  
PA (MIYA/) MIYAKE H.  
PA (NELS/) NELSON C.  
XX (ZELL/) ZELLMESER T.  
XX Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;  
DR WPI; 2003-778017/73.  
XX PT Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells  
PT that expresses testosterone-repressed prostate message-2 (TRPM-2)  
PT comprises administering a composition that inhibits expression of TRPM-2.  
XX PS Claim 4; SEQ ID NO 4; 14pp; English.  
XX CC The present invention provides a method for treating cancer in which  
CC cancer cells express testosterone-repressed prostate message-2 (TRPM-2).  
CC The invention is useful for enhancing the chemo-sensitivity or radiation-  
CC sensitivity of cancer cells for treating cancer such as prostate cancer,  
CC bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma  
CC (RCC). The invention is also useful in antisense gene therapy. The  
CC present sequence is human testosterone-repressed prostate message-2 (TRPM  
CC -2) antisense oligodeoxyribonucleotide (ODN).  
XX SQ Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;  
Query Match 100.0%; Score 21; DB 11; Length 21;  
Best Local Similarity 100.0%; Pred. No. 8.2;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGTCTTCATCAT 21  
DB 1 CAGCAGCAGAGTCTTCATCAT 21

```
RESULT 4
ADL70406
ID ADL70406 standard; DNA; 21 BP.
XX
AC ADL70406;
XX
XX 20-MAY-2004 (first entry)
XX
XX Antisense oligonucleotide to human clusterin.
DE
XX Human; clusterin; antisense; melanoma; cytostatic; gene silencing; ss.
XX
OS Homo sapiens.
OS Synthetic.
FH
FH Key Location/Qualifiers
FT 1..21
FT /*tag= b
FT /mod_base= OTHER
FT /note= "OTHER= phosphorothioate nucleotides"
FT modified_base
FT 1..4
FT /*tag= a
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-methoxyethyl modifications"
FT modified_base
FT 18..21
FT /*tag= c
FT /mod_base= OTHER
FT /note= "OTHER= 2'-O-methoxyethyl modifications"
XX
XX WO2004018675-A1.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001276.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 02-DEC-2002; 2002US-0319748P.
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX (GLEA/) GLEAVE M E.
XX
XX Jansen B;
XX
XX WPI; 2004-226851/21.
XX
XX Treating melanoma in a mammalian subject comprises administering to the
XX subject a therapeutic agent effective to reduce the effective amount of
XX clusterin in the melanoma cells.
XX
XX Claim 7; SEQ ID NO 4; 32pp; English.
XX
XX The present sequence is that of an antisense oligonucleotide targeted to
XX human clusterin ADL70403. The invention relates to the treatment of
XX melanoma through reduction in the effective amount of clusterin. The
XX therapeutic agent may be an antisense oligonucleotide ADL70404-ADL70421
XX or short interfering RNA (siRNA) ADL70422-ADL70445 targeted to clusterin.
XX The antisense oligonucleotides are complementary to a region of the
XX clusterin mRNA spanning either the translation initiation site or the
XX termination site. They may be modified to increase stability in vivo,
XX e.g. they may be employed as phosphorothioate derivatives and may have 2'-
XX -O-(2-methoxyethyl) (MOE) modifications in the 5' and 3' 'wings'. The
XX present antisense oligonucleotide is particularly preferred. It is
XX targeted to the translation initiation codon and next 6 codons of the
XX human clusterin sequence. It has a phosphorothioate backbone throughout
XX and MOE wings, the remaining nucleotides being 2'-deoxynucleotides. In an
XX example from the invention, this antisense oligonucleotide provided a
XX dose-dependent down-regulation of clusterin in human melanoma cells,
XX leading to an increase in apoptotic cell death. In one melanoma cell line
XX (607B) this alone was sufficient to lead to complete cell death. In
XX another melanoma cell line, the surviving cells showed increased
```

```
CC sensitivity to subsequent treatment with cisplatin. A claimed method for
CC regulating expression of bcl-xl in a subject or cell line comprises
CC administering an agent effective to modulate the amount of clusterin
CC expression. In clusterin-expressing cells, expression of bcl-xl is down-
CC regulated when the effective amount of clusterin is reduced. Such
CC inhibition is significant because bcl-xl is known to act as an inhibitor
CC of apoptosis.
XX
XX Sequence 21 BP; 6 A; 6 C; 4 G; 5 T; 0 U; 0 Other;
SQ
XX
XX Query Match 100.0%; Score 21; DB 12; Length 21;
XX Best Local Similarity 100.0%; Pred. No. 8.2;
XX Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 CAGCAGCAGAGCTTCATCAT 21
XX Db 1 CAGCAGCAGAGCTTCATCAT 21
XX
XX RESULT 5
XX ADL70521/C
XX ID ADL70521 standard; CDNA; 23 BP.
XX
XX ADL70521;
XX
XX 20-MAY-2004 (first entry)
XX
XX Human clusterin target for RNAi.
XX
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;
XX cytostatic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;
XX ss.
XX
XX Homo sapiens.
XX Synthetic.
XX
XX WO2004018676-A2.
XX
XX 04-MAR-2004.
XX
XX 21-AUG-2003; 2003WO-CA001277.
XX
XX 21-AUG-2002; 2002US-0405193P.
XX 03-SEP-2002; 2002US-0408152P.
XX 20-MAY-2003; 2003US-0472387P.
XX
XX (UYBR-) UNIV BRITISH COLUMBIA.
XX
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trogakos IP;
XX Gonos ES;
XX
XX WPI; 2004-226852/21.
XX
XX New RNA molecule less than 49 bases and having a sequence effective to
XX mediate degradation or block translation of mRNA that is the
XX transcriptional product of a target gene, useful for treating Alzheimer's
XX disease or cancer.
XX
XX Example 6; SEQ ID NO 66; 63pp; English.
XX
XX The present sequence is a human clusterin cDNA target for a double-
XX stranded short interfering RNA (siRNA) of the invention ADL70522-
XX ADL70523. It was used in an example from the invention to demonstrate
XX clusterin gene silencing in PC-3 prostate cancer cells. Clusterin, also
XX known as testosterone-repressed prostate message-2 (TRPM-2) or sulfated
XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate
XX tumor cells following androgen withdrawal, and has also been shown to be
XX critical for neuritic toxicity in mouse models of Alzheimer's disease.
XX siRNAs of the invention can be used alone or in combination with other
XX chemotherapies or apoptosis inducing treatments for the treatment of
XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,
XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,
XX anaplastic large cell lymphoma and melanoma, and also for the treatment
```

CC of Alzheimer's disease.  
XX  
SQ Sequence 23 BP; 5 A; 5 C; 7 G; 6 T; 0 U; 0 Other;  
Query Match 100.0%; Score 21; DB 12; Length 23;  
Best Local Similarity 100.0%; Pred. No. 8.3;  
Matches 21; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 1 CAGCAGCAGAGTCTTCATCAT 21  
23 CAGCAGCAGAGTCTTCATCAT 3  
Db 23 CAGCAGCAGAGTCTTCATCAT 3  
RESULT 6  
ADL70464/C  
ID ADL70464 standard; RNA; 21 BP.  
XX  
AC ADL70464;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
KW cytosolic; neuroprotective; neurotropic; gene silencing; DNA-RNA hybrid;  
KW ss.  
XX Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dTdT"  
XX  
PN WO2004018676-A2.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001277.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
PI Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
PI Gonos ES;  
XX  
DR WPI; 2004-226852/21.  
XX  
XX  
PT New RNA molecule less than 49 bases and having a sequence effective to  
PT mediate degradation or block translation of mRNA that is the  
PT transcriptional product of a target gene, useful for treating Alzheimer's  
PT disease or cancer.  
XX  
PS Claim 4; SEQ ID NO 9; 63pp; English.  
XX  
XX The present sequence is the gene strand of a short interfering RNA  
XX (siRNA) targeted to human clusterin. The antisense strand is also  
XX provided ADL70465. The siRNA can be used to interfere with the expression  
XX of clusterin. Clusterin, also known as testosterone-repressed prostate  
XX message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
XX increased amounts by prostate tumour cells following androgen withdrawal,  
XX and has also been shown to be critical for neuritic toxicity in mouse  
XX models of Alzheimer's disease. siRNAs of the invention can be used alone  
XX or in combination with other chemotherapy or apoptosis inducing  
XX treatments for the treatment of prostate cancer, sarcomas such as  
XX osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
XX cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
XX melanoma, and also for the treatment of Alzheimer's disease.

XX  
SQ Sequence 21 BP; 5 A; 4 C; 5 G; 2 T; 5 U; 0 Other;  
Query Match 95.2%; Score 20; DB 12; Length 21;  
Best Local Similarity 100.0%; Pred. No. 23;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 2 AGCAGCAGAGTCTTCATCAT 21  
20 AGCAGCAGAGTCTTCATCAT 1  
Db 20 AGCAGCAGAGTCTTCATCAT 1  
RESULT 7  
ADL70430/C  
ID ADL70430 standard; RNA; 21 BP.  
XX  
AC ADL70430;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytosolic; gene silencing;  
KW short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
PN WO2004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001276.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
PI Jansen B;  
PI  
XX  
DR WPI; 2004-226851/21.  
XX  
XX  
PT Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
PS Claim 20; SEQ ID NO 28; 32pp; English.  
XX  
XX The present sequence is that of a short interfering RNA (siRNA) molecule  
XX targeted to human clusterin ADL70403. The invention relates to the  
XX treatment of melanoma through reduction in the effective amount of  
XX clusterin. The therapeutic agent may be an antisense oligonucleotide  
XX ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
XX targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
XX mRNA. A method for regulating expression of bcl-xl in a subject or cell  
XX line comprises administering an agent effective to modulate the amount of  
XX clusterin expression. In clusterin-expressing cells, expression of bcl-xl  
XX is down-regulated when the effective amount of clusterin is reduced. Such  
XX inhibition is significant because bcl-xl is known to act as an inhibitor  
XX of apoptosis.  
SQ Sequence 21 BP; 5 A; 4 C; 5 G; 2 T; 5 U; 0 Other;

Query Match 95.2%; Score 20; DB 12; Length 21;  
Best Local Similarity 100.0%; Pred. No. 23;  
Matches 20; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 2 AGCAGCAGAGTCTTCATCAT 21  
Db 20 AGCAGCAGAGTCTTCATCAT 1

## RESULT 8

ADL70522/C  
ID ADL70522 standard; RNA; 19 BP.

AC ADL70522;

DT 20-MAY-2004 (first entry)

DE RNAi for human clusterin.

XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;

KM cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;

XX ss.

OS Homo sapiens.

OS Synthetic.

FT key

FT modified\_base

FT 18.19

FT /tag= a

FT /mod\_base= OTHER

FT /note= "OTHER= dtdt"

XX WO2004018676-A2.

XX 04-MAR-2004.

XX 21-AUG-2003; 2003WO-CA001277.

XX 21-AUG-2002; 2002US-0405193P.

XX 03-SEP-2002; 2002US-0408152P.

XX 20-MAY-2003; 2003US-0472387P.

XX (UVR-) UNIV BRITISH COLUMBIA.

XX Jansen B, Gleave ME, Sigmevsky M, Beraldi E, Trogakos IP;

XX Gonos ES;

XX WPI: 2004-226852/21.

XX New RNA molecule less than 49 bases and having a sequence effective to

XX mediate degradation or block translation of mRNA that is the

XX transcriptional product of a target gene, useful for treating Alzheimer's

XX disease or cancer.

XX Claim 4; SEQ ID NO 67; 63pp; English.

XX The present sequence is the sense strand of a short interfering RNA

XX (siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.

XX The antisense strand is also provided ADL70523. The siRNA can be used to

XX interfere with the expression of clusterin. Clusterin, also known as

XX testosterone-repressed prostate message-2 (TRPM-2) or sulfated

XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate

XX tumor cells following androgen withdrawal, and has also been shown to be

XX critical for neuritic toxicity in mouse models of Alzheimer's disease.

XX siRNAs of the invention can be used alone or in combination with other

XX chemotherapy or apoptosis inducing treatments for the treatment of

XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,

XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,

XX anaplastic large cell lymphoma and melanoma, and also for the treatment

XX of Alzheimer's disease. In an example from the invention, the present

XX siRNA was used to examine the effects of clusterin gene silencing in PC-3

XX prostate cancer cells. A reduction in clusterin transcript was observed.

SQ Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 90.5%; Score 19; DB 12; Length 19;  
Best Local Similarity 100.0%; Pred. No. 64;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 GCAGCAGAGTCTTCATCAT 21  
Db 19 GCAGCAGAGTCTTCATCAT 1

## RESULT 9

ADL70523  
ID ADL70523 standard; RNA; 19 BP.

AC ADL70523;

DT 20-MAY-2004 (first entry)

DE RNAi for human clusterin.

XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;

KM cytosolic; neuroprotective; nontropic; gene silencing; DNA-RNA hybrid;

XX ss.

OS Homo sapiens.

OS Synthetic.

FT key

FT modified\_base

FT 18.19

FT /tag= a

FT /mod\_base= OTHER

FT /note= "OTHER= dtdt"

XX WO2004018676-A2.

XX 04-MAR-2004.

XX 21-AUG-2003; 2003WO-CA001277.

XX 21-AUG-2002; 2002US-0405193P.

XX 03-SEP-2002; 2002US-0408152P.

XX 20-MAY-2003; 2003US-0472387P.

XX (UVR-) UNIV BRITISH COLUMBIA.

XX Jansen B, Gleave ME, Sigmevsky M, Beraldi E, Trogakos IP;

XX Gonos ES;

XX WPI: 2004-226852/21.

XX New RNA molecule less than 49 bases and having a sequence effective to

XX mediate degradation or block translation of mRNA that is the

XX transcriptional product of a target gene, useful for treating Alzheimer's

XX disease or cancer.

XX Claim 4; SEQ ID NO 68; 63pp; English.

XX The present sequence is the antisense strand of a short interfering RNA

XX (siRNA) targeted to a specific portion ADL70521 of human clusterin cDNA.

XX The sense strand is also provided ADL70522. The siRNA can be used to

XX interfere with the expression of clusterin. Clusterin, also known as

XX testosterone-repressed prostate message-2 (TRPM-2) or sulfated

XX glycoprotein-2 (SGP-2), is expressed in increased amounts by prostate

XX tumor cells following androgen withdrawal, and has also been shown to be

XX critical for neuritic toxicity in mouse models of Alzheimer's disease.

XX siRNAs of the invention can be used alone or in combination with other

XX chemotherapy or apoptosis inducing treatments for the treatment of

XX prostate cancer, sarcomas such as osteosarcoma, renal cell carcinoma,

XX breast cancer, bladder cancer, lung cancer, colon cancer, ovarian cancer,

XX anaplastic large cell lymphoma and melanoma, and also for the treatment

XX of Alzheimer's disease. In an example from the invention, the present

XX siRNA was used to examine the effects of clusterin gene silencing in PC-3

CC prostate cancer cells. A reduction in clusterin transcript was observed.  
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;  
XX  
Query Match 90.5%; Score 19; DB 12; Length 19;  
Best Local Similarity 73.7%; Pred. No. 64;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;  
QY 3 GCAGCAGAGTCTTCATCAT 21  
1 GCAGCAGAGCUCUUCACU 19  
DB  
RESULT 10  
ADL70444/C  
ID ADL70444 standard; RNA; 19 BP.  
XX  
AC ADL70444;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KM short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
PN W02004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001276.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
PI Jansen B;  
XX  
DR WPI; 2004-226851/21.  
XX  
PT Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
PS Claim 20; SEQ ID NO 42; 32pp; English.  
XX  
CC The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xl in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xl  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xl is known to act as an inhibitor  
CC of apoptosis.  
SQ Sequence 19 BP; 5 A; 4 C; 5 G; 0 T; 5 U; 0 Other;

Query Match 90.5%; Score 19; DB 12; Length 19;  
Best Local Similarity 100.0%; Pred. No. 64;  
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
QY 3 GCAGCAGAGTCTTCATCAT 21  
19 GCAGCAGAGTCTTCATCAT 1  
DB  
RESULT 11  
ADL70445  
ID ADL70445 standard; RNA; 19 BP.  
XX  
AC ADL70445;  
XX  
DT 20-MAY-2004 (first entry)  
XX  
DE RNAi for human clusterin.  
XX  
KW Human; clusterin; RNAi; melanoma; cytostatic; gene silencing;  
KM short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
OS Homo sapiens.  
OS Synthetic.  
XX  
FH Key Location/Qualifiers  
FT modified\_base 18..19  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"  
XX  
PN W02004018675-A1.  
XX  
PD 04-MAR-2004.  
XX  
PF 21-AUG-2003; 2003WO-CA001276.  
XX  
PR 21-AUG-2002; 2002US-0405193P.  
PR 03-SEP-2002; 2002US-0408152P.  
PR 02-DEC-2002; 2002US-0319748P.  
PR 20-MAY-2003; 2003US-0472387P.  
XX  
PA (UYBR-) UNIV BRITISH COLUMBIA.  
PA (GLEA/) GLEAVE M E.  
XX  
PI Jansen B;  
XX  
DR WPI; 2004-226851/21.  
XX  
PT Treating melanoma in a mammalian subject comprises administering to the  
PT subject a therapeutic agent effective to reduce the effective amount of  
PT clusterin in the melanoma cells.  
XX  
PS Claim 20; SEQ ID NO 43; 32pp; English.  
XX  
CC The present sequence is that of a short interfering RNA (siRNA) molecule  
CC targeted to human clusterin ADL70403. The invention relates to the  
CC treatment of melanoma through reduction in the effective amount of  
CC clusterin. The therapeutic agent may be an antisense oligonucleotide  
CC ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
CC targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
CC mRNA. A method for regulating expression of bcl-xl in a subject or cell  
CC line comprises administering an agent effective to modulate the amount of  
CC clusterin expression. In clusterin-expressing cells, expression of bcl-xl  
CC is down-regulated when the effective amount of clusterin is reduced. Such  
CC inhibition is significant because bcl-xl is known to act as an inhibitor  
CC of apoptosis.  
SQ Sequence 19 BP; 5 A; 5 C; 4 G; 0 T; 5 U; 0 Other;  
XX  
Query Match 90.5%; Score 19; DB 12; Length 19;  
Best Local Similarity 73.7%; Pred. No. 64;

Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21  
| | | | | : : : : :  
Db 1 GCAGCAGAGTCTTCATCAT 19

RESULT 12  
ADL70465  
ID ADL70465 standard; RNA; 21 BP.  
XX  
XX ADL70465;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX RNAi for human clusterin.  
XX  
XX RNA interference; RNAi; short interfering RNA; siRNA; human; clusterin;  
XX cytosolic; neuroprotective; nootropic; gene silencing; DNA-RNA hybrid;  
XX ss.  
XX Homo sapiens.  
XX OS Synthetic.  
XX  
XX Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= dtgt"

XX  
XX WO2004018676-A2.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001277.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX  
XX Jansen B, Gleave ME, Signaevsky M, Beraldi E, Trougakos IP;  
XX Gonos ES;  
XX  
XX WPI; 2004-226852/21.  
XX  
XX New RNA molecule less than 49 bases and having a sequence effective to  
XX mediate degradation or block translation of mRNA that is the  
XX transcriptional product of a target gene, useful for treating Alzheimer's  
XX disease or cancer.  
XX  
XX Claim 4; SEQ ID NO 10; 63pp; English.

XX The present sequence is the antisense strand of a short interfering RNA  
XX (siRNA) targeted to human clusterin. The sense strand is also provided  
XX ADL70464. The siRNA can be used to interfere with the expression of  
XX clusterin. Clusterin, also known as testosterone-repressed prostate  
XX message-2 (TRPM-2) or sulfated glycoprotein-2 (SGP-2), is expressed in  
XX increased amounts by prostate tumour cells following androgen withdrawal,  
XX and has also been shown to be critical for neuritic toxicity in mouse  
XX models of Alzheimer's disease. siRNAs of the invention can be used alone  
XX or in combination with other chemotherapy or apoptosis inducing  
XX treatments for the treatment of prostate cancer, sarcomas such as  
XX osteosarcoma, renal cell carcinoma, breast cancer, bladder cancer, lung  
XX cancer, colon cancer, ovarian cancer, anaplastic large cell lymphoma and  
XX melanoma, and also for the treatment of Alzheimer's disease.

XX Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;

Query Match 90.5%; Score 19; DB 12; Length 21;  
Best Local Similarity 73.7%; Pred. No. 65;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21  
| | | | | : : : : :  
Db 1 GCAGCAGAGTCTTCATCAT 19

RESULT 13  
ADL70431  
ID ADL70431 standard; RNA; 21 BP.  
XX  
XX ADL70431;  
XX  
XX 20-MAY-2004 (first entry)  
XX  
XX RNAi for human clusterin.  
XX  
XX Human; clusterin; RNAi; melanoma; cytosolic; gene silencing;  
XX short interfering RNA; siRNA; DNA-RNA hybrid; ss.  
XX  
XX Homo sapiens.  
XX OS Synthetic.  
XX  
XX Key Location/Qualifiers  
FT modified\_base 20..21  
FT /\*tag= a  
FT /mod\_base= OTHER  
FT /note= "OTHER= TT"

XX  
XX WO2004018675-A1.  
XX  
XX 04-MAR-2004.  
XX  
XX 21-AUG-2003; 2003WO-CA001276.  
XX  
XX 21-AUG-2002; 2002US-0405193P.  
XX 03-SEP-2002; 2002US-0408152P.  
XX 02-DEC-2002; 2002US-0319748P.  
XX 20-MAY-2003; 2003US-0472387P.  
XX  
XX (UYBR-) UNIV BRITISH COLUMBIA.  
XX (GLEAVE/) GLEAVE M E.  
XX  
XX Jansen B;  
XX PI  
XX  
XX WPI; 2004-226851/21.  
XX  
XX Treating melanoma in a mammalian subject comprises administering to the  
XX subject a therapeutic agent effective to reduce the effective amount of  
XX clusterin in the melanoma cells.  
XX  
XX Claim 20; SEQ ID NO 29; 32pp; English.

XX The present sequence is that of a short interfering RNA (siRNA) molecule  
XX targeted to human clusterin ADL70403. The invention relates to the  
XX treatment of melanoma through reduction in the effective amount of  
XX clusterin. The therapeutic agent may be an antisense oligonucleotide  
XX ADL70404-ADL70421 or short interfering RNA (siRNA) ADL70422-ADL70445  
XX targeted to clusterin. The siRNAs molecules direct cleavage of clusterin  
XX mRNA. A method for regulating expression of bcl-xl in a subject or cell  
XX line comprises administering an agent effective to modulate the amount of  
XX clusterin expression. In clusterin-expressing cells, expression of bcl-xl  
XX is down-regulated when the effective amount of clusterin is reduced. Such  
XX inhibition is significant because bcl-xl is known to act as an inhibitor  
XX of apoptosis.

XX Sequence 21 BP; 5 A; 5 C; 4 G; 2 T; 5 U; 0 Other;

Query Match 90.5%; Score 19; DB 12; Length 21;  
Best Local Similarity 73.7%; Pred. No. 65;  
Matches 14; Conservative 5; Mismatches 0; Indels 0; Gaps 0;

QY 3 GCAGCAGAGTCTTCATCAT 21  
| | | | | : : : : :  
Db 1 GCAGCAGAGTCTTCATCAT 19

Db 1 GCAGCAGAGCUCUACAUCAU 19

RESULT 14

ACF36409 standard; DNA; 21 BP.

ACF36409;

18-DEC-2003 (first entry)

DNA sequence of a TRPM-2 mismatch control oligonucleotide.

TRPM-2; testosterone-repressed prostate message-2; cytosstatic; androgen; prostate cancer; anti-apoptotic protein; antisense; ss.

Synthetic.

WO2003072591-A1.

04-SEP-2003.

20-FEB-2003; 2003WO-US005305.

22-FEB-2002; 2002US-00080794.

(UYBR-) UNIV BRITISH COLUMBIA.

Gleave M, Rennie PS, Miyake H, Nelson C, Monia BP,

WPI; 2003-689981/65.

New modified antisense oligonucleotide, useful particularly for treating prostatic cancer, inhibits the testosterone-repressed prostate message-2.

Example 13; Page 20; 44pp; English.

The invention relates to a compound consisting of an oligonucleotide with a phosphorothioate backbone throughout, in which: (a) sugars on nucleotide residues 1-4 and 18-21 are 2'-O-methoxyethyl modified, and the remaining nucleotides 5-17 are 2'-deoxy; and (b) the cytosines at positions 1, 4 and 19 are 5-methylated. Oligonucleotide shown in sequence ACF36498 (1) is used: (a) to delay progression of androgen-sensitive prostatic cancer cells to the androgen-independent state, in vivo or in vitro; (b) to treat prostatic cancer (after initially withdrawing androgens to induce apoptosis); and (c) to increase sensitivity of cancer cells (prostatic, renal, non-small cell lung, urothelial transitional, ovarian and some breast cancer cells) that express abnormal levels of TRPM-2 to chemotherapy or radiation. The modifications present in (1) increase stability in vivo and activity (both in vivo or in vitro) and result in a synergistic increase in effect when (1) is used with chemotherapeutic agents or other antisense oligonucleotides directed against other antiapoptotic genes. The present sequence represents a mismatch control oligonucleotide, used in antisense assays of anti-apoptotic protein TRPM-2 (testosterone-repressed prostate message-2)

Sequence 21 BP; 7 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 84.8%; Score 17.8; DB 10; Length 21;

Best Local Similarity 90.5%; Pred. No. 2.3e+02; Mismatches 2; Indels 0; Gaps 0;

1 CAGCAGCAGAGTCTTCATCAT 21  
1 CAGCAGCAGAGTATTATCAT 21

RESULT 15

ADM83080 standard; DNA; 21 BP.

ADM83080;

DT 03-JUN-2004 (first entry)

Control TRPM-2 mismatch oligonucleotide.

Testosterone-repressed prostate message-2; TRPM-2; chemo-sensitivity; radiation-sensitivity; prostate cancer; bladder cancer; ovarian cancer;

lung cancer; renal cell carcinoma; RCC; antisense gene therapy; ss.

Unidentified.

US200158130-A1.

21-AUG-2003.

28-SEP-2001; 2001US-00967726.

25-FEB-2000; 2000MO-US004875.

28-SEP-2000; 2000US-0236301P.

10-AUG-2001; 2001US-00913325.

(GLEA/) GLEAVE M.

(RENN/) RENNIE P S.

(MIYA/) MIYAKE H.

(NELS/) NELSON C.

(ZELL/) ZELLMER T.

Gleave M, Rennie PS, Miyake H, Nelson C, Zellweger T;

WPI; 2003-778017/73.

Enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells that expresses testosterone-repressed prostate message-2 (TRPM-2)

comprises administering a composition that inhibits expression of TRPM-2.

Disclosure; SEQ ID NO 15; 14pp; English.

The present invention provides a method for treating cancer in which cancer cells express testosterone-repressed prostate message-2 (TRPM-2). The invention is useful for enhancing the chemo-sensitivity or radiation-sensitivity of cancer cells for treating cancer such as prostate cancer, bladder cancer, ovarian cancer, lung cancer and renal cell carcinoma (RCC). The invention is also useful in antisense gene therapy. The present sequence is control testosterone-repressed prostate message-2 (TRPM-2) mismatch oligonucleotide. The oligonucleotide is used in the exemplification of the invention.

Sequence 21 BP; 7 A; 4 C; 4 G; 6 T; 0 U; 0 Other;

Query Match 84.8%; Score 17.8; DB 11; Length 21;

Best Local Similarity 90.5%; Pred. No. 2.3e+02; Mismatches 2; Indels 0; Gaps 0;

1 CAGCAGCAGAGTCTTCATCAT 21  
1 CAGCAGCAGAGTATTATCAT 21

Search completed: September 3, 2005, 14:58:27  
Job time : 435 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: September 3, 2005, 14:58:36 ; Search time 3027 Seconds  
(without alignments)  
264.073 Million cell updates/sec

Title: US-10-828-394-5

Perfect score: 21

Sequence: 1 cagcagcagcagcttcacat 21

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 159776

Minimum DB seq length: 0  
Maximum DB seq length: 50

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 45 summaries

Database : EST:\*

1: gb\_esc1: \*  
2: gb\_esc2: \*  
3: gb\_esc3: \*  
4: gb\_esc4: \*  
5: gb\_esc5: \*  
6: gb\_esc6: \*  
7: gb\_esc7: \*  
8: gb\_esc8: \*  
9: gb\_esc9: \*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB	ID	Description
1	14.8	70.5	46	1	AA916352	AA916352 chr08e11.8
2	14.6	69.5	44	7	W25663	W25663 zc64e08.r1
3	14	66.7	50	8	BH861678	BH861678 SALK_0877
4	13.6	64.8	42	9	CC794149	CC794149 SALK_0439
5	13.4	63.8	50	9	CG869035	CG869035 AB0164.Sa
6	13	61.9	21	8	AZ802584	AZ802584 2M0061105
7	13	61.9	41	8	BH908888	BH908888 SALK_0510
8	13	61.9	43	1	AA973632	AA973632 cc048b04.s
9	13	61.0	48	9	AL948370	AL948370 Arabidops
10	12.8	61.0	50	1	AU107924	AU107924 AU107924
11	12.8	61.0	50	1	AU107925	AU107925 AU107925
12	12.8	61.0	50	1	AU107928	AU107928 AU107928
13	12.8	61.0	50	1	AU107929	AU107929 AU107929
14	12.6	60.0	39	9	AL760945	AL760945 Arabidops
15	12.6	60.0	43	1	A1766391	A1766391 wh61d04.x
16	12.6	60.0	46	1	AA561123	AA561123 v141c01.r
17	12.6	60.0	46	6	CB213634	CB213634 OM003914
18	12.6	60.0	47	9	CL212422	CL212422 G040E010.G
19	12.6	60.0	50	1	AU105963	AU105963 AU105963
20	12.6	60.0	50	1	AU105967	AU105967 AU105967
21	12.6	60.0	50	1	AU105968	AU105968 AU105968
22	12.6	60.0	50	1	AU105972	AU105972 AU105972
23	12.6	60.0	50	1	AA566984	AA566984 1038.Lob1
24	12.4	59.0	37	8	AZ797149	AZ797149 2M0053009

C 25	12.2	58.1	35	8	AZ332831	AZ332831 1M0061C05
C 26	12.2	58.1	36	9	AJ587667	AJ587667 Arabidops
C 27	12.2	58.1	43	8	AZ610505	AZ610505 1M0435N18
C 28	12.2	58.1	46	1	AA109083	AA109083 mp37b05.r
C 29	12.2	58.1	49	1	AA052336	AA052336 mb35b02.r
C 30	12.2	58.1	49	1	AA664073	AA664073 vx86f02.r
C 31	12.2	58.1	50	1	AU104442	AU104442 AU104442
C 32	12.2	58.1	50	1	CR155807	CR155807 Reverse 8
C 33	12.2	57.1	33	8	AZ305164	AZ305164 1M0005M08
C 34	12	57.1	33	8	AZ185999	AZ185999 1M0037N24
C 35	12	57.1	34	1	AA116347	AA116347 mq70g12.r
C 36	12	57.1	34	1	B1246596	B1246596 602958318
C 37	12	57.1	34	9	AG201385	AG201385 Pan. trogl
C 38	12	57.1	35	9	BX285461	BX285461 Arabidops
C 39	12	57.1	40	8	BH910804	BH910804 SALK_0626
C 40	12	57.1	40	9	CG774406	CG774406 1123018G0
C 41	12	57.1	41	8	BZ586362	BZ586362 3590.1.16
C 42	12	57.1	46	6	CA964065	CA964065 CGL02A07
C 43	12	57.1	46	7	H92446	H92446 Yc89B09.r1
C 44	12	57.1	46	7	T74174	T74174 Yc60B12.s1
C 45	12	57.1	47	8	AZ772648	AZ772648 1M0583N12

#### ALIGNMENTS

RESULT 1  
LOCUS AA916352 46 bp mRNA linear EST 14-APR-1998  
DEFINITION chr08e11.81 NCI\_CGAP\_C08 Homo sapiens CDNA clone IMAGE:1473356 3'  
similar to TR:Q15347 Q15347 RAGA. [1] ; mRNA sequence.  
AA916352  
AA916352.1 GI:3055744

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT  
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.  
National Cancer Institute, Cancer Genome Anatomy Project (CGAP),  
Tumor Gene Index  
Unpublished (1997)  
Contact: Robert Strausberg, Ph.D.  
Email: cga@bbs-remail.nih.gov

CDNA Library Preparation: M. Bento Soares, Ph.D.  
CDNA Library Arrayed by: Greg Lennon, Ph.D.  
CDNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be  
found through the I.M.A.G.E. Consortium/LLNL at:  
[www.bio.llnl.gov/dbirp/image/image.html](http://www.bio.llnl.gov/dbirp/image/image.html)

Trace considered overall poor quality  
Seq primer: -40m3 fwd. BT from Amersham  
High quality sequence stop: 1.  
Location/Qualifiers  
1..46  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:1473356"  
/tissue\_type="adenocarcinoma"  
/lab\_host="DH10B"  
/note="Organ: colon; Vector: pTT73D-Pac (Pharmacia) with a  
modified polylinker; 1st strand cDNA was prepared from  
colon adenocarcinoma, and was then primed with a Not I -  
oligo(dT) primer. Double-stranded cDNA was ligated to Eco  
RI adaptors (Pharmacia), digested with Not I and cloned  
into the Not I and Eco RI sites of the modified pTT73  
vector. Library is normalized. Library was constructed by

#### FEATURES

source

ORIGIN Bento Soares and M. Fatima Bonaldo. "

Query Match 70.5%; Score 14.8; DB 1; Length 46;  
 Best Local Similarity 88.9%; Pred. No. 4.2e+04;  
 Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTCAT 18  
 |||||  
 20 CAGCAGCTTAGTCTTCAT 37

RESULT 2  
 W25663 44 bp mRNA linear EST 25-NOV-1996  
 LOCUS IMGE327110.5, similar to gb:U51583\_cdel HEAT SHOCK PROTEIN HSP  
 DEFINITION 90-ALPHA (HUMAN);, mRNA sequence.

ACCESSION W25663  
 VERSION W25663  
 KEYWORDS GI:1303517  
 SOURCE EST.  
 ORGANISM Homo sapiens (human)  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
 1 (bases 1 to 44)  
 Hillier, L., Clark, N., Dubuque, T., Elliston, K., Hawkins, M.,  
 Holtman, M., Hultman, M., Kucaba, T., Le, M., Lennon, G., Marra, M.,  
 Parsons, J., Rifkin, L., Rohlfing, T., Soares, M., Tan, F.,  
 Trevasakis, E., Waterston, R., Williamson, A., Woldmann, P. and  
 Wilson, R.  
 The Mashu-Merck EST Project  
 Unpublished (1995)  
 JOURNAL Contact: Wilson RK  
 COMMENT Washington University School of Medicine  
 4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
 Tel: 314 286 1800  
 Fax: 314 286 1810  
 Email: est@watson.wustl.edu  
 This clone is available royalty-free through LNL; contact the  
 IMAGE Consortium (info@image.lnl.gov) for further information.  
 Trace considered overall poor quality  
 Insert Length: 596 Std Error: 0.00  
 Seq primer: mob.REGA+ET  
 High quality sequence stops: 1.  
 Location/Qualifiers  
 1. 44  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="GDB:1261312"  
 /db\_xref="taxon:9606"  
 /clone="IMAGE:327110"  
 /sex="unknown"  
 /dev\_stage="19 weeks"  
 /lab\_host="DH10B (ampicillin resistant)"  
 /clone\_id="Soares fetal heart NBH19W"  
 /note="Organ: heart; Vector: pTZ19; Site 1: Not I; Site 2: Eco RI; 1st  
 modified polylinker; Site 1: Not I; Site 2: Eco RI; 1st  
 strand cDNA was primed with a Not I - oligo(dT) primer [5'  
 TGTTCACATCTGAAGTGGAGCGCGCCGATCTTTTCTTTTCTTTT 3'],  
 double-stranded cDNA was size selected, ligated to Eco RI  
 adapters (Pharmacia), digested with Not I and cloned into  
 the Not I and Eco RI sites of a modified pTZ19 vector  
 (Pharmacia). Library went through one round of  
 normalization to a Cot = 5. Library constructed by  
 M.Fatima Bonaldo. This library was constructed from the  
 same fetus as the fetal lung library, Soares fetal lung  
 NBH19W."

ORIGIN

Query Match 69.5%; Score 14.6; DB 7; Length 44;  
 Best Local Similarity 81.0%; Pred. No. 5.2e+04;  
 Matches 17; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTCAT 21  
 |||||  
 26 CAGCAGTAGGTCACTTCAT 6

RESULT 3  
 BH861678/c 50 bp DNA linear GSS 05-AUG-2002  
 LOCUS SALK\_087727 Arabidopsis thaliana TDNA insertion lines Arabidopsis  
 thaliana genomic clone SALK\_087727, genomic survey sequence.

ACCESSION BH861678  
 VERSION BH861678.1 GI:22097004  
 KEYWORDS GSS.  
 SOURCE Arabidopsis thaliana (thale cress)  
 ORGANISM Arabidopsis thaliana  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;  
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.  
 1 (bases 1 to 50)  
 Alonso, J.M., Leisner, T.J., Barajas, P., Chen, H., Cheuk, R.,  
 Gadrinab, C., Jeake, A., Karnes, M., Kim, C.J., Parker, H., Prednis, L.,  
 Shinn, P., Zimmerman, J. and Ecker, J.R.  
 A Sequence-Indexed Library of Insertion Mutations in the  
 Arabidopsis Genome  
 Unpublished (2001)  
 JOURNAL Contact: Joseph R. Ecker  
 COMMENT Salk Institute Genomic Analysis Laboratory (SIGNAL)  
 The Salk Institute for Biological Studies  
 10010 N. Torrey Pines Road, La Jolla, CA 92037, USA  
 Tel: 858 453 4100 x1752  
 Fax: 858 558 6379  
 Email: eckers@salk.edu  
 This is single pass sequence recovered from the left border of  
 TDNA.  
 Class: TDNA tagged.  
 Location/Qualifiers  
 1. 50  
 /organism="Arabidopsis thaliana"  
 /mol\_type="genomic DNA"  
 /ecotype="Col-0"  
 /db\_xref="taxon:3702"  
 /clone="SALK\_087727"  
 /note="PCR was performed on Arabidopsis thaliana lines  
 each of which contains one or more TDNA insertion  
 elements. The resultant fragment for each line was  
 directly sequenced to determine the genomic sequence at  
 the site of insertion. Details of the protocols used can  
 be found at [http://signal.salk.edu/cdna\\_protocols.html](http://signal.salk.edu/cdna_protocols.html)"

ORIGIN

Query Match 66.7%; Score 14; DB 8; Length 50;  
 Best Local Similarity 100.0%; Pred. No. 9.8e+04;  
 Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 3 CAGCAGAGTCTTC 16  
 |||||  
 41 GCACGAGGTCTTC 28

RESULT 4  
 CC794149 42 bp DNA linear GSS 01-JUL-2003  
 LOCUS SALK\_043910.30.25.x Arabidopsis thaliana TDNA insertion lines  
 Arabidopsis thaliana genomic clone SALK\_043910.30.25.x, genomic  
 survey sequence.

ACCESSION CC794149  
 VERSION CC794149  
 KEYWORDS GSS.  
 SOURCE Arabidopsis thaliana (thale cress)  
 ORGANISM Arabidopsis thaliana  
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;

REFERENCE  
AUTHORS

Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

## TITLE

1 (bases 1 to 42)  
Alonso, J.M., Leisse, T.J., Barajas, P., Chen, H., Cheuk, R., Gadrinb, C., Jeske, A., Karnes, M., Kim, C.J., Parker, H., Prednis, L., Shin, P., Zimmerman, J., and Ecker, J.R.  
A Sequence-indexed library of insertion Mutations in the Arabidopsis Genome

JOURNAL  
COMMENT

Unpublished (2001)

Contact: Joseph R. Ecker  
Salk Institute Genomic Analysis Laboratory (SIGAL)  
The Salk Institute for Biological Studies  
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA  
Tel: 858 453 4100 x1752  
Fax: 858 558 6379  
Email: ecker@salk.edu

This is single pass sequence recovered from the left border of TDNA.

## FEATURES

source  
Location/Qualifiers

1..42  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/ecotype="Col-0"  
/db\_xref="taxon:3702"  
/clone="SALK\_043910.30.25.x"  
/clone\_lib="Arabidopsis thaliana TDNA insertion lines"  
/note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at [http://signal.salk.edu/tdna\\_protocols.html](http://signal.salk.edu/tdna_protocols.html)"

## ORIGIN

Query Match 64.8%; Score 13.6; DB 9; Length 42;  
Best Local Similarity 80.0%; Pred. No. 1.5e+05;  
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2 AGCAGCAGAGTCTTCATCAT 21  
|||  
29 AGAAACCGAGTCATCATCAT 10

RESULT 5  
LOCUS

CG869035 50 bp mRNA linear GSS 26-NOV-2003  
AB0164 Sanger Institute Gene Trap Library pGT01xr Mus musculus

## DEFINITION

CG869035 cDNA, mRNA sequence.

## ACCESSION

CG869035 GI:38532715

## KEYWORDS

GSS.

## SOURCE

Mus musculus (house mouse)

## ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 50)

Sanger Institute Gene Trap Resource - SIGTR.

http://www.sanger.ac.uk/Postgenomics/genetrp/

Unpublished (2003)

Contact: Sanger Institute Gene Trap Resource - SIGTR

Wellcome Trust Sanger Institute

Email: info.genetraps@sanger.ac.uk

Sequence tag generated by 5' RACE of total RNA from gene trap ES

cell line. ES cell lines harboring insertion mutation of target

gene are available upon request from Sanger Institute Gene Trap

Resource. Annotation information available from

http://www.sanger.ac.uk/Postgenomics/genetrp/

Class: Gene Trap.

Location/Qualifiers

1..50  
/organism="Mus musculus"  
/mol\_type="mRNA"

## ORIGIN

Query Match 63.8%; Score 13.4; DB 9; Length 50;  
Best Local Similarity 93.3%; Pred. No. 1.8e+05;  
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 CAGAGTCTTCATCAT 21  
|||||  
48 CAGAGTCTTCATCAT 34

## RESULT 6

AZ802584

LOCUS

DEFINITION

21 bp DNA linear GSS 16-FEB-2001

2M0061105R Mouse 10kb plasmid UGCM library Mus musculus genomic

clone UGCM0061105 R, genomic survey sequence.

ACCESSION

AZ802584

VERSION

AZ802584.1 GI:12954907

KEYWORDS

GSS.

SOURCE

Mus musculus (house mouse)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

1 (bases 1 to 21)

Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,

Islam, H., Longacre, S., Mahmood, M., Meenen, E., Pedersen, T.,

Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von

Niederhuesern, A. and Wright, D., Weiss, R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

Contact: Robert B. Weiss

University of Utah Genome Center

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0061 row: 1 column: 05

Seq primer: CACACAGAAACGCTATGACC

Class: Plasmid ends

High quality sequence stop: 21.

Location/Qualifiers

1..21

/organism="Mus musculus"

/mol\_type="genomic DNA"

/strain="C57BL/6J"

/db\_xref="taxon:10090"

/clone="UGCM0061105"

/sex="Male"

/lab\_host="E. Coli strain XL10-Gold, T1-resistant, F-"

/clone\_lib="Mouse 10kb plasmid UGCM library"

/note="Vector: pMD42nv. Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

laboratory Mouse DNA Resource

(<http://www.jax.org/resources/documents/dnares/>). The DNA

was hydrodynamically sheared by repeated passage through a

0.005 inch orifice at constant velocity. The sheared DNA

was blunt end-repaired with T4 DNA polymerase and T4

polynucleotide kinase. Adaptor oligonucleotides were

ligated to the blunt ends in high molar excess. The

adapted DNA was purified and size-selected for a 9.5 to

10.5 kb range using preparative agarose gel

electrophoresis. Vector DNA was prepared from a derivative

of pMD42 (gi14732114|gb|AF129072.1), a copy-number

inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent *E. coli* XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

## ORIGIN

Query Match 61.9%; Score 13; DB 8; Length 21;  
Best Local Similarity 76.2%; Pred. No. 2.5e+05;  
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTCATCAT 21  
|||||  
1 CAGCAGCAGCATACACATCAT 21

RESULT 7  
BH908888 41 bp DNA linear GSS 04-SEP-2002  
LOCUS  
DEFINITION SALK\_051042.25.80.x Arabidopsis thaliana TDNA insertion lines  
Arabidopsis thaliana genomic clone SALK\_051042.25.80.x, genomic survey sequence.

ACCESSION BH908888  
VERSION BH908888.1 GI:22721821  
KEYWORDS  
SOURCE  
ORGANISM Arabidopsis thaliana (thale cress)

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots; rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.

REFERENCE 1 (bases 1 to 41)  
Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R., Garrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L., Shinn,P., Zimmermann,J. and Ecker,J.R.  
A Sequence-Indexed Library of Insertion Mutations in the Arabidopsis genome  
Unpublished (2001)

JOURNAL  
COMMENT Contact: Joseph R. Ecker  
The Salk Institute Genomic Analysis Laboratory (SIGAL)  
Salk Institute for Biological Studies  
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA  
Tel: 858 453 4100 X1752  
Fax: 858 558 6379  
Email: ecker@salk.edu

FEATURES  
This is single pass sequence recovered from the left border of TDNA. This sequence lies within an annotated exon of At5g58140.  
Class: TDNA tagged.  
Location/Qualifiers  
1..41  
/organism="Arabidopsis thaliana"  
/mol\_type="genomic DNA"  
/ecotype="Col-0"  
/db\_xref="taxon:3702"  
/clone\_lib="Arabidopsis thaliana TDNA insertion lines"  
/note="PCR was performed on Arabidopsis thaliana lines each of which contains one or more TDNA insertion elements. The resultant fragment for each line was directly sequenced to determine the genomic sequence at the site of insertion. Details of the protocols used can be found at [http://signal.salk.edu/tdna\\_protocols.html](http://signal.salk.edu/tdna_protocols.html)"

## ORIGIN

Query Match 61.9%; Score 13; DB 8; Length 41;  
Best Local Similarity 76.2%; Pred. No. 2.7e+05;  
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTCATCAT 21  
|||||  
19 CAGCAGGGGATCTTACCAT 39

RESULT 8  
AA973632 43 bp mRNA linear EST 17-JUN-1998  
LOCUS  
DEFINITION o04b04.s1 NCI CGAP Lys Homo sapiens cDNA clone IMAGE:156931 3', similar to SW:K0E\_CERAE P33194 POSSIBLE DNA-REPAIR PROTEIN XP-E, mRNA sequence.

ACCESSION AA973632  
VERSION AA973632.1 GI:3148812  
KEYWORDS  
SOURCE  
ORGANISM Homo sapiens (human)  
Homo sapiens

REFERENCE 1 (bases 1 to 43)  
NCI-CGAP <http://www.ncbi.nlm.nih.gov/ncicgap>.  
National Cancer Institute, Cancer Genome Anatomy Project (CGAP), Tumor Gene Index  
Unpublished (1997)

JOURNAL  
COMMENT Contact: Robert Strausberg, Ph.D.  
Email: cgapbs-remail.nih.gov  
Tissue Procurement: Christopher Moskalko, M.D., Ph.D., Michael R. Emert-Buck, M.D., Ph.D.

cDNA Library Preparation: M. Bento Soares, Ph.D.  
cDNA Library Arrayed by: Greg Lennon, Ph.D.  
DNA Sequencing by: Washington University Genome Sequencing Center  
Clone distribution: NCI-CGAP clone distribution information can be found through the I.M.A.G.E. Consortium/ILMIL at: [www-bio.lnl.gov/bdbp/image/image.html](http://www-bio.lnl.gov/bdbp/image/image.html)

FEATURES  
source  
Trace considered overall poor quality  
Insert Length: 703 Std Error: 0.00  
Seq primer: -40ml3 fwd. ET from Amersham  
High quality sequence stop: 1.  
Location/Qualifiers  
1..43  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone\_lib="IMAGE:156931"  
/tissue\_type="carcinoid"  
/lab\_host="DH10B"  
/clone\_lib="NCI-CGAP Lys"  
/note="Organ: Lung; Vector: pTT30-Pac (Pharmacia) with a modified polylinker; 1st strand cDNA was prepared from neuroendocrine lung carcinoid, and was then primed with a Not I - oligo(dT) primer. Double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Not I and cloned into the Not I and Eco RI sites of the modified pTT3 vector. Library is normalized. Library was constructed by Bento Soares and M. Fatima Bonaldo."

## ORIGIN

Query Match 61.9%; Score 13; DB 1; Length 43;  
Best Local Similarity 76.2%; Pred. No. 2.8e+05;  
Matches 16; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1 CAGCAGCAGAGTCTTCATCAT 21  
|||||  
1 CAGCATAGAGTCTTCACCAT 21

## RESULT 9

AL948370 48 bp DNA linear GSS 02-APR-2004  
LOCUS  
DEFINITION Arabidopsis thaliana T-DNA flanking sequence GK-311H09-015792,  
genomic survey sequence.  
ACCESSION AL948370  
VERSION AL948370.1 GI:24404992  
KEYWORDS  
SOURCE  
ORGANISM Arabidopsis thaliana (thale cress)

Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta; Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;

REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 MEDLINE  
 PUBMED  
 REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 MEDLINE  
 PUBMED  
 REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 PUBMED  
 REFERENCE  
 AUTHORS  
 COMMENT  
 FEATURES  
 SOURCE  
 ORIGIN  
 Query Match  
 Best Local Similarity  
 Matches  
 QY  
 Db  
 RESULT 10  
 AUT07924  
 LOCUS  
 DEFINITION  
 ACCESION  
 AUT07924  
 VERSION  
 KEYWORDS  
 SOURCE  
 1  
 2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494

ORGANISM	Homo sapiens									
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
AUTHORS	1 (bases 1 to 50)									
TITLE	Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hata,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.									
JOURNAL	Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites									
MEDLINE	EMBO Rep. 2 (5), 388-393 (2001)									
PUBMED	21270072									
COMMENT	Contact: Yutaka Suzuki Department of Virology Institute of Medical Science, University of Tokyo 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan Email: yusuzuki@ims.u-tokyo.ac.jp Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997)									
FEATURES	Location/Qualifiers									
source	1..50 /organism="Homo sapiens" /mol_type="mRNA" /db_xref="taxon:9606" /clone="HRC02185" /clone_id="Sugano Homo sapiens cDNA library"									
ORIGIN										
Query Match	61.0%; Score 12.8; DB 1; Length 50;									
Best Local Similarity	87.5%; Pred. No. 3.5e+05;									
Matches	14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;									
CY	2 AGCAGCAGAGCTTCTTA 17       									
Db	27 AGCAGCAGAGTCCGCA 42									
RESULT 11										
AUI07925	50 bp mRNA linear EST 28-JAN-2004									
LOCUS	AUI07925 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone									
DEFINITION	HG106916, mRNA sequence.									
ACCESSION	AUI07925									
VERSION	AUI07925.1 GI:13557447									
KEYWORDS	EST.									
SOURCE	Homo sapiens (human)									
ORGANISM	Homo sapiens									
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.									
AUTHORS	1 (bases 1 to 50)									
TITLE	Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Sese,J., Hata,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K., Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.									
JOURNAL	Diverse transcriptional initiation revealed by fine, large-scale mapping of mRNA start sites									
MEDLINE	EMBO Rep. 2 (5), 388-393 (2001)									
PUBMED	21270072									
COMMENT	Contact: Yutaka Suzuki Department of Virology Institute of Medical Science, University of Tokyo 4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan Email: yusuzuki@ims.u-tokyo.ac.jp Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and Sugano,S. Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2), 149-156 (1997)									
FEATURES	Location/Qualifiers									
source	1..50 /organism="Homo sapiens" /mol_type="mRNA"									

```

/db_xref="taxon:9606"
/clone="HS106916"
ORIGIN
  /clone_lib="Sugano Homo sapiens cDNA library"

Query Match      61.0%; Score 12.8; DB 1; Length 50;
Best Local Similarity 87.5%; Pred. No. 3.5e+05;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2 AGCAGCAGAGTCTTCA 17
Db 27 AGCAGCAGAGTCCGCA 42

RESULT 12
LOCUS AU107928 50 bp mRNA linear EST 28-JAN-2004
DEFINITION AU107928 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
ACCESSION ZR62348, mRNA sequence.
VERSION AU107928
KEYWORDS AU107928.1 GI:13557450
SOURCE EST.
ORGANISM Homo sapiens (human)
REFERENCE Homo sapiens
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 50)
TITLE Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Seese,J.,
Hata,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K.,
Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.
Diverse transcriptional initiation revealed by fine, large-scale
mapping of mRNA start sites
JOURNAL EMBO Rep. 2 (5), 388-393 (2001)
MEDLINE 21270072
PUBMED 11375929
COMMENT Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: yusuzuki@ims.u-tokyo.ac.jp
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and
Sugano,S. Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
FEATURES
source Location/Qualifiers
1..50
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="ZR62348"
/clone_lib="Sugano Homo sapiens cDNA library"

ORIGIN
Query Match      61.0%; Score 12.8; DB 1; Length 50;
Best Local Similarity 87.5%; Pred. No. 3.5e+05;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2 AGCAGCAGAGTCTTCA 17
Db 27 AGCAGCAGAGTCCGCA 42

RESULT 13
LOCUS AU107929 50 bp mRNA linear EST 28-JAN-2004
DEFINITION AU107929 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
ACCESSION ZR62402, mRNA sequence.
VERSION AU107929
KEYWORDS AU107929.1 GI:13557451
SOURCE EST.
ORGANISM Homo sapiens (human)
REFERENCE Homo sapiens
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
```

```

Mammalia; Eutheria; Primates; Catarrhini; Hominiidae; Homo.
1 (bases 1 to 50)
TITLE Suzuki,Y., Taira,H., Tsunoda,T., Mizushima-Sugano,J., Seese,J.,
Hata,H., Ota,T., Isogai,T., Tanaka,T., Morishita,S., Okubo,K.,
Sakaki,Y., Nakamura,Y., Suyama,A. and Sugano,S.
Diverse transcriptional initiation revealed by fine, large-scale
mapping of mRNA start sites
JOURNAL EMBO Rep. 2 (5), 388-393 (2001)
MEDLINE 21270072
PUBMED 11375929
COMMENT Contact: Yutaka Suzuki
Department of Virology
Institute of Medical Science, University of Tokyo
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
Email: yusuzuki@ims.u-tokyo.ac.jp
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and
Sugano,S. Construction and characterization of a full
length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),
149-156 (1997).
FEATURES
source Location/Qualifiers
1..50
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="ZR62402"
/clone_lib="Sugano Homo sapiens cDNA library"

ORIGIN
Query Match      61.0%; Score 12.8; DB 1; Length 50;
Best Local Similarity 87.5%; Pred. No. 3.5e+05;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Oy 2 AGCAGCAGAGTCTTCA 17
Db 29 AGCAGCAGAGTCCGCA 44

RESULT 14
LOCUS AL760945/c 39 bp DNA linear GSS 01-APR-2004
DEFINITION Arabidopsis thaliana T-DNA flanking sequence GK-204B10-014508,
genomic survey sequence.
ACCESSION AL760945
VERSION AL760945.1 GI:21501350
KEYWORDS GSS.
SOURCE Arabidopsis thaliana (chale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
1
REFERENCE Li,Y., Rosso,M.G., Strizhov,N., Viehoever,P. and Weisshaar,B.
GABI-Kat Simplesearch: a flanking sequence tag (FST) database for
the identification of T-DNA insertion mutants in Arabidopsis
thaliana
JOURNAL Bioinformatics 19 (11), 1441-1442 (2003)
MEDLINE 22755829
PUBMED 12874060
REFERENCE Rosso,M.G., Li,Y., Strizhov,N., Reiss,B., Dekker,K. and
Weisshaar,B.
An Arabidopsis thaliana T-DNA mutagenized population (GABI-Kat) for
flanking sequence tag-based reverse genetics
JOURNAL Plant Mol. Biol. 53 (1-2), 247-259 (2003)
PUBMED 14756321
REFERENCE Strizhov,N., Li,Y., Rosso,M.G., Viehoever,P., Dekker,K.A. and
Weisshaar,B.
High-throughput generation of sequence indexes from T-DNA
mutagenized Arabidopsis thaliana lines
JOURNAL Biotechniques 35 (6), 1164-1168 (2003)
PUBMED 14682050
```

REFERENCE	4 (bases 1 to 39)
AUTHORS	Strizhnov,N., Rosso,M.G., Li,Y. and Weisshaar,B
TITLE	Direct Submission
JOURNAL	Submitted (13-MAR-2004) Weisshaar B., Max-Planck Zuechtungsforschung, Carl-von-Linne-Weg 10, Koeln
COMMENT	This sequence has been recovered from the left end of the plasmid. The sequence of the plasmid is available in GenBank under the accession number F01111.1.

**ORIGIN**

Query Match	60.0%	Score 12.6;	DB 9;	Length 39;
Best Local Similarity	78.9%;	Pred. No. 4.2e+05;		
Matches 15;	Conservative 0;	Mismatches 4;	Indels 0;	Gaps 0;

QY 2 AGCAGCAGAGTCTTCATCA 20  
||| ||| ||| ||| ||  
Db 38 AGCGGACAGAGTGTCTCCA 20

RESULT 15						
AI766391/c						
LOCUS	AI766391	43 bp	mRNA	linear	EST 20-DEC-1999	
DEFINITION	wh1d04.x1 NCI_CGAP Kid1 Homo sapiens CDNA clone IMAGE:2385223 3'					

Trace considered overall poor quality  
Insert Length: 641 Std Error: 0.00  
Seq primer: -40UP from Gibco  
High quality sequence stop: 1.

FEATURES	Location/Qualifiers
source	1. .43

## ORIGIN

Query Match	60.0%	Score 12.6;	DB 1;	Length 43;
Best Local Similarity	78.9%	Pred. No. 4.2e+05;		
Matches 15; Conservative	0;	Mismatches 4;	Indels 0;	Gaps 0;

```

QY      1 CAGCAGCAGAGTCTTCATC 15
          |||||
Db     32 CATCATCATAGTCCCTCATC 14

```

Search completed: September 3, 2005, 16:20:16  
Job time : 3031 secs

**This Page Blank (uspto)**